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This book provides the reader with an overall understanding of the biology of 
pancreatic cancer, hereditary, complex signaling pathways and alternative therapies. 
The book explains nutrigenomics and epigenetics mechanisms such as DNA 
methylation, which may explain the etiology or progression of pancreatic cancer. Book 
also summarizes the molecular control of oncogenic pathways such as K-Ras and 
KLF4. Since pancreatic cancer metastasizes to vital organs resulting in poor prognosis, 
special emphasis is given to the mechanism of tumor cell invasion and metastasis. Role 
of nitric oxide and Syk kinase in tumor metastasis is discussed in detail.  Prevention 
strategies for pancreatic cancer are also described. The molecular mechanisms of the 
anti-cancer effects of curcumin, benzyl isothiocyante and vitamin D are discussed in 
detail. Furthermore, this book covers the basic mechanisms of resistance of pancreatic 
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Pancreatic  cancer  is one of  the most  fatal human malignancies with  extremely poor 
prognosis making  it  the  fourth  leading  cause of  cancer‐related deaths  in  the United 
States.  The  molecular  mechanisms  of  pancreatic  carcinogenesis  are  not  well 
understood. The major focus of these two books  is towards the understanding of the 




therapies.    The  book  explains  nutrigenomics  and  epigenetics mechanisms  such  as 
DNA methylation, which may explain the etiology or progression of pancreatic cancer. 
Apart  from  epigenetics,  book  summarizes  the  molecular  control  of  oncogenic 
pathways such as K‐Ras and KLF4. Since pancreatic cancer metastasizes to vital organs 
resulting in poor prognosis, special emphasis is given to the mechanism of tumor cell 






is  discussed  in  depth.  Major  emphasis  is  given  to  the  identification  of  newer 
therapeutic  targets  such  as  mesothalin,  glycosylphosphatidylinositol,  cell  cycle 
regulatory proteins, glycans, galectins, p53, toll‐like receptors, Grb7 and telomerase in 
pancreatic cancer for drug development.  
Book  2  covers  pancreatic  cancer  risk  factors,  treatment  and  clinical  procedures.  It 
provides  an  outline  of pancreatic  cancer  genetic  risk  factors,  signaling mechanisms, 
biomarkers and disorders and systems biology for the better understanding of disease. 
As pancreatic  cancer  suffers  from  lack of early diagnosis or prognosis markers,  this 
book encompasses stem cell and genetic makers to identify the disease in early stages. 
The book uncovers  the  rationale and effectiveness of monotherapy and combination 
therapy  in combating  the devastating disease. As  immunotherapy  is emerging as an 
attractive  approach  to  cease pancreatic  cancer progression,  the present  book  covers 
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attractive  approach  to  cease pancreatic  cancer progression,  the present  book  covers 
various  aspects  of  immunotherapy  including  innate,  adaptive,  active,  passive  and 
X Preface
bacterial approaches. The book also  focuses on  the disease management and clinical 
procedures.  Book  explains  the  role  of  pre‐existing  conditions  such  as  diabetes  and 
smoking  in  pancreatic  cancer. Management  of  anesthesia  during  surgery  and  pain 
after  surgery  has  been  discussed.  Book  also  takes  the  reader  through  the  role  of 
endoscopy and  fine needle guided biopsies  in diagnosing and observing  the disease 
progression.  As  pancreatic  cancer  is  recognized  as  a  major  risk  factor  for  vein 
thromboembolism,  this  book  reviews  the  basics  of  coagulation  disorders  and 
implication of expandable metallic stents in the management of portal vein stenosis of 
recurrent and  resected pancreatic  cancer. Emphasis  is given  to neuronal  invasion of 
pancreatic tumors along with management of pancreatic neuroendocrine tumors.  
We  hope  that  this  book will  be  helpful  to  the  researchers,  scientists  and  patients 
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Risk Factors in Pancreatic Cancer 
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First Surgical Clinic, Cluj-Napoca,  
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1. Introduction 
Pancreatic cancer is one of the most lethal malignant diseases with the worst prognosis. It is 
ranked as the fourth leading cause of cancer-related deaths in the United States. An 
unknown but important proportion of cancers develop in people who carry mutation in a 
cancer-predisposing gene. Identification of cancer-predisposing genetic mutations in 
susceptible individuals affords the opportunity to practise preventive medicine. Pancreatic 
cancer is an aetiologically complex disease whose development is contingent on the 
independent and joint effects of genes and environment. (Greer &Whitcomb, 2007). Recent 
analysis of human pancreas genomes showed that 12 common signaling pathways involved 
in cellular repair mechanisms, metabolism, cell-cycle regulation, genomic repair, and 
metastasis are affected in over two thirds of the pancreatic cancer genome, including mainly 
point mutations(Jones et al., 2008). 
Many risk factors have been associated with PC such as genetic factors and premalignant 
lesions, predisposing diseases and exogen factors. Genetic susceptibility, observed in 10% of 
cases includes inherited pancreatic cancer syndromes and familial cancers. However, the 
rest of 90% of pancreatic cancer recognise as risk factors a mix between genetic factors and 
environmental factors, too, but the exact etiopathogenesis remains unknown. 
2. Hereditary pancreatic cancer syndromes 
2.1 Hereditary breast ovarian cancer syndrome 
Hereditary breast ovarian cancer syndrome is associated with germ line mutation in the 
BRCA 2 and BRCA 1 gene and it is associated with a 7% lifetime risk in pancreatic cancer at 
70 years old. BRCA1 and 2 are tumour suppressor genes that are inherited in an autosomal 
dominant fashion with incomplete penetrance. They controls cell growth and differentiation 
and their loss drives tumorigenesis by involving in transcriptional regulation of gene 
expression and reairing of damaged DNA. The 6174delT mutation of BRCA2, occur ten 
times more frequently in Ashkenazi Jewish population and it is responsible for breast and 
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BRCA 2 and BRCA 1 gene and it is associated with a 7% lifetime risk in pancreatic cancer at 
70 years old. BRCA1 and 2 are tumour suppressor genes that are inherited in an autosomal 
dominant fashion with incomplete penetrance. They controls cell growth and differentiation 
and their loss drives tumorigenesis by involving in transcriptional regulation of gene 
expression and reairing of damaged DNA. The 6174delT mutation of BRCA2, occur ten 
times more frequently in Ashkenazi Jewish population and it is responsible for breast and 
ovarian familial cancer. BRCA2 mutations are found in as many as 12 to 17 percent of 
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patients with familial pancreatic cancer. Single nucleotide polymorphism of BRCA 1 and 2 
does not influence the risk for pancreatic cancer in sporadic pancreatic adenocarcinoma 
(McWilliams et al., 2009). For BRCA1 carriers, this relative risk is estimated to be 2-fold 
higher (Thomson et al., 2002) and for BRCA2 carriers, this relative risk is approximately 3-to 
4-fold higher (The Breast Cancer Linkage Consortium, 1999). Within 24/219 BRCA1 and 
17/156 BRCA2 families (representing 11% of overall individuals included in the study) there 
was at least 1 individual with pancreatic cancer. The onset of cancer was earlier than in 
general population : 59 in males and 69 in females in BRCA1families and 67 in males and 59 
in females in BRCA2 families (Kim et al., 2009). Compared to SEER data which showed a 
0.96:1 male:female ratio occurence of pancreatic cancer in general population, in BRCA1 
families, showed a 2:1 male: female ratio, possible linked to the competing mortality for 
breast and ovarian cancer in their female relatives (Kim et al., 2009). For these reasons, males 
under 65 years old in families with a strong history of breast, ovarian, and pancreatic cancer 
be considered for BRCA1/2 testing along with their female relatives. Cigarette smoking and 
exposure to oestrogen influences pancreatic cancer risk, but in a direction opposite to that of 
breast cancer risk in BRCA1/2 mutation carriers (Greer & Whitcomb, 2007). 
2.2 The Peutz-Jeghers syndrome 
The Peutz-Jeghers syndrome is an autosomally dominant hereditary disease with 
characteristic of hamartoma polyps of the gastrointestinal tract, and mucocutaneous 
melanin pigmentation. Almost half of these patients are carriers of a germinal serine-
treonine kinase 11STK11/LKB1 gene mutation (Giardiello et al., 2000). Wild-type 
STK11/LKB1 activates adenine monophosphate–activated protein kinase, which is a 
regulator of cellular energy metabolism. Activation of adenine monophosphate–activated 
protein kinase leads to inhibition of the mammalian target of rapamycin 1 (mTOR1), a 
serine/threonine kinase with a key position in the regulation of cell growth. The risk of PC 
is 132 times higher than for the general population (lifetime risk for cancer is 11-36%).  
2.3 Familial atypical multiple mole melanoma syndrome (FAMMM) 
Familial atypical multiple mole melanoma syndrome (FAMMM) is an autosomal dominant 
syndrome caused by a germline mutation in CDKN2A (or p16) gene on chromosome 9p21 
or in a minority of cases in the CDK4 gene on chromosome 12 (Goldstein et al., 2000; 
Wheelan et al., 1995). This syndrome is characterized by multiple nevi, multiple atypical 
nevi, and an increased risk of melanoma. The relative risk of developing pancreatic cancer is 
20 to 47 and the lifetime risk for pancreatic cancer is 16%(Vasen et al., 2000, De Snoo et al., 
2008). Among cases who reported having a first-degree relative with pancreatic cancer or 
melanoma, the carrier proportions were 3.3 and 5.3%, respectively. Penetrance for mutation 
carriers by age 80 was calculated to be 58% for pancreatic cancer and the risk of pancreatic 
cancer in smokers was 25 compared to non-carriers (McWilliams et al., 2011). The onset of 
pancreatis cancer in a historical cohort of 36 patients from 26 families with FAMM was 65 
years old. In a follow-up study group of 77 carriers of p16 mutation, 7 individuals 
developed a pancreatic cancer within 4 years and only 5 had curative resection, confirming 
rapidly growing tumor that could originate from small PanIN lesions in p16 mutation 
carriers(Vasen et al., 2010). 
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2.4 Lynch syndrome 
Lynch syndrome is an autosomal dominant condition caused by defects in mismatch repair 
genes (MLH1, MSH2, MSH6 or PMS2). It has recently been shown that in addition to 
colorectal and endometrial cancers these individuals have a 9-fold increased risk of 
developing pancreatic cancer compared with general population(Kastrinos et al., 2009). 
2.5 Hereditary pancreatitis 
Hereditary pancreatitis is a rare autosomal dominant disorder, in more than two-thirds of 
cases caused by a mutation in the SPINK1 and PRSS1 genes, with a high risk of pancreatic 
cancer. For this population, the cumulative risks of pancreatic cancer at the age of 50 and 75 
years are 11% and 49% for men and 8% and 55% for women, respectively(Rebours et al., 
2008). The risk was higher for smokers and for those with diabetes mellitus. 
2.6 Ataxia-teleangiectasia  
Ataxia-teleangiectasia with mutation of ATM gene on chromosome 17p is associated with 
pancreatic cancer , but the relative risk is unknown yet. 
3. Familial pancreatic cancer  
It may be considered in families with at least two first-degree relatives suffering from the 
disease, thus suggesting an autosomal dominant penetrance (Greenhalf et al., 2009). 
Families with only one relative with pancreatic cancer or with multiple pancreatic cancers in 
more distant relatives are considered as sporadic PC. The lifetime risk increases with the 
number of relatives involved. Individuals with two first-degree relatives with pancreatic 
cancer have a 6-fold increased risk of developing pancreatic cancer, and individuals with 
three or more first-degree relatives with pancreatic cancer have a 14 to 32-fold increased risk 
(Klein et al., 2004) . The risk of pancreatic cancer was similar in familial PC kindred 
compared to sporadic pancreatic cancer kindred members. Analysing more than 9000 
subjects, the presence of a young-onset pancreatic cancer patient, under 50 years old did not 
influence the risk of having pancreatic cancer inside familial PC kindred, but it added risk 
compared to sporadic pancreatic cancer (Brune et al., 2010). Smoking is a strong risk factor 
in familial pancreatic cancer kindred, particularly in males and people younger than 50 
years of age, as it increases the risk of pancreatic cancer by 2 to 3.7 times over the inherited 
predisposition and lowers the age of onset by 10 years (Rulyak et al., 2003).  
The genetic basis is not known, the BRCA2, palladin gene and PALB2 could play some role 
(Murphy et al., 2002; Couch et al., 2007; Pogue-Geile et al.,2006; Jones et al.,2009). The PALB2 
gene codes for a protein that binds to the BRCA2 protein and helps to localize BRCA2. 
(Tischkowitz et al.,2009, Jones et al.,2009). Palladin is a cytoskeleton-associated scaffold 
protein, with role in the formation of a desmoplastic tumor microenvironment (Giocoechea 
et al., 2010), but recent studies denied its involvement in carcinogenesis (Klein et al.,2009, 
Slater et al.,2007) 
There has been developed and validated a risk prediction model PancPRO based on age, 
pancreatic cancer status, age of onset, and relationship for all biological relatives (Wang et 
al., 2007). 
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2.4 Lynch syndrome 
Lynch syndrome is an autosomal dominant condition caused by defects in mismatch repair 
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disease, thus suggesting an autosomal dominant penetrance (Greenhalf et al., 2009). 
Families with only one relative with pancreatic cancer or with multiple pancreatic cancers in 
more distant relatives are considered as sporadic PC. The lifetime risk increases with the 
number of relatives involved. Individuals with two first-degree relatives with pancreatic 
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compared to sporadic pancreatic cancer (Brune et al., 2010). Smoking is a strong risk factor 
in familial pancreatic cancer kindred, particularly in males and people younger than 50 
years of age, as it increases the risk of pancreatic cancer by 2 to 3.7 times over the inherited 
predisposition and lowers the age of onset by 10 years (Rulyak et al., 2003).  
The genetic basis is not known, the BRCA2, palladin gene and PALB2 could play some role 
(Murphy et al., 2002; Couch et al., 2007; Pogue-Geile et al.,2006; Jones et al.,2009). The PALB2 
gene codes for a protein that binds to the BRCA2 protein and helps to localize BRCA2. 
(Tischkowitz et al.,2009, Jones et al.,2009). Palladin is a cytoskeleton-associated scaffold 
protein, with role in the formation of a desmoplastic tumor microenvironment (Giocoechea 
et al., 2010), but recent studies denied its involvement in carcinogenesis (Klein et al.,2009, 
Slater et al.,2007) 
There has been developed and validated a risk prediction model PancPRO based on age, 
pancreatic cancer status, age of onset, and relationship for all biological relatives (Wang et 
al., 2007). 
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Even genetic testing may be of benefit to many families, more than 80% of the clustering of 
pancreatic cancer in families remains unknown or the known mutation are not found. 
Mutations in the BRCA2gene account about 11% of families, PALB2 1–3% and the remaining 
genes account for <1% of familial pancreatic cancer. Genetic susceptibility for developing 
pancreatic cancer has been recently atributed to a single nucleotide polymorphism of gene 
located on 13q22.1 chromosome, considered as specific for pancreatic cancer, or of a gene 
located on 1p32.1 chromosome, which interact with betacatenin pathway(Petersen et al., 
2010). 
3.1 Genetic predisposition: ABO blood group  
Compared with blood group O, individuals with non-O blood group (type A, AB, or B) 
were significantly more likely to develop pancreatic cancer (adjusted hazard ratio for 
incident pancreatic cancer 1.32, 1.51. and 1.72, respectively)(Wolpin et al., 2009, Risch et al., 
2010), probably based on genetic variants in ABO locus 9q34 (Amundadottir et al, 2009). 
Another extended study identified susceptibility loci on 3 chromosomes- 13q22.1, 1q32.1 
and 5q15.33, the most specific being considered 13q22.1(Petersen et al., 2010). The incidence 
rates for pancreatic cancer (cases per 100,000 persons at risk) among White participants with 
blood types O, A, AB, and B were 28.9, 39.9, 41.8, and 44.5, respectively. In combination with 
smoking, overweight or diabetes, the non-O blood type was associated with ORs of 2.68, 
1.66, and 2.29, respectively, compared to subjects who had O blood type and lacked the 
exposure(Wolpin et al., 2010). The mechanism of influence of blood group antigens on risk 
for pancreatic cancer might be the alteration of the systemic inflammatory state (Wolpin et 
al., 2010). 
4. Premalignant lesions 
There are three known precursor lesions to pancreatic cancer: intraductal papillary 
mucinous neoplasm (IPMN), mucinous cystic neoplasia (MCN) and pancreatic intra-
epithelial neoplasia (PanIN). PanIN is by far the most common lesion and three grades of 
PanIN have been described as cellular atypia progresses from low grade dysplasia (PanIN 1) 
to high grade dysplasia (PanIN3), similar to colorectal cancer carcinogenesis. The 5-year-risk 
of PC is about 50% for MCN, 50% for main ductal IPMN while only 15% for branch IPMN. 
5. Predisposing diseases 
5.1 Chronic pancreatitis 
The risk of developing pancreatic cancer is about 5%(Raimondi et al., 2010), probably due to 
PanIN lesions or chronic inflammation. In a large multicentric study, the total risk reached 
1.8 percent at 10 years and 4 percent at 20 years, independently of the type of 
pancreatitis(Lowenfels et al., 1993; Howes et al., 2004). There is no need for systematic 
screening in patients with chronic pancreatitis, but acute onset of pain after long free-pain 
interval, a non-equilibrated diabetes without explanation, the onset of jaundice or weight 
loss require looking for pancreatic cancer. The risk is higher for non-alcoholic pancreatitis, 
as hereditary pancreatitis linked to PRSS1 mutations (40% at 70 years old) or tropical 
pancreatitis, form of hereditary pancreatitis linked to SPINK1 mutation (a 100 times higher 
risk than for the general population)(Lowenfels et al., 1993).  
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5.2 Diabetes mellitus 
Diabetes is associated with pancreatic cancer in about 40 to 60% of patients at the onset of 
symptoms, being a consequence or the cause of the disease. A meta-analysis of 20 studies 
(predominantly of patients with type 2 diabetes) estimated that the pooled relative risk for 
pancreatic compared to patients without diabetes was 2.1, especially among patients with 
long-standing diabetes(Everhart&Wright, 1995; Huxley et al., 2005).Diabetes associated with 
pancreatic cancer is often new-onset (<2-year duration), it resolves following cancer 
resection and appears to be associated with conventional risk factors for diabetes such as 
age, obesity and familial history (Pannala et al., 2008; Gupta et al., 2006). Even in the absence 
of frank diabetes mellitus, abnormal glucose metabolism and insulin resistance have been 
associated with pancreatic cancer(Stolzenberg-Solomon et al., 2005; Gapstur et al.,2000), and 
the insulin-growth factor(IGF) involvement might be the pathway in the pathogenesis. 
Although not all studies found an association between the risk of pancreatic cancer and the 
level of IGF, it seems that the polymorphism of IGF is associated with lower susceptibility to 
pancreatic cancer(Lin et al., 2004; Wolpin et al., 2007; Suzuki et al., 2008).The risk is higher in 
insulin ever users compared with nonusers (OR = 2.2, 95% CI = 1.6-3.7) and was restricted to 
insulin use of ≤3 years (OR = 2.4), but decreases after ten years of insulin use(Li et al., 2011). 
The explanation might be that the two diseases could share genetic risk factors in common. 
The CT screening is recommended for older patients with new-onset diabetes, especially 
those with family history or symptoms, as shown in a recent description of French families. 
5.3 Postgastrectomy or postcolecystectomy status 
Postgastrectomy or postcolecystectomy status were associated with an increased risk of 
pancreatic cancer, probably due to high level of circulating colecystokinin(Smith et al., 1990). 
5.4 Helicobacter pylori and hepatitis B  
Helicobacter pylori and hepatitis B have been found as associated factors to pancreatic 
cancer. The pathway may be represented by the polymorphism of genes involved in the 
inflammatory response, but further studies are needed for confirmation.  
6. Environmental factors 
6.1 Smoking 
The risk for pancreatic cancer is 1.5-2.5, higher with the numbers of cigarettes and in 
glutathione-S-transferase deficient persons and decreases 10 years after the smoking 
cessation. (Iodice et al, 2008). It increases the risk in hereditary chronic pancreatitis. 
Mutations in carcinogen-metabolizing genes, such as glutathione-S-transferase, N-acetyl-
transferase, cytochrome P450 and DNA-repair genes in oxidative metabolism(XRCC1, 
OGG1) with multiple sequence variants may be genetic modifiers for smoking-related 
pancreatic cancer (Duell et al., 2002; Li et al., 2006). In a recent case-control publication, the 
risk more than 15 years after smoking cessation was similar to that for never smokers. Also, 
there was a more significant risk for total exposure delivered at lower intensity for longer 
duration than for higher intensityfor shorter duration. These findings and the decline in risk 
after smoking cessation suggested that smoking has a latestage role in carcinogenesis. 
(Lynch et al., 2009). There is a synergistic interaction with diabetes mellitus and family 
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2010), probably based on genetic variants in ABO locus 9q34 (Amundadottir et al, 2009). 
Another extended study identified susceptibility loci on 3 chromosomes- 13q22.1, 1q32.1 
and 5q15.33, the most specific being considered 13q22.1(Petersen et al., 2010). The incidence 
rates for pancreatic cancer (cases per 100,000 persons at risk) among White participants with 
blood types O, A, AB, and B were 28.9, 39.9, 41.8, and 44.5, respectively. In combination with 
smoking, overweight or diabetes, the non-O blood type was associated with ORs of 2.68, 
1.66, and 2.29, respectively, compared to subjects who had O blood type and lacked the 
exposure(Wolpin et al., 2010). The mechanism of influence of blood group antigens on risk 
for pancreatic cancer might be the alteration of the systemic inflammatory state (Wolpin et 
al., 2010). 
4. Premalignant lesions 
There are three known precursor lesions to pancreatic cancer: intraductal papillary 
mucinous neoplasm (IPMN), mucinous cystic neoplasia (MCN) and pancreatic intra-
epithelial neoplasia (PanIN). PanIN is by far the most common lesion and three grades of 
PanIN have been described as cellular atypia progresses from low grade dysplasia (PanIN 1) 
to high grade dysplasia (PanIN3), similar to colorectal cancer carcinogenesis. The 5-year-risk 
of PC is about 50% for MCN, 50% for main ductal IPMN while only 15% for branch IPMN. 
5. Predisposing diseases 
5.1 Chronic pancreatitis 
The risk of developing pancreatic cancer is about 5%(Raimondi et al., 2010), probably due to 
PanIN lesions or chronic inflammation. In a large multicentric study, the total risk reached 
1.8 percent at 10 years and 4 percent at 20 years, independently of the type of 
pancreatitis(Lowenfels et al., 1993; Howes et al., 2004). There is no need for systematic 
screening in patients with chronic pancreatitis, but acute onset of pain after long free-pain 
interval, a non-equilibrated diabetes without explanation, the onset of jaundice or weight 
loss require looking for pancreatic cancer. The risk is higher for non-alcoholic pancreatitis, 
as hereditary pancreatitis linked to PRSS1 mutations (40% at 70 years old) or tropical 
pancreatitis, form of hereditary pancreatitis linked to SPINK1 mutation (a 100 times higher 
risk than for the general population)(Lowenfels et al., 1993).  
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5.2 Diabetes mellitus 
Diabetes is associated with pancreatic cancer in about 40 to 60% of patients at the onset of 
symptoms, being a consequence or the cause of the disease. A meta-analysis of 20 studies 
(predominantly of patients with type 2 diabetes) estimated that the pooled relative risk for 
pancreatic compared to patients without diabetes was 2.1, especially among patients with 
long-standing diabetes(Everhart&Wright, 1995; Huxley et al., 2005).Diabetes associated with 
pancreatic cancer is often new-onset (<2-year duration), it resolves following cancer 
resection and appears to be associated with conventional risk factors for diabetes such as 
age, obesity and familial history (Pannala et al., 2008; Gupta et al., 2006). Even in the absence 
of frank diabetes mellitus, abnormal glucose metabolism and insulin resistance have been 
associated with pancreatic cancer(Stolzenberg-Solomon et al., 2005; Gapstur et al.,2000), and 
the insulin-growth factor(IGF) involvement might be the pathway in the pathogenesis. 
Although not all studies found an association between the risk of pancreatic cancer and the 
level of IGF, it seems that the polymorphism of IGF is associated with lower susceptibility to 
pancreatic cancer(Lin et al., 2004; Wolpin et al., 2007; Suzuki et al., 2008).The risk is higher in 
insulin ever users compared with nonusers (OR = 2.2, 95% CI = 1.6-3.7) and was restricted to 
insulin use of ≤3 years (OR = 2.4), but decreases after ten years of insulin use(Li et al., 2011). 
The explanation might be that the two diseases could share genetic risk factors in common. 
The CT screening is recommended for older patients with new-onset diabetes, especially 
those with family history or symptoms, as shown in a recent description of French families. 
5.3 Postgastrectomy or postcolecystectomy status 
Postgastrectomy or postcolecystectomy status were associated with an increased risk of 
pancreatic cancer, probably due to high level of circulating colecystokinin(Smith et al., 1990). 
5.4 Helicobacter pylori and hepatitis B  
Helicobacter pylori and hepatitis B have been found as associated factors to pancreatic 
cancer. The pathway may be represented by the polymorphism of genes involved in the 
inflammatory response, but further studies are needed for confirmation.  
6. Environmental factors 
6.1 Smoking 
The risk for pancreatic cancer is 1.5-2.5, higher with the numbers of cigarettes and in 
glutathione-S-transferase deficient persons and decreases 10 years after the smoking 
cessation. (Iodice et al, 2008). It increases the risk in hereditary chronic pancreatitis. 
Mutations in carcinogen-metabolizing genes, such as glutathione-S-transferase, N-acetyl-
transferase, cytochrome P450 and DNA-repair genes in oxidative metabolism(XRCC1, 
OGG1) with multiple sequence variants may be genetic modifiers for smoking-related 
pancreatic cancer (Duell et al., 2002; Li et al., 2006). In a recent case-control publication, the 
risk more than 15 years after smoking cessation was similar to that for never smokers. Also, 
there was a more significant risk for total exposure delivered at lower intensity for longer 
duration than for higher intensityfor shorter duration. These findings and the decline in risk 
after smoking cessation suggested that smoking has a latestage role in carcinogenesis. 
(Lynch et al., 2009). There is a synergistic interaction with diabetes mellitus and family 
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history of pancreatic cancer (Hassan et al.,2007). Smoking can be reponsible for familial 
agregation of pancreatic cancer individuals with lung and larynx cancer (Hiripi et al., 2009). 
6.2 Obesity  
A body mass index of at least 30 kg/m2 was associated with a significantly increased risk of 
pancreatic cancer compared with a BMI of less than 23 kg/m2 (relative risk 1.72), but an 
inverse relationship was observed for moderate physical activity when comparing the 
highest versus the lowest categories (relative risk 0.45) (Michaud et al., 2001). Centralized fat 
distribution may increase pancreatic cancer risk,especially in women, (Arslan et al., 2010). 
There have recently been discovered genetic factors which can reduce the risk of PC (PPARγ 
P12A GG genotype, NR5A2 variants) or which can enhance th risk in overweight patients 
(FTO, ADIPOQ) (Tang et al., 2011). Others have suggested that overweight and obese 
individuals develop pancreatic cancer at a younger age than do patients with a normal 
weight, and that they also have lower rates and duration of survival once pancreatic cancer 
is diagnosed (Li et al., 2009). Obesity in early adulthood was a risk factor for pancreatic 
cancer (Genkinger et al., 2010). 
6.3 The diet 
The diet based on fat and meat has been linked to the development of pancreatic cancer in 
many (Nothlings et al., 2005; Thiebaut et al., 2009), but not all studies (Michaud et al,2003, 
2005). The consumption of fresh fruits and vegetables were not associated with pancreatic 
cancer risk (Coughlin et al.,2000). Lower serum levels of lycopene and selenium have been 
found in subjects who subsequently developed pancreatic cancer (Burney et al.,1989). 
Although the majority of prospective cohort studies found no significant increase in the risk 
of pancreatic cancer with moderate to high levels of alcohol intake in a general population., 
a recent study has shown that a certain polymorphism of genes involved in the production 
and/or oxidation of acetaldehyde is associated with an increasing risk in developping 
pancreatic cancer (Michaud, 2004;Kanda et al., 2008). Folate deficiency, involved in DNA 
mutations and DNA methylation, may increase the risk of cancer. Although at least two 
variants of genes involved in folate metabolism were found to be associated to pancreatic 
cancer and smoking, these findings were not confirmed in all studies. Because the sample 
size was considered to be insufficient and the criteria for control selection of patients were 
different,these evidence were considered inadequately powered for drawing a conclusion. 
(Wang et al., 2005; Matsubayashi et al., 2005; Suzuki et al., 2008; Ohnami et al., 2008). No 
epidemiologic study has provided evidence to support the hypothesis that high glycemic 
index or glycemic load increases the risk of pancreatic cancer (Jiao L et al., 2009). 
Also, the role of TGF-beta pathway, proved to be linked to pancreatic cancer, and its genetic 
variants, but it still remains unclear. 
6.4 Exposure to sunlight
Exposure to sunlight with increase of vitamin D synthesis might decrease the cancer risk and 
polymorphic variants in genes encoding the for synthesis enzyme is an important task for 
future research, as the role of melatonin receptor and genetic variants in clock genes. Based 
on different sun exposure in different geographic latitude, several studies sustained the 
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protective role of vitamin D against pancreatic cancer, in association with other factors as 
age and obesity (Grant, 2002, Guyton et al., 2003). The quantification of Vitamin D 
concentration must consider also the race (Afro-Americans has a higher risk for PC), the 
season of blood drawn and presence of supplemental in diet (Stolzenberg-Solomon, 2009). 
6.5 Alcohol consumption 
A recent study showed a moderate risk to heavy alcohol drinkers ( about 40 g alcohol daily) 
and liquor users ( relative risk 1.45-1.62) , probably due to their nitrosamine content (Jiao et 
al., 2009), sustained by other studies only in men (Hassan et al., 2007). 
6.6 Demographic factors 
Advanced age, between 60 and 80 is associated with 80% of pancreatic cancers. Other 
demographic factors that are associated with a modest (about 2-fold) increased risk include 
male gender, Jewish descent and black ethnicity(Lillemoe et al., 2000). 
Gene function  Gene 
symbol  





Transcription  ZNF  zinc finger protein  19q13.31  3.38  
 MIXL1  Mix1 homeobox-like 1  1q42.12  6.24  





breakpoint cluster region 
pseudogene 2  
22q11.21  3.02  
 AGRP  agouti related protein 
homolog  





coiled-coil domain containing 
88B  
11q12.3   4.61  
 UTP14
A  
U3 small nucleolar 
ribonucleoprotein  
Xq26.1   3.44  
 VPS11  vacuolar protein sorting 11 
homolog  





transmembrane domains  
10q23  3.33  
 CHRM3  cholinergic receptor, 
muscarinic 3  
1q43  3.01  
Table 1. Genes with significant different expression (overexpressed or underexpressed) in 
pancreatic cancer compared to normal pancreatic tissue.  
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cancer and smoking, these findings were not confirmed in all studies. Because the sample 
size was considered to be insufficient and the criteria for control selection of patients were 
different,these evidence were considered inadequately powered for drawing a conclusion. 
(Wang et al., 2005; Matsubayashi et al., 2005; Suzuki et al., 2008; Ohnami et al., 2008). No 
epidemiologic study has provided evidence to support the hypothesis that high glycemic 
index or glycemic load increases the risk of pancreatic cancer (Jiao L et al., 2009). 
Also, the role of TGF-beta pathway, proved to be linked to pancreatic cancer, and its genetic 
variants, but it still remains unclear. 
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Exposure to sunlight with increase of vitamin D synthesis might decrease the cancer risk and 
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and liquor users ( relative risk 1.45-1.62) , probably due to their nitrosamine content (Jiao et 
al., 2009), sustained by other studies only in men (Hassan et al., 2007). 
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Our research on 16 tissue samples of T3 pancreatic cancer comparing to normal tissue in the 
same patients analysed by microarray showed that there were 41 overexpressed genes and 402 
underexpressed genes. From those with tumor concentration three times modified compared 
to normal tissue we noticed genes involved in transcription, intracellular signaling and 
intracellular transport (Table I), which need further validation on larger sample groups (data 
unpublished). This showed that genomic tissue microarray analysis represents a powerful 
strategy for identification of potential biomarkers in pancreatic cancer.  
7. Conclusions  
Pancreatic cancer is a pathological status with clear inheritance in only 10% of cases, the 
others seems to be linked to premalignant situations, other diseases or environmental factors 
in which genetic implications need further investigations. The gene-gene and gene- 
environment interactions have to be more extensively studied, especially because there are 
not only single-nuclear polymorphisms, but also DNA copy number variations and 
variable-number tandem repeats which can be linked to the risk of pancreatic cancer. 
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Pancreatic ductal adenocarcinoma cancer is the 10th most commonly diagnosed cancer but is 
the 4th leading cause of cancer death in the United States. A number of risk factors have been 
proposed to play a role in the etiology of pancreatic cancer (1,2). Life-style factors such as 
smoking accounts for 20-30% of pancreatic cancer death, with approximately 10% having 
germline or somatic mutations association (3). Other risk factors include age, race, gender, 
chronic pancreatitis and diabetes; however, the role of dietary intake and specific nutrients 
remain an unexplored area of research, although diet is a risk factor (4,5). Epidemiological 
studies have long suggested the possibility that what we eat influence the state of our health. It 
is believed that dietary habits are important modifiable factors that can influence cancer risk 
and tumor behavior (6,7). In vivo, in vitro and epidemiological studies have shown that an 
individual’s diet may contribute to their susceptibility to develop cancer (8-11).   
Pancreatic cancer remains a very complex and challenging disease. This cancer carries one of 
the worst prognosis of any major malignancy, mainly due to its lack of early detection and 
lack of effective therapeutic agents. The American Cancer Society projected 43,140 new cases 
of the disease in 2010, and over 36,800 deaths (12). Improvements in imaging technology has 
aided in diagnosis and identification of patients with the disease; however, these new 
technologies have not greatly improved the mortality rate of pancreatic cancer. Clinical, 
pathological and genetics studies have identified three important different preneoplastic 
lesions of the pancreatic ductal adenocarinoma, the pancreatic intraepithelial neoplasia 
(PanIN), intraductal papillary mucinous neoplasm (IPMN) and mucinous cystic neoplasm 
(MCM) which could be studied to identify early changes in pancreatic cancer (13,14). 
Understanding molecular changes within these preneoplastic lesion, whether genetic or 
epigenetic, will greatly improve detection of pancreatic cancer at its earliest stages. 
Furthermore, the examining of these lesions with emerging “omics’ technologies and the 
emerging new science “nutriogenomics” will greatly contribute to our knowledge of this 
deadly cancer.   
2. Nutrigenomics 
Nutrigenomics is an emerging new field of science in which attempts are being made to 
study the effects of nutrition on the whole genome (15). Nutrigenomics is the study of 
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Nutrigenomics is an emerging new field of science in which attempts are being made to 
study the effects of nutrition on the whole genome (15). Nutrigenomics is the study of 
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specific genes or the affect of functional single nucleotide polymorphisms and bioactive 
food components interactions. Although great emphasis has been placed on understanding 
the role of nutrigenomics on regulation of gene expression in regards to polymorphisms, 
very little data are available on the role of nutrigenomics and its role in epigenetic 
regulation. We must also include in this new area of science, high energy or caloric intake 
because of its contribution to obesity. Nutrients are thought to be dietary signals that can be 
detected by various cellular systems involved in regulating gene and protein expressions, as 
well as affecting the production of metabolites (16,17). Therefore, each individual can 
establish dietary signatures in specific cells, tissues or organs according to their daily diets, 
which could utlimately influence homeostasis and their susceptibility to diseases, such as 
cancer. Studying the effects of nutrients at the genomic level can be through genetic or 
epigenetic mechanisms. This chapter focuses on the role of epigenetic mechanisms in 
pancreatic cancer and their modulation through dietary agents found in daily food intake. 
The influence of bioactive components in foods on various biological and physiological 
functions at the genomic level is a vastly unexplored area of research in cancer research. 
Dietary components are beginning to be observed as major determinants of cancer risk in 
humans (18-22). Nutrition can potentially modify, through epigenetic mechanisms 
molecular changes associated with carcinogenesis. Furthermore, employing this new science 
in understanding how bioactive components can affect the constant insults from external 
and internal factors to DNA, which results in chromatin changes, alteration in DNA repair, 
apoptosis and inflammation epigenetically will enhance our knowledge on pancreatic 
cancer. This new field of science can begin to investigate the role of various nutrients on 
mechanisms that may influence the etiology or progression of pancreatic cancer.  
3. Epigenetic mechanisms 
Epigenetic modifications can be altered by external or internal environmental factors, such 
as diets, and has the potential to also be reversed (23,24). Epigenetic mechanisms include 
DNA methylation, histone modifications, and changes in microRNAs (25-28). These 
mechanisms can lead to changes in gene expression and have been the focus of a  
number of diseases including cancer, type 2 diseases, obesity, cardiovascular diseases, 
neurodegenerative diseases and immune diseases (29-33). Tumors can exhibit widespread 
global DNA hypomethylation, region-specific hypermethylation and increased activities of 
the DNA methyltransferases. DNA methylation modification is established and maintained 
by a family of DNA methyltransferases (DNMTs), DNMT1, DNMT3a and DNMT3b (34,35). 
These enzymes catalyze the transfer of methyl groups from S-adenosylmethionine (SAM) to 
cytosine residues in the DNA. These critical enzymes have been shown to be highly expressed 
in pancreatic cancer and play critical roles in silencing important genes, such as p16, RASSFIA, 
cyclin D2, APC and others through promoter hypermethylation in various cellular pathways 
(36-38). Approximately 60% of human genes are associated with CpG islands that are subject 
to methylation in tissue specific patterns; however, these islands have been shown to increase 
their methylation status during aging and the development of certain diseases such as cancer 
(39,40). Several of the classic tumor suppressor genes, such as p16/CDKN1A, p53, SMAD4 
and STKll, have been genetically inactivated through DNA methylation in pancreatic cancer. 
hMLH1, which is associated with microsatellite instability, has been also shown to undergo 
methylation in pancreatic cancer (41,42). Several other genes with tumor suppressor properties 
have also been associated with pancreatic cancer (43).   
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Although much of the focus of cancer epigenetics is on inactivation of tumor suppressor 
genes by promoter methylation, the earliest observation of altered methylation patterns 
identified DNA hypomethylation as an important event in the etiology of cancer (44-46). 
Global DNA hypomethylation was first associated with the lack of critical nutrients such as 
methonine, folate, and vitamin B12 (47-49). These observations raised the importance of 
nutritional causes of methyl group deficiency and its association with the tumorigenesis. 
DNA hypomethylation is often associated with gene overexpression or gene activation. 
Nutrients deficiency can, therefore, influence the methylation status of an individual and 
increase their susceptibility to diseases such as pancreatic cancer. Given the role of the 
pancreas in digestion and absorption, diet may play a larger role in pancreatic disease and 
prevention.   
In addition to DNA methylation, histone modification has also been implicated in pancreatic 
cancer, particularly genes of the mucin family (50-52). These genes have been found to 
undergo histone modifications in pancreatic cancers (53,54). Mucin gene products are high 
molecular weight glycoproteins that are produced by pancreatic cancers. MUC1, MUC2 and 
MUC3 histone modifications have been investigated and their role in pancreatic cancer is 
described in relation to nutrigenomics (55,56). MUC1 in normal pancreas is the main 
membrane-bound mucin expressed. MUC1 has been used as a marker of pancreatic ductal 
cells. MUCs are known to play important roles in protection and epithelial repair in the 
intestinal mucosal (57). MUC2 is absent or weakly expressed in ductal and acinar cells in 
normal pancreas. MUC2 has been shown to demonstrate tumor suppressor properties (58). 
However, in pancreatic cancer there is an altered expression pattern of mucins at different 
stages of pancreatic tumor progression (59). MUC1 gene expression is regulated by a 
combination of DNA methylation and histone H3-K9 modification (60).  
4. Nutrigenomics and epigenetic regulation of signaling pathways 
The past decades have focused mainly on research involving genetic alterations or genetic 
susceptibility due to germline mutations (61-64). Mutated KRAS has high mutation 
prevalence in pancreatic cancer, reaching as much as 100% in advanced stages of the disease 
(65,66). However, dietary agents such as high fat diets have been shown to increase KRAS 
expression ( 67-69 ), while other studies have shown decreased expression with caloric 
restriction (70,71) and intake of bioactive components found in some vegetables and fruits ( 
72-75). Using global genomic screening, 12 altered core signaling pathways due to mutations 
have been found in pancreatic cancer (76). In addition to widespread genetic alterations, it is 
now apparent that epigenetic factors also play an important role in modulating a number of 
these signaling pathways in pancreatic cancer (77). Regulation of specific genes in a subset 
of regulatory pathways has been identified to be disrupted in pancreatic cancer and 
modulated by dietary agents (78). These pathways involve apoptosis, DNA damage control, 
K-ras signaling, JNK signalings, invasion, Hedgehog signaling, Wnt-Notch signaling, TGF-ß, 
and regulation of the G1/S phase transition (79-81). The dietary agent curumin, a yellow 
spice found in both turmeric and curry powder, inhibits JNK, COX2, NF-kappaB, STAT3 
and AP-1 activation (82) through epigenetic mechanisms. The Wnt-Notch signaling 
pathway, which is altered in pancreatic cancer, control key biological processes that impact 
tumor progression and patient survival. Epigenetic inactivation of key components, such as 
the secreted frizzed-repeated protein (SERP1), in this pathway can lead to constitutively 
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because of its contribution to obesity. Nutrients are thought to be dietary signals that can be 
detected by various cellular systems involved in regulating gene and protein expressions, as 
well as affecting the production of metabolites (16,17). Therefore, each individual can 
establish dietary signatures in specific cells, tissues or organs according to their daily diets, 
which could utlimately influence homeostasis and their susceptibility to diseases, such as 
cancer. Studying the effects of nutrients at the genomic level can be through genetic or 
epigenetic mechanisms. This chapter focuses on the role of epigenetic mechanisms in 
pancreatic cancer and their modulation through dietary agents found in daily food intake. 
The influence of bioactive components in foods on various biological and physiological 
functions at the genomic level is a vastly unexplored area of research in cancer research. 
Dietary components are beginning to be observed as major determinants of cancer risk in 
humans (18-22). Nutrition can potentially modify, through epigenetic mechanisms 
molecular changes associated with carcinogenesis. Furthermore, employing this new science 
in understanding how bioactive components can affect the constant insults from external 
and internal factors to DNA, which results in chromatin changes, alteration in DNA repair, 
apoptosis and inflammation epigenetically will enhance our knowledge on pancreatic 
cancer. This new field of science can begin to investigate the role of various nutrients on 
mechanisms that may influence the etiology or progression of pancreatic cancer.  
3. Epigenetic mechanisms 
Epigenetic modifications can be altered by external or internal environmental factors, such 
as diets, and has the potential to also be reversed (23,24). Epigenetic mechanisms include 
DNA methylation, histone modifications, and changes in microRNAs (25-28). These 
mechanisms can lead to changes in gene expression and have been the focus of a  
number of diseases including cancer, type 2 diseases, obesity, cardiovascular diseases, 
neurodegenerative diseases and immune diseases (29-33). Tumors can exhibit widespread 
global DNA hypomethylation, region-specific hypermethylation and increased activities of 
the DNA methyltransferases. DNA methylation modification is established and maintained 
by a family of DNA methyltransferases (DNMTs), DNMT1, DNMT3a and DNMT3b (34,35). 
These enzymes catalyze the transfer of methyl groups from S-adenosylmethionine (SAM) to 
cytosine residues in the DNA. These critical enzymes have been shown to be highly expressed 
in pancreatic cancer and play critical roles in silencing important genes, such as p16, RASSFIA, 
cyclin D2, APC and others through promoter hypermethylation in various cellular pathways 
(36-38). Approximately 60% of human genes are associated with CpG islands that are subject 
to methylation in tissue specific patterns; however, these islands have been shown to increase 
their methylation status during aging and the development of certain diseases such as cancer 
(39,40). Several of the classic tumor suppressor genes, such as p16/CDKN1A, p53, SMAD4 
and STKll, have been genetically inactivated through DNA methylation in pancreatic cancer. 
hMLH1, which is associated with microsatellite instability, has been also shown to undergo 
methylation in pancreatic cancer (41,42). Several other genes with tumor suppressor properties 
have also been associated with pancreatic cancer (43).   
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Although much of the focus of cancer epigenetics is on inactivation of tumor suppressor 
genes by promoter methylation, the earliest observation of altered methylation patterns 
identified DNA hypomethylation as an important event in the etiology of cancer (44-46). 
Global DNA hypomethylation was first associated with the lack of critical nutrients such as 
methonine, folate, and vitamin B12 (47-49). These observations raised the importance of 
nutritional causes of methyl group deficiency and its association with the tumorigenesis. 
DNA hypomethylation is often associated with gene overexpression or gene activation. 
Nutrients deficiency can, therefore, influence the methylation status of an individual and 
increase their susceptibility to diseases such as pancreatic cancer. Given the role of the 
pancreas in digestion and absorption, diet may play a larger role in pancreatic disease and 
prevention.   
In addition to DNA methylation, histone modification has also been implicated in pancreatic 
cancer, particularly genes of the mucin family (50-52). These genes have been found to 
undergo histone modifications in pancreatic cancers (53,54). Mucin gene products are high 
molecular weight glycoproteins that are produced by pancreatic cancers. MUC1, MUC2 and 
MUC3 histone modifications have been investigated and their role in pancreatic cancer is 
described in relation to nutrigenomics (55,56). MUC1 in normal pancreas is the main 
membrane-bound mucin expressed. MUC1 has been used as a marker of pancreatic ductal 
cells. MUCs are known to play important roles in protection and epithelial repair in the 
intestinal mucosal (57). MUC2 is absent or weakly expressed in ductal and acinar cells in 
normal pancreas. MUC2 has been shown to demonstrate tumor suppressor properties (58). 
However, in pancreatic cancer there is an altered expression pattern of mucins at different 
stages of pancreatic tumor progression (59). MUC1 gene expression is regulated by a 
combination of DNA methylation and histone H3-K9 modification (60).  
4. Nutrigenomics and epigenetic regulation of signaling pathways 
The past decades have focused mainly on research involving genetic alterations or genetic 
susceptibility due to germline mutations (61-64). Mutated KRAS has high mutation 
prevalence in pancreatic cancer, reaching as much as 100% in advanced stages of the disease 
(65,66). However, dietary agents such as high fat diets have been shown to increase KRAS 
expression ( 67-69 ), while other studies have shown decreased expression with caloric 
restriction (70,71) and intake of bioactive components found in some vegetables and fruits ( 
72-75). Using global genomic screening, 12 altered core signaling pathways due to mutations 
have been found in pancreatic cancer (76). In addition to widespread genetic alterations, it is 
now apparent that epigenetic factors also play an important role in modulating a number of 
these signaling pathways in pancreatic cancer (77). Regulation of specific genes in a subset 
of regulatory pathways has been identified to be disrupted in pancreatic cancer and 
modulated by dietary agents (78). These pathways involve apoptosis, DNA damage control, 
K-ras signaling, JNK signalings, invasion, Hedgehog signaling, Wnt-Notch signaling, TGF-ß, 
and regulation of the G1/S phase transition (79-81). The dietary agent curumin, a yellow 
spice found in both turmeric and curry powder, inhibits JNK, COX2, NF-kappaB, STAT3 
and AP-1 activation (82) through epigenetic mechanisms. The Wnt-Notch signaling 
pathway, which is altered in pancreatic cancer, control key biological processes that impact 
tumor progression and patient survival. Epigenetic inactivation of key components, such as 
the secreted frizzed-repeated protein (SERP1), in this pathway can lead to constitutively 
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activation of this pathway (83). EGCG, a component found in green tea extract, induces 
apoptosis and inhibits JNK signal pathway in pancreatic cancer (84,85). Inactivation of the 
human Runt-related transcription factor 3 (RUNX3), which play a role in TGF-ß signaling, 
decreases TGF-ß expression in pancreatic cancer (86). TGF-ß has been shown to be a potent 
inhibitor of pancreatic cancer cells in vitro (87). Recent data revealed the inactivation of the 
Hh-interaction protein (HHIP) through promoter hypermethylation in pancreatic cancer 
cells in vitro. HHIP is a negative regulator of the Hedgehog signaling pathway which is up-
regulated in pancreatic cancer (88). The Hedgehog signaling pathway has been highly 
conserved through evolution and plays a crucial role during embryonic development (89). 
Dietary agents have been shown to modulate homologus of this pathway (90). In humans, 
there are three different homologues of the pathway, Sonic Hedgehog (Shh), Indian 
Hedgehog (IH) and the Desert Hedgehog (Dhh). Epigenetic mechanisms involve altered 
gene expression without changes in genomic sequences, thus these mechanisms can alter the 
above pathways through many factors, such as diet and life-style factors (e.g., smoking). 
5. Dietary nutrients, obesity and caloric restriction 
In the nutritional field, epigenetics is important because nutrients and bioactive food 
components can modify the expression of genes at the transcriptional level (91-93). There is 
a critical lack of research examining the role of critical nutrients on the etiology of cancers 
such as pancreatic cancer, although animals studies have indicated its role in cancer 
development for a number of years (94,95). However, to critically examine an individual’s 
nutrients intake will require improvement over the current 24-hour recall survey often used 
in dietary studies.   
Deficiency in proper nutrients, critical micronutrients and increase in high fat-diets or high 
caloric intake have been implicated in a number of diseases, including cancers, such as 
pancreatic cancer (96,97). The relationship between food, nutrition science and diseases such 
as cancer through epidemological studies have been analyzed for a number of years. 
However, the genomic variation among individuals and populations remains an unexplored 
area of research, which can enhance our knowledge in understanding complex diseases such 
as pancreatic cancer and its impact on the etiology and progression of this disease. The 
genomic era has ushered in a new science called “nutriogenomic” to began to understand 
the importance of nutrition on complex diseases such as pancreatic cancer, in which the 
disease presents little or no early symptoms for early detection or diagnosis. Obesity is a risk 
factor for pancreatic cancer in certain populations (98). Understanding these interactions 
will provide critical information for understanding how the health consequences of eating 
behaviors may vary across individuals or different ethnic groups. Although the survival rate 
of pancreatic cancer has slightly improved, African Americans continue to have the highest 
incidence rate of pancreatic cancer than any other ethnic groups (99). Eating behaviors and 
types of diets in this group as it relates to its effects on changes in the genome related to 
diseases such as cancer, remains an unexplored area of research. Bioactive components in 
foods can act on the human genome directly or indirectly to affect gene expression or their 
gene products. This new research area “nutrigenomics”, in relation to pancreatic cancer, can 
ultimately identify molecular targets for nutritional intervention.   
Numerous dietary components are known to alter epigenetic events, and thus can influence 
the health of individuals. Folic acid and vitamin B12 play an important role in DNA 
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metabolism and are required for the Synthesis of Methionine and S-adenosylmethionine 
(SAM), the common methyl donor required for the maintenance of DNA methylation 
patterns (100). Essential and non-essential nutrients or bioactive components have been 
shown to modulated and number of cellular processes through epigenetic mechanisms 
involved in carcinogen metabolism, cell signaling, cell cycle control, apoptosis, hormonal 
balance and angiogenesis (101).   
Epidemiological evidence and the relation of nutrition and pancreatic cancer has been 
extensively reviewed (102). However, a number of these studies have included descriptive, 
case-control and often cohort studies, all showing a consistent pattern of positive association 
with nutrition and recently, research data showing correlation with increase pancreatic 
cancer and obesity (103). Some current studies have confirmed our early studies showing 
decreased rates of pancreatic cancer with caloric restriction (104). We reported this finding 
in the mid-90s and demonstrated that it occurred through DNA methylation, an epigenetic 
mechanism. Case-control studies have shown a correlation between caloric intake and 
higher risk of pancreatic cancer in African American and identified obesity as a risk factor 
for pancreatic cancer (105). Obesity during pregnancy and high-fat maternal diets have been 
shown to be associated with obesity in offsprings suggesting early imprinting (106). Studies 
are needed to address the specific nutrients or fats that may modulate gene expression 
through epigenetic mechanisms. Epigenetic biomarkers of obesity that have been identified 
include epigenetic regulation of genes involved in adipogenesis (SOCS1/SOCS3), 
methylation patterns of obesity-related genes (FGF2, PTEN, CDKN1A and ESR1), 
inflammation genes as well as genes involved in intermediary Metabolism and insulin 
signaling (107).  
The degree of methylation can be determined by the availability of methyl donors, methyl 
transferase activity, and also demethylation activity. Studies have shown that chronic 
administration of methionine- and choline-deficients diets results in global hypomethylation 
of hepatic DNA and development of spontaneous tumor formation (108). In those studies 
when the pancreas was examined in the methionine- and choline-deficients diets, a 
transdifferentiated (hepatocyte-like) phenotype was observed (109). The progentic of these 
cells have now been identified as pancreatic stem cells (PSCs) that are capable of producing 
cells with multiple markers of other non-pancreatic organs (110). The fact that pancreatic 
cancer contains tumorigenic cancer stem cells and are highly resistant to chemotherapy and 
can be induced by a lack of micronutrients strongly suggest this area of research greatly 
needs exploring. Research using nutrigenomics can address the importance of tumorigenic 
cancer stem cells in pancreatic cancer.  
6. DNA methylation and nutrigenomics 
Bioactive food components have been shown to have benefical effects on the genome 
through epigenetic mechanisms. Certain bioactive components, such as tea polyphenols, 
genistein from soybeans, and isothiocyanates from plant food, may have inhibitory effect on 
certain cancer, including pancreatic cancer. Dietary polyphenols is thought to have a direct 
inhibition by interaction with the catalytic site of the DMNT1 or it could have an influence 
on the methylation status indirectly. A number of cultured cells, animal models and human 
clinical trials have shown the protective role of dietary polyphenols against a number of 
cancers, including pancreatic cancer (111). However, understanding the timing of 
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cells in vitro. HHIP is a negative regulator of the Hedgehog signaling pathway which is up-
regulated in pancreatic cancer (88). The Hedgehog signaling pathway has been highly 
conserved through evolution and plays a crucial role during embryonic development (89). 
Dietary agents have been shown to modulate homologus of this pathway (90). In humans, 
there are three different homologues of the pathway, Sonic Hedgehog (Shh), Indian 
Hedgehog (IH) and the Desert Hedgehog (Dhh). Epigenetic mechanisms involve altered 
gene expression without changes in genomic sequences, thus these mechanisms can alter the 
above pathways through many factors, such as diet and life-style factors (e.g., smoking). 
5. Dietary nutrients, obesity and caloric restriction 
In the nutritional field, epigenetics is important because nutrients and bioactive food 
components can modify the expression of genes at the transcriptional level (91-93). There is 
a critical lack of research examining the role of critical nutrients on the etiology of cancers 
such as pancreatic cancer, although animals studies have indicated its role in cancer 
development for a number of years (94,95). However, to critically examine an individual’s 
nutrients intake will require improvement over the current 24-hour recall survey often used 
in dietary studies.   
Deficiency in proper nutrients, critical micronutrients and increase in high fat-diets or high 
caloric intake have been implicated in a number of diseases, including cancers, such as 
pancreatic cancer (96,97). The relationship between food, nutrition science and diseases such 
as cancer through epidemological studies have been analyzed for a number of years. 
However, the genomic variation among individuals and populations remains an unexplored 
area of research, which can enhance our knowledge in understanding complex diseases such 
as pancreatic cancer and its impact on the etiology and progression of this disease. The 
genomic era has ushered in a new science called “nutriogenomic” to began to understand 
the importance of nutrition on complex diseases such as pancreatic cancer, in which the 
disease presents little or no early symptoms for early detection or diagnosis. Obesity is a risk 
factor for pancreatic cancer in certain populations (98). Understanding these interactions 
will provide critical information for understanding how the health consequences of eating 
behaviors may vary across individuals or different ethnic groups. Although the survival rate 
of pancreatic cancer has slightly improved, African Americans continue to have the highest 
incidence rate of pancreatic cancer than any other ethnic groups (99). Eating behaviors and 
types of diets in this group as it relates to its effects on changes in the genome related to 
diseases such as cancer, remains an unexplored area of research. Bioactive components in 
foods can act on the human genome directly or indirectly to affect gene expression or their 
gene products. This new research area “nutrigenomics”, in relation to pancreatic cancer, can 
ultimately identify molecular targets for nutritional intervention.   
Numerous dietary components are known to alter epigenetic events, and thus can influence 
the health of individuals. Folic acid and vitamin B12 play an important role in DNA 
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metabolism and are required for the Synthesis of Methionine and S-adenosylmethionine 
(SAM), the common methyl donor required for the maintenance of DNA methylation 
patterns (100). Essential and non-essential nutrients or bioactive components have been 
shown to modulated and number of cellular processes through epigenetic mechanisms 
involved in carcinogen metabolism, cell signaling, cell cycle control, apoptosis, hormonal 
balance and angiogenesis (101).   
Epidemiological evidence and the relation of nutrition and pancreatic cancer has been 
extensively reviewed (102). However, a number of these studies have included descriptive, 
case-control and often cohort studies, all showing a consistent pattern of positive association 
with nutrition and recently, research data showing correlation with increase pancreatic 
cancer and obesity (103). Some current studies have confirmed our early studies showing 
decreased rates of pancreatic cancer with caloric restriction (104). We reported this finding 
in the mid-90s and demonstrated that it occurred through DNA methylation, an epigenetic 
mechanism. Case-control studies have shown a correlation between caloric intake and 
higher risk of pancreatic cancer in African American and identified obesity as a risk factor 
for pancreatic cancer (105). Obesity during pregnancy and high-fat maternal diets have been 
shown to be associated with obesity in offsprings suggesting early imprinting (106). Studies 
are needed to address the specific nutrients or fats that may modulate gene expression 
through epigenetic mechanisms. Epigenetic biomarkers of obesity that have been identified 
include epigenetic regulation of genes involved in adipogenesis (SOCS1/SOCS3), 
methylation patterns of obesity-related genes (FGF2, PTEN, CDKN1A and ESR1), 
inflammation genes as well as genes involved in intermediary Metabolism and insulin 
signaling (107).  
The degree of methylation can be determined by the availability of methyl donors, methyl 
transferase activity, and also demethylation activity. Studies have shown that chronic 
administration of methionine- and choline-deficients diets results in global hypomethylation 
of hepatic DNA and development of spontaneous tumor formation (108). In those studies 
when the pancreas was examined in the methionine- and choline-deficients diets, a 
transdifferentiated (hepatocyte-like) phenotype was observed (109). The progentic of these 
cells have now been identified as pancreatic stem cells (PSCs) that are capable of producing 
cells with multiple markers of other non-pancreatic organs (110). The fact that pancreatic 
cancer contains tumorigenic cancer stem cells and are highly resistant to chemotherapy and 
can be induced by a lack of micronutrients strongly suggest this area of research greatly 
needs exploring. Research using nutrigenomics can address the importance of tumorigenic 
cancer stem cells in pancreatic cancer.  
6. DNA methylation and nutrigenomics 
Bioactive food components have been shown to have benefical effects on the genome 
through epigenetic mechanisms. Certain bioactive components, such as tea polyphenols, 
genistein from soybeans, and isothiocyanates from plant food, may have inhibitory effect on 
certain cancer, including pancreatic cancer. Dietary polyphenols is thought to have a direct 
inhibition by interaction with the catalytic site of the DMNT1 or it could have an influence 
on the methylation status indirectly. A number of cultured cells, animal models and human 
clinical trials have shown the protective role of dietary polyphenols against a number of 
cancers, including pancreatic cancer (111). However, understanding the timing of 
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intervention is critical in cancer prevention, particularly for an aggressive cancer such as 
pancreatic cancer which lacks early biomarkers of detection. Epigenetic mechanisms are 
thought to play an early role in pancreatic cancer, such as inactivation of tumor suppression 
genes through hypermethylation of CpG islands in promoter regions of genes. Reversal of 
gene hypermethylation has been achieved by inhibiting DNMT activity in cancer cells. A 
number of studies are showing inhibition of DNMT activity with dietary components. We 
have shown reactivation of p16 in pancreatic cancer cells through DNA hypomethylation 
with the dietary agent indole-3-carbinol. Recently our laboratory has also shown that indole-
3-carbinol can greatly enhance the efficacy of gemcitabine, which is the first line treatment 
for pancreatic cancer (112).   
Epigallocatechin-3-gallate (EGCG) one the major components of green tea has been shown 
to be an effective DNMT1 inhibitor directly. Thus, activation of tumor suppression genes 
p16, RAR, MGMT and MLH1 have been demonstrated by EGCG. In addition, the protected 
effects associated with consumption of fruits and vegetables and various chemical 
components in pancreatic cancer have demonstrated various effects on pancreatic cancer 
cells, such as induction of apoptosis, inhibition of proliferation, inhibition of transcription 
factors, activation of suppressor genes and inhibiting K-ras signaling through epigenetic 
mechanisms (113). Modulation of these critical events by dietary factors through epigenetic 
changes is an important area of research that is needed in clinical trials with or without 
association with current chemotherapeutic agents. Table 1 shows a list of dietary factors 
know to regulate DNA methylation.  
 
Bioactive Component  
 Coumestrol  
 Methionine  
 Genistein  
 Vitamin B12   
 EGCG 
  Indole-3-Carbinol 





Table 1. Bioactive Components of Food that Influence DNA Methylation in Pancreatic 
Cancer 
7. Histone modifications and nutrigenomics 
Another epigenetic mechanisms that has been shown to be modulated by bioactive 
components in foods are histone modifications. Histones, which are the structural 
component of chromatin, are modified by methylation, acetylation, phosphorylation, 
biotinylation, ubiquitination, sumoylation, and ADP-ribosylation (114). Diverse histone 
modification is known to play an important role in gene regulation and tumorigenesis. The 
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modification involving epigenetic mechanisms occurs at the histone tails, that usually 
consist of about 15-38 amino acids. Majority of the modifications takes place at lysines, 
arginine and serine residues. These modifications can lead to either activation or repression 
depending on which resides are modified. Lysines residues in the tails can be either 
methylated or acetylated. Usually histone modification status is often balanced by a group 
of enzymes called histone acetyltransferases (HATs) and histone methyltransferases (HATs) 
which add acetyl and methyl groups; and histone deacetylases (HDACs) and histone 
demethylases (HDMs) which remove acetyl and methyl groups from histone protiens. 
Histone methylation is maintained by histone methyltransferases and histone demethylases. 
Histone acetylation results in an “open” chromatin structure thus allowing access to DNA 
and gene transcription. Acetylation of N-terminal lysine residues at positions 9,14,18, and 23 
of H3 and 5, 8,12, of H4 mediates the decondensation of the chromatin for accessibility to 
transcription factors. Histone acetylation is one the most extensively studied histone 
modification. Deacetylation is often associated with silencing of gene expression. Dietary 
agents have been identified that have structural features similar to the HDAC inhibitors 
(115,116). HDAC inhibitors are known to reactivate epigenetically silenced genes.   
Bioactive components have been found to act as HDAC inhibitors, such as butyrate, 
sulforophane, curcumin, resveratrol and diallyl disulphide. Butyrate, a short-chain fatty acid 
formed from the fermentation of fibre when consumed has been shown to downregulate 
transcription factors such as Sp1 and Sp2, which have been reported to be acetylated targets 
for HDAC1 and HDAC2 (117). This effect has been shown to increased p21 expression 
which will ultimately cause cell cycle arrest and an increase in Bax expression thus causing 
apoptosis. In pancreatic cancer cells sodium butyrate has been shown to sensitize these cells 
to Fas-mediated apoptosis as well as down regulation of Bcl-xL expression and apoptosis. 
Further research is needed to understand the role of dietary agents on histone modifications 
in pancreatic cancer. A number of studies have shown dietary agents such as curcumin, 
anacardic acid, garcinol, polyphenols, isothiocyanates, isoflavone and resveratrol to affect 
histone modifications. Resveratrol, a bioactive component of grape skins, exert its anti-
inflammatory effect through repression of NF-κB induced by histone deacetylation (118).  





 Diallyl disulphide 
 Anarcardic acid 
 Garcinol 
 Polyphenols 
Table 2. Bioactive Components of Food that Influence Histone Modification in Pancreatic 
Cancer 
In addition to bioactive nutrients modulating histone modifications, studies have also 
shown that caloric restriction, another unexplored area of research on epigenetics, reduces 
the expression of inflammatory genes such as NF-κB, AP1, COX-2, and iNOS (119). 
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of enzymes called histone acetyltransferases (HATs) and histone methyltransferases (HATs) 
which add acetyl and methyl groups; and histone deacetylases (HDACs) and histone 
demethylases (HDMs) which remove acetyl and methyl groups from histone protiens. 
Histone methylation is maintained by histone methyltransferases and histone demethylases. 
Histone acetylation results in an “open” chromatin structure thus allowing access to DNA 
and gene transcription. Acetylation of N-terminal lysine residues at positions 9,14,18, and 23 
of H3 and 5, 8,12, of H4 mediates the decondensation of the chromatin for accessibility to 
transcription factors. Histone acetylation is one the most extensively studied histone 
modification. Deacetylation is often associated with silencing of gene expression. Dietary 
agents have been identified that have structural features similar to the HDAC inhibitors 
(115,116). HDAC inhibitors are known to reactivate epigenetically silenced genes.   
Bioactive components have been found to act as HDAC inhibitors, such as butyrate, 
sulforophane, curcumin, resveratrol and diallyl disulphide. Butyrate, a short-chain fatty acid 
formed from the fermentation of fibre when consumed has been shown to downregulate 
transcription factors such as Sp1 and Sp2, which have been reported to be acetylated targets 
for HDAC1 and HDAC2 (117). This effect has been shown to increased p21 expression 
which will ultimately cause cell cycle arrest and an increase in Bax expression thus causing 
apoptosis. In pancreatic cancer cells sodium butyrate has been shown to sensitize these cells 
to Fas-mediated apoptosis as well as down regulation of Bcl-xL expression and apoptosis. 
Further research is needed to understand the role of dietary agents on histone modifications 
in pancreatic cancer. A number of studies have shown dietary agents such as curcumin, 
anacardic acid, garcinol, polyphenols, isothiocyanates, isoflavone and resveratrol to affect 
histone modifications. Resveratrol, a bioactive component of grape skins, exert its anti-
inflammatory effect through repression of NF-κB induced by histone deacetylation (118).  
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Table 2. Bioactive Components of Food that Influence Histone Modification in Pancreatic 
Cancer 
In addition to bioactive nutrients modulating histone modifications, studies have also 
shown that caloric restriction, another unexplored area of research on epigenetics, reduces 
the expression of inflammatory genes such as NF-κB, AP1, COX-2, and iNOS (119). 
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Reduction in total caloric intake has numerous health benefits, including reducing risk to 
certain cancers such as pancreatic cancer ( ).NF-κB is known to be activated by histone 
aceylation. Activation of NF-κB occurs through p300 HAT acetylation of the p50 subunit of 
NF-κB. This increases NF-κB binding and transactivation. Caloric restriction modulation of 
these pathways through epigenetics mechanisms allows numerous opportunities for 
prevention of diseases such as cancer.   
8. microRNAs and nutrigenomics 
In addition to DNA methylation and histone modification, another epigenetic mechanism, 
microRNAs is emerging as a key mediator in gene regulation which may be affected by 
bioactive dietary components. These small single-stranded RNAs, ~19-24 nucleotides in 
length, regulate gene expression through post-transcriptional silencing of targeted genes. 
MicroRNAs can play important roles in controlling both DNA methylation and histone 
modifications. This regulation creates a highly controlled feedback mechanism. In contrast, 
promoter methylation or histone acetylation can also modulate microRNA expression (120). 
Usually microRNAs can control a wide spectrum of biological function that may be relevant 
in cancer, such as cell proliferation, apoptosis, and differentiation. Aberrant expression of 
these small nucleotides have been associated with cancer. Several microRNAs have been 
identified that are regulated by DNA methylation in pancreatic cancers (121). Noncoding 
RNA and miRNAs are known to be involved in post-transcriptional gene silencing. Methyl-
deficient diets and folate deficiency induce global increase in microRNA expression in some 
cancers.The relevance of microRNA and nutrigenomics is a greatly unexplored area of 
research as it relates to pancreatic cancer. However, curcumin has been linked to changes in 
microRNA expression in pancreatic cancer cell lines. Curcumin represses human pancreatic 
cancer cells by upregulating miR-22 and downregulating miR-199a. MicroRNA-10a 
expression, which has been identified as a mediator of metastatic in pancreatic cancer, is 
repressed by retinoic acid receptor antagonists (122,123).  




Table 3. Bioactive Components of Food that Influence microRNAs in Pancreatic Cancer 
9. Conclusion 
Finally, understanding the role of nutrigenomics on pancreatic cancer etiology through 
epigenetic mechanisms could have a tremendous impact on decreasing the mortality of this 
disease. The beneficial aspects of various nutritional bioactive components and their effects 
on inhibiting or decreasing pancreatic cancer could also enhance the efficacy of current 
therapeutics used in treating pancreatic cancer. Understanding the role of nutrigenomics 
and its impact on modulating epigenetic mechanisms such DNA methylation, histone 
modification and microRNAs in pancreatic cancer will greatly enhance intervention or 
prevention stagergy for this disease. Our knowledge in the field of this emerging science is 
currently very limited, but the potential is vast in understanding the role of various 
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nutrients on the genome and its ability to contribute to healthy life-style, thus decreasing 
individuals risk to diseases such as cancer. Although intake of some dietary components 
may not improve health, research in this field will identify the interaction of these 
components with various macromolecules in the cell that are not Benefical. The study of 
nutrigenomics could identify molecular targets for nutritional preemption and information 
obtained from these studies are key to personalized nutrition. 
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1. Introduction 
Molecular genetic analyses have provided evidence that has helped characterize the 
carcinogenesis of pancreatic adenocarcinoma. Pancreatic carcinogenesis is a multistep 
process during which oncogenes are activated, and the function of tumor suppressor genes 
is lost. K-ras mutations, telomere shortening, loss of p16, loss of p53 and loss of smad4 are 
thought to contribute to pancreatic carcinogenesis. Recent studies have shown that some 
new signaling pathway contribute to pancreatic cancer development. Because the model of 
pancreatic cancer development suggests that several genetic alterations accumulate 
progressively, the molecular mechanisms underlying this disease should be investigated 
thoroughly. In addition, we have considered of the appearance of epigenetic and microRNA 
abnormalities in creating a profile of the molecular genetic mechanisms at work in 
pancreatic cancer carcinogenesis. 
This chapter provides an overview of the most relevant molecular genetic alterations that 
have been implicated in pancreatic cancer development and includes the characterization of 
the development of precancerous lesions and invasive carcinoma. 
2. Molecular genetics understanding of pathway in pancreatic cancer 
2.1 Alterations in oncogenes  
Many gene mutations have been implicated in the molecular mechanisms of pancreatic 
cancer formation. In this section, we focus on the oncogenic gene mutations that have been 
linked to pancreatic cancer. 
2.1.1 K-ras 
The most frequent genetic abnormality in invasive pancreatic cancer is mutation of the 
activating K-ras oncogene, which occurs in 75-90% of pancreatic cancers (Ji et al., 2009). K-
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ras is a member of the Ras gene family, which is located on chromosome 12p and encodes a 
21-kDa membrane-bound GTP-binding protein. This GTP-binding protein mediates various 
cellular functions, such as proliferation, cellular survival, motility, and cytoskeletal 
remodeling. The K-ras activating mutations abolish the regulated GTPase activity of the K-ras 
protein, which converts the Ras protein to the ‘on’ state and permanently activates 
downstream signaling events that may contribute to carcinogenesis. K-ras is activated by point 
mutations, most often in codon 12 but also in codons 13 and 61 (Jones et al., 2008). The role of 
H-ras, another member of the Ras family, in carcinogenesis is not as well characterized, but it 
has been reported that H-ras is responsible for mediating the growth-promoting effects in 
pancreatic cancer cells that possess K-ras mutations (Seufferlein et al., 1999).  
The critical role of Ras signaling in pancreatic cancer has been confirmed by many 
experimental studies. The mutations in the K-ras gene are observed in the earliest form of 
pancreatic intraepithelial neoplasia (PanIN) lesions and are considered to be one of the 
earliest genetic events to take place during pancreatic tumorigenesis (Jones et al., 2008; Tada 
et al., 1996). However, the hyperactivation of the Ras signaling cascade alone is neither 
sufficient for the malignant transformation nor restricted to malignant pancreatic cells. 
Instead, Ras hyperactivation may be combined with many genetic abnormalities and 
signaling pathways to promote pancreatic cancer development. Moreover, K-ras mutations 
were also detected in nearly 25% of chronic pancreatitis patients and even in healthy elderly 
subjects (Guerra et al., 2007). 
Until now, several studies have focused on K-ras as a therapeutic target and have worked to 
develop treatments, such as antisense therapy and RNA interference. In a phase II trial of 
patients with locally advanced and metastatic pancreatic cancers, the Ras family antisense 
inhibitor showed a response rate of 10.4% and a median survival of 6.6 months when the 
therapy was combined with gemcitabine treatment (Alberts et al., 2004). RNA interference 
technology is highly specific, but it has not yet entered the clinical trial stage. However, in 
vitro and in vivo studies have provided promising results for the use of RNAi as a pancreatic 
cancer therapy (Rejiba et al., 2007). 
2.1.2 The PI3K/AKT pathway 
The PI3K-AKT pathway is one of several signaling pathways that function downstream of 
K-ras, and it is also activated by mutations during carcinogenesis. AKT proteins are 
activated through PI3K in response to mitogenic stimulation, such as the activation of EGFR. 
Several downstream targets, including the mammalian target of rapamycin (mTOR) and the 
transcription factor NFκB, have a variety of roles in cell proliferation, survival, resistance to 
apoptosis, angiogenesis and invasion (Schneider & Wolf, 2009). 
AKT is amplified and the PI3K–AKT pathway is activated in 20% and 59% of pancreatic 
cancers, respectively (Schlieman et al., 2003). The amplification of AKT2 genes are also 
observed in 10% to 20% of pancreatic cancers, and its suppression by antisense RNA results 
in the reduced growth and tumorigenicity of pancreatic cancer cell lines (Cheng et al., 1996). 
Inhibition of this pathway through aberrant expression of PTEN (phosphatase and tensin 
homolog), which is a natural antagonist of PI3K, is frequently observed in pancreatic cancers 
(Asano et al., 2004). Furthermore, an architectural transcription factor, HMGA1, activates 
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PI3K–AKT signaling and appears to mediate resistance to gemcitabine. Together, these 
observations suggest that this gene is another potential target for inhibition therapy(Kim & 
Gallick, 2008; Liau & Whang, 2008). Other agents, including everolimus and sirolimus, are 
currently in phase II clinical trials (Azzariti et al., 2008). Furthermore, PTEN has also been 
described as a target for treating human pancreatic cancer. 
2.1.3 EGF receptor 
The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein receptor 
with an intracellular tyrosine kinase domain. Once bound to its ligands, the protein forms 
homodimers or heterodimers with other members of the ErbB family, which leads to the 
phosphorylation of tyrosine residues in its intracellular domain. Intracellular proteins were 
subsequently activated, which induce downstream signaling events through the PI3K–AKT 
family, STAT family, and, most notably, the MAPK signaling pathway. STAT proteins have 
roles in cell proliferation, survival, motility, invasion and adhesion. The mechanisms that 
lead to inappropriate activation of EGFR include receptor overexpression, activating 
mutations, overexpression of receptor ligands, and/or the loss of negative regulatory 
pathways. The overexpression of EGFR and its ligands (EGF and others) and/or the loss of 
the mechanisms that down-regulate the activity are frequently observed in pancreatic cancer 
(Bloomston et al., 2006; Preis & Korc, 2010). 
A phase III trial that combines gemcitabine and erlotinib, an orally active small molecule 
that binds to the ATP-binding site of EGFR, has revealed a small but statistically significant 
increase in the survival of patients with advanced pancreatic cancer compared with 
gemcitabine treatment alone (Moore et al., 2007). 
2.1.4 IGF  
The insulin-like growth factor receptor (IGF-R) is structurally similar to the insulin receptor. 
Insulin-like growth factor-1 (IGF) exhibits structural homology to proinsulin and binds to 
IGF-R with high affinity and to the insulin receptor with a much lower affinity. Therefore, 
the insulin-receptor substrate is able to interact with many signaling molecules. These 
interactions facilitate the activation of multiple downstream signaling pathways, including 
the PI3K/AKT, MAPK, and JAK/STAT3 pathways, and result in anti-apoptosis and 
growth-stimulating effects. IGF and its receptors have been extensively studied in various 
cancers, such as colon, breast and prostate cancer (Moschos & Mantzoros, 2002). 
A large portion of the exocrine pancreas is exposed to high levels of insulin, which may act 
on the exocrine cells via a proxicrine mechanism to provide the pancreatic cancer cells a 
growth advantage. These high insulin levels can activate both the insulin and IGF receptors. 
IGF-R is overexpressed in 64% of pancreatic cancers (Moschos & Mantzoros, 2002). 
Together, these alterations may work in combination to further enhance cancer growth, 
indicating that IGF-R may be an important therapeutic target in pancreatic cancer. There are 
several IGF-1R-targeting agents that are currently being tested in clinical trials. The anti-
IGF-R monoclonal antibodies, AMG-479 and IMC-A12, are in Phase I/II studies, which are 
currently enrolling patients. Moreover, small molecule inhibitors of IGF-R, such as BMS-
754807, may provide an alternate approach for targeting this important pathway in 
pancreatic cancer treatment (Ma & Adjei, 2009). 
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ras is a member of the Ras gene family, which is located on chromosome 12p and encodes a 
21-kDa membrane-bound GTP-binding protein. This GTP-binding protein mediates various 
cellular functions, such as proliferation, cellular survival, motility, and cytoskeletal 
remodeling. The K-ras activating mutations abolish the regulated GTPase activity of the K-ras 
protein, which converts the Ras protein to the ‘on’ state and permanently activates 
downstream signaling events that may contribute to carcinogenesis. K-ras is activated by point 
mutations, most often in codon 12 but also in codons 13 and 61 (Jones et al., 2008). The role of 
H-ras, another member of the Ras family, in carcinogenesis is not as well characterized, but it 
has been reported that H-ras is responsible for mediating the growth-promoting effects in 
pancreatic cancer cells that possess K-ras mutations (Seufferlein et al., 1999).  
The critical role of Ras signaling in pancreatic cancer has been confirmed by many 
experimental studies. The mutations in the K-ras gene are observed in the earliest form of 
pancreatic intraepithelial neoplasia (PanIN) lesions and are considered to be one of the 
earliest genetic events to take place during pancreatic tumorigenesis (Jones et al., 2008; Tada 
et al., 1996). However, the hyperactivation of the Ras signaling cascade alone is neither 
sufficient for the malignant transformation nor restricted to malignant pancreatic cells. 
Instead, Ras hyperactivation may be combined with many genetic abnormalities and 
signaling pathways to promote pancreatic cancer development. Moreover, K-ras mutations 
were also detected in nearly 25% of chronic pancreatitis patients and even in healthy elderly 
subjects (Guerra et al., 2007). 
Until now, several studies have focused on K-ras as a therapeutic target and have worked to 
develop treatments, such as antisense therapy and RNA interference. In a phase II trial of 
patients with locally advanced and metastatic pancreatic cancers, the Ras family antisense 
inhibitor showed a response rate of 10.4% and a median survival of 6.6 months when the 
therapy was combined with gemcitabine treatment (Alberts et al., 2004). RNA interference 
technology is highly specific, but it has not yet entered the clinical trial stage. However, in 
vitro and in vivo studies have provided promising results for the use of RNAi as a pancreatic 
cancer therapy (Rejiba et al., 2007). 
2.1.2 The PI3K/AKT pathway 
The PI3K-AKT pathway is one of several signaling pathways that function downstream of 
K-ras, and it is also activated by mutations during carcinogenesis. AKT proteins are 
activated through PI3K in response to mitogenic stimulation, such as the activation of EGFR. 
Several downstream targets, including the mammalian target of rapamycin (mTOR) and the 
transcription factor NFκB, have a variety of roles in cell proliferation, survival, resistance to 
apoptosis, angiogenesis and invasion (Schneider & Wolf, 2009). 
AKT is amplified and the PI3K–AKT pathway is activated in 20% and 59% of pancreatic 
cancers, respectively (Schlieman et al., 2003). The amplification of AKT2 genes are also 
observed in 10% to 20% of pancreatic cancers, and its suppression by antisense RNA results 
in the reduced growth and tumorigenicity of pancreatic cancer cell lines (Cheng et al., 1996). 
Inhibition of this pathway through aberrant expression of PTEN (phosphatase and tensin 
homolog), which is a natural antagonist of PI3K, is frequently observed in pancreatic cancers 
(Asano et al., 2004). Furthermore, an architectural transcription factor, HMGA1, activates 
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PI3K–AKT signaling and appears to mediate resistance to gemcitabine. Together, these 
observations suggest that this gene is another potential target for inhibition therapy(Kim & 
Gallick, 2008; Liau & Whang, 2008). Other agents, including everolimus and sirolimus, are 
currently in phase II clinical trials (Azzariti et al., 2008). Furthermore, PTEN has also been 
described as a target for treating human pancreatic cancer. 
2.1.3 EGF receptor 
The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein receptor 
with an intracellular tyrosine kinase domain. Once bound to its ligands, the protein forms 
homodimers or heterodimers with other members of the ErbB family, which leads to the 
phosphorylation of tyrosine residues in its intracellular domain. Intracellular proteins were 
subsequently activated, which induce downstream signaling events through the PI3K–AKT 
family, STAT family, and, most notably, the MAPK signaling pathway. STAT proteins have 
roles in cell proliferation, survival, motility, invasion and adhesion. The mechanisms that 
lead to inappropriate activation of EGFR include receptor overexpression, activating 
mutations, overexpression of receptor ligands, and/or the loss of negative regulatory 
pathways. The overexpression of EGFR and its ligands (EGF and others) and/or the loss of 
the mechanisms that down-regulate the activity are frequently observed in pancreatic cancer 
(Bloomston et al., 2006; Preis & Korc, 2010). 
A phase III trial that combines gemcitabine and erlotinib, an orally active small molecule 
that binds to the ATP-binding site of EGFR, has revealed a small but statistically significant 
increase in the survival of patients with advanced pancreatic cancer compared with 
gemcitabine treatment alone (Moore et al., 2007). 
2.1.4 IGF  
The insulin-like growth factor receptor (IGF-R) is structurally similar to the insulin receptor. 
Insulin-like growth factor-1 (IGF) exhibits structural homology to proinsulin and binds to 
IGF-R with high affinity and to the insulin receptor with a much lower affinity. Therefore, 
the insulin-receptor substrate is able to interact with many signaling molecules. These 
interactions facilitate the activation of multiple downstream signaling pathways, including 
the PI3K/AKT, MAPK, and JAK/STAT3 pathways, and result in anti-apoptosis and 
growth-stimulating effects. IGF and its receptors have been extensively studied in various 
cancers, such as colon, breast and prostate cancer (Moschos & Mantzoros, 2002). 
A large portion of the exocrine pancreas is exposed to high levels of insulin, which may act 
on the exocrine cells via a proxicrine mechanism to provide the pancreatic cancer cells a 
growth advantage. These high insulin levels can activate both the insulin and IGF receptors. 
IGF-R is overexpressed in 64% of pancreatic cancers (Moschos & Mantzoros, 2002). 
Together, these alterations may work in combination to further enhance cancer growth, 
indicating that IGF-R may be an important therapeutic target in pancreatic cancer. There are 
several IGF-1R-targeting agents that are currently being tested in clinical trials. The anti-
IGF-R monoclonal antibodies, AMG-479 and IMC-A12, are in Phase I/II studies, which are 
currently enrolling patients. Moreover, small molecule inhibitors of IGF-R, such as BMS-
754807, may provide an alternate approach for targeting this important pathway in 
pancreatic cancer treatment (Ma & Adjei, 2009). 
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2.1.5 VEGF 
Tumor angiogenesis is essential for tumor growth and is largely mediated by the vascular 
endothelial growth factor (VEGF) family of proteins and receptors. VEGF is a glycoprotein 
that promotes endothelial cell survival, mitogenesis, migration, differentiation and vascular 
permeability. The upregulation of VEGF expression is stimulated by hypoxia and oncogenic 
proteins, such as Ras. In addition, growth factors, such as EGF, TGF-α, TGF-β, PDGF, and 
HIF, and cytokines, such as IL-1α and IL-6, can also upregulate the expression of VEGF. 
VEGF and its receptors are overexpressed in more than 90% of pancreatic cancers and are 
associated with increased microvessel density, tumor progression and poor prognosis (Seo 
et al., 2000).  
The importance of VEGF and its receptor pathway for the growth of pancreatic tumors was 
demonstrated in several studies with animal models. These studies showed that VEGF and 
its receptors are the targets of numerous ongoing clinical trails that are evaluating the 
efficacy of these treatments in pancreatic cancer (Seo et al., 2000). Several other trials are 
being conducted to examine bevacizumab in combination with other agents or treatment 
modalities for pancreatic cancer; however, this agent seems unlikely to confer sufficient 
benefit to justify licensing for this condition. It has been suggested that angiogenic inhibitors 
that target other non-VEGF pathways may be better able to gain access to the tumor 
environment than an antibody (Whipple & Korc, 2008). 
2.2 Tumor-suppressor genes and pathways  
Tumor suppressor genes inhibit cell proliferation and signaling pathways and induce 
apoptosis and support DNA repair systems, which are thought to be key events that 
suppress transformation during tumor carcinogenesis. However, these genes are subjected 
genetic alterations that reduce or eliminate their normal function. 
In pancreatic cancer, the frequently affected tumor suppressors include p53, APC, 
SMAD4/DPC4, p16INK4A and some additional candidate genes. The loss of these tumor-
suppressor genes may participate and dominate the signaling pathways in pancreatic tissue 
carcinogenesis. A summary of these and other tumor-suppressor genes that are altered in 
pancreatic cancer are discussed below. 
2.2.1 p16INK4A/retinoblastoma 
The loss of function of the p16 gene, due to mutation, deletion or promoter 
hypermethylation, occurs in 80-95% of sporadic pancreatic cancers, which is a higher rate 
than that reported in any other tumor type (Caldas et al., 1994; Rozenblum et al., 1997). The 
p16 locus is located on chromosome 9q21, and it regulates cell cycle progression by limiting 
Rb phosphorylation through inhibition of the cyclin D/CDK4/6 complexes (Serrano et al., 
1996). The inactivation of the pRb/p16 tumor-suppressor pathway may alter the activity of 
pRb, CDK4, and cyclin D to promote tumor development (Freeman et al., 2004). 
The loss of p16 alone or in combination with the activity of other oncogenes has a significant 
role in the formation of pancreatic precursor lesions and the development of pancreatic 
cancer. Immunohistochemical analyses revealed that the loss of p16 protein expression 
occurred in approximately 30% of PanIN-1A lesions, 55% of PanIN-1B lesions and PanIN-2 
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lesions, 71% of PanIN-3 lesions and 100% of PDAC (Real et al., 2008). Recently, Aguirre et al. 
found that p16 limits the malignant conversion of these PanIN lesions to ductal 
adenocarcinoma in activated KRAS-initiated PanIN formation, which suggested that p16 is 
not the earliest event but is an important event in the progression of pancreatic 
carcinogenesis (Aguirre et al., 2003). 
Clinical research has focused on the contribution of p16 in pancreatic cancer. It appears that 
p16 plays a significant role in pancreatic carcinogenesis and is an important diagnostic or 
therapeutic target. Rosty et al. proposed that the loss of the expression of the suppressor 
gene p16 was a major risk factor for the development of pancreatic cancer in patients with 
chronic pancreatitis (Rosty et al., 2003). DNA hypermethylation of p16 in pancreatic juice 
was demonstrated to be a valuable diagnostic marker to predict pancreatic cancer 
progression. However, further studies are needed to provide evidence for the clinical 
applications that target the p16 gene (Matsubayashi et al., 2006; Yan et al., 2005). 
2.2.2 p53 
The p53 locus, which is on the 17p13 chromosome, regulates the cell cycle by integrating 
numerous signals to control cell death (Rozenblum et al., 1997). The abrogation of p53 
activity through mutation occurs in more than 50% of sporadic pancreatic cancers. Wild-
type p53 maintains a G2-M arrest and regulates the G1-S checkpoint to facilitate normal 
cell cycle progression (Vogelstein & Kinzler, 2004). The inactivation of p53 affects PTEN, 
which inhibits the AKT signaling pathway and induces apoptosis in pancreatic cancers. 
p53 is short-lived and expressed at very low levels in normal cells, but p53 becomes stable 
and accumulates if the cell has DNA damage. Pinho AV et al. found that p53 controls both 
growth and epithelial cell differentiation in the pancreas, which indicates that p53 
inactivation in tumors is associated with aggressive biological behavior (Pinho et al., 
2011). 
Because p53 mutations accumulate relatively late in carcinogenesis, clinical research has 
focused on the therapeutic contribution of p53 in pancreatic cancer. Patients with pancreatic 
cancer that carry a p53 mutation have shorter survival rates than patients with wild-type 
p53. Moreover, tumors that contain a mutated p53 are typically radioresistant and/or 
chemoresistant, indicating that p53 may serve as treatment indicator in pancreatic cancer 
(Dergham et al., 1998). In addition, p53 gene therapy strategies can induce tumor regression 
in patients with advanced NSCLC and with recurrent head and neck cancer (Roth et al., 
1999). 
2.2.3 SMAD4/DPC4 
The SMAD4/DPC4 locus on 18q21 is the critical component of the TGFβ signaling pathway 
and negatively regulates the growth of epithelial cells (Massague et al., 2000). SMAD4 (DPC) 
is another commonly mutated gene in PDAC, and it is activated in approximately 50% of 
pancreatic cancers as a result of homozygous deletion mutations. Wilentz et al. revealed that 
expression of the SMAD4 protein is associated with the histopathological grades of 
pancreatic cancer (Hahn et al., 1996). In addition, immunohistochemical assays revealed that 
the smad4 protein was not expressed in 31% (9/29) of the high-grade lesions (PanIN-3). 
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2.1.5 VEGF 
Tumor angiogenesis is essential for tumor growth and is largely mediated by the vascular 
endothelial growth factor (VEGF) family of proteins and receptors. VEGF is a glycoprotein 
that promotes endothelial cell survival, mitogenesis, migration, differentiation and vascular 
permeability. The upregulation of VEGF expression is stimulated by hypoxia and oncogenic 
proteins, such as Ras. In addition, growth factors, such as EGF, TGF-α, TGF-β, PDGF, and 
HIF, and cytokines, such as IL-1α and IL-6, can also upregulate the expression of VEGF. 
VEGF and its receptors are overexpressed in more than 90% of pancreatic cancers and are 
associated with increased microvessel density, tumor progression and poor prognosis (Seo 
et al., 2000).  
The importance of VEGF and its receptor pathway for the growth of pancreatic tumors was 
demonstrated in several studies with animal models. These studies showed that VEGF and 
its receptors are the targets of numerous ongoing clinical trails that are evaluating the 
efficacy of these treatments in pancreatic cancer (Seo et al., 2000). Several other trials are 
being conducted to examine bevacizumab in combination with other agents or treatment 
modalities for pancreatic cancer; however, this agent seems unlikely to confer sufficient 
benefit to justify licensing for this condition. It has been suggested that angiogenic inhibitors 
that target other non-VEGF pathways may be better able to gain access to the tumor 
environment than an antibody (Whipple & Korc, 2008). 
2.2 Tumor-suppressor genes and pathways  
Tumor suppressor genes inhibit cell proliferation and signaling pathways and induce 
apoptosis and support DNA repair systems, which are thought to be key events that 
suppress transformation during tumor carcinogenesis. However, these genes are subjected 
genetic alterations that reduce or eliminate their normal function. 
In pancreatic cancer, the frequently affected tumor suppressors include p53, APC, 
SMAD4/DPC4, p16INK4A and some additional candidate genes. The loss of these tumor-
suppressor genes may participate and dominate the signaling pathways in pancreatic tissue 
carcinogenesis. A summary of these and other tumor-suppressor genes that are altered in 
pancreatic cancer are discussed below. 
2.2.1 p16INK4A/retinoblastoma 
The loss of function of the p16 gene, due to mutation, deletion or promoter 
hypermethylation, occurs in 80-95% of sporadic pancreatic cancers, which is a higher rate 
than that reported in any other tumor type (Caldas et al., 1994; Rozenblum et al., 1997). The 
p16 locus is located on chromosome 9q21, and it regulates cell cycle progression by limiting 
Rb phosphorylation through inhibition of the cyclin D/CDK4/6 complexes (Serrano et al., 
1996). The inactivation of the pRb/p16 tumor-suppressor pathway may alter the activity of 
pRb, CDK4, and cyclin D to promote tumor development (Freeman et al., 2004). 
The loss of p16 alone or in combination with the activity of other oncogenes has a significant 
role in the formation of pancreatic precursor lesions and the development of pancreatic 
cancer. Immunohistochemical analyses revealed that the loss of p16 protein expression 
occurred in approximately 30% of PanIN-1A lesions, 55% of PanIN-1B lesions and PanIN-2 
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lesions, 71% of PanIN-3 lesions and 100% of PDAC (Real et al., 2008). Recently, Aguirre et al. 
found that p16 limits the malignant conversion of these PanIN lesions to ductal 
adenocarcinoma in activated KRAS-initiated PanIN formation, which suggested that p16 is 
not the earliest event but is an important event in the progression of pancreatic 
carcinogenesis (Aguirre et al., 2003). 
Clinical research has focused on the contribution of p16 in pancreatic cancer. It appears that 
p16 plays a significant role in pancreatic carcinogenesis and is an important diagnostic or 
therapeutic target. Rosty et al. proposed that the loss of the expression of the suppressor 
gene p16 was a major risk factor for the development of pancreatic cancer in patients with 
chronic pancreatitis (Rosty et al., 2003). DNA hypermethylation of p16 in pancreatic juice 
was demonstrated to be a valuable diagnostic marker to predict pancreatic cancer 
progression. However, further studies are needed to provide evidence for the clinical 
applications that target the p16 gene (Matsubayashi et al., 2006; Yan et al., 2005). 
2.2.2 p53 
The p53 locus, which is on the 17p13 chromosome, regulates the cell cycle by integrating 
numerous signals to control cell death (Rozenblum et al., 1997). The abrogation of p53 
activity through mutation occurs in more than 50% of sporadic pancreatic cancers. Wild-
type p53 maintains a G2-M arrest and regulates the G1-S checkpoint to facilitate normal 
cell cycle progression (Vogelstein & Kinzler, 2004). The inactivation of p53 affects PTEN, 
which inhibits the AKT signaling pathway and induces apoptosis in pancreatic cancers. 
p53 is short-lived and expressed at very low levels in normal cells, but p53 becomes stable 
and accumulates if the cell has DNA damage. Pinho AV et al. found that p53 controls both 
growth and epithelial cell differentiation in the pancreas, which indicates that p53 
inactivation in tumors is associated with aggressive biological behavior (Pinho et al., 
2011). 
Because p53 mutations accumulate relatively late in carcinogenesis, clinical research has 
focused on the therapeutic contribution of p53 in pancreatic cancer. Patients with pancreatic 
cancer that carry a p53 mutation have shorter survival rates than patients with wild-type 
p53. Moreover, tumors that contain a mutated p53 are typically radioresistant and/or 
chemoresistant, indicating that p53 may serve as treatment indicator in pancreatic cancer 
(Dergham et al., 1998). In addition, p53 gene therapy strategies can induce tumor regression 
in patients with advanced NSCLC and with recurrent head and neck cancer (Roth et al., 
1999). 
2.2.3 SMAD4/DPC4 
The SMAD4/DPC4 locus on 18q21 is the critical component of the TGFβ signaling pathway 
and negatively regulates the growth of epithelial cells (Massague et al., 2000). SMAD4 (DPC) 
is another commonly mutated gene in PDAC, and it is activated in approximately 50% of 
pancreatic cancers as a result of homozygous deletion mutations. Wilentz et al. revealed that 
expression of the SMAD4 protein is associated with the histopathological grades of 
pancreatic cancer (Hahn et al., 1996). In addition, immunohistochemical assays revealed that 
the smad4 protein was not expressed in 31% (9/29) of the high-grade lesions (PanIN-3). 
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Conversely, the loss of SMAD4 expression did not occur in PanIN-1 and -2, indicating that 
the loss of SMAD4 typically occurs late in PanIN progression to PDAC, similarly to p53 
(Miyaki & Kuroki, 2003; Wilentz et al., 2000). 
SMAD4 is an integral member of the TGF-β signaling cascade, which plays an integral role 
in tumor initiation and progression (Bierie & Moses, 2006; Massague, 2008). There are three 
TGF-β ligands (TGF-β1, TGF-β2 and TGF-β3), which bind to TbRII, TbRI and phosphorylate 
the downstream mediators SMAD2 and SMAD3. The phosphorylated SMAD2 and SMAD3 
for a complex with SMAD4 and enter the nucleus to modulate gene transcription (Derynck 
& Zhang, 2003). 
Clinical research has focused on the therapeutic contribution of smad4 in pancreatic cancer. 
Melisi D et al. found that the TGF-β/Smad-independent pathway can increase apoptosis 
inhibitors to produce pancreatic cancer cells that are resistant to the pro-apoptotic effects of 
gemcitabine (Melisi et al., 2011). Some ongoing clinical trials are employing different TGF-β 
inhibitors to inhibit the TGF-β signaling pathway in advanced pancreatic carcinoma (Korpal 
& Kang, 2010; Nagaraj & Datta, 2010). The loss of SMAD4 plays a crucial role in abrogating 
the TGFβ-mediated cancer cell growth and metastasis. However, further studies are needed 
to investigate and improve the effectiveness of combined TGFβ inhibitor treatment and 
SMAD4 gene therapy. 
2.2.4 Candidate tumor suppressor genes 
2.2.4.1 ARHI gene 
The maternally imprinted gene Aplesia Ras homolog member I (ARHI, DIRAS3) is a 
member of the Ras superfamily locus on chromosome 1q. It is a small 26-kDa GTPase that 
inhibits anchorage-dependent and independent growth, motility, invasion and 
angiogenesis, despite sharing 54-62% amino acid homology with Ras and Rap (Yu et al., 
1999). Artificially induced expression of ARHI in mice leads to small body size, infertility 
and decreased lactation (Xu et al., 2000) . Ectopic overexpression of ARHI in cancer cells that 
express low levels of ARHI triggers apoptosis through a caspase-independent, calpain-
dependent mechanism (Bao et al., 2002). Recent studies suggest that the return of ARHI to 
normal physiological expression levels also induces a G2/M cell cycle arrest, autophagy and 
tumor dormancy in ovarian cancer (Lu et al., 2008) . The expression and function of ARHI in 
pancreatic cancer has received relatively little attention. Because ARHI appears to oppose 
Ras function, and K-ras is frequently activated in pancreatic cancers, it is possible that the 
loss of ARHI contributes to pancreatic carcinogenesis. In the present study, we measured 
the expression of ARHI in normal and cancerous pancreatic tissue. Yang et al. found that 
ARHI is widely expressed in the ductal and acinar cells of normal pancreatic tissue but is 
down-regulated or lost in approximately 50% of pancreatic cancers (Yang et al., 2010). This 
study also examined the methylation status of ARHI in pancreatic cancer cell lines with low 
ARHI expression and found that hypermethylation was the main mechanism for the loss of 
function of ARHI. Stable transfections of ARHI can inhibit cell cycle progression and induce 
cell apoptosis in pancreatic cancer cells through the inhibition of PI3K/AKT signaling (Lu et 
al., 2009). The role of ARHI in regulating growth and its loss in half of pancreatic cancers 
suggest that the loss of ARHI could be an important event in the pathogenesis of pancreatic 
cancer. However, the identification of clinical applications of ARHI requires further studies.  
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2.2.4.2 KLF4 gene 
The KLF4 gene, which locus on chromosome 9q31.1-3, negatively regulates G protein-
coupled mitogenic signal transduction, cell proliferation, transformation, and oncogenesis. 
Zammarchi F et al. used immunohistochemical analysis to show that the KLF4 protein is 
expressed in 86.8% cases of DPC (33/38). The overexpression of KLF4 in a human pancreatic 
carcinoma cell line induced the up-regulation of p21 and the down-regulation of cyclin D1. 
It appears that the KLF4 gene may be a key suppressor in pancreatic tumorigenesis 
(Zammarchi et al., 2011).  
2.3 Telomere length abnormalities  
2.3.1 The definition and function of telomeres 
A telomere is a region of repetitive DNA sequences at the end of a chromosome. This region 
protects the end of the chromosome from deterioration and from fusion with neighboring 
chromosomes. Human telomeres are nucleoprotein complexes consisting of 8–15 kb of 
hexameric DNA repeat sequences (TTAGGG) and specifically bound proteins at 
chromosomes ends (Blackburn, 1991). These structures prevent the chromosome termini 
from being recognized as double-stranded DNA breaks and are essential for genomic 
stability (Artandi et al., 2000). During DNA replication, the DNA polymerase protein 
complex cannot replicate the sequences that are present at the ends. In somatic cells, 
telomeres become progressively shorter during each round of cell division through 
replication-dependent loss of the DNA termini (Harley et al., 1990). Over time, due to each 
cell division, the telomere ends become shorter. This is the reason why telomeres are so 
important in context of successful cell division; they "cap" the end sequences and are lost in 
the process of DNA replication. The cell has an enzyme termed telomerase, which carries 
out the task of adding repetitive nucleotide sequences to the ends of the DNA. Telomerase is 
the natural enzyme that promotes telomere repair. Its expression is low or absent in somatic 
cells, but it is active in stem cells, germ cells, hair follicles, and 90 percent of cancer cells 
(Blackburn, 1991). 
The consecutive shortening of telomeres ultimately leads to excessive telomere erosion, loss 
of telomere capping function, and eventually genetic instability and cellular senescence 
when telomeres become critically short (Counter et al., 1992). Consequently, epithelial cells 
with excessive telomere shortening are largely eliminated by protective mechanisms 
(Artandi et al., 2000). Therefore, telomere shortening has been suggested to be an important 
biological factor in aging and cellular senescence, which could limit the over-growth of cells 
and prevent them from transforming into cancer cells. 
2.3.2 The relationship between telomeres and human cancer 
It is clear that telomeres could function as protectors of chromosome stability and prevent 
uncontrolled cellular growth. In cancer progression, telomeres help to maintain genomic 
integrity, similar to the role played by caretaker genes. It is assumed that the loss of 
telomere function might permit subsequent accumulation of additional genomic changes at 
the chromosomal level, which may facilitate the progression toward a fully malignant 
phenotype (Hackett & Greider, 2002). 
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Conversely, the loss of SMAD4 expression did not occur in PanIN-1 and -2, indicating that 
the loss of SMAD4 typically occurs late in PanIN progression to PDAC, similarly to p53 
(Miyaki & Kuroki, 2003; Wilentz et al., 2000). 
SMAD4 is an integral member of the TGF-β signaling cascade, which plays an integral role 
in tumor initiation and progression (Bierie & Moses, 2006; Massague, 2008). There are three 
TGF-β ligands (TGF-β1, TGF-β2 and TGF-β3), which bind to TbRII, TbRI and phosphorylate 
the downstream mediators SMAD2 and SMAD3. The phosphorylated SMAD2 and SMAD3 
for a complex with SMAD4 and enter the nucleus to modulate gene transcription (Derynck 
& Zhang, 2003). 
Clinical research has focused on the therapeutic contribution of smad4 in pancreatic cancer. 
Melisi D et al. found that the TGF-β/Smad-independent pathway can increase apoptosis 
inhibitors to produce pancreatic cancer cells that are resistant to the pro-apoptotic effects of 
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study also examined the methylation status of ARHI in pancreatic cancer cell lines with low 
ARHI expression and found that hypermethylation was the main mechanism for the loss of 
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al., 2009). The role of ARHI in regulating growth and its loss in half of pancreatic cancers 
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cancer. However, the identification of clinical applications of ARHI requires further studies.  
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2.2.4.2 KLF4 gene 
The KLF4 gene, which locus on chromosome 9q31.1-3, negatively regulates G protein-
coupled mitogenic signal transduction, cell proliferation, transformation, and oncogenesis. 
Zammarchi F et al. used immunohistochemical analysis to show that the KLF4 protein is 
expressed in 86.8% cases of DPC (33/38). The overexpression of KLF4 in a human pancreatic 
carcinoma cell line induced the up-regulation of p21 and the down-regulation of cyclin D1. 
It appears that the KLF4 gene may be a key suppressor in pancreatic tumorigenesis 
(Zammarchi et al., 2011).  
2.3 Telomere length abnormalities  
2.3.1 The definition and function of telomeres 
A telomere is a region of repetitive DNA sequences at the end of a chromosome. This region 
protects the end of the chromosome from deterioration and from fusion with neighboring 
chromosomes. Human telomeres are nucleoprotein complexes consisting of 8–15 kb of 
hexameric DNA repeat sequences (TTAGGG) and specifically bound proteins at 
chromosomes ends (Blackburn, 1991). These structures prevent the chromosome termini 
from being recognized as double-stranded DNA breaks and are essential for genomic 
stability (Artandi et al., 2000). During DNA replication, the DNA polymerase protein 
complex cannot replicate the sequences that are present at the ends. In somatic cells, 
telomeres become progressively shorter during each round of cell division through 
replication-dependent loss of the DNA termini (Harley et al., 1990). Over time, due to each 
cell division, the telomere ends become shorter. This is the reason why telomeres are so 
important in context of successful cell division; they "cap" the end sequences and are lost in 
the process of DNA replication. The cell has an enzyme termed telomerase, which carries 
out the task of adding repetitive nucleotide sequences to the ends of the DNA. Telomerase is 
the natural enzyme that promotes telomere repair. Its expression is low or absent in somatic 
cells, but it is active in stem cells, germ cells, hair follicles, and 90 percent of cancer cells 
(Blackburn, 1991). 
The consecutive shortening of telomeres ultimately leads to excessive telomere erosion, loss 
of telomere capping function, and eventually genetic instability and cellular senescence 
when telomeres become critically short (Counter et al., 1992). Consequently, epithelial cells 
with excessive telomere shortening are largely eliminated by protective mechanisms 
(Artandi et al., 2000). Therefore, telomere shortening has been suggested to be an important 
biological factor in aging and cellular senescence, which could limit the over-growth of cells 
and prevent them from transforming into cancer cells. 
2.3.2 The relationship between telomeres and human cancer 
It is clear that telomeres could function as protectors of chromosome stability and prevent 
uncontrolled cellular growth. In cancer progression, telomeres help to maintain genomic 
integrity, similar to the role played by caretaker genes. It is assumed that the loss of 
telomere function might permit subsequent accumulation of additional genomic changes at 
the chromosomal level, which may facilitate the progression toward a fully malignant 
phenotype (Hackett & Greider, 2002). 
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Telomeres can be maintained through recombination or by telomerase activation. 
Telomerase is an RNA-dependent DNA polymerase that is generally inactivated in normal 
human somatic cells. Introduction of telomerase into normal human somatic cells may 
facilitate unlimited cellular growth and extend the cellular lifespan (Bodnar et al., 1998). 
In most human cancers, telomerase was activated through the accumulation of multiple 
genomic and epigenetic aberrations, and these changes help the cells restore the minimal 
length of telomeres required to maintain cell function and escape from cellular senescence 
(O'Hagan et al., 2002). Therefore, the reactivation of telomerase has become an additional 
hallmark of some human cancers, including pancreatic cancer (Hiyama et al., 1997). 
Telomeric fusion is mechanism of telomere dysfunction and leads to uncontrolled mitosis of 
cancer cells. Telomeric fusions between chromosomal arms may occur in the presence of 
critically shortened telomere repeat sequences; these fusions lead to ring and dicentric 
chromosomes that form anaphase bridges during mitosis (Gisselsson et al., 2001). 
Highly recombinogenic free DNA ends are generated when anaphase bridges are broken, 
and fusion of the broken ends results in novel chromosomal rearrangements. Some of these 
abnormal chromosomes may then form bridges during the next cell division, setting in 
motion a self-perpetuating breakage-fusion-bridge cycle. The presence of unbalanced 
chromosomal rearrangements is an essential feature of most human epithelial cancers 
(Gisselsson et al., 2001) . 
2.3.3 The relationship between telomeres and pancreatic cancer 
Pancreatic adenocarcinomas, which are remarkable for their highly complex karyotypes, 
numerous chromosomal abnormalities, and multiple deletions, often possess chromosome 
ends that lack telomeric repeat sequences (Griffin et al., 1995). The evidence for up-regulated 
human telomerase reverse transcriptase expression has been demonstrated in invasive 
pancreatic cancer (Hiyama et al., 1997) and in the intraductal papillary mucinous neoplasms 
(IPMN) of the pancreas (Hashimoto et al., 2008). Telomere dysfunction was also found to 
play a role in the multistep progression model for the development of pancreatic cancer. In 
this multistep model of pancreatic cancer development, noninvasive precursor lesions in the 
pancreatic ductules accumulate genetic alterations in cancer-associated genes that ultimately 
lead to the development of an invasive cancer. In the pancreas, the noninvasive precursor 
lesions are called pancreatic intraepithelial neoplasia or PanIN. PanINs are believed to 
progress from a flat and papillary appearance without dysplasia to a papillary appearance 
with dysplasia to carcinoma in situ (van et al., 2002). Telomere fluorescence in situ 
hybridization and immunostaining was used to assess the telomere length in tissue 
microarrays containing a variety of noninvasive pancreatic ductal lesions (van et al., 2002) 
found that the telomere signals were strikingly reduced in 79 of 82 (96%) of PanINs 
compared with adjacent normal structures. The 82 PanIN lesions that were examined 
included all histological grades (PanIN-1A, PanIN-1B, PanIN-2, and PanIN-3). Thus, this 
study reveals that telomere shortening is the most common early genetic abnormality in the 
progression of pancreatic adenocarcinomas. Telomeres may be an essential gatekeeper for 
maintaining chromosomal integrity and normal cellular physiology in pancreatic ductal 
epithelium. A critical shortening of telomere length in PanINs may predispose these 
noninvasive ductal lesions to accumulate progressive chromosomal abnormalities and to 
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progress toward the stage of invasive carcinoma. Another research group also found that 
the telomeres were significantly shortened (97.3%) in 37 intraductal papillary mucinous 
neoplasm (IPMN) loci of the pancreas, which has been increasingly identified as a precursor 
to infiltrating ductal adenocarcinoma (Hashimoto et al., 2008) .  
Therefore, telomere abnormalities may function as a cancer marker in invasive pancreatic 
cancer and may also function as the earliest known event in the cascade of pancreatic cancer 
development. 
Telomere shortening has been suggested to be an important biological factor in aging, 
cellular senescence, cell immortality, and transformation to cancer. Cellular immortality and 
transformation are associated with the reactivation of telomerase and with telomere 
dysfunction in cells with critically shortened telomeres and may play an important role in 
the development of pancreatic cancers. 
2.4 Epigenetic abnormalities  
Both epigenetic abnormalities and genetic alterations contribute greatly to cancer 
development at all stages and may drive the initial steps of cancer progression. DNA 
methylation and chromatin configurations underlie the abnormal patterns in cancer, and 
cumulative epigenetic abnormalities of the host genes without accompanying changes in the 
DNA sequences are critical contributors to oncogenesis. Interestingly, cancer-specific 
epigenetic alterations can be reversed by pharmacological targeting, and increasing 
attention has been given to this field as a means to treat cancer. 
In the United States, it is estimated that 44,030 new cases of pancreatic cancer were 
diagnosed and 37,660 deaths occurred in 2011(Siegel et al., 2011), which indicates that 
pancreatic ductal adenocarcinoma is an extremely aggressive and devastating neoplasm. 
Therefore, a better understanding of pancreatic cancer molecular genetics is important and 
can provide the basis for the development of valuable biomarkers and targets for 
therapeutic intervention. 
Over the past two decades, extensive interest has revealed many advances in the 
understanding of genetic alterations that are important in pancreatic cancer. The mutations 
and deletions of oncogenes and tumor suppressor genes, such as k-ras,p53 CDKN1A/p16, 
SMAD4/DPC4, etc., appear to play an important role in pancreatic carcinogenesis. In 
addition, by understanding of the progression of pancreatic cancer, a model of pancreatic 
carcinogenesis, from precursor lesions to invasive cancers with genetic alterations, was 
proposed. 
Recently, the epigenetic abnormalities found in pancreatic cancers were also of considerable 
interest among researchers and clinicians. This interest was especially piqued after 
demethylating drugs, 5-azacytidine (5-aza-CR) and 5-aza-29-deoxycytidine (5-aza-dC), were 
shown to be effective in treating myelodysplastic syndrome and were approved by the Food 
and Drug Administration (FDA) (Venturelli et al., 2011). The key epigenetic mechanisms 
that may affect gene expression include DNA methylation, histone modification, and 
microRNA expression (Hong et al., 2011). Epigenetic abnormalities may be functionally 
involved in precursor lesions, tumor growth, invasion and metastasis in pancreatic cancer. 
In the following section, we will review recent advances in our understanding of the 
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study reveals that telomere shortening is the most common early genetic abnormality in the 
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progress toward the stage of invasive carcinoma. Another research group also found that 
the telomeres were significantly shortened (97.3%) in 37 intraductal papillary mucinous 
neoplasm (IPMN) loci of the pancreas, which has been increasingly identified as a precursor 
to infiltrating ductal adenocarcinoma (Hashimoto et al., 2008) .  
Therefore, telomere abnormalities may function as a cancer marker in invasive pancreatic 
cancer and may also function as the earliest known event in the cascade of pancreatic cancer 
development. 
Telomere shortening has been suggested to be an important biological factor in aging, 
cellular senescence, cell immortality, and transformation to cancer. Cellular immortality and 
transformation are associated with the reactivation of telomerase and with telomere 
dysfunction in cells with critically shortened telomeres and may play an important role in 
the development of pancreatic cancers. 
2.4 Epigenetic abnormalities  
Both epigenetic abnormalities and genetic alterations contribute greatly to cancer 
development at all stages and may drive the initial steps of cancer progression. DNA 
methylation and chromatin configurations underlie the abnormal patterns in cancer, and 
cumulative epigenetic abnormalities of the host genes without accompanying changes in the 
DNA sequences are critical contributors to oncogenesis. Interestingly, cancer-specific 
epigenetic alterations can be reversed by pharmacological targeting, and increasing 
attention has been given to this field as a means to treat cancer. 
In the United States, it is estimated that 44,030 new cases of pancreatic cancer were 
diagnosed and 37,660 deaths occurred in 2011(Siegel et al., 2011), which indicates that 
pancreatic ductal adenocarcinoma is an extremely aggressive and devastating neoplasm. 
Therefore, a better understanding of pancreatic cancer molecular genetics is important and 
can provide the basis for the development of valuable biomarkers and targets for 
therapeutic intervention. 
Over the past two decades, extensive interest has revealed many advances in the 
understanding of genetic alterations that are important in pancreatic cancer. The mutations 
and deletions of oncogenes and tumor suppressor genes, such as k-ras,p53 CDKN1A/p16, 
SMAD4/DPC4, etc., appear to play an important role in pancreatic carcinogenesis. In 
addition, by understanding of the progression of pancreatic cancer, a model of pancreatic 
carcinogenesis, from precursor lesions to invasive cancers with genetic alterations, was 
proposed. 
Recently, the epigenetic abnormalities found in pancreatic cancers were also of considerable 
interest among researchers and clinicians. This interest was especially piqued after 
demethylating drugs, 5-azacytidine (5-aza-CR) and 5-aza-29-deoxycytidine (5-aza-dC), were 
shown to be effective in treating myelodysplastic syndrome and were approved by the Food 
and Drug Administration (FDA) (Venturelli et al., 2011). The key epigenetic mechanisms 
that may affect gene expression include DNA methylation, histone modification, and 
microRNA expression (Hong et al., 2011). Epigenetic abnormalities may be functionally 
involved in precursor lesions, tumor growth, invasion and metastasis in pancreatic cancer. 
In the following section, we will review recent advances in our understanding of the 
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epigenetic features associated with pancreatic neoplastic progression, specifically focusing 
on their role in precursor lesions and their potential clinical benefits. 
2.4.1 DNA methylation 
DNA methylation is a biochemical process where a methyl group is added to the fifth 
positon of the cytosine pyrimidine ring or the sixth nitrogen of the adenine purine ring. 
DNA methylation stably alters the gene expression pattern to provide cellular memory or 
decrease gene expression. DNA methylation also plays a crucial role in the development of 
nearly all types of cancer. Both hypermethylation and hypomethylation distinguish normal 
tissue from tissue associated with pancreatic cancer (Jaenisch & Bird, 2003). 
Hypermethylation is one of the major epigenetic modifications that repress transcription via 
the promoter region of tumor suppressor genes. Hypermethylation typically occurs at CpG 
islands in the promoter region and is associated with gene inactivation. Global 
hypomethylation has also been implicated in the development and progression of cancer 
through alternative mechanisms (Jeffrey & Nicholas, 2011). 
2.4.2 DNA methylation and precursor lesions 
It has been shown that PDAC develops through a stepwise progression from preinvasive 
lesions, including PanINs, IPMNs, and MCNs, to invasive neoplasms (Haugk, 2010). The 
discovery of abnormal methylation in pancreatic cancer has been followed by the 
investigation of methylation in precursor lesions. Many genes that are epigenetically 
silenced in pancreatic cancers also are silenced or have reduced expression in precursor 
lesions of pancreatic cancer. The molecular genesis of precursor lesions may lay the 
foundation for our understanding of pancreatic carcinogenesis and the identification of 
valuable tumor markers and therapeutic targets. 
Many genes showed epigenetic abnormalities in precursor lesions of pancreatic cancer, 
including Reprimo, SPARC, SAPR2, NPTX2, LHX1, CLDN5, CDH3, and ST14 for PanIN and 
119 CDKN1C/p57KIP2 and CyclinD2 for IPMN (Fukushima et al., 2002, 2003; Gerdes et al., 
2003; Matsubayashi et al., 2003; Sato et al., 2008). Using methylation-specific PCR analysis 
(Singh & Maitra, 2007), eight genes (Reprimo, SPARC, SAPR2, NPTX2, LHX1, CLDN5, 
CDH3, and ST14) were tested in 65 PanIN lesions. The results revealed that these eight 
genes may be detected in more than 70% of the earliest lesions (PanIN-1A). In addition, 
aberrant DNA methylation can be detected in PanIN-2 and PanIN-3 lesions, which suggests 
that DNA methylation alterations may begin in the early stages of precursor lesions, such as 
in PanINs, IPMNs, and MCNs. Moreover, their prevalence was shown to progressively 
increase during pancreatic carcinogenesis. Because DNA methylation of particular genes can 
occur in the precursor lesions, the methylation targets may be valuable tumor markers and 
treatment strategies. 
2.4.3 DNA methylation and pancreatic cancer 
Changes in the DNA methylation program are closely associated with pancreatic 
carcinogenesis, including CpG island hypermethylation and hypomethylation (Sato & 
Goggins, 2006). Recently, high-throughput screening technologies and single gene 
methylation technologies have identified several genes that are affected by aberrant DNA 
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methylation in pancreatic cancer. Tan AC et al. detected 1505 CpG sites across 807 genes to 
identify DNA methylation patterns in the pancreatic cancer genome and found that 289 
CpG sites show different patterns in the normal pancreas, pancreatic tumors and cancer cell 
lines (Tan et al., 2009). The promoter and CpG island array was used to compare the Panc-1 
cell lines with a non-neoplastic pancreatic duct line, and 1,010 of 87,922 probes on the 88 K 
promoter array (606 genes) had higher signals (log2 > 2) in the pancreatic cancer line. 
The aberrant hypermethylation of CpG islands is an important cause of altered tumor 
suppressor gene function in pancreatic cancers. Several of the classic tumor suppressor 
genes, such as p16, p53, and SMAD4/DPC4, showed DNA hypermethylation, which 
suggests that DNA hypermethylation is an important mechanism in pancreatic 
carcinogenesis. DNA hypermethylation has also been observed in many other genes that are 
implicated in pancreatic carcinogenesis, including TNFRSF10C, NPTX2, SPARC, FOXA1/2, 
RUNX3, GATA-4, GATA-5, ppENK, CDKN1C/p57KIP2, HHIP, DUSP6, CXCR4, TFPI-2, 
HIN-1, SOCS-1, WWOX, RASSF1A, CACNA1G, TIMP-3, E-cad, THBS1, hMLH1, DAP 
kinase, and ARHI (Cai et al., 2011; Dammann et al., 2003; Fendrich et al., 2005; Fu et al., 2007; 
Gao et al., 2010; Komazaki et al., 2004; Krop et al., 2004; Kuroki et al., 2004; Martin et al., 
2005; Nakayama et al., 2009; Nomoto et al., 2008; Ohtsubo et al., 2006; Park et al., 2007, 2011; 
Sato et al., 2003, 2005, 2005, 2005, 2005; Song et al., 2010; Ueki et al., 2000; Xu et al., 2005). 
DNA hypomethylation an additional type of epigenetic alteration that is found in pancreatic 
cancer (Ehrlich, 2002). Global DNA hypomethylation and hypomethylation of specific genes 
have been observed. Global DNA hypomethylation is associated with folate metabolism, 
indicating that essential nutrients are helpful for preventing cancer progression (Gaudet et 
al., 2003; Kim, 2004). DNA hypomethylation of many oncogenes, such as claudin4, 
lipocalin2, 14-3-3 sigma, trefoil factor 2, S100A4, mesothelin, PSA, has also been shown to be 
important for facilitating their over-expression during pancreatic carcinogenesis.  
2.4.4 DNA methylation and clinical applications 
Does targeting DNA methylation in pancreatic cancer show a clinical benefit as an early 
detection method or an effective treatment strategy? Initially, the serum level of the 
hypermethylation of specific genes appeared to hold potential diagnostic value. Gotoh M 
found that the methylation status of twelve bacterial artificial chromosome (BAC) clones 
could predict pancreatic tumors with 100% sensitivity and specificity and could also identify 
patients that would show early relapse with 100% specificity (Gotoh et al., 2011). Park JK 
found that the level of serum NPTX2 hypermethylation was a valuable diagnostic marker 
for identifying pancreatic cancers with 80% sensitivity and 76% specificity (Park et al., 2011). 
Gerdes B et al. found that p16(INK4a) alterations can be observed in a significant number of 
PanIN1 in chronic pancreatitis tissues, and methylation of the p16(INK4a) promoter may 
indicate a high-risk for progression from chronic pancreatitis to cancer (Gerdes et al., 2001). 
In addition, DNA methylation of p16, ppENK, SARP2 and some additional genes was 
demonstrated to be a valuable diagnostic tool to predict pancreatic cancer (Yan et al., 2005). 
Overall, the detection of DNA methylation, either alone or in combination with other tumor 
markers, will be helpful for screening and diagnosing pancreatic cancer. 
Importantly, DNA methylation, unlike genetic changes, are considered to be reversible 
biological alterations, so pharmacological agents that target this change are attractive potential 
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indicate a high-risk for progression from chronic pancreatitis to cancer (Gerdes et al., 2001). 
In addition, DNA methylation of p16, ppENK, SARP2 and some additional genes was 
demonstrated to be a valuable diagnostic tool to predict pancreatic cancer (Yan et al., 2005). 
Overall, the detection of DNA methylation, either alone or in combination with other tumor 
markers, will be helpful for screening and diagnosing pancreatic cancer. 
Importantly, DNA methylation, unlike genetic changes, are considered to be reversible 
biological alterations, so pharmacological agents that target this change are attractive potential 
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strategies for treating cancer. Drugs that target the DNA methyltransferase are promising 
chemotherapeutic agents because this enzyme is a limiting factor for DNA methylation.  
Yang et al (Yang et al., 2010). demonstrated that the inhibitor decitabine (5-aza-dC, 2'-deoxy-
5-azacytidine DNMT inhibitor) could inhibit pancreatic cancer cell growth, induce 
apoptosis, induce ARHI gene demethylation and induce ARHI re-expression. Many studies 
have demonstrated that tumor-suppressor gene expression can be restored by DNMT 
inhibitors to induce pancreatic cancer apoptosis, including NPTX2, BNIP3, SOCS-1, WWOX, 
and cyclin D2. Although demethylating drugs have been approved by the FDA to treat 
MDS, these demethylating drugs must be further investigated to understand the mechanism 
that prevents pancreatic cancer progression and to predict potential side effects 
(Matsubayashi et al., 2006; Sato & Goggins, 2006).  
2.4.5 Histone modifications and pancreatic cancer 
Histone proteins influence chromatin accessibility and gene activity through post-
translational modifications (Bernstein et al., 2007; Gaudet et al., 2003; Ting et al., 2006). 
Histone acetylases/deacetylases, the polycomb group proteins, and HP1 are the key histone 
protein complexes that influence chromatin accessibility and gene activity. Histone 
modifications have been linked to the altered expression of several critical genes in 
pancreatic cancer, including the IL-13 receptor, MUC17, MUC4, MUC1 and MUC2 (Esteller, 
2007; Fujisawa et al., 2011; Kitamoto et al., 2011; Vincent et al., 2008; Yamada et al., 2008).  
The importance of histone modifications lies in their potential use as a diagnostic and 
therapeutic intervention. For instance, it has been shown that histone deacetylase inhibitors 
induce apoptosis of human pancreatic cancer cells. Donadelli M found that histone 
deacetylase inhibitors, in combination with conventional chemotherapeutic drugs, such as 
gemcitabine, leads to a synergistic inhibition of pancreatic adenocarcinoma cell growth. In 
addition, targeting the Polycomb members and HP1 has also been shown to be effective in 
inhibiting pancreatic cancer cells. Furthermore, Manuyakorn A et al. showed that the 
pattern of H3K4ME2, H3K9me2 and H3K18ac can predict the prognosis and treatment 
response of patients (Donadelli et al., 2007; Garcia-Morales et al., 2005; Haefner et al., 2008; 
Manuyakorn et al., 2010; Yamada et al., 2006).  
Recently, many studies have focused only on somatic genetics; however, these areas 
represent only a small portion of mechanisms that contribute to gene alteration in pancreatic 
cancer. Epigenetic changes, including CpG island hypermethylation, hypomethylation, and 
histone modifications, comprise a new arena for pancreatic cancer research, which may 
provide new diagnostic and therapeutic tools to combat pancreatic cancer. However, many 
fundamental questions about the biological and clinical significance of epigenetic changes 
have yet to be answered, and further studies are needed to do to create effective clinical 
applications for pancreatic cancer.  
2.5 Aberrant microRNA expression in pancreatic cancer  
2.5.1 Introduction to microRNA 
MicroRNAs(miRNAs) are non-protein-coding RNA molecules that are approximately 22 
nucleotides and regulate gene function in various silencing pathways. These molecules are 
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also encoded by genes and are transcribed by RNA polymerase II. miRNAs are 
phylogenetically conserved and play an important role in cell survival, proliferation, 
differentiation, apoptosis and angiogenesis (Ambros, 2004; Farh et al., 2005). miRNAs 
expression patterns differ, depending upon the cell, tissue, and disease type. 
miRNAs regulate their targets by direct mRNA cleavage or translational inhibition and each 
miRNA can regulate multiple target genes.In the most recent database (miRBase release 15), 
over 21,643 mature miRNAs have been identified in 168 species (Kozomara & Griffiths-
Jones, 2011). 
2.5.2 miRNAs and pancreatic cancer 
The overexpression and deregulation of several miRNAs has been observed in human 
cancers (Lu et al., 2005; Metzler et al., 2004; Takamizawa et al., 2004). These studies have also 
shown that miRNA expression signatures correlate well with specific cancer clinical 
characteristics and could be used to differentiate normal and cancerous tissues, as well as 
subtypes of malignancy (Calin & Croce, 2006; Cummins & Velculescu, 2006; Dalmay & 
Edwards, 2006).Deregulation of miRNAs in cancer may be caused by several changes: (1) 
chromosomal regional gain, loss or translocation, (2) aberrant expression and activation of 
transcriptional factors, (3) epigenetic alterations, or (4) changes in miRNA processing (Deng 
et al., 2008).  
The miRNA expression profiles in pancreatic tumor tissues are different from those 
observed in the normal pancreas or in patients with chronic pancreatitis. Most miRNA 
expression profile analyses show that miRNAs are deregulated in tumor tissues compared 
with normal pancreatic tissue, and the expression pattern is tissue specific. 
Szafranska et al. (Szafranska et al., 2007) demonstrated that two miRNAs, miR-216 and miR-
217, are pancreas specific, which was in agreement with two previous studies (Sood et al., 
2006). Furthermore, both miR-216 and miR-217 are absent or only minimally expressed in 
pancreatic carcinoma tissues and cell lines. Therefore, miR-216 and miR-217 are potential 
biomarkers. Based on clustering analysis, the three pancreatic tissue types (normal pancreas, 
chronic pancreatitis and pancreatic cancer) can be classified according to their respective 
miRNA expression profiles. Among 26 miRNAs that have been identified as most 
prominently deregulated in PDAC, only miR-217 and miR-196a have been found to 
discriminate between normal pancreas, chronic pancreatitis and tumor tissues. These 
miRNAs are also potential biomarkers. 
Zhang et al. (Zhang et al., 2009) evaluated 95 miRNAs, which were selected from pancreatic 
cancer profiling, and correlated them with their potential biological functions, such as 
cancer biology, cell development, and apoptosis. Among them, eight miRNAs (miR-196a, 
miR-190, miR-186, miR-221, miR-222, miR-200b, miR-15b and miR-95) are differentially 
expressed in most pancreatic cancer tissues and cell lines. These eight genes are all 
significantly up-regulated, from 3- to 2018-fold, in pancreatic tumors compared with normal 
control samples. 
miRNAs are functionally classified as oncogenes or tumor suppressors based on whether 
their targets are oncogenes or tumor suppressor genes. Therefore, oncogenic miRNAs are 
upregulated in tumors, whereas tumor suppressor miRNAs are downregulated. Torrisani et 
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strategies for treating cancer. Drugs that target the DNA methyltransferase are promising 
chemotherapeutic agents because this enzyme is a limiting factor for DNA methylation.  
Yang et al (Yang et al., 2010). demonstrated that the inhibitor decitabine (5-aza-dC, 2'-deoxy-
5-azacytidine DNMT inhibitor) could inhibit pancreatic cancer cell growth, induce 
apoptosis, induce ARHI gene demethylation and induce ARHI re-expression. Many studies 
have demonstrated that tumor-suppressor gene expression can be restored by DNMT 
inhibitors to induce pancreatic cancer apoptosis, including NPTX2, BNIP3, SOCS-1, WWOX, 
and cyclin D2. Although demethylating drugs have been approved by the FDA to treat 
MDS, these demethylating drugs must be further investigated to understand the mechanism 
that prevents pancreatic cancer progression and to predict potential side effects 
(Matsubayashi et al., 2006; Sato & Goggins, 2006).  
2.4.5 Histone modifications and pancreatic cancer 
Histone proteins influence chromatin accessibility and gene activity through post-
translational modifications (Bernstein et al., 2007; Gaudet et al., 2003; Ting et al., 2006). 
Histone acetylases/deacetylases, the polycomb group proteins, and HP1 are the key histone 
protein complexes that influence chromatin accessibility and gene activity. Histone 
modifications have been linked to the altered expression of several critical genes in 
pancreatic cancer, including the IL-13 receptor, MUC17, MUC4, MUC1 and MUC2 (Esteller, 
2007; Fujisawa et al., 2011; Kitamoto et al., 2011; Vincent et al., 2008; Yamada et al., 2008).  
The importance of histone modifications lies in their potential use as a diagnostic and 
therapeutic intervention. For instance, it has been shown that histone deacetylase inhibitors 
induce apoptosis of human pancreatic cancer cells. Donadelli M found that histone 
deacetylase inhibitors, in combination with conventional chemotherapeutic drugs, such as 
gemcitabine, leads to a synergistic inhibition of pancreatic adenocarcinoma cell growth. In 
addition, targeting the Polycomb members and HP1 has also been shown to be effective in 
inhibiting pancreatic cancer cells. Furthermore, Manuyakorn A et al. showed that the 
pattern of H3K4ME2, H3K9me2 and H3K18ac can predict the prognosis and treatment 
response of patients (Donadelli et al., 2007; Garcia-Morales et al., 2005; Haefner et al., 2008; 
Manuyakorn et al., 2010; Yamada et al., 2006).  
Recently, many studies have focused only on somatic genetics; however, these areas 
represent only a small portion of mechanisms that contribute to gene alteration in pancreatic 
cancer. Epigenetic changes, including CpG island hypermethylation, hypomethylation, and 
histone modifications, comprise a new arena for pancreatic cancer research, which may 
provide new diagnostic and therapeutic tools to combat pancreatic cancer. However, many 
fundamental questions about the biological and clinical significance of epigenetic changes 
have yet to be answered, and further studies are needed to do to create effective clinical 
applications for pancreatic cancer.  
2.5 Aberrant microRNA expression in pancreatic cancer  
2.5.1 Introduction to microRNA 
MicroRNAs(miRNAs) are non-protein-coding RNA molecules that are approximately 22 
nucleotides and regulate gene function in various silencing pathways. These molecules are 
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also encoded by genes and are transcribed by RNA polymerase II. miRNAs are 
phylogenetically conserved and play an important role in cell survival, proliferation, 
differentiation, apoptosis and angiogenesis (Ambros, 2004; Farh et al., 2005). miRNAs 
expression patterns differ, depending upon the cell, tissue, and disease type. 
miRNAs regulate their targets by direct mRNA cleavage or translational inhibition and each 
miRNA can regulate multiple target genes.In the most recent database (miRBase release 15), 
over 21,643 mature miRNAs have been identified in 168 species (Kozomara & Griffiths-
Jones, 2011). 
2.5.2 miRNAs and pancreatic cancer 
The overexpression and deregulation of several miRNAs has been observed in human 
cancers (Lu et al., 2005; Metzler et al., 2004; Takamizawa et al., 2004). These studies have also 
shown that miRNA expression signatures correlate well with specific cancer clinical 
characteristics and could be used to differentiate normal and cancerous tissues, as well as 
subtypes of malignancy (Calin & Croce, 2006; Cummins & Velculescu, 2006; Dalmay & 
Edwards, 2006).Deregulation of miRNAs in cancer may be caused by several changes: (1) 
chromosomal regional gain, loss or translocation, (2) aberrant expression and activation of 
transcriptional factors, (3) epigenetic alterations, or (4) changes in miRNA processing (Deng 
et al., 2008).  
The miRNA expression profiles in pancreatic tumor tissues are different from those 
observed in the normal pancreas or in patients with chronic pancreatitis. Most miRNA 
expression profile analyses show that miRNAs are deregulated in tumor tissues compared 
with normal pancreatic tissue, and the expression pattern is tissue specific. 
Szafranska et al. (Szafranska et al., 2007) demonstrated that two miRNAs, miR-216 and miR-
217, are pancreas specific, which was in agreement with two previous studies (Sood et al., 
2006). Furthermore, both miR-216 and miR-217 are absent or only minimally expressed in 
pancreatic carcinoma tissues and cell lines. Therefore, miR-216 and miR-217 are potential 
biomarkers. Based on clustering analysis, the three pancreatic tissue types (normal pancreas, 
chronic pancreatitis and pancreatic cancer) can be classified according to their respective 
miRNA expression profiles. Among 26 miRNAs that have been identified as most 
prominently deregulated in PDAC, only miR-217 and miR-196a have been found to 
discriminate between normal pancreas, chronic pancreatitis and tumor tissues. These 
miRNAs are also potential biomarkers. 
Zhang et al. (Zhang et al., 2009) evaluated 95 miRNAs, which were selected from pancreatic 
cancer profiling, and correlated them with their potential biological functions, such as 
cancer biology, cell development, and apoptosis. Among them, eight miRNAs (miR-196a, 
miR-190, miR-186, miR-221, miR-222, miR-200b, miR-15b and miR-95) are differentially 
expressed in most pancreatic cancer tissues and cell lines. These eight genes are all 
significantly up-regulated, from 3- to 2018-fold, in pancreatic tumors compared with normal 
control samples. 
miRNAs are functionally classified as oncogenes or tumor suppressors based on whether 
their targets are oncogenes or tumor suppressor genes. Therefore, oncogenic miRNAs are 
upregulated in tumors, whereas tumor suppressor miRNAs are downregulated. Torrisani et 
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al. (Torrisani et al., 2009) have reported that the tumor suppressor let-7 miRNA is expressed 
in normal acinar pancreatic cells but is extensively downregulated in PDAC samples 
compared with adjacent unaffected tissues.  
2.5.3 miRNAs and clinical applications 
2.5.3.1 miRNAs as biomarkers for pancreatic cancer diagnosis 
Recent studies indicate that aberrant miRNA expression occurs early in the precursor 
lesions during the multiple stages of pancreatic cancer development. In addition, miRNA 
profiles may be assessed in more clinically accessible samples, such as pancreatic juice, and 
may be used as a diagnostic tool. 
Szafranska et al. (Szafranska et al., 2008) identified potential miRNA markers in EUS-FNA 
biopsies of pancreatic tissue. The results show that the combined expression pattern of miR-
196a and miR-217 can differentiate PDAC cases from healthy controls and chronic 
pancreatitis in the FNA samples. Furthermore, miR-196a expression is likely to be specific to 
PDAC cells and is positively associated with the progression of PDAC.  
The potential use of these miRNAs as biomarkers has been evaluated in pancreatic juices. 
Habbe et al. (Habbe et al., 2009) have observed significant overexpression of 10 miRNAs in 
IPMNs (n = 15). miR-155 and miR-21 show the highest relative fold-changes in the precursor 
lesions. The upregulation of both miR-155 and miR-21 in the subset of IPMN-associated 
pancreatic juices was observed. 
Wang et al. (Wang et al., 2009) have studied plasma samples from patients with PDAC and 
found that four miRNAs (miR-21, miR-210, miR-155 and miR-196a) are able to differentiate 
pancreatic cancer patients from healthy controls with moderate accuracy (64% sensitivity 
and 89% specificity). 
2.5.3.2 miRNAs as therapeutic targets in pancreatic cancer 
Several studies have shown that the events leading to EMT are regulated by miRNAs 
(Gregory et al., 2008; Korpal & Kang, 2008; Wellner et al., 2009). Li et al. (Li et al., 2009) 
investigated the effects of let-7 and miR-200 on the morphological changes of EMT in 
gemcitabine-resistant pancreatic cancer cells (GRPCCs). They noted several observations: (1) 
the expression of miR-200 and let-7 is significantly downregulated in GRPCCs, which have 
EMT characteristics; and (2) transfection of GRPCCs with miR-200 rescues the epithelial 
phenotype by upregulating the epithelial marker E-cadherin and downregulating the 
mesenchymal markers ZEB1 and vimentin. 
Oh et al. (Oh et al., 2010) have shown that upregulation of let-7a results in the attenuated 
expression of Kras and increased radiosensitization of pancreatic cancer cells. This suggests 
that miRNA could be used as a valuable therapeutic option in radioresistant tumors that 
have K-ras mutations. 
Weiss et al. (Weiss et al., 2009) have shown that miR-10a expression promotes metastasis, 
and repression of miR-10a inhibits invasion and metastasis in xenotransplantation 
experiments using zebrafish embryos. These data also suggest new therapeutic applications 
for miRNA in patients with metastatic pancreatic cancer. 
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Moriyama et al. (Moriyama et al., 2009) showed that miR-21 could be a target for a 
therapeutic strategy for patients with chemoresistant pancreatic cancer. Ji et al. (Ji et al., 
2009) showed that miRNAs, such as miR-34, can be a novel molecular therapy for human 
pancreatic cancer via inhibiting pancreatic cancer stem cell differentiation. 
Overall, many reasearchers suggest that miRNA play an important role in pancreatic 
carcinogenesis. However, many questions about the function and clinical application need 
to be further answered for pancreatic cancer.  
2.6 A multistep model that involves the accumulation of genetic alterations during the 
development of pancreatic cancer  
We now know that the development of pancreatic cancer, like other malignant diseases, is a 
multistep process involving the accumulation of genetic and epigenetic mutations. 
Furthermore, it has been shown that some genetic alterations occur early in the disease and 
can be designated disease-promoting mutations, whereas others occur later and enhance the 
oncogenic potential of earlier mutations. Three different types of preneoplastic lesions have 
been identified in the pancreas: pancreatic intraepithelial neoplasia (PanIN), intraductal 
papillary mucinous neoplasia (IPMN) and mucinous cystic neoplasms (MCN). Of these, 
PanIN lesions are the best characterized, both genetically and pathologically. A well-known 
progression model of pancreatic cancer development explains that normal pancreatic ductal 
cells progress from flat (PanIN-1A) and papillary lesions (PanIN-1B) without dysplasia to 
papillary lesions with dysplasia (PanIN-2) to carcinoma in situ (PanIN-3) and finally to 
invasive pancreatic cancer (Hruban et al., 2008).  
There are two distinct genetic events that occur in the early stages of pancreatic cancer 
PanIN -1 lesions: telomere shortening and K-ras mutations (Hruban et al., 2000). Activating 
point mutations of K-ras occur in approximately 45% of PanIN-1 lesions (Hingorani et al., 
2003). Telomere shortening is found in approximately 90% of PanIN-1 lesions and may 
contribute to global chromosomal abnormalities in PanINs (van et al., 2002). Inactivating 
mutations of CDKN2A/p16 begin to occur in PanIN-2 lesions, whereas inactivation of TP53, 
SMAD4/DPC4, and BRCA2 are generally associated with higher-grade PanIN lesions 
(PanIN-3) (Schonleben et al., 2008). 
Furthermore, a recent study described a cell surface marker-mediated system for identifying 
pancreatic cancer stem cells. Pancreatic cancer cells share several features with embryonic 
pancreatic cells, including activation of the Notch and Hedgehog signaling pathways, which 
regulate the growth of many organs during embryogenesis and is aberrantly activated in 
pancreatic cancer cells (Hong et al., 2011; Wong & Lemoine, 2009). The Notch pathway is a 
critical regulator of pancreatic development and appears to be active in the early stages of 
pancreatic cancer initiation as well as in invasive cancers. Activation of this pathway leads 
to the proteolytic intramembrane cleavage of Notch receptors, which results in the release 
and translocation of their active intracellular domain to the nucleus. Moreover, the 
upregulation of several Notch target genes in invasive pancreatic cancer as well as 
preneoplastic lesions suggests that this pathway is an important contributing factor in the 
development of pancreatic cancer (Maitra & Hruban, 2008). 
The activity of the Hedgehog pathway is another important pathway in the development of 
the gastrointestinal tract and has been implicated in the development and maintenance of 
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al. (Torrisani et al., 2009) have reported that the tumor suppressor let-7 miRNA is expressed 
in normal acinar pancreatic cells but is extensively downregulated in PDAC samples 
compared with adjacent unaffected tissues.  
2.5.3 miRNAs and clinical applications 
2.5.3.1 miRNAs as biomarkers for pancreatic cancer diagnosis 
Recent studies indicate that aberrant miRNA expression occurs early in the precursor 
lesions during the multiple stages of pancreatic cancer development. In addition, miRNA 
profiles may be assessed in more clinically accessible samples, such as pancreatic juice, and 
may be used as a diagnostic tool. 
Szafranska et al. (Szafranska et al., 2008) identified potential miRNA markers in EUS-FNA 
biopsies of pancreatic tissue. The results show that the combined expression pattern of miR-
196a and miR-217 can differentiate PDAC cases from healthy controls and chronic 
pancreatitis in the FNA samples. Furthermore, miR-196a expression is likely to be specific to 
PDAC cells and is positively associated with the progression of PDAC.  
The potential use of these miRNAs as biomarkers has been evaluated in pancreatic juices. 
Habbe et al. (Habbe et al., 2009) have observed significant overexpression of 10 miRNAs in 
IPMNs (n = 15). miR-155 and miR-21 show the highest relative fold-changes in the precursor 
lesions. The upregulation of both miR-155 and miR-21 in the subset of IPMN-associated 
pancreatic juices was observed. 
Wang et al. (Wang et al., 2009) have studied plasma samples from patients with PDAC and 
found that four miRNAs (miR-21, miR-210, miR-155 and miR-196a) are able to differentiate 
pancreatic cancer patients from healthy controls with moderate accuracy (64% sensitivity 
and 89% specificity). 
2.5.3.2 miRNAs as therapeutic targets in pancreatic cancer 
Several studies have shown that the events leading to EMT are regulated by miRNAs 
(Gregory et al., 2008; Korpal & Kang, 2008; Wellner et al., 2009). Li et al. (Li et al., 2009) 
investigated the effects of let-7 and miR-200 on the morphological changes of EMT in 
gemcitabine-resistant pancreatic cancer cells (GRPCCs). They noted several observations: (1) 
the expression of miR-200 and let-7 is significantly downregulated in GRPCCs, which have 
EMT characteristics; and (2) transfection of GRPCCs with miR-200 rescues the epithelial 
phenotype by upregulating the epithelial marker E-cadherin and downregulating the 
mesenchymal markers ZEB1 and vimentin. 
Oh et al. (Oh et al., 2010) have shown that upregulation of let-7a results in the attenuated 
expression of Kras and increased radiosensitization of pancreatic cancer cells. This suggests 
that miRNA could be used as a valuable therapeutic option in radioresistant tumors that 
have K-ras mutations. 
Weiss et al. (Weiss et al., 2009) have shown that miR-10a expression promotes metastasis, 
and repression of miR-10a inhibits invasion and metastasis in xenotransplantation 
experiments using zebrafish embryos. These data also suggest new therapeutic applications 
for miRNA in patients with metastatic pancreatic cancer. 
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Moriyama et al. (Moriyama et al., 2009) showed that miR-21 could be a target for a 
therapeutic strategy for patients with chemoresistant pancreatic cancer. Ji et al. (Ji et al., 
2009) showed that miRNAs, such as miR-34, can be a novel molecular therapy for human 
pancreatic cancer via inhibiting pancreatic cancer stem cell differentiation. 
Overall, many reasearchers suggest that miRNA play an important role in pancreatic 
carcinogenesis. However, many questions about the function and clinical application need 
to be further answered for pancreatic cancer.  
2.6 A multistep model that involves the accumulation of genetic alterations during the 
development of pancreatic cancer  
We now know that the development of pancreatic cancer, like other malignant diseases, is a 
multistep process involving the accumulation of genetic and epigenetic mutations. 
Furthermore, it has been shown that some genetic alterations occur early in the disease and 
can be designated disease-promoting mutations, whereas others occur later and enhance the 
oncogenic potential of earlier mutations. Three different types of preneoplastic lesions have 
been identified in the pancreas: pancreatic intraepithelial neoplasia (PanIN), intraductal 
papillary mucinous neoplasia (IPMN) and mucinous cystic neoplasms (MCN). Of these, 
PanIN lesions are the best characterized, both genetically and pathologically. A well-known 
progression model of pancreatic cancer development explains that normal pancreatic ductal 
cells progress from flat (PanIN-1A) and papillary lesions (PanIN-1B) without dysplasia to 
papillary lesions with dysplasia (PanIN-2) to carcinoma in situ (PanIN-3) and finally to 
invasive pancreatic cancer (Hruban et al., 2008).  
There are two distinct genetic events that occur in the early stages of pancreatic cancer 
PanIN -1 lesions: telomere shortening and K-ras mutations (Hruban et al., 2000). Activating 
point mutations of K-ras occur in approximately 45% of PanIN-1 lesions (Hingorani et al., 
2003). Telomere shortening is found in approximately 90% of PanIN-1 lesions and may 
contribute to global chromosomal abnormalities in PanINs (van et al., 2002). Inactivating 
mutations of CDKN2A/p16 begin to occur in PanIN-2 lesions, whereas inactivation of TP53, 
SMAD4/DPC4, and BRCA2 are generally associated with higher-grade PanIN lesions 
(PanIN-3) (Schonleben et al., 2008). 
Furthermore, a recent study described a cell surface marker-mediated system for identifying 
pancreatic cancer stem cells. Pancreatic cancer cells share several features with embryonic 
pancreatic cells, including activation of the Notch and Hedgehog signaling pathways, which 
regulate the growth of many organs during embryogenesis and is aberrantly activated in 
pancreatic cancer cells (Hong et al., 2011; Wong & Lemoine, 2009). The Notch pathway is a 
critical regulator of pancreatic development and appears to be active in the early stages of 
pancreatic cancer initiation as well as in invasive cancers. Activation of this pathway leads 
to the proteolytic intramembrane cleavage of Notch receptors, which results in the release 
and translocation of their active intracellular domain to the nucleus. Moreover, the 
upregulation of several Notch target genes in invasive pancreatic cancer as well as 
preneoplastic lesions suggests that this pathway is an important contributing factor in the 
development of pancreatic cancer (Maitra & Hruban, 2008). 
The activity of the Hedgehog pathway is another important pathway in the development of 
the gastrointestinal tract and has been implicated in the development and maintenance of 
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the pancreatic cancer phenotype. The Hedgehog family is composed of Sonic Hedgehog 
(Shh), Indian Hedgehog (Ihh), and Desert Hedgehog (Dhh). Many studies have shown that 
many of the components of the Hedgehog family show abnormal expression in pancreatic 
cancer and precursor lesions (Dosch et al., 2010). These studies indicate that Hedgehog 
signaling plays a role in the initiation and growth of pancreatic cancer (Kayed et al., 2006). 
Overall, multistep changes and pathway involves the development of pancreatic cancer. 
3. Conclusion 
As in colorectal cancer, two distinct tumor categories exist in pancreatic cancer, which are 
distinguishable by the predominant mutagenic mechanism. Most pancreatic cancers exhibit 
chromosomal instability (CIN), which causes numerous gross chromosomal changes that 
result in aneuploidy. A second category is characterized by microsatellite instability (MSI) 
(Vogelstein & Kinzler, 2004), which results in a drastically decreased fidelity of DNA 
replication and repair due to defects in the DNA mismatch-repair pathway. Therefore, MSI 
tumors exhibit frequent errors during DNA replication, which are particularly pronounced 
at repetitive sequences termed microsatellites.  
In the past decade, major advances have been made in understanding the earliest 
histological and molecular changes that occur in precursor lesions and cancers of the 
pancreas (Hruban & Adsay, 2009). In addition, the identification of molecular signatures 
that mark the earliest changes of carcinogenesis may lead to the earlier detection of 
pancreatic cancer. Understanding the signature of molecular alterations that occur before 
the development of invasive pancreatic cancer may lead to improved detection and survival 
of pancreatic cancer patients. 
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the pancreatic cancer phenotype. The Hedgehog family is composed of Sonic Hedgehog 
(Shh), Indian Hedgehog (Ihh), and Desert Hedgehog (Dhh). Many studies have shown that 
many of the components of the Hedgehog family show abnormal expression in pancreatic 
cancer and precursor lesions (Dosch et al., 2010). These studies indicate that Hedgehog 
signaling plays a role in the initiation and growth of pancreatic cancer (Kayed et al., 2006). 
Overall, multistep changes and pathway involves the development of pancreatic cancer. 
3. Conclusion 
As in colorectal cancer, two distinct tumor categories exist in pancreatic cancer, which are 
distinguishable by the predominant mutagenic mechanism. Most pancreatic cancers exhibit 
chromosomal instability (CIN), which causes numerous gross chromosomal changes that 
result in aneuploidy. A second category is characterized by microsatellite instability (MSI) 
(Vogelstein & Kinzler, 2004), which results in a drastically decreased fidelity of DNA 
replication and repair due to defects in the DNA mismatch-repair pathway. Therefore, MSI 
tumors exhibit frequent errors during DNA replication, which are particularly pronounced 
at repetitive sequences termed microsatellites.  
In the past decade, major advances have been made in understanding the earliest 
histological and molecular changes that occur in precursor lesions and cancers of the 
pancreas (Hruban & Adsay, 2009). In addition, the identification of molecular signatures 
that mark the earliest changes of carcinogenesis may lead to the earlier detection of 
pancreatic cancer. Understanding the signature of molecular alterations that occur before 
the development of invasive pancreatic cancer may lead to improved detection and survival 
of pancreatic cancer patients. 
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1. Introduction  
Pancreatic cancer remains to be one of the most lethal solid tumours of the gastrointestinal 
tract with a 5-year survival rate lower than 5%. It is characterised by late diagnosis, 
aggressive local invasion, early systemic dissemination and resistance to chemo- and radio-
therapy. At the time of diagnosis more than 85% of patients have already developed 
metastasis and are therefore not eligible for local treatments with curative intention such as 
surgery or radiotherapy. Chemotherapy with Gemcitabine is the mainstay of palliative 
treatment with modest antitumour effects in these patients.  
The process of cancer initiation, progression and metastasis remains to be poorly 
understood. Little is known about the development of metastatic progression and the 
dissemination of cells from the primary tumour site into distant organs. A better 
understanding and thorough investigation of the biology behind pancreatic cancer invasion 
and metastasis is urgently needed. Current concepts and emerging fields of research in 
pancreatic cancer metastasis shall be discussed in this chapter. 
2. Mechanisms of metastatic evolution  
Metastasis has been conventionally viewed as the last step in a cumulative process of 
genetic alterations within cells of a primary tumour mass. For metastatic cells to progress, 
they have to acquire distinct properties such as loss of cell adhesion, acquisition of an 
invasive potential, ability of intravasation, transport through the circulation, extravasation, 
formation of micro-metastases, and finally the ability to induce an angiogenic switch to form 
macro-metastasis (Coghlin & Murray, 2010). This hypothesis has been recently challenged 
by several groups (Bernards & Weinberg, 2002; Weinberg, 2008; Klein, 2008). An alternative 
model is proposed that considers the genetic alterations accumulated at the initial stages of 
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metastasis and are therefore not eligible for local treatments with curative intention such as 
surgery or radiotherapy. Chemotherapy with Gemcitabine is the mainstay of palliative 
treatment with modest antitumour effects in these patients.  
The process of cancer initiation, progression and metastasis remains to be poorly 
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invasive potential, ability of intravasation, transport through the circulation, extravasation, 
formation of micro-metastases, and finally the ability to induce an angiogenic switch to form 
macro-metastasis (Coghlin & Murray, 2010). This hypothesis has been recently challenged 
by several groups (Bernards & Weinberg, 2002; Weinberg, 2008; Klein, 2008). An alternative 
model is proposed that considers the genetic alterations accumulated at the initial stages of 
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tumour’s evolution to be sufficient to promote the metastasis process. Two distinct models 
arising from this hypothesis are discussed in the following section. 
2.1 Metastasis: Progression models 
2.1.1 Late metastasis (linear progression) model  
This model is based on Leslie Fould’s description of a step-wise progression of 
morphological abnormalities accompanying cancer (Klein, 2009). It places selection of 
genetic and epigenetic modifications mostly inside the established primary tumour for 
competitive fitness. After multiple rounds, the cells may be able to proliferate relatively 
autonomously at a competitive rate and seed to secondary metastatic niche sites (Fig.1). Late 
disseminating cells are expected to be genetically identical to the parental cells of the 
primary tumour and should be subject to similar tumour cell targeting therapeutic 
modalities (Klein, 2008, 2009; Coghlin & Murray, 2010).  
 
Fig. 1. Models of metastasis evolution: in the late metastasis model, cells acquire genetic and 
epigenetic modifications mainly in the primary tumour site of the organ. Mutated cells 
disseminate within the blood stream into the final metastatic niche. However, in the early 
metastasis model cells accumulate genetic alterations at distant sites and thus diverge from 
the primary tumours at both genetic and epigenetic levels. 
Pancreatic Cancer: Current Concepts in Invasion and Metastasis 63 
2.1.2 Early metastasis (parallel progression) model 
In contrast to the late metastasis model, here tumour cells are believed to leave the primary 
site quite early up-on activation of factors such as Twist (master regulator of embryonic 
morphogenesis) with a major role in metastasis during tumourigenesis (Yang et al., 2004) 
and to diverge genetically at ectopic sites whereby they generate a further cascade of 
metastatic cells (Fig.1). Owing to the different selection pressures at different niches 
(metastastic sites) and inherent genetic instability of tumour cells, parallel progression 
predicts greater variation among metastatic founder and primary tumour cells. 
Consequently they may respond differently to systemically administered drugs (Klein, 2008, 
2009; Coghlin & Murray, 2010).  
2.2 Progression of metastasis in pancreas cancer  
Whether the dismal prognosis of patients with pancreatic cancer compared to those with 
other cancer types is a consequence of late diagnosis or early dissemination to distant organs 
is still debated. In a study performed by Yachida et al., data generated from sequencing of 
the genomes of seven pancreatic cancer metastases, were used to evaluate any clonal 
relationship between primary and their corresponding metastatic cancers. After 
development of the parental clone, clonal evolution continues within the parental site giving 
rise to distant metastases. They provided evidence that primary pancreatic cancers contain a 
mix of geographically and genetically distinct sub-clones, each harbouring large numbers of 
cells that are present within the primary tumour years before the metastases become 
clinically apparent (Yachida et al., 2010). Additional studies led to estimation of at least three 
time-scales associated with tumour progression: the time between tumour initiation to 
establishment of the founder cell of the parental clone (average 10 years, T1); the sojourn 
time between the arising parental clone and its acquisition of metastatic potential (average 
6.8 years, T2); and the time from metastatic dissemination to patient’s death (average 2.7 
years, T3) (Yachida et al., 2010; Lubeck, 2010). Unfortunately, the vast majority of cancer 
patients are diagnosed within the last two years of tumour development. The great 
challenge would rather be the detection of these lesions during or shortly after T1, but 
before T2-T3 i.e., the seeding of metastases.  
3. The host and the tumour micro-environment 
Malignant cells do not exist in isolation, but are rather intensely communicating with the 
surrounding cells in their micro-environment such as microvessel endothelial cells, 
macrophages, fibroblasts, bone-marrow-derived cells etc. These interactions significantly 
contribute to tumour proliferation, local invasion and distant metastasis. 
3.1 Pancreatic stellate cells: Role in pancreatic cancer metastasis 
The transition of the pancreatic stellate cells (PSC) from a quiescent to an ‘’activated’’ or 
‘’myofibroblastic’’ state plays a key role in various pathogenic disorders of the exocrine 
pancreas. In quiescent state, PSC express intermediate filament proteins desmin, glial 
fibrillary acidic protein (GFAP), vimentin and nestin. Up-on activation, induced by various 
stimuli such as injury, PSC attain other markers such as smooth muscle actin (SMA), and 
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tumour’s evolution to be sufficient to promote the metastasis process. Two distinct models 
arising from this hypothesis are discussed in the following section. 
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modalities (Klein, 2008, 2009; Coghlin & Murray, 2010).  
 
Fig. 1. Models of metastasis evolution: in the late metastasis model, cells acquire genetic and 
epigenetic modifications mainly in the primary tumour site of the organ. Mutated cells 
disseminate within the blood stream into the final metastatic niche. However, in the early 
metastasis model cells accumulate genetic alterations at distant sites and thus diverge from 
the primary tumours at both genetic and epigenetic levels. 
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2.1.2 Early metastasis (parallel progression) model 
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‘’myofibroblastic’’ state plays a key role in various pathogenic disorders of the exocrine 
pancreas. In quiescent state, PSC express intermediate filament proteins desmin, glial 
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interstitial collagen type I. Therefore, activated PSC constitute a major source for 
development of tissue fibrosis attributed to e.g. chronic pancreatitis and pancreatic 
adenocarcinoma (PDAC) (Omary et al., 2007; Hwang et al., 2008). 
Intense fibrotic reaction referred to as tumour desmoplasia is a hallmark of pancreatic 
cancer (Cruickshank et al., 1986; Hwang et al., 2008; Bachem et al., 2008; He et al., 2007; 
Erkan et al., 2010) whereby infiltrating carcinoma cells get surrounded by a dense fibrotic 
stroma consisting mainly of collagen types I and III as well as fibronectin (Imamura et al., 
1995; Bachem et al., 2008). PSC, attracted by pancreatic cancer cells, get activated by various 
paracrine stimulants and growth factors, such as platelet-derived growth factor (PDGF) 
rendering them motile and proliferative, fibrogenic mediators such as transforming growth 
factor beta (TGFβ) which stimulate matrix synthesis resulting in this desmoplastic reaction, 
cytokines such as interleukin Il-1, Il-6, Il-8, and tumour necrosis factor alpha (TNFα) (Omary 
et al., 2007; Bachem et al., 2008). Among the key implications of the desmoplastic reaction 
are the promotion of survival and prevention of apoptosis of pancreatic tumour cells 
through direct interaction with extra-cellular matrix (ECM), increased production of matrix 
metalloproteases (MMP) and serine proteases such as members of the plasminogen activator 
system (Vaquero et al., 2003; Edderkaoui et al., 2005). 
Additionally, soluble factors produced by PSC themselves stimulate the proliferation and 
survival of pancreatic cancer cells. Hwang et al. have shown that co-injection of PSC along 
with pancreatic cancer cells increases tumour incidence, size, and metastasis in an 
orthotopic model of pancreatic cancer (Hwang et al., 2008). In addition, combined 
inoculation of human pancreatic cancer and stellate cells in a xenograft model was shown to 
promote tumour growth and progression as compared to inoculation of tumour cells alone 
(Bachem et al, 2008). In another study, significantly elevated expression of urokinase 
plasminogen activator (uPA) as well as fibroblastic uPA receptor (uPAR) was correlated 
with liver metastasis of human pancreatic cancers, indicating a possible role of stromal 
fibroblasts in promoting pancreas cancer dissemination. Co-culturing of peri-tumour 
fibroblasts with metastatic BxPC3 pancreas cancer cells activates matrix metalloprotease-2 
(MMP-2) and up-regulates uPAR expression, along with elevated expression of integrin 
α6β1 in BxPC3 cells. This suggests a possible interaction between integrins of cancer cells 
and the uPAR of the stromal fibroblasts along the uPAR-uPA-MMP-2 cascade (He et al, 
2007). Moreover, Buechler et al. demonstrate a de novo transcriptional regulation of uPAR 
mRNA by the hypoxia-inducible factor-1 (HIF-1), accompanied by an increased rate of 
hypoxia-induced metastasis (Buechler et al., 2009). Taken all together, pancreas cancer 
growth and progression are accelerated via an orchestrated functional interaction among 
carcinoma cells and stellate/stromal fibroblast cells. 
3.2 Tumour-associated macrophages: Role in cancer metastasis 
Tumour-associated macrophages (TAM) are bone-marrow-derived cells capable of 
promoting tumour invasion, angiogenesis, immune evasion, and migration (Allavena et al., 
2008; Coghlin & Murray, 2010). In normal tissues, pathogenic challenge or wounding results 
in the local expression of a variety of growth factors e.g. colony stimulating factor 1 (CSF1) 
also known as macrophage CSF, granulocyte-macrophage CSF (GM-CSF), TGFβ1, in 
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addition to various chemokines such as CCL2, CCL7, CCL8, CCL3 CCL4. Such a milieu 
recruits circulating monocytes and stimulates their differentiation into macrophages 
(Pollard et al., 2004).  
At the primary tumour site, hypoxia-related factors and oncogenic induction of pro-
inflammatory mediators mentioned above also result in the recruitment of macrophages 
(TAM) as well as mobilisation of bone-marrow-derived progenitor cells. TAM may there-
after stimulate angiogenesis by expressing factors such as vascular endothelial growth 
factor (VEGF), and angiopoietin 1/2 (ANG1-ANG2). Moreover, they recruit 
hematopoietic cells (e.g., mast cells or neutrophils) which exert similar functions (Pollard 
et al., 2004).  
Along with activated stromal cells, TAM act synergistically with malignant cells to degrade 
the ECM and release growth factors favouring invasiveness. TAM promote invasion by 
producing proteases that digest the basement membrane and remodel the stromal matrix. 
Additionally, they produce multiple growth factors which stimulate the growth of the 
tumour cells themselves (Pollard et al., 2004).  
4. Local invasion and distant metastasis 
4.1 The epithelial-to-mesenchymal transition (EMT) 
Epithelial-to-mesenchymal transition (EMT) describes a biologic process in which polarised 
epithelial cell under-go various bio-chemical modifications and ultimately gain 
mesenchymal characteristics i.e., enhanced migration and invasiveness, increased resistance 
to apoptosis, as well production of ECM components (Kalluri & Neilson, 2003). A proposal 
has been made which classifies EMT into three different sub-types. Type 1 EMT is associated 
with implantation and embryonic gastrulation and gives rise to the mesoderm, endoderm 
and to mobile neural crest cells. On the other hand, type 2 EMT promotes organ fibrosis 
mediated by inflammatory cells. The last type of EMT, type 3, is associated with cancer 
progression and metastasis (Kalluri & Weinberg, 2009).  
The EMT process is characterised by decreased expression of Epithelial cell-cell junction 
molecule E-cadherin along with increased expression of non-epithelial cadherins mostly N-
cadherin and acquisition of mesenchymal cytoskeleton markers such as vimentin and SMA, 
accompanied by nuclear beta-catenin accumulation (Shintani et al., 2006; Yang & Weinberg, 
2008; Coghlin & Murray, 2010). Tumour cells undergoing EMT are typically seen at the 
invasive fronts of primary tumours. These cells may eventually enter into subsequent steps 
of the invasion-metastasis cascade namely intravasation, transport through the circulation, 
extravasation, formation of micro-metastases, and colonisation (Fig. 2) (Thiery, 2002, 2003; 
Fidler & Poste, 2008; Brabletz et al., 2001).  
EMT is initiated by extra-cellular signals e.g. hepatocyte growth factor (HGF), fibroblast 
growth factor (FGF), epidermal growth factor (EGF), and TGFβ which activate multiple 
EMT-inducing transcription factors notably Snail, Slug, zinc finger E-box binding homoebox 
(ZEB1) and Twist (Savagner et al., 2001; Lee et al., 2006; Shintani et al., 2006; Kalluri & 
Weinberg, 2009). Activation of EMT cascade also involves the disruption of cell-cell 
adherens junctions and integrin-mediated adhesion in the ECM.  
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Fig. 2. The role of EMT in cancer metastasis: epithelial tumour cells lose their polarity and 
detach from the basement membrane. This situation is referred to as carcinoma in situ. 
During the EMT process, primary epithelial tumour cells undergo various modifications 
whereby they lose their epithelial markers and acquire mesenchymal properties, i.e. digest 
the basic membrane and invade the surrounding tissue. The onset of angiogenic switch and 
establishment of abnormal tumour neo-vasculature favours the intravasation of metastatic 
cells into the blood-stream. Only a small fraction of disseminated tumour cells (DTC) 
survive in circulation, extravasate into distant organs and form single cell or small tumour 
colonies also called micro-metastases. DTCs or micro-metastases could remain dormant for 
a prolonged period of time until they eventually switch to angiogenic macroscopic 
metastatic lesion and become clinically apparent (Folkman & Kalluri, 2004; Almog et al., 
2009). Interestingly, metastatic lesions derived from carcinomas demonstrate the epithelial 
characteristic of their primary tumour of origin suggesting that according to this model 
mesenchymal to epithelial transition (MET) occur during tumour colonisation in the distant 
sites.  
4.2 Matrix metalloproteases (MMP) 
MMP are a family of enzymes involved in degradation of ECM components e.g. collagen 
and fibronectin (Jimenez et al., 2000). MMP of either malignant cells or induced fibroblasts 
at the invasive front are thought to mediate cancer invasion and metastasis via disruption of 
tumour cell adhesion molecules and degradation of basement membranes and other matrix 
components.  
Immunohistochemical studies have demonstrated over-expression of active MMP-2, MMP-9 
(Gress et al., 1995; Koshiba et al., 1998), MMP-7 and MMP-11 (Bramhall et al. 1997) in 
tumours with lymph node metastasis. The involvement of MMP-1 in promoting 
angiogenesis and metastatic spread has been recently linked to pancreatic cancer (Abdollahi 
et al., 2007). Using an orthotopic mouse model of pancreatic cancer, the MMP inhibitor 
Batimastat was shown to improve the survival and to reduce growth of tumours in mice 
implanted with HPAC, a moderately differentiated pancreatic cancer cell line (Zevros et al., 
1997). Recent work in multiple carcinomas suggests a crucial role of transcriptional 
regulators Snail and Slug in the regulation of E-Cadherin expression (Gavert & Ben-Ze’ev, 
2008). In pancreatic cancer, Slug is shown to promote the invasiveness of tumour cells 
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through up-regulating ECM proteins such as MMP-9 along with remodeling of the actin 
cytoskeleton (Zhang et al., 2011).  
4.3 Growth factor expression patterns in pancreas metastasis  
Among its pleiotropic effects TGFβ was shown to potently induce EMT in different 
tumours. TGFβ signalling in pancreatic cancer is often attenuated because of alterations in 
components of this pathway (Jonson et al., 2001). Using genetic array data, genes responsive 
to TGFβ in pancreas cancer cell line PANC-1 are depicted to be involved in ECM 
remodeling, cell motility, adhesion, angiogenesis, cell cycle, proliferation and apoptosis 
(Gaspar et al., 2006). Negative regulation of E-cadherin necessary for EMT has been 
observed in PANC-1 cultures (Halder et al., 2005), and has been associated with lymph node 
metastasis (Pignatelli et al., 1994). Regulation of JAG1 by TGFβ on the array is interesting 
because its gene product Jagged1 (Notch ligand), is influenced by TGFβ in cultured 
epithelial cells. Notch signalling is an important cell signalling pathway involved in 
regulation of the balance between cell proliferation, differentiation, and apoptosis. Notch-1 
has been reported to induce nuclear factor κB (NFκB) promoter activity (Jang et al., 2004). 
Down-regulation of Notch-1, and consequently of NFκB and MMP-9 inhibits invasion of 
pancreatic cancer cells through matrigel (Wang et al., 2006). Inhibition of TGFβ signalling 
reduces PDAC growth and invasiveness (Gaspar et al., 2006). 
TGFβ signalling is altered in human pancreas cancer cells with one half of tumours showing 
allelic deletions or inactivating mutations of the Smad4 gene. These cells show an enhanced 
TGFβ-mediated EMT as determined by increased vimentin expression and decreased beta-
catenin and E-cadherin expression. TGFβ-mediated invasion is suppressed in Smad4 intact 
cells in vitro which show reduced dissemination in an orthotopic pancreatic cancer model 
(Zhao et al., 2008). Interestingly, cells with an intact Smad pathway reveal reduced 
activation of signal transducer and activator of transcription (STAT3). STAT3 is 
constitutively activated in various carcinomas and plays a pivotal role in regulating cell 
growth, cell survival and angiogenesis (Yu & Jove, 2003; Abdollahi et al., 2004). Inhibition of 
STAT3 phosphorylation by Smad4 suppresses TGFβ-mediated invasion and metastasis of 
pancreatic cancer cells (Zhao et al., 2008). Therefore, reconstitution of Smad4 activity or 
suppression of STAT3 down-stream signalling constitutes attractive targets to inhibit TGFβ-
induced EMT and pro-metastatic effects.  
Other factors known to be frequently over-expressed in several human malignancies and to 
be associated with invasion of tumour cells are the insulin-like growth factor I receptor (IGF-
IR) and HGF receptor c-Met. IGF-IR over-expression and excessive activation are associated 
with malignant transformation, tumour aggressiveness, and protection from apoptosis 
(Macaulay, 1992;  Sell et al., 1995). Over-expression of IGF-IR, reported in pancreatic 
carcinomas, is regulated by AKT activation thereby promoting invasiveness of human 
pancreatic cells (Tanno et al., 2001). Furthermore IGF-IR and c-Met co-operate 
synergistically to induce migration and invasion of human pancreatic carcinoma cells (Bauer 
et al., 2006). 
EGFR is over-expressed in approximately 90% of pancreatic carcinoma and is associated 
with poor prognosis. Blocking of EGFR signalling in various animal models reduces growth 
and spread of pancreas carcinoma (Baselga & Arteaga, 2005). Of note, low-molecular weight 
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tyrosine kinase inhibitors targeting EGFR such as erlotinib are the only class of targeted 
inhibitors so far demonstrating additional mild benefits when combined with gemcitabine 
versus gemcitabine mono-therapy in treatment of metastatic PDAC (Moore et al., 2007). 
Accordingly, erlotinib is the only targeted therapy currently approved for clinical use in 
PDAC. In extension of this work, dual inhibition of EGFR signalling using erlotinib (alone or 
in combination with gemcitabine) and of hedgehog signalling with cyclopamine were 
shown to inhibit tumour growth, increase apoptosis, and suppress the dissemination of 
pancreatic cancer cells (Feldman et al., 2007; Mimeault et al., 2005, Hu et al., 2007). 
4.4 Hypoxia and angiogenesis  
The presence of significant hypoxia in pancreatic cancers has been long suspected due to the 
relatively poor contrast agent enhancement of pancreatic cancer lesions suggestive of hypo-
vascular regions in e.g. computer tomography (CTscans, Megibow, 1992). Koong et al. 
directly detected hypoxia in pancreas cancer by placement of intra-tumoural needles 
measuring tissue oxygen levels at the time of resection in seven operable pancreatic cancer 
patients (Koong et al., 2000). Hypoxia renders tumours more aggressive, and resistant to 
chemo- and radio-therapy (Garcea et al., 2006, Abdollahi et al. 2005). Therefore, the 
combination of desmoplastic reaction and strong intra-tumoural hypoxia synergistically 
contribute to the inherent resistance of pancreas cancer against cancer therapies such as 
chemotherapy. 
For a tumour or any other tissue to grow above the size of 1mm3, recruitment of new vessels 
is required. This process is termed tumour angiogenesis (Folkman, 1971). The “angiogenic 
switch” is considered a hallmark of cancer and refers to the phenomenon in which the 
balance of pro- and anti-angiogenic factors is shifted towards the pro-angiogenic state 
(Hanahan & Folkman, 1996; Abdollahi et al., 2005; Hanahan & Weinberg, 2011). 
Nevertheless, the hypo-vascular phenotype of pancreatic tumours observed by contrast 
enhanced non-invasive imaging techniques misled the research in this field to precept that 
angiogenesis is not playing a key role in development of PDAC. The role of an angiogenic 
micro-environment in development of pancreatic cancer is only recently reported 
(Abdollahi et al., 2007). It is shown that the angiogenic state gradually switches from normal 
pancreas (off) to chronic inflammation (pancreatitis, intermediate) to primary pancreatic 
tumour and distant metastases (on). These data indicate that aberrant pro-angiogenic micro-
environment might contribute to the 19-fold increased cancer risk in patients with chronic 
pancreatitis (Abdollahi et al., 2007). Although several angiogenic factors have been 
associated with PDAC, most of the studies have so far focused on VEGF reporting its pivotal 
role in stimulation of endothelial cell proliferation, migration, gene activation, and apoptosis 
evasion (Dvorak et al., 1995; Ferrara, 1999, Abdollahi et al. 2005). VEGF is a dimeric cytokine 
with members including VEGF-A (most common isoform), VEGF-B, VEGF-C, VEGF-D and 
VEGF-E. VEGF-A exerts its effects on target endothelial cells via binding to its specific trans-
membrane tyrosine kinase receptors VEGFR-1 and VEGFR-2 (Ferrara, 1999; Dvorak, 2002). 
Hypoxia has been shown to stimulate VEGF transcription in pancreatic carcinoma cell lines. 
This requires Src activation and leads to increased steady-state levels of HIF-1α and 
increased phosphorylation of STAT3. Expression of VEGF in STAT3 or HIF-1α dominant 
negative mutants is significantly reduced. Together, STAT3 and HIF-1α are both required 
for maximum transcription of VEGF mRNA following hypoxia (Gray et al., 2005).  
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4.4.1 Local invasion and lymph-angiogenesis 
Tumour cell dissemination may follow several patterns e.g. local invasion, lymphatics, 
hematogenous spread, or direct seeding of body cavities or surfaces (Rubbia-Brandt et al., 
2004). The recent discovery of lymphatic endothelium-specific markers such as VEGFR-3, 
LYVE-1 and lymph-angiogenic growth factors VEGF-C and VEGF-D has allowed better 
understanding of tumour-associated de novo lymph-angiogenesis – the generation of new 
lymphatic vessel - in the metastatic process (Kopfstein et al., 2007). The expression of VEGF-
C and VEGF-D is reported in a variety of human tumours and is correlated with markers of 
lymphatic vessel density (LVD), lymph node metastasis and poor prognosis (Sleeman et al., 
2009). Tumour-associated lymphatic vessels have been reported to occur both peri- and/or 
intra-tumourally with the latter case correlating with lymph node metastasis and prognosis. 
In contrast to most tumours, in pancreatic carcinoma the correlation between lymph- 
angiogenesis marker and worse prognosis is still controversially debated (Sleeman &  
Thiele, 2009).  
VEGF-C and VEGF-D are the most extensively studied factors that enhance tumour-induced 
lymph-angiogenesis and lymph node metastsasis (Thiele & Sleeman, 2006). VEGF-C is 
highly expressed in pancreatic cancer tissue and cell lines, while its receptor VEGFR-3 is 
expressed on cancer stromal cells. Thus, local tumour growth is promoted via paracrine 
simulation of VEGFR-3 expressing stromal cells leading to the entry of cancer cells into peri-
tumoural lymphatics (Schneider et al., 2006). Kofstein et al. have used Rip1VEGF-D 
transgenic mouse model of pancreatic β-cell carcinogenesis to investigate the functional role 
of VEGF-D in inducing lymph-angiogenesis and tumour progression. They show that 
VEGF-D expressing tumours exhibit peri-tumoural lymphangiogenesis along with 
lymphocyte accumulations and hemorrhages, with frequent lymph node and lung but not 
hepatic metastases (Kofstein et al., 2007). Similar to VEFG-D, transgenic expression of VEGF-
C in Rip1VEGF-C model induces peri-tumoural, but not intra-tumoural lymph-
angiogenesis, and promoting lymph node metastasis without affecting blood vessel 
angiogenesis (Mandriota et al., 2001).  
Additional mechanisms are described to be involved in tumour lymph-angiogenesis e.g. 
insertion of endothelial cells into the existing lymphatic endothelium. The existence of 
lymphatic progenitor cells was attributed to the CD34+ CD133+ VEGFR-3+ expressing cells 
which could differentiate into cells expressing vascular and lymphatic endothelial cell 
markers (Salven et al., 2003). Moreover, expression of chemokine receptor CCR7 by tumour 
cells enables them to migrate to lymphatic endothelial cells expressing the cognate ligand 
CCL21. Interestingly, CCR7+ tumour cells could produce CCR7 ligands and migrate with 
the lymphatic fluid in a process referred to as autologous chemotaxis (Sleeman et al., 2009) 
4.4.2 VEGF and liver metastasis 
VEGF expression is closely related with micro-vessel density and seems to be a crucial 
indicator for liver metastasis and a poor prognosis in pancreatic adenocarcinoma (Seo et al., 
2000). Elevated VEGF levels are correlated with tumour size (Itakura et al., 1997) and liver 
metastasis (Seo et al., 2000). Others have shown that the presence of TGFβ in the tumour 
micro-environment plays an important role in enhancing liver metastasis by modulating the 
capacity of angiogenesis and immunogenicity (Teraoka et al., 2001). Histological studies in 
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tyrosine kinase inhibitors targeting EGFR such as erlotinib are the only class of targeted 
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pancreatic cancer patients often show invasion into large veins and dissemination into the 
liver. This is accompanied by elevated expression of MMP-2 and MMP-9 (Nagakawa et al., 
2002). VEGF levels were shown to be markedly elevated in liver metastases as compared to 
non-tumour bearing liver. However, no correlation was found in VEGF expression between 
liver metastases and primary pancreatic carcinoma (Tawada et al., 2008).  
4.5 Role of chemokines in pancreas metastasis  
Chemokines are low molecular-weight peptide ligands involved in the trafficking of 
leukocytes and other motile cells (Murphy et al., 2000; Mellado et al., 2001). Their receptors 
are cell-surface, seven trans-membrane G protein-coupled receptors. Many chemokines have 
more than one ligand and can activate more than one receptor.  
4.5.1 Role of the chemokine receptor CXCR4 in pancreas metastasis  
CXCR4 has been detected on many leukocytes such as lymphocytes, monocytes, natural 
killer cells, as well as on vascular smooth muscle cells, endothelial cells, and astrocytes 
(Caruz et al., 1998; Wegner et al., 1998; Zhang et al., 1998; Balkwill, 2004). The chemokine 
CXCL12, originally termed stromal derived factor 1 (SDF-1), is a ligand for CXCR4. In 
normal adult, the interplay between CXCR4 and CXCL12 is critical for homing and retention 
of hematopoietic progenitor cells in the bone-marrow (Richard & Blay, 2008). High levels of 
CXCR4 are expressed by these progenitor cells, which in turn get attracted to CXCL12 
produced by stromal cells in specialised bone-marrow niches (Aiuti et al., 1997). Stem cells 
and some other differentiated cells in the pathological contexts of inflammation and tissue 
regeneration or repair are also influenced by the chemo-attractant potency of CXCL12. It is 
postulated that metastatic cancer cells subvert the physiologic function of CXCR4/CXCL12 
in controlling cell migration and homing.  
It has been shown that CXCL12/CXCR4 axis promotes progression and dissemination of 
various carcinomas. CXCR4 is over-expressed at high levels on cells of solid epithelial 
cancers including pancreas, and CXCL12 concentrates in fluid-filled cavities through which 
many cancers disseminate and at tissue sites where metastases develop (Richard & Blay, 
2008). Most human pancreatic cancer tissues and more than 50% of pancreatic cell lines stain 
positively for CXCR4 and express CXCR4 protein, respectively. Chemotaxis induction of 
human pancreas carcinomas, as well as stimulation of their proliferation and survival is 
induced by CXCL12 (Figure 3) (Marchesi et al., 2004; Koshiba et al., 2000). Kayali and 
colleagues have shown in an interferon gamma-non-obese diabetic mouse model that 
CXCL12 stimulates the phosphorylation of AKT, mitogen-activated protein kinase (MAPK), 
and Src in pancreatic duct cells, and that it influences ductal cell migration. Blocking the 
CXCL12/CXCR4 axis in this model leads to a reduced proliferation and increased apoptosis 
of pancreatic ductal cells (Kayali et al., 2003). Moreover, CXCR4 small molecule antagonists, 
such as TN14003, were shown to inhibit migration of human pancreatic cancer cells in vitro 
via alteration of MAPK phosphorylation (Mori et al., 2004). 
Recently, a study in 30 patients with pancreatic cancer was initiated to evaluate the 
expression of CXCL12 and CXCR4 in tumour tissues, normal pancreas, and regional lymph 
nodes. They report low CXCL12 levels in tumour tissues as compared to para-cancerous 
tissues, normal pancreas, and lymph nodes. On the other hand, levels of CXCR4 in tumour 
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tissues were markedly higher. Additionally, they depict a significant correlation among the 
expression of CXCL12/CXCR4 axis and that of lymph node metastases (Cui et al., 2010).  
 
Fig. 3. Dissemination of tumour cells via the CXCL12/CXCR4 axis. Chemokine signalling 
enhances tumour invasion, tissue remodelling and tumour resistance to apoptotic stimuli. 
Moreover, pancreatic tumour cells expressing CXCR4 migrate towards the gradient of 
CXCL12 released by distant organs such as lymph nodes, lung, and liver. Hence, in addition 
to facilitating tumor invasion, the chemokine guidance plays a critical role in spread of 
tumour cells from primary sites to form distant metastases.  
Several factors regulating the expression of CXCR4 in tumour cells reside within the tumour 
micro-environment. It has been shown that hypoxia via hypoxia-inducible factor 1 alpha 
(HIF1α) upregulates CXCR4 (Staller et al., 2003). Accordingly, CXCR4 expression was found 
to be enhanced in CXCR4-positive cell lines cultured under hypoxic conditions (Marchesi et 
al., 2004). As mentioned above matrix metalloproteases such as MMP-2 and MMP-9 have 
been associated with haematogenous tumour spreading. Chemokine and MMP activity 
seems to be intertwined as treatment of tumour cell lines with CXCL12 were shown to 
activate MMPs and trigger tumour cell invasion (Marchesi et al., 2004). Gao et al. proposed a 
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crucial role for PSC in promoting the invasion of human pancreatic cancer cells through the 
CXCL12/CXCR4 axis (Gao et al., 2010). In addition, CXCL12 was shown to protect CXCR4-
positive pancreatic tumour cells from serum starvation-induced death or interleukin-1-
induced damage via decreasing their rate of apoptosis (Marchesi et al., 2004). Together, 
these data suggest an important role for chemokine signalling in matrix-remodelling, 
tumour invasion and enhanced cell survival by evading apoptotic stimuli.  
4.6 Influence of PPAR on pancreas metastasis  
Peroxisome proliferator-activated receptors (PPAR) are ligand-activated transcription 
factors belonging to the super-family of nuclear hormone receptors (Isseman & Green, 1990). 
Three major sub-types have been described so far: PPAR-α, PPAR-β/δ, and PPAR-γ. PPAR-
γ has been recently shown to be over-expressed in pancreatic cancers (Eibl et al., 2004). 
Troglitazone, a synthetic PPAR-γ agonist/ligand, leads to G1 cell cycle accumulation and 
inhibits cellular proliferation in vitro (Itami et al., 2001). Implantation of PANC-1 tumours in 
nude mice shows significant inhibition of tumour growth treated with pioglitazone, another 
PPAR-γ agonist (Itami et al., 2001). In another study, both ciglitazone and 15d-prostaglandin 
J2 (15d-PGJ2) were shown to inhibit the growth of four tested pancreatic cancer lines. 
Treatment with 15d-PGJ2 significantly suppresses pancreatic cancer cell invasiveness which 
is accompanied by a reduction of MMP-2 and MMP-9 protein levels and activity 
(Hashimoto et al., 2002). The anti-tumour activity on pancreas cancer cell invasion was in 
part attributed to the influence of PPAR-γ ligands on the serine protease urokinase-type 
plasminogen activator (uPA) and its receptor (uPAR) (Sawai et al., 2006). In addition, 
synthetic PPAR-γ agonists may impede metastasis formation via interference with 
chemokine signalling by decreasing CXCR4 expression levels (Richard & Blay, 2008). Of 
note, data generated with synthetic PPAR ligands known as PPAR “agonists” or 
“antagonists” are not always matching data generated by genetic knock-down studies 
suggesting that binding of synthetic ligands may induce additional or different effects, by 
e.g. release of endogenous ligands (Lee et al., 2003; Plutzky, 2003). In this context, anti-
metastatic but not anti-proliferative effects were also reported after treatment of pancreas 
cancer with a synthetic PPAR-γ ligand (T0070907), known to be a specific PPAR-γ 
antagonist (Nakajima et al., 2008). In contrast, PPAR-γ agonists were shown to inhibit the 
growth of pancreas tumours via downregulation of VEGF and thus inhibition of tumour 
angiogenesis (Dong et al., 2009). This is in line with previous observations suggesting an 
involvement of PPAR-γ signalling in the angiogenesis process (Panigrahy et al. 2002). 
PPAR-α and PPAR-β/δ, the two other members of this family were also proposed to play a 
critical role in tumor growth and angiogenesis (Park et al., 2001, Abdollahi et al. 2007; 
Müller-Brüsselbach et al., 2007; Wang et al., 2006; Kaipainen et al., 2007; Panigrahy et al. 
2008). In particular, PPAR-β/δ expression levels were shown to be gradually increased from 
normal pancreas to chronic pancreatitis to primary tumor and distant metastasis of pancreas 
cancer (Abdollahi et al. 2007). Moreover, PPAR-β/δ was found to play a central role within 
a network of genes that govern the angiogenic switch process. Accordingly, targeted 
removal of PPAR-β/δ in tumor microenviroment via implantation of wt-tumors in PPAR-
β/δ knockdown mouse resulted in impaired tumor growth and angiogenesis (Abdollahi et 
al. 2007). This data are consistent with other studies reporting on impaired wound healing 
and reduced body fat; both processes known to be angiogenesis dependent (Peters et al., 
2000; Michalik et al., 2001).  
Pancreatic Cancer: Current Concepts in Invasion and Metastasis 73 
4.7 Genomic studies 
Recent advances in high-through put sequencing analysis have improved our 
understanding of genetic alterations in pancreatic cancer. In 2008 Jones et al. reported on 
sequencing protein-coding exons from 20,735 genes in 24 pancreatic cancers. They found 
that pancreatic cancer contains an average of 63 genetic alterations, the majority of which 
were point mutations that could be assigned to a core set of 12 cellular signalling pathways 
being altered in 67% to 100% percent of pancreatic cancers. These include, apoptosis (100% 
affected), DNA damage control (83%), regulation of G1/S phase transition (100%), 
hedgehog signalling (100%), homophilic cell adhesion (79%), integrin signalling (67%), c-Jun 
N-terminal kinase signalling (96%), K-Ras signalling (100%), regulation of invasion (92%), 
small GTP-ase Ras-independent signalling (79%), TGF-β signalling (100%), and Wnt/Notch 
signalling (100%). Although these pathways partially over-lap in the majority of the patients 
tested, every individual tumour might reveal variations in the alterations observed in 
pathway components. This perspective likely applies to most of epithelial cancers, and 
explains the heterogeneity within individual genes and within individual tumours (Jones et 
al., 2008). 
Shi et al. have established a highly metastatic pancreatic cancer line SW1990HM from intra-
splenic injection of SW1990 tumor cells. Gene expression profiles of SW1990HM and 
SW1990 cells show 40 metastasis-related genes expressed with a 3-fold difference. From the 
40 genes 32.5% are assigned to be adhesion and ECM-related genes, namely matrix 
metalloproteases (MMP-10, MMP-9, MMP-7), E-cadherin tumour suppressor gene (CDH1), 
and the golgi enzyme glycosyltransferase (MGAT5). Another 30% are found to be cell-
growth and proliferation-related such as insulin growth factor 1 (IGF1), interleukin 8 
receptor beta (IL8RB), integrin A7 (ITGA7), murine double minute oncogene (MDM2), 
mesenchymal epithelial transition factor (MET), somatostatin receptor 2 (SSTR2), and VEGF 
(Shi et al., 2009).  
Thakur and colleagues have utilized Ela-c-myc transgenic mice, described previously to 
develop acinar carcinoma (50%) as well as mixed ductal and acinar cell carcinoma (50%), to 
show spontaneous metastasis to the liver (Liao et al., 2006, 2007; Thakur et al., 2008). 
Microarray analyses revealed up-regulation of genes involved in DNA replication, cell 
proliferation and cell cycle regulation, chromosome organization, and signal transduction. 
Many genes are related to the maintenance of chromosomal structure and integrity such as 
mini-chromosome maintenance 2 (MCM2), MCM5; MCM10; structural maintenance of 
chromosome 211 (SMC21l), SMC41l, SMC51l, RAD51, and BRCA1.  
In alignment with these data expression analysis of two established cell lines (HPAC and 
PANC1) in terms of their patterns of invasiveness, reveals significant increase in the 
expression of DNA repair genes. DNA copy number of BRCA1 and RAD51 genes is also 
found to be increased in tissues isolated from metastatic pancreas cancer in comparison to 
normal tissue from the respective sites (Mathews et al., 2011).  
Thakur et al also described elevated expression levels of IGFBP1 and Serpin1 in liver 
metastatic tissues as compared to primary pancreatic tumours and normal pancreas. Both 
genes are also known to be over-expressed in highly metastatic human pancreatic cell lines 
(PANC28, CoLo357fg, L3.6pl) in comparison to less metastatic cell lines (PANC1 and 
BxPC3) (Thakur et al., 2008). 
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4.7 Genomic studies 
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5. Peri-neural invasion 
Tumour peri-neural invasion (PNI), i.e., the neurotropism of pancreatic tumour cells and 
their metastasis into the peri-neural space of peripheral nerves constitutes a unique feature 
of pancreatic ductal adenocarcinoma (PDAC). PNI is associated with poor prognosis in 
patients due to the fact that tumour cells disseminating along nerve fascicles are spared by 
surgery and could therefore contribute to the local recurrence of pancreatic cancer (Marchesi 
et al., 2010; Pour et al., 2003). The human pancreas harbours a large amount of neural tissue 
and is innervated by the autonomic nervous system through plexi from the celiac and 
superior mesenteric artery ganglia. In majority of pancreatic cancer patients (~90%) tumor 
cells infiltrate intra-pancreatic nerves, with involvement of about 70% of extra-pancreatic 
nerves. Neural infiltration by cancer cells along with the accompanying ultimate nerve 
damage serve to cause the characteristic severe pain in pancreatic cancer patients (Pour et 
al., 2003). Morphologic changes at the migration front include characteristic increased neural 
density and hypertrophy and clustering of malignant cells around the neuritis (Ceyhan et 
al., 2008; Dai et al., 2007). 
5.1 Mediators and molecular mechanisms of PNI  
Investigation of many pathologic sections reports an increase in the size of nerve fibres in 
the vicinity of pancreatic tumours, suggesting the necessity of neurotropic factors, growth 
factors, and axonal guidance molecules as key players in this aspect (Chedotal et al., 2005; 
Chilton et al., 2006). Major neurotropic factors, such as neurotropins (NT) which include 
nerve growth factor (NGF), brain-derived nerve growth factors (BDNF), NT-3, NT-4, and 
NT-5, are over-expressed in tumour cells and intra-tumoural nerves (Ketterer et al., 2003). 
Other factors including hematopoietic colony stimulating factors (G-CSF) and their 
receptors (G-CSFR and GM-CSFRα) have also been shown to be expressed at high levels in 
pancreatic tumour micro-environment and to be associated with induction of pain. To this 
end, injection of anti-sera containing neutralising anti-bodies against G-CSF and GM-CSF 
receptors in a murine model of tumour-induced bone pain prevents hyperalgesia and 
reduces the number of nerves branching into the skin surrounding the tumour 
(Schweizerhof et al., 2009). In addition, myelin associated glycoprotein (MAG or Siglec-4a), 
expressed by Schwann cells bind to mucin 1 (MUC1) enriched on the surface of pancreas 
tumour cells (Swanson et al., 2007). 
5.2 Chemokines and tumour PNI  
CX3C chemokine receptor 1 (CX3CR1) also known as the fractalkine receptor or G-protein 
coupled receptor 13 (GPR13) are known to be involved in leukocyte adhesion and 
migration. Cells expressing this receptor bind to corresponding ligand CX3CL1 expressed 
on the surface of neurons, nerve fibres, and activated endothelial cells (Marchesi et al., 2010). 
In contrast to normal pancreas cells, tumour cells over-express CX3CR1 which in turn 
stimulates PNI. A large fraction (~90%) of pancreatic cancer biopsies are CX3CR1 positive 
and high receptor expression is associated with prominent PNI in pancreas cancer (Marchesi 
et al., 2008). A novel CX3CR1 antagonist has been recently developed and shown to block 
the cell adhesion along the CX3CL1/CX3CR1 axis (Dorgham et al., 2009). Thus, interference 
with CX3CL1/CX3CR1 signalling poses an attractive approach in prevention of PNI. Figure 
4 illustrates some molecular mechanisms known to be involved in PNI. 
Pancreatic Cancer: Current Concepts in Invasion and Metastasis 75 
 
Fig. 4. Molecular mechanisms of PNI: Tumour cells expressing CX3CR1 and MUC-1 
infiltrate the peri-neural space and adhere to CX3CL1 and Siglec-4a on the surface of neural 
cells. Both cell types secrete neurotropins which are crucial for sustaining growth and 
survival of both cell types. Pain perception is influenced upon the interaction between CSF 
secreted by tumour cells and their receptors CSFR on the surface of neural cells. 
A novel method has been developed by Abiatari et al. to monitor ex vivo PNI of PDAC 
tumor cells into surgically resected rat vagal nerves. Genome-wide transcriptional analyses 
deciphered a set of differentially regulated genes in high versus low invasive pancreas 
tumour cells. Kinesin family member 14 (KIF14) and Rho-GDP dissociation inhibitor β 
(ARHGDIβ) are among two candidate PNI genes identified. Increased expression of both 
proteins was confined to tumour cells invading the peri-neural niche in pancreatic tumour 
patients. Finally, functional knock-down of KIF14 and ARHGDIβ resulted in altered PNI of 
tumour cells (Abiatari et al., 2009). These data indicate that a better molecular 
characterization of the PNI process is a prerequisite for development of targeted therapies 
aiming to inhibit the pancreatic cancer metastasis.  
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6. Pancreatic cancer stem cells 
An emerging field of cancer research attempts to identify cellular hierarchies among the 
tumour cell population. Evidence are provided for tumor cells with self-renewing and stem-
cell-like characteristics within solid tumours termed tumour-initiating cells (TICs) or cancer 
stem cells (CSC) (Reya et al., 2001; Al Hajj et al., 2003; Singh et al., 2004 O’Brien et al., 2007; 
Ricci-Vitani et al., 2007). It is hypothesised that CSC undergo EMT at the invasive front of 
primary tumours and migrate to colonise new tissue. The concept of ‘’migrating CSC’’ 
describes a cancer stem cell which possess both an element of stemness and mobility 
(Brabletz et al., 2005). The relationship between CSC and pancreatic cancer progression was 
investigated by Li et al. (2007). They have chosen cancer stem cell markers based on 
previous work on breast cancer stem cells. These include the cell surface markers CD44, 
CD24, and epithelial-specific antigen (ESA). CD44+ CD24+ ESA+ pancreatic CSC 
demonstrate typical features observed in adult stem cells such as the ability of self-renewal, 
generation of differentiated progeny, and activation of developmental signalling pathways 
such as sonic hedgehog (Li et al., 2007). They further reported that only hundred human 
CD44+ CD24+ ESA+ pancreatic CSC are required to generate subcutaneous tumours in 50% 
of immuno-compromised SCID mice.  
CD133 is yet another potential marker discussed to be characteristic for pancreatic CSC 
(Hermann et al., 2007). They showed that the capacity of cells to form primary tumours 
following orthotopic implantation in nude mice was exclusive to the CD133+ sub-population 
which also demonstrated inherent resistance to gemcitabine chemotherapy. Further studies on 
highly metastatic pancreatic cancer cell line L3.6pl identified two sub-sets of tumour cells 
based on the expression of CXCR4 receptor (Miller et al., 2008). Depletion of CXCR4 subset of 
CD133+ pancreatic CSCs precluded the formation of spontaneous liver metastases. In line with 
above mentioned data, CXCL12 appears to be the strongest inducer of migration in CD133+ 
cancer cells in vitro. A component of the therapeutic plant Boswellia serrata, acetyl-11-keto-β-
boswellic acid (AKBA), has been shown to down-regulate CXCR4 expression in pancreatic 
tumour cells and suppress cancer cell invasion (Park et al., 2011). Negative staining of 
cytokeratin epithelial cell marker in the CD133+ (in contrast to CD133- CSC) indicated EMT 
phenotype, thereby explaining their invasive potential (Mani et al., 2008). Blocking of the 
CXCL12/CXCR4 interaction with the CXCR4 non-peptidic antagonist reduces the spread of 
CD133+/CXCR4+ invasive pancreas cancer cells (Hermann et al., 2007).  
Correlation between CD133 expression and lymph node metastasis in pancreatic cancer was 
investigated by Maeda et al. Immunohistochemical assessment of samples from 80 patients 
with PDAC after surgery revealed <15% CD133+ tumours cells per tumour in only 60% of 
specimen (48/80) suggesting a low frequency of these cells in PDAC. However, if CD133+ 
cells were detected they were cytokeratin negative and were confined to the glandular 
structures in the periphery of tumours. CD133 expression significantly correlated with 
clinicopathological parameter including VEGF-C expression, lymphatic invasion and lymph 
node metastasis (Maeda et al., 2008).  
7. Conclusion  
A better comprehension of the processes governing the formation of metastases is critical 
towards development of more advanced cancer treatment modalities. Various theories of 
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metastatic cancer progression have lately emerged. In contrast to late dissemination model 
early dissemination and parallel evolution of tumours in primary vs. metastatic sites impact 
current perception of tumour heterogeneity and consequently will impact the development 
of targeted cancer treatment strategies. The emergence of novel sequencing and high-
through put genetics methods will hopefully assist cancer research in defining the relevance 
of each model in pancreatic cancer development.  
Acquisition of multiple genetic aberrations in the tumour cells is crucial for initiation of 
cancer. However, the communication of tumour cells with tumour-micro-environment is a 
prerequisite for successful tumour progression towards metastatic disease. Therefore, a 
better understanding of molecular mechanism underlying the orchestrated action between 
tumor cells and its micro-environmetal participants such as stellate cells, endothelial cells, 
pericytes, immune cells and bone-marrow derived cells are urgently needed. The 
contribution of angiogenesis, EMT, cytokine/chemokine axis, neurotropism, hypoxia and 
tissue remodelling in development of pancreatic cancer are still in an early stage. Further 
research is needed to elaborate the molecular characteristics of specific niches such as liver 
vs. lymph nodes in development of PDAC metastases. In contrast to dynamic models 
considering tumour cell plasticity as the pivotal force behind its ability to gain specific traits 
when exposed to e.g. EMT or hypoxia stimuli, the existence of deterministic hierarchies 
among pancreatic tumour cells as proposed by the emerging tumour stem cell community 
remain elusive. In conclusion, a concerted multidisciplinary effort is needed to identify 
novel targets, rationally design therapies and ultimately improve the treatment of this 
devastating disease.  
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Growth factor signaling plays a critical role in cancer proliferation and invasion. Therefore, 
molecules, involved in growth factor signaling have become the targets of cancer therapy, 
and many drugs targeting growth factor signaling pathways have been developed. Some of 
these drugs have been used clinically, while many more are being tested in clinical trials. 
However, to date, molecule-targeted therapies for pancreatic cancer have not been 
developed.  
Nitric oxide (NO) was discovered two decades ago and was initially identified as an 
endothelial relaxing factor. Subsequently, NO has been shown to play key roles in the post-
translational modification of proteins and the regulation of protein enzymatic activity. In 
this paper, we present evidence indicating that NO influences cancer proliferation and 
invasion, and discuss the mechanisms trough which NO is thought to exert these effects. 
2. Production of NO in cells and tissues 
NO is produced by three distinct genes products: neuronal and endothelial nitric-oxide 
synthases (nNOS and eNOS) and inducible nitric-oxide synthases (iNOS) (Palmer et al., 
1987). The activities of nNOS and eNOS are tightly regulated by calcium-dependent 
calmodulin binding, whereas iNOS does not require calcium ion or posttranslational 
modification for its activity. As a result, iNOS expression is associated with prolonged, 
exaggerated NO generation of up to > 1,000-fold greater than that generated by nNOS and 
eNOS. Although iNOS expression is increased in macrophages and endothelial cells by 
various stimuli, including acute inflammation, recent studies have revealed that iNOS is 
expressed even in normal conditions in many tissues, including skeletal muscle and cancer 
(Perreault and Marette, 2001; Xie and Fidler, 1998). The expression of iNOS protein has been 
reported in pancreatic cancer cells, colon cancer cells, gastric cancer, breast cancer, 
hepatocellular carcinoma, glioma cells, melanoma cells, and laryngeal squamous cell 
carcinoma. 
Pancreatic Cancer – Molecular Mechanism and Targets 88
Zhang, L; He, T; Talal, A; Wang, G; Frankel, SS; & Ho, DD. (1998). In vivo distribution of the 
human immunodeficiency virus/simian immunodeficiency virus coreceptors: 
CXCR4, CCR3, and CCR5. J Virol., 72, Jun 1998, 5035-5045 
Zhao, S; Venkatasubbarao, K; Lazor, JW; Sperry, J; Jin, C; Cao, L; & Freeman, JW. (2008). 
Inhibition of STAT3 Tyr705 phosphorylation by Smad4 suppresses transforming 
growth factor beta-mediated invasion and metastasis in pancreatic cancer cells. 
Cancer Res., 68, Jun 2008, 4221-4228 
5 
Nitric Oxide Regulates  
Growth Factor Signaling in  
Pancreatic Cancer Cells 
Hiroki Sugita1,2, Satoshi Furuhashi1 and Hideo Baba1  
1Department of Surgery, Kumamoto City Municipal Hospital,  
2Department of Gastroenterological Surgery,  




Growth factor signaling plays a critical role in cancer proliferation and invasion. Therefore, 
molecules, involved in growth factor signaling have become the targets of cancer therapy, 
and many drugs targeting growth factor signaling pathways have been developed. Some of 
these drugs have been used clinically, while many more are being tested in clinical trials. 
However, to date, molecule-targeted therapies for pancreatic cancer have not been 
developed.  
Nitric oxide (NO) was discovered two decades ago and was initially identified as an 
endothelial relaxing factor. Subsequently, NO has been shown to play key roles in the post-
translational modification of proteins and the regulation of protein enzymatic activity. In 
this paper, we present evidence indicating that NO influences cancer proliferation and 
invasion, and discuss the mechanisms trough which NO is thought to exert these effects. 
2. Production of NO in cells and tissues 
NO is produced by three distinct genes products: neuronal and endothelial nitric-oxide 
synthases (nNOS and eNOS) and inducible nitric-oxide synthases (iNOS) (Palmer et al., 
1987). The activities of nNOS and eNOS are tightly regulated by calcium-dependent 
calmodulin binding, whereas iNOS does not require calcium ion or posttranslational 
modification for its activity. As a result, iNOS expression is associated with prolonged, 
exaggerated NO generation of up to > 1,000-fold greater than that generated by nNOS and 
eNOS. Although iNOS expression is increased in macrophages and endothelial cells by 
various stimuli, including acute inflammation, recent studies have revealed that iNOS is 
expressed even in normal conditions in many tissues, including skeletal muscle and cancer 
(Perreault and Marette, 2001; Xie and Fidler, 1998). The expression of iNOS protein has been 
reported in pancreatic cancer cells, colon cancer cells, gastric cancer, breast cancer, 
hepatocellular carcinoma, glioma cells, melanoma cells, and laryngeal squamous cell 
carcinoma. 
Pancreatic Cancer – Molecular Mechanism and Targets 90
3. NO-donors 
Several types of reagents called NO-donors, are capable of releasing NO constitutively 
(Table 1). S-Nitrosothiols (RSNO), which break down to form NO and the corresponding 
disulphide (RSSR), are an important class of NO -donor drugs. NO-donors containing R-NO 
(S-NO), are unstable and release NO upon breakdown. Decomposition of these compounds 
is catalysed by Cu+ ions, which themselves can be formed by reduction of Cu2+ ions by 
thiols. Breakdown is accelerated by light at ultraviolet and optical wavelength and is 
influenced by PH. 
Organic nitrates such as nitroglycerin, isosorbide dinitrate and mononitrate, which have 
long been used as vasodilators for the treatment of angina pectoris, release NO via both 
enzymatic and non-enzymatic pathways. Iron-nitrosyl complexes such as sodium 
nitroprusside (SNP), sydnonimine, and amine NONOate, all demonstrate NO donating 
capacity. NO -donating non-steroidal anti-inflammatory drugs (NO-NSAIDs), which were 
developed recently, are potential anti-cancer drugs (Gao et al., 2005). NO-NSAIDs consist of 
a conventional NSAID to which an NO-releasing moiety is attached covalently. Glutathione 
S-transferase -activated NO-donors such as JS-K, have shown some therapeutic promise in 
cancer without hypotension (Weiss et al.).  
NO-donor reagents offer a convenient source of NO for in vitro and in vivo experiments. 
Researchers can thereby avoid use NO gas but must consider intrinsic half-life, metabolites, 






isosorbide dinitrate (ISDN) 
Iron-nitrosyl complex 










Nitric oxide-donating aspirin (NO-ASA) 
NO-naproxen 
NONO-ASA 
Table 1. NO donors 
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4. Actions of NO in vivo 
4.1 cGMP-dependent actions 
Guanylyl cyclases (GC) are expressed in the cytoplasm of almost all mammalian cells and 
mediate a wide range of important physiological functions, including inhibition of platelet 
aggregation, relaxation of smooth muscle, vasodilation, neuronal signal transduction, and 
immunomodulation (Collier and Vallance, 1989). GCs have evolved to synthesize cGMP in 
response to diverse signals, such as NO. NO activates GC by binding directly to heme to 
form a ferrous-nitrosyl-heme complex. Endogenous and exogenous compounds, including 
autocoids, hormones, neurotransmitters, and toxins, produce cellular responses through 
cGMP. The specificity of cellular responses to cGMP is dictated by cGMP-binding motifs in 
target proteins PKA (cAMP-dependent protein kinase) and PKG (cGMP-dependent protein 
kinase) (Francis and Corbin, 1999), cyclic nucleotide-gated cation channels (Biel et al., 1999; 
Kaupp, 1995) and cGMP-regulated phosphodiesterases (Beavo, 1995).  
4.2 cGMP-independent actions 
The major cGMP-independent actions of NO are nitrosative post-translational 
modifications, including protein S-nitrosylation and tyrosine nitration. Post-translational 
modification of proteins by S-nitrosylation, attachment of nitrosonium ion (NO) to cysteine 
sulfhydryls, is a major mode of signaling in mammalian cells 
Indeed, critical signaling molecules and transcription factors are primary targets of NO 
(Stamler et al., 2001). To date, over 100 proteins have been shown to be S-nitrosylated both in 
vitro and in vivo. In many of these proteins, S-nitrosylation leads to functional alterations. 
Signaling proteins that are directly modified by S-nitrosylation include Ras, Akt, JNK, 
PTEN, IκB kinase, and Bcl2. (Azad et al.; Lander et al., 1997; Numajiri et al.; Park et al., 2000; 
Reynaert et al., 2004; Yasukawa et al., 2005) 
5. Roles for NO in cancer 
Conflicting results have been reported regarding the roles of NO in cancer. Recent papers 
reported that endogenous NO promotes oncogenesis and angiogenesis in various cancers 
(Ambs et al., 1998; Camp et al., 2006). In contrast, other studies have shown that NO inhibits 
cell proliferation and induces apoptosis in various cells including cancer cells, in vitro and in 
vivo (Chawla-Sarkar et al., 2003; Jarry et al., 2004; Kalivendi et al., 2001; Kotamraju et al., 2007; 
Notas et al., 2006; Peshes-Yaloz et al., 2007; Wang et al., 2003). These studies suggest that NO 
can act either as a tumor suppressor or a tumor enhancer depending on cell type and the 
level of NO in the cells. However, the molecular mechanism underlying the inhibitory 
effects of NO on cancer viability, remains unclear. 
5.1 Roles in carcinogenesis and cancer promotion 
NO and reactive nitrogen species (RNOS) induce the formation of nitrosamines, which can 
cause cancers in a wide variety of animal species. Nitrosation of nucleic acid bases leads to 
deamination which in turn results in mutagenic or carcinogenic conversion cytosine to uracil, 
guanine to xanthine, methylcytosine to thymine and adenine to hypoxanthine (Caulfield et al., 
1998; Wink et al., 1991). RNOS can cause both single- and double- strand breaks in DNA. 
Pancreatic Cancer – Molecular Mechanism and Targets 90
3. NO-donors 
Several types of reagents called NO-donors, are capable of releasing NO constitutively 
(Table 1). S-Nitrosothiols (RSNO), which break down to form NO and the corresponding 
disulphide (RSSR), are an important class of NO -donor drugs. NO-donors containing R-NO 
(S-NO), are unstable and release NO upon breakdown. Decomposition of these compounds 
is catalysed by Cu+ ions, which themselves can be formed by reduction of Cu2+ ions by 
thiols. Breakdown is accelerated by light at ultraviolet and optical wavelength and is 
influenced by PH. 
Organic nitrates such as nitroglycerin, isosorbide dinitrate and mononitrate, which have 
long been used as vasodilators for the treatment of angina pectoris, release NO via both 
enzymatic and non-enzymatic pathways. Iron-nitrosyl complexes such as sodium 
nitroprusside (SNP), sydnonimine, and amine NONOate, all demonstrate NO donating 
capacity. NO -donating non-steroidal anti-inflammatory drugs (NO-NSAIDs), which were 
developed recently, are potential anti-cancer drugs (Gao et al., 2005). NO-NSAIDs consist of 
a conventional NSAID to which an NO-releasing moiety is attached covalently. Glutathione 
S-transferase -activated NO-donors such as JS-K, have shown some therapeutic promise in 
cancer without hypotension (Weiss et al.).  
NO-donor reagents offer a convenient source of NO for in vitro and in vivo experiments. 
Researchers can thereby avoid use NO gas but must consider intrinsic half-life, metabolites, 






isosorbide dinitrate (ISDN) 
Iron-nitrosyl complex 










Nitric oxide-donating aspirin (NO-ASA) 
NO-naproxen 
NONO-ASA 
Table 1. NO donors 
Nitric Oxide Regulates Growth Factor Signaling in Pancreatic Cancer Cells 91 
4. Actions of NO in vivo 
4.1 cGMP-dependent actions 
Guanylyl cyclases (GC) are expressed in the cytoplasm of almost all mammalian cells and 
mediate a wide range of important physiological functions, including inhibition of platelet 
aggregation, relaxation of smooth muscle, vasodilation, neuronal signal transduction, and 
immunomodulation (Collier and Vallance, 1989). GCs have evolved to synthesize cGMP in 
response to diverse signals, such as NO. NO activates GC by binding directly to heme to 
form a ferrous-nitrosyl-heme complex. Endogenous and exogenous compounds, including 
autocoids, hormones, neurotransmitters, and toxins, produce cellular responses through 
cGMP. The specificity of cellular responses to cGMP is dictated by cGMP-binding motifs in 
target proteins PKA (cAMP-dependent protein kinase) and PKG (cGMP-dependent protein 
kinase) (Francis and Corbin, 1999), cyclic nucleotide-gated cation channels (Biel et al., 1999; 
Kaupp, 1995) and cGMP-regulated phosphodiesterases (Beavo, 1995).  
4.2 cGMP-independent actions 
The major cGMP-independent actions of NO are nitrosative post-translational 
modifications, including protein S-nitrosylation and tyrosine nitration. Post-translational 
modification of proteins by S-nitrosylation, attachment of nitrosonium ion (NO) to cysteine 
sulfhydryls, is a major mode of signaling in mammalian cells 
Indeed, critical signaling molecules and transcription factors are primary targets of NO 
(Stamler et al., 2001). To date, over 100 proteins have been shown to be S-nitrosylated both in 
vitro and in vivo. In many of these proteins, S-nitrosylation leads to functional alterations. 
Signaling proteins that are directly modified by S-nitrosylation include Ras, Akt, JNK, 
PTEN, IκB kinase, and Bcl2. (Azad et al.; Lander et al., 1997; Numajiri et al.; Park et al., 2000; 
Reynaert et al., 2004; Yasukawa et al., 2005) 
5. Roles for NO in cancer 
Conflicting results have been reported regarding the roles of NO in cancer. Recent papers 
reported that endogenous NO promotes oncogenesis and angiogenesis in various cancers 
(Ambs et al., 1998; Camp et al., 2006). In contrast, other studies have shown that NO inhibits 
cell proliferation and induces apoptosis in various cells including cancer cells, in vitro and in 
vivo (Chawla-Sarkar et al., 2003; Jarry et al., 2004; Kalivendi et al., 2001; Kotamraju et al., 2007; 
Notas et al., 2006; Peshes-Yaloz et al., 2007; Wang et al., 2003). These studies suggest that NO 
can act either as a tumor suppressor or a tumor enhancer depending on cell type and the 
level of NO in the cells. However, the molecular mechanism underlying the inhibitory 
effects of NO on cancer viability, remains unclear. 
5.1 Roles in carcinogenesis and cancer promotion 
NO and reactive nitrogen species (RNOS) induce the formation of nitrosamines, which can 
cause cancers in a wide variety of animal species. Nitrosation of nucleic acid bases leads to 
deamination which in turn results in mutagenic or carcinogenic conversion cytosine to uracil, 
guanine to xanthine, methylcytosine to thymine and adenine to hypoxanthine (Caulfield et al., 
1998; Wink et al., 1991). RNOS can cause both single- and double- strand breaks in DNA. 
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Furthermore, NO inhibits DNA repair proteins and poly- (ADP-ribose) polymerase (PARP), 
which regulates DNA repair and apoptosis (Sidorkina et al., 2003). Thus, NO induces DNA 
damage that can lead to carcinogenesis. 
NO can promote cancer by enhancing vascularization, which favors growth and metastasis , 
and by inhibiting apoptosis. NO induces the expression of VEGF in carcinoma cells and 
suppresses angiostatin and thrombospondin-1, inhibitors of angiogenesis, resulting in 
promotion of tumor vascularization (Cooke and Losordo, 2002; Dulak et al., 2000). The 
growth of xenografted murine mammary adenocarcinoma which expresses iNOS is reduced 
by treatment with iNOS inhibitor (Thomsen et al., 1997). Nitric oxide (NO)-mediated S-
nitrosylation of Bcl-2 prevents its ubiquitination and subsequent proteasomal degradation, 
leading to inhibition of apoptosis. NO-mediated S-nitrosylation and stabilization of Bcl-2 
protein was the primary mechanism involved in the malignant transformation of 
nontumorigenic lung epithelial cells in response to long-term carcinogen exposure (Azad  
et al.). 
5.2 Anti-cancer effects 
In contrast to the aforementioned effects of NO, other studies have shown that NO inhibits 
cell proliferation and induces apoptosis in various cells including cancer cells, in vitro and in 
vivo (Chawla-Sarkar et al., 2003; Jarry et al., 2004; Kalivendi et al., 2001; Kotamraju et al., 2007; 
Notas et al., 2006; Peshes-Yaloz et al., 2007; Wang et al., 2003). Nitrosylcobalamin (NO-Cbl), 
an analog of vitamin B12 that delivers nitric oxide (NO) and xhibits anti-tumor activity; NO-
Cbl increases the expression of tumor necrosis factor-related apoptosis-inducing ligand 
(Apo2L/TRAIL) and its receptors, resulting in apoptosis of human tumors. (Chawla-Sarkar 
et al., 2003). The tumor suppressor P53 participates in numerous critical cellular functions 
including gene transcription, DNA repair, cell cycle control, genomic stability, and 
apoptosis (Gottlieb and Oren, 1996; Harris, 1996) . DNA damage, especially DNA double 
strand breaks caused by ionizing radiation or other exogenous mutagens, induces p53 
protein accumulation and activation, leading to cell cycle arrest during G1/S transition 
(Huang et al., 1996). High concentrations of nitric oxide (NO), inducing DNA damages, also 
triggers wild-type p53 protein accumulation and apoptosis (Messmer et al., 1994). In 
addition, nitric oxide induces death of colon cancer cells through down-regulation of beta-
catenin via proteasome-independent degradation (Prevotat et al., 2006). Some report 
document specific effects of NO in pancreatic cancer. Decker et al. reported that human 
pancreatic cancer cells engineered to overexpress eNOS show down-regulation of liver 
metastasis and tumor growth in mice (Decker et al., 2008). Wang et al. established a role of 
NOS2 in pancreatic cancer growth and metastasis in an animal model. They demonstrated 
that pancreatic cancer clones expressing low levels of NOS 2 produced tumors in the 
pancreas which metastasized to the liver, whereas those expressing high levels of NOS 2 did 
not (Wang et al., 2003).  
6. Growth signaling in cancer 
Insulin/insulin-like growth factor (IGF) signals play a key role in cancer proliferation and 
invasion (Bergmann et al., 1995; Furukawa et al., 2005; Kim et al., 2007). Insulin/IGF-I and 
IGF-II bind to insulin/IGF-I receptors, leading to tyrosine phosphorylation of the cognate 
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receptors. Insulin receptor substrate (IRS)-1, an adaptor protein, exists mainly in the cytosol, 
and binds to phosphorylated insulin receptor (IR) and IGF-I receptor (IGF-IR), resulting in 
the phosphorylation and activation of IRS-1. IRS-1 activates phosphatidylinositol-3 kinase 
(PI3K), which in turn activates further down-stream components, including Akt/PKB and 
glycogen synthase kinase (GSK)-3β. Alternatively, phosphorylated and activated IRS-1 can 
also bind to another adaptor protein, Grb-2, which activates mitogen-activated protein 
kinase (MAPK), another major insulin/IGF signaling cascade parallel to the PI3K-Akt/PKB 
pathway (Ito et al., 1996; Tanaka and Wands, 1996). IRS-1 protein expression is detected in 
several types of cancer, including pancreatic cancer, breast cancer, and hepatic cell 
carcinoma (Asano et al., 2005; Chang et al., 2002). Thus, insulin/IGF signaling is thought to 
play a major role in not only metabolic actions, including stimulation of glucose uptake and 
synthesis of glycogen and protein, but also in cancer viability including proliferation and 
invasion. IRS-1 is a key molecule in insulin/IGF signaling that transduces a signal from 
IR/IGF-IR to both PI3K and MAPK pathways (Asano et al., 2005).  
Epidermal growth factor (EGF) signaling also plays a key role in cancer proliferation and 
invasion. EGF binds to EGF receptor (EGFR) and triggers tyrosine phosphorylation of the 
receptor. Phosphorylated EGFR activates phosphatidylinositol-3-kinase (PI3K), which 
activates further down-stream components, including Akt. Alternatively, phosphorylated 
EGFR can also activate the Ras/MEK/ERK pathway, another major EGF signaling cascade 
parallel to the PI3K/Akt pathway.  
In the section to follow, we present our data showing effects of nitric oxide on growth factor 
signaling. 
 
Fig. 1. Insulin/IGF-I and EGF signaling 
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Furthermore, NO inhibits DNA repair proteins and poly- (ADP-ribose) polymerase (PARP), 
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Fig. 1. Insulin/IGF-I and EGF signaling 
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7. NO regulates growth signaling 
7.1 NO regulates insulin signaling in skeletal muscle 
Expression of iNOS is elevated in skeletal muscle of patients with type 2 diabetes (Torres et 
al., 2004) and in high fat diet-induced diabetic mice. Perreault and Marette showed that 
disruption of the iNOS gene protects against high fat diet-induced insulin resistance in mice 
(Perreault and Marette, 2001). Furthermore, we demonstrated that disruption of the iNOS 
gene reverses IRS-1 protein reduction in skeletal muscles of leptin deficient obese mice and 
NO-donor treatment induces proteasome-dependent IRS-1 degradation in skeletal muscle 
cells (Sugita et al., 2005). Thus, NO inhibits insulin signaling and is associated with IRS-1 
protein degradation, resulting in insulin resistance. This may explain the occurrence of 
insulin resistance in patients with inflammation or diabetes. 
7.2 NO influences insulin/IGF signals in MIAPaCa-2 cells 
We examined whether NO influences on insulin/IGF-I signaling in MIAPaCa-2 cells, a 
pancreatic cancer cell line. Protein expression and phosphorylation were detected by 
immunoblotting using specific antibodies. SNAP, a NO -donor, inhibited insulin-stimulated 
tyrosine phosphorylation of IR, IRS-1, the phosphorylation of Akt/PKB at Ser 473, and GSK-
3β at Ser 9. In addition, SNAP inhibited IGF-I-stimulated tyrosine phosphorylation of IGF-IR 
and IRS-1, phosphorylation of Akt/PKB at Ser 473, and GSK-3β at Ser 9. Furthermore, SNAP 
reduced IRS-1 protein expression, although this did not alter the expression of other IGF 
signaling proteins, including IGF-IR, Akt/PKB, GSK-3β and Erk 1/2 or of β-actin protein. 
SNAP induced phosphorylation of Erk 1/2 without stimulation by insulin/IGF-I, and 
enhanced the insulin/IGF-1-stimulated phosphorylation of Erk 1/2; however, SNAP did not 
influence Erk 1/2 protein expression in MIAPaCa-2 cells (Figure 2A and B).  
 
Fig. 2. NO influences IGF signals in MIAPaCa-2 cells 
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GSNO, a NO-donor, inhibited IRS-1 protein expression in MCF-7 as well as MIAPaCa-2 cells 
in a dose-dependent manner, but did not influence IRS-1 protein expression in MB 468 and 
Panc-1 cells, which exhibited less IRS-1 protein expression (Figure 3A). The proteasome 
inhibitor, MG132, completely reversed the reduction of IRS-1 protein expression by NO-
donors in MIAPaCa-2 cells. Neither GSNO nor MG132 influenced GSK-3β and β-actin 
protein expression (Figure 3B). To further investigate IRS-1 protein degradation induced by 
NO-donor, cDNA constructs of IRS-1 full-length, IRS-1 DM1, IRS-1 DM2, and IRS-1 DM3 
were produced and sub-cloned into mammalian expression vectors (Figure 3C). MIAPaCa-2 
cells were transfected with these expression vectors. GSNO reduced IRS-1 full-length, IRS-1 
DM1, and IRS-1 DM3 protein expression, although GSNO did not alter IRS-1 DM2 and β-
actin protein expression (Figure 3D). Ubiquitination of wild-type and mutant IRS-1 was 
detected by immunoprecipitation using anti-Flag antibody followed by immunoblotting 
with anti-ubiquitin. SNAP induced the ubiquitination of IRS-1 full-length, IRS-1 DM1, and 
IRS-1 DM3, but did not induce the ubiquitination of IRS-1 DM2 (Figure 3E). These results 
indicate that NO-donor is capable of inducing ubiquitination at multiple sites in the 
carboxy-terminus of the IRS-1 protein. 
 
Fig. 3. NO donor downregulates IRS-1 protein expression through proteasome-mediated 
degradation in MIAPaCa-2 cells 
iNOS protein was detected by immunoblotting in Panc-1 cells, a pancreatic cancer -derived 
cell line. IRS-1 protein expression was significantly increased by 1400 W, an iNOS specific 
inhibitor, in a dose-dependent manner. Expression of Akt/PKB, β-actin, and Erk 1/2 protein 
was unaffected by treatment (Figure 4A). GSNO inhibited IRS-1 protein expression, 
upregulated by 1400W (Figure 4B). Treatment of 1400W enhanced IGF-I-stimulated tyrosine 
phosphorylation of IRS-1, phosphorylation of Akt/PKB at Ser 473, and GSK-3β at Ser 9 in 
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Panc-1 cells. In contrast, 1400 W did not alter IGF-I-stimulated phosphorylation of Erk 1/2 
(Figure 4C). These results indicate that endogenous NO produced by iNOS plays a role in 
insulin/IGF-I signaling. 
 
Fig. 4. iNOS inhibitor 1400W upregulates IRS-1 protein expression and IRS-1/Akt pathway 
in Panc-1 cells, a pancreatic cancer cell line 
Mammalian expression vectors, pCMV Tag 4/IRS-1 full- length, pCMV Tag 4/IRS-1 DM2 
and pCMV Tag 4A vector alone, were transfected into MIAPaCa-2 and incubated with G418 
for the selection of protein-expressing cells for more than 14 days. Subsequently, the cells 
expressing high IRS-1 full-length protein or IRS-1 DM2 protein were cloned.  
Proliferation of MIAPaCa-2 cells was elevated in a culture medium containing serum or 
IGF-I, while no proliferation was observed in a culture medium without serum or IGF-I. 
Proliferation of cells overexpressing full-length IRS-1 was greater than that of vector alone-
transefected cells in the culture medium containing 10 % FBS. By contrast, the proliferation 
of cells expressing IRS-1 DM2 was attenuated compared to cells transfected with full-length 
IRS-1 or vector alone (Figure 5). The proliferation of cells transfected with full- length- IRS-1 
was greater compared to that of vector alone-transfected cells in the culture medium 
containing 100 nM IGF-I without 10% FBS, while IGF-I-stimulated proliferation of IRS-1 
DM2- transfected cell was not observed (Figure 5). GSNO (200 µM) significantly reduced the 
proliferation of vector alone-, IRS-1 full- length-, and IRS-1 DM2- transfected cells in culture 
medium containing 10 % FBS or IGF-I. To further investigate the role of iNOS in IGF-I-
stimulated proliferation, we evaluated the effects of selective iNOS inhibitor, 1400W, in 
Panc-1 cells cultured with IGF-I in the absence of FBS. Proliferation in Panc-1 cells was not 
observed in the presence and absence of 1400W (100 µM), when cultured without serum or 
IGF-1 (Figure 6A). 1400W significantly enhanced the proliferation of Panc-1 cells when 
cultured with 10% FBS (Figure 6B). In the absence of 1400W, IGF-I failed to increase the cell 
numbers of Panc-1. The combination of IGF-I and 1400W, however, increased the number of 
Panc-1 cells (Figure 6C). These results provide further evidence for the involvement of 
downregulation of IGF-I signaling in NO-induced inhibition of cancer cell proliferation. 
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Fig. 5. and 6. NO inhibited the proliferation of cancer cell lines and IRS-1 protein expression 
was associated with cancer cell proliferation 
In vitro invasive potential of MIAPaCa-2 cells and Panc-1 cells was determined using 
BioCoat Matrigel Invasion Chambers (Becton Dickinson, Bedford, MA). There was no 
difference between the invasion of vector alone-, IRS-1 full-length-, and IRS-1 DM2-
transfected MIAPaCa-2 cells in the absence of the NO -donor. The addition of 200 µM GSNO 
markedly reduced invasion in vector alone- and IRS-1 full-length-transfected MIAPaCa-2 
cells but did not alter invasion in IRS-1 DM2-transfected MIAPaCa-2 cells (Figure 7A). 
Invasion in Panc-1 cells incubated with 1400W (5 and 100 µM) was significantly greater than 
that of untreated cells (Figure 7B). 
 
Fig. 7. Sensitivity of NO to invasion was dependent on IGF signaling 
NO-donor treatment leads to several effects on insulin/IGF signaling in pancreatic cancer 
cells. NO-donor treatment reduced IRS-1 protein expression via proteasome-dependent 
degradation, and inhibited insulin/IGF-I-stimulated phosphorylation of Akt/PKB and GSK-
3β, while enhancing phosphorylation of Erk 1/2 in pancreatic cancer cells (Figure 2, 3, 4). 
NO-donor inhibited IGF-I-induced phosphorylation of Akt/PKB and GSK-3β in MIAPaCa-2 
cells transfected with IRS-1 wild-type or vector, but not in cells transfected with a dominant 
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Panc-1 cells. In contrast, 1400 W did not alter IGF-I-stimulated phosphorylation of Erk 1/2 
(Figure 4C). These results indicate that endogenous NO produced by iNOS plays a role in 
insulin/IGF-I signaling. 
 
Fig. 4. iNOS inhibitor 1400W upregulates IRS-1 protein expression and IRS-1/Akt pathway 
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negative carboxy-terminal deletion mutants (Tanaka and Wands, 1996) of IRS-1. This 
indicates the importance of IRS-1 in the inhibition of insulin/IGF signal by NO. IRS-1 
expression and IGF-I signaling have important roles in the proliferation and invasion of 
MIAPaCa-2 cells and Panc-1 cells, consistent with previous reports on other cancer cells 
(Kim et al., 2007; Shi et al., 2007; Tanaka and Wands, 1996). NO donor inhibited IGF-I 
signaling, proliferation, and invasion in MIAPaCa-2 cells transfected with IRS-1 full-length 
or vector. In contrast, treatment with a selective iNOS inhibitor upregulated IRS-1 protein 
expression and insulin/IGF signaling, resulting in enhanced proliferation and invasion 
activity in Panc-1 cells. These results indicate that the expression of IRS-1 protein is 
regulated by endogenous NO production by iNOS as well as by exogenous NO, resulting in 
the downregulation of IGF-I signaling and the inhibition of cancer proliferation and 
invasion in MIAPaCa-2 and Panc-1 cells (Figure 4, 5, 6).  
Furthermore, the carboxy-terminus as the site responsible for IRS-1 protein degradation by 
NO, which is located in SH2-containing molecule binding site next the phosphotyrosine 
binding (PTB) domain was detected. The observation of the ubiquitination and degradation 
of IRS-1 deletion mutants indicates the possibility that there may be at least two sites 
responsible for NO donor-induced ubiquitination in the IRS-1 protein. These data had been 
published in 2010 (Sugita et al.) 
In addition, NO inhibits Akt activity directly through post-translational modification, 
(Yasukawa et al., 2005), which seems to contribute to NO-induced cancer inhibition. 
Furthermore, we confirmed that NO-donors down-regulate EGF-stimulated phosphorylation 
of EGFR and Akt in colon cancer cells(data not shown).  
8. Therapeutic prospects 
The usefulness of cancer therapy using NO, including iNOS gene therapy and 
administration of NO-donor, was recently confirmed in animal models (Adams et al., 2008; 
Kiziltepe et al., 2007; Wang et al., 2004). Consequently, NO therapy has been focused on, and 
is currently undergoing clinical evaluation for cancer prevention (Ma et al., 2007). This 
should leads to clinical trials using NO -donors in the near future. Nitroglycerin, a NO-
donor, has long been used as a vasodilating, and the safety of nitroglycerin therapies is well 
established. Nitroglycerin treatment on non-small cell lung cancer is currently planned as 
a phase II clinical trial. A promising novel class of drugs, nitric oxide-donating NSAIDs 
(NO-NSAIDs), has been found to be more active than classical NSAIDs against cancer (Rigas 
and Williams, 2008). The effects of the NO-donating aspirin derivative, NCX 4040, on three 
human pancreatic adenocarcinoma cell lines were recently described (Capan-2, MIA PaCa-2 
and T3M4)(Rosetti et al., 2006). Clinical trials using NO-donors or NO-donating aspirin 
derivatives are urgently required. 
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1. Introduction  
Syk (spleen tyrosine kinase) is a nonreceptor tyrosine kinase containing two tandem 
amino-terminal SH2 domains, followed by an extended linker region and a carboxy-
terminal kinase domain (Sada et al., 2001). Tyrosine-352 (Y352) in the linker region is 
trans-phosphorylated by src family members, promoting the activation of syk (Kimura et 
al., 1996; Sada et al., 2001). Activation further involves the autophosphorylation of syk on 
tyrosines 525 and 526 (YY525/6) in the activation loop of the kinase domain, which 
promotes substrate-specific catalytic activity and is required for signaling by syk (Sada et 
al., 2001; Zhang et al., 1998); this modification is thus indicative of the functional enzyme. 
The active form of syk then localizes to appropriate substrates or bridging molecules 
primarily through interactions with its SH2 domains and linker tyrosines (Kimura et al., 
1996; Sada et al., 2001). 
Syk has been identified as a putative tumor suppressor in human breast cancer since 
reintroduction of syk retarded the growth of syk-negative breast cancer cells, and 
suppression of endogenous syk enhanced the tumorigenic phenotype of the resulting cells 
(Coopman et al., 2000). Loss of syk correlates with poor survival and metastasis of breast 
cancer in patients (Toyama et al., 2003), and syk regulates breast cancer cell mitosis (Zyss et 
al., 2005) and transcription (Wang et al., 2005). Previously we identified syk as being a 
pancreatic ductal adenocarcinoma (PDAC) tumor suppressor. Syk is uniformly expressed by 
normal pancreatic ductal epithelium and well-differentiated (grade1; G1) PDAC; however 
moderately-differentiated (grade2; G2) PDAC demonstrates progressive loss of syk, and 
high-grade (grade3; G3), poorly-differentiated lesions are essentially devoid of syk in situ 
(Layton et al., 2009). In fact, syk expression is a strong positive indicator of patient survival 
(Layton et al., 2009). Mechanistically, we demonstrated that syk is a central mediator of 
phenotypic changes regulating PDAC progression, including anchorage-independent 
growth, cellular invasion, and gene expression changes responsible for epithelial-
mesenchymal transition (Layton et al., 2009). To assess the utilization of syk in pancreatic 
ductal cells, we examined phosphorylation states of syk that correspond to upstream 
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activation (tyrosine-352) and catalytic activity (tyrosines-525/6). We further examined the 
activity of syk and the requirement for syk kinase activity in regulating cell growth and 
invasion. Herein we show that although blockade of syk activity suppressed growth of 
endogenously syk-positive PDAC cells in vitro, kinase activity is not required for syk-
dependent regulation of PDAC cell invasion. Phosphorylation of tyrosine-352 and tyrosines-
525/6 is detectable in pancreatic ductal epithelial cells in situ and in vitro, and inhibition of 
syk kinase activity specifically retards the growth of endogenously syk-positive PDAC cells 
in vitro. In contrast to our previous demonstration that syk regulates the invasion of v3-
positive Panc1 PDAC cells by attenuation of the matrix metalloproteinase-2 axis (Layton et 
al., 2009), invasion of v3-negative MIAPaCa2 and BxPC3 PDAC cells is metalloproteinase-
independent and involves the urokinase/plasminogen system, which is regulated by syk in 
these cells. Thus we demonstrate that endogenous syk is active in pancreatic ductal 
epithelial cells, and that syk kinase activity is required for growth regulation, but not 
invasion suppression, by syk in this cell type.  
2. Materials and methods 
2.1 Cell lines and transfection  
CAPAN2(G1), CFPAC1(G2), AsPC1(G2), BxPC3(G2), Panc1(G3) and MIAPaCa2(G3+) cells 
were originally from ATCC and cultured accordingly. pCDNA3.1/IH/sykwt encoding myc-
tagged human syk linked to a hygromycin phosphotransferase gene through an IRES was 
described previously (Layton et al., 2009). Kinase-dead (KD) syk was produced by  
site-directed mutagenesis of lysine-402 in the ATP-binding pocket of  
pCDNA3.1/IH/sykwt using the following primers (K402R-FWD: 5’-
GTGAAAACCGTGGCTGTGAGAATACTGAAAAACGAGGC-3’; K402R-REV: 5’-
GCCTCGTTTTTCAGTATTCTCACAGCCACGGTTTTCAC-3’). MIAPaCa2 cells were 
transfected using Lipofectamine2000 (Invitrogen, Carlsbad, CA). BxPC3 cells were 
electroporated as described previously (Layton et al., 2009). Stable populations were 
hygromycin-selected and assessed for protein expression. For transient studies, pEF4-LacZ 
reporter (Invitrogen, Carlsbad, CA) was cotransfected, and cells stained with x-gal to identify 
and specifically quantitate transfected cells; average MIAPaCa2 transfection efficiency >95%. 
In all cases, serum-free (SF-) media consisted of all components except serum, as appropriate 
for the cell line, supplemented with 0.5% bovine serum albumin (BSA). 
2.2 Antibodies and reagents  
Anti-syk mAb 4D10 and anti-erk2 pAb C14 were from Santa Cruz Biotechnology (Santa 
Cruz, CA). Anti-syk phospho-Y352 and anti-syk phospho-YY525/6 pAbs were from Cell 
Signaling (Beverly, MA). Anti-phosphotyrosine mAb 4G10 and anti-myc tag mAb 4A6 were 
from UBI (Lake Placid, NY). Function-blocking anti-integrin antibodies LM609 (v3) and 
PIF6 (v5) and the MMP inhibitor N-(R)-[2-(Hydroxyaminocarbonyl)methyl]-4-
methylpentanoyl-L-napthylalanyl-L-alanine, 2-aminoethylamide (TAPI-1) were from 
Chemicon/EMD (San Diego, CA). Function-blocking anti-uPA mAb 3689 was from 
American Diagnostica (Stamford, CT). HRP- and FITC-conjugated secondary antibodies 
were from Jackson Immunoresearch Laboratories (West Grove, PA). Nonspecific mouse 
IgG1 antibody MOPC-21, purified rabbit IgG, piceatannol (3,4,3’,5’- tetrahydroxy-trans-
stilbene), Crystal Violet and other chemicals were from Fisher Scientific (Pittsburg, PA). 
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2.3 Immunohistochemistry 
Patient tissue samples were obtained under approved UCSD Institutional Review Board 
protocol from the UCSD Dept. of Pathology archives and stained essentially as described 
previously (Layton et al., 2009). Briefly, samples were deparaffinized with xylenes, 
rehydrated through sequential alcohols (100%, 95%, 70%, 50%), and incubated with 1% H2O2 
to inactivate endogenous peroxidases. Slides were quenched with 50 mM glycine, and 
blocked with 2% horse serum/5% BSA/phosphate-buffered saline (PBS), pH7.4, before 
renaturing for 20min in a steamer using Target Retrieval Solution (DAKO North America; 
Carpinteria, CA). Slides were allowed to cool and then incubated with the appropriate 
primary antibody overnight at 4C. Slides were washed and biotinylated-anti-rabbit applied 
according to the VectaStain Elite ABC Kit (Vector Labs; Burlingame, CA, USA). Sections 
were developed with DAB, counterstained with hematoxylin, dehydrated through 
sequential alcohols and mounted. Brightfield images were acquired on a Nikon TE600 
microscope with a Model 3.2.0 CCD camera (Diagnostic Instruments, Sterling Heights, MI, 
USA) using SpotBasic software at the Moores UCSD Cancer Center. 
2.4 Immunoblotting 
Immunoblotting was performed essentially as described previously (Chen et al., 2010). 
Briefly, cells were lysed on the plate in NP40 lysis buffer (50mM Tris pH7.4, 150mM NaCl, 
1% NP-40) containing Complete™ Protease Inhibitor Cocktail (Roche, Indianapolis, IN) 
supplemented with 10mM PMSF, 1mM NaF and 10mM Na3VO4. Samples were separated by 
SDS-PAGE under reducing conditions and electroblotted to a PVDF membrane. Membranes 
were blocked with 10% nonfat dry milk in tris-buffered saline (TBS) containing 0.1% Tween-
20 (TBS-T) and incubated 2h to overnight in 2% milk/TBS-T with the indicated primary 
antibody. Primary antibody was detected with HRP-conjugated secondary antibody, and 
complexes were visualized by enhanced chemiluminescence with PS-3 (Lumigen, Inc.; 
Southfield, MI). 
2.5 Flow cytometry (FACS) 
FACS was performed on a FACScalibur (BD Biosciences, Bedford, MA) at the Moores UCSD 
Cancer Center Flow Cytometry Shared Resource as described previously (Chen et al., 2010). 
Cells were harvested with 0.1% trypsin/versene, inactivated with 0.1% soybean trypsin 
inhibitor and resuspended in FACS buffer (1mM MgCl2, 1mM CaCl2, 0.1% NaN3 0.5% BSA 
in PBS pH 7.4) before sequential labelling with primary and FITC-conjugated secondary 
antibodies. Gates were set with secondary alone, and 5μg/ml propidium iodide was 
included to exclude dead and dying cells. 
2.6 Proliferation assays 
Cell growth was assessed with the CellTiter96 Aqueous One Solution Cell Proliferation 
Assay (MTS) kit (Promega, Madison, WI), or as follows: cells (5x102/well) were seeded into 
a 48-well plate. After 24 hours (and every 72 hours thereafter), fresh growth medium was 
replaced and the initial time point fixed with 1% paraformaldehyde/PBS, pH7.4. Additional 
triplicate wells were fixed at 24 hour intervals. All wells were stained with 1% Crystal 
Violet, which was subsequently extracted with 10% acetic acid, quantitated at 550nm and 
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compared to a standard curve of cells. For proliferation assays in the presence of the syk 
inhibitor, piceatannol, a titration of cells was plated and allowed to adhere for 24 hours before 
fresh growth medium (full serum) containing the indicated concentrations of piceatannol or 
DMSO vehicle was replaced. Medium was replenished in the same manner every other day 
for a total of 3 treatments, and the cells were fixed and stained with Crystal Violet 24h after the 
last treatment. Dye was extracted with 10% acetic acid and quantitated at 550nm. 
2.7 Anchorage-independent growth 
Anchorage-independent growth was assessed as described previously (Layton et al., 2009). 
Briefly, a top layer containing 5x103 cells in 0.5% agar/DMEM/10%FBS was seeded onto a 
base layer of 0.7% agar/DMEM containing 10% FBS in a 6 well plate. Cultures were 
incubated at 37°C, media was replaced every 3rd day, and the assay stopped on day 10. 
Cultures were stained with 0.01% Crystal Violet and colonies were enumerated on a Bio-
Rad GelDocXR using QuantityOne Software (Sensitivity=8.1, Average=5). 
2.8 Invasion assay 
Invasion assays were performed as described previously (Layton et al., 2009) using BioCoat 
Growth Factor-Reduced Matrigel Invasion Chambers (BD Biosciences, Bedford, MA, USA). 
Briefly, cells were applied in SF-media to the upper chamber with or without 15min 
preincubation with TAPI1 (40μg/mL), aprotinin (100μg/mL), anti-uPA monoclonal 
antibody 3689 (25μg/mL), nonspecific IgG1 control antibody MOPC-21 (25g/ml), or an 
equal volume of DMSO or PBS control included in both chambers. SF-media or growth 
media was provided in the lower chamber and cells were allowed to invade for 24h before 
removal of uninvaded cells, and enumeration of invaded cells. 
2.9 Reverse Transcription (RT)-PCR 
cDNA was synthesized from 1μg of total RNA using oligo-dT primer. PCR was performed 
on 1μL of resulting cDNA using primers described previously (Layton et al., 2009; Leissner 
et al., 2006). GAPDH primers were from Stratagene (San Diego, CA) and served as internal 
controls. Densitometry was performed on unadjusted images using NIH Image 1.61 software 
and GAPDH as reference control. 
2.10 Statistics 
Experiments were performed in triplicate and independently repeated at least twice. Data 
shown are mean + standard deviation unless otherwise indicated. Colony-formation and 
cellular invasion were analyzed by two-tailed Students t-Test. 
3. Results  
3.1 Endogenously–expressed syk is functional in pancreatic ductal cells in situ and in 
vitro 
Previously we demonstrated the expression of syk in normal pancreatic ductal epithelial 
cells in situ (Layton et al., 2009). In order to assess whether this endogenous syk is 
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functionally active, we performed immunohistochemistry with antibodies specific for the 
phosphorylated form of Y352, which is representative of syk activation by upstream 
mediators, or YY525/6, which is indicative of substrate-specific activity of the syk kinase 
domain (Kimura et al., 1996; Sada et al., 2001; Zhang et al., 1998). These antibodies react with 
both isoforms of syk and do not recognize more distantly related src family members (Cell 
Signaling Technology, Beverly, MA). Strong staining for both phospho-Y352 (Fig.1A-C) and 
phospho-YY525/6 (Fig.1D-F) was observed in individual cells of independent ducts as well 
as ductules associated with acinar clusters. No staining was observed in the absence of 
primary antibody or when purified rabbit IgG was used as a control (not shown).  
  
Fig. 1. Syk is functional in pancreatic ductal cells in situ. Immunohistochemical staining 
(brown-black) of normal pancreas with phospho-Y352 (A-C) and phospho-YY525/6 (D-F). 
Arrowheads in (C,F) denote nuclear staining. Scale bars in m.  
Nuclear staining was observed in a subset of the duct cells (arrowheads in Fig.1C,F), 
consistent with the detection of nuclear syk in pancreatic ductal cells in situ (Layton et al., 
2009) and previous reports of syk nuclear translocalization (Wang et al., 2003) and 
regulation of cell division (Zyss et al., 2005) and transcription (Wang et al., 2005). Of the 20 
samples analyzed, all showed evidence of syk activation in a subset of ductal cells and none 
showed widespread constitutive phosphorylation at either site, demonstrating the active 
regulation of syk activation and activity in ductal cells of the normal human pancreas and 
suggesting an active role for syk in regulating the phenotype of this cell type.  
We also previously established the expression of syk in well- to moderately-differentiated 
PDAC cells (CAPAN2-G1, CFPAC1-G2, BxPC3-G2, AsPC1-G2), to the exclusion of poorly-
differentiated PDAC cells (Panc1-G3, MIAPaCa2-G3+)(Layton et al., 2009). In order to 
establish the utilization of syk by these endogenously syk-positive PDAC cells, we analyzed 
the activation surrogate readout of Y352 and YY525/6 phosphorylation in BxPC3 cells. 
Serum-starved cells were stimulated with insulin and then lysates immunoblotted with the 
phospho-syk-specific pAbs used for IHC. Interestingly, both Y352 and YY525/6 are 
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Fig. 1. Syk is functional in pancreatic ductal cells in situ. Immunohistochemical staining 
(brown-black) of normal pancreas with phospho-Y352 (A-C) and phospho-YY525/6 (D-F). 
Arrowheads in (C,F) denote nuclear staining. Scale bars in m.  
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showed widespread constitutive phosphorylation at either site, demonstrating the active 
regulation of syk activation and activity in ductal cells of the normal human pancreas and 
suggesting an active role for syk in regulating the phenotype of this cell type.  
We also previously established the expression of syk in well- to moderately-differentiated 
PDAC cells (CAPAN2-G1, CFPAC1-G2, BxPC3-G2, AsPC1-G2), to the exclusion of poorly-
differentiated PDAC cells (Panc1-G3, MIAPaCa2-G3+)(Layton et al., 2009). In order to 
establish the utilization of syk by these endogenously syk-positive PDAC cells, we analyzed 
the activation surrogate readout of Y352 and YY525/6 phosphorylation in BxPC3 cells. 
Serum-starved cells were stimulated with insulin and then lysates immunoblotted with the 
phospho-syk-specific pAbs used for IHC. Interestingly, both Y352 and YY525/6 are 
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constitutively phosphorylated under starvation conditions, and dephosphorylated in 
response to insulin (Fig.2). Similar results were obtained with serum stimulation (not 
shown), and with endogenously syk-positive CAPAN2 cells (not shown). These data 
demonstrate the active regulation of syk activity in response to specific signalling pathways 
in endogenously syk-positive, well-differentiated PDAC cells, consistent with the restricted 
syk activation observed in situ and suggesting that syk is an active participant in regulating 
the phenotype of these cells. 
 
Fig. 2. Syk is functional in PDAC cells in vitro. Immunoblot of phospho-Y352 and 
phospho-YY525/6 in BxPC3 cells that had been serum-starved for 24h prior to stimulation 
with 10ng/ml insulin for the indicated times. NT, no treatment. Total syk levels determined 
with the 4D10 mAb are shown as a control. 
3.2 Syk-dependent regulation of cell growth requires syk kinase activity  
Syk regulates proliferation of immune cells in response to specific receptor activation events 
(Kimura et al., 1996; Sada et al., 2001; Wieder et al., 2001), and ectopic expression of an RFP-
tagged syk caused anomalous cell division and mitotic catastrophe in breast cancer cells, 
where it was observed to interact with -tubulin of the mitotic spindle (Zyss et al., 2005). We 
observed localization of syk to the perinuclear region of dividing PDAC cells (not shown), 
therefore we assessed whether syk might be involved in regulating the proliferation of 
endogenously syk-positive PDAC cells in a manner analogous to that described in breast 
cancer (Coopman et al., 2000). Consistent with such a role, the in vitro growth of 
endogenously syk-positive CAPAN2, CFPAC1, BxPC3 and AsPC1 cells was suppressed in a 
dose-dependent manner by piceatannol, a phytochemical that inhibits the kinase activity of 
syk, suppressing downstream phosphorylation events by a largely unknown mechanism  
(Geahlen et al., 1989; Ferrigni et al., 1984; Wieder et al., 2001)(Fig.3A). Significantly, the only 
G1 cells in this group, CAPAN2, were completely eradicated by the highest dose of  
inhibitor, suggesting cytotoxicity in addition to any cytostatic effect of this compound in 
these highly differentiated cells. 
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Fig. 3. Kinase activity is required for syk-dependent regulation of cell growth. (A) Cell 
growth of syk-positive versus syk-negative PDAC cell lines after 7 days of piceatannol 
treatment, plotted as percent of untreated control. (B) Proliferation of stable BxPC3/mock 
and BxPC3/sykKD cells after 5 days. (B,inset) Immunoblot of total syk (syk) and the myc-tag 
(myc) of sykKD. Erk2, loading control. (C) Proliferation of MP2/mock and MP2/sykwt cells 
after 5 days. (D) MP2/sykwt and Panc1/syk cell growth assay after 7 days of piceatannol 
treatment, as in (A). (E) Phase contrast images demonstrating the effect of stable syk 
expression on MIAPaCa2 cell morphology. Both populations were maintained under 
identical culture conditions including maintenance doses of the selectable marker 
hygromycin. (F) Effect of syk on anchorage-independent growth of MIAPaCa2 cells. A 
representative example of replicate plates is shown with quantitation points superimposed. 
The specificity of this effect to the inhibition of syk is demonstrated by the following facts. 
First, trans-stilbene, which is the base molecule from which piceatannol is derived, had no 
effect on the proliferation of any of these cells (not shown). Second, syk-negative 
MIAPaCa2 and Panc1 cells demonstrated no growth response to piceatannol in this assay 
(Fig. 3A). Third, although piceatannol has been reported to inhibit FAK, src, PI3K and 
IB/NF-B kinases (Ashikawa et al., 2002; Choi et al., 2010; Law et al., 1999), inhibition of 
these kinases has been shown to retard the proliferation of both syk-positive and syk-
negative lines used in this study (Hering et al., 2007; Hochwald, et al., 2009; Ito et al., 2003; 
Perugini et al., 2000). Together, these points demonstrate that the antiproliferative effect of 
piceatannol reported here is likely restricted to the inhibition of syk itself. It should be noted 
that the concentrations of piceatannol used in this study are based on prior established 
parameters designed to minimize non-specific effects (Ashikawa et al., 2002; Choi et al., 
2010; Geahlen et al., 1989; Law et al., 1999; Seow et al., 2002; Wieder et al., 2001). 
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To extend these pharmacological inhibitor studies, we stably transfected endogenously syk-
positive BxPC3 cells with a kinase-dead syk construct harbouring a point mutation (K402R) 
in the ATP binding site of the kinase domain (BxPC3/KD cells). This construct has been 
shown to act as a dominant-negative in endogenously syk-positive cells through an 
incompletely understood mechanism (Coopman et al., 2000). BxPC3/KD cells demonstrated 
a consistently reduced growth rate versus mock-transfectants (Fig.3B). Stable expression of 
wildtype syk did not affect the proliferation rate of these cells (not shown). It should be 
noted that these engineered cells are non-clonal populations, being the result of a bicistronic 
system that links transgene expression to drug resistance through an IRES sequence. 
Moreover, repeated generation of stable populations using this system resulted in stable 
“lines” that behaved similarly, demonstrating that these data are not artifactual in nature. 
Since stable reexpression of syk in G3 Panc1 cells reduced their growth rate in vitro (Layton 
et al., 2009), we questioned whether stable reexpression of syk in MIAPaCa2 (MP2/sykwt) 
cells would have a similar effect on these G3+ PDAC cells. Unlike Panc1 cells, no growth 
rate difference was observed between MP2/mock and MP2/sykwt cells in culture (Fig.3C). 
Moreover, piceatannol did not suppress the growth of MIAPaCa2 or Panc1 cells stably 
reexpressing syk (Fig.3D), suggesting that PDAC cells that have progressed to syk-negative 
status are able to bypass the growth requirement for endogenous syk when it is ectopically 
reintroduced. It should be noted, however, that piceatannol was functional in this assay, 
since it caused a slight dose-dependent increase in the growth rate of Panc1/syk cells 
(Fig.3D) that is commensurate with overcoming the minor growth rate reduction that 
resulted from the original stable reexpression of syk in these cells (Layton et al., 2009). In 
contrast, however, we did observe an effect of stable syk reexpression on overall MIAPaCa2 
morphology similar to that observed in Panc1/syk cells (Layton et al., 2009). As such, 
MP2/sykwt cells demonstrate increased cell-cell interactions, resulting in more of a 
traditional monolayer characteristic of epithelial cells in culture, and a reduced propensity 
for cells to remain separate in between cell clusters (Fig.3E). This suggests the 
reestablishment of a more differentiated phenotype by syk in these cells. Accordingly, 
MP2/sykwt cells demonstrate a dramatically reduced ability to grow in an anchorage-
independent growth assay (Fig.3F), exhibiting a plating efficiency of 1.7%, versus 9.0% for 
MP2/mock cells, less dramatic but similar to the effect observed previously in Panc1/syk 
cells (Layton et al., 2009). 
3.3 Stable expression, but not kinase activity, is required for syk-dependent invasion 
suppression  
We previously observed a negative regulation of Panc1 invasion by stable reexpression of 
syk (Layton et al., 2009). Therefore, we assessed the in vitro invasion capabilities of 
MP2/mock and MP2/sykwt cells. Stable MP2/sykwt cells exhibit 90% less invasion towards 
serum-containing media compared to MP2/mock, and essentially no invasion in the 
absence of serum attractant (Fig.4A). To determine whether the kinase activity of syk is 
required for this effect, we stably expressed the K402R kinase-dead (KD) mutant syk in 
MIAPaCa2 cells (MP2/sykKD); both wildtype and KD proteins were expressed at equal 
levels (Fig.4A, inset). Importantly, stable MP2/sykKD cells exhibit nearly identical invasion 
suppression to MP2/sykwt cells (Fig.4A), demonstrating that kinase activity is not required 
for syk’s invasion-suppressor function in these cells. Consistent with this finding, 48h 
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pretreatment with piceatannol did not affect the invasion of either endogenously syk-
positive BxPC3 cells or stable MP2/sykwt cells (Fig.4B). Additionally, transient transfection 
with sykwt or sykKD did not retard MIAPaCa2 invasion (Fig.4C), suggesting that long-term 
expression is required for syk to influence invasion, likely through gene expression changes 
as described previously in Panc1 cells (Layton et al., 2009).  
 
Fig. 4. Stable expression, but not kinase activity, is required for invasion suppression by 
syk. (A) The indicated stable MIAPaCa2 populations were provided serum-containing (FBS) 
or serum-free (SF) medium in the lower compartment of invasion chambers and allowed to 
invade for 24h before removal of uninvaded cells and enumeration of invaded cells. 
(A,inset) Immunoblot of ectopic syk expression with the 4D10 mAb (syk). Erk2, loading 
control. (B) Cells were pretreated for 48h with 25M piceatannol (PC) or DMSO vehicle (NT) 
prior to seeding into invasion chambers with serum-containing media in the lower 
compartment. (C) MIAPaCa2 cells were transiently cotransfected with lacZ reporter and 
empty vector (mock), or wildtype (WT) or kinase-dead (KD) syk and 48h later seeded into 
invasion chambers. After 24 hours cells were stained with x-gal and invaded transfected 
cells (blue) were enumerated and plotted as percent of mock.  
3.4 MIAPaCa2 invasion is regulated by urokinase–type plasminogen activators  
We previously demonstrated that Panc1 invasion is dependent upon the matrix 
metalloproteinase (MMP)-2 axis, and that syk specifically attenuates the expression of 
MMP2 and its inhibitor, TIMP2, in these cells (Layton et al., 2009). In contrast to Panc1 cells, 
the MMP inhibitor TAPI1 did not suppress MIAPaCa2/mock invasion (Fig.5A), and RT-
PCR (Fig.5B) and zymography (not shown) showed that MIAPaCa2 cells do not produce 
MMP2 in culture. MMP2 and MMP9 products were detected in parallel reactions run at the 
same time on unrelated samples (not shown), demonstrating that lack of signal in these 
samples is not the result of failed amplification reactions. These results demonstrate that 
MIAPaCa2 invasion is MMP-independent in vitro.  
Another key regulator of epithelial cell invasion is the urokinase-type plasminogen activator 
(uPA)/uPA receptor (uPAR) axis (Leissner et al., 2006; McMahon and Kwaan, 2009), whose 
components are expressed by MIAPaCa2 cells in culture (Fig.5B). Consistent with the 
potential involvement of this system, MP2/mock invasion was completely suppressed by 
the serine protease inhibitor aprotinin (Fig.5C). This effect was not due to toxicity, as 
Pancreatic Cancer – Molecular Mechanism and Targets 110 
To extend these pharmacological inhibitor studies, we stably transfected endogenously syk-
positive BxPC3 cells with a kinase-dead syk construct harbouring a point mutation (K402R) 
in the ATP binding site of the kinase domain (BxPC3/KD cells). This construct has been 
shown to act as a dominant-negative in endogenously syk-positive cells through an 
incompletely understood mechanism (Coopman et al., 2000). BxPC3/KD cells demonstrated 
a consistently reduced growth rate versus mock-transfectants (Fig.3B). Stable expression of 
wildtype syk did not affect the proliferation rate of these cells (not shown). It should be 
noted that these engineered cells are non-clonal populations, being the result of a bicistronic 
system that links transgene expression to drug resistance through an IRES sequence. 
Moreover, repeated generation of stable populations using this system resulted in stable 
“lines” that behaved similarly, demonstrating that these data are not artifactual in nature. 
Since stable reexpression of syk in G3 Panc1 cells reduced their growth rate in vitro (Layton 
et al., 2009), we questioned whether stable reexpression of syk in MIAPaCa2 (MP2/sykwt) 
cells would have a similar effect on these G3+ PDAC cells. Unlike Panc1 cells, no growth 
rate difference was observed between MP2/mock and MP2/sykwt cells in culture (Fig.3C). 
Moreover, piceatannol did not suppress the growth of MIAPaCa2 or Panc1 cells stably 
reexpressing syk (Fig.3D), suggesting that PDAC cells that have progressed to syk-negative 
status are able to bypass the growth requirement for endogenous syk when it is ectopically 
reintroduced. It should be noted, however, that piceatannol was functional in this assay, 
since it caused a slight dose-dependent increase in the growth rate of Panc1/syk cells 
(Fig.3D) that is commensurate with overcoming the minor growth rate reduction that 
resulted from the original stable reexpression of syk in these cells (Layton et al., 2009). In 
contrast, however, we did observe an effect of stable syk reexpression on overall MIAPaCa2 
morphology similar to that observed in Panc1/syk cells (Layton et al., 2009). As such, 
MP2/sykwt cells demonstrate increased cell-cell interactions, resulting in more of a 
traditional monolayer characteristic of epithelial cells in culture, and a reduced propensity 
for cells to remain separate in between cell clusters (Fig.3E). This suggests the 
reestablishment of a more differentiated phenotype by syk in these cells. Accordingly, 
MP2/sykwt cells demonstrate a dramatically reduced ability to grow in an anchorage-
independent growth assay (Fig.3F), exhibiting a plating efficiency of 1.7%, versus 9.0% for 
MP2/mock cells, less dramatic but similar to the effect observed previously in Panc1/syk 
cells (Layton et al., 2009). 
3.3 Stable expression, but not kinase activity, is required for syk-dependent invasion 
suppression  
We previously observed a negative regulation of Panc1 invasion by stable reexpression of 
syk (Layton et al., 2009). Therefore, we assessed the in vitro invasion capabilities of 
MP2/mock and MP2/sykwt cells. Stable MP2/sykwt cells exhibit 90% less invasion towards 
serum-containing media compared to MP2/mock, and essentially no invasion in the 
absence of serum attractant (Fig.4A). To determine whether the kinase activity of syk is 
required for this effect, we stably expressed the K402R kinase-dead (KD) mutant syk in 
MIAPaCa2 cells (MP2/sykKD); both wildtype and KD proteins were expressed at equal 
levels (Fig.4A, inset). Importantly, stable MP2/sykKD cells exhibit nearly identical invasion 
suppression to MP2/sykwt cells (Fig.4A), demonstrating that kinase activity is not required 
for syk’s invasion-suppressor function in these cells. Consistent with this finding, 48h 
Kinase Activity is Required for Growth Regulation but not 
Invasion Suppression by Syk Kinase in Pancreatic Adenocarcinoma Cells 111 
pretreatment with piceatannol did not affect the invasion of either endogenously syk-
positive BxPC3 cells or stable MP2/sykwt cells (Fig.4B). Additionally, transient transfection 
with sykwt or sykKD did not retard MIAPaCa2 invasion (Fig.4C), suggesting that long-term 
expression is required for syk to influence invasion, likely through gene expression changes 
as described previously in Panc1 cells (Layton et al., 2009).  
 
Fig. 4. Stable expression, but not kinase activity, is required for invasion suppression by 
syk. (A) The indicated stable MIAPaCa2 populations were provided serum-containing (FBS) 
or serum-free (SF) medium in the lower compartment of invasion chambers and allowed to 
invade for 24h before removal of uninvaded cells and enumeration of invaded cells. 
(A,inset) Immunoblot of ectopic syk expression with the 4D10 mAb (syk). Erk2, loading 
control. (B) Cells were pretreated for 48h with 25M piceatannol (PC) or DMSO vehicle (NT) 
prior to seeding into invasion chambers with serum-containing media in the lower 
compartment. (C) MIAPaCa2 cells were transiently cotransfected with lacZ reporter and 
empty vector (mock), or wildtype (WT) or kinase-dead (KD) syk and 48h later seeded into 
invasion chambers. After 24 hours cells were stained with x-gal and invaded transfected 
cells (blue) were enumerated and plotted as percent of mock.  
3.4 MIAPaCa2 invasion is regulated by urokinase–type plasminogen activators  
We previously demonstrated that Panc1 invasion is dependent upon the matrix 
metalloproteinase (MMP)-2 axis, and that syk specifically attenuates the expression of 
MMP2 and its inhibitor, TIMP2, in these cells (Layton et al., 2009). In contrast to Panc1 cells, 
the MMP inhibitor TAPI1 did not suppress MIAPaCa2/mock invasion (Fig.5A), and RT-
PCR (Fig.5B) and zymography (not shown) showed that MIAPaCa2 cells do not produce 
MMP2 in culture. MMP2 and MMP9 products were detected in parallel reactions run at the 
same time on unrelated samples (not shown), demonstrating that lack of signal in these 
samples is not the result of failed amplification reactions. These results demonstrate that 
MIAPaCa2 invasion is MMP-independent in vitro.  
Another key regulator of epithelial cell invasion is the urokinase-type plasminogen activator 
(uPA)/uPA receptor (uPAR) axis (Leissner et al., 2006; McMahon and Kwaan, 2009), whose 
components are expressed by MIAPaCa2 cells in culture (Fig.5B). Consistent with the 
potential involvement of this system, MP2/mock invasion was completely suppressed by 
the serine protease inhibitor aprotinin (Fig.5C). This effect was not due to toxicity, as 
Pancreatic Cancer – Molecular Mechanism and Targets 112 
aprotinin-treated cells remained 100% viable after 24h (Fig.5C, inset), which is the duration 
of the invasion assay. Specifically demonstrating the involvement of the uPA/uPAR axis, 
MP2/mock invasion was almost completely inhibited by a function-blocking anti-uPA 
antibody (Fig.5C). An isotype-matched (IgG1) control antibody (MOPC-21) had no effect 
(not shown). Importantly, densitometry demonstrated >75% reduction in uPA mRNA levels 
by both sykwt and sykKD in MIAPaCa2 cells (Fig.5B), suggesting a potential mechanism for 
syk’s effect on MIAPaCa2 invasion. Interestingly, expression of the uPA inhibitor, PAI-1, 
was also suppressed >30% by both wildtype and kinase-dead syk (Fig.5B). However, the 
uPA receptor, uPAR, was actually increased ~50% by sykwt, but suppressed by >60% by 
sykKD, suggesting that kinase activity may be required for appropriate regulation of uPAR, 
but not uPA or PAI-1.  
 
Fig. 5. MIAPaCa2 invasion is mediated by the uPA/uPAR axis. (A) MP2/mock invasion 
towards serum-containing (FBS) or serum-free (SF) medium +/- the MMP inhibitor TAPI1. 
(B) Semi-quantitative RT-PCR from the indicated stable MIAPaCa2 transfectants for the 
indicated products. GAPDH, control. (C) MP2/mock invasion +/- the serine protease 
inhibitor aprotinin or function-blocking anti-uPA antibody. (C,inset) Viability of aprotinin-
treated cells after 24h.  
Previous studies have demonstrated the regulation of the MMP2 axis by the v3 integrin 
(Deryugina et al., 2001; Nisato et al., 2005), and an association of the uPA/uPAR axis with 
the v5 integrin (Yebra et al., 1995; 1996). Moreover, MMP2 activation has been linked to 
v3 in PDAC (Hosotani et al., 2002), and v3 engagement suppresses the expression of 
uPA/uPAR components (Hapke et al., 2001). Therefore, to assess whether the different 
protease dependencies observed in this and our former study (Layton et al., 2009) are 
related to differential integrin expression, FACS analysis was performed on live cells from 
standard culture. Consistent with MMP2-dependence, Panc1 cells proved to be strongly 
v3-positive (Fig.6A). In contrast, MIAPaCa2 cells are v3-negative (Fig.6B), 
commensurate with their MMP2-independent/uPA-dependent phenotype. These results on 
cell surface integrin expression were corroborated at the total expression level by 
immunoblotting of whole cell lysates (not shown). Further demonstrating the integrin-
dependent phenotypes of these cells, MIAPaCa2 invasion could be fully suppressed by a 
v5 integrin-specific function-blocking mAb, while Panc1 invasion also involves v3 and 
could only be fully blocked by combination of v5- and v3-specific function blocking 
mAbs (Fig.6C). 
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Fig. 6. The invasion mechanism of MIAPaCa2 and Panc1 cells is related to their integrin 
expression profiles. (A,B) FACS analysis of integrin v3 and v5 surface expression in 
Panc1 (A) and MIAPaCa2 cells (B). (C) Invasion of MIAPaCa2 (left) and Panc1 (right) cells in 
the presence or absence of 50g/ml of function-blocking antibodies directed against the 
indicated integrins.  
To further test the role of syk in regulating PDAC invasion, we examined the BxPC3/KD 
cells, which stably express the dominant-negative kinase-dead syk in addition to their 
endogenous wildtype syk. While BxPC3/mock cells show marginal invasion towards 
serum-containing media and essentially no invasion in the absence of serum attractant, 
stable BxPC3/KD cells demonstrate a >75% increase in invasion towards serum-containing 
media and significant de novo invasion in the absence of serum attractant (Fig.7A). FACS 
demonstrated that BxPC3 cells are also v3-negative (not shown) and, consistent with this 
finding, the MMP inhibitor TAPI1 had no effect on serum-free BxPC3/KD invasion (Fig.7B). 
However, both aprotinin and anti-uPA mAb treatment reduced serum-free BxPC3/KD 
invasion significantly (Fig.7B), demonstrating a role for the uPA/uPAR axis in the syk-
regulated invasion of these endogenously syk-positive PDAC cells. An isotype-matched 
(IgG1) control antibody (MOPC-21) had no effect (not shown). It should be stressed that 
BxPC3/mock cells do not invade under these conditions, thereby allowing us to assess the 
role of uPA in a phenotype that was dependent upon syk inhibition and allowing us to 
exclude confounding issues derived from the endogenous phenotype.  
4. Discussion  
Previously we identified syk as being expressed not only in normal pancreatic ductal 
epithelium, but also in well- to moderately-differentiated PDAC in situ (Layton et al., 2009). 
The expression of syk in normal ductal epithelium of the breast has also been reported, as 
has a role for syk as a tumor suppressor in that tissue (Coopman et al., 2000). As such, loss of 
syk expression in primary breast tumors is associated with a poor prognosis (Toyama et al., 
2003). We found that syk similarly correlates with patient survival in PDAC patients 
(Layton et al., 2009). However, we observe consistent loss of syk expression in poorly-
differentiated PDAC, and have not observed loss of syk in well-differentiated PDAC 
samples. This differs from breast cancer, where syk is absent from a subset of well- 
differentiated lesions and expressed normally in many poorly-differentiated samples 
(Toyama et al., 2003), suggesting potentially dramatic differences in the regulation or 
function of syk in the ductal epithelium of these two glandular tissues. Indeed, we present 
evidence that syk functions to facilitate growth of PDAC cells that express it. This is perhaps 
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Fig. 5. MIAPaCa2 invasion is mediated by the uPA/uPAR axis. (A) MP2/mock invasion 
towards serum-containing (FBS) or serum-free (SF) medium +/- the MMP inhibitor TAPI1. 
(B) Semi-quantitative RT-PCR from the indicated stable MIAPaCa2 transfectants for the 
indicated products. GAPDH, control. (C) MP2/mock invasion +/- the serine protease 
inhibitor aprotinin or function-blocking anti-uPA antibody. (C,inset) Viability of aprotinin-
treated cells after 24h.  
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Fig. 6. The invasion mechanism of MIAPaCa2 and Panc1 cells is related to their integrin 
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indicated integrins.  
To further test the role of syk in regulating PDAC invasion, we examined the BxPC3/KD 
cells, which stably express the dominant-negative kinase-dead syk in addition to their 
endogenous wildtype syk. While BxPC3/mock cells show marginal invasion towards 
serum-containing media and essentially no invasion in the absence of serum attractant, 
stable BxPC3/KD cells demonstrate a >75% increase in invasion towards serum-containing 
media and significant de novo invasion in the absence of serum attractant (Fig.7A). FACS 
demonstrated that BxPC3 cells are also v3-negative (not shown) and, consistent with this 
finding, the MMP inhibitor TAPI1 had no effect on serum-free BxPC3/KD invasion (Fig.7B). 
However, both aprotinin and anti-uPA mAb treatment reduced serum-free BxPC3/KD 
invasion significantly (Fig.7B), demonstrating a role for the uPA/uPAR axis in the syk-
regulated invasion of these endogenously syk-positive PDAC cells. An isotype-matched 
(IgG1) control antibody (MOPC-21) had no effect (not shown). It should be stressed that 
BxPC3/mock cells do not invade under these conditions, thereby allowing us to assess the 
role of uPA in a phenotype that was dependent upon syk inhibition and allowing us to 
exclude confounding issues derived from the endogenous phenotype.  
4. Discussion  
Previously we identified syk as being expressed not only in normal pancreatic ductal 
epithelium, but also in well- to moderately-differentiated PDAC in situ (Layton et al., 2009). 
The expression of syk in normal ductal epithelium of the breast has also been reported, as 
has a role for syk as a tumor suppressor in that tissue (Coopman et al., 2000). As such, loss of 
syk expression in primary breast tumors is associated with a poor prognosis (Toyama et al., 
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(Toyama et al., 2003), suggesting potentially dramatic differences in the regulation or 
function of syk in the ductal epithelium of these two glandular tissues. Indeed, we present 
evidence that syk functions to facilitate growth of PDAC cells that express it. This is perhaps 
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Fig. 7. BxPC3 invasion is regulated by syk and mediated by the uPA/uPAR axis. 
(A) Invasion of stable BxPC3/mock (Bx/mock) and BxPC3/KD (Bx/KD) cells towards 
serum-containing (FBS) or serum-free (SF) medium. (B) Serum-free BxPC3/KD invasion +/- 
TAPI1 (left), or aprotinin or function-blocking anti-uPA antibody (right). BxPC3/mock cells 
were not assessed as they exhibit no invasion in the absence of serum in the lower chamber. 
not entirely unexpected since syk promotes immune cell proliferation in response to 
antigenic stimulation (Kimura et al., 1996; Sada et al., 2001), and vascular defects observed in 
syk-deficient mice are attributable to a reduction in endothelial cell number (Yanagi et al., 
2001). Indeed, syk was subsequently shown to be required for endothelial cell proliferation 
in vitro (Yanagi et al., 2001).  
Mechanistically, syk has been shown to regulate mitosis through direct interactions with -
tubulin and catalytic activity within the centrosome (Zyss et al., 2005). Morphological 
examination of piceatannol-treated PDAC cells stained with DAPI revealed that 
aberrant/dysfunctional mitosis may be responsible for the reduced cell numbers observed 
in this assay (not shown). This finding is consistent with prior ectopic expression studies 
that demonstrated localization of a carboxy-terminally RFP-tagged syk to centrosomes (Zyss 
et al., 2005); this chimera caused aberrant mitosis that likely resulted from steric interference 
of the RFP molecule on the directly adjacent kinase domain, further supporting our 
contention that syk kinase activity is required for syk-dependent regulation of cell division, 
and hence growth. 
Similarly, since pharmacological inhibition of syk does not affect BxPC3 invasion, but stable 
expression of sykKD does, this suggests that this effect of sykKD is not due to direct 
suppression of endogenous syk signaling in these cells. As such, this construct may function 
by sequestering binding partners that would normally be phosphorylated by catalytically 
active syk, or a similar mechanism, since this construct can still be phosphorylated by 
upstream mediators such as src. Indeed, phosphorylation of Y352 couples syk to binding 
partners such as phospholipaseC and vav through the SH2 domains of these proteins (Sada 
et al., 2001). Mutation of Y352 impairs signaling in immune cells (Sada et al., 2001), 
demonstrating that Y352 is an important regulator of syk function in these cells. The 
presence of phosphorylated Y352 in pancreatic cells in situ and in vitro suggests that these or 
similar pathways are functional in syk-mediated processes in this cell type as well. 
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Proteolytic degradation of the extracellular matrix during tumor progression often involves 
uPA, its inhibitor, PAI-1, and its receptor, uPAR (Binder and Mihalay, 2008; McMahon and 
Kwaan, 2009). This system regulates the activation of the serine protease plasmin, and in the 
pancreas uPAR has been shown to regulate PDAC phenotype through interaction with 
integrin v5 and PKC signalling (Yebra et al., 1995; 1996). More importantly, studies have 
shown a correlation between uPA and PAI-1 expression and tumor aggressiveness (Hansen 
et al., 2003), and PAI-1 has been shown to be necessary for tumor invasion (Binder and 
Mihaly, 2008). We recently reported that stable reexpression of syk dramatically reduced the 
invasion of endogenously syk-negative Panc1 cells at least partly by attenuating the MMP2 
axis (Layton et al., 2009). Herein, we demonstrate that MIAPaCa2 and BxPC3 invasion is 
MMP-independent and mediated by the urokinase/plasminogen system, and that syk 
attenuates the expression of both uPA and PAI-1. This difference in protease utilization may 
be due to the differential expression and/or involvement of specific integrins since Panc1 
cells are v3-positive while MIAPaCa2 and BxPC3 cells are v3-negative. Integrin v3 
suppresses uPA/uPAR expression in ovarian cancer cells (Hapke et al., 2001) and, as noted 
previously, the MMP2 axis has been associated with expression of the v3 integrin and 
v3 is required for MMP2 activation in some cell types (Deryugina et al., 2001); Nisato et 
al., 2005), including PDAC (Hosotani et al., 2002). Reciprocally, the uPA/uPAR axis is linked 
to v5 (Yebra et al., 1995; 1996) and other integrins including 31 (Zhu et al., 2009), which 
is also expressed by both MIAPaCa2 and BxPC3 cells (S. Silletti, unpublished data). 
Importantly, the differential integrin utilization by these cells extended to the regulation of 
invasion as well. Therefore, this differential use of protease pathways in an integrin-specific 
manner by PDAC cells may be useful from a diagnostic and/or prognostic standpoint if 
further studies bear out this relationship in this tumor type.  
In summary, we have further characterized the activity of syk in the growth and invasion 
regulation of pancreatic ductal epithelial cells. The expression of syk in these cells is 
associated with phosphorylation of tyrosines indicative of syk activation and activity, both 
in vitro and in situ, and syk activity is involved in regulating the proliferation/survival of 
syk-positive PDAC cells in vitro. This effect may be related to syk’s role in transducing 
signals from growth factor receptors, or from syk’s regulation of the mitotic spindle during 
mitosis. Irrespective, there has been a recent surge of interest in inhibitor-based strategies to 
target syk for conditions such as asthma, rheumatoid arthritis, and other immune disorders 
(Scott, 2011; Ulanova et al., 2005; Wong et al., 2004). Therefore, we propose that, aside from 
being a potential regulator of PDAC biology and biomarker of more differentiated  
PDAC tumors in situ, syk may be a viable target for therapeutic intervention in the clinic, 
since all grades of PDAC are uniformly fatal (NCI PDQ Database 
[http://www.cnacer.gov/cancertopics/pdq]; NCI-PANC-PRG) and syk expression is 
maintained in G1 and G2 PDAC in situ (Layton et al., 2009). 
5. Conclusion  
In this report we demonstrate that upstream activated and catalytically active syk kinase 
states can be detected in pancreatic ductal epithelial cells, both in vitro and in situ. The 
activity of syk is further demonstrated with regard to the regulation of cellular growth and 
invasion. Importantly, we have found that syk-dependent regulation of invasion is via 
modulation of the urokinase/plasminogen system in v3-negative PDAC cells. This is in 
Pancreatic Cancer – Molecular Mechanism and Targets 114 
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contrast to the MMP-dependent invasion-suppressor effect of syk in v3-positive PDAC 
cells, which are the exception, rather than the norm in this tumor type. These data provide 
further evidence of a central role for syk in regulating pancreatic ductal epithelial cell 
phenotype, and support the potential utility of targeting syk as a potential therapeutic 
modality in well- to moderately-differentiated PDAC patients, which are the majority of 
clinical cases. The significance of this is highlighted by the fact that PDAC is characterized 
by extensive dissemination at the time of diagnosis, irrespective of grade of disease. 
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1. Introduction 
Pancreatic ductal adenocarcinoma (PDAC) is the fourth cause of cancer-related death in the 
US, accounting for an estimated 37.000 in 2010 (Jemal et al., 2010). Only about 10-15% of 
newly diagnosed PDAC are potentially resectable, while the majority of patients present 
with locally advanced or metastatic cancer. The median survival of non operable patients 
treated with standard chemotherapy ranges between 3 and 10 months, with less than 20% 
alive at 1 year (Van Cutsem et al., 2004a). Survival rates have not substantially improved 
during the past 25 years, and gemcitabine, currently considered as the standard for the 
treatment of patients with advanced PDAC, only offers a limited advantage over 5-
fluorouracil. Moreover, in these patients the tolerance of chemotherapy is often limited, due 
to the frequent occurence of pain and poor performance status. Given the limited efficacy of 
conventional chemotherapy, there is an urgent need of new treatment options for this 
disease. It is now clear that development and progression of PDAC is a complex process 
involving alterations of a core set of signalling pathways implicated in the regulation of 
multiple processes such as proliferation, cell cycle, migration, invasion, metastatization, 
metabolism, angiogenesis and resistance to apoptosis (S. Jones et al., 2008).  
This chapter will overview the more relevant cellular pathways involved in the 
development and progression of PDAC, and the results obtained in preclinical models and 
clinical trials with the use of novel agents specifically targeting them. 
2. Tyrosine kinases  
Proteins endowed with tyrosine kinase activity (TKs), i.e. able to transfer the terminal 
phosphate of ATP to the hydroxyl group of tyrosine on acceptor molecule, have long been 
established as key regulators of multiple cellular processes including cell growth, 
proliferation, migration, invasion and resistance to apoptosis. TKs include receptor tyrosine 
kinase (RTKs) and non-receptor TKs (NRTKs) (Natoli et al., 2010).  
2.1 RTKs 
RTKs are structurally divided in 20 subfamilies of single transmembrane alpha-helic 
proteins, with the exception of the IGFR family that retains a permanent dimeric 
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conformation. The binding of a specific ligand to the extracellular domain of the receptor 
induces receptor dimerization and autophosphorylation at a regulatory tyrosine within the 
intracellular activation loop of the kinase. This triggers a cascade of intracellular reactions 
that mainly follows the p42/p44 mitogen-activated protein kinase (MAPK) and the 
phosphatidylinositol 3 kinase (PI3K)/protein kinase B (AKT) pathways, and culminates 
with the activation of genes involved in cell proliferation and survival.  
2.1.1 MAPK and PI3K/AKT pathways 
In the MAPK pathway a pivotal role is played by Ras proteins (k-Ras, N-Ras and H-Ras), 
enzymes with intrinsic GTPase activity (Ramos, 2008). Ras proteins are attached to the 
plasma membrane by virtue of farnesyl or geranylgeranyl chains covalently linked to their 
C-terminal end. These post-translational modifications are essential for membrane-
anchorage and function of Ras. 
Following RTKs activation, a variety of proteins are recruited nearby the plasma membrane. 
The tyrosine phosphorylation of RTKs creates a specific binding site for the SH2 domain of 
adaptor proteins, such as Grb2, that in turn allows the recruitment of Guanine Nucleotide 
Exchange Factors (GEFs), such as SOS1. GEFs directly activate Ras by promoting the release 
of GDP and the binding of GTP. Activated (GTP-bound) Ras induces the activation of the 
Raf/MEK/MAPK signaling, and eventually of downstream transcription factors such as 
Jun/Fos. 
The key regulator of the PI3K/AKT pathway is PI3K, an enzyme that phosphorylates the 
membrane lipid phosphatidyl inositol 4,5-P2 (PIP2) in 3,4,5-P3 (PIP3). PIP3 is then 
responsible for AKT activation (Osaki et al., 2004). A negative regulator of this pathway is 
the Phosphatase and Tensin homolog (PTEN), that switchs off the signalling by 
dephosphorylating PIP3 in PIP2. 
PI3K is recruited to the plasma membrane by activated RTKs directly through its SH2 
domain, or indirectly through adaptor proteins such as Grb2/Gab1, or IRS1/2 in the case of 
IGFR. Once PI3K is activated and PIP3 is produced, the serine-threonine kinase AKT and the 
phosphoinositide-dependent kinase 1 (PDK1) are co-recruited to the plasma membrane, 
resulting in the phosphorylation and activation of AKT by PDK1. Activated AKT is able to 
phosphorylate multiple downstream targets, such as BAD, MDM2 and mTOR. In particular, 
phoshorylation of mTOR activates many biological processes essential for angiogenesis, cell 
metabolism and proliferation (Dowling et al., 2010). AKT activates mTOR complex 1 
(mTORC1) via the small GTPase, Rheb. In basal condition, Rheb activity is suppressed by 
the TSC1/TSC2 complex, a GTPase activating protein. AKT determines TSC2 
phosphorylation and inhibition of TSC1/TSC2 function, changes that unleash Rheb activity 
and mTOR signalling. Once activated, mTOR increases mRNA translation via two major 
downstream targets: the eIF4E-binding proteins (4EBPs) and the S6 kinases (S6K1 and 
S6K2). The 4EBPs are suppressors of the initiation translation factor eIF4E. After 
phosphorylation by mTOR, 4EBPs release eIF4E and make it available for the assembling of 
the eIF4F initiation complex that activates mRNA translation. In addition, the 
phosphorylation of S6K determines the subsequent phosphorylation of the ribosomal 
protein S6, a component of the 40S ribosomal subunit, that further facilitates mRNA 
translation. Proteins encoded by “eIF4E-sensitive mRNAs” include VEGF, cyclins, c-Myc 
and Bcl-xl, molecules involved in angiogenesis, cell proliferation and survival.  
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2.2 NRTKs 
Based on structure, at least 10 subfamilies of NRTKs have been identified (Natoli et al., 2010). 
ABL and Src families have been particularly investigated for their implication in hematological 
and non-hematological malignancies. Physiologically, these proteins play a critical role in 
relaying intracellular signalling to the nucleus, regulating RTKs downstream signals, MAPK 
and PI3K/Akt, and several other key pathways, such as focal adhesion kinase (FAK) and 
signal transducers and activator of transcription (STAT transcription factors). NRTKs are 
maintained in an inactive state by intramolecular autoinhibition or by cellular inhibitor 
proteins or lipids. They are activated by diverse intracellular signals, including recruitment to 
RTK, dissociation of inhibitors, and trans-phosphorylation by other kinases. Activated NRTKs 
critically participate in the regulation of cell proliferation, differentiation, migration, adhesion, 
angiogenesis, invasion, and immune function. 
2.3 Dysregulation of TKs signalling in PDAC 
Given the central role of TKs in the regulation of cell growth and survival, it is not 
surprising that TKs and/or their downstream signalling mediators are aberrantly activated 
in different types of cancers, including PDAC.  
In PDAC different RTKs have been shown to be frequently overexpressed, such as 
Epidermal Growth Factor Receptor (EGFR) in 90% (Lemoine et al., 1992), HER2 in 45-70% 
(Yamanaka et al., 1993b), Insulin-like Growth Factor-1 Receptor (IGF-1R) in about 50% 
(Bergmann et al., 1995), and cMET in 70% of the cases (M. Ebert et al., 1994). Overexpression 
is often reported to be associated with enhanced tumor growth, motility, invasion and drug 
resistance (M. Ebert et al., 1994; Freeman et al., 1995; Yamanaka et al., 1993a). 
Consistent with RTKs overexpression, the downstream MAPK and PI3K/AKT pathways are 
often activated in PDAC. Activation of the MAPK pathway has been shown to be 
responsible for the malignant transformation of pancreatic cells (Matsuda et al., 2002). 
However, activation of Ras in PDCA is mostly RTK-independent, since activating mutations 
of this oncogene occur in about 90% of cases in advanced disease (Hruban, 2001). Because of 
an impaired GTPase activity, mutated Ras maintains a GTP-bound state, resulting in a 
continuous activation of the downstream Raf/MEK/MAPK signalling. Activating mutation 
of Raf has also been described in pancreatic cancer (Hruban, 2001).  
Activation of PI3K/AKT pathway has been described in 50% of PDAC cases and is 
associated with a worse prognosis (Schlieman et al., 2003). PI3K has been shown to stimulate 
proliferation and to be involved in drug resistance of pancreatic cancer cells (Perugini et al., 
2000), while overexpression of AKT promotes invasion (Cheng et al., 1996) and expression 
of IGF-IR (Tanno et al., 2001).  
Among NRTKs, aberrant Src activation has been described in multiple malignancies, 
including pancreatic cancer (Dehm & Bonham, 2004), and shown to be related to increased 
cell motility and invasiveness (Shah & Gallick, 2007). 
The importance of TKs signalling in the maintenance of the neoplastic phenotype is 
emphasized by the fact that inhibition of these pathways induces cell-cycle arrest and 
apoptosis in preclinical models of pancreatic cancer (Asano et al., 2005; Bondar et al., 2002; 
Ng et al., 2002; Yip-Schneider & Schmidt, 2003). 
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2.4 TKs therapeutic targeting  
Preclinical studies have shown dependency of pancreatic tumor cell proliferation upon TKs 
activity and tumor regression by its blockade. 
In the last decade a number of molecules have been developed to inhibit TKs signalling. 
These agents can be divided into two major groups: small molecules that inhibit the catalytic 
activity of the kinase by interfering with the binding of ATP or substrates, and antibodies 
against RTKs or their ligands. In addition, other agents have been designed to block TKs’ 
downstream signalling molecules, in particular Ras, Raf, MEK, AKT and mTOR. The most 
relevant anti-TKs strategies applied in PDCA are detailed below, along with ongoing clinical 
trials. 
2.4.1 Anti-EGFR therapies 
Cetuximab, a chimeric monoclonal antibody that targets the extracellular domain of human 
EGFR, has been tested in a phase III randomized trial by the Southwestern Oncology Group 
(SWOG trial S0205) in combination with gemcitabine in patients with unresectable, locally 
advanced or metastatic PDAC. The study showed no significant improvement in overall or 
progression-free survival with the addition of cetuximab, with a minimal although 
significant advantage in time-to-treatment-failure (Philip et al., 2010). A similar study design 
was used to test the efficacy of panitumumab, a humanized anti-EGFR antibody 
(clinicaltrial.gov: NCT00613730). The study was early terminated based on the results of the 
S0205 trial. A randomized phase II trial of panitumumab, erlotinib and gemcitabine vs. 
erlotinib and gemcitabine in patients with untreated, metastatic PDAC (clinicaltrial.gov: 
NCT00550836) has been recently completed and results are awaited. 
Erlotinib, an EGFR tyrosine kinase inhibitor, has been tested in combination with gemcitabine 
in a randomized phase III trial (Moore et al., 2007). A very modest benefit in OS (median 6.24 
vs 5.91 months, P=.038) was observed compared with gemcitabine alone. Even if approved for 
the treatment of advanced PDAC, erlotinib is not routinely used because of increased toxicity 
and cost. Erlotinib is currently studied in the adjuvant setting (RTOG-led study 0848). 
Other EGFR tyrosine kinase inhibitors, including gefitinb and lapatinib, have been tested in 
pilot studies, but failed to demonstrate a clinically significant activity (Brell et al., 2009; 
Ignatiadis et al., 2006; Safran et al., 2008). 
2.4.2 Anti-HER2 therapies 
Trastuzumab, a recombinant humanized antibody directed against HER2 and largely used 
in the treatment of HER2-positive breast cancer, has been tested in combination with 
gemcitabine in 34 PDAC patients with HER2-overexpressing tumors. No significant survival 
benefit was observed (Safran et al., 2004). 
2.4.3 Anti-IGF-1R therapies 
Several trials testing the safety and activity of inhibitors of IGF-1R are ongoing. 
IMC-A12, an anti-IGF-1R monoclonal antibody, is currently being used in a randomized 
phase II study (SWOG 0727) in combination with chemotherapy and erlotinib in advanced 
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PDAC. The dual block of IGF-1R and EGFR has a strong preclinical rationale since the 
inhibition of IGF-1R might reverse resistance to anti-EGFR agents (Camirand et al., 2005). 
A study with the same design, carried out at the MD Anderson Cancer Center, is testing MK-
0646, a humanized monoclonal antibody against the IGF-1R (clinicaltrial.gov: NCT00769483). 
Finally, AMG-479, another anti-IGF-1R antibody, is being used in combination with 
gemcitabine in a three-arm randomized phase II study. Preliminary results have been 
presented showing a trend toward longer PFS in the combination arm (Kindler et al., 2010a). 
2.4.4 Anti-c-MET therapies 
AMG-102, a fully humanized monoclonal antibody against c-MET, has been tested in a 
phase I study in patients with advanced solid tumors, including pancreatic cancer (Gordon 
et al., 2010). The drug was safe and well tolerated and it is going to be tested in a phase II 
study, in monotherapy or in combination with other agents. 
2.4.5 Anti-MAPK therapies 
Tipifarnib, a Ras inhibitor, has been studied in combination with gemcitabine in a 
randomized phase III clinical trial (Van Cutsem et al., 2004b). The combination has an 
acceptable toxicity profile, but does not prolong overall survival in advanced PDAC as 
compared with single-agent gemcitabine. 
In a phase II study, Sorafenib, a TK inhibitor targeting Raf, VEGFR and PDGFR, has been 
tested in combination with gemcitabine in patients with advanced PDCA (Kindler et al., 
2010b), but failed to demonstrate clinical benefit. Other Raf inhibitors are currently tested in 
clinical trials (W. W. Ma & Adjei, 2009). 
CI-1040, an oral MEK inhibitor, has been used in a pilot phase II study in advanced tumors, 
including PDAC. Although generally well tolerated, CI-1040 demonstrated insufficient 
antitumor activity to warrant further development (Rinehart et al., 2004). 
2.4.6 Anti-PI3K/AKT therapies 
Clinical experience with inhibitors of the PI3K/Akt pathway in PDAC is mostly limited to 
mTOR or AKT inhibitors. Everolimus and enzastaurin failed to demonstrate significant 
clinical activity when tested in gemcitabine-refractory (Wolpin et al., 2009) or advanced 
PDAC (Richards et al., 2011), respectively.  
2.4.7 Anti-Src therapies 
Among NRTK-inhibitors, AZD0530, a Src kinase inhibitor, is currently being tested in a 
phase II trial in gemcitabine resistant patients and in a phase I/II trial in combination with 
gemcitabine in unresectable disease (clinicaltrial.gov: NCT00735917). 
3. Angiogenesis 
Angiogenesis, the process by which new blood vessels are formed from pre-existing ones, is 
critical for the growth, progression and metastatization of solid tumors, including PDAC.  
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presented showing a trend toward longer PFS in the combination arm (Kindler et al., 2010a). 
2.4.4 Anti-c-MET therapies 
AMG-102, a fully humanized monoclonal antibody against c-MET, has been tested in a 
phase I study in patients with advanced solid tumors, including pancreatic cancer (Gordon 
et al., 2010). The drug was safe and well tolerated and it is going to be tested in a phase II 
study, in monotherapy or in combination with other agents. 
2.4.5 Anti-MAPK therapies 
Tipifarnib, a Ras inhibitor, has been studied in combination with gemcitabine in a 
randomized phase III clinical trial (Van Cutsem et al., 2004b). The combination has an 
acceptable toxicity profile, but does not prolong overall survival in advanced PDAC as 
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tested in combination with gemcitabine in patients with advanced PDCA (Kindler et al., 
2010b), but failed to demonstrate clinical benefit. Other Raf inhibitors are currently tested in 
clinical trials (W. W. Ma & Adjei, 2009). 
CI-1040, an oral MEK inhibitor, has been used in a pilot phase II study in advanced tumors, 
including PDAC. Although generally well tolerated, CI-1040 demonstrated insufficient 
antitumor activity to warrant further development (Rinehart et al., 2004). 
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Clinical experience with inhibitors of the PI3K/Akt pathway in PDAC is mostly limited to 
mTOR or AKT inhibitors. Everolimus and enzastaurin failed to demonstrate significant 
clinical activity when tested in gemcitabine-refractory (Wolpin et al., 2009) or advanced 
PDAC (Richards et al., 2011), respectively.  
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Among NRTK-inhibitors, AZD0530, a Src kinase inhibitor, is currently being tested in a 
phase II trial in gemcitabine resistant patients and in a phase I/II trial in combination with 
gemcitabine in unresectable disease (clinicaltrial.gov: NCT00735917). 
3. Angiogenesis 
Angiogenesis, the process by which new blood vessels are formed from pre-existing ones, is 
critical for the growth, progression and metastatization of solid tumors, including PDAC.  
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This multistep process is tightly controlled by a fine-tuned balance between positive and 
negative regulators that emanate from cancer cells, endothelial cells, stromal cells, blood and 
the extracellular matrix. 
Although several positive regulators of angiogenesis have been described, vascular 
endothelial growth factor (VEGF or VEGF-A) represents the prototypical pro-angiogenic 
factor (Ferrara et al., 2003). VEGF belongs to a gene family which includes placental growth 
factor (PLGF), VEGF-B, VEGF-C and VEGF-D. When released mainly by tumor cells, VEGF 
binds two specific receptor tyrosine kinases, VEGFR-1 (de Vries et al., 1992) and VEGFR-2 
(Terman et al., 1992). This triggers receptor autophosphorylation and initiates a series of 
downstream signalling that promotes proliferation, survival and migration of endothelial 
cells.VEGFR-3 is also included in the same family of RTKs, but binds VEGF-C and VEGF-D 
(Karkkainen et al., 2002).  
Overexpression of VEGF has been associated with tumor progression and poor prognosis in 
several tumor types. The increasingly recognized importance of VEGF signalling in 
promoting tumor angiogenesis has led to the development and clinical validation of several 
agent that selectively target this pathway. Today, inhibition of angiogenesis is considered a 
valid treatment approach in a number of solid tumours, although with limited efficacy 
(Carmeliet & Jain, 2011).  
Agents affecting the VEGF pathway include drugs targeting VEGF itself (antibodies or 
“traps”) or the extracellular domain of VEGFR, small molecules targeting intracellular 
domains of VEGFR and those of other tyrosine kinases, and drugs inhibiting the 
intranuclear production of VEGFR mRNA, such as angiozyme. 
Bevacizumab, a humanized monoclonal antibody with a high binding affinity for circulating 
vascular endothelial growth factor A (VEGF-A), has been demonstrated to enhance the 
response rate, progression-free and overall survival of patients with advanced cancer when 
added to various chemotherapeutic regimens. The cellular mechanisms of action of 
bevacizumab are multifactorial and include inhibition of vascular neogenesis, vascular 
regression and normalization of tumour vasculature (Ellis & Hicklin, 2008). Several studies 
have shown that VEGF and its receptors are overexpressed in pancreatic cancer tissue and 
associated with liver metastases and poor prognosis (Kuehn et al., 1999; Seo et al., 2000). In 
PDAC, antiangiogenic therapy is still in an experimental phase with rare promising results. 
In the pre-clinical setting, inhibition of secreted VEGF by an antisense oligonucleotide led to 
decreased neoangiogenesis in a mouse xenograft model of pancreatic cancer resulting in 
reduced tumor growth and metastasis (Hotz et al., 2005). In the clinical setting, two 
randomized phase III trials of bevacizumab and gemcitabine (with or without erlotinib) 
failed to show any significant improvement of overall survival (Kindler et al., 2010c; Van 
Cutsem et al., 2009), and in one of them (Van Cutsem et al., 2009) only a marginal gain in 
progression-free survival was observed. The modest clinical benefit so far observed might 
be, at least in part, dependent on the development of resistance. Upregulation of 
compensatory angiogenic signalling pathways, such as those modulated by platelet-derived 
growth factor (PDGF) and fibroblast growth factor (FGF), has been suggested as a potential 
mechanism of resistance to anti-VEGF therapy (Casanovas et al., 2005).  
As opposed to isolated VEGF/VEGFR inhibition, multitargeted antiangiogenic TK 
inhibitors may more completely inhibit angiogenesis by blocking overlapping pathways 
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(Erber et al., 2004). A number of multitargeted antiangiogenic TK inhibitors are being tested 
in PDAC, including dual VEGFR/PDGFR and VEGFR/FGFR inhibitors (i.e. Sunitinib), as 
well as triple VEGFR/PDGFR/FGFR inhibitors (i.e. sorafenib), but limited activity in phase 
II trials ended further investigations on these agents. 
Axitinib, an oral and selective inhibitor of VEGFR 1,2 and 3 and PDGFR-β, has been 
investigated in a phase II randomized trial in PDAC, associated with gemcitabine versus 
gemcitabine alone (Spano et al., 2008). The trial showed a small, non-statistically significant 
gain in overall survival for the combination arm. A randomized double-blind phase III trial 
with a similar design has been recently completed (Clinicaltrials.gov: NCT00471146) and 
results are awaited. 
The persistent failure of anti-VEGF/VEGFR targeting in pancreatic cancer raises questions 
and concerns about choice of agents, trial design and our understanding of the biology of 
this disease.  
4. The hedgehog pathway  
The Hedgehog (Hh) signalling controls the proper tissue formation or “patterning” during 
normal embryonic development, modulating cell migration, proliferation and 
differentiation (Ingham & McMahon, 2001).  
The Hh signalling is mediated by three secreted proteins with high degree of homology, 
known as Sonic Hh, Desert Hh and Indian Hh. These proteins act in an autocrine/paracrine 
manner by binding the cellular transmembrane receptor Patched 1 (PTCH1). In the absence 
of the Hh ligand, PTCH1 inhibits the activity of another transmembrane protein, 
Smoothened (Smo), preventing its localization to the cell surface. After Hh binding, PTCH1 
is internalized and degraded, allowing Smo to translocate to the cell membrane where it 
initiates a downstream signalling responsible for the release of the glioma-associated (Gli) 
proteins from the inhibitor complex Suppressor of Fused (SUFU). The subsequent activation 
and nuclear translocation of Gli transcriptional factors results in increased expression of 
genes encoding for growth factors, cell cycle regulators, cell adhesion molecules, matrix 
proteins, other transcription factors, and inhibitors of the Hh pathway itself (Cohen, 2010; 
Ruiz i Altaba et al., 2002). 
A negative regulator of Hh pathway is Hh-interaction protein (HIP), a transmembrane 
protein that binds all 3 Hh proteins and prevent ligand inactivation of PTCH1 (Chuang & 
McMahon, 1999). 
Increased expression of the Hedgehog pathway components has been demonstrated in 
PDAC and its precursor lesions, indicating a role of this pathway during early stages of 
tumorigenesis (Morton et al., 2007). Moreover, reduced or absent expression of HIP is related 
to Hh signalling activation in pancreatic cancer cell lines (Martin et al., 2005). In a recent 
microarray study, nineteen altered genes of the Hh pathway were identified and 100% of 
tumors had alterations in at least one of the Hh pathway genes (S. Jones et al., 2008). 
Given the major role of Hh signalling in cancer development, the targeting of this pathway 
is considered a promising approach in the treatment of patients with PDCA. Indeed, in 
preclinical models, the inhibition of Hh signalling increased tumor cell apoptosis, decreased 
metastases, and significantly extended animal survival (Feldmann et al., 2008). 
Pancreatic Cancer – Molecular Mechanism and Targets 124 
This multistep process is tightly controlled by a fine-tuned balance between positive and 
negative regulators that emanate from cancer cells, endothelial cells, stromal cells, blood and 
the extracellular matrix. 
Although several positive regulators of angiogenesis have been described, vascular 
endothelial growth factor (VEGF or VEGF-A) represents the prototypical pro-angiogenic 
factor (Ferrara et al., 2003). VEGF belongs to a gene family which includes placental growth 
factor (PLGF), VEGF-B, VEGF-C and VEGF-D. When released mainly by tumor cells, VEGF 
binds two specific receptor tyrosine kinases, VEGFR-1 (de Vries et al., 1992) and VEGFR-2 
(Terman et al., 1992). This triggers receptor autophosphorylation and initiates a series of 
downstream signalling that promotes proliferation, survival and migration of endothelial 
cells.VEGFR-3 is also included in the same family of RTKs, but binds VEGF-C and VEGF-D 
(Karkkainen et al., 2002).  
Overexpression of VEGF has been associated with tumor progression and poor prognosis in 
several tumor types. The increasingly recognized importance of VEGF signalling in 
promoting tumor angiogenesis has led to the development and clinical validation of several 
agent that selectively target this pathway. Today, inhibition of angiogenesis is considered a 
valid treatment approach in a number of solid tumours, although with limited efficacy 
(Carmeliet & Jain, 2011).  
Agents affecting the VEGF pathway include drugs targeting VEGF itself (antibodies or 
“traps”) or the extracellular domain of VEGFR, small molecules targeting intracellular 
domains of VEGFR and those of other tyrosine kinases, and drugs inhibiting the 
intranuclear production of VEGFR mRNA, such as angiozyme. 
Bevacizumab, a humanized monoclonal antibody with a high binding affinity for circulating 
vascular endothelial growth factor A (VEGF-A), has been demonstrated to enhance the 
response rate, progression-free and overall survival of patients with advanced cancer when 
added to various chemotherapeutic regimens. The cellular mechanisms of action of 
bevacizumab are multifactorial and include inhibition of vascular neogenesis, vascular 
regression and normalization of tumour vasculature (Ellis & Hicklin, 2008). Several studies 
have shown that VEGF and its receptors are overexpressed in pancreatic cancer tissue and 
associated with liver metastases and poor prognosis (Kuehn et al., 1999; Seo et al., 2000). In 
PDAC, antiangiogenic therapy is still in an experimental phase with rare promising results. 
In the pre-clinical setting, inhibition of secreted VEGF by an antisense oligonucleotide led to 
decreased neoangiogenesis in a mouse xenograft model of pancreatic cancer resulting in 
reduced tumor growth and metastasis (Hotz et al., 2005). In the clinical setting, two 
randomized phase III trials of bevacizumab and gemcitabine (with or without erlotinib) 
failed to show any significant improvement of overall survival (Kindler et al., 2010c; Van 
Cutsem et al., 2009), and in one of them (Van Cutsem et al., 2009) only a marginal gain in 
progression-free survival was observed. The modest clinical benefit so far observed might 
be, at least in part, dependent on the development of resistance. Upregulation of 
compensatory angiogenic signalling pathways, such as those modulated by platelet-derived 
growth factor (PDGF) and fibroblast growth factor (FGF), has been suggested as a potential 
mechanism of resistance to anti-VEGF therapy (Casanovas et al., 2005).  
As opposed to isolated VEGF/VEGFR inhibition, multitargeted antiangiogenic TK 
inhibitors may more completely inhibit angiogenesis by blocking overlapping pathways 
New Targets for Therapy in Pancreatic Cancer  125 
(Erber et al., 2004). A number of multitargeted antiangiogenic TK inhibitors are being tested 
in PDAC, including dual VEGFR/PDGFR and VEGFR/FGFR inhibitors (i.e. Sunitinib), as 
well as triple VEGFR/PDGFR/FGFR inhibitors (i.e. sorafenib), but limited activity in phase 
II trials ended further investigations on these agents. 
Axitinib, an oral and selective inhibitor of VEGFR 1,2 and 3 and PDGFR-β, has been 
investigated in a phase II randomized trial in PDAC, associated with gemcitabine versus 
gemcitabine alone (Spano et al., 2008). The trial showed a small, non-statistically significant 
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is considered a promising approach in the treatment of patients with PDCA. Indeed, in 
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metastases, and significantly extended animal survival (Feldmann et al., 2008). 
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Currently, a phase I/II clinical trial is evaluating IPI-926, a small molecule inhibitor of Smo, 
in combination with gemcitabine in patients with previously untreated metastatic PDAC. 
(ClinicalTrials.gov: NCT01130142). Other agents targeting various components of the Hh 
pathway are in preclinical or early clinical development, including Hh antagonist and Gli 
inhibitor. 
5. DNA repair mechanisms 
Mammalian cells are constantly exposed to exogenous (e.g. ultraviolet or ionising radiation 
and genotoxic chemicals) and endogenous (e.g. cellular metabolism and free radical 
generation) stresses responsible for DNA damage (Hoeijmakers, 2001). In order to preserve 
genomic integrity, cells are equipped with several DNA repair mechanisms, including 
nucleotide-excision repair (NER), base-excision repair (BER), mismatch repair (MMR), 
homologous recombination (HR) and non-homologous end-joining (NHEJ) pathways. Loss 
of function in one of these pathways determines an increased rate of chromosome breakage 
and, as a consequence, activation of oncogenes by translocations, inactivation of tumor 
suppressor genes by deletions and amplification of drug resistance genes, thus fostering 
tumor progression and drug resistance. 
NER, BER and MMR pathways are involved in DNA single strand breaks (SSBs) repairing 
process, where the complementary DNA strand is intact and serves as a template 
(Hoeijmakers, 2001).  
In particular, NER acts on damaged nucleotides that distort DNA helix, such as pyrimidine 
dimers induced by UV or adducts formed by chemotherapeutic agents. Interestingly, this 
pathway may confer resistance to platinum-based chemotherapy.  
BER acts on nitrogenous bases damaged by reactive oxygen species or by spontaneous 
depurinations (Lindahl, 1993). Key enzymes in this pathway are PARP1 and PARP2, two 
nuclear proteins that catalyze the transfer of ADP-ribose units from intracellular NAD+ to 
nuclear acceptor proteins with the formation of ADP-ribose polymers.  
MMR removes mispaired nucleotides derived from replication error (Li, 2008) and is 
involved in the repair of DNA adducts such as those resulting from platinum-based 
chemotherapy (Kinsella, 2009). MMR pathway includes proteins encoded by different genes, 
such as MSH2, MSH3, MSH6, MLH1, MLH3, PMS1, and PMS2. It is noteworthy that an 
intact MMR pathway is required for cisplatin sensitivity, indicating a role for MMR proteins 
in the apoptotic signalling (Pani et al., 2007).  
On the contrary, HR and NHEJ pathways are recruited in the case of DNA double-strand 
breaks (DSBs), which are devoid of a viable chromatid template (Hoeijmakers, 2001). HR 
acts using sister chromatid as template, and therefore it functions only during the late S and 
G2 phases of the cell cycle, when a homologous region of DNA is available. HR repairs 
DNA DSBs caused by reactive oxygen species, ionizing radiation and certain antineoplastic 
drugs, such as bleomycin and anthracyclines. HR is initiated by the MRN complex which, 
thanks to its 3’-5’ exonuclease activity, exposes the 3’ ends on either side of the DSB (Zhong 
et al., 1999). Another complex, RPA, binds to the exposed single strand DNA to avoid 
degradation. Then, RAD51 is recruited at the site of DNA damage to initiate repair (Yu et 
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al., 2003). BRCA1 and BRCA2, known for their implication in familial breast and ovarian 
cancers, play an important role in this pathway. BRCA1 is required to retain RPA at the sites 
of DSBs (Durant & Nickoloff, 2005), while BRCA2 is required for RAD51 translocation (Yang 
et al., 2005). 
NHEJ repairs DSBs during G1/S phase of the cell cycle. This pathway is activated by the 
DNA-dependent protein kinase Ku70/Ku80 and requires additional proteins, including the 
artemis protein and DNA ligase IV, for proper conclusion (Meek et al., 2004).  
PDAC cells frequently harbor defects in DNA repair pathways, in particular as a result of 
BRCA2 or MMR gene mutation/deletion. BRCA2 mutation carriers have a 3-10-fold 
increased lifetime risk of developing PDAC (Shi et al., 2009). Germline BRCA2 gene 
mutations are responsible for approximately 10% of familial pancreatic cancer, whereas 
somatic mutations have been associated with 7–10% of sporadic PDAC (Shi et al., 2009).  
The discovery that FANCD1, one of at least 13 Fanconi anemia (FA) proteins interacting in a 
common pathway involved in HR, is identical to BRCA2, resulted in a search for mutations 
in other FA genes as possible pancreatic-cancer risk genes. Recently, a pancreatic cancer 
susceptibility gene, PALB2 (FANCN), has been found to encode for a BRCA2-stabilizing 
protein (Tischkowitz et al., 2009) and a germline deletion in the PALB2 gene has been 
described in a patient with familial PDAC (S. Jones et al., 2009). 
Alterations in the MMR genes have also been described in pancreatic cancer (Dong et al., 
2011). A direct consequence of MMR impaired function is microsatellite instability that 
makes the genome vulnerable to other specific genetic alterations. However, tumors of the 
pancreas with microsatellite instability are relatively rare as compared to other malignancies 
of the digestive tract, and represent only 5% of PDAC.  
Although abnormal DNA repair mechanisms critically contribute to tumor development 
and progression, they also provide a weakness that can be exploited therapeutically. In fact, 
tumors harboring defective DNA repair mechanisms might be particularly sensitive to 
DNA-damaging agents. For example, BRCA deficient cancer cells show increased sensitivity 
to agents causing DSBs, such as irradiation, mitomycin C, adriamycin, and cisplatin 
(Sonnenblick et al., 2011; van der Heijden et al., 2005). It has been shown that HR-deficient 
tumor cells, including those with defects in BRCA1/2, are highly sensitive to blockade of the 
BER pathway via inhibition of the PARP enzymes (Bryant et al., 2005; Farmer et al., 2005). In 
fact, PARP inhibitors (PARPis) lead to accumulation of SSBs that degenerate into stalled 
replication forks and, eventually, in DSBs, damage preferentially repaired by HR. Exposure 
of BRCA2-deficient murine tumors to PARPis resulted in a marked decrease in tumor 
growth and survival (Hay et al., 2009). A human pancreatic cancer cell line with defective 
BRCA2 function, CAPAN-1, has been shown to be very sensitive to the potent PARPis 
KU0058684 and KU0058948 (McCabe et al., 2005). The potential clinical application of PARP 
inhibition in BRCA2-related pancreatic cancer is encouraged by a recent published case 
report. A patient with a germline BRCA2 mutation affected by pancreatic cancer 
demonstrated a complete pathologic response after treatment with iniparib (BSI-201), a 
PARPi (Fogelman et al., 2011).  
As expected, PARPis have also been shown to significantly enhance the cytotoxicity of 
chemotherapeutic agents, such as cisplatin and 5-fluorouracil (De Soto & Mullins, 2011), and 
of radiotherapy (Tuli et al., 2011) in pancreatic cancer cell lines.  
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Currently, a phase I/II clinical trial is evaluating IPI-926, a small molecule inhibitor of Smo, 
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(ClinicalTrials.gov: NCT01130142). Other agents targeting various components of the Hh 
pathway are in preclinical or early clinical development, including Hh antagonist and Gli 
inhibitor. 
5. DNA repair mechanisms 
Mammalian cells are constantly exposed to exogenous (e.g. ultraviolet or ionising radiation 
and genotoxic chemicals) and endogenous (e.g. cellular metabolism and free radical 
generation) stresses responsible for DNA damage (Hoeijmakers, 2001). In order to preserve 
genomic integrity, cells are equipped with several DNA repair mechanisms, including 
nucleotide-excision repair (NER), base-excision repair (BER), mismatch repair (MMR), 
homologous recombination (HR) and non-homologous end-joining (NHEJ) pathways. Loss 
of function in one of these pathways determines an increased rate of chromosome breakage 
and, as a consequence, activation of oncogenes by translocations, inactivation of tumor 
suppressor genes by deletions and amplification of drug resistance genes, thus fostering 
tumor progression and drug resistance. 
NER, BER and MMR pathways are involved in DNA single strand breaks (SSBs) repairing 
process, where the complementary DNA strand is intact and serves as a template 
(Hoeijmakers, 2001).  
In particular, NER acts on damaged nucleotides that distort DNA helix, such as pyrimidine 
dimers induced by UV or adducts formed by chemotherapeutic agents. Interestingly, this 
pathway may confer resistance to platinum-based chemotherapy.  
BER acts on nitrogenous bases damaged by reactive oxygen species or by spontaneous 
depurinations (Lindahl, 1993). Key enzymes in this pathway are PARP1 and PARP2, two 
nuclear proteins that catalyze the transfer of ADP-ribose units from intracellular NAD+ to 
nuclear acceptor proteins with the formation of ADP-ribose polymers.  
MMR removes mispaired nucleotides derived from replication error (Li, 2008) and is 
involved in the repair of DNA adducts such as those resulting from platinum-based 
chemotherapy (Kinsella, 2009). MMR pathway includes proteins encoded by different genes, 
such as MSH2, MSH3, MSH6, MLH1, MLH3, PMS1, and PMS2. It is noteworthy that an 
intact MMR pathway is required for cisplatin sensitivity, indicating a role for MMR proteins 
in the apoptotic signalling (Pani et al., 2007).  
On the contrary, HR and NHEJ pathways are recruited in the case of DNA double-strand 
breaks (DSBs), which are devoid of a viable chromatid template (Hoeijmakers, 2001). HR 
acts using sister chromatid as template, and therefore it functions only during the late S and 
G2 phases of the cell cycle, when a homologous region of DNA is available. HR repairs 
DNA DSBs caused by reactive oxygen species, ionizing radiation and certain antineoplastic 
drugs, such as bleomycin and anthracyclines. HR is initiated by the MRN complex which, 
thanks to its 3’-5’ exonuclease activity, exposes the 3’ ends on either side of the DSB (Zhong 
et al., 1999). Another complex, RPA, binds to the exposed single strand DNA to avoid 
degradation. Then, RAD51 is recruited at the site of DNA damage to initiate repair (Yu et 
New Targets for Therapy in Pancreatic Cancer  127 
al., 2003). BRCA1 and BRCA2, known for their implication in familial breast and ovarian 
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A phase I/II study of the PARPi veliparib (ABT-888) in combination with chemotherapy 
(modified FOLFOX-6), is currently being conducted in patients with metastatic pancreatic 
cancer (Pishvaian et al., 2011). Another phase I study is testing the safety and tolerability of 
the PARPi olaparib (AZD2281) in combination with gemcitabine in PDAC (clinicaltrials.gov: 
NCT00515866). The same drug is being used as monotherapy in a phase II trial in patients 
with advanced cancers, including PDAC, with confirmed genetic BRCA1 and/or BRCA2 
mutation (clinicaltrials.gov: NCT01078662). 
6. Histone deacetylase (HDACs) 
This large family of enzymes is composed of 18 members which are grouped into four 
classes according to their primary homology to similar yeast HDACs (de Ruijter et al., 2003). 
Classes I, II, and IV are structurally similar to the yeast proteins Hda1/Rpd3 and are zinc-
dependent for their catalytic activity (de Ruijter et al., 2003), while class III HDACs include 7 
different members of the sirtuin (SIRT) family and require NAD+ for their catalytic activity 
(Blander & Guarente, 2004). These families differ for subcellular localization, catalytic 
activity and susceptibility to different inhibitors. HDACs are known to play a key role in the 
epigenetic regulation of gene expression (P. A. Jones & Baylin, 2007). The process of 
deacetylation of histones by HDACs results in a closed chromatin structure, decreased 
access of transcription factors to promoter regions and repression of gene transcription 
leading to the silencing of tumor suppressor genes involved in cancer cell growth, 
differentiation and/or apoptosis (de Ruijter et al., 2003). Apart from regulating histone 
modification, HDACs also regulate the post-translational acetylation status of many non-
histone proteins involved in cancer cell proliferation, such as transcription factors, nuclear 
receptors and cytoskeletal proteins (Glozak et al., 2005).  
Dysregulation of HDACs has been detected in hematological malignancies and several 
different types of solid tumors (Federico & Bagella, 2011), including pancreatic cancer 
(Ouaissi et al., 2008; Ouaissi et al., 2011). 
During the 1990s, a clear link between the suppression of tumor cell growth and survival 
and the inhibition of HDAC activity was established (Xu et al., 2007), so that histone 
deacetylase inhibitors (HDACIs) have recently emerged as promising antineoplastic agents 
(Elaut et al., 2007). HDACIs can induce cell-cycle arrest, promote differentiation, and 
stimulate tumor cell death. Dimethyl sulfoxide (DMSO) and sodium butyrate (NaBu) are the 
first chemical agents identified as HDACIs (Friend et al., 1971) 
The preferential toxicity of HDAC inhibitors in transformed cells (Burgess et al., 2004; J. H. 
Lee et al., 2010) and their ability to synergistically enhance the anticancer activity of many 
chemotherapeutic agents (Sigalotti et al., 2007) has generated a great deal of interest in 
developing new HDACIs for cancer therapy. Indeed, several compounds, including pan-
HDAC inhibitors and class-selective or isoform-selective HDACIs, have been synthesized 
and tested in phase I, II and III clinical trials in cancer patients, either alone or in 
combination with other chemotherapeutic agents.  
Currently, two HDACIs are available for cancer treatment, suberoylanilide hydroxamic acid 
(SAHA or Vorinostat) (Vrana et al., 1999) and romidepsin (Khan et al., 2004) which have 
been approved by FDA for the treatment of cutaneous T-cell lymphoma. Vorinostat as well 
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as other HDACI such as Entinostat (MS-275) (Gojo et al., 2007) and MGCD0103 (Kell, 2007) - 
both of them in clinical trials (Kell, 2007; Tomillero & Moral, 2010) - have been shown to 
exert proapoptotic effects on pancreatic tumor cells and to chemosensitize them to 
gemcitabine (Arnold et al., 2007; Iwahashi et al., 2011; Sung et al., 2011). These drugs are 
now being tested in phase I-II trials recruiting advanced pancreatic cancer patients. 
7. Checkpoint kinase-1 (Chk1) 
The Chk1, downstream the nuclear protein kinase ataxia-telangiectasia mutated -ATM- 
(Kurz & Lees-Miller, 2004), arrests cells in the S- and G2-phases of the cell cycle in the 
presence of replication stress or DNA double-strand breaks, thus allowing cells to repair the 
damage (Koniaras et al., 2001). When this mechanism is defective, cells accumulate DNA 
damages which lead to apoptosis. p53-deficient cancer cells, rely on CHK1 for the damage 
response and agents able to disrupt this pathway could induce a specialized form of cell 
death known as mitotic catastrophe.  
Inhibitors of the Chk1 are currently in development with the aim to improve the efficacy 
and selectivity of a variety of DNA-damaging agents or antimetabolites (Bolderson et al., 
2009; Du et al., 2011; C. X. Ma et al., 2011). Recently, novel Chk1 inhibitors, such as 
AZD7762, have been shown to be able to sensitize pancreatic cancer cells and tumors to 
gemcitabine and are now in Phase I clinical trials (Morgan et al., 2010; Parsels et al., 2011) 
8. microRNAs 
Two main classes of RNAs are known: messenger RNAs (mRNAs), which are translated 
into proteins, and non-protein-coding RNAs (ncRNAs), whose function has been related to 
the regulation of intracellular and extracellular signalling involved in cell differentiation and 
development (Amaral & Mattick, 2008; Dinger et al., 2008).  
The following molecules have been included in the group of ncRNAs:  
 long ncRNAs, longer than 100 nucleotides, with a positive effect on regulation of gene 
expression (Orom et al., 2010); 
 small nucleolar RNAs (snoRNAs), able to modify or guide the pseudouridylation or the 
methylation of other RNAs (Mallardo et al., 2008); 
 small interfering RNAs (siRNA), regulating gene expression post-transcriptionally, by 
silencing specific mRNA molecules (J. Wang et al., 2010); 
 piwi-interacting RNAs (piRNA), involved in the silencing of retrotransposons in germ 
cells 
 riboswitches, a part of RNA that binds small molecule ligands (Siomi et al., 2011); 
 microRNAs (miRNAs), small (18–24 nucleotide in lenght) single stranded RNA 
molecules that negatively regulate gene expression (Bartel, 2004).  
Among all these regulatory ncRNSa, miRNAs are now acquiring a major relevance as 
potential therapeutic targets. miRNA were first discovered in Caenorhabditis elegans (R. C. 
Lee et al., 1993) and subsequently shown to be evolutionarily conserved genes (Moss, 2007), 
more than 1000 miRNAs being so far identified (miRBase database, release 17).  
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The biogenesis pathway of miRNA in animal cells is a complex multi-step process starting 
in the nucleus and (through many post-transcriptional modifications) ending in the 
cytoplasm to generate the mature, single stranded miRNA (Huang et al., 2011). miRNAs 
silence gene expression by binding to the 3'UTR of the target mRNAs with imperfect 
complementarity, thus causing repression of translation or inducing target mRNA molecule 
degradation, with consequent reduction or loss of the protein product (Carthew & 
Sontheimer, 2009; Huntzinger & Izaurralde, 2011). 
miRNAs have been shown to be missing or down-regulated in a variety of medical 
conditions including cancer, diabetes, and cardiovascular diseases (Medina & Slack, 2008; Z. 
Wang et al., 2011). For their role in cancer initiation and/or progression, miRNAs have been 
included in the family of genes recognized as tumor suppressors and oncogenes, with the 
name of oncomiRs or anti-oncomiRs (Iorio & Croce, 2009; Kent & Mendell, 2006). Moreover, 
because of these critical functions in the regulation of signalling pathways, miRNAs are 
regarded as new promising therapeutic targets for cancer treatment (Bader et al., 2011).  
Direct therapeutic approaches are based on the development of new drugs able to modulate 
miRNA expression levels, including:  
 miRNA mimics, to inhibit the expression of target protein-coding genes, for miRNAs 
whose expression is reduced in diseases (Kota et al., 2009) 
 miRNA inhibitors, with antisense constructs like antagomiRs, to increase gene expression 
(M. S. Ebert et al., 2007) 
However, there are still many problems to be solved, such as stability, effective in vivo 
delivery systems, and selectivity. 
These therapeutic strategies could be of high relevance for pancreatic cancer treatment. 
Recently, deregulation of miRNAs expression has been correlated to diagnosis, prognosis and 
chemotherapy resistance of pancreatic cancer (Chakraborty et al., 2011; Dhayat et al., 2011). 
Among the several miRNAs reported to be up regulated in pancreatic cancer such as miR-21, 
miR-221/222, miR-25, miR-27a, miR-210, miR-200b, miR-148a,b, miR-196a-2, miR-155, and 
members of the miR-17-92 family (Chakraborty et al., 2011; Liffers et al., 2011; Nana-Sinkam & 
Croce, 2011; Zhang et al., 2011), the oncomiR miR-21 appears of high relevance as potential 
therapeutic target in pancreatic cancer, regulating proliferation, invasion, apoptosis and 
chemosensitivity (Ali et al., 2010; Giovannetti et al., 2010; Hwang et al., 2010; Park et al., 2009). 
miR-21 mimics, transfected into MIA PaCa-2 pancreatic cancer cells, have been shown to 
upregulate Bcl-2, to downregulate Bax expression, to decrease chemosensitivity to gemcitabine 
and to increase proliferation as compared with control cells. Transfection with miR-21 
inhibitors had opposite effects, decreasing cell proliferation (J. Dong et al., 2011). 
Further, miRNA-based biomarkers have a significant impact on the development of 
treatment strategy that combines therapeutics with diagnostics, a concept known as 
theranostics (Pene et al., 2009) and are highly relevant for drug development and 
personalized medicine. 
9. Conclusion 
In the last decade, a variety of molecularly targeted agents potentially useful in the 
treatment of PDAC have been developed. However, in contrast with the encouraging results 
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obtained in animal models, results in humans have been quite disappointing. The still 
limited knowledge of the molecular pathogenesis of PDAC, the inappropriateness of the 
experimental models, the suboptimal combinations and schedules selected for clinical trials 
can be suggested as possible reasons for this failure. Given the complexity of the molecular 
pathogenesis of PDAC, it is very likely that a substantial improvement of clinical outcome 
can derive from the rational targeting of more than a single altered pathway.  
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miR-21 mimics, transfected into MIA PaCa-2 pancreatic cancer cells, have been shown to 
upregulate Bcl-2, to downregulate Bax expression, to decrease chemosensitivity to gemcitabine 
and to increase proliferation as compared with control cells. Transfection with miR-21 
inhibitors had opposite effects, decreasing cell proliferation (J. Dong et al., 2011). 
Further, miRNA-based biomarkers have a significant impact on the development of 
treatment strategy that combines therapeutics with diagnostics, a concept known as 
theranostics (Pene et al., 2009) and are highly relevant for drug development and 
personalized medicine. 
9. Conclusion 
In the last decade, a variety of molecularly targeted agents potentially useful in the 
treatment of PDAC have been developed. However, in contrast with the encouraging results 
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obtained in animal models, results in humans have been quite disappointing. The still 
limited knowledge of the molecular pathogenesis of PDAC, the inappropriateness of the 
experimental models, the suboptimal combinations and schedules selected for clinical trials 
can be suggested as possible reasons for this failure. Given the complexity of the molecular 
pathogenesis of PDAC, it is very likely that a substantial improvement of clinical outcome 
can derive from the rational targeting of more than a single altered pathway.  
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1. Introduction  
Pancreatic cancer is one of the most lethal forms of cancer and it is estimated that there will 
be about 44,000 new cases in US in the year 2011. With 37,600 estimated deaths in 2011, 
pancreatic cancer is the fourth leading cause of cancer related deaths in US (American Cancer 
Society, 2011). In spite of numerous efforts, the 5-year survival rate for pancreatic cancer has 
not improved much for the last few decades. The suggested reasons for low survival among 
the pancreatic cancer patients include late disease diagnosis, highly invasive and metastatic 
nature, lack of effective therapies, and acquisition of resistant characteristics (American cancer 
Society 2007; Moore, et al., 2003; NIH 2007). Only two drugs – gemcitabine (GEM) and 5-
fluorouracil (5FU) – have been shown to improve the survival of patients consistently. 5FU 
was the first drug to be approved as adjuvant therapy for pancreatic cancer (Kalser and 
Ellenberg, 1985; Moertel, et al., 1981). Since then, GEM has been used as the first line 
chemotherapeutic drug for pancreatic cancer. However, GEM treatment does not always 
provide extended survival benefits. A study found that in post-operative patients, GEM 
treatment increased the survival by merely 6 months (Shore, et al., 2003). 5FU is also widely 
used as an adjuvant and neoadjuvant chemotherapeutic agent to treat pancreatic cancers 
(Ahlgren, 1996; Blaszkowsky, 1998; Snady, et al., 2000).  
Although the cell death mechanisms induced by GEM and 5FU are well understood, their 
efficacy is limited due to the acquisition of drug-resistant characteristics by the cancer cells. 
Various molecular mechanisms have been suggested to play a role in development of 
resistance against these drugs. Upregulation of Akt (protein kinase B), NFκB, MDR (p-
glycoprotein) and hypoxia have been shown to impart resistance against GEM (Bergman, et 
al., 2002; Galmarini, et al., 2002; Garcia-Manteiga, et al., 2003; Nakano, et al., 2007; Yokoi and 
Fidler, 2004). Similarly, modulation of thymidylate synthetase (TS), dihydropyrimidine 
dehydrogenase (DPDY), MAPK, p53 and src imparts 5FU resistant characteristics to 
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1. Introduction  
Pancreatic cancer is one of the most lethal forms of cancer and it is estimated that there will 
be about 44,000 new cases in US in the year 2011. With 37,600 estimated deaths in 2011, 
pancreatic cancer is the fourth leading cause of cancer related deaths in US (American Cancer 
Society, 2011). In spite of numerous efforts, the 5-year survival rate for pancreatic cancer has 
not improved much for the last few decades. The suggested reasons for low survival among 
the pancreatic cancer patients include late disease diagnosis, highly invasive and metastatic 
nature, lack of effective therapies, and acquisition of resistant characteristics (American cancer 
Society 2007; Moore, et al., 2003; NIH 2007). Only two drugs – gemcitabine (GEM) and 5-
fluorouracil (5FU) – have been shown to improve the survival of patients consistently. 5FU 
was the first drug to be approved as adjuvant therapy for pancreatic cancer (Kalser and 
Ellenberg, 1985; Moertel, et al., 1981). Since then, GEM has been used as the first line 
chemotherapeutic drug for pancreatic cancer. However, GEM treatment does not always 
provide extended survival benefits. A study found that in post-operative patients, GEM 
treatment increased the survival by merely 6 months (Shore, et al., 2003). 5FU is also widely 
used as an adjuvant and neoadjuvant chemotherapeutic agent to treat pancreatic cancers 
(Ahlgren, 1996; Blaszkowsky, 1998; Snady, et al., 2000).  
Although the cell death mechanisms induced by GEM and 5FU are well understood, their 
efficacy is limited due to the acquisition of drug-resistant characteristics by the cancer cells. 
Various molecular mechanisms have been suggested to play a role in development of 
resistance against these drugs. Upregulation of Akt (protein kinase B), NFκB, MDR (p-
glycoprotein) and hypoxia have been shown to impart resistance against GEM (Bergman, et 
al., 2002; Galmarini, et al., 2002; Garcia-Manteiga, et al., 2003; Nakano, et al., 2007; Yokoi and 
Fidler, 2004). Similarly, modulation of thymidylate synthetase (TS), dihydropyrimidine 
dehydrogenase (DPDY), MAPK, p53 and src imparts 5FU resistant characteristics to 
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pancreatic cancer cells (Eisold, et al., 2004; Kang and Saif, 2008; Zhang, et al., 2008; Zhao, et al., 
2006b). Epidermal growth factor receptor (EGFR) is a mitogenic receptor which has also 
been shown to provide cancer cells with proliferative and anti-apoptotic advantage (Arteaga, 
2001; Citri and Yarden, 2006). EGFR is found to be upregulated in pancreatic cancer patients’ 
tumors and the levels of EGFR correlate with aggressiveness and poor prognosis of the 
disease (Yamanaka, et al., 1993).  
2. Pancreatic cancer chemotherapy  
In spite of numerous efforts, the 5-year survival rate for pancreatic cancer has not improved 
much for last few decades. One reason contributing to this is the lack of chemotherapeutic 
agents which would effectively improve the survival of patients (American Cancer Society, 
2011; Moore, et al., 2003).  
2.1 Gemcitabine 
Gemcitabine (2’, 2’- difluorodeoxycytidine) is a difluoro analog of deoxycytidine and is the 
first line chemotherapeutic agent used in the treatment of pancreatic cancer cells. In 1997, a 
randomized trial found gemcitabine to have better clinical benefit response of 23.8% to 4.8% 
when compared to 5-fluorouracil. In the same study, the median survival for gemcitabine 
treated patients was 5.65 months versus 4.41 months for 5FU treated subjects. Comparative 
12-month survival was also increased in gemcitabine patients (18% to 2% for 5FU) (Burris, et 
al., 1997). Gemcitabine is used either alone or in combination with other agents in the 
treatment of pancreatic cancer. 
               
dCK: deoxycytidine kinase; dFdCMP: difluorodeoxycytidine monophosphate; dFdCDP: 
difluorodeoxycytidine diphosphate; dFdCTP: difluorodeoxycytidine triphosphate; CTP: cytidine 
triphosphate; CDP: cytidine diphosphate. 
Fig. 1. Gemcitabine mechanism of action 
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Gemcitabine mainly acts by three mechanisms as shown in figure 1. First, it forms dFdCTP 
(di-fluorodeoxycytidine triphosphate) by the action of enzyme deoxycytidine kinase (dCK). 
dFdCTP competes with cytidine triphosphate (CTP) to get incorporated into the DNA. 
Secondly, its diphosphate metabolite (dFdCDP) inhibits ribonucleotide reductase, further 
preventing the formation of triphosphate nucleotide. Thirdly, triphosphate metabolite 
(dFdCTP) inhibits DNA polymerase which is important for DNA repair (Huang, et al., 1991; 
Kang and Saif, 2008). Gemcitabine enters the cell via human equillibrative nucleotide 
transporter 1 (hENT1) (Mackey, et al., 1998). Patients with detectable expression of hENT had 
significantly longer survival than patients with low levels or absence of this protein 
(Spratlin, et al., 2004).  
2.2 5-Fluorouracil (5FU) 
5FU belongs to the antimetabolite class of chemotherapeutic drug and is structurally similar 
to the uracil molecule with an additional fluorine atom at position 5. The drug 5FU gets mis-
incorporated into DNA and RNA and also prevents nucleic acid synthesis by inhibiting the 
enzyme thymidylate synthase (TS). 5FU was the first drug to be approved as an adjuvant 
therapy for the treatment of pancreatic cancer. Combination of 5FU to radiation therapy 
increased the survival (10 months vs 6 months, no drug treatment) of pancreatic cancer 
patients with locally unresectable cancer (Kalser and Ellenberg, 1985; Moertel, et al., 1981). 
 
dUMP: deoxyuridine monophosphate; THF: tetrahydrofolate; dTMP: deoxythymidine monophosphate; 
DHF: dihydrofolic acid; DPDY: dihyropyrimidine dehydrogenase; dTTP: deoxythymidine triphosphate; 
TS: thymidylate synthetase; 5FU: 5-fluorouracil. 
Fig. 2. 5FU mechanism of action 
Degradation 
product 
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dCK: deoxycytidine kinase; dFdCMP: difluorodeoxycytidine monophosphate; dFdCDP: 
difluorodeoxycytidine diphosphate; dFdCTP: difluorodeoxycytidine triphosphate; CTP: cytidine 
triphosphate; CDP: cytidine diphosphate. 
Fig. 1. Gemcitabine mechanism of action 
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Gemcitabine mainly acts by three mechanisms as shown in figure 1. First, it forms dFdCTP 
(di-fluorodeoxycytidine triphosphate) by the action of enzyme deoxycytidine kinase (dCK). 
dFdCTP competes with cytidine triphosphate (CTP) to get incorporated into the DNA. 
Secondly, its diphosphate metabolite (dFdCDP) inhibits ribonucleotide reductase, further 
preventing the formation of triphosphate nucleotide. Thirdly, triphosphate metabolite 
(dFdCTP) inhibits DNA polymerase which is important for DNA repair (Huang, et al., 1991; 
Kang and Saif, 2008). Gemcitabine enters the cell via human equillibrative nucleotide 
transporter 1 (hENT1) (Mackey, et al., 1998). Patients with detectable expression of hENT had 
significantly longer survival than patients with low levels or absence of this protein 
(Spratlin, et al., 2004).  
2.2 5-Fluorouracil (5FU) 
5FU belongs to the antimetabolite class of chemotherapeutic drug and is structurally similar 
to the uracil molecule with an additional fluorine atom at position 5. The drug 5FU gets mis-
incorporated into DNA and RNA and also prevents nucleic acid synthesis by inhibiting the 
enzyme thymidylate synthase (TS). 5FU was the first drug to be approved as an adjuvant 
therapy for the treatment of pancreatic cancer. Combination of 5FU to radiation therapy 
increased the survival (10 months vs 6 months, no drug treatment) of pancreatic cancer 
patients with locally unresectable cancer (Kalser and Ellenberg, 1985; Moertel, et al., 1981). 
 
dUMP: deoxyuridine monophosphate; THF: tetrahydrofolate; dTMP: deoxythymidine monophosphate; 
DHF: dihydrofolic acid; DPDY: dihyropyrimidine dehydrogenase; dTTP: deoxythymidine triphosphate; 
TS: thymidylate synthetase; 5FU: 5-fluorouracil. 
Fig. 2. 5FU mechanism of action 
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Due to structural similarity, 5FU enters the cell using the same facilitator transporter as 
uracil (Diasio and Harris, 1989; Santi, et al., 1974; Wohlhueter, et al., 1980). Once inside the cell 
(Fig. 2), it forms various metabolites. Among these metabolites, fluorodeoxyuridine 
monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine 
triphosphate (FUTP) are the active metabolites which disrupt RNA synthesis and inhibit TS. 
5, 10-Methylenetetrahydrofolate (CH2THF) acts as the methyl donor for the conversion of 
dUMP to dTMP. 5FU binds to TS resulting in depletion of deoxythymidine triphosphate 
(dTTP) which further causes depletion in the levels of dATP, dCTP and dGTP. Imbalance in 
the ATP/dTTP ratio leads to disruption of DNA synthesis and repair (Diasio and Harris, 
1989; Howell, et al., 1981; JL, 1996; Santi, et al., 1974). 
3. Anticancer drug specific resistance 
3.1 Gemcitabine resistance 
Resistance to chemotherapeutic agents is observed commonly in mammalian tumors. 
Resistance can arise de novo or can be acquired after drug exposure. The vast genetic 
heterogeneity of cancer cells is considered to be the reason for the acquired resistance (Casa, 
et al., 2008). Cancer cells can acquire resistance against a drug through various mechanisms. 
It can prevent a drug’s entry into the cell or increase its exit from the cell. Once the drug is 
inside the cell, it can be degraded into inactive metabolites by over-expression of the 
catabolic enzyme or by inhibiting the activity of the enzyme responsible for converting the 
pro-drug into an active agent (Gottesman, 2002). Drug resistance is one of the important 
factors responsible for low survival rate of pancreatic cancer patients. Numerous studies 
over the past two decades have suggested that pancreatic cancer is associated with various 
genetic alterations which contribute to its resistant characteristics (Almoguera, et al., 1988; 
Feldmann, et al., 2007; Hruban and Fukushima, 2007). Some of these mechanisms are listed in 
table 1: 
Mechanisms 5-Fluoruracil (Santi, McHenry et al. 1974; 
Wohlhueter, McIvor et al. 1980; Howell, 
Mansfield et al. 1981; Diasio and Harris 
1989; Lowe, Ruley et al. 1993; JL 1996; 
Ahnen, Feigl et al. 1998; Lenz, Hayashi et al. 
1998; Bunz, Hwang et al. 1999; Eisold, 
Linnebacher et al. 2004;  
Zhang, Yin et al. 2008) 
Gemcitabine (Bergman, 
Pinedo et al. 2002; 
Galmarini, Clarke et al. 
2002; Garcia-Manteiga, 
Molina-Arcas et al. 2003; 
Yokoi and Fidler 2004; 
Nakano,  
Tanno et al. 2007) 
MOA 
related 
Thymidylate synthetase Ribonucleotide reductase 
Transporters MRP 3 and 5 MDR1 
Molecular Akt, src Akt, NF κB, src 
Table 1. Suggested mechanisms for drug resistance in pancreatic cancer 
Some of the markers of gemcitabine resistance include decreased expression of dCK, 
increased levels of competing dCTP, low levels of hENT, and alteration of PI3K/Akt/NFκB 
pathway, FAK, and hypoxia (Almoguera, et al., 1988; Feldmann, et al., 2007; Hruban and 
Fukushima, 2007) 
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3.2 5FU resistance 
Resistance to 5FU induced cytotoxicity or cancer cells’ response to 5FU treatment is 
controlled/characterized by various factors (Kang and Saif, 2008; Zhang, et al., 2008), as 
discussed below. 
3.2.1 Thymidylate Synthase (TS)  
TS controls several aspects of a tumor’s response to 5FU therapy. Increase in the TS level can 
reduce the accumulation of activated metabolites of 5FU and hence reduce toxicity. Also, 
mutation of the enzyme can decrease 5FU’s affinity to TS. TS overexpression is considered 
as a major mechanism responsible for 5FU resistance. Decreased levels of reduced folate 
substrate, 5,10-methyltetrahydrofolate, also reduces 5FU response. 
3.2.2 Dihydropyrimidine dehydrogenase (DPDY) 
Increase in the activity of DPDY can increase the catabolism of 5FU leading to its 
inactivation. Other studies have shown that low-DPDY tumors are more responsive to 5FU 
treatment. 
3.2.3 Slow down of cell cycle 
This mechanism can prevent the incorporation of 5FU metabolites in the cells and provide 
the cells with sufficient time to correct the misincorporated nucleotides. 
3.2.4 Human Equilibrative Nucleoside Transporters (hENT)
These transporters are important for delivery of 5FU from the extra-cellular space into cells. 
Levels of hENT1 has been correlated with pancreatic cancer cell sensitivity to 5FU response 
and few studies have suggested that hENT plays an important role in 5FU resistance. 
hENT1 mRNA levels are suggested to be a useful marker to predict 5FU sensitivity (Kang 
and Saif, 2008; Zhang, et al., 2008) 
3.2.5 Other factors causing 5FU resistance 
Mutated p53 
This tumor suppressor gene, which is mutated in 30-70 % of pancreatic cancer cases, can 
affect 5FU response in pancreatic cancer cases. Wild type p53 expression is required for 5FU- 
induced apoptosis and p53 status of tumor cells can determine the response to 5FU-based 
chemotherapy (Ahnen, et al., 1998; Bunz, et al., 1999; Lenz, et al., 1998; Lowe, et al., 1993). 
Another study found that transfection of pancreatic cancer cells with wild type p53 
synergistically enhances the cytotoxicity of 5FU both in vivo and in vitro. The same study 
also showed that pancreatic cancer cell line with wild type p53 status was more sensitive to 
5FU as compared to the p53 mutated line (Eisold, et al., 2004). 
Mutated EGFR-Ras-MAPK cascade 
This signaling pathway is important for growth, survival and proliferation of cells. The 
signaling cascade is found to be mutated at various levels in pancreatic cancer, leading to 
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catabolic enzyme or by inhibiting the activity of the enzyme responsible for converting the 
pro-drug into an active agent (Gottesman, 2002). Drug resistance is one of the important 
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Transporters MRP 3 and 5 MDR1 
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Table 1. Suggested mechanisms for drug resistance in pancreatic cancer 
Some of the markers of gemcitabine resistance include decreased expression of dCK, 
increased levels of competing dCTP, low levels of hENT, and alteration of PI3K/Akt/NFκB 
pathway, FAK, and hypoxia (Almoguera, et al., 1988; Feldmann, et al., 2007; Hruban and 
Fukushima, 2007) 
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3.2 5FU resistance 
Resistance to 5FU induced cytotoxicity or cancer cells’ response to 5FU treatment is 
controlled/characterized by various factors (Kang and Saif, 2008; Zhang, et al., 2008), as 
discussed below. 
3.2.1 Thymidylate Synthase (TS)  
TS controls several aspects of a tumor’s response to 5FU therapy. Increase in the TS level can 
reduce the accumulation of activated metabolites of 5FU and hence reduce toxicity. Also, 
mutation of the enzyme can decrease 5FU’s affinity to TS. TS overexpression is considered 
as a major mechanism responsible for 5FU resistance. Decreased levels of reduced folate 
substrate, 5,10-methyltetrahydrofolate, also reduces 5FU response. 
3.2.2 Dihydropyrimidine dehydrogenase (DPDY) 
Increase in the activity of DPDY can increase the catabolism of 5FU leading to its 
inactivation. Other studies have shown that low-DPDY tumors are more responsive to 5FU 
treatment. 
3.2.3 Slow down of cell cycle 
This mechanism can prevent the incorporation of 5FU metabolites in the cells and provide 
the cells with sufficient time to correct the misincorporated nucleotides. 
3.2.4 Human Equilibrative Nucleoside Transporters (hENT)
These transporters are important for delivery of 5FU from the extra-cellular space into cells. 
Levels of hENT1 has been correlated with pancreatic cancer cell sensitivity to 5FU response 
and few studies have suggested that hENT plays an important role in 5FU resistance. 
hENT1 mRNA levels are suggested to be a useful marker to predict 5FU sensitivity (Kang 
and Saif, 2008; Zhang, et al., 2008) 
3.2.5 Other factors causing 5FU resistance 
Mutated p53 
This tumor suppressor gene, which is mutated in 30-70 % of pancreatic cancer cases, can 
affect 5FU response in pancreatic cancer cases. Wild type p53 expression is required for 5FU- 
induced apoptosis and p53 status of tumor cells can determine the response to 5FU-based 
chemotherapy (Ahnen, et al., 1998; Bunz, et al., 1999; Lenz, et al., 1998; Lowe, et al., 1993). 
Another study found that transfection of pancreatic cancer cells with wild type p53 
synergistically enhances the cytotoxicity of 5FU both in vivo and in vitro. The same study 
also showed that pancreatic cancer cell line with wild type p53 status was more sensitive to 
5FU as compared to the p53 mutated line (Eisold, et al., 2004). 
Mutated EGFR-Ras-MAPK cascade 
This signaling pathway is important for growth, survival and proliferation of cells. The 
signaling cascade is found to be mutated at various levels in pancreatic cancer, leading to 
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over-activation of the pathway and hence increased growth and proliferation of the cancer 
cells (References). Protein expression of members of this pathway can modulate the 
cytotoxic effect of 5FU on pancreatic cancer cells. Blockade of EGFR increases the 
cytotoxicity of 5FU in both in vivo and in vitro conditions (Overholser, et al., 2000). 
Furthermore, activation of MAPK reduces the sensitivity of pancreatic cancer cells to 5FU 
treatment in vitro (Wey, et al., 2005). K-ras mutation is the hallmark of pancreatic cancer and 
occurs early during the development of pancreatic neoplasia. Ras-mutated pancreatic cells 
have shown to respond better to 5FU treatment as compared to their non-ras-transformed 
counterparts (Hiwasa, et al., 1996). 
4. Relationship of resistance to cellular processes 
The mechanisms involved in drug resistance in pancreatic cancer are different for different 
drugs. In a broad sense, drug resistance in pancreatic cancer can be linked to modulation of 
enzymes, receptors, DNA repair and other processes. These are discussed in depth in this 
section. For drugs to be effective, they should be transported successfully into the cells, 
reach their respective effective concentrations and should form their active forms before 
they are transported out of cells (Longley, et al., 2003; Plunkett, et al., 1995)  
4.1 Enzyme linked mechanisms 
The expression levels of the enzyme DCK determines the patient survival and the sensitivity 
of a tumor to gemcitabine (Hagmann, et al., 2010a; Plunkett, et al., 1995). HuR is a RNA-
binding protein that modulates the translation of DCK mRNA and multiple other proto-
oncogenic proteins in cancer cells (Williams, et al., 2010). Modulation of mRNA is dependent 
on stress conditions and includes the presence of therapeutic agents. Expression of HuR 
increases in pancreatic cancer cells treated with gemcitabine and an increased level of HuR 
in the cytoplasm is a marker of gemcitabine sensitivity (Costantino, et al., 2009). pp32 is a 
protein phosphatase and tumor suppressor gene that regulates the post- transcriptional 
activity of mRNA to which the HuR protein binds. Although the exact mechanism by which 
pp32 regulates HuR is yet to be unveiled, researchers have cited possible ways by which 
pp32 regulates the post-transcriptional changes of transcribed mRNA. The possibilities 
include: a) disrupting the interaction of HuR with mRNA in the nucleus, b) inhibiting 
translocation of the HuR-bound mRNA into cytosol and thereby inhibiting translation of 
oncogenic proteins, and other possible mechanisms (References). Overexpression of pp32 
can result in inhibition of dCK mRNA translation and hence poor gemcitabine efficacy 
(Williams, et al., 2010). 
Thymidylate synthetase (TS) controls a tumor’s response to 5FU therapy. Increase in the TS 
level can reduce the accumulation of activated metabolites of 5FU and hence reduce toxicity. 
Additionally, mutation of the enzyme can decrease its affinity to TS. TS overexpression is 
considered as a major mechanism responsible for 5FU resistance. Decreased levels of 
reduced folate substrate, 5,10-methyltetrahydrofolate, also reduces 5FU response (Zhang, et 
al., 2008). 
Increase in the activity of dihydropyrimidine dehydrogenase (DPDY) can increase the 
catabolism of 5FU leading to its inactivation. Few studies have shown that low-DPDY 
tumors are more responsive to 5FU treatment. 
Failure of Pancreatic Cancer Chemotherapy: Consequences of Drug Resistance Mechanisms 149 
5FU resistance can result from induction of TS levels upon administration of 5FU which 
brings about the activation of autoregulatory feedback pathway where the TS protein 
regulates the translation of its mRNA. The salvage pathway involving the enzyme 
thymidine kinase, the biochemical reaction in which thymidylate is derived from thymidine 
could be one of the ways the cells acquire resistance to 5FU. (Zhang, et al., 2008) 
4.2 Receptor linked mechanisms 
4.2.1 Drug uptake 
Due to structural similarity to the nucleosides, a drug can enter the cells through uptake by 
the concentrative nucleoside transporters (CNT's) and equilibrative nucleoside transporters 
(ENT's). CNT1 and CNT3 have high affinity for gemcitabine whereas ENT1 and ENT2 have 
lower affinity for gemcitabine. Pancreatic tumor cells exhibit higher expression levels of 
ENT1 but low to negligible levels of CNT 3. This phenotype affects the transport of 
gemcitabine into the cancer cells and ultimately gemcitabine’s action on DNA and RNA 
synthesis. The expression levels of ENT1 and CNT3 provide an index of patient survival 
after gemcitabine treatment (Hagmann, et al., 2010b). 
In the case of 5FU, resistance was found to be imparted due to overexpression of ENT1. A 
study using 7 pancreatic cancer cell lines (AsPC1, BxPC3, MiaPaCa-2, PSN1, Panc1, PCI6, 
and KMP-4) reported an increased expression of ENT1 mRNA, which correlated with the 
IC50 of 5FU in the AsPC1 cell line, a cell line most resistant to 5FU among the cell lines tested 
(Tsujie, et al.; 2007). Thymidylate synthase (a target of 5FU) and dihydropyrimidine 
dehydrogenase (DPDY), which metabolizes 5FU, were not overexpressed with simultaneous 
overexpression of ENT1: this phenotype implies that the toxicity of 5FU was countered by 
increased uptake of nucleosides and nucleotide bases through the salvage pathway (Tsujie, 
et al., 2007). It is therefore widely accepted that ENT1 overexpression serves as a marker of 
5FU resistance (Huber-Ruano and Pastor-Anglada, 2009; Tsujie, et al., 2007). 
4.2.2 Drug efflux 
Drug efflux is one of the potential means by which cancer cells exhibit chemoresistance: it is 
mediated by a family of proteins, ATP binding cassette (ABC) proteins, which involve ATP 
utilization (Wu, et al., 2008). The human genome encodes 49 members of this protein family 
and about 15 proteins are implicated in cancer chemoresistance. These transporters have an 
intracellular nucleotide binding domain that hydrolyses ATP and results in conformational 
change in its structure leading to the transmembrane domain forming a channel-like structure 
through which the drug is effluxed to the extracellular space(Santisteban, 2010). P glycoprotein, 
multidrug resistance associated protein (MRP1) and breast cancer resistance protein (BCRP) 
constitute the universal drug efflux transporters (Santisteban, 2010; Wu, et al., 2008). 
The efflux of gemcitabine and its triphosphate metabolite is mediated by multidrug resistant 
protein 5 (MRP5), which is a member of the ATP binding cassette (ABC) family of proteins. 
Evidences in support of the role of MRP3, MRP4 and MRP5 in the efflux of etoposide, 5FU 
and gemcitabine suggest that these MRP's are directly linked with the resistance phenotype 
(Hagmann, et al., 2010a; Hagmann, et al., 2010b). Transcriptional regulation of MRP's by 
nuclear factor like 2 protein (Nrf2) is an important target to overcome resistance because 
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over-activation of the pathway and hence increased growth and proliferation of the cancer 
cells (References). Protein expression of members of this pathway can modulate the 
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cytotoxicity of 5FU in both in vivo and in vitro conditions (Overholser, et al., 2000). 
Furthermore, activation of MAPK reduces the sensitivity of pancreatic cancer cells to 5FU 
treatment in vitro (Wey, et al., 2005). K-ras mutation is the hallmark of pancreatic cancer and 
occurs early during the development of pancreatic neoplasia. Ras-mutated pancreatic cells 
have shown to respond better to 5FU treatment as compared to their non-ras-transformed 
counterparts (Hiwasa, et al., 1996). 
4. Relationship of resistance to cellular processes 
The mechanisms involved in drug resistance in pancreatic cancer are different for different 
drugs. In a broad sense, drug resistance in pancreatic cancer can be linked to modulation of 
enzymes, receptors, DNA repair and other processes. These are discussed in depth in this 
section. For drugs to be effective, they should be transported successfully into the cells, 
reach their respective effective concentrations and should form their active forms before 
they are transported out of cells (Longley, et al., 2003; Plunkett, et al., 1995)  
4.1 Enzyme linked mechanisms 
The expression levels of the enzyme DCK determines the patient survival and the sensitivity 
of a tumor to gemcitabine (Hagmann, et al., 2010a; Plunkett, et al., 1995). HuR is a RNA-
binding protein that modulates the translation of DCK mRNA and multiple other proto-
oncogenic proteins in cancer cells (Williams, et al., 2010). Modulation of mRNA is dependent 
on stress conditions and includes the presence of therapeutic agents. Expression of HuR 
increases in pancreatic cancer cells treated with gemcitabine and an increased level of HuR 
in the cytoplasm is a marker of gemcitabine sensitivity (Costantino, et al., 2009). pp32 is a 
protein phosphatase and tumor suppressor gene that regulates the post- transcriptional 
activity of mRNA to which the HuR protein binds. Although the exact mechanism by which 
pp32 regulates HuR is yet to be unveiled, researchers have cited possible ways by which 
pp32 regulates the post-transcriptional changes of transcribed mRNA. The possibilities 
include: a) disrupting the interaction of HuR with mRNA in the nucleus, b) inhibiting 
translocation of the HuR-bound mRNA into cytosol and thereby inhibiting translation of 
oncogenic proteins, and other possible mechanisms (References). Overexpression of pp32 
can result in inhibition of dCK mRNA translation and hence poor gemcitabine efficacy 
(Williams, et al., 2010). 
Thymidylate synthetase (TS) controls a tumor’s response to 5FU therapy. Increase in the TS 
level can reduce the accumulation of activated metabolites of 5FU and hence reduce toxicity. 
Additionally, mutation of the enzyme can decrease its affinity to TS. TS overexpression is 
considered as a major mechanism responsible for 5FU resistance. Decreased levels of 
reduced folate substrate, 5,10-methyltetrahydrofolate, also reduces 5FU response (Zhang, et 
al., 2008). 
Increase in the activity of dihydropyrimidine dehydrogenase (DPDY) can increase the 
catabolism of 5FU leading to its inactivation. Few studies have shown that low-DPDY 
tumors are more responsive to 5FU treatment. 
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Drug efflux is one of the potential means by which cancer cells exhibit chemoresistance: it is 
mediated by a family of proteins, ATP binding cassette (ABC) proteins, which involve ATP 
utilization (Wu, et al., 2008). The human genome encodes 49 members of this protein family 
and about 15 proteins are implicated in cancer chemoresistance. These transporters have an 
intracellular nucleotide binding domain that hydrolyses ATP and results in conformational 
change in its structure leading to the transmembrane domain forming a channel-like structure 
through which the drug is effluxed to the extracellular space(Santisteban, 2010). P glycoprotein, 
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constitute the universal drug efflux transporters (Santisteban, 2010; Wu, et al., 2008). 
The efflux of gemcitabine and its triphosphate metabolite is mediated by multidrug resistant 
protein 5 (MRP5), which is a member of the ATP binding cassette (ABC) family of proteins. 
Evidences in support of the role of MRP3, MRP4 and MRP5 in the efflux of etoposide, 5FU 
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overexpression of Nrf2 is associated with increased resistance of cells towards 
chemotherapy-induced cell death (Hagmann, et al., 2010a). 
Evidences in support of overexpression of these transporters in cancer stem cells and failure 
of the classical concept of direct inhibition of transporters in resistant cells using the first 
generation inhibitors like verapamil and quinidine and second generation inhibitors like 
valspodar and biricodar have led researchers to focus on the pathways that may be involved 
(Santisteban, 2010). 
4.3 Role of hedgehog pathway in resistance 
Hedgehog signaling between the tumor cells and stromal cells brings about a desmoplastic 
reaction where the stromal fibroblasts secrete collagen in higher amounts and result in 
fibrosis of the surrounding stromal tissue. Hedgehog signaling also has a key role in 
promoting epithelial mesenchymal transition and the acquisition of mesenchymal 
phenotype is associated with over expression of ABC transporters in breast cancer and in 
pancreatic adenocarcinoma (Santisteban, 2010). Studies using KPC (Kras and p53 mutant) 
mice with PDAC (Pancreatic Ductal Adenocarcinoma) highlighted the role of hedgehog 
pathway in resistance aided by the desmoplastic reaction where the mean vascular density 
to the tumor tissue decreased and resulted in decreased delivery of gemcitabine to the 
tumor tissue (Olive, et al., 2009). Use of a pathway inhibitors like cyclopamine derivatives, 
that inhibit the protein smoothened, which is downstream of hedgehog signaling prevents 
transcriptional activation of target genes that bring about resistance by promoting 
overexpression of ABC transporters and by preventing desmoplasia (Olive, et al., 2009; 
Santisteban, 2010). 
4.4 Role of MAPK in resistance 
Three types of mitogen activated protein kinases (MAPK) have been identified in humans, 
including the extracellular signal regulated kinases (ERK), c-Jun N-terminal kinases and the 
p38 MAP kinases and all these act by serine/threonine phosphorylation of target proteins 
(Wagner and Nebreda, 2009). Interestingly, ERK pathway activation promotes survival while 
activation of JNK and p38 MAPK pathways induce apoptotic cell death as they are activated 
under stress conditions (Wagner and Nebreda, 2009; Zhao, et al., 2006a). Involvement of 
MAPKinase pathways in acquired chemoresistance has been studied by researchers but a 
clear idea of the mechanisms involved has yet to be established. ERK pathway which is 
downstream of EGFR signaling, promotes cell survival through its pro-survival signals which 
may be responsible for chemoresistance. Employing the SW 1990 cell line, Zhao et al 
demonstrated that ERK signaling regulates chemoresistance depending on the 
chemotherapeutic agent. Resistant cell lines exhibit a higher level of ERK activity as compared 
to sensitive cell lines and that inhibition of ERK pathway resulted in 5FU sensitivity but 
increased GEM resistance. 5FU acts by activating intrinsic apoptotic pathway whereas GEM 
induces cell death by activating extrinsic apoptotic pathway (Zhao, et al., 2006a). 
4.5 Role of PI3K/Akt pathway in resistance 
As opposed to earlier notions that drug resistance arises by increased drug metabolism or 
efflux or decreased transport of the drugs into the cells, Ng et al.(2000), using PK1 and PK8 
cell lines, demonstrated that the anti-apoptotic advantage of cells towards gemcitabine is 
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conferred not by the classical resistance mechanisms alone but also by the activation of 
PI3K/Akt pathway when the intracellular concentration of gemcitabine was found to be 
effective to affect DNA and cell cycle (Ng, et al., 2000). PI3K/Akt pathway activation stems 
from phosphorylation of receptor tyrosine kinases and the regulatory subunit of PI3K, the 
p85 interacts with the active tyrosine kinase domains for activation. Activation of PI3K 
results in phosphorylation of its substrates which includes phosphoinositides and protein 
kinase B (PKB), otherwise called Akt. Phosphorylation of Akt and its subsequent nuclear 
translocation results in transcriptional activation of genes that promote cell survival 
(Hennessy, et al., 2005; Ng, et al., 2000). Apart from this mechanism, the phosphorylated Akt 
is also shown to inactivate the pro-apoptotic protein BAD by phosphorylating it and thereby 
giving the anti-apoptotic advantage to the cells. In addition, the activation of PI3K can also 
occur by interaction of the catalytic subunit of PI3K (p110 subunit) with constitutively active 
membrane bound Ras (Ng, et al., 2000). 
4.6 Role of Zeb-1 in resistance 
Zeb1 is a transcriptional suppressor of E-cadherin which is involved in cell-cell adhesion 
and is the marker of epithelial cells. By doing so, it promotes epithelial-mesenchymal 
transition (EMT) upon which the cells metastasize and form secondary tumors (Wellner, et 
al., 2010). Epithelial mesenchymal transition is a process by which the tumor cells with 
epithelial lineage origin acquire the mesenchymal phenotype. This process gives them an 
advantage of migrating from the primary tumor site into the blood stream and  
develop secondary tumors at various sites depending on the availability of suitable 
microenvironment. The whole process is called metastasis which is dependent on EMT. 
During EMT, the epithelial cells lose epithelial cell surface markers, express mesenchymal 
markers and undergo cytoskeletal remodeling in which the cell polarity, a characteristic of 
the epithelial cells, is lost and the cells acquire an invasive phenotype. Downregulation of E-
cadherin and upregulation of mesenchymal markers vimentin, smooth muscle actin, 
gamma-actin, beta-filamin, talina and extracellular matrix components like fibronectin and 
collagen precursors are key features of EMT (Christiansen and Rajasekaran, 2006; Kalluri and 
Weinberg, 2009). 
Recent studies on the role of Zeb-1 by Arumugam et al. (2009) confirmed the role of Zeb-1 not 
only in promoting metastasis but also in drug resistance. This group found that the cancer 
cell lines which are sensitive to gemcitabine (L3.6pl, BxPC3, CFPAC, SU86.86) are more 
sensitive to 5FU and cisplatin as compared to the gemcitabine-resistant cancer cell lines 
(PANC-1, Hs766T, AsPC-1, MIAPaCa-2, MPanc96). When Zeb-1 activity was silenced using 
siRNA in PANC1, MIAPaCA-2 and Hs766T cell lines, there was increased apoptosis in these 
cell lines on treatment with gemcitabine, 5FU or cisplatin, separately. This finding suggests 
an important role for Zeb-1 in drug resistance. Erlotinib is an EGFR inhibitor that is used in 
combination with gemcitabine to treat pancreatic cancer. Resistance to EGFR inhibition is a 
hallmark of EMT which can be reverted by silencing the activity of Zeb-1, which in turn 
increases sensitivity of the cells to EGFR inhibition (Arumugam, et al., 2009). 
4.7 Role of NFκB in inducing gemcitabine resistance 
Nuclear factor kappa light chain enhancer of activated B-cells (NFκB) is a complex involved 
in important cellular processes like inflammation, apoptosis regulation and stress 
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overexpression of Nrf2 is associated with increased resistance of cells towards 
chemotherapy-induced cell death (Hagmann, et al., 2010a). 
Evidences in support of overexpression of these transporters in cancer stem cells and failure 
of the classical concept of direct inhibition of transporters in resistant cells using the first 
generation inhibitors like verapamil and quinidine and second generation inhibitors like 
valspodar and biricodar have led researchers to focus on the pathways that may be involved 
(Santisteban, 2010). 
4.3 Role of hedgehog pathway in resistance 
Hedgehog signaling between the tumor cells and stromal cells brings about a desmoplastic 
reaction where the stromal fibroblasts secrete collagen in higher amounts and result in 
fibrosis of the surrounding stromal tissue. Hedgehog signaling also has a key role in 
promoting epithelial mesenchymal transition and the acquisition of mesenchymal 
phenotype is associated with over expression of ABC transporters in breast cancer and in 
pancreatic adenocarcinoma (Santisteban, 2010). Studies using KPC (Kras and p53 mutant) 
mice with PDAC (Pancreatic Ductal Adenocarcinoma) highlighted the role of hedgehog 
pathway in resistance aided by the desmoplastic reaction where the mean vascular density 
to the tumor tissue decreased and resulted in decreased delivery of gemcitabine to the 
tumor tissue (Olive, et al., 2009). Use of a pathway inhibitors like cyclopamine derivatives, 
that inhibit the protein smoothened, which is downstream of hedgehog signaling prevents 
transcriptional activation of target genes that bring about resistance by promoting 
overexpression of ABC transporters and by preventing desmoplasia (Olive, et al., 2009; 
Santisteban, 2010). 
4.4 Role of MAPK in resistance 
Three types of mitogen activated protein kinases (MAPK) have been identified in humans, 
including the extracellular signal regulated kinases (ERK), c-Jun N-terminal kinases and the 
p38 MAP kinases and all these act by serine/threonine phosphorylation of target proteins 
(Wagner and Nebreda, 2009). Interestingly, ERK pathway activation promotes survival while 
activation of JNK and p38 MAPK pathways induce apoptotic cell death as they are activated 
under stress conditions (Wagner and Nebreda, 2009; Zhao, et al., 2006a). Involvement of 
MAPKinase pathways in acquired chemoresistance has been studied by researchers but a 
clear idea of the mechanisms involved has yet to be established. ERK pathway which is 
downstream of EGFR signaling, promotes cell survival through its pro-survival signals which 
may be responsible for chemoresistance. Employing the SW 1990 cell line, Zhao et al 
demonstrated that ERK signaling regulates chemoresistance depending on the 
chemotherapeutic agent. Resistant cell lines exhibit a higher level of ERK activity as compared 
to sensitive cell lines and that inhibition of ERK pathway resulted in 5FU sensitivity but 
increased GEM resistance. 5FU acts by activating intrinsic apoptotic pathway whereas GEM 
induces cell death by activating extrinsic apoptotic pathway (Zhao, et al., 2006a). 
4.5 Role of PI3K/Akt pathway in resistance 
As opposed to earlier notions that drug resistance arises by increased drug metabolism or 
efflux or decreased transport of the drugs into the cells, Ng et al.(2000), using PK1 and PK8 
cell lines, demonstrated that the anti-apoptotic advantage of cells towards gemcitabine is 
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conferred not by the classical resistance mechanisms alone but also by the activation of 
PI3K/Akt pathway when the intracellular concentration of gemcitabine was found to be 
effective to affect DNA and cell cycle (Ng, et al., 2000). PI3K/Akt pathway activation stems 
from phosphorylation of receptor tyrosine kinases and the regulatory subunit of PI3K, the 
p85 interacts with the active tyrosine kinase domains for activation. Activation of PI3K 
results in phosphorylation of its substrates which includes phosphoinositides and protein 
kinase B (PKB), otherwise called Akt. Phosphorylation of Akt and its subsequent nuclear 
translocation results in transcriptional activation of genes that promote cell survival 
(Hennessy, et al., 2005; Ng, et al., 2000). Apart from this mechanism, the phosphorylated Akt 
is also shown to inactivate the pro-apoptotic protein BAD by phosphorylating it and thereby 
giving the anti-apoptotic advantage to the cells. In addition, the activation of PI3K can also 
occur by interaction of the catalytic subunit of PI3K (p110 subunit) with constitutively active 
membrane bound Ras (Ng, et al., 2000). 
4.6 Role of Zeb-1 in resistance 
Zeb1 is a transcriptional suppressor of E-cadherin which is involved in cell-cell adhesion 
and is the marker of epithelial cells. By doing so, it promotes epithelial-mesenchymal 
transition (EMT) upon which the cells metastasize and form secondary tumors (Wellner, et 
al., 2010). Epithelial mesenchymal transition is a process by which the tumor cells with 
epithelial lineage origin acquire the mesenchymal phenotype. This process gives them an 
advantage of migrating from the primary tumor site into the blood stream and  
develop secondary tumors at various sites depending on the availability of suitable 
microenvironment. The whole process is called metastasis which is dependent on EMT. 
During EMT, the epithelial cells lose epithelial cell surface markers, express mesenchymal 
markers and undergo cytoskeletal remodeling in which the cell polarity, a characteristic of 
the epithelial cells, is lost and the cells acquire an invasive phenotype. Downregulation of E-
cadherin and upregulation of mesenchymal markers vimentin, smooth muscle actin, 
gamma-actin, beta-filamin, talina and extracellular matrix components like fibronectin and 
collagen precursors are key features of EMT (Christiansen and Rajasekaran, 2006; Kalluri and 
Weinberg, 2009). 
Recent studies on the role of Zeb-1 by Arumugam et al. (2009) confirmed the role of Zeb-1 not 
only in promoting metastasis but also in drug resistance. This group found that the cancer 
cell lines which are sensitive to gemcitabine (L3.6pl, BxPC3, CFPAC, SU86.86) are more 
sensitive to 5FU and cisplatin as compared to the gemcitabine-resistant cancer cell lines 
(PANC-1, Hs766T, AsPC-1, MIAPaCa-2, MPanc96). When Zeb-1 activity was silenced using 
siRNA in PANC1, MIAPaCA-2 and Hs766T cell lines, there was increased apoptosis in these 
cell lines on treatment with gemcitabine, 5FU or cisplatin, separately. This finding suggests 
an important role for Zeb-1 in drug resistance. Erlotinib is an EGFR inhibitor that is used in 
combination with gemcitabine to treat pancreatic cancer. Resistance to EGFR inhibition is a 
hallmark of EMT which can be reverted by silencing the activity of Zeb-1, which in turn 
increases sensitivity of the cells to EGFR inhibition (Arumugam, et al., 2009). 
4.7 Role of NFκB in inducing gemcitabine resistance 
Nuclear factor kappa light chain enhancer of activated B-cells (NFκB) is a complex involved 
in important cellular processes like inflammation, apoptosis regulation and stress 
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adaptation. In the cell, it is present tightly bound to inhibitory proteins like IkBa and is 
released in response to stimuli that bring about activation of IkB kinase (IKK). The free 
cytosolic NFκB then translocates into the nucleus where it regulates gene expression. The 
role of NFκB in gemcitabine resistance has been demonstrated. Arlt et al. (2003), using 
gemcitabine resistant (BxPC3 and Capan1) and gemcitabine sensitive (T3M4 and PT45-P1) 
cell lines, found that the autocrine loops for generation of NFκB play an important role in 
gemcitabine resistance. Employing NFκB inhibitors (MG132 or sulfasalazine), they found 
basal NFκB levels confer resistance and the basal NFκB levels are not affected by the 
activated or inactive state of PI3K/Akt pathway (Arlt, et al., 2003). 
4.8 Role of notch signaling in chemoresistance 
Notch signaling is a developmental pathway which is implicated in organogenesis, 
development of nervous and vascular systems and hematopoietic stem cell generation in 
adults (Chiba, 2007). Notch signaling is important for self-renewal of stem cell and along with 
Wnt signaling, it prevents terminal differentiation of cells (Katoh, 2007). Overactivity of Notch 
signaling is observed in various hematopoietic and solid tumors leading to proliferation, and 
inhibition of differentiation and apoptosis. In pancreatic cancer cells, Notch signaling is 
implicated in drug resistance. Wang et al. found that components of Notch signaling pathway 
are upregulated in gemcitabine resistant pancreatic cancer cells and are associated with 
increase invasiveness (Bao, et al., 2011b; Wang, et al., 2009). Yao and Qian (2010) observed that 
inhibition of Notch3 by the siRNA approach increases gemcitabine-induced cytotoxicity in 
pancreatic cancer cell via affecting the PI3K/Akt pathway. The studies mentioned above 
strongly suggest that cancer stem cell signaling pathways could be attractive targets for 
increasing their sensitivity to chemotherapeutic agents (Bao, et al., 2011b). 
4.9 Miscellaneous other mechanisms 
A role of for the glycoprotein, mucin MUC4, in pancreatic cancer cell resistance to the first line 
chemotherapeutic agent, gemcitabine has recently emerged. Mucin MUC4 is overexpressed on 
the membrane of pancreatic cancer cells but not normal pancreatic cells (Santisteban, 2010). 
Studies on this glycoprotein’s involvement in gemcitabine resistance have revealed the 
interaction of this glycoprotein with the HER2 receptor and the subsequent activation of ERK 
pathway and phosphorylation of the pro-apoptotic protein BAD which inhibits apoptosis 
induced by gemcitabine (Ponnusamy, et al., 2008; Santisteban, 2010). 
5. Overall strategies to overcome resistance 
5.1 miRNA 
miRNA (miR) are 18-24 nucleotide-long RNA molecules which can regulate the translation 
of mature RNA into protein. They are synthesized as a 60-80 nucleotide-long, hairpin-
shaped RNA molecule which is transported to the cytoplasm where it undergoes processing 
to form 18-24 nucleotide-long double stranded RNA molecule. One of the strands then 
interacts with RNA-induced silenced complex (RISC) and targets RNA translation. Various 
miRNAs have been demonstrated to play a role in development and cancer progression. 
Dysregulation of miRNAs has also been observed in pancreatic cancer tissues and cell lines. 
Bloomston et al. (2007) found that the levels of miRNAs can be used to differentiate between 
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pancreatic tumor, chronic pancreatitis and benign pancreatic tissue. They also found that the 
expression of six miRNAs can predict the survival of the pancreatic cancer patients 
(Bloomston, et al., 2007). Zhang et al. (2009) profiled the levels of 95 miRNAs in pancreatic 
tumors, pancreatic cancer cell lines, pancreatic tissues and pancreatic ductal epithelial cells. 
They found that the expression of 8 miRNAs were significantly upregulated in pancreatic 
cancer tissues and cancer cell lines compared to the pancreatic tissues and pancreatic ductal 
cells (Zhang, et al., 2009). 
Deregulated miRNA levels could serve as attractive targets for treatment of pancreatic 
cancer. Moriyama et al. (2009) found that the level of miR21 is upregulated in pancreatic 
cancer cells and its inhibition decreases proliferation, invasion, chemoresistance and induces 
cell cycle arrest and apoptosis in pancreatic cancer cells. On the other hand, Banerjee et al., 
(2007) found that the expression of miRNAs can be modulated by natural compounds which 
reduce EMT and chemoresistance in pancreatic cancer cells. These studies strongly suggest 
that deregulated levels of miRNA in pancreatic cancer can be exploited as putative 
therapeutic targets for overcoming pancreatic cancer drug resistance. 
5.2 Stem cell signaling 
Some studies have suggested that a tumor comprises of heterogeneous populations of cells 
rather than just homogenous cell types. One subset is suggested to be distinct cells that have 
limited proliferative capacity but are responsible for initiation, progression and 
differentiation of cancer cells. Due to their ability to self-renew and differentiate like stem 
cells, these cells are termed as “cancer stem cells.” There have been attempts with some 
successes to isolate the cancer stem cells so that they can be employed to elucidate genotypic 
and phenotypic characteristics as well as develop effective therapies to target to them 
because of their ability to self-renew and their resistance to conventional chemo- and/or 
radiation therapies.  
Li et al. ( 2007) isolated pancreatic cancer cells which were highly tumorigenic and had the 
ability to self-renew based on their cell surface markers. These cells (CD44*CD24* ESA*) 
comprises of 0.2-0.8% of all pancreatic cancer cells and were able to produce differentiated 
progeny. Similarly, Herman et al. (2007) isolated pancreatic cancer stem cells which were 
CD133+.  
The cancer stem cells are known to be resistant to conventional chemo-radiation therapies. 
Michor et al. showed that a subpopulation of chronic myeloid leukemia stem cells were 
resistant to imatinib (Michor, et al., 2005). In glioblastoma, enrichment of CD133+ cells was 
observed after treatment with ionizing radiation. These cells activate DNA damage response 
upon irradiation and therefore are resistant to ionizing radiation (Bao, et al., 2006). Similarly, 
enrichment of cells with stem cell characteristics is observed on treatment of pancreatic 
cancer with radio- or chemotherapy (Hermann, et al., 2007; Li, et al., 2007). 
5.3 Natural compounds for reversing resistance 
Dietary habit of individuals has been correlated with development of pancreatic cancer. 
High cholesterol diet increases the risk of pancreatic cancer (Baghurst, et al., 1991; Ghadirian, 
et al., 1991; Howe, et al., 1992; Stolzenberg-Solomon, et al., 2002). Diet rich in fruits and 
vegetables is associated with reduced risk while intake of red meat is associated with 
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adaptation. In the cell, it is present tightly bound to inhibitory proteins like IkBa and is 
released in response to stimuli that bring about activation of IkB kinase (IKK). The free 
cytosolic NFκB then translocates into the nucleus where it regulates gene expression. The 
role of NFκB in gemcitabine resistance has been demonstrated. Arlt et al. (2003), using 
gemcitabine resistant (BxPC3 and Capan1) and gemcitabine sensitive (T3M4 and PT45-P1) 
cell lines, found that the autocrine loops for generation of NFκB play an important role in 
gemcitabine resistance. Employing NFκB inhibitors (MG132 or sulfasalazine), they found 
basal NFκB levels confer resistance and the basal NFκB levels are not affected by the 
activated or inactive state of PI3K/Akt pathway (Arlt, et al., 2003). 
4.8 Role of notch signaling in chemoresistance 
Notch signaling is a developmental pathway which is implicated in organogenesis, 
development of nervous and vascular systems and hematopoietic stem cell generation in 
adults (Chiba, 2007). Notch signaling is important for self-renewal of stem cell and along with 
Wnt signaling, it prevents terminal differentiation of cells (Katoh, 2007). Overactivity of Notch 
signaling is observed in various hematopoietic and solid tumors leading to proliferation, and 
inhibition of differentiation and apoptosis. In pancreatic cancer cells, Notch signaling is 
implicated in drug resistance. Wang et al. found that components of Notch signaling pathway 
are upregulated in gemcitabine resistant pancreatic cancer cells and are associated with 
increase invasiveness (Bao, et al., 2011b; Wang, et al., 2009). Yao and Qian (2010) observed that 
inhibition of Notch3 by the siRNA approach increases gemcitabine-induced cytotoxicity in 
pancreatic cancer cell via affecting the PI3K/Akt pathway. The studies mentioned above 
strongly suggest that cancer stem cell signaling pathways could be attractive targets for 
increasing their sensitivity to chemotherapeutic agents (Bao, et al., 2011b). 
4.9 Miscellaneous other mechanisms 
A role of for the glycoprotein, mucin MUC4, in pancreatic cancer cell resistance to the first line 
chemotherapeutic agent, gemcitabine has recently emerged. Mucin MUC4 is overexpressed on 
the membrane of pancreatic cancer cells but not normal pancreatic cells (Santisteban, 2010). 
Studies on this glycoprotein’s involvement in gemcitabine resistance have revealed the 
interaction of this glycoprotein with the HER2 receptor and the subsequent activation of ERK 
pathway and phosphorylation of the pro-apoptotic protein BAD which inhibits apoptosis 
induced by gemcitabine (Ponnusamy, et al., 2008; Santisteban, 2010). 
5. Overall strategies to overcome resistance 
5.1 miRNA 
miRNA (miR) are 18-24 nucleotide-long RNA molecules which can regulate the translation 
of mature RNA into protein. They are synthesized as a 60-80 nucleotide-long, hairpin-
shaped RNA molecule which is transported to the cytoplasm where it undergoes processing 
to form 18-24 nucleotide-long double stranded RNA molecule. One of the strands then 
interacts with RNA-induced silenced complex (RISC) and targets RNA translation. Various 
miRNAs have been demonstrated to play a role in development and cancer progression. 
Dysregulation of miRNAs has also been observed in pancreatic cancer tissues and cell lines. 
Bloomston et al. (2007) found that the levels of miRNAs can be used to differentiate between 
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pancreatic tumor, chronic pancreatitis and benign pancreatic tissue. They also found that the 
expression of six miRNAs can predict the survival of the pancreatic cancer patients 
(Bloomston, et al., 2007). Zhang et al. (2009) profiled the levels of 95 miRNAs in pancreatic 
tumors, pancreatic cancer cell lines, pancreatic tissues and pancreatic ductal epithelial cells. 
They found that the expression of 8 miRNAs were significantly upregulated in pancreatic 
cancer tissues and cancer cell lines compared to the pancreatic tissues and pancreatic ductal 
cells (Zhang, et al., 2009). 
Deregulated miRNA levels could serve as attractive targets for treatment of pancreatic 
cancer. Moriyama et al. (2009) found that the level of miR21 is upregulated in pancreatic 
cancer cells and its inhibition decreases proliferation, invasion, chemoresistance and induces 
cell cycle arrest and apoptosis in pancreatic cancer cells. On the other hand, Banerjee et al., 
(2007) found that the expression of miRNAs can be modulated by natural compounds which 
reduce EMT and chemoresistance in pancreatic cancer cells. These studies strongly suggest 
that deregulated levels of miRNA in pancreatic cancer can be exploited as putative 
therapeutic targets for overcoming pancreatic cancer drug resistance. 
5.2 Stem cell signaling 
Some studies have suggested that a tumor comprises of heterogeneous populations of cells 
rather than just homogenous cell types. One subset is suggested to be distinct cells that have 
limited proliferative capacity but are responsible for initiation, progression and 
differentiation of cancer cells. Due to their ability to self-renew and differentiate like stem 
cells, these cells are termed as “cancer stem cells.” There have been attempts with some 
successes to isolate the cancer stem cells so that they can be employed to elucidate genotypic 
and phenotypic characteristics as well as develop effective therapies to target to them 
because of their ability to self-renew and their resistance to conventional chemo- and/or 
radiation therapies.  
Li et al. ( 2007) isolated pancreatic cancer cells which were highly tumorigenic and had the 
ability to self-renew based on their cell surface markers. These cells (CD44*CD24* ESA*) 
comprises of 0.2-0.8% of all pancreatic cancer cells and were able to produce differentiated 
progeny. Similarly, Herman et al. (2007) isolated pancreatic cancer stem cells which were 
CD133+.  
The cancer stem cells are known to be resistant to conventional chemo-radiation therapies. 
Michor et al. showed that a subpopulation of chronic myeloid leukemia stem cells were 
resistant to imatinib (Michor, et al., 2005). In glioblastoma, enrichment of CD133+ cells was 
observed after treatment with ionizing radiation. These cells activate DNA damage response 
upon irradiation and therefore are resistant to ionizing radiation (Bao, et al., 2006). Similarly, 
enrichment of cells with stem cell characteristics is observed on treatment of pancreatic 
cancer with radio- or chemotherapy (Hermann, et al., 2007; Li, et al., 2007). 
5.3 Natural compounds for reversing resistance 
Dietary habit of individuals has been correlated with development of pancreatic cancer. 
High cholesterol diet increases the risk of pancreatic cancer (Baghurst, et al., 1991; Ghadirian, 
et al., 1991; Howe, et al., 1992; Stolzenberg-Solomon, et al., 2002). Diet rich in fruits and 
vegetables is associated with reduced risk while intake of red meat is associated with 
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increased risk of developing pancreatic cancer (Boyle, et al., 1989; Inoue, et al., 2003; Ohba, et 
al., 1996; Tavani, et al., 2000).  
Various natural compounds have been tested for their anti-pancreatic cancer properties in 
laboratory settings. Kunnumakkara et al. (2001) showed that curcumin inhibits NFκB 
activation and increases the cytotoxicity of gemcitabine in vitro and in vivo. That study also 
found that curcumin decreases the microvascular density thereby decreasing angiogenesis 
(Kunnumakkara, et al., 2007). NFκB is involved in mediating resistance against gemcitabine 
and TRAIL, which may explain the increase in cytotoxicity. Curcumin also increased the 
accumulation of MRP5 substrate intracellularly in MRP5 positive cells; however, in the 
absence of MRP5, drug accumulation was not observed. Additionally, curcumin increased 
the cell’s sensitivity to 5FU (Li, et al., 2010). Furthermore, hydroethanolic extract of curcumin 
(Tumeric Force) was more effective than curcumin in this effect. 
Another group of natural compounds which are currently being investigated are 
isoflavones. One of the most well studied isoflavones, genistein has been tested extensively 
in pancreatic cancer. Various groups have shown that treatment with genistein controls 
proliferation, mitogenic signaling, invasion, migration and induces apoptosis in pancreatic 
cancer. Benerjee et al (2007) showed that genistein augments in vitro and in vivo efficacy of 
cisplatin in pancreatic cancer (Banerjee, et al., 2007). Previously, genistein was known to 
affect the activation of NFκB via the Akt pathway(El-Rayes, et al., 2006), which have been 
shown to be involved in pancreatic cancer drug resistance. Natural compounds (e.g., 
genistein, curcumin) have also been shown to inhibit the hedgehog and Notch signaling 
which provide the cancer cells with stem-cell like property of self-renewal and resistance 
(Slusarz, et al., 2010). A recent study noted upregulation of FOXM1, increased EMT, and 
cancer stem cell phenotype in pancreatic cancer (Bao, et al., 2011a). Treatment with natural 
compounds also reduced the levels of FOXM1 in pancreatic cancers. 
Apart from the above mentioned approaches and based on the literature cited in this 
chapter, there are some other strategies to overcome resistance including potential targets 
and areas for drug discovery like developing agents that regulate Nrf2 activity selectively in 
tumor cells, agents that inhibit interaction between mucin MUC4 and HER2, selective 
inhibition of hedge hog pathway in the tumor cells, selective inhibition of PI3K/Akt 
pathway in tumor cells, combination of anti-NFkB agents with gemcitabine and Zeb1 
silencing. Targeting sphingolipid metabolism is another approach to overcome resistance to 
gemcitabine (Guillermet-Guibert, et al., 2009). Recent renewed interests in the metabolic 
phenotypes of pancreatic and other cancers have raised possibilities of metabolic pathway(s) 
as drug targets for new anti-cancer drug discovery. 
6. Conclusions 
Although these strategies to overcome resistance to drugs are crucial for improving the 
outcome of chemotherapy, there is an urgent need to achieve early detection of pancreatic 
cancer. Finding novel biomarkers for detecting pancreatic cancer should be emphasized. 
Recent renewed interests in the metabolic phenotypes of pancreatic and other cancers have 
raised possibilities of metabolic pathway(s) as targets for strategies for developing agents for 
early tumor detection to addition to exploiting them as targets for new anti-cancer drug 
discovery. 
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increased risk of developing pancreatic cancer (Boyle, et al., 1989; Inoue, et al., 2003; Ohba, et 
al., 1996; Tavani, et al., 2000).  
Various natural compounds have been tested for their anti-pancreatic cancer properties in 
laboratory settings. Kunnumakkara et al. (2001) showed that curcumin inhibits NFκB 
activation and increases the cytotoxicity of gemcitabine in vitro and in vivo. That study also 
found that curcumin decreases the microvascular density thereby decreasing angiogenesis 
(Kunnumakkara, et al., 2007). NFκB is involved in mediating resistance against gemcitabine 
and TRAIL, which may explain the increase in cytotoxicity. Curcumin also increased the 
accumulation of MRP5 substrate intracellularly in MRP5 positive cells; however, in the 
absence of MRP5, drug accumulation was not observed. Additionally, curcumin increased 
the cell’s sensitivity to 5FU (Li, et al., 2010). Furthermore, hydroethanolic extract of curcumin 
(Tumeric Force) was more effective than curcumin in this effect. 
Another group of natural compounds which are currently being investigated are 
isoflavones. One of the most well studied isoflavones, genistein has been tested extensively 
in pancreatic cancer. Various groups have shown that treatment with genistein controls 
proliferation, mitogenic signaling, invasion, migration and induces apoptosis in pancreatic 
cancer. Benerjee et al (2007) showed that genistein augments in vitro and in vivo efficacy of 
cisplatin in pancreatic cancer (Banerjee, et al., 2007). Previously, genistein was known to 
affect the activation of NFκB via the Akt pathway(El-Rayes, et al., 2006), which have been 
shown to be involved in pancreatic cancer drug resistance. Natural compounds (e.g., 
genistein, curcumin) have also been shown to inhibit the hedgehog and Notch signaling 
which provide the cancer cells with stem-cell like property of self-renewal and resistance 
(Slusarz, et al., 2010). A recent study noted upregulation of FOXM1, increased EMT, and 
cancer stem cell phenotype in pancreatic cancer (Bao, et al., 2011a). Treatment with natural 
compounds also reduced the levels of FOXM1 in pancreatic cancers. 
Apart from the above mentioned approaches and based on the literature cited in this 
chapter, there are some other strategies to overcome resistance including potential targets 
and areas for drug discovery like developing agents that regulate Nrf2 activity selectively in 
tumor cells, agents that inhibit interaction between mucin MUC4 and HER2, selective 
inhibition of hedge hog pathway in the tumor cells, selective inhibition of PI3K/Akt 
pathway in tumor cells, combination of anti-NFkB agents with gemcitabine and Zeb1 
silencing. Targeting sphingolipid metabolism is another approach to overcome resistance to 
gemcitabine (Guillermet-Guibert, et al., 2009). Recent renewed interests in the metabolic 
phenotypes of pancreatic and other cancers have raised possibilities of metabolic pathway(s) 
as drug targets for new anti-cancer drug discovery. 
6. Conclusions 
Although these strategies to overcome resistance to drugs are crucial for improving the 
outcome of chemotherapy, there is an urgent need to achieve early detection of pancreatic 
cancer. Finding novel biomarkers for detecting pancreatic cancer should be emphasized. 
Recent renewed interests in the metabolic phenotypes of pancreatic and other cancers have 
raised possibilities of metabolic pathway(s) as targets for strategies for developing agents for 
early tumor detection to addition to exploiting them as targets for new anti-cancer drug 
discovery. 
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1. Introduction 
It is an intriguing problem whether human cells and/or bodies have the physiological 
function which supervises and selects survival and death fate in response to various kinds 
of stressors such as radiation. For example, what are the physiological effects of X-ray 
irradiation for examination of breast conditions including the risk of genetic mutation and 
cancer occurrence (Fig. 1A).  
Based on a protease-activation signal in E.Coli SOS response we have attempted to search for 
human SOS response, particularly signals which protect stability of genetic information 
(Fig.1B) by estimation of plasminogen activator-like protease (PA) activity in peripheral blood-
derived lymphocytes and cultured human RSa cells with hyper-mutability and their variant 
hypo-mutable cells (Fig.1C) (Suzuki et al., 2005). Levels of PA activity in lymphocytes are 
changed after X-ray irradiation for breast examination and after exposure in vitro to chemical 
such as bisphenol A (Takahashi et al., 2000). The activity in variant cells was found to be 
associated with heat shock protein (HSP) 27 expression, resulting in enhancement of error-free 
DNA repair function (Wano et al., 2004). A HSP27-bound protein, annexin II, was also 
suggested to play some roles on the error-free function in human cell nuclei (Tong et al., 2008 
and Jin et al., 2009). We recently developed a method to analyze base substitution mutation of 
the K-ras codon 12 and found that a decreased mutation frequency accompanied increased 
GRP78 expression in human RSa cells (Hirano et al., 2008 and Zhai et al., 2005). The repair 
function seems to suppress base substitution mutation of K-ras codon 12. The base substitution 
mutation was also found to be regulated by extracellular factors, human interferon and serum 
factors from cancer patients and stressors-exposed persons (Suzuki et al., 2005, Hirano et al., 
2008 and Chi et al., 2007). This regulation seems to be mediated by PA activation and the 
following chaperones expression (Suzuki et al., 2005, Isogai et al., 1994, Takahashi et al., 2003 
and Kita et al., 2009). Thus, studies on molecular mechanisms to supervise cellular mutability, 
including frequency of Ras gene mutation, are important for discussion about relationships 
with a network of proteases and chaperones and/or cytokines. 
* Shigeru Sugaya1, Qian Ren1, Tetsuo Sato1, Takeshi Tanaka1, Fujii Katsunori2, Kazuko Kita1 
and Nobuo Suzuki1 
1Department of Environmental Biochemistry, Graduate School of Medicine, Chiba University, Inohana 1-8-1 
Chuo-ku, Chiba, Japan 
2Department of Pediatrics, Chiba University Graduate School of Medicine, Chiba, Japan 
Pancreatic Cancer – Molecular Mechanism and Targets 160 
Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, Ali S, Abbruzzese JL, Gallick GE, 
Sarkar FH (2009). Acquisition of epithelial-mesenchymal transition phenotype of 
gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch 
signaling pathway. Cancer Res 69:2400-2407. 
Wellner U, Brabletz T, Keck T (2010). ZEB1 in Pancreatic Cancer. Cancers 2:1617-1628. 
Wey JS, Gray MJ, Fan F, Belcheva A, McCarty MF, Stoeltzing O, Somcio R, Liu W, Evans DB, 
Klagsbrun M, Gallick GE, Ellis LM (2005). Overexpression of neuropilin-1 promotes 
constitutive MAPK signalling and chemoresistance in pancreatic cancer cells. Br J 
Cancer 93:233-241. 
Williams TK, Costantino CL, Bildzukewicz NA, Richards NG, Rittenhouse DW, Einstein L, 
Cozzitorto JA, Keen JC, Dasgupta A, Gorospe M, Gonye GE, Yeo CJ, Witkiewicz 
AK, Brody JR (2010). pp32 (ANP32A) Expression Inhibits Pancreatic Cancer Cell 
Growth and Induces Gemcitabine Resistance by Disrupting HuR Binding to 
mRNAs. PLoS ONE 5:e15455. 
Wohlhueter RM, McIvor RS, Plagemann PG (1980). Facilitated transport of uracil and 5-
fluorouracil, and permeation of orotic acid into cultured mammalian cells. J Cell 
Physiol 104:309-319. 
Wu CP, Calcagno AM, Ambudkar SV (2008). Reversal of ABC drug transporter-mediated 
multidrug resistance in cancer cells: evaluation of current strategies. Current 
Molecular Pharmacology 1:93-105. 
Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG, Korc M (1993). Coexpression of 
epidermal growth factor receptor and ligands in human pancreatic cancer is 
associated with enhanced tumor aggressiveness. Anticancer Res 13:565-569. 
Yao J, Qian C (2010). Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic 
cancer through an inactivation of PI3K/Akt-dependent pathway. Med Oncol 
27:1017-1022. 
Yokoi K, Fidler IJ (2004). Hypoxia increases resistance of human pancreatic cancer cells to 
apoptosis induced by gemcitabine. Clin Cancer Res 10:2299-2306. 
Zhang N, Yin Y, Xu SJ, Chen WS (2008). 5-Fluorouracil: mechanisms of resistance and 
reversal strategies. Molecules 13:1551-1569. 
Zhang Y, Li M, Wang H, Fisher WE, Lin PH, Yao Q, Chen C (2009). Profiling of 95 
microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR 
analysis. World J Surg 33:698-709. 
Zhao Y, Shen S, Guo J, Chen H, Greenblatt DY, Kleeff J, Liao Q, Chen G, Friess H, Leung PS 
(2006a). Mitogen-activated protein kinases and chemoresistance in pancreatic 
cancer cells. Journal of Surgical Research 136:325-335. 
Zhao Y, Shen S, Guo J, Chen H, Greenblatt DY, Kleeff J, Liao Q, Chen G, Friess H, Leung PS 
(2006b). Mitogen-activated protein kinases and chemoresistance in pancreatic 
cancer cells. J Surg Res 136:325-335. 
9 
Prevention of Pancreatic Cancer 
Xia Jiang et al.*   
Department of Environmental Biochemistry, Graduate School of Medicine,  
Chiba University, Inohana 1-8-1 Chuo-ku, Chiba,  
Japan 
1. Introduction 
It is an intriguing problem whether human cells and/or bodies have the physiological 
function which supervises and selects survival and death fate in response to various kinds 
of stressors such as radiation. For example, what are the physiological effects of X-ray 
irradiation for examination of breast conditions including the risk of genetic mutation and 
cancer occurrence (Fig. 1A).  
Based on a protease-activation signal in E.Coli SOS response we have attempted to search for 
human SOS response, particularly signals which protect stability of genetic information 
(Fig.1B) by estimation of plasminogen activator-like protease (PA) activity in peripheral blood-
derived lymphocytes and cultured human RSa cells with hyper-mutability and their variant 
hypo-mutable cells (Fig.1C) (Suzuki et al., 2005). Levels of PA activity in lymphocytes are 
changed after X-ray irradiation for breast examination and after exposure in vitro to chemical 
such as bisphenol A (Takahashi et al., 2000). The activity in variant cells was found to be 
associated with heat shock protein (HSP) 27 expression, resulting in enhancement of error-free 
DNA repair function (Wano et al., 2004). A HSP27-bound protein, annexin II, was also 
suggested to play some roles on the error-free function in human cell nuclei (Tong et al., 2008 
and Jin et al., 2009). We recently developed a method to analyze base substitution mutation of 
the K-ras codon 12 and found that a decreased mutation frequency accompanied increased 
GRP78 expression in human RSa cells (Hirano et al., 2008 and Zhai et al., 2005). The repair 
function seems to suppress base substitution mutation of K-ras codon 12. The base substitution 
mutation was also found to be regulated by extracellular factors, human interferon and serum 
factors from cancer patients and stressors-exposed persons (Suzuki et al., 2005, Hirano et al., 
2008 and Chi et al., 2007). This regulation seems to be mediated by PA activation and the 
following chaperones expression (Suzuki et al., 2005, Isogai et al., 1994, Takahashi et al., 2003 
and Kita et al., 2009). Thus, studies on molecular mechanisms to supervise cellular mutability, 
including frequency of Ras gene mutation, are important for discussion about relationships 
with a network of proteases and chaperones and/or cytokines. 
* Shigeru Sugaya1, Qian Ren1, Tetsuo Sato1, Takeshi Tanaka1, Fujii Katsunori2, Kazuko Kita1 
and Nobuo Suzuki1 
1Department of Environmental Biochemistry, Graduate School of Medicine, Chiba University, Inohana 1-8-1 
Chuo-ku, Chiba, Japan 
2Department of Pediatrics, Chiba University Graduate School of Medicine, Chiba, Japan 





























































Fig. 1. Strategy of the method to search for human SOS response. 
(A) A question concerning X-ray effects on genetic mutation and the following cancer. (B) A 
physiological function which supervises protection mechanisms for genetic information 
stability. (C) Modulation of cellular fate by serum factors and plasminogen activator-like 
protease (PA) activation, elucidated by the observation of peripheral blood lymphocytes and 
cultured human cells after stressors exposure. 
Incidence of K-ras gene mutation is high in pancreatic carcinomas, and therefore suppression 
of the mutation could be beneficial for inhibiting pancreatic cancer occurrence (Hirano et al., 
2008). We were intrigued by the possibility that this carcinogen-induced mutation could be 
suppressed, via modulation of GRP78 expression, by agents such as foods. 
In the present chapter, cellular levels of GRP78 in RSa cells that had been cultured with 
aqueous extracts of Japanese miso and the unfermented ingredients of miso are shown 
using immunoblotting analysis. The mutability of the treated cells are also evaluated after 
ultraviolet light C (UVC)(principally 254 nm in wave length) irradiation using the 
differential dot-blot hybridization test for K-ras codon 12 mutation. In previous reports, 
dietary supplementation with long-term fermented miso has been shown to act as a 
chemopreventive agent against gastric and colon carcinogenesis in rats (Ohara et al., 2002a, 
2002b, and Ohuchi et al., 2005). Miso is a fermented food that has formed an important part 
of the Japanese diet for over 1300 years (Yoshikawa et al., 1998). It is prepared by the 
microbial fermentation of a mixture of raw materials (soybean, wheat, barley and rice) over 
C
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a long period until the ripe miso is obtained (Hesseltine ＆ Shibasaki,1961). Little is known 
about the ability of miso to modulate the mutability of human cells. 
2. Human SOS response and suppression of K-ras mutation by Japanese 
miso possibly via GRP78 expression in human RSa cells 
2.1 Effect of miso samples on RSa cell viability 
2.1.1 Preparation of miso samples 
The Japanese Enbunhikae miso (EM) was purchased from Marui Co., Ltd. (Chino, Japan). 
Rice-koji, a raw material used in the preparation of miso, was obtained from Hanamaruki 
Co., Ltd (Nagano, Japan). Aqueous extracts of miso and rice-koji were prepared as follows: 
each (10 g) was suspended in 20 ml of MilliQ water, and the suspension was heated at 90 °C 
for 5 minutes and then at 70 °C for 10 minutes. The suspension was centrifuged at 1,780 x g 
and 4 °C for 10 minutes and the supernatant was then filtered through a 0.22 μm membrane. 
The dose of sample used in each treatment is shown as a percentage of volume per volume 
(v/v); 1% is equivalent to 5 mg of miso or rice-koji per ml. 
2.1.2 Culture conditions and UVC irradiation 
RSa cells were established from human embryo-derived fibroblast cells by double infection 
with the Simian virus 40 and the Rous sarcoma virus. The cells were confirmed to have high 
UV sensitivity and low DNA-repair activity (Kuwata et al., 1976, Suzuki ＆ Fuse, 1981, 
Suzuki,1984). Cells were cultured in Eagle's minimal essential medium (EMEM) ( Nissui, 
Tokyo, Japan) containing 10% calf serum (CS) (Invitrogen, Carlsbad, CA, USA) at 37 °C in a 
humidified atmosphere containing 5% CO2. UVC was generated by a 6 W National 
germicidal lamp (Panasonic, Osaka, Japan). The intensity of UVC was 1 J/m2/s, as 
measured by a UV radiometer, UVR-254 (Tokyo Kogaku Kikai, Tokyo, Japan). Irradiation of 
the cells with UVC was performed as described previously (Suzuki ＆ Fuse, 1981) and mock 
irradiation of cells was carried out in the same manner but without UVC irradiation. 
2.1.3 Colony survival assay 
To determine the optimal concentration of miso sample for use in the culture medium in cell 
mutability tests, the colony survival capacity of RSa cells cultured with or without EM 
extracts was examined (Fig. 2). The survival capacity of cells treated with or without miso 
extracts was measured using a colony survival assay as reported previously (Suzuki et al., 
1984). Logarithmically growing cells were seeded in 100 mm dishes (800 cells/dish), 
incubated for 20 h to allow the cells to attach, and then treated with or without miso 
extracts. One h after treatment, the cells were grown in fresh medium containing 5% CS in 
100 mm dishes for about 14 d and were then stained with 0.2% methylene blue in 30% 
methanol. The results of the colony survival assay are expressed as percentages of the 
colony numbers observed for miso extracts-treated cells relative to those of untreated cells. 
Colony survival rates were over 85% when a miso extract concentration of 1% was used, but 
at concentrations higher than 1% a decrease of more than 10% in survival rate was observed 
(Fig. 2). An MTT assay showed that miso extract concentrations of less than 1% were not 
cytotoxic after 48 h of culture (data not shown). 





























































Fig. 1. Strategy of the method to search for human SOS response. 
(A) A question concerning X-ray effects on genetic mutation and the following cancer. (B) A 
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Fig. 2. Effect of EM extracts on cell survival. 
RSa cells were treated with or without the indicated concentrations of EM extracts for 1 h. 
After treatment, the cells were cultured with fresh medium containing 5% CS in 100 mm 
dishes for 14 d and were then stained with 0.2% methylene blue in 30% methanol. Data are 
the means ±SD for three experiments. 
2.2 Effect of miso extracts on GRP78 expression and the mutability of RSa cells 
2.2.1 GRP78 expression 
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mM EGTA, 0.5% NP-40 and protease inhibitors, 1 mM phenylmethylsulfonyl fluoride, 0.05 
mM leupeptin, 0.05 mM antipain and 0.05 mM pepstain A. The cell lysates were centrifuged at 
15,000 × g and 4 °C for 20 min, and the supernatant was then treated with SDS sample buffer. 
Detection of the GRP78 protein was performed using mouse monoclonal anti-GRP78 (1:2000 
dilution; SPA-827; StressGen, Victoria, Canada) antibodies. β-Actin was also analyzed using 
mouse monoclonal anti-β-actin antibodies (1:30000 dilution; ab40864; Abcam, Cambridge, UK) 
as a loading control. The antigen-antibody complexes were detected by horseradish 
peroxidase (HRP) conjugated anti-mouse IgG (Amersham Biosciences, Buckinghamshire, UK) 
following the ECL system (GE Healthcare, Buckinghamshire, UK). The GRP78 protein was 
quantified using Multi Gauge Ver2.2 image analysis software (Fuji Foto film, Tokyo, Japan) 
and expressed relative to the quantity of β-actin measured. When RSa cells were cultured with 
EM extracts at a concentration of 1%, expression of GRP78 was enhanced by over 1.5 fold 
compared with the expression observed in mock-treated cells (Fig 3A). 
2.2.2 Mutability 
Mutations in K-ras codon 12 were detected according to a method described previously 
(Suzuki N ＆ Suzuki H., 1993). Logarithmically growing cells were inoculated at near 
confluency (5×l05 cells/100 mm dish) to avoid cell selection by the lethal effects of UVC 
irradiation, as described elsewhere (Suzuki N ＆ Suzuki H., 1995). Six d after UVC  
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as described in Materials and Methods. 
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codon 12 was used as a positive control for genomic DNA. Target sequences of sample DNA  
were amplified in vitro by PCR using the primers 5’-GACTGAATATAAACTTGTGG-3’ and 
5’-CTATTGTTGGATCATATTCG-3’, and the amplified DNA (0.25 μg) was dot-blotted onto 
nylon membranes. After hybridization with digoxigenin-11-dUTP-3’ end-labeled K-ras 
codon 12 probes, the membranes were reacted with alkaline phosphatase conjugated 
polyclonal sheep anti-Dig Fab (Boehringer Ingelheim, Mannheim, Germany) and colored 
with the nitro blue tetrazolium chloride and 5-bromo-4-chloro-3-indolyl phosphate solution 
(Boehringer Ingelheim, Mannheim, Germany). As a control probe, the oligonucleotide 5’- 
GTTGGAGCTGGTGGCGTAGG-3’ was used, and a mixed mutant probe, containing the 
following oligonucleotides mixed at the same concentration ratios,  
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GTTGGAGCTGCTGGCGTAGG-3’, 5’-GTTGGAGCTGTTGGCGTAGG-3’. Photographs 
were taken as permanent records of the results. To determine whether miso extracts 
suppress the mutability of RSa cells, the K-ras codon 12 mutation assay was performed. A 
black dot, indicating base substitution mutation, was detected after hybridization of the PCR 
products from genomic DNA of SW480 cells containing the K-ras codon 12 mutation, and 
this was used as a positive control (Fig. 3B). Under the assay conditions, the intensity of the 
black dot was clearly enhanced after UVC irradiation in mock-treated RSa cells (Fig. 3B). 
However, EM extracts-treated RSa cells did not show black dot signals either after UVC or 
mock irradiation (Fig. 3B). 
2.3 Effect of GRP78 siRNA on the modulation of UVC cell mutability by miso extracts 
To further examine whether GRP78 expression levels are causally related to the miso 
treatment modulation of RSa cells mutability, its expression was inhibited by GRP78 siRNA 
transfection. Duplex small interfering RNA (siRNA) with Stealth modification against 
human GRP78 (GRP78 siRNA) was synthesized based on the protein’s nucleotide sequence 
(Invitrogen), as described previously (Suzuki T et al., 2007). The sequence of the duplex was  
 
  
Fig. 4. Effect of GRP78 siRNA transfection on UVC-induced mutagenicity. 
(A) After GRP78 or NC siRNA transfection, cell lysates were separated by SDS–PAGE and 
analyzed by immunoblotting analysis using anti-GRP78 and anti-β-actin (loading control) 
antibodies. (B) After siRNA transfection, cells were treated with or without EM extracts for 
24 h and then irradiated with UVC (6 J/m2). Mutability of RSa cells was determined by the 
K-ras codon 12 mutation assay using PCR and differential dot-blot hybridization, as 
described in Materials and Methods. 
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as follows: 5’-UAC CCU UGU CUU CAG CUG UCA CUC G-3’ / 3’-AUG GGA ACA GAA 
GUC GAC AGU GAG C-5’. Stealth RNAi negative control duplex (NC siRNA), with a GC 
content similar to that of the above Stealth RNAi, was used as a negative control. The NC 
siRNA was designed to minimize sequence homology to any known vertebrate transcript 
and for use in RNA interference (RNAi) experiments as a control for sequence independent 
effects following Stealth RNAi delivery in any vertebrate cell line. Treatment of cells with 
siRNA was carried out as described previously (Harborth et al., 2001), with minor 
modifications. The siRNAs (128 nM) were transfected for 5 h into RSa cells using 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. The cells were 
detached from the test dish 48 h after transfection and used for each experiment. 
In GRP78 siRNA-transfected cells, cellular levels of GRP78 protein were decreased in EM 
extracts-treated cells as well as in mock-treated cells, while no decrease was observed in NC 
siRNA-transfected cells (Fig. 4A). The decrease observed was up to 50% of the NC siRNA 
control (Fig. 4A). In RSa cells with GRP78 siRNA transfection that had been treated with 
miso extracts, the dot signal of K-ras codon 12 mutation was enhanced after UVC irradiation 
(Fig. 4B). 
2.4 Effect of miso components on cell mutability 
The effect of rice-koji, a component of miso, on the mutability of RSa cells was examined. 
The survival rate, measured by a colony survival assay (Fig. 5) and an MTT assay (data not 
shown), of cells treated with rice-koji at concentrations of less than 10% were more than 
80%. On the basis of these results, we used 1% rice-koji in subsequent experiments to allow 
direct comparison with experiments using EM extracts. 
 
Fig. 5. Effect of rice-koji on cell survival.  
RSa cells were treated at the indicated concentrations with rice-koji. After rice-koji treatment 
(1h) cells were grown in fresh medium containing 5% CS in 100 mm dishes for about 14 d, 
and then stained with 0.2% methylene blue in 30% methanol. Data are the means ±SD for 
three experiments. 
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Expression levels of GRP78 in rice-koji-treated RSa cells were slightly increased, at about 1.5 
fold of the untreated cells (Fig. 6A). Rice-koji-treated cells showed no detectable black dot 




Fig. 6. Effect of rice-koji on GRP78 expression and mutability. 
(A) Cells were treated with rice-koji (1%) for 24 h, and the cell lysates were subjected to 
immunoblotting analysis of GRP78 and β-actin proteins. (B) After rice-koji treatment, cells 
were irradiated with UVC (6 J/m2). Six d after UVC irradiation genomic DNA was 
extracted, and the K-ras codon 12 mutation was detected using PCR and differential dot-blot 
hybridization. 
We also examined whether GRP78 siRNA transfection affected UVC mutagenicity in rice-
koji-treated RSa cells. In GRP78 siRNA-transfected cells, GRP78 expression levels decreased 
to about 40% of those in NC siRNA-transfected cells (Fig. 7A). Cells transfected with GRP78 
siRNA and then treated with rice-koji, showed black dot signals indicating UVC-induced K-
ras codon 12 mutation, similar to the signal observed in cells treated with UVC irradiation 
alone, and in SW480 cells (Fig. 7B). 
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Fig. 7. Effect of GRP78 siRNA transfection on UVC-induced mutagenicity in rice-koji treated 
cells. 
(A) After GRP78 or NC siRNA transfection, cell lysates were separated by SDS–PAGE and 
analyzed by immunoblotting analysis using anti-GRP78 and anti-β-actin (loading control) 
antibodies. (B) After siRNA transfection, cells were treated with or without rice-koji extracts 
for 24 h and then irradiated with UVC (6 J/m2). Mutability of RSa cells was determined by 
the K-ras codon 12 mutation assay using PCR and differential dot-blot hybridization. 
3. Conclusion 
The K-ras base substitution mutation is thought to be a cancer-causing DNA sequence 
change in human cells, and its incidence is particularly high in pancreatic carcinomas. We 
previously found that proteases are activated in stress-exposed cells and/or human 
bodies, leading to modulation of chaperone expression and cellular mutability (so-called 
SOS response). Increased levels of glucose-regulated protein 78 (GRP78) expression are 
associated with the suppression of the K-ras mutation in human RSa cells irradiated with 
ultraviolet C UVC. RSa cells are hyper-mutable and are used to examine the modulation 
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of cell mutability using various agents. Here, we describe investigations into the effect of 
RSa cell treatment with Japanese miso on GRP78 expression and the suppression of UVC 
mutagenicity. Aqueous extracts of miso and its components were tested. Miso treatment 
was found to increase GRP78 levels, as estimated by immunoblotting analysis, and to 
decrease UVC-induced K-ras codon 12 base substitution mutation frequency. Increases in 
GRP78 expression and decreases in mutation frequency were not observed in cells whose 
GRP78 levels had been down-regulated using GRP78 siRNA transfection. This suggests 
that miso extracts suppress UVC mutagenicity by increasing GRP78 expression in human 
cells. 
In the present study Japanese miso was tested concerning the modulation activity of genetic 
mutation, K-ras codon 12 base substitution mutation, in addition of human cytokines and 
serum factors. Several dietary factors have been postulated to act as risk factors for human 
carcinogenesis (Sugimura, 2000 and Mirvish, 1983). In Japan, intensive studies of the causal 
relationship between diet and cancer incidence have focused on stomach, lung and 
colorectal cancers (Masaki et al., 2003, Ngoan et al., 2002, Takezaki et al., 2001, Ozasa et al., 
2001, Tajima ＆ Tominaga, 1985). The association of dietary factors with pancreatic cancer 
has been significantly less well studied. In this study, the modulation of cell mutability via 
the GRP78 chaperone was examined by measuring GRP78 expression in Japanese miso-
treated human RSa cells. It was found that levels of GRP78 expression increased upon 
treatment of RSa cells with EM and rice-koji extracts (Figs. 3A and 6A). The pretreatment of 
cells with these extracts was also found to suppress UVC mutagenicity (Figs. 3B and 6B). An 
intimate relationship between GRP78 up-regulation and hypo-mutability was also 
suggested by the results of experiments using GRP78 silencing (Figs. 4 and 7). 
We reported that the down-regulation of GRP78 in RSa cells reduces DNA repair capacity 
in the nucleotide excision repair pathway. Nucleotide excision repair, a highly conserved 
DNA repair system in human cells, is essential for protection against UVC-induced DNA 
damage leading to, for example, (6-4)-photoproducts and cyclobutane thymine dimmers 
(Batty ＆ Wood, 2000, de Laat et al., 1999). Thus, one plausible mechanism for the 
observed hypo-mutable change in RSa cells pre-cultured with miso and rice-koji extracts 
may be the enhancement of cellular DNA repair function by the up-regulation of GRP78 
expression.  
The K-ras point mutation-enhancing activity of conditioned medium is detected from 
culture of human pancreatic cancer cells (Hirano et al., 2008), suggesting involvement of 
extracellular factors from pancreatic cancer cells in tumor-worsening process. Extracellular 
materials released from cancer cells play crucial roles in development of cancers and 
resistance to anticancer treatment (Hidalgo et al., 2010). Pancreas carcinoma shows 
resistance to chemotherapeutic agents (Gong et al., 2010). Thus, we tried to search for the 
above materials in conditioned medium from pancreatic cancer cells, and identified one of 
HSP27-bound proteins, annexin II, by molecular mass analysis. Although the functions of 
extracellular annexin II are not fully understood, annexin II is known to act as a cell surface 
receptor for extracellular ligands and is suggested to play roles in regulation of proteolytic 
cascades including PA activities (Hajjar et al., 1994), signal transduction (Singh, 2007), and 
tumor invasion and metastasis (Chung et al., 1996, Esposito et al., 2006, Singh et al., 2007, Mai 
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et al., 2000). Studies on the mechanisms of PA-involved SOS functions are required for 
prevention of pancreatic cancer. 
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above materials in conditioned medium from pancreatic cancer cells, and identified one of 
HSP27-bound proteins, annexin II, by molecular mass analysis. Although the functions of 
extracellular annexin II are not fully understood, annexin II is known to act as a cell surface 
receptor for extracellular ligands and is suggested to play roles in regulation of proteolytic 
cascades including PA activities (Hajjar et al., 1994), signal transduction (Singh, 2007), and 
tumor invasion and metastasis (Chung et al., 1996, Esposito et al., 2006, Singh et al., 2007, Mai 
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et al., 2000). Studies on the mechanisms of PA-involved SOS functions are required for 
prevention of pancreatic cancer. 
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Pancreatic adenocarcinoma (PCA), although infrequent, is one of the most lethal human 
malignancies. PCA ranks fourth in the Western countries and sixth worldwide among the 
most common cancer-related mortality based on GLOBOCAN 2008 (Jemal et al. 2011). 
Worldwide, an estimated 277,000 new cases of PCA were diagnosed in 2008 (Ferlay et al. 
2008). In 2011, 44,000 new cases of PCA will be identified and 37,700 individuals will die 
from this disease in the US (Siegel et al. 2011). The nearly 1:1 ratio of incidence to mortality 
clearly implicates a poor prognosis and the lethal nature of PCA, which is the result of the 
difficulty of early diagnosis, early local spread, distant metastasis and resistance to 
traditional chemotherapy and radiotherapy. The overall five-year survival rate is estimated 
to be within the range of 1–4%, much lower than that of other types of cancers (Jemal et al. 
2011). Up to the present time, the standard treatment for PCA is surgical extirpation, which 
may improve the overall five-year survival rate to 10-29% (Trede et al. 1990; Nitecki et al. 
1995; Yeo et al. 1997). However, 40% of PCA patients already had distant metastasis at the 
time of diagnosis and another 40% were diagnosed with locally advanced cancer (Haller 
2003; Jemal et al. 2011; Siegel et al. 2011), excluding them from being good candidates for 
resection.  
Although the definite causes of pancreatic cancer are still poorly understood, several 
environmental risk factors have been implicated. Abundant epidemiological studies have 
indicated that the use of tobacco increases the risk of pancreatic cancer (Raimondi et al. 
2009) and increased incidence of pancreatic cancer is positively associated with frequency 
and length of tobacco exposure (Hassan et al. 2007). A recent study based on a pooled 
analysis also concludes smoking is associated with an 18% increased risk of PCA (Lynch et 
al. 2009). On the other hand, the risk of PCA would dwindle after cessation of cigarette 
smoking for 10 years or longer (Iodice et al. 2008). Although alcohol has been related to 
increased risk of several types of cancers, the exact relationship between alcohol and PCA 
has not been established yet (Rohrmann et al. 2009; Jiao et al. 2009). A pooled analysis of 14 
cohort studies reported a positive relationship between pancreatic cancer and women 
consuming more than 30 g of alcohol per day (Genkinger et al. 2009). A recent meta-analysis 
study also indicates that a 22% increased risk of PCA is observed in subjects with heavy 
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clearly implicates a poor prognosis and the lethal nature of PCA, which is the result of the 
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2011). Up to the present time, the standard treatment for PCA is surgical extirpation, which 
may improve the overall five-year survival rate to 10-29% (Trede et al. 1990; Nitecki et al. 
1995; Yeo et al. 1997). However, 40% of PCA patients already had distant metastasis at the 
time of diagnosis and another 40% were diagnosed with locally advanced cancer (Haller 
2003; Jemal et al. 2011; Siegel et al. 2011), excluding them from being good candidates for 
resection.  
Although the definite causes of pancreatic cancer are still poorly understood, several 
environmental risk factors have been implicated. Abundant epidemiological studies have 
indicated that the use of tobacco increases the risk of pancreatic cancer (Raimondi et al. 
2009) and increased incidence of pancreatic cancer is positively associated with frequency 
and length of tobacco exposure (Hassan et al. 2007). A recent study based on a pooled 
analysis also concludes smoking is associated with an 18% increased risk of PCA (Lynch et 
al. 2009). On the other hand, the risk of PCA would dwindle after cessation of cigarette 
smoking for 10 years or longer (Iodice et al. 2008). Although alcohol has been related to 
increased risk of several types of cancers, the exact relationship between alcohol and PCA 
has not been established yet (Rohrmann et al. 2009; Jiao et al. 2009). A pooled analysis of 14 
cohort studies reported a positive relationship between pancreatic cancer and women 
consuming more than 30 g of alcohol per day (Genkinger et al. 2009). A recent meta-analysis 
study also indicates that a 22% increased risk of PCA is observed in subjects with heavy 
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alcohol consumption (> 30g/day) (Tramacere 2010). High caloric intake and obesity are also 
identified to be risk factors for PCA (Reeves et al. 2007; Fryzek et al. 2005; Patel et al. 2005: 
Berrington de Gonzalez et al. 2003). While natural, plant-produced antioxidants, such as 
some flavonoids, are thought of traditional lyas protective factors for some cancers, their 
roles in PCA are still not established (Nothlings et al. 2007). Fruits and vegetables also failed 
to offer definitive protective benefit for PCA in a large-scaled cohort study (Vrieling et al. 
2009). Other risk factors, such as intake of coffee, use of aspirin, previous cholecystectomy, 
and history of diabetes or chronic pancreatitis, although less conclusive, may contribute to 
pancreatic cancer as well (Batty et al. 2009: Landi 2009; Lowenfels & Maisonneuve 2006). 
While investigating the incidence of PCA in different locations, a geographical variation has 
been observed; that is in the northern latitudes, the incidence of pancreatic cancer is three- to 
four-times higher than that in areas closer to equator (Curado et al. 2007). This finding has 
been attributed to sunlight or ultraviolet (UVB) exposure, which is directly related to 
vitamin D synthesis and the main determinant of vitamin D status in humans. In this 
regard, abundant epidemiologic studies have shown that vitamin D status is inversely 
associated with the incidence of some cancers such as prostate, colon and breast (Garland & 
Garland 1980; Gorham et al. 1990; Schwartz & Chen 2005). 
Recently, due to the dismal outcome of PCA treatments and resistance of PCA to available 
chemotherapy and radiotherapy, some new regimens or strategies have been developed. In 
this chapter, we describe the recent findings on the relationship between sunlight, vitamin D 
and pancreatic cancer incidence, the potential role of vitamin D analogues for the prevention 
and treatment of pancreatic cancer, and the metabolism and functions of vitamin D as well 
as a brief history of vitamin D. 
2. Current treatment of pancreatic cancer 
Currently, the standard treatment for resectable pancreatic cancer remains surgery, 
including radically resection of the primary tumor, surrounding tissues, as well as 
neighboring lymph nodes. However, as described above, only 20% of PCA patients are 
suitable candidates for operation when diagnosed with PCA (Haller 2003; Jemal et al. 2011; 
Siegel et al. 2011). After operation, adjuvant chemotherapy with either gemcitabine or a 
combination of fluorouracil and leucovorin is able to improve progression-free period and 
overall survival (Neoptolemos et al. 2004; Oettle et al. 2007; Regine et al. 2008). Combination 
of adjuvant chemotherapy and radiation therapy seems to increase overall survival; 
however, the results are not impressive (Herman et al. 2008). For unresectable pancreatic 
cancer, the principle of treatment is mainly palliative. The standard chemotherapy for this 
group of patients is gemcitamine alone (Renouf & Moore 2010). Once gemcitamine fails to 
provide benefit in this group of patients, according to National Comprehensive Cancer 
Network guidelines, capecitabine, FOLFOX, or a combination of capecitabine and oxliplatin 
should be considered (National Comprehensive Network guidelines 2008). It has been 
reported that in general PCA patients who respond poorly to the first line therapy may have 
an unfavorable response to the second line therapy as well (Herrmann et al. 2007). Recently, 
target therapy has gained attention for the treatment of certain cancers. However, at the 
present time, no suitable target therapy is available against PCA. Under these bleak 
conditions, the development of new therapies to treat PCA should be one of the priorities in 
cancer research. 
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3. History of vitamin D 
The discovery of vitamin D is closely associated with the disease rickets. Rickets was 
prevalent in the 17th century when two English physicians, Daniel Whistler and Francis 
Glisson described this deformality of bone in 1645 and 1650, respectively (Hess 1929). It was 
not until 1822, Sniadecki made an important observation relating the prevalence of rickets to 
locations of residence; lower incidence of rickets was found among children living on farms 
than children living in the city of Warsaw, Poland (Mozolowski, 1939). In 1889, Theodore 
Palm, a medical missionary and epidemiologist, reported that children living near the 
equator did not suffer from rickets and, thus, suggested sunbathing as a possible cure and 
strategy for rickets prevention (Palm 1890). Both of them attributed their finding of 
geographic differences in rickets incidence to varied exposures to sunlight. In 1919, Edward 
Mellanby successfully made dogs rachitic by keeping them indoors and feeding them with 
oats exclusively, followed by curing this disease with cod liver oil (Mellanby 1919). During 
that period, cod liver oil was used to treat night blindness and fracture. Mellanby did not 
know at that time whether the cure of rickets was attributed to the newly discovered 
vitamin A present in cod liver oil (McCollum et al., 1916) or another substance within. It was 
not until 1922 that McCollum clearly demonstrated that the anti-rachitic substance present 
in cod liver oil was a new substance and named it “vitamin D” (McCollum 1922). Around 
the same period, Huldshinsky in 1919 discovered that sunlight exposure could cure rachitic 
children (Huldshinsky 1919). Subsequently, there seemed to be a relationship between the 
cure of rickets by sunlight exposure and vitamin D in the cod liver oil. Steenbock and Black 
(1924) and Hess and Weinstock (1924) then noted independently that UV-irradiated food 
could cure rickets, which suggested that UV light was capable of transforming one 
substance stored in food to cure rickets. In other words, UV irradiation could produce 
vitamin D, which was responsible for the anti-rachitic activity found in food.  
Vitamin D was believed as biologically active for decades until DeLuca’s laboratory showed 
that injected radioactive vitamin D3 disappeared instantly in the circulation of rats and the 
label appeared again later in the blood. The major radioactive compound in the blood was 
isolated and tested for its ability in stimulating intestinal calcium transport (Norman et al. 
1964). His group reported that this unknown compound acted much quicker and had higher 
activity than the parent substance vitamin D3 (Morii et al. 1967), suggesting that vitamin D3 
might be further metabolized to become active. Subsequently, the unknown compound was 
isolated in pure form and identified as 25-hydroxyvitamin D3 [25(OH)D3] in 1968 (Blunt et 
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3. History of vitamin D 
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in the circulation. The subsequent conversion of 25(OH)D3 to the active form, 1α,25-
dihydroxyvitamin D3 [1α,25(OH)2D3], occurs in the kidneys and is catalyzed by a tightly 
regulated enzyme 25(OH)D-1α-hydroxylase (1α-OHase or CYP27B1). The active form then 
will be bound to DBP in the circulation and transported to its target organs, tissues and cells 
to induce gene transcription, including the up-regulation of CYP24A1 as shown in Figure 2. 
The activation of 25(OH)D3 may also take place in many extra-renal tissues, including 
pancreas, bone, breast, colon, prostate. The extra-renal synthesis of 1α,25(OH)2D may 
explain why serum 25(OH)D level, instead of the circulating level of the active form, 
1α,25(OH)2D, is the index of vitamin D nutritional status. 1α,25(OH)2D3, either obtained 
from the circulation or within the cells in an autocrine fashion, will be hydroxylated by 
CYP24A1 (or 24-OHase) to form 1α,24,25-trihydroxyvitamin D3 [1α,24,25(OH)3D3], the first 
step to inactivate 1α,25(OH)2D3, leading to the formation of calcitroic acid, which is water-
soluble and is secreted in the urine. 
4. Sources and metabolism of vitamin D 
Two major forms of vitamin D exist in nature: vitamin D2 and vitamin D3. Commonly, 
vitamin D2 (ergocalciferol) is produced from ergosterol of yeast and vitamin D3 
(cholecalciferol) is synthesized from 7-dehydrocholesterol (7-DHC) of lanolin. Vitamin D 
(representing D2 and D3) is rare in foods, only few foods contain sufficient vitamin D 
naturally (Chen et al. 2010). Therefore, fortification of vitamin D in foods, like orange juice, 
cheese, cereal and milk, is becoming popular in some countries. For most humans, exposure 
to sunlight remains the major source, accounting for about 90% of vitamin D requirement 
(Chen et al. 2010) (Figure 1). The basal and suprabasal layers of human skin contain 7-DHC, 
which can be converted to pre-vitamin D3 as the skin receives UV irradiation (wavelength 
290–315 nm). Pre-vitamin D3 is further thermoisomerized to vitamin D3 in the skin. Vitamin 
D, obtained from food (may contain vitamin D2 and/or vitamin D3) or synthesized from 
skin after exposure to sunlight, enters the blood circulation carried by vitamin D binding 
protein (DBP). Upon entering the liver, vitamin D is hydroxylated at the C-25, catalyzed by 
vitamin D-25-hydroxylase (25-OHase) (Schuster 2011), to produce 25(OH)D3. 25(OH)D is 
further hydroxylated by the enzyme 1α-OHase or CYP27B1 mainly in the renal proximal 
tubules at the C-1 position to form the active metabolite, 1α,25(OH)2D3. While 1α,25(OH)2D3 
is the active form and is responsible for the various biological activities exerted by vitamin 
D3, 25(OH)D3 is the major circulating form of vitamin D3 and is considered as the most 
reliable index of vitamin D nutritional status. 25(OH)D3 has the highest affinity for DBP and 
circulates as a DBP-bound form in the blood stream. Another renal enzyme, which also 
plays a crucial role in vitamin D metabolism, is 25(OH)D-24-hydroxylase (24-OHase or 
CYP24A1). CYP24A1 is responsible for the degradation of 1α,25(OH)2D3, forming 
1α,24,25(OH)3D3, and thus terminating the actions of 1α,25(OH)2D3. In addition, when there 
is an excess of 25(OH)D3, 24-OHase in the kidneys is capable of converting it into 
24,25(OH)2D3 to prevent the over-production of 1α,25(OH)2D3 (Schuster 2011). Of note, 
originally it was believed that CYP27B1 and CYP24A1 exist exclusively in the kidneys, the 
two enzymes have been found to express in many extra-renal tissues (Zehnder et al. 2001; 
Chen & Holick 2003; Schwartz et al. 2004; Kemmis et al. 2006; Chiang & Chen 2009), 
including the pancreas. Given that anephric individuals have no detectable 1α,25(OH)2D3 in 
their circulation, it is believed that extrarenal-generated 1α,25(OH)2D3 acts and is degraded 
only locally in an autocrine and paracrine manner. This autocrine/paracrine pathway seems 
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to be regulated in a tissue-specific manner and is not associated with systemic calcium 
homeostasis. Based on this theory, once 25(OH)D3 is internalized into the cells, the fate of 
25(OH)D3 may depend on the relative expression levels of CYP27B1 to CYP24A1. In the cells 
with dominant expression of CYP27B1, 25(OH)D3 will be converted to 1α,25(OH)2D3 to exert 
its cellular functions. Meanwhile, the locally generated 1α,25(OH)2D will up-regulate the 
expression of CYP24A1 within the cells to hydroxylate 1α,25(OH)2D3 and excess 25(OH)D3 
to form their respective 24-hydroxylated metabolites leading to their catabolism. On the 
other hand, in cells dominated with the expression of CYP24A1, the generated 1α,25(OH)2D3 
will be degraded very quickly with little or no chance to exert biological actions (Ly et al. 
1999; Schuster 2011). 
5. Functions of vitamin D  
The genomic action of 1α,25(OH)2D is mediated through its binding to vitamin D receptor 
(VDR) to modulate various gene expressions in a cell- and tissue- specific manner (Norman 
2006) (Figure 2). VDR is a member of the nuclear receptor superfamily and is expressed in 
almost all tissues (Hausller et al. 1997). To date, 1α,25(OH)2D3 has been well described to 
exert anti-proliferation, anti-inflammation, pro-differentiation, pro-apoptosis and immune 
regulation in a tissue- and cell-specific manner (Chiang & Chen 2009; Bikle 2009; Adams & 
Hewison 2010). So far, more than 2770 VDR binding sites have been identified within 229 
vitamin D-regulated genes as shown by a Chip-sequencing method (Ramagopalan et al. 
2010). Many cancer cell lines, including prostate, lung, liver, breast, pancreas and liver 
cancers, have been shown to express VDR, and 1α,25(OH)2D3 has been found to have 
growth inhibitory effect on these cells (Colston et al., 1980; Skowronski et al., 1993; Hulla et 
al., 1995; Chen & Holick 2003; Flanagan et al., 2009; Chiang et al., 2009). 
The active form of vitamin D3, 1α,25(OH)2D3, either synthesized in an autocrine fashion or 
obtained from the kidneys, exerts its genomic effects by binding to the VDR/retinoid X 
receptor (RXR) complex on vitamin D response element (VDRE) in the promoter region of 
vitamin D-regulated genes. The transcriptional effects include cell cycle arrest, pro-
differentiation, pro-apoptosis, anti-inflammation, regulation of immune response and etc. 
After 1α,25(OH)2D3 elicits its function, it is then inactivated by CYP24A1. Since many tissues 
possess CYP27B1 and CYP24A1 simultaneously, the internalized 25(OH)D3 can be activated 
or inactivated to form 1α,25(OH)2D3 or 24-25(OH)D3 based on the expression rates of 1α-
OHase to 24-OHase. 
Once 1α,25(OH)2D3 is internalized into cells, it binds to VDR. The liganded VDR then form a 
heterodimer with RXR and binds to VDRE (Tsai & Omalley 1994) located in the promoter 
regions of vitamin D responsive genes to modulate the gene expression. In cancer cells, the 
action mainly leads to the inhibition of cancer growth and the prevention of cancer cells 
from invading to surrounding normal tissues. Mechanistically, the genomic pathways are 
regulated by multiple co-factors (Haussler et al. 1998). The VDR conformational change 
occurs upon 1α,25(OH)2D3 binding to VDR, leading to subsequent phosphorylation, and 
gives rise to the release of co-repressors and the recruitment of co-activators (Tagami et al. 
1998; Li et al. 2007). In addition to the genomic pathways, 1α,25(OH)2D3 has been shown to 
be able to induce instant biologic reaction at the plasma membrane or in the cytoplasm by 
changing transmembrane signals quickly (Norman 2006). 
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This kind of action does not influence gene expression directly, though, its cross-talk with 
varied signaling pathways still can modulate gene transcripton (Losel & Wehling 2003). To 
date, the exact mechanisms for non-genomic actions of 1α,25(OH)2D3 are not well 
understood. Nevertheless, the existence of non-classical membrane VDR has been found to 
be related to the rapid actions (Huhtakangas et al. 2004), including activation of protein 
kinase C and protein phosphatase PP1c. The actions have been shown to result in 
subsequent ion channel activity modulation (Bettoun et al. 2002; Shah et al. 2006), which is 
also implicated in the growth inhibition of cancer cells. 
6. Vitamin D and pancreatic cancer- biological studies 
To date, 1α,25(OH)2D3 has been shown to possess anti-tumor activity in many cancer cells 
expressing VDR through its anti-proliferative, pro-apoptotic, and pro-differentiation actions 
in a cell- and tissue-specific manner. In terms of pancreatic cancer, 1α,25(OH)2D3 has been 
demonstrated to up-regulate the expression of p21 and p27 and down-regulate the 
expression of cyclins A, D1, and E and cyclin dependent kinases 2 and 4, leading to cell cycle 
arrest at G0/G1 phase (Kawa et al. 1997). However, 1α,25(OH)2D3 is known to cause 
hypercalcemia and hypercalciuria side effects when administered systemically. To overcome 
these lethal side effects caused by systemic administration of 1α,25(OH)2D3, thousands of 
1α,25(OH)2D3 analogues have been synthesized in an effort to potentiate its anti-tumor effect 
while decreasing its hypercalcemic activity. Some of them have been found to induce 
greater cell-cycle arrest, differentiation, and/or apoptosis on pancreatic cancer cells in vitro 
and to inhibit tumor growth in the xenograft animal model. For example, 22-oxa-
1α,25(OH)2D3 has been reported to cause growth inhibition on three pancreatic cancer cell 
lines and to inhibit xenografted BxPC-3 cell growth in vivo (Kawa et al. 1996). Similarly, EB-
1089, a well-studied1α,25(OH)2D3 analogue, has been shown to inhibit pancreatic cancer 
growth in vitro and in vivo (Colston et al. 1997; Pettersson 2000), and has been investigated in 
a phase II clinical trial to treat advanced pancreatic cancer. While EB-1089 failed to prolong 
the survival of patients significantly in this trial (Evans et al. 2002), 1α,25(OH)2D3 ( 0.5 g/kg 
) in a combination with docetaxel successfully increased the period of time-to-progress of 
pancreatic cancer in a recently published phase II study enrolling 25 advanced pancreatic 
cancer patients as compared to treatment with docetaxel alone (Blanke et al. 2009). Several 
new analogues have been shown to possess promising results in in vitro studies. For 
example, a VDR-alkylating derivative of 1α,25(OH)2D3, 1α,25-dihydroxyvitamin D3-3-
bromoacetate (1α,25(OH)2D3-3-BE), was able to inhibit pancreatic cancer cell grow at a lower 
concentration and to a greater extent than 1α,25(OH)2D3, especially in combination with 5-
amino-imidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) (Persons et al. 2010). In 
another study, 19-nor-1,25(OH)2D2 (Paricalcitol), which has been approved by the Food 
and Drug Administration for treating secondary hyperparathorodism, has been 
demonstrated to have comparable growth inhibition as 1,25(OH)2D3 in pancreatic cancer in 
vitro and in vivo (Schwartz et al. 2008). Given that 19-nor-1,25(OH)2D2 and 19-nor-
1,25(OH)2D3, are less calcemic analogues of 1α,25(OH)2D3, we have studied a carbon-2 
modified analogue of 19-nor-1,25(OH)2D3, 19-nor-2-(3-hydroxypropyl)-1,25(OH)2D3 or 
MART-10, in pancreatic cancer cells in vitro and found to be 100-1000 times as potent as 
1α,25(OH)2D3 to inhibit tumor cell growth. Most importantly, MART-10 does not increase 
serum calcium in rats (Iglesias-Gato, D. et al, 2011). Furthermore, MART-10 has been shown 
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to be a poor substrate of CYP24A1 and has a lower binding affinity for DBP compared to 
1α,25(OH)2D3, suggesting that this analogue is likely more bio-available than 1α,25(OH)2D3 
in circulation (Flanagan et al. 2009). Thus, MART-10 is a promising compound to treat 
pancreatic cancer. 
7. Epidemiological evidence associating vitamin D and pancreatic cancer  
Circulating vitamin D level, primarily determined by solar UVB exposure and partially 
influenced by food uptake and oral vitamin D supplementation, has been shown to be 
inversely associated with the incidence of many cancers, including prostate, colon and 
breast cancers in a number of epidemiological studies (Garland & Garland 1980; Gorham et 
al., 1990; Schwartz & Chen 2005). Garland et al. (2009) further reported that 58,000 new cases 
of breast cancer and 49000 new cases of colon cancer could be prevented annually through 
vitamin D supplement. In addition, recent studies applying Hill’s criteria for causality also 
clearly showed that UVB exposure and vitamin D status are negatively associated with 
cancer risk (Grant 2009; Grant & Boucher 2009). For pancreatic cancer, its exact relationship 
to vitamin D status has not been well understood. Although two earlier epidemiologic 
studies published in 2006 showed inconsistent findings about the relationship between 
pancreatic cancer incidence and serum 25(OH)D level (Skinner et al. 2006; Stolzenberg-
Solomon et al. 2006), the death rate of pancreatic cancer has been shown to be inversely 
related to sun exposure (Mizoue 2004; Boscoe & Schymura 2006; Grant 2007; Tuohimaa et al. 
2007). More recently, Stoleznberg-Solomon et al. (2010) conducted two pooled nested case 
control studies to investigate the potential association of vitamin D status and pancreatic 
cancer, and reported that the circulating 25(OH)D concentration was not related to the risk 
of pancreatic cancer. Furthermore, Stoleznberg-Solomon et al. showed that a high 25(OH)D 
level, exceeding 100 nmol/L (40 ng/mL), increased pancreatic cancer incidence two folds 
(odds ratio = 2.12, 95% confidence interval: 1.23, 3.64) (Stoleznberg-Solomon et al. 2010). 
However, they did find subjects with lower estimated annual residential solar UVB 
exposure would have higher risk of pancreatic cancer (Stoleznberg-Solomon et al. 2009). The 
reason behind the lack of association between serum levels and pancreatic cancer and other 
cancers maybe that serum 25(OH)D levels were only measured at one time point years prior 
to diagnosis of pancreatic cancer and, in fact, 25(OH)D levels change from season to season. 
For this reason, Yin et al. (2010) conducted case-control studies with zero lag time between 
diagnosis and serum 25(OH)D measurement, not nested studies, and found an inverse 
correlation between serum 25(OH)D level and breast cancer. Mohr SB et al. (2010) also 
demonstrated an inverse association between UVB irradiation and incidence rates of 
pancreatic cancer worldwide. They found that the incidence rate of pancreatic cancer was 
only half in countries with estimated serum 25(OH)D> 30 ng/ml as compared to those with 
serum 25(OH)D ≤ 30 ng/mL. There are other studies also showing inverse relationship 
between UVB and pancreatic cancer (Kato et al. 1985; Giovannucci et al. 2006; Neale et al. 
2009). Interestingly, high insulin and glucose levels have been found to be related to 
pancreatic cancer positively (Hennig et al. 2004; Stolzenberg-Solomon et al. 2005; Huxley et 
al. 2005; Michaud et al. 2007). Since vitamin D is able to regulate the synthesis, binding and 
actions of insulin (Maestro et al. 2000; Maestro et. 2003; Mathieu et al. 2005), there seems to 
be an inverse relationship between pancreatic cancer incidence and vitamin D status. Due to 
these contradictory findings, more careful studies should be conducted to investigate the 
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kinase C and protein phosphatase PP1c. The actions have been shown to result in 
subsequent ion channel activity modulation (Bettoun et al. 2002; Shah et al. 2006), which is 
also implicated in the growth inhibition of cancer cells. 
6. Vitamin D and pancreatic cancer- biological studies 
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expressing VDR through its anti-proliferative, pro-apoptotic, and pro-differentiation actions 
in a cell- and tissue-specific manner. In terms of pancreatic cancer, 1α,25(OH)2D3 has been 
demonstrated to up-regulate the expression of p21 and p27 and down-regulate the 
expression of cyclins A, D1, and E and cyclin dependent kinases 2 and 4, leading to cell cycle 
arrest at G0/G1 phase (Kawa et al. 1997). However, 1α,25(OH)2D3 is known to cause 
hypercalcemia and hypercalciuria side effects when administered systemically. To overcome 
these lethal side effects caused by systemic administration of 1α,25(OH)2D3, thousands of 
1α,25(OH)2D3 analogues have been synthesized in an effort to potentiate its anti-tumor effect 
while decreasing its hypercalcemic activity. Some of them have been found to induce 
greater cell-cycle arrest, differentiation, and/or apoptosis on pancreatic cancer cells in vitro 
and to inhibit tumor growth in the xenograft animal model. For example, 22-oxa-
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lines and to inhibit xenografted BxPC-3 cell growth in vivo (Kawa et al. 1996). Similarly, EB-
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growth in vitro and in vivo (Colston et al. 1997; Pettersson 2000), and has been investigated in 
a phase II clinical trial to treat advanced pancreatic cancer. While EB-1089 failed to prolong 
the survival of patients significantly in this trial (Evans et al. 2002), 1α,25(OH)2D3 ( 0.5 g/kg 
) in a combination with docetaxel successfully increased the period of time-to-progress of 
pancreatic cancer in a recently published phase II study enrolling 25 advanced pancreatic 
cancer patients as compared to treatment with docetaxel alone (Blanke et al. 2009). Several 
new analogues have been shown to possess promising results in in vitro studies. For 
example, a VDR-alkylating derivative of 1α,25(OH)2D3, 1α,25-dihydroxyvitamin D3-3-
bromoacetate (1α,25(OH)2D3-3-BE), was able to inhibit pancreatic cancer cell grow at a lower 
concentration and to a greater extent than 1α,25(OH)2D3, especially in combination with 5-
amino-imidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) (Persons et al. 2010). In 
another study, 19-nor-1,25(OH)2D2 (Paricalcitol), which has been approved by the Food 
and Drug Administration for treating secondary hyperparathorodism, has been 
demonstrated to have comparable growth inhibition as 1,25(OH)2D3 in pancreatic cancer in 
vitro and in vivo (Schwartz et al. 2008). Given that 19-nor-1,25(OH)2D2 and 19-nor-
1,25(OH)2D3, are less calcemic analogues of 1α,25(OH)2D3, we have studied a carbon-2 
modified analogue of 19-nor-1,25(OH)2D3, 19-nor-2-(3-hydroxypropyl)-1,25(OH)2D3 or 
MART-10, in pancreatic cancer cells in vitro and found to be 100-1000 times as potent as 
1α,25(OH)2D3 to inhibit tumor cell growth. Most importantly, MART-10 does not increase 
serum calcium in rats (Iglesias-Gato, D. et al, 2011). Furthermore, MART-10 has been shown 
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in circulation (Flanagan et al. 2009). Thus, MART-10 is a promising compound to treat 
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Circulating vitamin D level, primarily determined by solar UVB exposure and partially 
influenced by food uptake and oral vitamin D supplementation, has been shown to be 
inversely associated with the incidence of many cancers, including prostate, colon and 
breast cancers in a number of epidemiological studies (Garland & Garland 1980; Gorham et 
al., 1990; Schwartz & Chen 2005). Garland et al. (2009) further reported that 58,000 new cases 
of breast cancer and 49000 new cases of colon cancer could be prevented annually through 
vitamin D supplement. In addition, recent studies applying Hill’s criteria for causality also 
clearly showed that UVB exposure and vitamin D status are negatively associated with 
cancer risk (Grant 2009; Grant & Boucher 2009). For pancreatic cancer, its exact relationship 
to vitamin D status has not been well understood. Although two earlier epidemiologic 
studies published in 2006 showed inconsistent findings about the relationship between 
pancreatic cancer incidence and serum 25(OH)D level (Skinner et al. 2006; Stolzenberg-
Solomon et al. 2006), the death rate of pancreatic cancer has been shown to be inversely 
related to sun exposure (Mizoue 2004; Boscoe & Schymura 2006; Grant 2007; Tuohimaa et al. 
2007). More recently, Stoleznberg-Solomon et al. (2010) conducted two pooled nested case 
control studies to investigate the potential association of vitamin D status and pancreatic 
cancer, and reported that the circulating 25(OH)D concentration was not related to the risk 
of pancreatic cancer. Furthermore, Stoleznberg-Solomon et al. showed that a high 25(OH)D 
level, exceeding 100 nmol/L (40 ng/mL), increased pancreatic cancer incidence two folds 
(odds ratio = 2.12, 95% confidence interval: 1.23, 3.64) (Stoleznberg-Solomon et al. 2010). 
However, they did find subjects with lower estimated annual residential solar UVB 
exposure would have higher risk of pancreatic cancer (Stoleznberg-Solomon et al. 2009). The 
reason behind the lack of association between serum levels and pancreatic cancer and other 
cancers maybe that serum 25(OH)D levels were only measured at one time point years prior 
to diagnosis of pancreatic cancer and, in fact, 25(OH)D levels change from season to season. 
For this reason, Yin et al. (2010) conducted case-control studies with zero lag time between 
diagnosis and serum 25(OH)D measurement, not nested studies, and found an inverse 
correlation between serum 25(OH)D level and breast cancer. Mohr SB et al. (2010) also 
demonstrated an inverse association between UVB irradiation and incidence rates of 
pancreatic cancer worldwide. They found that the incidence rate of pancreatic cancer was 
only half in countries with estimated serum 25(OH)D> 30 ng/ml as compared to those with 
serum 25(OH)D ≤ 30 ng/mL. There are other studies also showing inverse relationship 
between UVB and pancreatic cancer (Kato et al. 1985; Giovannucci et al. 2006; Neale et al. 
2009). Interestingly, high insulin and glucose levels have been found to be related to 
pancreatic cancer positively (Hennig et al. 2004; Stolzenberg-Solomon et al. 2005; Huxley et 
al. 2005; Michaud et al. 2007). Since vitamin D is able to regulate the synthesis, binding and 
actions of insulin (Maestro et al. 2000; Maestro et. 2003; Mathieu et al. 2005), there seems to 
be an inverse relationship between pancreatic cancer incidence and vitamin D status. Due to 
these contradictory findings, more careful studies should be conducted to investigate the 
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potential impacts of gene polymorphisms, including VDR, DBP, CYP27B1, and CYP24A1, on 
vitamin D status in order to determine whether adequate vitamin D nutrition has a survival 
and/or a preventive benefit against the pancreatic cancer. 
8. Conclusion 
Pancreatic cancer is often diagnosed at a late stage with a 5-year survival of merely 1-4%. Its 
characteristics of early spread and distant metastasis at the time of diagnosis make it a poor 
candidate for surgical treatment. Moreover, traditional chemotherapy and radiotherapy fail 
to show significant benefit on survival of PCA patients, and no effective target therapy 
against PCA is available at the present time. Since clinicians are faced with the dilemma of 
dealing with advanced PCA, developing new regimens against PCA deserve more attention. 
Vitamin D, originally discovered for treating rickets a century ago, has been found to go 
through a series of hydroxylation steps, leading to the synthesis of the active metabolite, 
1,25(OH)2D. The active metabolite exerts an array of actions through its binding to VDR, 
which is found to exist in almost all tissues in humans. Although 1,25(OH)2D3 possesses 
antitumor effects on many cancer cells in vitro and in vivo, its clinical application is impeded 
by the lethal side effect of hypercalcemia when administered systemically. To overcome this 
drawback, thousands of 1,25(OH)2D3 analogues have been synthesized, and some of them 
have much less calcemic activity and/or a more potent antitumor effect. Regarding 
pancreatic cancer, although several analogues have shown promising antiproliferative effect 
on cells in culture and animal experiments, they fail to offer any benefits in clinical trials. 
However, in combination with docetaxel, 1,25(OH)2D3 was able to prolong the period of 
time-to-progression of patients with advanced pancreatic cancer. Recently, two analogues of 
1,25(OH)2D3, 1,25(OH)2D3-3-BE and MART-10, have been shown to exert much greater 
antiproliferative effect on pancreatic cancer cells in vitro. Under the current situation without 
an effective treatment for the advanced PCA, further investigation of these two analogues in 
animal models and clinical trials is warranted. 
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1. Introduction  
Addiction of cancer cells to survival pathways has been well documented in most of the 
cancer models including the pancreatic cancer. Pancreatic cancer is one of the most 
aggressive tumors with an average five year survival rate of less than 5% (Jemal A et al., 
2010). It is associated with high expression levels of various survival pathways, such as 
KRAS, STAT3, AKT, NFkB, HDAC etc. Furthermore, pancreatic cancer acquires resistance to 
various apoptosis signals such as FasL, TRAIL. In addition, pancreatic cancer gets resistance 
to various chemo-drugs including gemcitibine by altering survival pathways.   
Currently, there is no effective treatment for pancreatic cancer because conventional 
chemotherapy including the gemcitabine and 5-FU, and radiation treatment has shown very 
limited success in improving the patient survival. Therefore, the development of novel 
approaches to prevent and treat pancreatic cancer is an important mission. 
Evidence from epidemiological, pharmacological, and case-control studies continue to 
support the notion that isothiocyanates (ITCs) present in cruciferous vegetables may have 
substantial chemopreventive activity against various human malignancies including 
pancreatic cancer (Zhang Y et al., 1992); Stoner GD & Morse MA, 1997). Benzyl 
isothiocyanate (BITC), an agent that is present in cruciferous vegetables such as, watercress, 
cabbage, cauliflower, mustard, and horseradish, is widely consumed as part of a routine 
diet. BITC has been reported to inhibit initiation, growth, and metastasis of human cancers 
in rodents (Batra S et al., 2010; Boreddy SR et al., 2011a; Boreddy SR etal., 2011b; Kim EJ et 
al., 2011; Sahu RP & Srivastava SK, 2009; Zhang Y et al., 1992). The structure of BITC is 
shown in Fig.1. 
 
Fig. 1. Chemical structure of BITC 
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Our laboratory has shown that BITC potentially suppresses the growth and induces 
apoptosis in pancreatic cancer cells by targeting various key survival molecules (Batra S et 
al., 2010; Boreddy SR et al., 2011a; Sahu RP & Srivastava SK, 2009). In the present chapter, 
we discuss the current understanding of BITC, its targets and mechanism of action in 
pancreatic cancer.  
2. Effect of BITC on STAT3 signalling pathway 
Signal Transducer Activator Transcription (STAT3) transcription factors are latent proteins 
that bind to the genome on activation to either induce or to repress gene expression 
(Bromberg et al., 1999). STAT3 is aberrantly activated in majority of the cancers including 
pancreatic cancer (Wei et al., 2003). Clinical specimens have revealed that more than 50% of 
the breast and lung cancer, and over 95% of head and neck cancers have hyperactive STAT3 
signaling (Darnell, 2005). Interestingly, STAT3 deficient mice in a chemical carcinogenesis 
model have shown the reduced proliferation of epithelial cells due to inability to pass 
through G1-S-G2 cell cycle progression (Chan et al., 2004). Furthermore, Chiarle et al. have 
demonstrated that disruption of STAT3 signaling by anti-sense oligoneclosides was 
sufficient to impair the growth of solid tumors (Chiarle, 2005), highlighting the potential of 
anti-STAT3 therapy in clinical medicine. Recently, numerous natural and synthetic 
compounds have been discovered to target STAT3 signaling. Results from our laboratory 
showed that benzyl isothiocyanate (BITC) targets STAT3 signaling to induce apoptosis in 
pancreatic cancer (Sahu & Srivastava, 2009).  
Our laboratory showed that BITC significantly suppress the phosphorylation of STAT3 at 
both Tyr-705 and Ser-727 to induce apoptosis in BxPC-3 (Fig. 2), MIA PaCa-2, Capan-1 and 
PanC-1 pancreatic cancer cell lines, in a dose and time dependent manner (Sahu & 
Srivastava, 2009). Interestingly, BITC also down regulated the protein levels of STAT3 in 
these cell lines, although its functional implications are yet to be explored. Furthermore, 
down regulation of STAT3 protein expression by BITC was transcriptional, as evidenced by 
RT-PCR analysis of BITC treated BxPC-3 cells (Fig. 2). 
 
Fig. 2. Benzyl isothiocyanate induces apoptosis in pancreatic cancer cells by inhibiting the 
phosphorylation of STAT3. (J Natl Cancer Inst 2009;101: 176  –  193). 
BITC-induced apoptosis was further substantiated by IL-6 treatment, which specifically 
phosphorylates STAT3 at Tyr-705 (Berishaj, 2007) and STAT3α overexpression. IL-6 pre-
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treated BxPC-3 cells showed significant resistance to BITC-induced apoptosis (Fig. 3). 
Similarly, when STAT3α was over expressed in BxPC-3 cells, BITC-induced apoptosis was 
severely abrogated, indicating that BITC targets STAT3 to induce apoptosis in pancreatic 
cancer cells. 
 
Fig. 3. IL-6 pre-treatment or STAT3α overexpression abrogates BITC-induced apoptosis in 
pancreatic cancer cells. (J Natl Cancer Inst 2009:101; 176  –  193). 
3. Effect of BITC on AKT/FOXO/Bim signaling pathway 
Phosphotidyl inositol 3phosphate (PI3K)/AKT signaling plays a critical role in cell survival 
and growth during embryonic development as well as during normal cell survival 
(Finkielsztein & Kelly, 2009). However, cancer cells exploit the same pathway to overcome 
apoptosis induced by either therapeutic drugs or internal stimuli such as oxidative stress. 
Upon binding of growth factors to Tyrosine Kinase Receptor (TKR), PI3K is directly or 
indirectly activated by TKRs by inhibiting or removing the P85 regulatory unit of PI3K 
(Vivanco & Sawyers, 2002). Activated PI3K phosphorylates phosphatidylinositol and 
converts inositol 4,5biphosphate (PIP2) into PIP3. Consequently, AKT and PDK translocate 
to membrane and interact with PIP3 through PH domain leading to conformational changes 
in AKT to expose phosphorylation sites. AKT is phosphorylated by PDK1 at Ser-308 leading 
to stabilization of AKT. Yet another phosphorylation takes place at Tyr-473, which is 
required for full activation of AKT. In addition, another protein complex mTOR has been 
shown to be required for the phosphorylation of AKT (Sarbassov et al., 2005). This pathway 
is negatively regulated by phosphatases, such as PTEN, which dephosphorylates PIP3 thus 
limiting its availability (Osaki et al., 2004). 
Recently, FOXO transcription factors received ample of attention in cancer because of direct 
involvement in apoptosis and drug resistance (Salih & Brunet, 2008). FOXO1 and FOXO3a 
are the members of FOXO transcription factors, which operate right under the AKT 
signaling. Upon growth signal stimulation, AKT is activated by phosphorylation at Ser-473, 
BxPC‐3 
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Fig. 2. Benzyl isothiocyanate induces apoptosis in pancreatic cancer cells by inhibiting the 
phosphorylation of STAT3. (J Natl Cancer Inst 2009;101: 176  –  193). 
BITC-induced apoptosis was further substantiated by IL-6 treatment, which specifically 
phosphorylates STAT3 at Tyr-705 (Berishaj, 2007) and STAT3α overexpression. IL-6 pre-
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treated BxPC-3 cells showed significant resistance to BITC-induced apoptosis (Fig. 3). 
Similarly, when STAT3α was over expressed in BxPC-3 cells, BITC-induced apoptosis was 
severely abrogated, indicating that BITC targets STAT3 to induce apoptosis in pancreatic 
cancer cells. 
 
Fig. 3. IL-6 pre-treatment or STAT3α overexpression abrogates BITC-induced apoptosis in 
pancreatic cancer cells. (J Natl Cancer Inst 2009:101; 176  –  193). 
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which further phosphorylates FOXO1 or FOXO3a transcription factors. Phosphorylated 
FOXOs bind to 14-3-3 chaperons and transported out of nucleus and subjected to 
proteosomal degradation (Tzivion et al., 2011). But during oxidative stress or growth factor 
withdrawal, AKT is dephosphorylated leading to nuclear import of FOXOs and induction of 
pro-apoptotic proteins such as Bim and PUMA (Obexer, 2011).  
A recent report has shown that 59% of the pancreatic tumors harbor aberrantly activated 
AKT signaling (Schlieman et al., 2003). One of the possible reasons behind hyperactive AKT 
signaling in pancreatic cancer is due to mutation or deletion of PTEN gene (Sawai et al., 
2008). Indeed, strategies aimed at blocking AKT activation could be a promising treatment 
for pancreatic cancer. Interestingly BITC significantly inhibited AKT signaling in vitro and  
in vivo. 
 
Fig. 4. BITC down regulates the phosphorylation of key molecules of PI3K/AKT pathway. 
(Clin Cancer Res; 17(7); 1784–1795).  
BITC suppressed the phosphorylation of AKT at both Ser-308 and Ser-473 in BxPC-3 and 
PanC-1 cells, in dose dependent manner (Boreddy et al., 2011a). Furthermore, BITC also 
suppressed the phosphorylation of various other key molecules of PI3K/AKT pathway such 
as PI3K (Tyr-458), PDK1 (Ser-241), mTOR (Ser-2448) etc. (Fig. 4), indicating that BITC targets 
PI3K/AKT signaling to induce apoptosis in pancreatic cancer cells. Interestingly, BITC was 
almost ineffective in human pancreatic ductal epithelial (HPDE-6) cells (Fig. 4). Over 
expression of AKT blocked the apoptosis inducing effects of BITC in pancreatic cancer cells. 
Recently, FOXO transcription factor received plenty of attention as a potential target for 
cancer therapy, as they are directly involved in apoptosis induction. Interestingly, BITC 
significantly suppressed the phosphorylation of FOXO1 (Ser-256) and FOXO3a (Ser-253), 
without effecting the protein levels in both BxPC-3 and PanC-1 cells (Fig. 5). Moreover, 
immunoprecipitation studies showed that BITC treatment significantly masked 14-3-3 
binding motif on FOXO proteins indicating that more of FOXO proteins were retained in the 
nucleus (Fig. 5B). Furthermore, BITC significantly increased the expression FOXO1 
transactive genes such as P21, P27 and Bim in both the cell lines, BxPC-3 and PanC-1  
(Fig. 5C). 
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Apart from phosphorylation, another tier of FOXO transcription factor regulation is 
acetylation. Interestingly, BITC also reduced the acetylation of FOXO proteins. Probably, 
inhibition of acetylation by BITC was due to down regulation of CBP protein expression, 
since SIRTs were not altered by BITC treatment.   
 
Fig. 5. BITC activates FOXO transcription factors and pro-apoptotic proteins in pancreatic 
cancer cells. (Clin Cancer Res; 17(7); 1784–1795). 
Role of AKT in BITC-induced apoptosis was further confirmed by using PI3K inhibitor LY-
294002 and overexpression of wild type AKT in BxPC-3 cells. Interestingly, when BxPC-3 
cells were pre-treated with LY-294002 followed BITC (10µM) for 24h, apoptosis induction 
was potentiated, as compared to BITC alone treated cells (Fig. 6), whereas AKT 
overexpression severely abrogated BITC-induced apoptosis in BxPC-3 cells (Fig. 6). In line 
with apoptosis results, phosphorylation of FOXO proteins were increased with AKT 
overexpression, whereas Bim, P27, P21 expression was reduced. However, BITC partially 
blocked these effects, indicating that BITC targets AKT pathway to induce apoptosis in 
pancreatic cancer cells lines (Fig. 6).  
4. BITC Regulates NFkB Activity by Inhibiting HDACs 
NFkB transcription factors are mainly involved in the regulation of immune and 
inflammatory response, apart from cell proliferation and apoptosis Ghosh et al., 1998; Hart 
et al., 1998). NFkB is normally located in the cytoplasm sequestered by its endogenous 
inhibitor IkB. Upon cellular stimulation, IkB proteins are phosphorylated at Ser-32/36 
liberating NFkB, which translocates to the nucleus and gets involved in the transcription of 
responsive genes such as Cyclin D1 (Sun & Andersson, 2002). 
Pancreatic Cancer – Molecular Mechanism and Targets 196 
which further phosphorylates FOXO1 or FOXO3a transcription factors. Phosphorylated 
FOXOs bind to 14-3-3 chaperons and transported out of nucleus and subjected to 
proteosomal degradation (Tzivion et al., 2011). But during oxidative stress or growth factor 
withdrawal, AKT is dephosphorylated leading to nuclear import of FOXOs and induction of 
pro-apoptotic proteins such as Bim and PUMA (Obexer, 2011).  
A recent report has shown that 59% of the pancreatic tumors harbor aberrantly activated 
AKT signaling (Schlieman et al., 2003). One of the possible reasons behind hyperactive AKT 
signaling in pancreatic cancer is due to mutation or deletion of PTEN gene (Sawai et al., 
2008). Indeed, strategies aimed at blocking AKT activation could be a promising treatment 
for pancreatic cancer. Interestingly BITC significantly inhibited AKT signaling in vitro and  
in vivo. 
 
Fig. 4. BITC down regulates the phosphorylation of key molecules of PI3K/AKT pathway. 
(Clin Cancer Res; 17(7); 1784–1795).  
BITC suppressed the phosphorylation of AKT at both Ser-308 and Ser-473 in BxPC-3 and 
PanC-1 cells, in dose dependent manner (Boreddy et al., 2011a). Furthermore, BITC also 
suppressed the phosphorylation of various other key molecules of PI3K/AKT pathway such 
as PI3K (Tyr-458), PDK1 (Ser-241), mTOR (Ser-2448) etc. (Fig. 4), indicating that BITC targets 
PI3K/AKT signaling to induce apoptosis in pancreatic cancer cells. Interestingly, BITC was 
almost ineffective in human pancreatic ductal epithelial (HPDE-6) cells (Fig. 4). Over 
expression of AKT blocked the apoptosis inducing effects of BITC in pancreatic cancer cells. 
Recently, FOXO transcription factor received plenty of attention as a potential target for 
cancer therapy, as they are directly involved in apoptosis induction. Interestingly, BITC 
significantly suppressed the phosphorylation of FOXO1 (Ser-256) and FOXO3a (Ser-253), 
without effecting the protein levels in both BxPC-3 and PanC-1 cells (Fig. 5). Moreover, 
immunoprecipitation studies showed that BITC treatment significantly masked 14-3-3 
binding motif on FOXO proteins indicating that more of FOXO proteins were retained in the 
nucleus (Fig. 5B). Furthermore, BITC significantly increased the expression FOXO1 
transactive genes such as P21, P27 and Bim in both the cell lines, BxPC-3 and PanC-1  
(Fig. 5C). 
Molecular Targets of Benzyl Isothiocyanates in Pancreatic Cancer 197 
Apart from phosphorylation, another tier of FOXO transcription factor regulation is 
acetylation. Interestingly, BITC also reduced the acetylation of FOXO proteins. Probably, 
inhibition of acetylation by BITC was due to down regulation of CBP protein expression, 
since SIRTs were not altered by BITC treatment.   
 
Fig. 5. BITC activates FOXO transcription factors and pro-apoptotic proteins in pancreatic 
cancer cells. (Clin Cancer Res; 17(7); 1784–1795). 
Role of AKT in BITC-induced apoptosis was further confirmed by using PI3K inhibitor LY-
294002 and overexpression of wild type AKT in BxPC-3 cells. Interestingly, when BxPC-3 
cells were pre-treated with LY-294002 followed BITC (10µM) for 24h, apoptosis induction 
was potentiated, as compared to BITC alone treated cells (Fig. 6), whereas AKT 
overexpression severely abrogated BITC-induced apoptosis in BxPC-3 cells (Fig. 6). In line 
with apoptosis results, phosphorylation of FOXO proteins were increased with AKT 
overexpression, whereas Bim, P27, P21 expression was reduced. However, BITC partially 
blocked these effects, indicating that BITC targets AKT pathway to induce apoptosis in 
pancreatic cancer cells lines (Fig. 6).  
4. BITC Regulates NFkB Activity by Inhibiting HDACs 
NFkB transcription factors are mainly involved in the regulation of immune and 
inflammatory response, apart from cell proliferation and apoptosis Ghosh et al., 1998; Hart 
et al., 1998). NFkB is normally located in the cytoplasm sequestered by its endogenous 
inhibitor IkB. Upon cellular stimulation, IkB proteins are phosphorylated at Ser-32/36 
liberating NFkB, which translocates to the nucleus and gets involved in the transcription of 
responsive genes such as Cyclin D1 (Sun & Andersson, 2002). 
Pancreatic Cancer – Molecular Mechanism and Targets 198 
   
Fig. 6. AKT inhibitor potentiates BITC-induced apoptosis, whereas AKT overexpression 
abrogates BITC-induced apoptosis in BxPC-3 pancreatic cancer cells. (Clin Cancer Res2011: 
17(7); 1784–1795). 
NFkB may activate various survival signals to promote cell survival. NFkB is known to 
interfere with inducers of extrinsic apoptosis pathway by up regulating the FLIP-like 
inhibitory protein (Kreuz et al., 2001). NFkB also induces the expression of inhibitors of 
apoptosis proteins such as IAP (Deveraux et al., 1998) and some members of the Bcl2 (Shou et 
al., 2002) family proteins, thereby protecting the cells from various apoptosis stimuli.  NFkB is 
also known to play critical role in drug resistance is various cancer models (Arlt et al., 2003). 
Hence, inhibiting of NFkB activation may potentiate the clinical efficacy of the drugs. 
BITC significantly inhibits the phosphorylation of NFkB at both Ser-276 and Ser-536 in both 
BxPC-3 and Capan-2 pancreatic cancer cells, in a dose and time dependent manner (Fig. 
7A&B). Interestingly, BITC down regulated the expression of NFkB in BxPC-3 cells but not 
in Capan-2 cells, indicating that BITC differentially act on different cells (Batra et al., 2010). 
Furthermore, BITC drastically inhibited the nuclear localization of NFkB in BxPC-3 cells 
(Fig. 7C). BxPC-3 cells that were transfected with a luciferase gene containing NFkB-
promoter and treated with BITC demonstrated around 90% decrease in luciferase activity, as 
compared to control cells (Fig. 7D). Furthermore, BITC also decreased Cyclin D1 expression 
and transcriptional activity, as it is one of the target genes of NFkB (Fig. 7E & Fig. 7F). 
Interestingly expression of IKK was decreased with BITC treatment, but neither 
phosphorylation (Ser32/36) nor protein levels of IkB were altered in BITC treated BxPC-3 
cells (Fig 7A), indicating that down regulation of IKK by BITC treatment could be the reason 
for inhibition of NFkB phosphorylation (Ser-536). 
Apart from the phosphorylation, NFkB is known to be regulated by acetylation. 
Interestingly, BITC also inhibited the acetylation of NFkB on lysine residue in BxPC-3 cells. 
BITC suppressed the acetylation of NFkB by altering the expression of HDAC1 and HDAC3 
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(Fig. 8A&B), as these molecules play critical role in NFkB acetylation. In agreement with 
other HDAC inhibitors’ data, such as veronistat (SAHA) and tricostatin A (TSA), BITC also 
up regulated the expression of p21 in BxPC-3 and Capan-2 cells, in a dose dependent 
manner (Fig. 8C). 
 
Fig. 7. BITC treatment causes inhibition of NF-κB and cyclin D1 in BxPC-3 pancreatic cancer 
cells. (Mol Cancer Ther 2010: 9(6):1596-608). 
 
Fig. 8. BITC down regulates the expression of HDACs and p21 in BxPC-3 cells. (Mol Cancer 
Ther. 2010: 9(6);1596-608).  
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Role of HDACs in BITC-induced NFkB deacetylation was further substantiated by HDAC 
overexpression in BxPC-3 cells. HDAC1/3 overexpression significantly outweighed the 
effects of BITC in BxPC-3 cells. Furthermore, overexpression of HDACs protected BxPC-3 
cells from BITC-induced apoptosis, as indicated by the reduced cleavage of caspase-3, PARP 
and increased survival in HDACs overexpressing BxPC-3 cells, as compared to BITC alone 
treated cells (Fig. 9). 
 
Fig. 9. Over expression of HDAC1/HDAC2 rescue BxPC-3 cells from BITC-induced 
apoptosis. (Mol Cancer Ther. 2010: 9(6);1596-608). 
5. BITC induces ROS generation, DNA damage and cell cycle arrest in 
pancreatic cancer cells 
As many drugs induce cell death in cancer cells by triggering ROS generation, it was quite 
obvious to see whether BITC could induce ROS generation in pancreatic cancer cells. In 
agreement with other drugs, BITC caused significant generation of H2O2 in Capan-2 cells in 
a dose and time dependent manner (Fig. 10). On the contrary, BITC induced a modest 
increase in the generation of hROS, such as singlet oxygen, superoxide, nitric oxide, 
hydroxyl and alkyl peroxide radicals in response to BITC treatment.  
Eventually, BITC-induced ROS production substantially increased the phosphorylation of 
stress sensors, such as ERK (Thr202/Thy204), JNK (Thr183/Tyr185) and P38 
(Thr180/Tyr182), (Fig. 11). The activation of ERK and JNK was as early as1 h after BITC 
treatment and was sustained until 12h. On the other hand, activation of P38 was observed 
around 24 h of BITC treatment (Sahu et al., 2009b).  
BITC–induced ROS generation also resulted in DNA damage as evidenced by the 
phosphorylation of H2A.X at Ser-139, which is considered to be the hall mark of DNA 
double strand breaks (Sedelnikova et al., 2003). Interestingly, when BITC-treated cells were 
cultured in fresh medium without BITC for additional 48h cells showed persistent H2A.X 
phosphorylation (Fig. 12), indicating that BITC induce permanent DNA damage in Capan-2 
cells (Zhang et al., 2006). As protective mechanism, DNA damage lead to cell cycle arrest to 
obtain brief window of time to compensate/repair the damage that occurred due to ROS 
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production. Accordingly, treatment of Capan-2 cells with BITC (10µM) for 24h resulted in 
the increased accumulation of cells in G2/M phase (42%) (Srivastava, 2004). The increased 
expression and phosphorylation of Chk2 (Thr-68) by BITC treatment caused G2/M arrest. 
Furthermore,   BITC also decreased the phosphorylation and expression of Cdc25C (ser-216), 
Cdc2 (Tyr-15) and Cyclin B1in apan-2 cells, as compared to control cells (Fig.12).  
 
Fig. 10. BITC induces ROS generation in Capan-2 cells. (Carcinogenesis 2009: 30;1744–1753). 
 
 
Fig. 11. BITC induces phosphorylation of MAP kinases. (Carcinogenesis 2009: 30;1744–1753). 
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Fig. 12. Effect of BITC on cell cycle proteins. (J. Nutr. 2006: 136; 2728–2734). 
Interestingly, although ERK, JNK and P38 were activated in response to BITC treatment, 
they had different roles in BITC-induced cell cycle arrest and apoptosis. MEK-1 inhibitor 
PD98059 significantly abrogated BITC induced G2/M cell cycle arrest and apoptosis (Fig. 
13A, B&D). Whereas, both JNK (SP600125) and P38 (SB202190) inhibitors failed to protect 
the cells from BITC-mediated G2/M cell cycle arrest. Further, MEK-1 inhibitor blocked 
BITC-mediated activation of ERK as well as down-regulation of G2/M regulatory proteins 
such as cyclin-dependent kinase-1 (Cdk1), cyclin B1, Cdc25C and cleavage of caspase-3 and 
PARP, suggesting the involvement of ERK in BITC-induced G2/M cell cycle arrest and 
apoptosis (Fig. 13C). BITC-mediated apoptosis was almost completely blocked in the cells 
pre-treated with ERK, JNK or P38 inhibitors as evaluated by cell death apoptosis ELISA 
assay (Fig.13D). Similar results were obtained with MAPK8-shRNA in Capan-2 cells, 
indicating that all the MAPK were involved in BITC-induced apoptosis but only ERK was 
involved in BITC-induced cell cycle arrest. 
Involvement of BITC-induced ROS generation in cell cycle arrest and apoptosis was further 
confirmed by treatment with antioxidants such as NAC, tiron, GSH and SOD. BITC-induced 
phosphorylation of MAPK and down regulation of cell cycle proteins such as GSH, Cdk1, 
Cdc25C, Cyclin B1 were significantly blocked by the treatment also with NAC (Fig.14). 
Furthermore, BITC-induced apoptosis was inhibited when cells were pre-treated with 
antioxidants, such as tiron, GSH and SOD. These results indicate that BITC induces ROS in 
pancreatic cancer cells which leads to DNA damage, cell cycle arrest and apoptosis.  
Molecular Targets of Benzyl Isothiocyanates in Pancreatic Cancer 203 
 
Fig. 13. MAPK inhibitors rescue pancreatic cancer cells from BITC induced apoptosis and 
cell cycle arrest. (Carcinogenesis 2009: 30;1744–1753). 
 
 
Fig. 14. Antioxidants protects Capan-2 cells from BITC-induced cell cycle arrest and 
apoptosis. (Carcinogenesis 2009: 30;1744–1753). 
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6. BITC sensitizes human pancreatic cancer cells to radiation and TRAIL 
treatment 
Increased systemic toxicity and resistance are the major drawbacks of radiation therapy in 
pancreatic cancer treatment. Interestingly, BITC potentiated therapeutic effect of γ-
irradiation in BxPC-3 cells. BxPC-3 cells were pre-treated with 2.5 or 5 µM BITC for 24h, 
followed by treatment with different doses of γ-irradiation (2.5, 5, 10 and 20Gy) at a dose of 
4Gy/minute. The cells were allowed for 24 or 48h before being analyzed for survival assay. 
BxPC-3 cells pre-treated with BITC and treated with 5Gy γ-irradiation show intense cell 
death, as compared to either treatment alone, indicating that BITC sensitizes the cells to γ-
irradiation (Sahu et al., 2009c). Furthermore, as shown in Table 1, more cells were 
accumulated in G2/M arrest in response to combination treatment, as compared to either 
treatment alone. In addition, expression of cell cycle proteins Chk2 and Cdc25 was increased 
in combination treated cells, as compared to control cells. Interestingly, DNA damage 
markers H2A.X (Ser-139) and ATR (Ser-428) also increased in combination treatment, 
indicating that BITC sensitizes cells to γ-irradiation. In agreement with cell cycle data, 
apoptosis induction was more in combination treated cells. 
Similarly, BITC also potentiated the apoptosis inducing activity of TRAIL in pancreatic cancer 
cells. BxPC3 cells had a 3.84 fold increase in apoptosis upon treatment with BITC alone, an 8.65 
fold increase was observed with TRAIL alone, and a 12.39 fold increase was seen when cells 
were treated with BITC combined with TRAIL. Similarly, Panc-1 cells underwent a 1.49 fold 
increase in apoptosis upon treatment with BITC, a 1.82 fold increase with TRAIL alone, and a 
3.45 fold increase with BITC combined with TRAIL compared to vehicle. Interestingly, 
sensitization of pancreatic cancer cells to TRAIL by BITC was more in Kras wild type cells 
(BxPC-3) as compared to Kras mutated cells (PanC-1 and MIA PaCa-2). Further studies are 
needed to elucidate the role of Kras mutation in TRAIL or BITC-induced apoptosis.  
7. BITC inhibits pancreatic cancer angiogenesis 
Pancreatic tumors can acquire substantial development of new blood vessels in a process 
called angiogenesis (Philip, 2008). This vascular development is a necessary component of 
solid tumor growth and progression. Numerous reports have shown that disrupting tumor 
angiogenesis could effectively inhibit tumor growth and metastasis. BITC has shown 
promising potentials as anti-angiogenesis agent for pancreatic cancer vitro and in vivo. 
In a rat aorta ring assay model, treatment with 5 µM BITC reduced sprouting of new blood 
vessels by 67% as compared to control aortic rings (Fig. 15A). Furthermore, 5 µmol BITC 
treatment drastically (70%) suppressed new embryonic blood vessel growth in each egg as 
compared to control eggs in a CAM assay model (Fig. 15B), indicating that BITC has 
potential to inhibit tumor angiogenesis (Boreddy et al., 2011b). 
BITC was also effective in suppressing the secretion of pro-angiogenic factors from pancreatic 
cancer cells under both, normoxia and hypoxia conditions. Hypoxia alone induced the 
secretion of both MMP-2 and VEGF around 2-4 folds in both BxPC-3 and PanC-1 cells; 
however, BITC significantly inhibited the secretion of both VEGF and MMP-2 from the both 
BxPC-3 and PanC-1 cells under normoxia and hypoxia conditions (Fig. 16A-D). Interestingly, 
BITC significantly inhibited the migration and invasion of both, BxPC-3 and PanC-1 cells in a 
dose dependent manner. These steps are critical for the migration of the tumor cells in vivo. 
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Furthermore, BITC was quite effective in down regulating various angiogenic factors such 
as, HIF1-α, VEGFR-2, MMP-2, Rho A, Rho C and RAC1,2,3 in dose dependent manner in 
BxPC-3 and PanC-1 cells (Fig. 17A). Similarly, BITC inhibited the expression of angiogenic 
proteins in human endothelial cells (HUVEC) (Fig. 17B), in a dose dependent manner. 
Interestingly, BITC was ineffective in STAT3-overexpressing BxPC-3 cells. Furthermore, 
when STAT-3 was silenced in BxPC-3 cells the molecular changes were similar to that of 
BITC treatment changes indicating that BITC inhibits tumor angiogenesis by targeting 




Fig. 17. BITC down regulates the critical molecules of angiogenesis in BxPC-3, PanC-1 and 
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8. BITC suppresses pancreatic tumor growth and angiogenesis in vivo 
BITC exhibited similar results in vivo as observed in culture. Tumor growth in BITC-fed 
mice was substantially retarded, as compared to control mice. Tumors appeared to grow 
more slowly in BITC-fed mice as compared with control mice. For example, 6 weeks after 
treatment with12 μmol BITC, the average tumor volume in control mice was about 1.92-fold 
higher than that in BITC-treated mice (mean tumor volume, control vs BITC treated: 334 
vs172 mm3, difference = 162 mm3, 95% CI = 118 to 204 mm3 ;P = .008; Fig.18A). Furthermore, 
average tumor weight in BITC-treated mice was 225mg, whereas in control mice tumor 
weight was 425mg (Fig. 18B), indicating that BITC potentially suppress the growth of 
pancreatic tumors in vivo. Interestingly, BITC-treated mice did not show any toxicity 
symptoms such as weight loss (Fig. 18C). 
  
Fig. 18. BITC suppresses the growth of pancreatic cancer xenografts in vivo. (J Natl Cancer 
Inst 2009;101: 176-193). 
It is noteworthy that when animals were orally gavaged with 12µmol/day BITC for 46 days, 
mean BITC concentration in plasma after1 hour of BITC administration was 6.5 ± 0.1 mmol/ 
L (n=10), whereas accumulated BITC concentration in the tumors after 46 days was 7.5 ± 0.3 
µmol/g (n=10). These results indicate that the therapeutic concentration of BITC could be 
achieved in vivo by oral feeding. 
A 76% reduction in hemoglobin content was observed in BITC-treated matrigel plugs that 
were implanted in Nu-Nu athymic nude mice as compared to untreated plugs (Fig. 19A). 
Similarly, BITC-treated tumor xenografts showed 61% reduced hemoglobin content as 
compared to untreated xenografts (Fig. 19B).  
Tumors excised from BITC-treated mice showed reduced phosphorylation of STAT3 (Tyr-
705 and Ser-727) (Fig. 20A), AKT (Ser-473 and Ser-308), FOXO1 (Ser-256) and FOXO3a (Ser-
253) (Fig. 20B). Furthermore, protein expression of STAT3 and angiogenic proteins (Fig. 
20C) was down regulated, whereas expression of AKT, FOXO1, FOXO3a remained 
unaltered. Nonetheless, Bim expression was significantly increased in BITC-treated tumor as 
compared to vehicle alone treated tumors indicating that the in vivo effect of BITC was 
similar to in vitro effects.   
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Fig. 19. BITC inhibits angiogenesis in vivo. (Clin Cancer Res 2011: 17(7); 1784–1795).  
 
 
Fig. 20. BITC down regulates key molecules of survival and angiogenesis pathways. (Natl 
Cancer Inst 2009;101: 176-193. Clin Cancer Res 2011: 17(7); 1784–1795. PLoS ONE 2011: 6(10); 
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9. Conclusion 
9.1 Does BITC have multiple targets in pancreatic cancer? 
Since, BITC inhibits the phosphorylation and protein levels of various key survival 
molecules such as STAT3, AKT and NFkB, indicating that BITC has multiple targets in 
pancreatic cancer. However, at this time, it is not clear whether BITC is targeting various 
survival pathways individually or it is the tandem effect upstream regulators. Since 
previous reports showed that STAT3 is being regulated by AKT through FOXO1 
(Kortylewski  et al., 2003) and NFkB is a direct target of AKT (Dan, 2008), presently we 
assume that AKT is the main target of BITC and other targets are obligated events but 
further studies are needed to conclude interaction of these pathways (Fig. 21). 
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Gemcitabine has been the standard chemotherapy for advanced pancreatic cancer since 
1997, when a randomized phase III study demonstrated that gemcitabine significantly 
improved cancer-related symptoms in comparison with 5-fluorouracil (5-FU) (Burris et al., 
1997). However, the survival benefit of gemcitabine is modest and the median survival 
time was 5.7 and 4.4 months for gemcitabine and 5-FU arm, respectively. Thus the 
prognosis of this disease still remains dismal and the development of a more effective 
therapy is urgently needed in daily clinical practice. For the past decade, many efforts 
have been made to improve the overall survival of patients with this disease by adding a 
second cytotoxic agent to gemcitabine. Several large phase III trials have compared 
gemcitabine alone with gemcitabine combination therapy (e.g. capecitabine, 5-
fluorouracil, irinotecan, oxaliplatin, pemetrexed). However, none of them could 
demonstrate a significant survival advantage for the gemcitabine combination therapy 
over the gemcitabine monotherapy, despite a significant improvement in response rates 
(Berlin et al., 2002; Herrmann et al., 2007; Louvet et al., 2005; Oettle et al., 2005; Rocha Lima 
et al., 2004). It is likely that the benefit of adding a second cytotoxic agent to gemcitabine is 
countered by increased toxicity and the decreased dose intensity of gemcitabine. 
Therefore, a new approach other than adding cytotoxic agents to gemcitabine is 
warranted. Since pancreatic cancer patients often suffer from cancer-related symptoms 
(e.g. fatigue, appetite loss, pain), it is very important to maintain a balance between 
efficacy and quality of life in palliative chemotherapy.  
Curcumin is derived from turmeric (Curcuma longa) and is a natural polyphenol (Figures 
1 and 2). Curcumin has long been used as a food (e.g. the popular Indian curry), coloring 
agent and traditional medicine (Aggarwal et al., 2007; Strimpakos & Sharma, 2008).  
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Fig. 1. Turmeric (left panel) and curcumin (right panel)  
 
Fig. 2. Chemical structure of curcumin 
A number of preclinical studies have demonstrated the anticancer effects of curcumin in a 
variety of tumors including pancreatic cancer, both in vitro and in vivo, and these promising 
data are now attracting the interest of many researchers in developing this agent as a 
chemopreventive as well as a chemotherapeutic drug (Corson & Crews, 2007). In contrast to 
conventional cytotoxic drugs, curcumin causes little toxicity, which is a great advantage of 
developing this agent for the treatment of pancreatic cancer patients, who are often 
intolerant to cytotoxic combination therapy due to their poor clinical condition. Safety is 
another advantage of this agent. The safety of curcumin has been approved by the Food and 
Drug Administration (FDA) and World Health Organization (WHO); however, its safety is 
most strongly supported by the fact that this agent has been used as a traditional Hindu or 
Chinese medicine for thousands of years. In this chapter, we highlight the potential role of 
curcumin for the treatment of pancreatic cancer by reviewing the published preclinical and 
clinical data. 
2. Anticancer effects of curcumin 
A Pubmed search using the key words ‘curcumin’ and ‘cancer’ demonstrated that more than 
1500 articles have been published since 1983 and that this number has rapidly increased 
over the past 5 years (Figure 3). The potential anticancer effects of curcumin have been 
reported in a variety of preclinical models including breast, colon, gastric, head and neck, 
hepatic, ovarian, pancreatic and prostate cancer, leukemia and multiple myeloma, and well 
described in several review articles (Aggarwal et al., 2007; Shishodia et al., 2007; Strimpakos 
& Sharma, 2008). Curcumin can modulate a variety of molecules which play an important 
role in cancer progression. Among these molecules, nuclear transcription factor-B (NF-B) 
is one of the major targets of curcumin. Diverse upstream signals (e.g. growth factors, 
cytokines, hypoxia) can induce constitutive NF-B activation in patients with cancer, 
including those with pancreatic cancer, and its activity is positively correlated with cancer 
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progression (Fujioka et al., 2003; Wang et al., 1999). For example, NF-B activation can up-
regulate the expression of a number of genes involved in anti-apoptosis (e.g. Bcl-2, Bcl-xL), 
proliferation (e.g. cyclin D1, c-myc), angiogenesis (e.g. vascular endothelial growth factor 
(VEGF), interleukin-6), and invasion (e.g. matrix metalloproteinases (MMP)), all of which 
play a pivotal role in cancer progression (Aggarwal, 2004). Therefore, inhibition of NF-B 
activity by curcumin can effectively suppress tumor growth (Figure 4).  
 
Fig. 3. Pubmed search results using the key words ‘curcumin’ and ‘cancer’ 












Fig. 4. NF-B is one of the major molecular targets of curcumin 
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Other mechanisms involved in the anticancer effects of curcumin include the down-
regulation of Akt, cyclooxygenase-2 (COX2), prostaglandin E2 or signal transducers and 
activators of transcription 3 (STAT3) (Aggarwal & Shishodia, 2006), which prevents cancer 
cells from escaping through alternative signaling pathways. Curcumin can also potentiate 
the anticancer effects of cytotoxic agents such as cisplatin, 5-fluorouracil and gemcitabine 
(Du et al., 2006; Kunnumakkara et al., 2007; Tsai et al., 2011). 
3. Preclinical data on anticancer effects of curcumin 
Li et al. first reported the anticancer effects of curcumin on pancreatic cancer cells in vitro (Li 
et al., 2004). They demonstrated that curcumin can suppress tumor growth of pancreatic 
cancer cell lines in a time and dose dependent manner through NF-B inhibition. The 
efficacy of curcumin in vivo has also been demonstrated using an orthotopic mouse model of 
pancreatic cancer (Kunnumakkara et al., 2007). While treatment with either curcumin (1 
g/kg orally) or gemcitabine (25 mg/kg through intraperitoneal injection) demonstrated 
modest antitumor effects, the combination of curcumin with gemcitabine suppressed tumor 
growth more effectively than curcumin or gemcitabine alone. As expected, inhibition of NF-
B activity as well as the down-regulation of a variety of NF-B-dependent gene products 
(cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, 
matrix metalloproteinase and VEGF) was observed in orthotopic tumor tissue after 
administration of curcumin. Other preclinical studies have also demonstrated the anticancer 
effects of curcumin either alone or in combination with gemcitabine in pancreatic cancer (Ali 
et al., 2010; Strimpakos & Sharma, 2008; Wang et al., 2006).  
Based on these promising preclinical data, the main focus of research has now moved on to 
demonstrating the anticancer effects of curcumin in clinical trials. 
4. Clinical trials using curcumin in patients with pancreatic cancer 
Although the number of clinical trials is still limited compared to the numerous preclinical 
studies, several phase I or pharmacokinetic studies have been conducted with curcumin and 
found no dose limiting toxicity (DLT) up to at least 12 g/day when administered orally in 
both healthy volunteers (Lao et al., 2006; Vareed et al., 2008) and cancer patients (Cheng et al., 
2001; Garcea et al., 2005; Sharma et al., 2004). Minor toxicities of Grade 1-2 diarrhea and 
nausea have been reported, probably due to the oral intake of a bulky volume of curcumin 
at one time. Higher doses than 8 g/day of oral curcumin do not cause any DLT; however, 
these bulky volumes are unacceptable for daily oral intake. Moreover, doses above 8 g/day 
did not lead to a further increase in plasma curcumin levels due to poor bioavailability 
(Cheng et al., 2001; Lao et al., 2006; Vareed et al., 2008). For these reasons, 8 g of daily oral 
curcumin is accepted to be the optimal dose for clinical trials in cancer patients.  
Dhillon et al. were the first to report a phase II clinical trial, using 8 g of daily oral curcumin 
in patients with pancreatic cancer (Dhillon et al., 2008). Twenty-five patients were enrolled 
in this study and 22 patients (88%) had a history of prior chemotherapy. Out of the 22 
patients evaluable for response, 2 patients demonstrated some clinical benefit. One patient 
had stable disease for more than 18 months and the other patient achieved a partial response 
in a liver metastasis (73% decrease in the size), although it lasted for only 1 month. 
Curcumin was safe in patients with pancreatic cancer and no toxicity associated with 
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curcumin intake was reported. Furthermore, inhibition of NF-B activity after curcumin 
intake was demonstrated using peripheral mononuclear cells from patients.  
We also conducted a phase I/II clinical trial using curcumin for patients with pancreatic 
cancer who had become resistant to gemcitabine-based chemotherapy (Kanai et al., 2010). In 
contrast to the study by Dhillon et al. which tested the safety and efficacy of curcumin 
monotherapy, our study evaluated the safety and feasibility of adding curcumin to 
gemcitabine-based chemotherapy, because no previous studies had demonstrated the safety 
and feasibility of this combination. In the phase I study, the safety of 8 g of daily curcumin 
in combination with gemcitabine-based chemotherapy was evaluated. In line with previous 
reports evaluating curcumin monotherapy, the first 3 assessable patients enrolled for the 
phase I study completed their first cycle without a predefined DLT (Grade 4 leucopenia; 
Grade 4 neutropenia; Grade 3 or more thrombocytopenia; non-hematological of Grade 3 or 
more; patient refusal due to the intolerability of curcumin intake). Therefore, we selected 
this dose as the recommended dose for the following phase II study. In total, 21 patients 
who showed disease progression during gemcitabine-based chemotherapy (gemcitabine/S-
1 combination therapy for 19 patients and gemcitabine monotherapy for 2 patients) were 
enrolled. Adding curcumin did not increase the risk of clinically relevant toxicity, and the 
toxicity profile was comparable with that observed in pancreatic cancer patients treated 
with gemcitabine-based chemotherapy. No patients showed intolerance to 8 g of daily oral 
curcumin, and the median compliance rate was as high as 100% (range 79-100%), indicating 
that there was little toxicity due to curcumin even if administered concurrently with 
cytotoxic agents. Cumulative toxicity due to curcumin was not observed and 4 patients were 
able to continue this intake for more than 6 months, which indicates the safety of this agent 
for long-term use. Albeit the preliminary results from a small sample size, the median 
survival time (MST) of 161 days (95% CI 109-223 days) and a 1-year survival rate of 19% 
(95% CI 4.4-41.4%) were encouraging considering the poor prognosis of pancreatic cancer 
patients for whom gemcitabine-based chemotherapy has failed (Figure 5).  
 
Fig. 5. Overall survival of patients with advanced pancreatic cancer treated with 
gemcitabine-based chemotherapy plus curcumin (n = 21) (adapted from Kanai et al. 2011) 
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Interestingly, several patients reported an improvement in cancer- or chemotherapy-related 
symptoms (e.g. fatigue, pain, constipation). We cannot rule out the placebo effect; however, 
several preclinical studies demonstrating that curcumin can improve fatigue, depression or 
neuropathic pain support our current observation (Gupta et al., 2011; Sharma et al., 2006; Xu 
et al., 2005). Therefore, curcumin could improve the quality of life of patients with pancreatic 
cancer by alleviating cancer-related symptoms, and this could indirectly contribute to the 
improved overall survival.  
Recently, another clinical trial has been reported by Epelbaum et al., who investigated the 
efficacy and feasibility of curcumin in combination with gemcitabine monotherapy in 
patients with advanced pancreatic cancer (Epelbaum et al., 2010). Seventeen chemo-naïve 
patients were enrolled and received a standard dose and schedule of gemcitabine in 
combination with 8 g of daily oral curcumin. In contrast to our results showing a good 
compliance rate and low toxicity using 8 g of daily oral curcumin, this study reported that 5 
patients (29%) discontinued curcumin after a few days to 2 weeks due to intractable 
abdominal fullness or pain. Furthermore, the dose of curcumin was reduced to 4 g/day 
because of abdominal complaints in 2 other patients. They discussed the possibility that 
increased gastrointestinal toxicity could be caused by the combination of curcumin and 
gemcitabine and concluded that 8 g of oral curcumin is not feasible when combined with 
gemcitabine in patients with pancreatic cancer. The reasons for the discrepancy between our 
study and that of Epelbaum et al. are unclear at this moment. Ethnic differences may exist in 
compliance to the combination therapy of curcumin and gemcitabine. Another possible 
explanation is that the patients’ clinical condition at base line was poorer in Epelbaum’s 
study than in ours, and abdominal fullness or pain could therefore be mainly attributable to 
cancer-related symptoms. 
Table 1 summarizes the published clinical trials using curcumin in patients with pancreatic 
cancer.  
Dhillon et al. Epelbaum et al. Our study
Sample size 25 17 21
Study design Phase II Phase II Phase I/II
Study period 2008* 2004-2006 2008-2009







Toxicity none 5 (Abdominal
discomfort )
none
* Publication year  
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5. Development of a new form of curcumin with improved bioavailability 
Several investigators, including ourselves, have tested plasma curcumin levels in clinical 
trials, and most studies report that plasma curcumin levels remained at low ng/ml levels in 
spite of taking gram doses of curcumin (Cheng et al., 2001; Garcea et al., 2005; Kanai et al., 
2010; Sharma et al., 2004; Shoba et al., 1998) (Table 2). As described in the previous section, 
the intake of more than 8 g of oral curcumin did not lead to a further increase in plasma 
curcumin levels in human subjects (Cheng et al., 2001; Lao et al., 2006; Vareed et al., 2008). 
Thus, poor bioavailability is the major weak point of curcumin and has been the main 
challenge for physicians seeking to verify the therapeutic efficacy of this promising agent in 
clinical trials. Therefore, many efforts have been made to improve its bioavailability 
through several approaches including innovative drug delivery systems (liposomes, 
nanoparticles and phospholipids) (Anand et al., 2010; Antony et al., 2008; Bisht et al., 2007; 
Das et al., 2010; Gupta et al., 2009; Koppolu et al., 2010; Li et al., 2005; Liu et al., 2006; 
Marczylo et al., 2007; Mukerjee & Vishwanatha, 2009; Sahu et al., 2008; Shaikh et al., 2009; 
Sou et al., 2008; Takahashi et al., 2009), or the development of new curcumin analogues 
(Lin et al., 2011; Mosley et al., 2007; Ohori et al., 2006; Sato et al., 2011). A nanoparticle-
based drug delivery system is effective in improving the water solubility of hydrophobic 
agents like curcumin, and the development of at least 8 different types of nanoparticle-






level  (mean ± SE)
Reference
Healthy volunteers 2 g/day 8 6 ± 5 ng/ml  (Shoba et al. , 1998)
Patients with precancerous
lesions
8 g/day 2 651 ± 688 ng/ml  (Cheng et al. , 2001)
Patients with colorectal ca. 3.6 g/day 3 4 ± 0.2 ng/ml  (Sharma et al. , 2004)
Healthy volunteers 12 g/day 3 (1) 57 ng/ml*1  (Lao et al. , 2006)
Patients with colorectal ca. 3.6 g/day 3 below 1 ng/ml  (Garcea et al. , 2005)
Healthy volunteers 8 g/day 6 2300 ± 260 ng/ml  (Vareed et al. , 2008)
Patients with pancreatic ca. 8 g/day 5 134 ± 70 ng/ml  (Kanai et al. , 2010)
Healthy volunteers 0.03 g/day*2 7 29.5± 13 ng/ml  (Sasaki, 2011)
Healthy volunteers 0.21 g/day*2 6 275 ± 67 ng/ml  (Kanai et al. , 2011)
*1 Plasma curcumin was detected in only one subject.
*2 THERACURMIN was used in these studies  
Table 2. Comparison of the published plasma curcumin levels in human subjects (adapted 
from Kanai et al. 2011) 
®
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Das et al., 2010; Gupta et al., 2009; Mukerjee & Vishwanatha, 2009; Sasaki, 2011; Shaikh et 
al., 2009; Sou et al., 2008). 
Out of these new forms of nanoparticle-based curcumin, we chose to focus on 
THERACURMIN®, which demonstrated a more than 30-fold higher bioavailability compared 
to that of conventional curcumin in rat models (Sasaki, 2011). We conducted a dose-escalation 
and pharmacokinetic study using this newly developed nanoparticle curcumin to verify its 
improved bioavailability in human subjects. Six healthy human volunteers were recruited and 
received THERACURMIN® at a single oral dose of 150 mg. After an interval of 2 weeks, the 
same subjects then received THERACURMIN® at a single oral dose of 210 mg. Cmax for 
THERACURMIN® at 150 mg and 210 mg was 189 ± 48 and 275 ± 67 ng/ml (mean ± S.E.M.), 
respectively and the area under the curve for 24 h was estimated to be 2649 ± 350 and 3649 ± 
430 ng/ml × h (mean ± S.E.M.), respectively (Figure 6. Kanai, 2011).  
These results indicate that an intake of 150 mg of THERACURMIN® could lead to similar or 
even higher plasma curcumin levels in comparison with those observed after the intake of 8 
g of conventional curcumin (Table 2). As for the safety, only one subject reported grade 1 
diarrhea lasting from day 1 to day 4 after 150 mg of THERACURMIN® intake. However, 
diarrhea did not recur after the second, 210 mg dose of THERACURMIN® intake in this 
subject. No other adverse events were observed. These results suggest that 
THERACURMIN® can safely increase plasma curcumin levels in a dose dependent manner 
up to at least 210 mg without saturating the absorption system. If we can achieve higher 
plasma curcumin levels, there is a greater chance that patients will benefit from this agent. 
Therefore, we consider that this new form of curcumin could be a promising tool when 
testing the potential anticancer effects of curcumin in clinical trials, and we are now 
conducting clinical trials to test this new agent in patients with pancreatic cancer.  
 
Fig. 6. Time course of plasma curcumin levels after intake of 150mg (solid line) and 210 mg 
(dash line) of THERACURMIN® (n = 6). Error bar represents S.E.M. (adapted from Kanai et 
al. 2011) 
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6. Conclusion 
More and more data support the idea that curcumin could be a promising anticancer drug. 
Curcumin can exhibit anticancer effects through inhibiting diverse signaling pathways with 
minimal toxicity. On the other hand, poor bioavailability has been the main challenge in 
demonstrating the benefits of this promising agent in clinical trials. This problem has now 
been overcome by the development of nanoparticle curcumin and we can achieve higher 
plasma curcumin levels without saturating the absorption system. We are now conducting 
clinical trials to test the safety and efficacy of this new form of curcumin in patients with 
pancreatic cancer. 
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1. Introduction  
Patients with pancreatic cancer have an especially poor prognosis, with a 5-year survival 
rate of <1% and a median survival of 4-6 months (Jemal, Siegel et al., 2010). The 
management of patients with pancreatic cancer depends on the extent of the disease at 
diagnosis. However, approximately 80% of patients present with advanced-stage disease 
that precludes surgical resection (pancreaticoduodenectomy) and long-term survival is poor 
(Sener, Fremgen et al., 1999). Even after resection, the majority of patients relapse, leading to 
a median survival of about 18 months after resection (Neoptolemos, Stocken et al., 2004). In 
this time, gemcitabine-based chemotherapy is typically offered as standard of care. 
However, most patients treated with gemcitabine alone do not survive longer than 6 
months, as the tumor cells are naturally resistant to current chemotherapy (Neoptolemos, 
Stocken et al., 2004). Importantly, the tumors that develop gemcitabine resistance would still 
be a suitable target for immunotherapy. Therefore, cancer immunotherapy for pancreatic 
cancer may be one attractive approach to treatment. This chapter summarizes the effect of 
immunotherapy for inducing cytotoxic T lymphocytes (CTLs) in patients with pancreatic 
cancer and discusses recent advances in concept of combination therapy of immunotherapy 
and chemotherapy. 
2. Chemotherapy 
Gemcitabine (2’2’-difluorodeoxycytidine) is a synthetic pyrimidine nucleoside analog that 
has become the standard first-line treatment for patients with advanced pancreatic cancer 
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based on clinical benefit and survival improvement compared with 5‑fluorouracil (5-
FU)‑based chemotherapy (Burris, Moore et al., 1997). Gemcitabine is phosphorylated 
intracellularly to difluorodeoxycytidine triphosphate, which terminates DNA-chain 
elongation and competitively inhibits DNA polymerase and ribonucleotide reductase, 
leading the cells into the apoptotic pathway (Storniolo, Allerheiligen et al., 1997). However, 
most patients treated with gemcitabine alone do not survive longer than 6 months. 
Moreover, the addition of the cytotoxic agents (platinums, fluoropyrimidines, or 
topoisomerase inhibitors) or radiation therapy to gemcitabine did not lead to a 
statistically significant improvement in overall survival (OS) in patients with metastatic 
pancreatic cancer (Moore, Goldstein et al., 2007; Van Cutsem, Verslype et al., 2007; Philip 
2008b; Cascinu, Berardi et al., 2008). Recently, Thierry Conroy and colleagues randomly 
assigned 342 patients to receive combination chemotherapy regimen of FOLFIRINOX 
(consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin) (n=171) or gemcitabine 
(n=171) (Conroy, Desseigne et al., 2011). In selected patients with good performance 
status ECOG 0-1, the FOLFIRINOX regimen, when compared with gemcitabine, was 
associated with significantly increased median survival from 6.8 to 11.1 months. 
However, as compared with gemcitabine, FOLFIRINOX had increased toxicity. 
Gemcitabine is still the reference treatment in patients with ECOG performance status 2. 
Therefore, there is still great need for a novel therapeutic approach with low toxicity for 
advanced pancreatic cancer. Cancer immunotherapy for pancreatic cancer may be one 
attractive approach to cancer treatment. 
3. Targeted therapy 
The era of targeted therapies has generated a lot of interest in discovering better approaches 
for patients with pancreatic cancer. While traditional cytotoxic drugs also target specific 
cellular process, the newer generation of agents is set apart by their targeting of a pathway 
or molecule that derives the growth, speed, survival, or maintenance of tumor cells 
specially. Overexpression of human epidermal growth factor receptor type 1 (HER1/EGFR) 
has been suggested to be associated with the malignant transformation of pancreatic cancer 
(Tobita, Kijima et al., 2003). Therefore, there is a sound rationale for combining HER1/EGFR 
inhibitor and gemcitabine in pancreatic cancer. Erlotinib (Taraceva, Genentech, South San 
Francisco) is a small molecule HER1/EGFR tyrosine kinase inhibitor. Pancreatic cancer 
patients given the combination of erlotinib with gemcitabine showed a statistically 
significant improved survival compared with those given gemcitabine alone (Moore, 
Goldstein et al., 2007). The median and 1-year survival rates were better for the combination 
treatment: 6.24 months versus 5.91 months and 23% versus 17%, respectively. Therefore, the 
US Food and Drug Administration (FDA) recently approved erlotinib for use in the first-line 
setting of advanced pancreatic cancer in combination with gemcitabine. However, this 
survival benefit was small and, therefore, erlotinib has not yet been widely incorporated 
into standard treatment protocols. On the other hand, cetuximab, a monoclonal antibody, 
has been shown to significantly suppress the growth of implanted pancreatic cancer cells, 
and this effect was enhanced by the addition of gemcitabine in mice study (Bruns, Harbison 
et al., 2000). The study evaluating cetuximab in pancreatic cancer has been completed. In 
patients with advanced pancreas cancer, cetuximab did not improve the outcome compared 
with patients treated with gemcitabine alone (Philip, Benedetti et al., 2010). Moreover, the 
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addition of cetuximab to gemcitabine did not contribute to improvement in the patient-
reported health-related quality of life (HRQL) outcomes (Moinpour, Vaught et al., 2010). 
The next generation of single-target trials is moving toward a focus on antiangiogenic 
agents, including anti-VEGF and anti-VEGFR strategies combined with gemcitabine. 
However, the addition of Axitinib that is a potent, selective inhibitor of vascular endothelial 
growth factor (VEGF) receptors 1, 2, and 3 tyrosine kinase also did not improve overall 
survival in advanced pancreatic cancer (Kindler, Ioka et al., 2011). These results add to 
increasing evidence that targeting of EGFR or VEGF signaling is an ineffective strategy in 
pancreatic cancer. Other chemotherapy, including S-1, ixabepilone, nanoparticle albumin-
bound (nab) paclitaxel, FOLFOX (5-FU, leucovorin, oxaliplatin), and XELOX (capecitabine, 
oxaliplatin) may be better partners with targeted agents (Philip 2008a). 
4. Immunotherapy  
T cells with the αβ T-cell receptor (TCR) generally express CD4+ or CD8+ lineage markers 
and mostly fall into helper or cytotoxic subsets, respectively (Boon, Coulie et al., 1997). On 
the other hand, T cells expressing the alternate γδ TCR generally do not express lineage 
markers. Although CD8+ naive T cells recognize peptides (usually 8-10 amino acids) 
derived from tumor-associated antigens (TAAs) bound by major histocompatibility complex 
(MHC) class I molecules on tumor cells, it is not sufficient to initiate a productive generation 
of antigen-specific CTLs. Induction of CD8+ CTLs need peptides derived from TAAs to be 
presented on the surface of antigen presenting cells (APCs) in the context of MHC 
molecules. Moreover, CD4+ T cells recognize peptides (usually 10-30 amino acids) in 
association with MHC class II molecules on APCs and mediate their helper functions by 
enhancing the persistence of antigen-specific CD8+ CTLs or through secretion of cytokines 
such as interleukin (IL)-2 and interferon (IFN)-γ (Steinman and Swanson 1995; Banchereau 
& Steinman 1998). Therefore, the αβ TCR interaction with complex of peptides and MHC 
class I and class II molecules on APCs is a central event in T-cell-mediated antitumor 
immune responses. Antigen-specific CD8+ CTLs can respond to TAAs derived peptides 
presented in the context of MHC class I molecules on tumor cells. Therefore, efforts have 
focused on generating TAAs-specific αβ CD8+ CTLs (Waldmann 2003). 
Dendritic cells (DCs) are powerful APCs that play a pivotal role in the initiation, 
programming, and regulation of tumor-specific immune responses (Steinman 1991). DCs 
can process endogenously synthesized antigens into antigenic peptides, presented to the cell 
surface as MHC class I-peptide complexes, and recognized by the αβ TCR in CD8+ naive T 
cells (Steinman 1991). DCs are also capable of capturing and processing of exogenous 
antigens, and presenting antigenic peptide on MHC class I molecules through an 
endogenous pathway, a process known as antigen cross-presentation (Berard, Blanco et al., 
2000). In the case of cancer, cross-presentation after uptake and processing of soluble or 
particulate matter from apoptotic, necrotic cancer or even live cancer cells is the only 
important natural mode of presentation (Melief 2003). On the other hand, exogenous 
antigens from the extracellular environment are captured and delivered to the 
compartments of the endosome/lysosome, where they are degraded to antigenic peptides 
by proteases and peptidases, which are complexed with MHC class II and recognized by the 
αβ TCR in CD4+ naive T cells (Steinman 1991). Although both immature and mature DCs 
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based on clinical benefit and survival improvement compared with 5‑fluorouracil (5-
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cellular process, the newer generation of agents is set apart by their targeting of a pathway 
or molecule that derives the growth, speed, survival, or maintenance of tumor cells 
specially. Overexpression of human epidermal growth factor receptor type 1 (HER1/EGFR) 
has been suggested to be associated with the malignant transformation of pancreatic cancer 
(Tobita, Kijima et al., 2003). Therefore, there is a sound rationale for combining HER1/EGFR 
inhibitor and gemcitabine in pancreatic cancer. Erlotinib (Taraceva, Genentech, South San 
Francisco) is a small molecule HER1/EGFR tyrosine kinase inhibitor. Pancreatic cancer 
patients given the combination of erlotinib with gemcitabine showed a statistically 
significant improved survival compared with those given gemcitabine alone (Moore, 
Goldstein et al., 2007). The median and 1-year survival rates were better for the combination 
treatment: 6.24 months versus 5.91 months and 23% versus 17%, respectively. Therefore, the 
US Food and Drug Administration (FDA) recently approved erlotinib for use in the first-line 
setting of advanced pancreatic cancer in combination with gemcitabine. However, this 
survival benefit was small and, therefore, erlotinib has not yet been widely incorporated 
into standard treatment protocols. On the other hand, cetuximab, a monoclonal antibody, 
has been shown to significantly suppress the growth of implanted pancreatic cancer cells, 
and this effect was enhanced by the addition of gemcitabine in mice study (Bruns, Harbison 
et al., 2000). The study evaluating cetuximab in pancreatic cancer has been completed. In 
patients with advanced pancreas cancer, cetuximab did not improve the outcome compared 
with patients treated with gemcitabine alone (Philip, Benedetti et al., 2010). Moreover, the 
Immunotherapy for Pancreatic Cancer 227 
addition of cetuximab to gemcitabine did not contribute to improvement in the patient-
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can process endogenously synthesized antigens into antigenic peptides, presented to the cell 
surface as MHC class I-peptide complexes, and recognized by the αβ TCR in CD8+ naive T 
cells (Steinman 1991). DCs are also capable of capturing and processing of exogenous 
antigens, and presenting antigenic peptide on MHC class I molecules through an 
endogenous pathway, a process known as antigen cross-presentation (Berard, Blanco et al., 
2000). In the case of cancer, cross-presentation after uptake and processing of soluble or 
particulate matter from apoptotic, necrotic cancer or even live cancer cells is the only 
important natural mode of presentation (Melief 2003). On the other hand, exogenous 
antigens from the extracellular environment are captured and delivered to the 
compartments of the endosome/lysosome, where they are degraded to antigenic peptides 
by proteases and peptidases, which are complexed with MHC class II and recognized by the 
αβ TCR in CD4+ naive T cells (Steinman 1991). Although both immature and mature DCs 
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are capable of processing and presenting MHC/peptide complexes to TCR, mature DCs are 
significantly better at CTL induction due to higher expression of MHC class I and class II 
and costimulatory molecules (Banchereau & Steinman 1998). On the other hand, 
presentation of antigens by immature DCs, in the absence of proper costimulation, may lead 
to tolerance induction (Banchereau & Palucka 2005). After antigens uptake and 
inflammatory stimulation, immature DCs in peripheral tissues undergo a maturation 
process characterized by the up-regulation of MHC class I and class II and costimulatory 
molecules, chemokine receptors such as CCR7, and the secretion of cytokines such as IL-12 
(Banchereau & Steinman 1998; Forster, Schubel et al., 1999; Steinman 1991). During the 
process, mature DCs migrate to T-cell areas of secondary lymphoid organs, where they 
present antigens to CD4+ and CD8+ T cells through MHC class I and class II pathways, 
respectively (Steinman 1991; Banchereau & Steinman 1998; Banchereau & Palucka 2005). The 
αβ TCR in CD8+ CTL can recognize MHC class I-peptide complexes on cancer cells and 
destroy cancer cells through effector molecules such as granzyme B and perforin (Finn 
2008). On the other hand, γδ T cells generally do not require MHC for antigen presentation, 
and recognize nonpeptidic antigens. As effective antitumor responses depend on the 
presence and function of immune cells that are able to recognize and eliminate cancer cells, 
the aim of immunotherapy is to activate both CD8+ CTLs that recognize TAAs-specific 
antigens and CD4+ T helper (Th) cells that mediate helper function.  
4.1 Immune homeostasis 
Now, it is becoming clear that CD4+ Th cells are critical in combating cancer cells and 
maintaining immune homeostasis. Upon TCR-mediated cell activation, naive CD4+ T cells 
can differentiate into at least four major polarization patterns including Th1, Th2, 
regulatory T (Treg), and Th17 cells, all of which participate in different types of immune 
responses (Zhu & Paul 2010) (Fig. 1). Mainly, immune homeostasis is controlled by two 
distinct helper T cell subsets, Th1 and Th2 cells. The Th1 cells secrete type I cytokines such 
as IFN-γ, tumor necrosis factor (TNF)-α, and TNF-β, to activate DCs, which can regulate 
the survival and persistence of CD8+ CTLs as memory cells (Bachelet, Mariethoz et al., 
1998). IL-12 secreted from DCs is a potent inducer of Th1 differentiation. Both CD8+ CTLs 
and Th1 cells secrete IFN-γ, which can further sensitize tumor cells to CTLs by 
upregulation of MHC class I molecules on tumor cells and antigen-processing machinery 
of DCs (Steinman 1991). On the other hand, Th2 cells secrete type II cytokines, such as IL-
4 and IL-10 resulted in enhanced generation of a humoral immunity, antibody-based 
antitumor response (Steinman 1991; Bradley, Yoshimoto et al., 1995; Banchereau & 
Steinman 1998; Wiethe, Debus et al., 2008). The newly identified Th17 cells secrete IL-17 
and IL-22, eliciting tissue inflammation implicated in autoimmunity (Dong 2008). 
Importantly, cancer cells-derived soluble factors promote the induction of tolerance 
through the generation of CD4+α chain of IL-2R (CD25)+ forkhead box P3 (Foxp3)+ 
natural (n) Treg cell subset (Koido, Homma et al., 2008). Induced (i) Treg cells 
(CD4+CD25+Foxp3-) secrete transforming growth factor-β (TGF-β) and IL-10 and 
suppress effector T cells of either Th1 or Th2 phenotype in a cell contact and antigen-
specific manner (Shevach 2009; Mougiakakos, Choudhury et al., 2010). Treg cells play a 
pivotal role in the tumor progression and the suppression of antitumor immunity.  
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Fig. 1. Immune homeostasis. Upon TCR-mediated cell activation, naive CD4 T cells can 
differentiate into at least four major lineages, Th1, Th2, Treg, and Th17 cells, all of which 
participate in different types of immune responses. The Th1 cells produce signature type I 
cytokines, such as IFN-γ and IL-2 resulting in induction of CD8+ CTLs. Th2 cells secrete 
type II cytokines, such as IL-4 and IL-10. The Th2 response is associated with the humoral, 
antibody-based antitumor response. Treg cells that secrete TGF-β and IL-10 suppress Th1 or 
Th2 cells. Th17 cells secrete IL-17 and IL-22, eliciting tissue inflammation implicated in 
autoimmunity.  
4.2 Immunosuppression in tumor microenvironment 
Pancreatic cancer cells express TAAs such as Wilms' Tumor gene 1 (WT1) (Sugiyama 2005), 
mucin 1(MUC1) (Mukherjee, Ginardi et al., 2000), human telomerase reverse transcriptase 
(hTERT) (Seki, Suda et al., 2001), mutated K-RAS (Gjertsen, Bakka et al., 1995), survivin 
(Wobser, Keikavoussi et al., 2006), carcinoembryonic antigen (CEA) (Nair, Hull et al., 1999), 
HER-2/neu (Larbouret, Robert et al., 2007), or p53 (Hoffmann, Nakano et al., 2000) as 
potential targets for immunotherapy. Therefore, immunotherapy targeted such a TAA may 
be an approach in patients with advanced pancreatic cancer. However, the 
microenvironment in pancreatic cancer is consisted not only cancer cells but also stroma 
cells such as cancer-associated fibroblasts (CAFs), tolerogenic DCs, myeloid-derived 
suppressor cells (MDSCs), immunosuppressive tumor-associated macrophages (TAMs), and 
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the survival and persistence of CD8+ CTLs as memory cells (Bachelet, Mariethoz et al., 
1998). IL-12 secreted from DCs is a potent inducer of Th1 differentiation. Both CD8+ CTLs 
and Th1 cells secrete IFN-γ, which can further sensitize tumor cells to CTLs by 
upregulation of MHC class I molecules on tumor cells and antigen-processing machinery 
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(CD4+CD25+Foxp3-) secrete transforming growth factor-β (TGF-β) and IL-10 and 
suppress effector T cells of either Th1 or Th2 phenotype in a cell contact and antigen-
specific manner (Shevach 2009; Mougiakakos, Choudhury et al., 2010). Treg cells play a 
pivotal role in the tumor progression and the suppression of antitumor immunity.  
Immunotherapy for Pancreatic Cancer 229 
 
Fig. 1. Immune homeostasis. Upon TCR-mediated cell activation, naive CD4 T cells can 
differentiate into at least four major lineages, Th1, Th2, Treg, and Th17 cells, all of which 
participate in different types of immune responses. The Th1 cells produce signature type I 
cytokines, such as IFN-γ and IL-2 resulting in induction of CD8+ CTLs. Th2 cells secrete 
type II cytokines, such as IL-4 and IL-10. The Th2 response is associated with the humoral, 
antibody-based antitumor response. Treg cells that secrete TGF-β and IL-10 suppress Th1 or 
Th2 cells. Th17 cells secrete IL-17 and IL-22, eliciting tissue inflammation implicated in 
autoimmunity.  
4.2 Immunosuppression in tumor microenvironment 
Pancreatic cancer cells express TAAs such as Wilms' Tumor gene 1 (WT1) (Sugiyama 2005), 
mucin 1(MUC1) (Mukherjee, Ginardi et al., 2000), human telomerase reverse transcriptase 
(hTERT) (Seki, Suda et al., 2001), mutated K-RAS (Gjertsen, Bakka et al., 1995), survivin 
(Wobser, Keikavoussi et al., 2006), carcinoembryonic antigen (CEA) (Nair, Hull et al., 1999), 
HER-2/neu (Larbouret, Robert et al., 2007), or p53 (Hoffmann, Nakano et al., 2000) as 
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microenvironment in pancreatic cancer is consisted not only cancer cells but also stroma 
cells such as cancer-associated fibroblasts (CAFs), tolerogenic DCs, myeloid-derived 
suppressor cells (MDSCs), immunosuppressive tumor-associated macrophages (TAMs), and 
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Treg cells (Fig. 2). These immune suppressive cells secrete vascular endothelial growth 
factor (VEGF), IL-6, IL-10, TGF-β, soluble Fas ligand (Fas-L), and indolamine-2,3-
dioxygenase (IDO) (Koido, Homma et al., 2010c). As a result, immunosuppressive cells 
inhibit antitumor immunity by various mechanisms, including depletion of arginine and 
elaboration of reactive oxygen species (ROS) and nitrogen oxide (NO). The tumor 
microenvironment also promotes the accumulation of Treg cells that suppress CD8+ CTL 
function through secretion of IL-10 or TGF-β from Treg cells and tumors. Therefore, 
immunotherapies that struggle against pancreatic cancer cells with CTLs as well as 
inhibition of Treg cells may tip the balance in favor of immunostimulation. Currently, the 
field of cancer immunotherapy using peptide- or cell (DC or whole tumor cell)-based 
approaches is in an active state of preclinical and clinical investigations.  
 
Fig. 2. Immunosuppression in tumor microenvironment. Pancreatic cancer cells secrete 
various factors such as VEGF, IL-6, IL-10, TGF-β, Fas-L, and IDO, all of which promote the 
accumulation of heterogeneous populations of CAFs, TAMs, MDSCs, or tolerogenic DCs. 
These immunosuppressive cells in tumor microenvironment inhibit antitumor immunity by 
various mechanisms, including depletion of arginine and elaboration of ROS and NO. The 
tumor microenvironment also promotes the accumulation of Treg cells that suppress CD8+ 
CTL function. 
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5. Peptide vaccines 
Peptide-based cancer vaccines are preparations made from antigenic protein fragments that 
represent the minimal immunogenic region of TAA (Purcell and McCluskey 2007; Bijker, 
Melief et al., 2007). As peptide vaccines are simple, safe, stable, and economical, multiple 
MHC class I-binding peptides have been identified and vaccination with synthetic peptides 
has been examined for their immunogenicity in clinical trials for pancreatic cancer (Dummer 
2001; Jaffee, Hruban et al., 2001; Yanagimoto, Mine et al., 2007; Miyazawa, Ohsawa et al., 
2010). In early phase clinical trials, vaccination of mutant K-ras (Gjertsen, Bakka et al., 1995; 
Gjertsen, Buanes et al., 2001; Abou-Alfa, Chapman et al., 2011), MUC1 (Yamamoto, Ueno et 
al., 2005b; Ramanathan, Lee et al., 2005), or telomerase (Bernhardt, Gjertsen et al., 2006) 
peptide to patients with advanced pancreatic cancer are significantly associated with 
antitumor responses. As almost all pancreatic cancers involve mutations in the K-ras 
oncogene, it is believed that activating K-ras mutations are critical for initiation of pancreatic 
cancer (Gjertsen, Bakka et al., 1995; Gjertsen, Buanes et al., 2001; Abou-Alfa, Chapman et al., 
2011). In a clinical phase I/II trial involving 48 patients with pancreatic cancer (10 surgically 
resected and 38 with advanced disease), vaccination of synthetic mutant K-ras peptides in 
combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) produced 
immune responses to mutant K-ras and showed prolonged survival from the start of 
treatment compared to non-responders (Gjertsen, Buanes et al., 2001). Abou-Alfa et al. 
(Abou-Alfa, Chapman et al., 2011) also vaccinated 24 patients with resected pancreatic 
cancer with mutant K-ras peptide in combination of GM-CSF and found that the vaccination 
proved to be safe and tolerable with no elicitable immunogenicity and unproven efficacy. 
On the other hand, almost all pancreatic cancer cells also express MUC1 that is high 
molecular weight glycoproteins (Chhieng, Benson et al., 2003). The MUC1 peptide derived 
from tandem repeat core was also recognized by CD8+ T cells in an MHC-restricted and -
unrestricted manner. Therefore, MUC1 peptide vaccine was subsequently used in the 
immunization of patients with pancreatic cancer (Finn, Jerome et al., 1995). Ramanathan et 
al. (Ramanathan, Lee et al., 2005) used 100 mer MUC1 peptide with SB-AS2 adjuvant in 16 
patients with resected or locally advanced pancreatic cancer. They found that 100 mer 
MUC1 peptide with SB-AS2 adjuvant induced low but detectable MUC1-specific humoral 
and T-cell responses in some patients. Yamamoto et al. (Yamamoto, Ueno et al., 2005b) also, 
in a clinical phase I trial involving 6 patients with advanced pancreatic cancer, reported that 
vaccination with 100 mer MUC1 peptide and incomplete Freund's adjuvant resulted in 
increased circulating anti MUC1 IgG antibody in some patients. Moreover, human 
telomerase reverse transcriptase (hTERT) is the catalytic subunit of telomerase and a 
prototype for a novel class of universal tumor antigens due to its expression in the vast 
majority of human tumors (Beatty & Vonderheide, 2008). Therefore, it is one of widely 
applicable target antigen recognized by CTLs in pancreatic cancer. Bernhardt et al. 
(Bernhardt, Gjertsen et al., 2006) reported the results of a phase I trial of telomerase peptide 
in combination with GM-CSF for non-resectable pancreatic cancer patients (n=48). The 
immunotherapy was safe and induction of an immune response was correlated with 
prolonged survival. Recently, Itoh et al. (Itoh, Yamada et al., 2009) have developed 
personalized peptide vaccines. In this regimen, pre-vaccination peripheral blood 
mononuclear cells (PBMCs) were screened for their reactivity in vitro to each peptide in 
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mononuclear cells (PBMCs) were screened for their reactivity in vitro to each peptide in 
Pancreatic Cancer – Molecular Mechanism and Targets 232 
patients, and only the reactive peptides were used as vaccines to 11 patients with advanced 
pancreatic cancer. In the personalized peptide vaccine, increased cellular and humoral 
immune responses to at least one of peptides used for vaccination were observed in the 
post-vaccination PBMCs (Yamamoto, Mine et al., 2005a). In all of these peptide vaccines, 
only a limited success has occurred in clinical trials. Generally, the drawback of this strategy 
comes from numerous factors: (i) only a limited number of known synthesized antigenic 
peptides can be available (Mocellin, Pilati et al., 2009), (ii) CD8+ CTLs may be ineffective in 
reacting with pancreatic cancer cells due to down regulation of certain antigens and MHC 
class I molecules, (iii) impaired function of DCs in patients with advanced pancreatic cancer 
(Yanagimoto, Takai et al., 2005; Koido, Hara et al., 2010a), and (iv) tumor microenvironment 
where immune suppressive cells such as Treg cells, CAFs, MDSCs, or TAMs exist (Finn 2008). 
The more attractive peptide-based vaccines may be synthetic long peptides. As synthetic long 
peptides are not able to bind directly on MHC class I and class II molecules on DCs, they need 
to be taken up, processed and presented by DCs. Therefore, the long peptide vaccines can be 
presented on MHC class I and class II molecules long time resulted in induction of antigen-
specific polyclonal CD4+ and CD8+ T cells (Melief & van der Burg 2008; Bijker, van den Eeden 
et al., 2008). Peptide vaccines for the treatment of established pancreatic cancer may require 
long-lived presentation of epitopes by MHC class I and class II molecules on appropriately 
activated DCs. Such presentation is essential for induction of robust therapeutic CD4+ and 
CD8+ T-cell responses. Recently, Weden et al. (Weden, Klemp et al., 2011) treated 23 patients 
who were vaccinated after surgical resection for pancreatic cancer with long synthetic mutant 
K-ras peptides designed mainly to elicit T-helper responses. Surprisingly, 10-year survival was 
20% (four patients out of 20 evaluable) versus zero (0/87) in a cohort of nonvaccinated patient 
treated in the same period. The key elements for the development of therapeutic peptide 
vaccines for pancreatic cancer may be the combination with chemotherapy to overcome robust 
cancers. Indeed, Wobser et al. (Wobser, Keikavoussi et al., 2006) reported a case of complete 
remission (CR) of liver metastasis of pancreatic cancer refractory to gemcitabine chemotherapy 
under vaccination with a survivin peptide. Peptide vaccines alone should be tested in cancer 
patients in remission to prevent recurrence and metastasis after surgical resection. 
6. DC-based vaccines 
For T-cell activation, three signals are required: (i) effective presentation of multiple TAAs in 
MHC class I and class II molecules; (ii) costimulation by membrane-bound receptor-ligand 
pairs; and (iii) soluble factors to direct polarization of the ensuing efficient antitumor 
immune responses. DCs derive their potency from constitutive and inducible expression of 
essential costimulatory ligands on the cell surface including B7, ICAM-1, LFA-1, LFA-3, and 
CD40 (Inaba, Witmer-Pack et al., 1994). These proteins function in concert to generate a 
network of secondary signals essential for reinforcing the primary antigen-specific signal in 
T-cell activation (Inaba, Pack et al., 1997). Therefore, now it is clear that DCs have the ability 
to provide all three signals essential for induction of antitumor immunity (Banchereau & 
Palucka 2005). These findings have provided the rationale for ex vivo antigen loading of DC 
as vaccines. More than 200 clinical trials have been performed using DC as cellular 
adjuvants in cancer. Several strategies to deliver TAAs into DCs have been developed to 
generate potent antitumor immune responses (Fig. 3). 
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Fig. 3. Strategies to deliver defined or whole antigens to DCs. DCs used for cancer vaccines 
have been generated from the peripheral blood monocytes of the patients using cytokines 
including GM-CSF and IL-4 etc. To generate antigen-specific CTL responses against tumor 
cells, DCs loaded with synthetic peptide, antigenic cDNA, or mRNA have been used. 
Moreover, whole tumor associated antigens including defined and unidentified have been 
also loaded to DCs.  
DCs have been loaded with tumor antigens in the form of peptides (Nestle, Alijagic et al., 
1998), tumor lysates (Mackensen, Herbst et al., 2000), apoptotic tumor cells (Palucka, Ueno 
et al., 2006), or mRNA (Nair, Boczkowski et al., 1998; Koido, Kashiwaba et al., 2000). 
Alternatively, whole tumor cells have been fused with DCs to facilitate the entry of TAAs, 
including both known and unidentified, into the endogenous antigen-processing pathway 
in the DCs (Fig.4). The strategy for DC/tumor fusion vaccine is based on the fact that DCs 
are the most potent antigen-presenting cells in the body, whereas tumor cells express 
abundant tumor antigens. In animal studies, DC/tumor fusion vaccines have been shown to 
possess the elements essential for processing and presenting tumor antigens to host immune 
cells, for inducing effective immune response, and for breaking T-cell tolerance to TAAs 
(Gong, Chen et al., 1997; Koido, Hara et al., 2007; Gong, Koido et al., 2008; Koido, Hara et al., 
2009; Koido, Hara et al., 2010a; Koido, Homma et al., 2010b). Recently, we have reported 
that fusions of human pancreatic cancer cells and DCs induce CTL responses against 
pancreatic cancer cells in vitro (Koido, Hara et al., 2010a). Although DC/tumor fusion 
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vaccines have proven clinically safe and efficient to induce tumor-specific immune 
responses, only a limited number of objective clinical responses have been reported in 
cancer patients (Avigan, Vasir et al., 2004; Kikuchi, Akasaki et al., 2004; Homma, Kikuchi et 
al., 2005; Homma, Sagawa et al., 2006). 
 
Fig. 4. Fusions of DC and tumor cell. DC/tumor fusions express MHC class I and class II, 
costimulatory molecules (CD80 and CD86), and multiple tumor-associated antigens. The 
DC/tumor fusions are able to process multiple TAAs derived from tumor. They form MHC 
class I-peptide complexes, in the endoplasmic reticulum, which are transported to the cell 
surface of DC/tumor fusions and presented to CD8+ T cells. The DC/tumor fusions can also 
synthesize antigenic peptides in the endoplasmic reticulum, which are transported to the 
cytoplasm, where MHC class II-peptide complexes are assembled with multiple tumor-
derived peptides. These complexes are presented to CD4+ T cells, which are essential for 
induction of efficient antigen-specific polyclonal CTLs.  
Clinical trials of antigen-pulsed DCs have been conducted in patients with various types of 
tumors including pancreatic cancer. In a phase I/II clinical trial of a MUC1 peptide-loaded 
DC vaccines in pancreatic and biliary cancer patients following resection of their primary 
tumors, 4 of the 12 patients followed for over four years were alive, all without evidence of 
recurrence (Lepisto, Moser et al., 2008). Moreover, MUC1 specific immune responses were 
observed even in patients with pretreated and advanced disease, following immunization 
with DC transfected with MUC1 cDNA (Pecher, Haring et al., 2002). Findings from initial 
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clinical trials demonstrate that hTERT-specific immune responses can be safely induced in 
cancer patients. Suso et al. (Suso, Dueland et al., 2011) recently reported that vaccination 
with DC transfected with hTERT mRNA (DC/hTERT mRNA) had the potential to induce 
strong immune responses to multiple hTERT epitopes. In this therapy, a patient who could 
not continue chemotherapy due to sever neutropenia had been treated with DC/hTERT 
mRNA alone for 3 years and resulted in no evidence of active disease. Moreover the CR was 
associated with induction of hTERT-specific immune responses against several hTERT-
derived Th and CTL epitopes. Therefore, DC/hTERT mRNA may be an attractive approach 
to induce potent antitumor immunity. On the other hand, combined injection of unloaded 
DCs and activated lymphocytes resulted in prolonged survival of refractory pancreatic 
cancer patients (Nakamura, Wada et al., 2009). To improve the clinical efficacy of DC-based 
cancer vaccines, we need to design novel and improved strategies that can boost adaptive 
antitumor immunity to break overcome the immunosuppressive tumor microenvironment. 
7. Whole tumor cell-based vaccines 
Although cancer vaccines with defined TAAs are commonly used, the advantage of using 
autologous whole tumor cells is that tumor cells express a whole array of TAAs that are 
both characterized and uncharacterized. Moreover, this rich source of antigens contains 
epitopes of both CD8+CTLs and CD4+ T helper cells (Koido, Hara et al., 2005; Koido, Hara 
et al., 2009; Koido, Homma et al., 2010c). Thus, whole tumor cells could greatly diminish the 
chance of tumor escape compared to using single epitope peptide vaccines. In clinical trials, 
autologous tumor cells have been used as cancer vaccines to induce polyclonal CTL 
induction against colorectal (Harris, Ryan et al., 2000), renal cell cancer (Jocham, Richter et 
al., 2004), or melanoma (Berd, Sato et al., 2004), and several trials have shown clinical 
responses in the initial clinical studies. However, in many cases, even though a tumor-
specific immune response has been observed, none has shown significant efficacy in the 
randomized phase III trials. To improve immunogenicity of vaccines, autologous whole 
tumor cells have been genetically modified to secrete GM-CSF and have shown promising 
results in patients with prostate (Simons, Jaffee et al., 1997) renal cell (Simons, Mikhak et al., 
1999), metastatic non-small-cell lung carcinoma (Salgia, Lynch et al., 2003), and melanoma 
(Soiffer, Hodi et al., 2003). This approach is based on the concept that GM-CSF is required at 
the site of the tumor to prime TAAs-specific immunity effectively (Nemunaitis 2005).  
Autologous cancer cells would be the best source of immunizing proteins, however, only 10-
15% of pancreatic cancer patients diagnosed are eligible for surgical treatment. Therefore, 
autologous tumor cells may not be provided in almost of the patients with pancreatic 
cancer. Moreover, even if the patients are treated by surgical resection, it is difficult to 
prepare sufficient amounts of autologous tumor cells due to the length of culture time and 
potential contamination of bacteria and fungus (Koido, Hara et al., 2005a). To circumvent 
this problem, allogeneic pancreatic tumor cell lines with shared TAAs have been used 
instead of autologous tumor cells to deliver shared TAAs into autologous DCs (Jaffee, 
Hruban et al., 2001; Lutz, Yeo et al., 2011). The whole allogeneic tumor cell line-based 
vaccines have numerous advantages. (i) Allogeneic tumor cell lines that share one or even 
several of the TAAs as autologous tumor cells. (ii) Allogeneic tumor cell lines can be 
propagated in large quantities in cell factories. (iii) It is not necessary to determine HLA 
typing of patients and allogeneic tumor cells, because autologous DCs can process and 
Pancreatic Cancer – Molecular Mechanism and Targets 234 
vaccines have proven clinically safe and efficient to induce tumor-specific immune 
responses, only a limited number of objective clinical responses have been reported in 
cancer patients (Avigan, Vasir et al., 2004; Kikuchi, Akasaki et al., 2004; Homma, Kikuchi et 
al., 2005; Homma, Sagawa et al., 2006). 
 
Fig. 4. Fusions of DC and tumor cell. DC/tumor fusions express MHC class I and class II, 
costimulatory molecules (CD80 and CD86), and multiple tumor-associated antigens. The 
DC/tumor fusions are able to process multiple TAAs derived from tumor. They form MHC 
class I-peptide complexes, in the endoplasmic reticulum, which are transported to the cell 
surface of DC/tumor fusions and presented to CD8+ T cells. The DC/tumor fusions can also 
synthesize antigenic peptides in the endoplasmic reticulum, which are transported to the 
cytoplasm, where MHC class II-peptide complexes are assembled with multiple tumor-
derived peptides. These complexes are presented to CD4+ T cells, which are essential for 
induction of efficient antigen-specific polyclonal CTLs.  
Clinical trials of antigen-pulsed DCs have been conducted in patients with various types of 
tumors including pancreatic cancer. In a phase I/II clinical trial of a MUC1 peptide-loaded 
DC vaccines in pancreatic and biliary cancer patients following resection of their primary 
tumors, 4 of the 12 patients followed for over four years were alive, all without evidence of 
recurrence (Lepisto, Moser et al., 2008). Moreover, MUC1 specific immune responses were 
observed even in patients with pretreated and advanced disease, following immunization 
with DC transfected with MUC1 cDNA (Pecher, Haring et al., 2002). Findings from initial 
Immunotherapy for Pancreatic Cancer 235 
clinical trials demonstrate that hTERT-specific immune responses can be safely induced in 
cancer patients. Suso et al. (Suso, Dueland et al., 2011) recently reported that vaccination 
with DC transfected with hTERT mRNA (DC/hTERT mRNA) had the potential to induce 
strong immune responses to multiple hTERT epitopes. In this therapy, a patient who could 
not continue chemotherapy due to sever neutropenia had been treated with DC/hTERT 
mRNA alone for 3 years and resulted in no evidence of active disease. Moreover the CR was 
associated with induction of hTERT-specific immune responses against several hTERT-
derived Th and CTL epitopes. Therefore, DC/hTERT mRNA may be an attractive approach 
to induce potent antitumor immunity. On the other hand, combined injection of unloaded 
DCs and activated lymphocytes resulted in prolonged survival of refractory pancreatic 
cancer patients (Nakamura, Wada et al., 2009). To improve the clinical efficacy of DC-based 
cancer vaccines, we need to design novel and improved strategies that can boost adaptive 
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propagated in large quantities in cell factories. (iii) It is not necessary to determine HLA 
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present multiple TAAs from allogeneic tumor cells owing to cross-presentation in the 
context of autologous MHC class I and class II alleles. (iv) Both antigens-specific polyclonal 
CD4+ and CD8+ T cells can be induced simultaneously. While currently explored allogeneic 
approaches as whole tumor cell-based vaccines represent an improvement in terms of 
standardization over their autologous counterparts, they nevertheless entail the culture of 
large batches of cells under good manufacturing practice (GMP) grade conditions. Further 
optimization of these in vitro culture methodologies may be required. Moreover, the quality 
must be easily assessed and monitored in GMP facilities. One of the challenges that face the 
generation of whole allogeneic tumor-based vaccines for clinical use may be to overcome the 
potential hazards of fetal calf serum (FCS) (Koido, Hara et al., 2010a).  
In a phase I trial, cancer vaccines using irradiated allogeneic pancreatic cancer cells secreting 
GM-CSF were safe and induced systemic antitumor immunity in patients with surgically 
resected pancreatic cancer (Jaffee, Hruban et al. 2001). From the same group, GM-CSF 
secreting allogeneic pancreatic cancer cells alone or in sequence with cyclophosphamide in 
patients with advanced pancreatic cancer showed minimal treatment-related toxicity and 
induction of mesothelin-specific T-cell responses (Laheru, Lutz et al., 2008). In addition, 
cyclophosphamide-modulated immunotherapy resulted in prolonged overall survival in a 
gemcitabine-resistant population. Recently, a single institution phase II study of 60 patients 
with resected pancreatic adenocarcinoma was performed (Lutz, Yeo et al., 2011). This 
approach integrated with chemoradiation was safe and demonstrated prolonged overall 
survival in resected pancreas cancer. While this approach for pancreatic cancer is a safe and 
promising therapy, their clinical efficacy remains to be established. Further clinical 
evaluation of the approach in patients with pancreatic cancer is warranted. 
8. Combined therapy of immunotherapy and chemotherapy 
In established pancreatic cancer patients, the effect of immunotherapy alone is limited by 
the number of CTLs able to penetrate tumor and by the number of tumor cells expressing 
specific antigens. Even if large numbers of CTLs generated ex vivo were injected into the 
patients, CTLs cannot penetrate into tumor site because of tumor stroma. Moreover, in 
tumor site, Treg cells or MDSCs produce immunosuppressive cytokines such as IL-10 and 
TGF-β As a result, antitumor clinical responses may not induce in patients with advanced 
pancreatic cancer treated with immunotherapy alone. 
Cytotoxic chemotherapy is well known to blunt immune responses, because of its toxicity 
for dividing cells in peripheral lymphoid tissue as well as the bone marrow. Indeed, several 
of the cancer chemotherapeutics agents such as cyclophosphamide (Weiner and Cohen 
2002) and methotrexate (Weinblatt, Coblyn et al., 1985) are also used as 
immunosuppressants for the treatment of severe systemic autoimmune diseases. Therefore, 
the chemotherapeutic approach was considered to be inappropriate based on a widely held 
belief that the immunosuppressive effects of the chemotherapy would negate the efficacy of 
cancer vaccines (Zitvogel, Apetoh et al., 2008). However, increasing evidences have been 
mounting to suggest that immunotherapy has the possibility of achieving better success 
when used in combination with conventional chemotherapy (Gabrilovich 2007; Smith, 
Kasamon et al., 2010). Gemcitabine that is a standard cytotoxic agent for pancreatic cancer 
has been also generally considered immunosuppressive due to neutropenia and 
lymphopenia being common adverse side effects. There is increasing evidence, however, 
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that gemcitabine plays important roles in the induction of antitumor immune responses. 
Gemcitabine inhibited B cells (Nowak, Robinson et al., 2002) and CD11b+GR1+ MDSCs 
(Suzuki, Kapoor et al., 2005), the phenomenon that may skew antitumor immunity towards 
beneficial T‑cell responses (Qin, Richter et al., 1998). Moreover, gemcitabine treatment in 
patients with pancreatic cancer induced the proliferation of CD14+ monocytes and CD11c+ 
DCs (Soeda, Morita-Hoshi et al., 2009). To induce efficient therapeutic CTL responses, cross-
presentation of TAAs by DCs is essential. Treatment of pancreatic cancer cells and DCs with 
gemcitabine results in enhanced cross-presentation of TAAs by DCs, CTL expansion, and 
infiltration of the tumor, all of which are associated with augmented CTL (Nowak, Lake et 
al., 2003a; Nowak, Robinson et al., 2003b; Dauer, Herten et al., 2005; Correale, Cusi et al., 
2005). A recent report that chemotherapeutic agents caused up-regulation of cation-
independent mannose 6-phosphate receptor (CI-MPR) expression on cancer cells and a 
concurrent increase in the uptake of granzyme B by activated CTLs also strongly suggests 
chemotherapy can function in synergy with induction of CTL responses to cure established 
pancreatic cancer (Ramakrishnan, Assudani et al., 2010).  
These findings open a novel field of investigations for future clinical trial design, taking into 
account the immunostimulatory capacity of chemotherapeutic agents such as gemcitabine, 
and using them in combined chemoimmunotherapy strategies in patients with pancreatic 
cancer (Correale, Aquino et al., 2003; Nowak, Lake et al., 2003a; Correale, Cusi et al., 2005; 
Dauer, Herten et al., 2005; Correale, Del Vecchio et al., 2008). Now the immunostimulatory 
effects of gemcitabine have been confirmed in patients with cancer. In patients with 
pancreatic (Plate, Plate et al., 2005), nonsmall-cell lung (Levitt, Kassem et al., 2004) or colon 
(Galetto, Buttiglieri et al., 2003) cancer, standard cytotoxic agent, gemcitabine combined 
with recombinant cytokines or cancer vaccines could synergistically enhanced the frequency 
of tumor-specific CTL precursors. Therefore, patients with advanced pancreatic cancer have 
been treated by combination therapy of gemcitabine with peptide vaccine. For instance, both 
clinical and immune responses to personalized peptide vaccination combined with 
gemcitabine were evaluated in 21 patients with non-resectable pancreatic cancer 
(Yanagimoto, Mine et al., 2007; Yanagimoto, Shiomi et al., 2010). In this report, the reactive 
personalized peptides (maximum of 4 kinds of peptides) were administered with 
gemcitabine. Median overall survival time of all 21 patients was 9.0 months with a one-year 
survival rate of 38%. Immune boosting in both cellular and humoral responses was well 
correlated with overall survival. Combination therapy of a epitope peptide from vascular 
endothelial growth factor receptor 2 (VEGFR2) with gemcitabine was also conducted in 18 
patients with metastatic and unresectable pancreatic cancer (Miyazawa, Ohsawa et al., 
2010). The median overall survival time of all 18 patients who completed at least one course 
of the treatment was 8.7 months. Moreover, VEGFR2-specific CTL responses could be 
induced by the combination therapy. Similar findings were observed in 5 patients with 
inoperable locally advanced pancreatic cancer using gemcitabine, OK-432 stimulated DCs 
injected into the tumor sites, and intravenous infusion of lymphokine-activated killer (LAK) 
cells stimulated with anti-CD3 monoclonal antibody (Hirooka, Itoh et al., 2009). In this 
regimen, one patient had partial remission (PR) and 2 had long stable disease (SD) more 
than 6 months. Recently, we also reported that combination therapy of DC-based 
immunotherapies with gemcitabine/S-1 was effective in patients with advanced pancreatic 
cancer refractory to standard chemotherapy (Kimura, Imai et al., 2011). As WT1 is one of the 
excellent TAAs for the target of immunotherapy and is frequently expressed in pancreatic 
cancer cells (Oka, Tsuboi et al., 2004; Cheever, Allison et al., 2009), 38 out of 49 patients had 
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present multiple TAAs from allogeneic tumor cells owing to cross-presentation in the 
context of autologous MHC class I and class II alleles. (iv) Both antigens-specific polyclonal 
CD4+ and CD8+ T cells can be induced simultaneously. While currently explored allogeneic 
approaches as whole tumor cell-based vaccines represent an improvement in terms of 
standardization over their autologous counterparts, they nevertheless entail the culture of 
large batches of cells under good manufacturing practice (GMP) grade conditions. Further 
optimization of these in vitro culture methodologies may be required. Moreover, the quality 
must be easily assessed and monitored in GMP facilities. One of the challenges that face the 
generation of whole allogeneic tumor-based vaccines for clinical use may be to overcome the 
potential hazards of fetal calf serum (FCS) (Koido, Hara et al., 2010a).  
In a phase I trial, cancer vaccines using irradiated allogeneic pancreatic cancer cells secreting 
GM-CSF were safe and induced systemic antitumor immunity in patients with surgically 
resected pancreatic cancer (Jaffee, Hruban et al. 2001). From the same group, GM-CSF 
secreting allogeneic pancreatic cancer cells alone or in sequence with cyclophosphamide in 
patients with advanced pancreatic cancer showed minimal treatment-related toxicity and 
induction of mesothelin-specific T-cell responses (Laheru, Lutz et al., 2008). In addition, 
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gemcitabine-resistant population. Recently, a single institution phase II study of 60 patients 
with resected pancreatic adenocarcinoma was performed (Lutz, Yeo et al., 2011). This 
approach integrated with chemoradiation was safe and demonstrated prolonged overall 
survival in resected pancreas cancer. While this approach for pancreatic cancer is a safe and 
promising therapy, their clinical efficacy remains to be established. Further clinical 
evaluation of the approach in patients with pancreatic cancer is warranted. 
8. Combined therapy of immunotherapy and chemotherapy 
In established pancreatic cancer patients, the effect of immunotherapy alone is limited by 
the number of CTLs able to penetrate tumor and by the number of tumor cells expressing 
specific antigens. Even if large numbers of CTLs generated ex vivo were injected into the 
patients, CTLs cannot penetrate into tumor site because of tumor stroma. Moreover, in 
tumor site, Treg cells or MDSCs produce immunosuppressive cytokines such as IL-10 and 
TGF-β As a result, antitumor clinical responses may not induce in patients with advanced 
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Cytotoxic chemotherapy is well known to blunt immune responses, because of its toxicity 
for dividing cells in peripheral lymphoid tissue as well as the bone marrow. Indeed, several 
of the cancer chemotherapeutics agents such as cyclophosphamide (Weiner and Cohen 
2002) and methotrexate (Weinblatt, Coblyn et al., 1985) are also used as 
immunosuppressants for the treatment of severe systemic autoimmune diseases. Therefore, 
the chemotherapeutic approach was considered to be inappropriate based on a widely held 
belief that the immunosuppressive effects of the chemotherapy would negate the efficacy of 
cancer vaccines (Zitvogel, Apetoh et al., 2008). However, increasing evidences have been 
mounting to suggest that immunotherapy has the possibility of achieving better success 
when used in combination with conventional chemotherapy (Gabrilovich 2007; Smith, 
Kasamon et al., 2010). Gemcitabine that is a standard cytotoxic agent for pancreatic cancer 
has been also generally considered immunosuppressive due to neutropenia and 
lymphopenia being common adverse side effects. There is increasing evidence, however, 
Immunotherapy for Pancreatic Cancer 237 
that gemcitabine plays important roles in the induction of antitumor immune responses. 
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patients with metastatic and unresectable pancreatic cancer (Miyazawa, Ohsawa et al., 
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inoperable locally advanced pancreatic cancer using gemcitabine, OK-432 stimulated DCs 
injected into the tumor sites, and intravenous infusion of lymphokine-activated killer (LAK) 
cells stimulated with anti-CD3 monoclonal antibody (Hirooka, Itoh et al., 2009). In this 
regimen, one patient had partial remission (PR) and 2 had long stable disease (SD) more 
than 6 months. Recently, we also reported that combination therapy of DC-based 
immunotherapies with gemcitabine/S-1 was effective in patients with advanced pancreatic 
cancer refractory to standard chemotherapy (Kimura, Imai et al., 2011). As WT1 is one of the 
excellent TAAs for the target of immunotherapy and is frequently expressed in pancreatic 
cancer cells (Oka, Tsuboi et al., 2004; Cheever, Allison et al., 2009), 38 out of 49 patients had 
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received vaccination with WT1 peptide pulsed DCs with or without combination of other 
peptides such as MUC1, CEA and CA125 in this report. Prior to this combination therapy, 46 
out of 49 patients had been treated with chemotherapy, radiotherapy, heavy particle 
radiotherapy, or hyperthermia, but elicited no significant effects. In spite of these handicapped 
conditions, surprisingly, of 49 patients, 2 patients showed CR, 5 PR, and 10 SD, and median 
survival time was 360 days. We recently reported that gemcitabine sensitized the pancreatic 
cancer cells with WT1 specific T cell-mediated antitumor responses in vitro (Takahara, Koido 
et al., 2011), also supporting the significance of the combination therapy (Fig.5). In this study, 
gemcitabine treatment of human pancreatic cancer cells increased WT1 mRNA, and this 
increase was associated with nuclear factor kappa B (NF-B) activation. Gemcitabine treatment 
also shifted WT1 protein from the nucleus to the cytoplasm, which may promote proteasomal 
processing of WT1 protein and generation of antigenic WT1 peptide. Moreover, presentation 
of HLA-A*2402-restricted WT1 peptide increased in gemcitabine-treated pancreatic cancer 
cells. Indeed, we observed clinical response in a phase I clinical trial of combination therapy of 
WT1 peptide vaccine and gemcitabine (manuscript in preparation). Pancreatic cancer cells 
already, which have acquired gemcitabine resistance by the activation of NF-kB might be 
killed by WT1-specific CTLs. Assessment of the clinical response to the combined therapy of 
WT1 peptide vaccine and gemcitabine is presently underway. 
   
Fig. 5. Synergistic therapeutic antitumor effects of gemcitabine and WT1-specific CTLs. 
Gemcitabine enhanced WT1 expression in human pancreatic cancer cells and sensitized 
pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune responses. 
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Although the concept is still far from being firmly established, these reports may be 
sufficient to provide a platform for the combination of immunotherapy with chemotherapy. 
A combined approach of conventional therapies such as radiation or chemotherapy kill the 
bulk of tumor cells and CTLs that target TAAs may represent a promising approach for the 
treatment of patients with advanced pancreatic cancer. Evaluation is warranted to examine 
the effect of the combined approach on disease-free survival and overall survival. 
9. Immunotherapy targeting cancer stem cells 
It has been well known that the majority of patients with advanced pancreatic cancer that 
respond initially to standard chemotherapies ultimately undergo relapse due to the survival 
of small populations of cells with cancer-initiating/cancer stem cell (CSC) fraction (Wang, Li 
et al., 2011). These CSCs are a subpopulation of the tumor more capable than other cancer 
cells (CC) to self-propagate, initiate new tumors differentiate into bulk tumor, and therefore 
sustain tumor growth. It has been reported that pancreatic cancer cells resistant to 
chemoradiotherapy are rich in CSC fraction (Du, Qin et al., 2011). Moreover, CSCs could be 
 
Fig. 6. Combination therapies of immunotherapy and standard radio- and chemotherapy. 
Currently applied standard therapies such as radio- and chemotherapy target bulk CCs that 
are less resistant than CSCs. This leads to initial regression of the tumor mass but eventually 
regrowth from residual CSCs. Combined therapies of standard therapies and 
immunotherapeutic approach targeting CSCs would cut off the rejuvenating supply of CSCs 
and resulted in tumor eradication. 
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expanded during the acquisition of gemcitabine resistance (Hong, Wen et al., 2009). Thus, 
targeted therapy against CSC fraction that is resistant to chemotherapy could be applied to 
overcome drug resistance in the treatment of pancreatic cancer (Fig. 6). Importantly, the 
tumors that develop chemotherapeutic drug resistance would still be a candidate target for 
immunotherapy. TAAs can be classified into two categories: i) CSC-specific antigens, such 
as SOX2 (Hong, Wen et al., 2009) or ALDH1A1 (Inoda, Hirohashi et al., 2011) and ii) shared 
antigens, such as CEP55 (Hirohashi, Torigoe et al., 2010), MUC1 (Engelmann, Shen et al., 
2008; Weng, Song et al., 2010), or WT1 (Cheever, Allison et al., 2009; Sugiyama 2010) 
between CSCs and more differentiated subpopulations. Therefore, the development of 
strategies that target the CSC population by immunotherapy may be highly desirable. For 
example, DC-based cancer vaccine, γδ T cells, or natural killer (NK) cells killed human 
cancer stem cells (Pellegatta, Poliani et al., 2006; Todaro, D'Asaro et al., 2009; Pietra, Manzini 
et al., 2009; Weng, Song et al., 2010), in vitro. Success of these potential therapies will depend 
on how well immunological responses to CSCs can be modulated for example by vaccines 
upregulating antigen-processing and -presentation in DCs. Recently, we used fusions of DC 
and CSC to activate potent CSC-specific CTL responses and resulted in expression CTLs 
with elevated levels of IFN-γ and enhanced killing of CSCs in vitro (Weng, Song et al., 2010). 
Moreover, the classification of conclusive CSC markers followed by the identification of 
defined T cell-recognized CSC epitopes in the future may also lead to the clinical application 
of anti-CSC vaccination strategies.  
10. Conclusion 
The prognosis of patients with pancreatic cancer remains grim, and current thinking toward 
the development of curative therapy is likely to require eradication of the CSC population. 
A combined approach of conventional therapies such as radiation or chemotherapy kill the 
bulk of pancreatic cancer and CTLs that target CSC and CC fraction may represent a more 
promising approach for the treatment of patients with advanced pancreatic cancer. Clinical 
evaluation is warranted to examine the effect of the combined approach earlier in the 
disease course and in patients with less aggressive disease. 
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1. Introduction 
Mesothelin (MSLN) is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein 
and differentiation antigen. MSLN gets its name from typically limited expression in the 
mesothelial lining of the pleural cavity, where it was first identified in 1996 by Chang and 
Pastan1. The human MSLN gene (localized to 16p21)2 encodes a 71-kDa precursor protein that 
is cleaved by furin-like proteinases to produce an amino-terminal 31 kDa soluble fragment, 
termed the megakaryocyte-potentiating factor (MPF), which is released to the extracellular 
fluid, and a carboxy-terminal 40 kDa membrane-bound fragment1,3,4. 
The normal function of MSLN has remained elusive. Following the initial report of 
megakaryocyte colony-forming activity5, a mutant mouse model generated by homologous 
recombination showed that platelet numbers in both wild-type and MSLN null mice, were 
not changed, which suggested that MSLN is not required for megakaryocyte growth and 
differentiation in vivo6. These mice also showed no discernable phenotype, indicating that 
either MSLN does not play a significant role in vivo or that other molecules may be filling in 
for MSLN by playing a similar role in normal tissues. MSLN is predicted to have a 
superhelical structure made of ARM-type helical repeats, and is thereby predicted to 
function as superhelical lectins that bind the extracellular carbohydrate moiety of 
glycoproteins7. Supporting a potential role in cell-to-cell adhesion, it has been shown that 
MSLN interacts with mucin MUC16 to enhance cell-cell binding, which can play a role in 
leading to peritoneal metastatic dissemination of tumors8. 
Where the importance of MSLN is evident in the progression of cancers. MSLN is 
overexpressed in a variety of cancers, including mesotheliomas, stomach, and endometrial 
cancers, as well as in squamous cell carcinomas of the esophagus, lung, and cervix9,10. In 
addition, several studies have reported the overexpression of MSLN in virtually all human 
pancreatic ductal adenocarcinomas11. In tumors, MSLN may function as a mediator of cell 
survival under anchorage-independent conditions, where it facilitates anchorage-
independent growth and confers resistance to anoikis12.  
2. Mesothelin in pancreatic cancers 
Despite the fact that it is only the tenth most common type of cancer and accounts for only 
6% of new cancer cases in North America, pancreatic cancer is the deadliest cancer, with the 
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Despite the fact that it is only the tenth most common type of cancer and accounts for only 
6% of new cancer cases in North America, pancreatic cancer is the deadliest cancer, with the 
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worst prognosis of all solid tumors13. Due to its highly aggressive nature characterized by 
invasive growth and early metastasis, and compounded by late diagnosis and lack of 
effective therapies for treatment, pancreatic cancer remains the fourth leading cause of 
cancer-related deaths, 35,000 deaths from 42,000 new cases per year3,14 and a 5 year survival 
rate of less than 5%13,14.  
In addition to its role in other cancers, MSLN is increasingly becoming established as a key 
factor in human pancreatic adenocarcinomas. The soluble fragment of MSLN, MPF, was first 
detected in the supernatant of the HPC-Y5 human pancreatic cell line in 1994 5. In fact, HPC-
Y5 had the highest MPF activity of 64 cancer cell lines tested, implicating MPF as an 
important factor in pancreatic anomalies. The latest research confirms the MPF is in fact 
responsible for increased phosphorylation of ERK1/2, leading to a decreased rate of cell 
death and an increase in cell number15. 
MSLN expression has since been assessed in pancreatic cancers, where it is found to be 
overexpressed in a majority of pancreatic ductal adenocarcinomas4,9,16, with little expression 
in normal pancreas and chronic pancreatitis11. In their studies, for instance, Argani et al. 
used serial analysis of gene expression (SAGE) as well as in situ hybridization, RT-PCR, and 
immunohistochemistry to show that MSLN is consistently overexpressed in 60 of 60 
pancreatic tumors. Meanwhile, MSLN does not seem to be expressed in normal pancreatic 
tissues 4,17,18. Recently, for instance, Glass et al. showed that MSLN 24 of 42 (57%) 
adenocarcinomas stained for MSLN, while only 0 of 16 non-carcinomas (0%) did so19.  
Exactly what the molecular mechanisms are which give rise to MSLN overexpression are 
not well documented. However, a recent study attributed MSLN overexpression in 
pancreatic cancers to an upstream enhancer element containing a transcription enhancer 
factor (TEF-1) dependent MCAT motif termed Canscript2, although the presence of this 
factor was required but not sufficient for MSLN expression. The oncogenic transcription co-
factor YAP1, normally phosphorylated and inactivated by the Hippo-YAP1 pathway, has 
been implicated in the activation of MSLN expression through the regulation of Canscript 
activity. Knocking down YAP1 expression in HeLa cells dramatically reduced endogenous 
MSLN expression and suppressed Canscript reporter activity; yet overexpression of YAP1 
in HEK293 cells did not turn on MSLN expression, indicating that YAP1 may be necessary 
but not sufficient for MSLN overexpression20. Another study analyzed the methylation state 
of several pancreatic cancer-associated genes, and found that MSLN was hypomethylated in 
adenocarcinoma compared to its methylated state in normal pancreatic tissues, indicating an 
epigenetic event trigger is involved in MSLN overexpression21.  
Pancreatic cancer studies have revealed roles for MSLN in increasing aggressiveness of 
tumor cells, including enhancement of proliferation and migration. Li et al. found that 
overexpression of MSLN is also associated with an increased S-phase cell population in a 
cell cycle analysis. This resulted in a 90% increase in proliferation for MIA-PaCa2 cells 
overexpressing MSLN compared to vector controls16. Subsequent studies by Bharadwaj et al. 
elucidated a mechanism through which MSLN promotes proliferation of pancreatic cancer 
cells through alteration of Cyclin E as a result of constitutive activation of Signal Transducer 
and Activator of Transcription protein 3 (STAT3)3. Bharadwaj et al. have further shown that 
MSLN overexpression results in upregulation of growth/survival pathways through 
autocrine production of growth factors such as IL-622. MSLN also induces in an increase in 
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NF-B activation which leads to resistance to TNF-α-induced apoptosis23, indicating a 
mechanism through which MSLN may help to increase survival of tumor cells in the highly 
inflammatory milieu evident in pancreatic cancer through Akt/PI3K/NF-B Activation and 
IL-6 overexpression. MSLN overexpression results in secretion of high levels of IL-6, which 
could in turn be responsible for the cells’ increased viability and proliferation under serum-
reduced conditions through a IL-6/soluble IL-6R (sIL-6R) trans-signaling mechanism and 
the induction of the IL-6-STAT3 pathway3,22. 
MSLN overexpression has also been associated with increased metastatic potential in 
pancreatic cancers. In vitro experiments showed that MSLN increases pancreatic cancer cell 
migration by 300%, while in vivo results showed and increase in local and liver metastases 
following orthotopic injection, with control cells without MSLN expression showing no 
metastases16. Cancer antigen-125 (CA125), the circulating antigen encoded by the MUC16 
gene, has been identified as a marker for differential diagnosis of pancreatic mass lesions 
with an 88.2% positive predictive value for diagnosis of pancreatic tumors24. Taking into 
account that the high affinity of mesothelin-CA125 interaction might be the cause of 
intracavitary tumor metastasis8,25, a recent study by Einama et al. determined that co-
expression of these two factors plays a significant role in the acquisition of aggressive 
clinical behavior of pancreatic tumors, finding that co-expression of MSLN and CA125 
correlated with unfavorable patient survival outcome 25. 
3. Advances in diagnosis and treatment of mesothelin-overexpressing 
pancreatic cancers 
MSLN is an attractive candidate for targeted therapy given its limited expression on normal 
tissues and high expression in tumors and the fact that it is expressed on the surface of cells. 
Immunostaining against MSLN has been demonstrated to be an effective adjunct to cytology 
for diagnosis of pancreatic adenocarcinoma26, with a 90% accuracy rate in diagnosing 
pancreatic malignancies. In addition, the release of the MPF from the cell surface following 
furin cleavage makes it an attractive target for diagnostic detection.  
Elevated circulating MSLN levels have been detected in patients with pancreatic disease27. 
Using ELISA, 73 of 74 (99%) patients with pancreatic adenocarcinoma were found to have 
elevated circulating levels of MSLN compared with none of 5 healthy controls27. Other 
approaches, including using multiplexed Proximity Ligation Assay (PLA) have been used to 
effectively detect levels of mesothelin-MUC16 complex in serum and plasma levels28. MSLN 
has also been used as a biomarker to test the efficacy of new technologies for early, 
minimally invasive diagnosis of pancreatic adenocarcinoma. In a study involving minimally 
invasive fine needle aspirations MSLN has helped to differentiate pancreatic 
adenocarcinomas from chronic pancreatitis with near 100% accuracy29. Another study 
utilized acoustic wave device-based immunosensors in molecular cancer biomarker 
detection in real-time, and effectively identified MSLN expression in three different 
pancreatic cancer cell supernatants, although further study is needed with this technology to 
determine its effectiveness in patient tissues30. 
Most recently, ELISA has been used not just to test for MSLN circulation in patients with 
advanced tumors, but for attempted early detection of pancreatic anomalies. A pancreatic 
ductal carcinoma transgenic animal model was established in rats using a Cre/loxP 
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immunohistochemistry to show that MSLN is consistently overexpressed in 60 of 60 
pancreatic tumors. Meanwhile, MSLN does not seem to be expressed in normal pancreatic 
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of several pancreatic cancer-associated genes, and found that MSLN was hypomethylated in 
adenocarcinoma compared to its methylated state in normal pancreatic tissues, indicating an 
epigenetic event trigger is involved in MSLN overexpression21.  
Pancreatic cancer studies have revealed roles for MSLN in increasing aggressiveness of 
tumor cells, including enhancement of proliferation and migration. Li et al. found that 
overexpression of MSLN is also associated with an increased S-phase cell population in a 
cell cycle analysis. This resulted in a 90% increase in proliferation for MIA-PaCa2 cells 
overexpressing MSLN compared to vector controls16. Subsequent studies by Bharadwaj et al. 
elucidated a mechanism through which MSLN promotes proliferation of pancreatic cancer 
cells through alteration of Cyclin E as a result of constitutive activation of Signal Transducer 
and Activator of Transcription protein 3 (STAT3)3. Bharadwaj et al. have further shown that 
MSLN overexpression results in upregulation of growth/survival pathways through 
autocrine production of growth factors such as IL-622. MSLN also induces in an increase in 
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IL-6 overexpression. MSLN overexpression results in secretion of high levels of IL-6, which 
could in turn be responsible for the cells’ increased viability and proliferation under serum-
reduced conditions through a IL-6/soluble IL-6R (sIL-6R) trans-signaling mechanism and 
the induction of the IL-6-STAT3 pathway3,22. 
MSLN overexpression has also been associated with increased metastatic potential in 
pancreatic cancers. In vitro experiments showed that MSLN increases pancreatic cancer cell 
migration by 300%, while in vivo results showed and increase in local and liver metastases 
following orthotopic injection, with control cells without MSLN expression showing no 
metastases16. Cancer antigen-125 (CA125), the circulating antigen encoded by the MUC16 
gene, has been identified as a marker for differential diagnosis of pancreatic mass lesions 
with an 88.2% positive predictive value for diagnosis of pancreatic tumors24. Taking into 
account that the high affinity of mesothelin-CA125 interaction might be the cause of 
intracavitary tumor metastasis8,25, a recent study by Einama et al. determined that co-
expression of these two factors plays a significant role in the acquisition of aggressive 
clinical behavior of pancreatic tumors, finding that co-expression of MSLN and CA125 
correlated with unfavorable patient survival outcome 25. 
3. Advances in diagnosis and treatment of mesothelin-overexpressing 
pancreatic cancers 
MSLN is an attractive candidate for targeted therapy given its limited expression on normal 
tissues and high expression in tumors and the fact that it is expressed on the surface of cells. 
Immunostaining against MSLN has been demonstrated to be an effective adjunct to cytology 
for diagnosis of pancreatic adenocarcinoma26, with a 90% accuracy rate in diagnosing 
pancreatic malignancies. In addition, the release of the MPF from the cell surface following 
furin cleavage makes it an attractive target for diagnostic detection.  
Elevated circulating MSLN levels have been detected in patients with pancreatic disease27. 
Using ELISA, 73 of 74 (99%) patients with pancreatic adenocarcinoma were found to have 
elevated circulating levels of MSLN compared with none of 5 healthy controls27. Other 
approaches, including using multiplexed Proximity Ligation Assay (PLA) have been used to 
effectively detect levels of mesothelin-MUC16 complex in serum and plasma levels28. MSLN 
has also been used as a biomarker to test the efficacy of new technologies for early, 
minimally invasive diagnosis of pancreatic adenocarcinoma. In a study involving minimally 
invasive fine needle aspirations MSLN has helped to differentiate pancreatic 
adenocarcinomas from chronic pancreatitis with near 100% accuracy29. Another study 
utilized acoustic wave device-based immunosensors in molecular cancer biomarker 
detection in real-time, and effectively identified MSLN expression in three different 
pancreatic cancer cell supernatants, although further study is needed with this technology to 
determine its effectiveness in patient tissues30. 
Most recently, ELISA has been used not just to test for MSLN circulation in patients with 
advanced tumors, but for attempted early detection of pancreatic anomalies. A pancreatic 
ductal carcinoma transgenic animal model was established in rats using a Cre/loxP 
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controlled human Kras oncogene 13. Using this system, Fukamachi et al. demonstrated that 
the rat homolog of human MSLN, Erc (expressed in renal carcinoma), could be detected in 
the serum of pre-symptomatic, pre-malignant pancreas lesions, opening the door to 
potential early diagnosis of mesothelin-induced pancreatic malignancies, as well as testing 
of early stage chemotherapeutic intervention to prevent progression of malignancies.  
Potential treatments focusing on MSLN are already undergoing clinical trials. One example 
is use of a mouse-human chimeric antibody (MORAb-009), an IgG1kappa monoclonal 
antibody with an affinity of 1.5 nM for human MSLN containing the murine SS1 Fv for 
MSLN, which is currently being examined in a Phase II clinical trial31,32. This antibody 
prevents adhesion of mesothelin-bearing tumor cells to MUC16 positive cells and also elicits 
cell-mediated cytotoxicity on mesothelin-bearing tumor cells. A newer study using phage 
display has shown successful isolation of HN1, a human scFv, which recognizes a 
conformation-sensitive epitope of MSLN on cancer cells and promotes apoptosis by acting 
as an immunotoxin31. While this particular study focused on ovarian cancer treatment, it 
stands to reason that pancreatic cancer would make an effective target for future treatments 
with this antibody. MSLN has also been used as a targeting factor for pancreatic tumors in 
conjunction with quantum dot (QD) technology. QDs are semi-conductor nanocrystals 
which, when encapsulated in carboxyl-functionalized amphiphilic polymers form stable, 
micelle-like structures which form a potential platform for visualization and drug delivery 
to tumors33. Ding et al. conjugated MSLN-specific Ab to QD micelles and used them for 
effective targeted delivery to pancreatic cancer sites in vitro and in vivo33. The high level of 
overexpression of MSLN in pancreatic cancer cells and tumors compared to normal tissues 
allowed for selective targeting of QDs, indicating the potential of MSLN-targeted QDs or 
other MSLN-conjugated vehicles to serve as agents for tumor diagnosis, imaging, and 
treatment through drug delivery. 
Another approach for MSLN focused therapy comes from studies involving SS1P 
(SS1(dsFv)PE38), a recombinant anti-mesothelin immunotoxin. SS1P was developed 
consisting of an anti-mesothelin Fv (SS1) fused to PE38, a 38-kDa portion of Pseudomonas 
exotoxin A34,35, which kills cells upon internalization following binding to MSLN on the cell 
surface. A phase I study was conducted involving 34 patients, 2 of which had pancreatic 
adenocarcinoma35. The patients tolerated the doses given, indicating a potential for 
progressing to additional studies. Although results were encouraging in patients with 
ovarian cancer or mesotheliomas, no response was seen in the 2 pancreatic cancer patients. 
A second Phase I trial, this time involving continuous infusion of SS1P, was more recently 
conducted36 to measure toxicity tolerance, also with promising results. Newer studies by the 
same group are currently examining methods for improving the efficacy of SS1P therapy by 
combining treatement with Taxol, which appears to limit the binding of SS1P with shed 
MSLN in the extracellular fluid rather than on the cell surface, thereby increasing the 
effectiveness of SS1P internalization and the killing of tumor cells37. Yet another toxin 
insertion approach used a a biodegradable nanoparticulate delivery system targeted 
specifically to mesothelin-overxpressing cell lines to deliver diphtheria toxin DNA, which 
effectively inhibited protein translation of targeted cells in vitro38.  
Finally, approaches using pancreatic cancer vaccines show that MSLN has great potential as 
an immunotherapeutic targets10,39. Johnston et al. showed that mesothelin-specific T cells can 
be induced in patients with pancreatic cancer. Their results indicated that mesothelin-
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specific CD4+ and CD8+ T cells were generated from peripheral blood lymphocytes of 50% 
of patients with pancreatic cancer, up from only 20% of healthy individuals27, and another 
study showed consistent induction of CD8+ T cell responses to multiple MSLN epitopes in a 
small number of patients40. A study by Yokokawa et al. sought to define additional MSLN 
epitotpes capable of more efficiently activating T cells to lyse tumors10. Jaffee et al. carried 
out a phase I trial in patients with surgically resected adenocarcinoma of the pancreas was 
conducted using an allogeneic granulocyte-macrophage colony-stimulating factor (GM-
CSF)-secreting tumor vaccines39. In a phase II trial, these results were confirmed through 
induction of mesothelin-specific CD8+ T cell responses following exposure to different 
MSLN epitopes, leading to a correlation of the posttreatment induction of mesothelin-
specific T cell responses with improved overall response 41. 
The latest attempts at immunotherapy with MSLN involved vaccination with virus-like 
particles (VLPs) to induce protective antiviral immune responses against MSLN, yielding 
promising results. Li et al. investigated the effect and mechanism of chimeric VLPs that 
contain human MSLN (VLP-hMSLN) as a candidate vaccine for controlling pancreatic 
cancer progression in an orthotopic pancreatic cancer mouse model16. In the study, VLP-
hMSLN vaccination inhibited tumor progression in C57BL/6J mice, and increased 
mesothelin-specific antibodies and CTL activity and decreased regulatory T cells, resulting 
in reduced tumor progression and prolonged survival. Most recently, dendritic cells 
transduced with full-length MSLN cDNA-encoding adenoviral vectors have been shown to 
elicit mesothelin-specific cytotoxicity against pancreatic cancer cells in vitro, through 
activation of both CD8+ T cells and CD4+ helper T cells42, suggesting the therapeutic 
potential of using MSLN-targeted DC vaccines in future clinical applications.  
4. Conclusion 
MSLN is an important molecule overexpressed in a variety of cancerous human 
malignancies, and in particular has been identified as a biomarker of pancreatic cancers. The 
high expression of MSLN in pancreatic tumors compared with its limited expression in 
normal tissues makes it an interesting candidate for targeted therapies and diagnostic 
screening. In addition, MSLN has been shown to play important roles in proliferation, 
survival, and metastatic potential of pancreatic tumors where it is overexpressed. While 
much progress has been made in understanding the molecular mechanisms that give rise to 
MSLN-associated pancreatic cancer pathogenesis, further studies are needed to truly 
elucidate the functions and effects of this molecule with regards to what still remains the 
deadliest of human cancers.  
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to tumors33. Ding et al. conjugated MSLN-specific Ab to QD micelles and used them for 
effective targeted delivery to pancreatic cancer sites in vitro and in vivo33. The high level of 
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allowed for selective targeting of QDs, indicating the potential of MSLN-targeted QDs or 
other MSLN-conjugated vehicles to serve as agents for tumor diagnosis, imaging, and 
treatment through drug delivery. 
Another approach for MSLN focused therapy comes from studies involving SS1P 
(SS1(dsFv)PE38), a recombinant anti-mesothelin immunotoxin. SS1P was developed 
consisting of an anti-mesothelin Fv (SS1) fused to PE38, a 38-kDa portion of Pseudomonas 
exotoxin A34,35, which kills cells upon internalization following binding to MSLN on the cell 
surface. A phase I study was conducted involving 34 patients, 2 of which had pancreatic 
adenocarcinoma35. The patients tolerated the doses given, indicating a potential for 
progressing to additional studies. Although results were encouraging in patients with 
ovarian cancer or mesotheliomas, no response was seen in the 2 pancreatic cancer patients. 
A second Phase I trial, this time involving continuous infusion of SS1P, was more recently 
conducted36 to measure toxicity tolerance, also with promising results. Newer studies by the 
same group are currently examining methods for improving the efficacy of SS1P therapy by 
combining treatement with Taxol, which appears to limit the binding of SS1P with shed 
MSLN in the extracellular fluid rather than on the cell surface, thereby increasing the 
effectiveness of SS1P internalization and the killing of tumor cells37. Yet another toxin 
insertion approach used a a biodegradable nanoparticulate delivery system targeted 
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in reduced tumor progression and prolonged survival. Most recently, dendritic cells 
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potential of using MSLN-targeted DC vaccines in future clinical applications.  
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high expression of MSLN in pancreatic tumors compared with its limited expression in 
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screening. In addition, MSLN has been shown to play important roles in proliferation, 
survival, and metastatic potential of pancreatic tumors where it is overexpressed. While 
much progress has been made in understanding the molecular mechanisms that give rise to 
MSLN-associated pancreatic cancer pathogenesis, further studies are needed to truly 
elucidate the functions and effects of this molecule with regards to what still remains the 
deadliest of human cancers.  
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1. Introduction  
Pancreatic ductal adenocarcinoma (PDAC) is by far the most common type of tumor in the 
exocrine pancreas, accounting for 85% to 100% of all malignant pancreatic tumors (Kloppel 
et al., 2004). During the last 30 years, little improvement in the prognosis of patients with 
PDAC has been achieved (Jemal et al., 2009). A better understanding of the biological nature 
of this neoplasm might improve the prognosis of patients. For this purpose, permanent 
cultured cell lines are helpful, since their convenience of use facilitates a variety of 
experiments (Ku et al., 2002). However, the amount of viable tumor-derived material is 
limited. The majority of research in PDAC has been done in a few cell lines; only 19 
pancreatic carcinoma cell lines are broadly available for research. In addition to their small 
number, permanent cell lines have another disadvantage: the long culture times leave the 
cells prone to genetic drift (Kato et al., 1999; McQueen et al., 1991).  
To obtain a greater phenotypic heterogeneity of the disposable cell lines, and to circumvent 
the use of “old” cell lines, it is advantageous for research laboratories that focus on 
pancreatic cancer to establish their own primary carcinoma cell lines (Ruckert et al., 2011). 
Before using these cell lines in basic research, the origin of the cell line should be confirmed 
to exclude cross-contamination by existing cell lines. This is important, because some 
studies suggest that 15–20% of the cell lines used in experiments have been misidentified or 
contaminated with another cell line, which is also true for primary cell lines (Cabrera et al., 
2006; Drexler et al., 1999). A characterization of the cell lines is further necessary to analyze 
and document the typical biochemical and pathophysiological features of the tumor cell 
lines (Henderson et al., 1996). In the present article we give information on how to isolate 
and characterize primary pancreatic cancer cell lines.  
2. Techniques for the isolation of primary pancreatic cancer cell lines  
The principle of tissue culture was established by Wilhelm Roux in the 19th century. 
However, it took nearly 60 years before the establishment of the first human cancer cell line 
(Gey et al., 1952). The first report on the culture of pancreatic cancer cell lines was in l963 
(Dobrynin, 1963). Cells that are cultured directly from a subject are known as primary cell 
lines and different techniques have been used to establish such pancreatic cancer cell lines. 
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Some of these primary cells can be cultured successfully over a long time period and are 
then named permanent or immortal cell lines.  
The most frequent used techniques are explant culture (where the culture grows from a 
solid tumor sample), xenografting, enzymatic digestion and culture of malignant bodily 
fluids. In the following, we describe these techniques in detail.  
2.1 Explant cultures 
The two most frequently used explant culture techniques are the “mechanical dissociation” 
and the “outgrowth method”. To obtain sterile conditions, the tumor specimen should be 
rinsed three times in wash medium.  
Most scientist use the mechanical dissociation to establish pancreatic cancer cell lines (Table 
1). In this technique after washing, the specimen is transferred to a sterile petridish and cut 
up into smaller pieces about 1-2 mm3 using sterile scalpel and forceps. The fragments and 
the spilled cells are then placed in a tissue culture flask and medium is added. The 
production of proteolytic factors (Diamantidis et al., 2008; Mahadevan et al., 2007) and 
augmented cell motility (Hotz et al., 2007; Rückert et al., 2010) enables pancreatic cancer 
cells to actively leave the tissue fragment. Complexes of tumor cells can be seen within the 
medium after 24 h (Figure 1, C and D). The presence of these “STC´s” (small trabecular 
complex) is generally a good predictive parameter for the successful isolation of primary 
tumor cell lines and under standard cell culture conditions cancer cell colonies will grow, as 
well as other contaminating cell types such as fibroblasts or lymphocytes (Rückert et al., 
2011).  
The other explant culture technique is the outgrowth method. As in the mechanical 
dissociation- technique, little pieces of the solid tumor are produced by dissection of the 
tumor sample with an sterile scalpel. Those little fragments are placed within a 6-well plate 
and left to dry until the pieces stick on to the surface. Medium is then added cautiously. 
Tumor cells as well as fibroblast will grow out of the tissue fragment (Figure 1, A and B; for 
a pictured tutorial see Rückert et al., 2011).   
2.2 Xenografts 
Xenografting of tumor samples into athymic mice is a way to establish pancreatic tumor 
lines with a good success rate and is frequently used by scientist for this purpose (Hotz et 
al., 2000). By repeated passages of the tumor lines in nude mice the cells are said to become 
more aggressive. Some of these tumor lines are used as source for the establishment of cell 
lines by either explant cultures or enzymatic digestion (Dexter et al., 1982; Yachida et al., 
2011) (Table 1).   
2.3 Enzymatic digestion 
Enzymatic digestion can be used to free cancer cells from adherent connective tissue and 
produce a suspension of cells. For this purpose different enzymes are used, such as trypsin 
(Kaku et al., 1980) or collagenase type IV (Chifenti et al., 2009; Kalinina et al., 2010). 
However, this method is laborious and rarely used to establish pancreatic cancer cell lines 
(Table 1).   




year Name Method used Medium Characterisation 
(Dobrynin  
et al., 1963) CaPa 
Explant 
culture 
Medium 199, 5% 
human serum, 5% FCS M, DD, chr 
(Lieber 
et al., 1975) Panc-1 
Explant 
culture DMEM, 10% FCS 
M, DD, chr, xeno, 
FA 
(Owens  
et al., 1976) 
Hs 700T Enzymatic 
digestion DMEM, 10% FCS 
M, DD, chr, 
plating efficiency HS 766T 
(Yunis  





DMEM, 10% FCS, 2.5% 
horse serum 
M, DD, chr, HC, 
FA, EM 
(Akagi & 
Kimoto, 1977) HCG-25 
Ascites w/ 
medium RPMI 1640, 10% FCS 
M, DD, chr, xeno, 
HC, FA, EM, 
plating efficiency 
(Fogh  
et al., 1977) Capan-1 n.n. RPMI 1640, 15% FCS 
M, DD, HC, xeno, 
FA 
(Grant  
et al., 1979) Ger 
Explant 
culture 
(Ham's F12 + Eagle's) or 
DMEM, 10% FCS, 
amino acids, 1 mM 
glutamine,  
AA, 50 tzg/ml soya-
bean trypsin  
inhibitor 
M, DD, chr, xeno, 
FA,TM 
(Kaku  
et al., 1980) QCP-1 
Enzymatic 
digestion  Medium 199, 10% FCS 
M, DD, chr, HC, 
FA 
(Morgan  
et al., 1980) COLO 357 
Explant 
culture RPMI 1640, 20% FCS 




et al., 1982) AsPC-1 
Ascites w/ 
medium RPMI 1640, 10% FCS 
M, HC, chr, xeno, 
FA 
(Metzgar  
et al., 1982) HPAF 
Ascites w/ 




RPMI 1640, 20% FCS, 
buffered 
  
M, DD, chr, HC, 
xeno, FA,  
plating efficiency RWP2 
(von Bulow  
et al., 1982)  PancTuI-I n.n. n.n.   
(Kyriazis 
et al., 1983) SW-1990 
Explant 
culture L-15-CI 
M, DD, chr, HC, 
xeno, FA, plating 
efficiency 
(Yamaguchi  
et al., 1983) HPC-Y1 n.n. RPMI 1640, 10% FCS M, xeno, TM 
(Okabe  
et al., 1983) T3M-4 Xenograft F10, 15% FCS, AA M, DD, chr, HC 
(Kyriazis  
et al., 1986) Capan-2 n.n. 
RPMI 1640, 15% FCS, 
AA 
M, DD, chr, HC, 
xeno, FA, plating 
efficiency 
Pancreatic Cancer – Molecular Mechanism and Targets 
 
260
Some of these primary cells can be cultured successfully over a long time period and are 
then named permanent or immortal cell lines.  
The most frequent used techniques are explant culture (where the culture grows from a 
solid tumor sample), xenografting, enzymatic digestion and culture of malignant bodily 
fluids. In the following, we describe these techniques in detail.  
2.1 Explant cultures 
The two most frequently used explant culture techniques are the “mechanical dissociation” 
and the “outgrowth method”. To obtain sterile conditions, the tumor specimen should be 
rinsed three times in wash medium.  
Most scientist use the mechanical dissociation to establish pancreatic cancer cell lines (Table 
1). In this technique after washing, the specimen is transferred to a sterile petridish and cut 
up into smaller pieces about 1-2 mm3 using sterile scalpel and forceps. The fragments and 
the spilled cells are then placed in a tissue culture flask and medium is added. The 
production of proteolytic factors (Diamantidis et al., 2008; Mahadevan et al., 2007) and 
augmented cell motility (Hotz et al., 2007; Rückert et al., 2010) enables pancreatic cancer 
cells to actively leave the tissue fragment. Complexes of tumor cells can be seen within the 
medium after 24 h (Figure 1, C and D). The presence of these “STC´s” (small trabecular 
complex) is generally a good predictive parameter for the successful isolation of primary 
tumor cell lines and under standard cell culture conditions cancer cell colonies will grow, as 
well as other contaminating cell types such as fibroblasts or lymphocytes (Rückert et al., 
2011).  
The other explant culture technique is the outgrowth method. As in the mechanical 
dissociation- technique, little pieces of the solid tumor are produced by dissection of the 
tumor sample with an sterile scalpel. Those little fragments are placed within a 6-well plate 
and left to dry until the pieces stick on to the surface. Medium is then added cautiously. 
Tumor cells as well as fibroblast will grow out of the tissue fragment (Figure 1, A and B; for 
a pictured tutorial see Rückert et al., 2011).   
2.2 Xenografts 
Xenografting of tumor samples into athymic mice is a way to establish pancreatic tumor 
lines with a good success rate and is frequently used by scientist for this purpose (Hotz et 
al., 2000). By repeated passages of the tumor lines in nude mice the cells are said to become 
more aggressive. Some of these tumor lines are used as source for the establishment of cell 
lines by either explant cultures or enzymatic digestion (Dexter et al., 1982; Yachida et al., 
2011) (Table 1).   
2.3 Enzymatic digestion 
Enzymatic digestion can be used to free cancer cells from adherent connective tissue and 
produce a suspension of cells. For this purpose different enzymes are used, such as trypsin 
(Kaku et al., 1980) or collagenase type IV (Chifenti et al., 2009; Kalinina et al., 2010). 
However, this method is laborious and rarely used to establish pancreatic cancer cell lines 
(Table 1).   




year Name Method used Medium Characterisation 
(Dobrynin  
et al., 1963) CaPa 
Explant 
culture 
Medium 199, 5% 
human serum, 5% FCS M, DD, chr 
(Lieber 
et al., 1975) Panc-1 
Explant 
culture DMEM, 10% FCS 
M, DD, chr, xeno, 
FA 
(Owens  
et al., 1976) 
Hs 700T Enzymatic 
digestion DMEM, 10% FCS 
M, DD, chr, 
plating efficiency HS 766T 
(Yunis  





DMEM, 10% FCS, 2.5% 
horse serum 
M, DD, chr, HC, 
FA, EM 
(Akagi & 
Kimoto, 1977) HCG-25 
Ascites w/ 
medium RPMI 1640, 10% FCS 
M, DD, chr, xeno, 
HC, FA, EM, 
plating efficiency 
(Fogh  
et al., 1977) Capan-1 n.n. RPMI 1640, 15% FCS 
M, DD, HC, xeno, 
FA 
(Grant  
et al., 1979) Ger 
Explant 
culture 
(Ham's F12 + Eagle's) or 
DMEM, 10% FCS, 
amino acids, 1 mM 
glutamine,  
AA, 50 tzg/ml soya-
bean trypsin  
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digestion  Medium 199, 10% FCS 
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et al., 1980) COLO 357 
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et al., 1982) AsPC-1 
Ascites w/ 
medium RPMI 1640, 10% FCS 
M, HC, chr, xeno, 
FA 
(Metzgar  
et al., 1982) HPAF 
Ascites w/ 




RPMI 1640, 20% FCS, 
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M, DD, chr, HC, 
xeno, FA,  
plating efficiency RWP2 
(von Bulow  
et al., 1982)  PancTuI-I n.n. n.n.   
(Kyriazis 
et al., 1983) SW-1990 
Explant 
culture L-15-CI 
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year Name Method used Medium Characterisation 
(Yamada  
et al., 1986) PSN-1 Xenograft RPMI 1640, 10% FCS M 
(Yamaguchi  
et al., 1986) HPC-YT n.n. RPMI 1640, 10% FCS 
M, DD, chr, xeno, 
FA 
(Tan et al., 1986) BxPC-3 Explant culture 
RPMI 1640, 20% FCS, 
buffered 
M, DD, chr, HC, 
xeno  
(Kobari  
et al., 1986) 
PK-1 
Explant 
culture MEM, 20% FCS 









et al., 1987) SUIT-2 
Explant 
culture DMEM, 5% FCS 
M, DD, xeno, TM, 
EM  
(Sujino 
et al., 1988) JHP-1 
Ascites w/ 
medium  n.n. 




et al., 1988) SU.86 
Explant 
culture RPMI 1640, 20% FCS 
M, DD, HC, chr, 
xeno, TM 
(Nagata  
et al., 1989) FA6 Xenograft RPMI 1640, 10% FCS FA 
(Frazier  





(L-15 + DMEM), 16 
kg/ml glutathione, 5 
kg/rnl insulin, 5 pg/ml 
transferring, 5 ng/ml 
selenium,  
5 ng/ml EGF,  
10% FCS, AA 
M, DD, chr,  
HC, EM  
(Fujii  
et al., 1990) SOJ 
Explant 
culture RPMI 1640, 10% FCS 
M, DD, chr, xeno, 
TM 
(Schoumacher 
et al., 1990) CFPAC-1 
Explant 
culture RPMI 1640, 10% FCS IHC, xeno, FA 
(Ikeda  
et al., 1990) 
KP-1N 
Xenograft Daigos T, 10%FCS IHC, xeno, TM KP-2 
KP-3 
(Yamaguchi  
et al., 1990) 
HPC-Y0 
Explant 
culture  RPMI 1640, 10% FCS 














year Name Method used Medium Characterisation 
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et al., 2007) SPH 
Ascites w/ 
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et al., 2010) PaCa 5061 
Enzymatic 
digestion  
RPMI 1640,  
10% FCS, 
AA, 50 nmol/ml 
transferrin,  
0.01 μg/ml insulin, 
0.01 μg/ml EGF,  
0.01 μg/ml basic FGF 
M, DD,  
IHC, xeno, FA, 
TM, FISH 
(Rückert  
et al., 2011)  
PaCaDD-43 
Explant 
culture Dresden-Medium  







et al., 2011) a99 Xenograft DMEM, 20% FCS 
M, DD,  
chr, mut,  
xeno, colony 
formation  
(DD= doubling rate/ growth curve; M= morphology; STR= standard tandem repeat/DNA-fingerprint; 
chr= chromosomal analysis; mut= mutational analysis; xeno= xenograft; FA= functional analysis;  
HC= histochemistry; IHC= immunohistochemistry; EM= electron microscopy, TM= tumor marker; 
AA= antibiotics).  
Table 1. Human pancreatic tumor cell lines (adapted from Iwamura & Hollingsworth,  
1998). This list is not exhaustive. Some of the cell lines are available at ATCC 
(www.lgcstandards-atcc.org) or the German Collection of Microorganisms and Cell 
Cultures (www.dsmz.de)  
2.4 Processing of malignant pleural effusion or ascites 
This method is frequently used to obtain primary cancer cell lines. Although the success rate 
is not higher than in other methods many scientist favour this technique as material is easily 
obtainable. For establishing cancer cell lines with this method, bodily fluids are added to 
variable amounts of cell culture medium (Akagi et al., 1977; Chen et al., 1990; Nishimura et 
al., 1993) (Table 1).  




Fig. 1. Typical morphology of a primary pancreatic cancer colony (A). Fibroblasts growing 
out of a tissue fragment (B). Figures C and D depict complexes of cancer cells (full arrow) 
which the author calles “STC´s” (small trabecular complex). In (C) there is also a cluster of 
mesenchymal cells (interrupted arrow).  
2.5 General remarks on the establishment of primary cell lines 
The processing of samples should be as fast as possible. The success rate for the 
establishment of cell lines is considerably shortened if processing starts more than 2 hours 
after harvesting of the sample.  
Parenchymal cells in culture are generally obvious due to their close cell-cell contacts and 
their tendency to grow in colonies (Figure 1, A). However, parenchymal cells are often 
overgrown by cells from the stromal compartment (Figure 1, B). Those fibroblasts can be 
removed by different techniques. One possibility is to mechanically remove fibroblasts by a 
sterile cannula under phase contrast microscope. Another method uses a solution of trypsin 
to enzymatic remove fibroblasts. This enzymatic removement is possible because tumor 
cells adhere much more firm to the surface than fibroblasts do. 
The successful establishment of primary cell lines is often impeded by contamination by 
fungi and bacteria. For this purpose we advise to always use antibiotics within the cell 
culture media. A way to protect cell lines from fungal infection is reported in Rückert et al, 
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2011. Cell lines should be cryoconserved early and often during the early passages. As a 
general rule, cultures of pancreatic tumor cell lines should be split at high density (l : 2) 
(Iwamura et al., 1998; Rückert et al., 2011). 
3. Cell culture conditions and medias  
The majority of pancreatic cancer cell lines are grown in vitro in a basic culture medium such 
as DMEM or RPMI 1640 substituted with foetal calf serum (FCS) in varying percentages 
(Table 1). However, there are also successful isolations using other media. Generally, after a 
primary cell culture is established it should be assessed if growth might be optimized by a 
different media and/or a different ratio of FCS. Some pancreatic tumor cells can be adapted 
to growth in reduced serum (0.5% or less) or serum free conditions.  
Cell cultures are generally maintained at 37°C in a humidified atmosphere of 5% CO2 in air, 
and the medium should be replaced every 3 d in established cultures.  
To guarantee the availability of primary cell lines for the further experiments, all cell lines 
should be cryoconserved. Storage of cryotubes should always be performed in liquid nitrogen.   
4. Characterisation of primary tumor cell lines  
Characterization of primary cell lines should be conducted to proof the origin from the parent 
tumor and to proof the absence of cross-contamination. Only by this the researcher can be sure 
that in vitro studies with a certain cell line can be related to a distinct tumor and its 
clinicophysiological properties. Most malignant tumors are heterogeneous in morphology 
and biological properties, e.g. degree of differentiation, malignant transformation, and 
metastatic properties. This fundamental facet of all solid tumors is called tumor 
heterogeneity (Heppner, 1984). Therefore it is essential to further define the cytostructural and 
pathophysiological characteristics of the cell line.  
For these purposes different standards have been defined, which will be further explained 
below (Henderson & Kirkland, 1996; Iwamura & Hollingsworth, 1998).  
4.1 Morphology and cytostructural characteristics 
4.1.1 Growth pattern  
Pancreatic tumors are generally categorized according to morphological criteria as grades of 
differentiation and invasiveness. Many cell lines exhibit morphological characteristics that 
are consistent with the grades of differentiation reported for the tumor from which the cell 
line was derived. In cell lines, morphology is normally assessed by phase contrast 
microscopy, but some authors also use electron microscopy or histochemical staining. 
Features that should be described are: 
- the growth pattern (e.g. epithelial, disorganized, mesenchymal) 
- size of the cells (e.g. homogenous, inhomogenous, small, big) 
- form of the cell (e.g. round, polygonal, elongated, swirly) 
- size and form of the nucleus (e.g. small, big, ovoid, round) 
Some examples of growth patterns of primary cells are given in Figure 2.   






Fig. 2. Examples of the morphology and growth pattern of the primary carcinoma cell lines 
from our research lab as seen with phase contrast microscopy (Details from 40x, pictures by 
Felix Rückert).   
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Cell surface antigen characteristics can be used to discriminate pancreatic cancer cells from 
contaminating cell types like stromal and immune cells. The immunohistochemical 
phenotype can be compared to the native tumor tissue and thereby further proof its origin. 
Typical markers for pancreatic cancer are CK 8/18, E-cadherin, ezrin, p53, SMAD4, and 
Vimentin (Rückert et al., 2011). 
4.2 Pathophysiological characteristics 
4.2.1 Doubling time 
The doubling time is an important feature of each cell line, because it can be correlated with 
an important pathophysiological parameter: aggressive growth. Furthermore, conclusion 
can be drawn on how often medium should be changed and in which ratio cell lines should 
be split.  
The cell doubling time can be determined by plating a certain number of viable cells in to a 
well. Cells should then be counted at 24 h intervals for 7 d in triplicate. The doubling time of 
the cell population can then be calculated from the logarithmic growth curve by the 
following formula: 
ϑ = lgN - lgN0/lg2 (t-t0), 
with doubling time = 1/ ϑ 
Of course there are other possibilites to define the growth rate e.g. BrdU-staining or ki-67 
staining.   
4.2.2 Tumorigenicity 
One notable feature of pancreatic cancer, which is amenable to study through the use of cell 
lines, is invasiveness and metastasis. Tumorigenicity can be measured by assessing the 
tumor formation of cell lines in athymic mice (Henderson & Kirkland, 1996). This can be 
done by orthotope (pancreas) or ectope (subcutaneous) injection of tumor cells. The number 
of cells required ranges from 100,000 to 2,000,000 cells. Pancreatic cancer cell lines should 
form a tumor within 3-4 weeks. If the cell line has tumorigenic potential, the progression of 
tumor volume/time as well as the ability to form metastasis should be documented.   
4.3 Chromosomal and mutational analysis 
Chromosomal and mutational analyses are used to proof the origin and the uniqueness of 
each cell line. They give further evidence on the role of mutations for the pathophysiology of 
the tumor. The origin of the cell lines, however, can also be proofed by other techniques as 
microsatellite analyses (Rückert et al., 2011).  
4.3.1 Chromosomal analysis 
Chromosomal analysis has long been the standard method to proof the uniqueness of an 
certain cell line. Classically, karyotype analysis was undertaken by chromosome banding. 
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By this method numerical and structural chromosomal aberrations could be identified. 
However, the chromosomal origins of markers, subtle translocations, or complex 
chromosomal rearrangements were often difficult to identify with certainty (Schrock et al., 
1997). Because of this, new methods are recommended like the spectral karyotyping (SKY) 
or the comparative genomic hybridisation (array CGH).  
During SKY, chromosomes are hybridized simultaneously with 24 chromosome-specific 
painting probes. The measurement of defined emission spectra allows for the definitive 
discernment of all human chromosomes in different colors (Schrock, 1997). The array CGH 
is a method to analyse copy number changes (gains/losses) in the DNA content of a given 
cell. By this, gains or losses of genes in tumor chromosomes compared to normal DNA can 
be detected (Wessendorf et al., 2002).   
4.3.2 Mutational analysis 
Pre-malignant and malignant tumors evolve by clonal expansion of mutant cells that have 
either a reproductive or survival advantage over other cells in the tissue. This competitive 
advantage is acquired by the overexpression of oncogenes and inactivation of tumor 
suppressor genes. Numerous studies have found a relatively unique molecular fingerprint 
in PDAC that is comprised of frequent alterations of four genes: kRAS, p16INK4A, DPC4 and 
p53 (Bardeesy et al., 2002; Krautz et al., 2011). Because of the importance of these genes for 
the pathophysiology of PDAC the mutational analysis of these genes is recommended.   
5. Conclusion   
Basic research in cancer is absolutely dependent on cancer cell lines. The establishment of 
primary pancreatic cancer cell lines in laboratories with focus on pancreatic cancer has 
considerable advantages and can be done with reasonable expense. We hope that the 
present chapter encourages more scientists to start establishing own cell lines.   
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1. Introduction 
This chapter discusses the role of cell cycle machinery in initiation and progression of 
pancreatic cancer. Normal pancreatic cells—their types, organization, and functions—are 
first described to characterize the environment in which cellular transformation and tumor 
expansion occurs. The epidemiology and histology of pancreatic cancer is then briefly 
presented to emphasize the urgent need for earlier diagnosis and more effective treatments. 
Current efforts towards this goal are focused on understanding the disease at the molecular 
level, so the hallmarks of cancerous cells are discussed with respect to the progression 
model of pancreatic cancer development. Because the pancreas is composed of various cell 
types with different genetic backgrounds and regulatory systems, identifying the cell in 
which cancer originates is of utmost importance. Molecular mechanisms of normal 
proliferative control are then presented so that mechanisms by which they are disrupted can 
be appreciated. Particular attention is paid to how signaling transduction pathways and the 
cell cycle machinery cooperate to make cell fate decisions at the Restriction point. This 
analysis sets the stage for evaluating the role of cell cycle control mechanisms in 
transformation of the initiating cell in pancreatic cancer. The chapter concludes by arguing 
that genetic alterations associated with pancreatic cancer indicate disrupted cell cycle 
control mechanisms play a central role in disease development and progression. 
2. Pancreatic tissue organization and cellular function 
Evaluating the role of cell cycle machinery in pancreatic cancer requires understanding the 
architecture and cellular organization of this dual-function gland. The pancreas is an 
approximately six inch long cylindrical organ in the abdomen, located between the stomach 
and the spine (Romer & Parsons, 1977). 
The endocrine component is composed of clusters of alpha, beta, and PP (pancreatic 
peptide) cell types that form structures called the islets of Langerhans (Jain & Lammert, 
2009). These cells produce metabolic hormones involved in energy metabolism. Major cell 
types and their organization are summarized in Figure 1.  
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1. Introduction 
This chapter discusses the role of cell cycle machinery in initiation and progression of 
pancreatic cancer. Normal pancreatic cells—their types, organization, and functions—are 
first described to characterize the environment in which cellular transformation and tumor 
expansion occurs. The epidemiology and histology of pancreatic cancer is then briefly 
presented to emphasize the urgent need for earlier diagnosis and more effective treatments. 
Current efforts towards this goal are focused on understanding the disease at the molecular 
level, so the hallmarks of cancerous cells are discussed with respect to the progression 
model of pancreatic cancer development. Because the pancreas is composed of various cell 
types with different genetic backgrounds and regulatory systems, identifying the cell in 
which cancer originates is of utmost importance. Molecular mechanisms of normal 
proliferative control are then presented so that mechanisms by which they are disrupted can 
be appreciated. Particular attention is paid to how signaling transduction pathways and the 
cell cycle machinery cooperate to make cell fate decisions at the Restriction point. This 
analysis sets the stage for evaluating the role of cell cycle control mechanisms in 
transformation of the initiating cell in pancreatic cancer. The chapter concludes by arguing 
that genetic alterations associated with pancreatic cancer indicate disrupted cell cycle 
control mechanisms play a central role in disease development and progression. 
2. Pancreatic tissue organization and cellular function 
Evaluating the role of cell cycle machinery in pancreatic cancer requires understanding the 
architecture and cellular organization of this dual-function gland. The pancreas is an 
approximately six inch long cylindrical organ in the abdomen, located between the stomach 
and the spine (Romer & Parsons, 1977). 
The endocrine component is composed of clusters of alpha, beta, and PP (pancreatic 
peptide) cell types that form structures called the islets of Langerhans (Jain & Lammert, 
2009). These cells produce metabolic hormones involved in energy metabolism. Major cell 
types and their organization are summarized in Figure 1.  
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Fig. 1. Global View of Pancreas. The pancreas is located in the abdomen behind the 
stomach. It is composed of four areas: The head, neck, body, and tail. It is comprised of two 
types of parenchymal tissue: The islets of Langerhans, composed of alpha, beta, and gamma 
cells are in charge of endocrine signal and hormone detection, while the pancreatic ancine 
are in charge of exocrine signaling and production of digestive enzymes. 
It plays major roles in the vertebrate hormonal (endocrine) and digestive (exocrine) systems 
(Jain & Lammert, 2009, Means & Leach, 2001). The pancreas contains two different types of 
parenchymal (i.e. functional) tissue that is of endodermal origin (Gittes, 2009). Most of its 
mass is clustered acinar cells that synthesize digestive pro-enzymes (Means & Leach, 2001). 
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The most prevalent type of pancreatic cancer is infiltrating ductal adenocarcinoma, which 
appears to initiate in distinct subsets of cells within the exocrine tissue (Maitra, A & Hruban, 
2008). However, other cell types can participate and/or be affected by the disease. This 
includes “enabling cells”, which are local, untransformed populations that can contribute to 
disease development. Pancreatic stellate cells, for instance, are stromal cells recruited by the 
tumor to help create an environment promoting disease progression (Vonlaufen, et al., 2008).  
2.1 Endocrine function 
Endocrine function is mediated by groups of cells called the islets of Langerhans, which 
secrete essential peptide hormones regulating energy metabolism into the bloodstream (Jain 
& Lammert, 2009). The pancreas contains approximately 1 million of these cell clusters, each 
composed of four different cell types distinguished by their secretatory role. The alpha and 
beta cells work together to maintain blood sugar levels. Alpha cells produce glucagon to 
promote release of stored glucose in response to an unfed state (Gromada, et al., 2007). In 
contrast, β cells generate insulin in response to eating so that incoming glucose can be 
utilized by body tissues (Collombat, et al., 2010). These functionalities are fine-tuned by 
somatostatin secreted from δ cells (Brink, 2003). PP cells are so called because they produce 
pancreatic polypeptide that helps regulate endocrine and exocrine secretions, control 
hepatic glycogen levels, and participate in regulation of gastrointestinal secretions 
(Lonovics, et al., 1981). Insulin and glucagon are rapidly disseminated by a capillary 
network that is connected to blood vessels via layers of endocrine cells (Jain & Lammert, 
2009, Means & Leach, 2001). Less than 10% of pancreatic cancers originate in endocrine cells. 
Nevertheless, these cells could play an important secondary role in more common ductal 
adenocarcinomas via their ability to produce hormones affecting cell fate decisions. In 
addition, their extensive capillary network could be exploited by metastasizing tumor cells. 
2.2 Exocrine function 
The majority of pancreatic cancers (>90%) are infiltrating ductal adenocarcinomas of the 
exocrine system (Maitra, A & Hruban, 2008). Thus, identifying the potential cell types 
involved and their normal function is essential for evaluating how cell cycle machinery 
contributes to cancer development. Exocrine function is mediated by clusters of acinar cells 
(called acinus) that secrete bicarbonate ions and digestive pro-enzymes (Means & Leach, 
2001). These products are transported in the pancreatic juice to the duodemun by a ductal 
system lined with a layer of mucinous columnar epithelial cells. Exocrine function is under 
control of the hormones gastrin, cholecystokinin and secretin, which are secreted by 
gastrointestinal cells in response to physical distension and food intake (Jean, 2008).  
The alkaline bicarbonate secreted by centroacinar cells regulates pH in the small intestine by 
neutralizing the acidic chyme arriving from the stomach (Freedman & Scheele, 1994). 
Centroacinar cells also secrete mucins, a family of high-molecular-weight, heavily 
glycosylated proteins known primarily for forming biological gels (Nagata, et al., 2007). 
They are involved in signaling, barrier formation, lubrication, and the immune response via 
binding and/or blocking pathogens (Hollingsworth & Swanson, 2004). Overexpression of 
mucin proteins (e.g. MUC1) occurs in many different types of cancers, including pancreatic 
(Moniaux, et al., 2004). Based on their unique genetic background, centroacinar cells have 
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been implicated as the potential cell of origin giving rise to ductal adenocarcinomas (Singer 
& Niebergall-Roth, 2009, Stanger & Dor, 2006).  
Digestive pro-enzymes for breaking down fats and protein are secreted into the lumen of 
the acinus by basophilic cells, so-called because they tend to stain intensely with basic dyes 
(Singer & Niebergall-Roth, 2009). These cells contain large cytoplasmic secretory granules in 
which digestive pro-enzymes are maintained in an inactive state, a method of regulatory 
control that is essential to prevent auto-degradation of the cell and subsequent development 
of a condition called acute pancreatitis (Waldthaler, et al., 2010). This type of cellular damage 
increases the risk of pancreatic cancer, an observation that provides insight into identity of 
the originating cell and how it is transformed (Suda, et al., 2007). 
3. Pancreatic cancer 
Epidemiology studies have revealed pancreatic cancer runs in some families and is 
associated with specific genetic mutations (Chakraborty, et al., 2011, Greer, et al., 2009, 
Lowenfels & Maisonneuve, 2006, Shi, et al., 2009). As is the case for all cancers, pancreatic 
cancer arises when a normal cell is transformed by accumulated genetic alterations into a 
cancer cell that seeks to duplicate itself at the expense of the organism. If this transformed 
cell can escape internal and external fail-safe mechanisms, obtain nutrients, and successfully 
activate its proliferative program, it can eventually form a more complex mass of cancerous 
cells. Continued growth of the tumor depends on space availability and promoting growth 
of blood vessels (angiogenesis) to supply nutrients and remove waste. Further tumor 
growth can result in loss of pancreatic function, impairment of local blood vessels and 
organs, and finally metastasis and secondary tumor formation at distal parts of the body. An 
unfortunate characteristic of pancreatic cancer is its propensity for metastasis early in tumor 
growth, which is likely responsible in part for its aggressive nature (Bardeesy & DePinho, 
2002). 
Pancreatic cancer is not exceptionally rare, with approximately 43,000 cases in 2010, making 
it the tenth-most-common form of the disease (ACS, 2007, ACS, 2010, NCI, 2010). However, 
37,000 of those died, illustrating its high mortality rate and ranking pancreatic cancer as the 
fourth leading cause of cancer fatalities worldwide (ACS, 2007, ACS, 2010, NCI, 2010). The 
lack of early symptoms results in delayed diagnosis and a higher likelihood of metastasis, 
thus dramatically limiting treatment options and outcome (Hansel, et al., 2003). The percent 
of patients alive one year after diagnosis is about 25%, while the five year rate is a 
depressing 6% (Hariharan, et al., 2008). The five year survival increases substantially with 
early detection and surgical removal of the tumor (approximately 22%), emphasizing the 
importance of developing better diagnostic tools and markers (Benson, et al., 2010). Even 
with early detection and conventional treatment, however, pancreatic cancer is still quite 
deadly. The ineffectiveness of standard therapy suggests its development and 
aggressiveness might involve unique molecular features.  
The pancreas is composed of head, body, and tail sections, with cancer most commonly 
occurring in the head region (see Figure 1) (Romer & Parsons, 1977). The majority of cases 
are malignant adenocarcinomas arising in the exocrine component (Maitra, A & Hruban, 
2008). Typically, the cancer initiates in the pancreatic ducts (infiltrating ductal 
adenocarcinoma), or less frequently in the acini (acinar adenocarcinoma). It presents as a 
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dense mass with crennolated extensions into surrounding tissue. Histological analysis 
reveals a neoplastic epithelium composed of poorly differentiated, gland-forming cells that 
illicit a very strong growth of fibrous and/or connective tissue around the neoplaisa (i.e. a 
desmoplastic reaction) (Hartel, et al., 2004, Maitra, Anirban, et al., 2006). A much smaller 
subset of exocrine pancreatic tumors present as adenosquamous carcinomas, squamous cell 
carcinomas, and giant cell carcinomas (Hruban & Zamboni, 2009). Metastatic endocrine 
cancers (also called islet cell tumors) are much less common and only account for 
approximately 1% of pancreatic cancers (Spiegel & Libutti, 2010).  
3.1 Molecular events underlying cellular transformation 
Cancers are recognized as such despite diverse physiological presentation because they all 
share a limited set of underlying causative characteristics. These so-called “hallmarks of 
cancer” are the distillation of extensive efforts to understand how a normal cell is 
transformed into a cancerous version (Hanahan & Weinberg, 2000).  
 
Fig. 2. Hallmarks of Cancer. Genetic insults to the pancreatic cells can result in the 
accumulation of the six hallmarks associated with cancer. The relative percentage of 
transformed cells types in the pancreas is also shown. 
For this reason they are the predominant paradigm for understanding its molecular basis 
and developing better diagnostics and treatments. In order to evaluate how disrupted cell 
cycle control specifically contributes to pancreatic cancer, it is first necessary to appreciate 
why it has been designated as a fundamental hallmark of the disease.  
3.2 Hallmarks of cancer 
Normal cells perform specific tasks and exist for the greater good of the organism. For this 
reason, their proliferative capability is a double-edged sword that must be highly 
constrained by internal checkpoints and external signals from other cells or the 
microenvironment (Bogenrieder & Herlyn, 2003). Cancer cells evade these constraints via 
accumulated genetic alterations, resulting in a selfish cell whose allegiance is now to its own 
survival and expansion. A multi-cellular organism protects itself by making cell duplication 
dependent on externally generated signals. Positive growth-promoting factors are required 
for proliferation while negative growth-inhibitory factors must be withdrawn. Two 
hallmarks of cancer are therefore self-sufficiency in growth signals (i.e. cell division in the 
absence of mitogenic factors) and insensitivity to growth-inhibitory factors (i.e. cell division 
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despite the presence of anti-mitogenic signals) (Hanahan & Weinberg, 2000). Extensive 
analysis of cell signaling pathways has identified myriad ways in which genetic alterations 
can satisfy these two criteria (Brognard & Hunter, 2011). Typically, multiple biological 
targets must be compromised due to redundancies and control mechanisms that evolved to 
prevent deregulated signaling.  
Self-sufficiency in growth signals and insensitivity to growth-inhibitory factors is not 
sufficient to generate a transformed cell capable of tumor formation. Most cells have an 
internal clock that limits their replicative potential so that they can only duplicate a fixed 
number of times before entering a senescent or non proliferative state (Hornsby, 2005). As 
will be discussed in more detail below, stem cells (and cell populations with stem cell-like 
characteristics) are an important exception to this rule and likely play a central role in the 
initiation of pancreatic cancer. The mechanism of this clock centers on telomere 
maintenance, the process whereby chromosome ends are protected from degradation (Yang, 
Q., 2008). Loss of telomere protection occurs after a fixed number of duplications, sending a 
signal that causes cells to exit the proliferative cycle and enter a senescent state (Yibin, et al., 
2008). Cancer cells typically overcome this internal checkpoint—for instance by 
hyperactivation of the telomere synthesizing enzyme telomerase—to acquire the 
proliferative capacity needed for tumor formation (Artandi & DePinho, 2010). Telomere 
maintenance is also disrupted in pancreatic cancer, but in a complex manner that varies 
with disease progression (van Heek, et al., 2002). This pattern provides insight into its 
origins and development. 
Cells have additional mechanisms to prevent inappropriate proliferation and mount a 
protective response should it occur. In the event of irreparable damage or grow-promoting 
mutations, for example, the cell can initiate an apoptotic pathway resulting in its death and 
deconstruction (Wyllie, 2010). A major hallmark of cancer is, thus, evasion of apoptosis 
(Hanahan & Weinberg, 2000).  
Once immortalized, the transformed cell can proliferate and begin to generate cancer cells, 
comprising the bulk of the tumor. However, cellular expansion can only occur up to a 
certain point as determined by available space and nutrients. A hallmark of cancer is, 
therefore, formation of new blood vessels (angiogenesis) so nutrients can be obtained and 
delivered throughout the tumor and so waste products can be removed (Hanahan & 
Weinberg, 2000). As a result, the tumor can further increase in size and complexity, 
compromising not only the affected organ itself but also nearby blood vessels and tissues.  
The final hallmark of cancer is perhaps most responsible for threatening organism survival. 
Even with angiogenesis, tumor size will eventually be constrained by physical barriers. As a 
consequence, the tumor is subjected to selective pressure, driving invasion of surrounding 
tissue and metastasis to distal locations (Hanahan & Weinberg, 2000). In this process, cancer 
cells detach from the primary tumor and secrete enzymes (e.g. MMPs) that allow passage 
through the extracellular matrix (Singh, et al., 2002). They can then migrate and start 
secondary tumors in surrounding tissue or in distal areas by commuting through the body’s 
highways (lymph and hematopoietic systems). Once a tumor has metastasized, the potential 
for successful therapeutic intervention is severely reduced, as is the case with pancreatic 
cancer (Bardeesy & DePinho, 2002).  
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3.3 Progression model of pancreatic cancer development  
The current view of pancreatic cancer development is summarized in a progression model 
wherein the temporally ordered accumulation of genetic mutations drive transitions 
through a series of pre-cancerous legions culminating with infiltrating ductal 
adenocarcinoma (in the majority of cases) (Koorstra, et al., 2008a). These steps were defined 
by histology of precancerous lesions at various stages that are collectively described as 
pancreatic intraepithelial neoplasias (PanINs) (Koorstra, et al., 2008b). They are further 
subdivided into PanIN-1A, PanIN-1B, and PanIN-2/3 based on distinct histology and 
genetic background (Koorstra, et al., 2008b, Koorstra, et al., 2008a). PanINs present as 
microscopic lesions situated in the smaller pancreatic ducts (Maitra, Anirban, et al., 2005). 
Genetic analysis of these distinct cell populations revealed ordered accumulation of 
alterations associated with the more advanced adenocarcinoma (Koorstra, et al., 2008a). The 
types of genetic insults present in pancreatic cancer are quite diverse and include large 
chromosomal alterations such as breaks, duplications, deletions, fusions, and translocations 
(Campbell, et al., 2010). There is also CpG island methylation of promoters, telomere 
disruptions, and microsatellite instability, along with specific mutations in important 
oncogenes and tumor suppressors (Lin, et al., 2011, López-Casas & López-Fernández, 2010, 
Welsch, et al., 2007). Precursor lesions display an increasing proliferation rate as they 
progress towards an adenocarcinoma (Koorstra, et al., 2008b). 
From a molecular biology perspective, three pertinent questions are: 1) What type of cell 
undergoes transformation? 2) What genetic elements are disrupted? 3) What biological 
activities are compromised and how do they contribute to transformation? Each of these 
questions will be addressed, with particular emphasis on the role of cell cycle machinery. 
The first task is to consider the cell type in which pancreatic cancer originates, since its 
genetic makeup and regulatory systems will dictate how to interpret genetic alterations 
associated with the disease.  
3.4 Identity of the cell initiating tumor formation 
Identifying the cell in which cancer originates is essential for understanding the 
consequences of genetic alterations and their effect on cell cycle control. This initiating cell 
has not yet been definitively described, but we can speculate it accumulates genetic 
mutations that, if not resolved (via repair or cell death), culminate in the hallmarks of 
cancer. The average age of onset for infiltrating ductal adenocarcinoma is approximately 73 
years, indicating it develops in the mature organ (Greer, et al., 2009, Lowenfels & 
Maisonneuve, 2006). One obvious candidate for transformation is the differentiated acinar 
ductal cell itself, which could be induced to re-enter the cell cycle and proliferate in 
opposition to internal and environmental cues. Such a transition seems quite daunting, 
because the mature cell must first de-differentiate to a more primitive state with 
proliferative capacity via genomic reorganization and altered gene expression. Secondly, 
this reverted cell must be induced to proliferate inappropriately, which likely requires 
disruption of different biological pathways. Thirdly, it is likely that fail-safe systems unique 
to each transition would have to be inactivated. Despite these hurdles, centroacinar cells are 
a possible candidate because they reside at the junction between acini and ducts and are the 
only differentiated cells in the developed pancreas with activated signaling pathways 
associated with proliferation (Miyamoto, et al., 2003). Thus, fewer genetic changes might be 
required in this background to generate the initiating transformed cell.  
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An alternative possibility is that cancer arises from transformation of a pancreatic stem cell. 
This model posits that the originating cell in cancer development is either a stem cell or has 
stem cell-like characteristics (Stanger & Dor, 2006). Their defining feature is unlimited self-
renewal capabilities. Normal stem cells play key roles in development and tissue 
maintenance by dividing asymmetrically to give one progeny with self-renewing capacity 
and another that commits to a differentiation pathway (Leeb, et al., 2011). Cancer stem cells 
are thought to follow the same process, except that their asymmetrical division generates 
cancer cells comprising the bulk of the tumor (Clevers, 2011, Stanger & Dor, 2006). 
Transformation of a cell with proliferative capacity seems more likely because it already 
exhibits one or more of the hallmarks of cancer. Evidence suggests that stem cells only make 
up 0.1-1% of the tumor cell population and show greater resistance to chemotherapy and 
radiation compared to their progeny (Bomken, et al., 2010). Consistent with this idea, 
subpopulations of pancreatic cancer cells have been isolated that can initiate a new tumor 
when implanted in mice (Reya, et al., 2001). Given that disease arises in the mature organ, a 
likely candidate for initial transformation would be a pancreatic adult stem cell. Such a cell 
type has not yet been identified, but their presence in other organs makes a pancreatic 
version a distinct possibility (Li, et al., 2007). These observations could help explain the well-
known unresponsiveness of pancreatic cancer to traditional chemotherapies (Wang, Zhiwei, 
et al., 2011c).  
A third possibility is involvement of what are called facultative progenitor cells located in 
the acinar environment (Leach, 2005). In the case of pancreatic injury (e.g. acute 
pancreatitis), differentiated cells can be recruited back into the proliferative cycle to replace 
old or damaged cells (Raimondi, et al., 2010). Such cells exhibit a more “stem cell-like” 
phenotype and hence are more susceptible to transformation. There is experimental 
evidence supporting this idea. Acute pancreatitis is a risk factor for pancreatic cancer, and, 
in a chemically induced version of this disease, acinar cells de-differentiate to replenish the 
cell supply (Guerra, et al., 2007, Jensen, et al., 2005). In addition, growth-factor stimulation 
can cause acinar cells to undergo an abnormal transdifferentiation event to generate what is 
called an acinar-to-ductal metaplasia (Husain & Thrower, 2009). Taken together, these 
observations strongly implicate facultative progenitors as the initiating cell in pancreatic 
cancer. While further efforts to definitively characterize the relevant cell type are required, 
armed with the above possibilities we can now discuss the basics of proliferative control 
mechanisms and the important role of the cell cycle machinery.  
4. Molecular mechanisms of proliferative control 
The cell cycle is an experimentally based, theoretical construct describing the stages through 
which a cell proceeds to generate a faithful copy of itself (Vermeulen, et al., 2003). These 
discrete steps must be transversed in sequential fashion with DNA replication in S phase 
followed by chromosome segregation and division in M phase. Gap 1 and Gap 2 phases 
separate DNA replication from chromosome segregation. They are also important for 
increasing cell mass (e.g. protein synthesis) and monitoring S and M phases to ensure 
accurate transmission of the genetic material. Progression through the cell cycle is controlled 
by a diverse group of molecular components collectively called the cell cycle machinery 
(Suryadinata, et al., 2010). Disruption of this regulatory network is a fundamental event 
required for the expansion of cancer cells (Hanahan & Weinberg, 2000). Understanding how 
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this machinery functions at the molecular level and is linked to cell fate decisions is 
therefore crucial to evaluating its role in development and progression of pancreatic cancer.  
 
Fig. 3. The Cell Cycle. The stages of the cell cycle (G1, S, G2, M) that take place during the 
duplication of the cell. The Restriction point, the regulatory checkpoint of the cell cycle after 
which the cell is committed to replication is shown, along with the option of senescence. 
4.1 Cell fate decisions 
It is essential to evaluate proliferative capacity within the context of cell function and 
contribution to the organism as a whole. During development, proliferation is transcendent, 
since exponential cell division is required to generate large number of cells. Once maturity is 
reached, proliferative capacity is utilized less frequently (e.g. tissue maintenance and 
repair). A classic example is the hematopoietic system, where immortal stem cells generate 
progeny destined to become distinct functional cells in the blood (Heike & Nakahata, 2004). 
As these cells proceed along differentiation pathways and initiate specific genetic programs, 
their capacity for division diminishes (Congdon & Reya, 2008). External information 
combined with internal preparedness are key components determining cell fate decisions. 
Cell cycle machinery is intimately involved in this process because it coordinates and 
interprets incoming signals to decide whether to proliferate or adopt an alternative fate. This 
decision is called the Restriction point, and its disruption is an essential event in cellular 
transformation (Blagosklonny & Pardee, 2002).  
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this machinery functions at the molecular level and is linked to cell fate decisions is 
therefore crucial to evaluating its role in development and progression of pancreatic cancer.  
 
Fig. 3. The Cell Cycle. The stages of the cell cycle (G1, S, G2, M) that take place during the 
duplication of the cell. The Restriction point, the regulatory checkpoint of the cell cycle after 
which the cell is committed to replication is shown, along with the option of senescence. 
4.1 Cell fate decisions 
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combined with internal preparedness are key components determining cell fate decisions. 
Cell cycle machinery is intimately involved in this process because it coordinates and 
interprets incoming signals to decide whether to proliferate or adopt an alternative fate. This 
decision is called the Restriction point, and its disruption is an essential event in cellular 
transformation (Blagosklonny & Pardee, 2002).  
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A major challenge for the cell is properly interpreting external signals, establishing and 
maintaining connections between signal and cell cycle systems, and maintaining control of 
proliferative potential. For example, withdrawal of growth factors or anti-mitogenic signals 
will cause a tissue culture cell to exit the proliferative cycle and enter a quiescent state 
(Zetterberg, et al., 1995). Such cells can be induced to re-enter the cell cycle by growth factor 
addition, which rapidly activates signal transduction cascades that communicate this 
information to the nucleus (Pomerening, 2009). A key pathway in this regard is Ras/Map 
kinase, which transmits a proliferative signal to the nucleus that jump-starts the cell cycle 
machinery and initiates the gene expression program required for cell duplication (Chang, et 
al., 2003, Coleman, et al., 2004, Takuwa & Takuwa, 2001). In addition, it is imperative that the 
nucleus alert signaling systems that their information has been received and properly acted 
upon. An example of such feedback will be discussed in more detail below. The Ras/Map 
kinase pathway and its regulation of cell cycle machinery play a key role in initiation and 
development of pancreatic cancer (Caldas & Kern, 1995, Moskaluk, et al., 1997). 
Understanding normal functioning of the major cell cycle components and their connection 
to signal transduction pathways is therefore essential to elucidating how and why they are 
disrupted in the disease state.  
4.2 Cell cycle machinery  
Regulation of cell cycle progression is designed to ensure DNA replication and chromosome 
segregation occur in response to the proper signals, proceed in the required temporal order, 
and are carried out accurately (Suryadinata, et al., 2010). The cell cycle machinery that 
control events can be promoters, inhibitors, or evaluators of cell cycle progression but in all 
cases are responsive to internal and extracellular signaling pathways (Novák, et al., 2010). 
The six major types of activity regulated by this machinery include: 1) Establishment of 
ordered biochemical pathways responsible for sequential progression through the cycle; 2) 
Assembly/disassembly of required structures (e.g. formation of DNA origins of replication, 
transcription start sites, chromosome segregation sites, telomeres, etc); 3) Regulation of 
nanomachines controlling production (DNA/RNA polymerases, ribosomes, lipid 
production etc); 4) Communication of outcomes (e.g. informing signaling components that 
transmitted information has been received); 5) Monitoring fidelity of ongoing or completed 
tasks (e.g. mechanisms ensuring cell cycle events are carried out in an accurate and timely 
fashion); 6) Self-regulation of activities (e.g. cell cycle components often regulate themselves 
or each other to drive cell cycle transitions and maintain ordered progression ).  
Cyclin-Dependent Kinases (CDKs) phosphorylate specific protein substrates at 
serine/threonine residues to initiate specific events (e.g. DNA replication) and drive cell 
cycle transitions (Malumbres & Barbacid, 2005). Regulating CDK activity is therefore crucial, 
as indicated by the multiple distinct and redundant pathways controlling its function. The 
CDK subunit alone lacks kinase activity, so it must bind a cell cycle-specific cyclin subunit 
and undergo both phosphorylation and dephosphorylation at unique sites to be activated 
(Harper & Adams, 2001). Functional cyclin-CDK complexes can be inhibited by 
phosphorylation/dephosphorylation, cyclin degradation, and by tight binding of small 
inhibitory proteins such as members of the CIP/KIP family (p21CIP1, p27KIP1 and p57KIP2) and 
the INK family (p15INK4b; p16INK4a; p18INK4c and p19INK4d) (Ekholm & Reed, 2000, Morgan, 
1997, Pavletich, 1999, Sheaff, 1997, Wang, Q., et al., 2011a). The CDK inhibitors are typically 
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thought to function as tumor suppressor proteins (Sherr, C. J. & Roberts, 1995). Genetic 
analysis of pancreatic cancer reveals both cyclin and CDK inhibitors are commonly 
disrupted in the disease, either directly or by alteration of upstream signaling pathways 
(Chen, Jinyun, et al., 2009b, Gansauge, et al., 1997, Kornmann, Marko, et al., 1998a, Lee, et al., 
2009, Schutte, et al., 1997).  
4.3 The restriction point 
The Restriction point represents an operationally defined transition in G1 when the cell 
decides whether to proceed with the proliferative cycle or withdraw and adopt an 
alternative fate (Blagosklonny & Pardee, 2002). The cell cycle machinery makes the decision 
based on evaluation of external signals and internal preparedness. Before the Restriction 
point, cell cycle progression is dependent on mitogen stimulation and thus represents a 
period in which the cell is still receiving information and evaluating its ability to 
successfully divide (Blagosklonny & Pardee, 2002, Sheaff & Roberts, 1998). After the 
Restriction point, cell cycle progression no longer requires growth factor stimulation and the 
cell is committed to completing the proliferative cycle (Blagosklonny & Pardee, 2002, Sheaff 
& Roberts, 1998). Mitogen signaling performs three main functions: 1) It establishes and 
maintains extracellular contact with the cell, transmitting the need for duplication; 2) It 
activates and communicates with cell cycle machinery to drive progression through the 
cycle; and 3) It initiates the gene expression programs required for cell duplication. 
 
Fig. 4. The Ras/Map Pathway. External growth factors bind to the receptor tyrosine kinase 
(RTK) and initiate the transduction of the signal down the protein chain, the end result of 
which is the transcription of factors required for initiation of the cell cycle and cellular 
division. 
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To elucidate the molecular events describing the Restriction point, recall how tissue culture 
cells exit the cell cycle in response to mitogen withdrawal. Re-stimulating these quiescent 
cells with growth factors causes a rapid activation of various signal transduction cascades, 
including the Ras/Map kinase pathway (see Figure 4). In normal cells, this process typically 
involves transient accumulation of active Ras-GTP, which presumably reflects successful 
communication with the nucleus. While growth factor binding to receptor tyrosine kinases 
is responsible for the rapid accumulation of Ras-GTP, it does not explain the transient 
nature of Ras activation. Work from our lab suggests activation of the Map kinase cascade 
initiates a negative feedback loop that indicates successful transmission and so prevents 
further Ras activation (Moeller, et al., 2003).  
 
Fig. 5. CDK2 Regulation. Mitogen stimulation eventually leads to the activation of Cdk2, a 
important late G1 and S phase regulator through the production and subsequent binding of 
cyclins follow by phosphorylation of the complex. Inhibitory signals can lead to 
dephosphorylation of the complex, the degredation of the complex, or it be bound by cyclin 
kinase ihhibitors (CKI). 
Map kinase is translocated into the nucleus, where it initiates transcriptional programs 
required for cell cycling and duplication. It also phosphorylates the CDK2 inhibitor p27kip1, 
resulting in its export from the nucleus. Cytoplasmic p27 targets GRB2 and prevents its 
interaction with the guanine nucleotide exchange factor SOS, thereby preventing formation 
of the GRB2-SOS complex that recruits Ras to the membrane. These observations led us to 
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hypothesize that p27 plays an important role in a negative feedback loop ensuring that: 1) 
The successful transmission of external information to the nucleus is communicated to the 
signaling system; 2) The magnitude and duration of the signal is properly maintained and 
regulated to prevent activation of fail-safe checkpoints and/or hyperproliferation. As will be 
discussed below, our more recent evidence suggests disruption of this pathway could be 
relevant to the initiation and progression of pancreatic tumorigenesis.  
In addition to opening lines of communication, an early response to growth factor 
stimulation is synthesis of cyclin D and activation of CDK4/CDK6 (Ladha, et al., 1998, 
Ohtsubo & Chibazakura, 1996). Cyclin D-CDK4/6 phosphorylates the retinoblastoma 
protein (pRb), a well known tumor suppressor that binds and inhibits the transcription 
factor E2F (Knudsen & Knudsen, 2008). As a result, E2F is released and mediates 
transcription of genes whose products are required for cell cycle progression, mass increase, 
and DNA replication (Chen, Hui-Zi, et al., 2009a, Nevins, 2001). Activity of cyclin D-
CDK4/6 complexes is negatively regulated by the tight binding inhibitor p16 (Sherr, C. J. & 
Roberts, 1999, Wang, Q., et al., 2011a). In pancreatic cancer, cyclin D1 overexpression and 
p16 inactivation are very common events, emphasizing the importance of disrupting G1 
progression to disease development (Chen, Jinyun, et al., 2009b, Fry, et al., 2008, Gansauge, 
et al., 1997, Kornmann, Marko, et al., 1998a, Schutte, et al., 1997). A major goal of E2F 
liberated by cyclin D-CDK4/6 is synthesizing cyclin E, which binds and activates CDK2 to 
continue progression through G1 and prepare for the S phase transition (Roberts & Sherr, 
2003, Sheaff & Roberts, 1998). Cyclin E-CDK2 further phosphorylates pRb and releases E2F 
to make more cyclin E, thus establishing a positive feedback loop. The result is a burst of 
cyclin E-CDK2 activity that is thought to drive the transition from mitogen-dependent to 
mitogen-independent cell cycle progression (Sheaff & Roberts, 1998).  
It will be argued below that compromised Restriction point control is the major focus of 
genetic alterations in pancreatic cancer development. 
Another positive feedback loop is established as cells approach the G1/S phase transition. 
Cyclin E-CDK2 phosphorylates and inactivates its own inhibitor, p27kip1, resulting in a 
burst of cyclin E-CDK2 activity (Sheaff, et al., 1997). As a consequence cyclin A-CDK2 is 
generated to propel cells into S phase and monitor its progression (Woo & Poon, 2003). After 
accomplishing its goals, cyclin E-CDK2 initiates its own destruction by phosphorylating 
cyclin E and targeting it for proteasomal degradation (Clurman, et al., 1996). Once DNA is 
replicated, the cell transitions into G2 where the accuracy of DNA synthesis is evaluated and 
the cell prepares for chromosome segregation (Clarke & Gimenez-Abian, 2000). Cyclin B-
CDK1 is in control during these processes (Kishimoto & Okumura, 1997). After division the 
system resets and cells must again evaluate internal and external signals to decide whether to 
continue the proliferative cycle or withdraw and adopt an alternative fate (Sheaff & Roberts, 
1998). In the case of transformed cells, the default decision is generally proliferation.  
5. Cell cycle machinery in development and progression of pancreatic cancer 
The previously discussed hallmarks of cancer—self-sufficiency in growth signals, 
insensitivity to growth-inhibitory factors, unlimited replicative potential, evasion of 
apoptosis, angiogenesis, and metastasis—identify the biological processes which must be 
genetically altered to generate a transformed pancreatic cell (Hanahan & Weinberg, 2000). 
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As the discussion of cancer cell origins hopefully made clear, however, differentiated 
quiescent cells can sometimes acquire some of these characteristics during normal organism 
functioning. If such a facultative progenitor cell initiates pancreatic cancer, then genetic 
alterations likely affect the remaining uncompromised biological systems. This section will 
argue that a major consequence of genetic mutations in pancreatic cancer is accelerating G1 
progression and disrupting Restriction point control via deregulation of the cell cycle 
machinery. Proliferative control mechanisms can be disrupted in one of two ways: 1) 
Directly, by mutation of the machinery itself; 2) Indirectly, by disruption of upstream 
signaling pathways. As is always the case with cancer, enhanced genetic instability 
underlies accumulation of transforming mutations (Negrini, et al., 2010). One such genetic 
alteration occurring very early in pancreatic cancer is telomere abnormalities (Gisselsson, et 
al., 2001, Hong, et al., 2011, Kobitsu, et al., 1997, van Heek, et al., 2002).  
5.1 Telomere abnormalities 
Most cells have limited replicative potential determined by the rate of telomere loss 
(Hornsby, 2005). Chromosome ends present a special challenge to DNA replication, since 
the directionality of DNA polymerase and the subsequent removal of RNA primers means 
that genetic material is lost each round unless special precautions are taken (Gilson & Géli, 
2007). The resulting ends become “sticky” and potentially interact, resulting in aberrant 
recombination events and chromosome breakage during anaphase. This repeated cycle of 
chromosome fusion and breakage has been implicated in genetic abnormalities such as 
amplifications and deletions that contribute to transformation (Murnane, 2010). 
Chromosome ends are therefore protected by TTAGGG repeats which are enzymatically 
added to the ends by an enzyme called telomerase (Osterhage & Friedman, 2009).  
In many types of cancer telomerase is inappropriately activated in order to maintain the 
ends and prevent cell cycle exit (Artandi & DePinho, 2010). In the case of pancreatic cancer, 
however, telomere shortening appears to be a very early event in the formation of PanIN 
precursor lesions (Bogenrieder & Herlyn, 2003, Hong, et al., 2011). It results in greatly 
enhanced genomic instability that causes global genome rearrangements and facilitates 
accumulation of subsequent point mutations. Telomerase appears to be re-activated if these 
lesions progress and become ductal adenocarcinomas, perhaps to reduce genome 
rearrangements that threaten cancer cell viability (Hong, et al., 2011). The early onset of 
telomere shortening in pancreatic cancer suggests that the affected cell may not be subject to 
limited replicative potential, further evidence supporting a stem cell origin for the disease. 
5.2 Mutational activation of ras signaling  
K-ras appears to be the major proto-oncogene mutated in pancreatic cancer (~90% of cases), 
acting as an initiating event occurring very early in pre-cancerous lesions (Caldas & Kern, 
1995, Moskaluk, et al., 1997). The high likelihood of K-ras disruption strongly suggests that it 
is also disrupted in the remaining 10% of cases, albeit by different mechanisms. As will be 
discussed below, work from our laboratory on the CDK inhibitor p27kip1 has identified a 
novel pathway by which this could occur. Ras is a member of the GTPase family that plays a 
key role in receiving and transmitting extracellular signals to the nucleus, where they 
modulate gene expression and make cell fate decisions (Takuwa & Takuwa, 2001). It is 
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recruited to the membrane upon activation of receptor tyrosine kinases by association with 
GRB2-SOS (Chang, et al., 2003). This complex activates Ras by converting it to the GTP-
bound form, which initiates signal transmission via activation of the Map kinase cascade 
(see Figure 4) (Coleman, et al., 2004). The ability to turn off signaling is crucial, so Ras is a 
GTPase that can hydrolyze GTP to GDP (Bernards, 2003). Ras regulation therefore centers in 
large part on controlling GTP hydrolysis and GDP dissociation to achieve the proper degree 
and duration of downstream signaling.  
Sequencing of primary pancreatic cancer samples revealed that K-ras mutations tend to 
target codon 12 and inactivate GTPase activity (Caldas & Kern, 1995, Moskaluk, et al., 1997) . 
The resulting K-ras-GTP continues downstream signaling in the absence of upstream 
effectors and in spite of inhibitory signals. Although mutated K-ras is in its active GTP 
bound form, it may still need to be localized to the membrane in order to initiate 
downstream signaling (Weise, et al., 2011). Thus, other regulatory events help determine the 
level and duration of downstream signaling from mutated K-ras. For this reason, additional 
mutations affecting Ras regulation are also observed. These results illustrate how disrupting 
key signaling pathways requires the synergistic effects of multiple genetic disruptions due 
to fail-safe mechanisms and checkpoints that have evolved to prevent cell transformation 
(Hanahan & Weinberg, 2000).  
Signaling pathways affected to be activated by mutant K-ras are the Raf-Map kinase 
cascade, PI3K-AKT, and RalGDS, with each making a distinct contribution to development 
of the transformed cell (Calvo, et al., 2010). As discussed above, Ras/Map kinase plays a key 
role in promoting cell cycle re-entry and progression. PI3K-AKT is involved in cell survival, 
while RalGDS is one of several Ras-regulated guanine-nucleotide exchange factors that 
activates Ral A and B GTPases (Carnero, et al., 2008, Ferro & Trabalzini, 2010). Ral proteins 
regulate key cellular processes such as endocytosis, exocytosis, and actin organization, as 
well as contributing to regulation of gene expression (Carnero, et al., 2008, Ferro & 
Trabalzini, 2010). A number of additional genetic disruptions appear to be required for 
mutant K-ras induced transformation. Of particular interest is excess cyclin D1, itself a 
downstream target of Ras that is commonly mutated in the disease state (Fry, et al., 2008, 
Gansauge, et al., 1997, Kornmann, Marko, et al., 1998a). Given the pleotropic effects of Ras 
signaling, further work is required to completely describe its contribution to transformation. 
5.3 Mutational activation of other proto-oncogenic signaling pathways  
The Ras/Map kinase pathway is only one of twelve core signaling pathway disrupted in the 
disease (Jones, et al., 2008). It is beyond the scope of this chapter to discuss each pathway in 
detail, other than to note that the consequences of their disruption likely mimic, enhance, or 
synergize with K-ras mutations to drive transformation and cancer progression. 
Involvement of Notch and hedgehog signaling deserves special mention, as these critical 
pathways are best known for maintaining cells in an undifferentiated state during 
development (Kelleher, 2011, Ristorcelli & Lombardo, 2010). In the adult organism, these 
pathways are involved in tissue homeostasis via maintenance of tissue stem cell 
populations. During injury, there is a transient induction and expansion of Hedgehog or 
Notch dependent stem cell populations to replace damaged or lost cells (Siveke, et al., 2008). 
In the mature pancreas, Notch signaling is restricted to centroacinar cells, suggesting they 
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machinery. Proliferative control mechanisms can be disrupted in one of two ways: 1) 
Directly, by mutation of the machinery itself; 2) Indirectly, by disruption of upstream 
signaling pathways. As is always the case with cancer, enhanced genetic instability 
underlies accumulation of transforming mutations (Negrini, et al., 2010). One such genetic 
alteration occurring very early in pancreatic cancer is telomere abnormalities (Gisselsson, et 
al., 2001, Hong, et al., 2011, Kobitsu, et al., 1997, van Heek, et al., 2002).  
5.1 Telomere abnormalities 
Most cells have limited replicative potential determined by the rate of telomere loss 
(Hornsby, 2005). Chromosome ends present a special challenge to DNA replication, since 
the directionality of DNA polymerase and the subsequent removal of RNA primers means 
that genetic material is lost each round unless special precautions are taken (Gilson & Géli, 
2007). The resulting ends become “sticky” and potentially interact, resulting in aberrant 
recombination events and chromosome breakage during anaphase. This repeated cycle of 
chromosome fusion and breakage has been implicated in genetic abnormalities such as 
amplifications and deletions that contribute to transformation (Murnane, 2010). 
Chromosome ends are therefore protected by TTAGGG repeats which are enzymatically 
added to the ends by an enzyme called telomerase (Osterhage & Friedman, 2009).  
In many types of cancer telomerase is inappropriately activated in order to maintain the 
ends and prevent cell cycle exit (Artandi & DePinho, 2010). In the case of pancreatic cancer, 
however, telomere shortening appears to be a very early event in the formation of PanIN 
precursor lesions (Bogenrieder & Herlyn, 2003, Hong, et al., 2011). It results in greatly 
enhanced genomic instability that causes global genome rearrangements and facilitates 
accumulation of subsequent point mutations. Telomerase appears to be re-activated if these 
lesions progress and become ductal adenocarcinomas, perhaps to reduce genome 
rearrangements that threaten cancer cell viability (Hong, et al., 2011). The early onset of 
telomere shortening in pancreatic cancer suggests that the affected cell may not be subject to 
limited replicative potential, further evidence supporting a stem cell origin for the disease. 
5.2 Mutational activation of ras signaling  
K-ras appears to be the major proto-oncogene mutated in pancreatic cancer (~90% of cases), 
acting as an initiating event occurring very early in pre-cancerous lesions (Caldas & Kern, 
1995, Moskaluk, et al., 1997). The high likelihood of K-ras disruption strongly suggests that it 
is also disrupted in the remaining 10% of cases, albeit by different mechanisms. As will be 
discussed below, work from our laboratory on the CDK inhibitor p27kip1 has identified a 
novel pathway by which this could occur. Ras is a member of the GTPase family that plays a 
key role in receiving and transmitting extracellular signals to the nucleus, where they 
modulate gene expression and make cell fate decisions (Takuwa & Takuwa, 2001). It is 
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recruited to the membrane upon activation of receptor tyrosine kinases by association with 
GRB2-SOS (Chang, et al., 2003). This complex activates Ras by converting it to the GTP-
bound form, which initiates signal transmission via activation of the Map kinase cascade 
(see Figure 4) (Coleman, et al., 2004). The ability to turn off signaling is crucial, so Ras is a 
GTPase that can hydrolyze GTP to GDP (Bernards, 2003). Ras regulation therefore centers in 
large part on controlling GTP hydrolysis and GDP dissociation to achieve the proper degree 
and duration of downstream signaling.  
Sequencing of primary pancreatic cancer samples revealed that K-ras mutations tend to 
target codon 12 and inactivate GTPase activity (Caldas & Kern, 1995, Moskaluk, et al., 1997) . 
The resulting K-ras-GTP continues downstream signaling in the absence of upstream 
effectors and in spite of inhibitory signals. Although mutated K-ras is in its active GTP 
bound form, it may still need to be localized to the membrane in order to initiate 
downstream signaling (Weise, et al., 2011). Thus, other regulatory events help determine the 
level and duration of downstream signaling from mutated K-ras. For this reason, additional 
mutations affecting Ras regulation are also observed. These results illustrate how disrupting 
key signaling pathways requires the synergistic effects of multiple genetic disruptions due 
to fail-safe mechanisms and checkpoints that have evolved to prevent cell transformation 
(Hanahan & Weinberg, 2000).  
Signaling pathways affected to be activated by mutant K-ras are the Raf-Map kinase 
cascade, PI3K-AKT, and RalGDS, with each making a distinct contribution to development 
of the transformed cell (Calvo, et al., 2010). As discussed above, Ras/Map kinase plays a key 
role in promoting cell cycle re-entry and progression. PI3K-AKT is involved in cell survival, 
while RalGDS is one of several Ras-regulated guanine-nucleotide exchange factors that 
activates Ral A and B GTPases (Carnero, et al., 2008, Ferro & Trabalzini, 2010). Ral proteins 
regulate key cellular processes such as endocytosis, exocytosis, and actin organization, as 
well as contributing to regulation of gene expression (Carnero, et al., 2008, Ferro & 
Trabalzini, 2010). A number of additional genetic disruptions appear to be required for 
mutant K-ras induced transformation. Of particular interest is excess cyclin D1, itself a 
downstream target of Ras that is commonly mutated in the disease state (Fry, et al., 2008, 
Gansauge, et al., 1997, Kornmann, Marko, et al., 1998a). Given the pleotropic effects of Ras 
signaling, further work is required to completely describe its contribution to transformation. 
5.3 Mutational activation of other proto-oncogenic signaling pathways  
The Ras/Map kinase pathway is only one of twelve core signaling pathway disrupted in the 
disease (Jones, et al., 2008). It is beyond the scope of this chapter to discuss each pathway in 
detail, other than to note that the consequences of their disruption likely mimic, enhance, or 
synergize with K-ras mutations to drive transformation and cancer progression. 
Involvement of Notch and hedgehog signaling deserves special mention, as these critical 
pathways are best known for maintaining cells in an undifferentiated state during 
development (Kelleher, 2011, Ristorcelli & Lombardo, 2010). In the adult organism, these 
pathways are involved in tissue homeostasis via maintenance of tissue stem cell 
populations. During injury, there is a transient induction and expansion of Hedgehog or 
Notch dependent stem cell populations to replace damaged or lost cells (Siveke, et al., 2008). 
In the mature pancreas, Notch signaling is restricted to centroacinar cells, suggesting they 
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might be the originating cancer cell (Miyamoto, et al., 2003). Support for this idea comes 
from mice with conditional knockout of the PTEN tumor suppressor in the pancreas, which 
develop ductal metaplasias resulting from expansion of CACs (Hill, et al., 2010). Similarly, 
expression of Notch components is elevated in PanIN lesions and invasive cancer (Wang, 
Zhiwei, et al., 2011b). Mutational activation of these pathways cooperates with K-ras 
mutations throughout development of pancreatic cancer, from generating precancerous 
PanIN lesions to involvement in tumor maintenance and metastases. Both the Hedgehog 
and Notch pathways appear to be disrupted by ligand overexpression rather than direct 
mutational targeting of pathway constituents. 
5.4 Mutational inactivation of tumor suppressors 
Temporal disruption of specific tumor suppressors is also observed in the PanIN 
progression model and again seem to converge on enhancing genomic instability and/or 
disrupting Restriction point control. For most cancers, mutations in the tumor suppressor 
p53 or one of its regulatory components (e.g. ARF) are present in the majority of cases 
(Sherr, C. J., 1998). p53 is the central transcriptional regulator responding to all types of cell 
stress. It induces expression of proteins to stop the cell cycle and determine if damage can be 
repaired; if not, it helps activate the apoptotic pathway (Muller, et al., 2011). Inactivation of 
this pathway is so common because it contributes to cell immortalization and allows 
accumulation of further genetic mutations (Hanahan & Weinberg, 2000). It is somewhat 
curious that p53 mutations are observed in only 50% of pancreatic cancers, and they tend to 
occur later in the progression model (Morton, et al., 2011). This observation (as was the case 
with telomere shortening), suggests the initiating cell might already be immortal or at least 
more resistant to apoptosis. Mutation of p53 could therefore contribute something else to 
development of pancreatic cancer. A central target of p53 is p21cip1, a CDK2 inhibitor that 
blocks cell cycle progression in G1 phase (Doucas, et al., 2006, el-Deiry, 1998). Thus, its 
mutation could enhance the rate of G1 progression and passage through the Restriction 
point.  
The p16INK4A CDK inhibitor specifically targets cyclin D and is inactivated in >80% of 
pancreatic cancers (Gansauge, et al., 1997, Kornmann, Marko, et al., 1998a). This suggests 
enhanced activity of cyclin D-CDK4/6 complexes makes an important contribution to 
development of pancreatic cancer, consistent with the common overexpression of cyclin D1 
(Fry, et al., 2008). The mechanism of p16 loss is diverse, involving homozygous deletion 
(40%), intragenic mutation followed by inactivation of the second allele (40%), and 
methylation inactivation of the promoter (10-15%) (Gansauge, et al., 1997, Kornmann, 
Marko, et al., 1998a). The locus encoding for this gene is unique in that it also encodes for 
p14ARF, an alternative reading frame gene product that plays a key role in activating p53 by 
preventing its degradation (Sherr, C. J., 2001). Specific inactivation of p16 plays a greater 
role in pancreatic cancer than loss of ARF function, as mutations have been characterized 
that compromise p16 while leaving ARF intact (Jeong, et al., 2005, Maitra, A & Hruban, 
2008). As discussed above, this observation is intriguing since loss of ARF is the major 
alternative pathway for inactivating p53 (Sherr, C. J., 2001). Preferential targeting of p16 
further illustrates the importance of compromising Restriction point control via disruption 
of the cyclins and CDKs controlling G1 progression.  
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Other identified mutations support this idea. SMAD4 is a cytoplasmic transcription factor 
involved in G1 cell cycle arrest mediated by the TGFB pathway (Yang, Guan & Yang, 2010). 
It is mutated ~50% of pancreatic cancers (Blackford, et al., 2009). Its normal function involves 
association with SMAD2/3 and translocation into the nucleus where it mediates 
transcriptional activation of growth inhibitory genes like p27kip1 (Yang, Guan & Yang, 
2010). Again, these results can be interpreted as modulating the cell cycle machinery 
controlling G1 progression and the Restriction point.  
5.5 Animal models of pancreatic cancer 
Genetically engineered mice have been developed in which genes of interest can be 
expressed in the pancreas using organ-specific promoter constructs. Mutant K-ras 
expression in the mature ductal epithelium gave little phenotype and no precursor lesions, 
suggesting these are not the cells of origin (Brembeck, et al., 2003). However, the K-ras 
mutation was able to induce carcinogenesis when combined with chemically induced 
pancreatic injury (Guerra, et al., 2007). Under these conditions mature differentiated cells are 
directed to re-enter the cell cycle to replace lost cells. This result strongly supports the idea 
of a stem cell or facultative progenitor cell as the originating cancer cell.  
In contrast, mice developed a spectrum of precursor lesions when oncogenic K-ras was 
expressed from its endogenous promoter in the developing pancreas (Guerra, et al., 2007). 
Only 10% developed into metastatic adenocarcinoma, however, and it required a long 
latency period. Similar results were observed when mutant K-ras was specifically expressed 
during development in acinar cells under control of the elastase promoter (Hruban, et al., 
2006). Ras-induced senescence may be responsible for the lack of tumor formation, 
underscoring the importance of cooperating mutations (Dimauro & David, 2010). This 
hypothesis was confirmed by the much greater penetrance in mice with combinations of 
mutations (K-ras plus p53 or p16) (Wang, Zhiwei, et al., 2011b). Under these conditions, the 
putative cell of origin responds to mutated K-ras by differentiating along a ductal lineage 
(hence the ductal adenocarcinomas). Inactivating the tumor suppressors p16 or p53 alone 
did not give an obvious phenotype or precursor lesions, suggesting K-ras acts as an initiator 
mutation (Wang, Zhiwei, et al., 2011b). Similarly, conditional Smad4 or TGFB receptor 
deletions were not sufficient to induce mPanIN lesions or cancer, although they clearly 
cooperated with K-ras to induce pancreatic neoplasia (Bardeesy, et al., 2006).  
5.6 Centrality of disrupted restriction point control  
Altered G1 progression and Restriction point control appear to be key events in 
development of pancreatic cancer based on mutations involved and the putative cell of 
origin. The central role of cell cycle disruptions can be modeled by considering mutations in 
the context of the progression model. Greater than 90% of low-grade PanIN lesions show 
shortened telomeres, providing a mechanism for rapidly generating genetic alterations 
required for cell transformation (Hong, et al., 2011, van Heek, et al., 2002). K-ras mutation is 
one of the earliest abnormalities and is likely an initiating event, being present in 36% of 
PanIN-1A, 44% of PanIN-1B, and 87% of PanIN-2/3 precursor lesions (Caldas & Kern, 1995, 
Moskaluk, et al., 1997). That such a dramatic alteration occurs so early is interesting, since 
expressing mutated K-ras in animal models typically results in senescence or apoptosis as a 
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might be the originating cancer cell (Miyamoto, et al., 2003). Support for this idea comes 
from mice with conditional knockout of the PTEN tumor suppressor in the pancreas, which 
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and Notch pathways appear to be disrupted by ligand overexpression rather than direct 
mutational targeting of pathway constituents. 
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progression model and again seem to converge on enhancing genomic instability and/or 
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(Sherr, C. J., 1998). p53 is the central transcriptional regulator responding to all types of cell 
stress. It induces expression of proteins to stop the cell cycle and determine if damage can be 
repaired; if not, it helps activate the apoptotic pathway (Muller, et al., 2011). Inactivation of 
this pathway is so common because it contributes to cell immortalization and allows 
accumulation of further genetic mutations (Hanahan & Weinberg, 2000). It is somewhat 
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blocks cell cycle progression in G1 phase (Doucas, et al., 2006, el-Deiry, 1998). Thus, its 
mutation could enhance the rate of G1 progression and passage through the Restriction 
point.  
The p16INK4A CDK inhibitor specifically targets cyclin D and is inactivated in >80% of 
pancreatic cancers (Gansauge, et al., 1997, Kornmann, Marko, et al., 1998a). This suggests 
enhanced activity of cyclin D-CDK4/6 complexes makes an important contribution to 
development of pancreatic cancer, consistent with the common overexpression of cyclin D1 
(Fry, et al., 2008). The mechanism of p16 loss is diverse, involving homozygous deletion 
(40%), intragenic mutation followed by inactivation of the second allele (40%), and 
methylation inactivation of the promoter (10-15%) (Gansauge, et al., 1997, Kornmann, 
Marko, et al., 1998a). The locus encoding for this gene is unique in that it also encodes for 
p14ARF, an alternative reading frame gene product that plays a key role in activating p53 by 
preventing its degradation (Sherr, C. J., 2001). Specific inactivation of p16 plays a greater 
role in pancreatic cancer than loss of ARF function, as mutations have been characterized 
that compromise p16 while leaving ARF intact (Jeong, et al., 2005, Maitra, A & Hruban, 
2008). As discussed above, this observation is intriguing since loss of ARF is the major 
alternative pathway for inactivating p53 (Sherr, C. J., 2001). Preferential targeting of p16 
further illustrates the importance of compromising Restriction point control via disruption 
of the cyclins and CDKs controlling G1 progression.  
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Other identified mutations support this idea. SMAD4 is a cytoplasmic transcription factor 
involved in G1 cell cycle arrest mediated by the TGFB pathway (Yang, Guan & Yang, 2010). 
It is mutated ~50% of pancreatic cancers (Blackford, et al., 2009). Its normal function involves 
association with SMAD2/3 and translocation into the nucleus where it mediates 
transcriptional activation of growth inhibitory genes like p27kip1 (Yang, Guan & Yang, 
2010). Again, these results can be interpreted as modulating the cell cycle machinery 
controlling G1 progression and the Restriction point.  
5.5 Animal models of pancreatic cancer 
Genetically engineered mice have been developed in which genes of interest can be 
expressed in the pancreas using organ-specific promoter constructs. Mutant K-ras 
expression in the mature ductal epithelium gave little phenotype and no precursor lesions, 
suggesting these are not the cells of origin (Brembeck, et al., 2003). However, the K-ras 
mutation was able to induce carcinogenesis when combined with chemically induced 
pancreatic injury (Guerra, et al., 2007). Under these conditions mature differentiated cells are 
directed to re-enter the cell cycle to replace lost cells. This result strongly supports the idea 
of a stem cell or facultative progenitor cell as the originating cancer cell.  
In contrast, mice developed a spectrum of precursor lesions when oncogenic K-ras was 
expressed from its endogenous promoter in the developing pancreas (Guerra, et al., 2007). 
Only 10% developed into metastatic adenocarcinoma, however, and it required a long 
latency period. Similar results were observed when mutant K-ras was specifically expressed 
during development in acinar cells under control of the elastase promoter (Hruban, et al., 
2006). Ras-induced senescence may be responsible for the lack of tumor formation, 
underscoring the importance of cooperating mutations (Dimauro & David, 2010). This 
hypothesis was confirmed by the much greater penetrance in mice with combinations of 
mutations (K-ras plus p53 or p16) (Wang, Zhiwei, et al., 2011b). Under these conditions, the 
putative cell of origin responds to mutated K-ras by differentiating along a ductal lineage 
(hence the ductal adenocarcinomas). Inactivating the tumor suppressors p16 or p53 alone 
did not give an obvious phenotype or precursor lesions, suggesting K-ras acts as an initiator 
mutation (Wang, Zhiwei, et al., 2011b). Similarly, conditional Smad4 or TGFB receptor 
deletions were not sufficient to induce mPanIN lesions or cancer, although they clearly 
cooperated with K-ras to induce pancreatic neoplasia (Bardeesy, et al., 2006).  
5.6 Centrality of disrupted restriction point control  
Altered G1 progression and Restriction point control appear to be key events in 
development of pancreatic cancer based on mutations involved and the putative cell of 
origin. The central role of cell cycle disruptions can be modeled by considering mutations in 
the context of the progression model. Greater than 90% of low-grade PanIN lesions show 
shortened telomeres, providing a mechanism for rapidly generating genetic alterations 
required for cell transformation (Hong, et al., 2011, van Heek, et al., 2002). K-ras mutation is 
one of the earliest abnormalities and is likely an initiating event, being present in 36% of 
PanIN-1A, 44% of PanIN-1B, and 87% of PanIN-2/3 precursor lesions (Caldas & Kern, 1995, 
Moskaluk, et al., 1997). That such a dramatic alteration occurs so early is interesting, since 
expressing mutated K-ras in animal models typically results in senescence or apoptosis as a 
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protective response to loss of proliferative control (Dimauro & David, 2010, Overmeyer & 
Maltese, 2011). Taken together, telomere shortening and K-ras activation point to the initial 
transformation involving a stem cell or facultative progenitor that re-enters the cell cycle in 
response to injury/tissue maintenance.  
Such cells likely already possess characteristics of cancer cells such as immortality and 
replicative potential. Thus, mutations are not required to drive cells back into the 
proliferative cycle from a quiescent state. Their predisposition to immortality means tumor 
suppressors like p53 or ARF need not be immediately inactivated, while telomere 
shortening is tolerated and beneficial since it induces genomic instability. What then is the 
limiting factor in transformation and expansion of the cancer cell? It is becoming 
increasingly apparent that the kinetics of stem cell cycling are quite different that those of 
somatic cells in culture (Nacusi & Sheaff, 2007, Neganova & Lako, 2008). Although they 
have limitless replicative capacity, stem cells generally take much longer to duplicate (i.e. 
doubling time of days). If the initiating cell in pancreatic cancer replicates so slowly, a major 
consequence of K-ras mutation might be to speed up the duplication rate. The overall time 
required for cell cycling is determined in large part by the rate of G1 progression (the 
longest phase of the cell cycle), so mutations would be expected to speed up this process 
and ensure passage through the Restriction point (Salomoni & Calegari, 2010).  
One way mutant K-ras might increase the proliferative rate is by increasing activity of cell 
cycle components involved in the rate limiting step(s) for G1 progression (see Figure 7). 
Experiments in tissue culture cells suggest that overexpressing G1 cyclins or otherwise 
increasing CDK activity (e.g. blocking its inhibition) can accelerate G1 phase (Roberts & 
Sherr, 2003, Sherr, C. J. & Roberts, 1999). Similarly, cyclin D1 is commonly overexpressed 
and its inhibitor p16 inactivated in pancreatic cancers (Chen, Jinyun, et al., 2009b, Fry, et al., 
2008, Gansauge, et al., 1997, Kornmann, Marko, et al., 1998a, Lee, et al., 2009, Schutte, et al., 
1997). Experiments using pancreatic cancer cell lines show blocking activity of excess cyclin 
D retarded cell growth and reduce their ability to generate tumors in nude mice (Kornmann, 
M., et al., 1998b). Various drugs (e.g. celecoxib, green tea constituents) displaying efficacy 
against pancreatic cancer cell lines often target excess cyclin D (Tseng, et al., 2002). 
Disruptions during the early stage of mitogen dependent cell cycle progression leading up 
to the Restriction point therefore appear critical to development of pancreatic 
adenocarcinoma. One obvious consequence would be to enhance cyclin D/CDK4/6 activity, 
suggesting Rb phosphorylation and inactivation is crucial to transformation of the initiating 
cell. While these early events could certainly accelerate G1 progression, the transition to 
mitogen independence reflected in the Restriction point is also likely to be rate limiting. 
Thus, cyclin E-CDK2 activity is likely to be enhanced given its role in this process (see 
Figure 7) (Sheaff & Roberts, 1998). Evidence in support of this hypothesis comes from 
analyzing the contribution of K-ras mutation on proliferation of pancreatic cancer cell lines.  
Using small molecule inhibitors of MEK, Gysin et al. found that cells arrested in G1 due to 
increased expression of the tumor suppressor p27kip1 (Gysin, et al., 2005). As a 
consequence, CDK2 was inhibited, Rb was not phosphorylated, and the E2F activity 
required for G1 progression was absent. These results indicate that inhibiting p27 expression 
is a major role of K-ras mutation, thereby enhancing CDK2 activity and accelerating G1 
progression. As described below, we propose that an additional rationale for decreasing p27 
is to ensure continued activation of the mutated K-ras pathway driving transformation. In 
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contrast, MEK inhibition had little effect on CDK4 activity, suggesting K-ras mutation is not 
responsible for effects on early G1 progression (Gysin, et al., 2005). The obvious candidates 
for affecting this period are the aforementioned cyclin D1 overexpression and inactivation of 
p16. It should be noted that there are also mechanisms through which increasing cyclin D1 
levels could contribute to enhanced CDK2 activity. Additional support for the importance of 
CDK2 comes from analysis of OGF signaling, which negatively regulates progression of 
pancreatic cancer (Fan, et al., 2008). It does so by inducing expression of the CDK2 inhibitor 
p21cip1, further evidence that accelerating G1 progression is a key step in disease 
development (Fan, et al., 2008).  
 
Fig. 6. Ras/Map Regulation by p27. Mitogen stimulation of the Ras/Map pathway leads to 
the phosphorylation and export of p27 from the nucleus. This exported P-p27 binds 
competitively for Grb2 against SOS. The dissociation of the Grb2/SOS complex leads to the 
down regulation of the Ras/Map pathway signal. 
In addition to its effects on early G1 phase, overexpressed cyclin D1 is known to bind and 
sequester p27 (Sherr, C. J. & Roberts, 1999). This would indirectly enhance CDK2 activity 
and hence progression through the Restriction point. Work in our lab has shown that p27 
also functions in a negative feedback loop regulating Ras activation by GRB2 (see Figure 6) 
(Moeller, et al., 2003). If cyclin D1 were to sequester p27, this negative feedback would be 
disrupted, thereby contributing to sustained K-ras signaling and accelerated cell cycle  
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Fig. 7. E2F Activation and Positive Feedback. Mitogen stimulation leads to the 
phosphorylation and removal of the cell cycle regulating protein Rb from the E2F-Rb 
complex. E2F goes on to activate cyclin E, whose complex with CDK2 further activates more 
E2F by Rb phosphorylation. This self-sustained postive feedback marks the transition from 
mitogen stimulated to self-sustained cell cycle progression. 
progression. We have recently investigated this possibility in breast cancer cells (which often 
overexpress cyclin D1) and found that it preferentially sequestered the phosphorylated p27 
that is exported to inhibit GRB2 (submitted). We are now investigating whether the excess 
cyclin D1 in pancreatic cancer cell lines causes a similar disruption in p27 regulation of the 
Ras pathway. These observations could help explain why cyclin D1 overexpression is 
necessary for the oncogenic effects of K-ras in pancreatic cancer (Fry, et al., 2008). Given that 
the activation of facultative progenitor cells in response to injuries is normally transient, 
inappropriate K-ras signaling could also play an important role in preventing their 
withdrawal from the cell cycle. This hypothesis is consistent with results showing that 
constitutive K-ras activation is required for maintenance of pancreatic cancer (Caldas & 
Kern, 1995). 
6. Conclusions 
Given the aggressiveness and poor prognosis of pancreatic cancer compared to many other 
forms of the disease, it is worthwhile to consider what makes it unique. This chapter 
provides an evaluation of mutational changes and disrupted biological function within the 
context of cancer hallmarks and identity of the originating cell. We argue that mutations 
Disruption of Cell Cycle Machinery in Pancreatic Cancer 295 
directly and indirectly affecting G1 progression and the Restriction point are crucial to 
development of the pancreatic cancer cell. This analysis will hopefully stimulate further 
research into methodologies for treating the disease by targeting disruptions in or activity of 
the relevant cell cycle machinery. This approach may offer greater specificity and fewer side 
effects than previously expected. Increasing evidence provides tantalizing clues that 
proliferative control mechanisms in normal and transformed cells might be different 
(Moeller & Sheaff, 2006). Mice lacking cyclins and CDKs, for example, can still develop 
normally (Sherr, Charles I. & Roberts, 2004). The dispensability of some cell cycle machinery 
in normal development and untransformed cells is in stark contrast to its apparent necessity 
in pancreatic cancer. Thus, the cell cycle machinery and its activities may represent viable 
therapeutic targets with unanticipated specificity for preferentially inhibiting proliferation 
of the pancreatic cancer cell. 
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1. Introduction 
Pancreatic cancer is one of the tumors with worst prognosis. Its low survival rate is due to 
late diagnosis because of the lack of symptoms when the tumor initiates, being frequently 
diagnosed when it metastasizes to other organs. Thus, new early diagnostic biomarkers are 
an urgent need to improve pancreatic cancer survival rates. Aberrant protein glycosylation 
is common in tumoral cells, involving changes in glycosyltransferases and glycosidases that 
could be mediated by inflammatory cytokines and growth factors. These alterations are 
functionally important in cancer progression influencing cell migration and adhesion, 
metastatic capability and immune escape. These changes in protein glycosylation during 
tumor progression can lead to alterations in membrane proteins clustering and lectin 
binding, conferring functional advantages to tumoral cells. In this regard, differential 
reactivity towards endogenous lectins, especially galectins, has been reported in several 
cancers. Galectins are involved in a variety of biological processes including tumor growth 
and malignant transformation. This chapter focuses on the specific alterations in protein 
glycosylation and galectin expression and binding during pancreatic cancer progression, as 
well as their potential use as prognostic biomarkers and therapeutic targets. Interestingly, 
we have characterized the importance of the interaction between a glycoprotein (tissue 
plasminogen activator, tPA) and Galectin-1 (Gal-1) in pancreatic cancer, suggesting that 
strategies targeting this interplay might result in successful treatments.  
2. Glycosylation in cancer 
2.1 Glycans: General features 
Glycosylation is one of the most common post-translational modifications and nearly half of 
all proteins in eukaryotes are glycosylated (Spiro, 2002). Glycans (oligosaccharides from 
glycoproteins) are classified considering their linkage to the protein backbone in N-Glycans 
(bound to the amide side chain of Asn) and O-Glycans (bound to the hydroxyl of Thr  
or Ser).   
Studies focused on the carbohydrate moiety of proteins are methodologically complicated 
due to the extremely high diversity and flexibility of these structures. N-glycan content at 
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1. Introduction 
Pancreatic cancer is one of the tumors with worst prognosis. Its low survival rate is due to 
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diagnosed when it metastasizes to other organs. Thus, new early diagnostic biomarkers are 
an urgent need to improve pancreatic cancer survival rates. Aberrant protein glycosylation 
is common in tumoral cells, involving changes in glycosyltransferases and glycosidases that 
could be mediated by inflammatory cytokines and growth factors. These alterations are 
functionally important in cancer progression influencing cell migration and adhesion, 
metastatic capability and immune escape. These changes in protein glycosylation during 
tumor progression can lead to alterations in membrane proteins clustering and lectin 
binding, conferring functional advantages to tumoral cells. In this regard, differential 
reactivity towards endogenous lectins, especially galectins, has been reported in several 
cancers. Galectins are involved in a variety of biological processes including tumor growth 
and malignant transformation. This chapter focuses on the specific alterations in protein 
glycosylation and galectin expression and binding during pancreatic cancer progression, as 
well as their potential use as prognostic biomarkers and therapeutic targets. Interestingly, 
we have characterized the importance of the interaction between a glycoprotein (tissue 
plasminogen activator, tPA) and Galectin-1 (Gal-1) in pancreatic cancer, suggesting that 
strategies targeting this interplay might result in successful treatments.  
2. Glycosylation in cancer 
2.1 Glycans: General features 
Glycosylation is one of the most common post-translational modifications and nearly half of 
all proteins in eukaryotes are glycosylated (Spiro, 2002). Glycans (oligosaccharides from 
glycoproteins) are classified considering their linkage to the protein backbone in N-Glycans 
(bound to the amide side chain of Asn) and O-Glycans (bound to the hydroxyl of Thr  
or Ser).   
Studies focused on the carbohydrate moiety of proteins are methodologically complicated 
due to the extremely high diversity and flexibility of these structures. N-glycan content at 
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one particular site is frequently miscellaneous. Their structural diversity embraces the 
number and nature of monomeric units, their position, anomeric configuration and 
branching. Glycoproteins display site-occupancy heterogeneity (macroheterogeneity), which 
refers to the diversity on the presence or absence of glycan chains in specific aminoacids. 
Moreover, not all N-linked glycan sites are occupied. Apart from this source of variation, 
glycoproteins also present site-specific heterogeneity (microheterogeneity), which describes 
differences found regarding the carbohydrate content and structure present in a single 
glycosylation site.   
Glycosylation of proteins can affect their folding, enhance solubility, intracellular trafficking, 
localization, secretion and rate of degradation (Hakomori, 2002). Apart from conferring 
specific properties to proteins themselves, glycans significantly affect protein/protein 
interactions, preventing the non-specific ones. In this direction, they mediate accurate 
cell/cell communication and signal transduction as well as the interaction between a cell 
and the extracellular milieu and soluble signaling molecules. Carbohydrate structures are 
key in many cell biological functions and indeed eighteen different types of congenital 
disorders of glycosylation (CDG) have been genetically defined (Freeze & Aebi, 2005).   
2.2 Altered glycosylation in cancer 
Typically, cancer has been associated with gain-of-functions in oncogenes or loss-of-function 
in tumor suppressor genes. However, there are many other mechanisms responsible for 
orchestrating all the events triggering cancer stepwise progression. In spite of the marked 
physiological glycan heterogeneity, cancer progression and metastasis have been 
characterized by significant alterations of the carbohydrate signature. Indeed, aberrant 
glycosylation is one of the cancer cell hallmarks (Varki et al., 2009), and certain structures 
are well-known markers of tumor development (Hakomori, 2002; Lau & Dennis, 2008). 
Besides, changes in glycosylation are presented not only by cancerous cells but also by cells 
surrounding the tumor (Rabinovich & Toscano, 2009). This specific pattern of glycosylation 
linked to neoplasia might affect protein functionality significantly, altering cell behavior in 
many different ways. Distinctive glycosylation profiles favor or impede interactions with 
different proteins.   
Some of the best characterized glycan specific alterations in cancer are a general increase in 
sialic acid content, an increase in glycan branching and overexpression of specific 
carbohydrate antigens like sialyl Lewis antigens (SLea and SLex) (Fig.1). The tight regulation 
of enzymes during protein glycosylation is crucial and indeed, the population of sugars 
attached to each glycosylated site depends on the cell type in which the glycoprotein is 
expressed and in the physiological status of the cell. Inflammatory cytokines and growth 
factors such as IL-1β, TNF-α, IL-6 and EGF, mediate changes in concentration of 
glycosyltransferases and glycosidases, altering the proportion of the glycoforms present in a 
particular glycoprotein.   
Glycan alterations are functionally important in cancer progression by affecting cell 
proliferation and survival, adhesion and migration, angiogenesis and metastatic capability, 
as well as the immune escape. For instance, a very common feature in cancer is the increased 
activity of β1-6-N-acetylglucosaminyltransferase V (GlcNAcT-V or MGAT5), which is in 
charge of β1-6 branching of both O and N-glycans. As a functional example of this fact,  
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Fig. 1. Most frequent N-glycan altered patterns observed in tumorigenesis. Common 
features of cancer glycosylation include sialylation, increased β-1,6-branching, core 
fucosylation and sialyl-Lewis antigens.   
increased branching in the β1 subunit of α5β1 integrin due to enhanced MGAT5 expression, 
inhibits integrin clustering, reducing the attachment of cancer cells to fibronectin and thus 
inducing migration (Guo et al., 2002). This enzyme is also involved in enrichment of the SLex 
group, which confers cells the ability to extravasate and metastasize. In vivo, progression of 
mammary tumors in MGAT5 knockout mice is significantly impaired (Granovsky et al., 
2000). Various factors including oncogenes as Src, Her-2/neu, H-Ras, and V-sis and known 
cancer altered signaling pathways as Ras-Raf-Ets regulate MGAT5 transcription. What still 
remains to be determined is whether changes in glycosylation are a cause or a consequence 
of transformation. Cytokine regulation of glycosyltransferase activity suggests that signaling 
from the tumor microenvironment can be the responsible for cancer-associated 
glycosylation. 
2.3 Glycosylation in pancreatic cancer 
Specific alterations in pancreatic cancer glycoproteins have been described, such as 
increased N-glycan branching and increased fucosylation and sialylation (Zhao et al., 2007). 
Importantly, some of the aberrantly glycosylated proteins have been suggested as 
biomarkers (Lacunza et al., 2007; Okuyama et al., 2006; Peracaula et al., 2008). Lectin 
antibody microarrays have been used to detect unique glycosylation patterns in pancreatic 
cancer serum in high throughput strategies (Li et al., 2009; Wu et al., 2009). These assays 
proved efficient specificity and sensitivity and shed some light in distinguishing between 
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pancreatic cancer and chronic pancreatitis, a matter that has been for long unresolved. Major 
alterations in glycan-linked gene expression associated to pancreatic cancer epithelial to 
mesenchymal transition in vitro have been also reported (Maupin et al., 2010).   
Data proposing some of the causes of altered glycosylation have emerged. Proinflammatory 
stimuli such as IFNγ, TNFα and IL-1α, in pancreatic cancer cells are responsible for altering 
Muc1, Muc5AC and Muc16 glycosylation in a cell type specific manner (Wu et al., 2009), and 
indeed, cytokine secretion has also been considered in pancreatic cancer diagnosis (Fearon 
et al., 1999; Wigmore et al., 2002).   
One of the current pancreatic tumor markers is the monoclonal antibody CA19-9 (Ferrone et 
al., 2006), whose epitope is the SLea antigen in gangliosides and mucins. SLea physiologically 
functions in the extravasation of lymphocytes from the bloodstream by interacting with 
selectins on endothelial cells. In accordance with these data, its expression on the surface of 
pancreatic cancer cells has been linked to metastasis spread to other tissue sites (Aubert et 
al., 2000). Nevertheless, CA19-9 generally does not have the specificity and sensitivity 
required for general screening, being frequently restricted to monitor patient’s progress after 
surgery. RNase-1 was long ago proposed as a tumor marker in pancreatic cancer but both its 
levels and its activity in serum failed in diagnosis. However, differences in glycosylation in 
this protein exist, finding neutral structures in healthy pancreas whereas charged structures 
(such as SLex and SLea antigens) and a significant increase in core fucosylation and 
sialylation are observed in pancreatic cancer (Peracaula et al., 2003). Increased core 
fucosylation is a general cancer feature and it is also common in pancreatic cancer. Serum 
haptoglobin and other acute phase proteins are also found to be more core fucosylated 
specifically in pancreatic cancer (Okuyama et al., 2006; Sarrats et al., 2010).  
3. Galectins in cancer 
3.1 The galectin family: Main features 
Galectins belong to the lectin family of proteins, which are highly evolutionary conserved 
finding their members in all animal kingdoms and even in plants, fungi and viruses. All the 
proteins of the family share two main features: high affinity for β-galactosides and a well 
conserved carbohydrate recognition domain (CRD) of 130 aminoacids (Barondes et al., 
1994). However, each galectin has a specific carbohydrate binding preference, as a result of 
their ability to accommodate different saccharides attached to galactose.  
15 galectins have been described in mammals (11 of which are expressed in humans) and 
they can be structurally clustered in three groups (Fig.2): 1) Prototype galectins (1, 2, 5, 7, 10, 
11) consist of a single CRD with a short N-terminal sequence; 2) Tandem-repeat galectins (4, 
6, 8, 9) are composed of two differents CRDs joined by a short linker peptide sequence; and 
3) Chimaeric galectins (Gal-3) have an extended N-terminal tail containing a consensus nine 
aminoacid residue-repeat rich in Pro, Tyr and Gly.   
Galectins are differently distributed in animal tissue and its expression is modulated during 
differentiation and tissue development, changing in some physiological and pathological 
conditions (Yang et al., 2008), such as in cancer (Danguy et al., 2002). Galectins are secreted 
by a non-canonical pathway and display a wide variety of intra and extracellular functions.  
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Fig. 2. Galectin structural classification. Prototype galectins (Gal-1,2,5,7,10,11,13,14,15) have 
one CRD domain. Tandem repeat galectins (Gal-4,6,8,9,12) are composed of two different 
CRD. The only chimaeric galectin (Gal-3) has an extended N-terminal domain.   
3.2 Gal-1: Structure and functions 
The first protein discovered in the human galectin family was Gal-1 (Couraud et al., 1989; 
Gitt & Barondes, 1986), which is encoded by LGALS1 gene located in chromosome 22q12-
13.1. Splicing of its four exons results in a 0.6 Kb transcript that is translated into a protein of 
135 aminoacids, without suffering any post-translational modification. Gal-1 expression 
might be modulated by histone acetylation and promoter methylation.   
Gal-1 is a symmetrical dimer of 14.5 KDa subunits and it has a β-sandwich “jelly-roll” 
conformation involving two parallel β-sheets, which form a central hydrophobic core 
holding both amino and carboxy-terminus of each monomer. Gal-1 CRD has a binding 
grove that allows the presence of a tetrasaccharide (A, B, C and D). C site includes the eight 
 
Fig. 3. Human dimeric Gal-1 jelly-roll structure complexed with lactose. Ribbon diagram 
prepared with MOLSCRIPT. Five-stranded (F) and six-stranded (S) sheets of each monomer 
are labelled in the image and the aminoacids involved in lactose binding are highlighted in 
the enlargement (His44, Asn46, Arg48, His52, Asn61, Trp68, Glu71 and Arg73). Adapted 
from (Lopez-Lucendo et al., 2004).  
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so well conserved aminoacids responsible for galactose binding (Fig.3), and this is common 
among all galectins. The rest of the sites are involved in galectin recognition specificity. Both 
Gal-1 and Gal-3 typically lodge a terminal LacNAc in site C-D but binding is inhibited by 
the presence of NeuAcα2-6 in the galactose located in B. Functional differences and binding 
avidities between Gal-1 and Gal-3 suggest the existence of additional determinants of 
binding specificity.   
Gal-1 is found in the cytoplasm, membrane, extracellular matrix (ECM) and nucleus, being 
involved in a wide variety of cellular functions through its ability to recognize many 
different proteins (Elola et al., 2005). Extracellular functions depend on Gal-1 lectin activity 
whereas intracellular functions are usually independent and involve protein/protein 
interactions.  
3.3 Role of galectins in cancer  
Galectins have been reported to be clear modulators of tumor progression (Liu & 
Rabinovich, 2005) and their heightened expression usually correlates with tumor clinical 
aggressiveness and metastasis. Several members of the family have been involved in 
tumor progression, being Gal-1 and Gal-3 the best characterized ones (Danguy et al., 2002; 
Yang et al., 2008). These proteins display important functions in several aspects of cancer 
biology including cell adhesion, migration, tumor transformation, apoptosis, cell cycle 
progression, angiogenesis and immune response regulation. Indeed, galectin inhibitors 
have been well considered for cancer therapy (John et al., 2003; Sorme et al., 2003; Zou et 
al., 2005).  
Gal-1 expression has been identified as a prognostic factor for tumor progression in many 
different neoplasms (Demydenko & Berest, 2009). Gal-1 involvement in tumor progression 
is focused on different aspects: neoplastic transformation, tumor cell proliferation and 
survival, angiogenesis, metastasis and evasion from the immune response (Fig.4).   
Inhibition of Gal-1 expression impairs transformation in glioma cells (Yamaoka et al., 2000). 
Among all Gal-1 partners, H-Ras could be the one closer linked to tumor transformation 
(Paz et al., 2001) although this interaction is lectin independent. Gal-1 is also very important 
in fibroblast activation in different tumor settings (Fitzner et al., 2005; Masamune et al., 
2006), and indeed, Gal-1 knockdown in cancer associated fibroblasts inhibits in vivo tumor 
progression (Wu et al., 2011).  
Gal-1 effects in cell proliferation are controversial. It is mitogenic in several cell types, such 
as in mammalian vascular cells and hepatic stellate cells, but it is also able to hamper cell 
growth in other cell types, such as in stromal bone marrow cells. Intracellular Gal-1 can 
induce not only cell cycle arrest but also apoptosis in cancer cells. Gal-1 concentration seems 
to be key when deciding the final outcome: high doses (μM) of Gal-1 inhibit cell 
proliferation independently of its lectin activity whereas low doses (nM) are mitogenic 
through its ability to recognize carbohydrates (Adams et al., 1996). Apart from this dose 
response effect, the cell type and cell activation status, the distribution of monomeric versus 
dimeric forms and Gal-1 compartimentalization, might be also affecting the overall result on 
cell cycle progression.   
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Fig. 4. Gal-1 is involved in many different tumor progression events. Gal-1 participates in 
cell transformation, proliferation, adhesion, migration, angiogenesis and T cell apoptosis.  
Gal-1 has been actively involved in the long range dissemination of tumoral cells or 
metastasis (Camby et al., 2006), as it participates in adhesion, migration, motility and 
invasion. Gal-1 can decrease tumor cell adhesion to the ECM, resulting in cell detachment 
from primary sites and invasion. Alternatively, the dimeric nature of Gal-1 allows 
crosslinking integrins on the cell surface of tumoral cells to proteins on the ECM, mediates 
tumoral cell/cell interactions favoring aggregation and their interaction with endothelial 
cells, facilitating tumor cell dispersion on the blood stream and establishment at distal sites 
during metastasis. In addition, Gal-1 has been also involved in invasion through adhesion 
independent mechanisms by upregulating well known ECM degradators like MMP-2, 
MMP-9, or by reorganizing the actin cytoskeleton through Cdc42 or RhoA upregulation.   
Gal-1 also plays a key role in angiogenesis as it is able to stimulate the growth of vascular 
endothelial cells. The lectin is overexpressed in activated tumor endothelium and it is 
involved in endothelial cell function (by NRP-1 interaction and VEGFR-2 activation). Gal-1 
deficiency impairs tumor growth and angiogenesis in vivo (Le Mercier et al., 2009; Thijssen 
et al., 2006). Moreover, Gal-1 modulates the expression of BEX2 and several hypoxia related 
genes involved in angiogenesis. Paracrine mechanisms involving the uptake by endothelial 
cells of Gal-1 secreted from tumoral cells have been linked to endothelial cell activation and 
tumor angiogenesis stimulation, through Ras and Erk1/2 activation (Thijssen et al., 2010).   
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through its ability to recognize carbohydrates (Adams et al., 1996). Apart from this dose 
response effect, the cell type and cell activation status, the distribution of monomeric versus 
dimeric forms and Gal-1 compartimentalization, might be also affecting the overall result on 
cell cycle progression.   
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Fig. 4. Gal-1 is involved in many different tumor progression events. Gal-1 participates in 
cell transformation, proliferation, adhesion, migration, angiogenesis and T cell apoptosis.  
Gal-1 has been actively involved in the long range dissemination of tumoral cells or 
metastasis (Camby et al., 2006), as it participates in adhesion, migration, motility and 
invasion. Gal-1 can decrease tumor cell adhesion to the ECM, resulting in cell detachment 
from primary sites and invasion. Alternatively, the dimeric nature of Gal-1 allows 
crosslinking integrins on the cell surface of tumoral cells to proteins on the ECM, mediates 
tumoral cell/cell interactions favoring aggregation and their interaction with endothelial 
cells, facilitating tumor cell dispersion on the blood stream and establishment at distal sites 
during metastasis. In addition, Gal-1 has been also involved in invasion through adhesion 
independent mechanisms by upregulating well known ECM degradators like MMP-2, 
MMP-9, or by reorganizing the actin cytoskeleton through Cdc42 or RhoA upregulation.   
Gal-1 also plays a key role in angiogenesis as it is able to stimulate the growth of vascular 
endothelial cells. The lectin is overexpressed in activated tumor endothelium and it is 
involved in endothelial cell function (by NRP-1 interaction and VEGFR-2 activation). Gal-1 
deficiency impairs tumor growth and angiogenesis in vivo (Le Mercier et al., 2009; Thijssen 
et al., 2006). Moreover, Gal-1 modulates the expression of BEX2 and several hypoxia related 
genes involved in angiogenesis. Paracrine mechanisms involving the uptake by endothelial 
cells of Gal-1 secreted from tumoral cells have been linked to endothelial cell activation and 
tumor angiogenesis stimulation, through Ras and Erk1/2 activation (Thijssen et al., 2010).   
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Finally, Gal-1 is involved in the tumor immune response promoting an immunosuppressive 
environment at tumor sites by inhibiting full T cell activation, triggering T cell growth arrest 
and apoptosis and protecting the tumor by negatively regulating Th1 and proinflammatory 
cytokines. These effects are mediated by Gal-1 recognition of cell surface glycoproteins 
present on T cell membranes such as CD2, CD3, CD7, CD43 and CD45 (Galvan et al., 2000; 
Pace et al., 1999).  
3.4 Galectins in pancreatic cancer  
In pancreatic cancer, Gal-1 and Gal-3 are found to be overexpressed (Berberat et al., 2001; 
Chung et al., 2008; Grutzmann et al., 2004; Schaffert et al., 1998).   
Gal-3 expression is faint in ductal cells of normal pancreas but it is high in intrapapillary 
mucin neoplasms, chronic pancretatitis, cancerous pancreatic tissue and metastatic cells, 
suggesting its role in cancer cell proliferation and metastasis formation. However, decreased 
Gal-3 expression has been linked to advanced stage, tumor de-differentiation and metastasis 
in ductal adenocarcinomas, implying a fine tuned regulation of its levels in different steps of 
tumor progression. Gal-3 secreted by pancreatic cells plays a role in pancreatic stellate cell 
proliferation and in pancreatic cancer cell proliferation and invasion in vitro. A negative 
correlation between anoikis and Gal-3 presence has been established, too. Besides, the 
interaction between Gal-3 and Muc4 has been proven to be functional to dock tumor cells to 
the endothelial surface, what might present a possible mechanism to explain Gal-3 
involvement in metastasis.   
Gal-1 has found to be overexpressed in pancreatic tumors compared to normal tissue 
(Berberat et al., 2001; Grutzmann et al., 2004; Iacobuzio-Donahue et al., 2003; Shen et al., 
2004) (Fig.5). Interestingly, its expression levels correlate not only with histology but also 
with T stage, N stage and global AJCC stage of pancreatic cancer disease (Chung et al., 
2008), suggesting that Gal-1 might also participate in tumor progression and that its 
presence does not seem to be a random event. Gal-1 expression by immunohistochemical 
analysis has been reported to be mainly restricted to the ECM and fibroblasts in and around 
the cancer mass, but not to pancreatic cancer cells, suggesting its importance in the so 
characteristic desmoplastic reaction. Gal-1 is also found in the stroma of PanIN-2 and 
PanIN-3 (Pan et al., 2009) and in chronic pancreatitis (Wang et al., 2000).   
 
Fig. 5. Gal-1 is overexpressed in precursor lesions and pancreatic cancer. Gal-1 
immunohistochemistry in mouse pancreatic normal tissue, in Ela-1-myc pancreatic ductal 
adenocarcinoma (PDA) lesions and in human pancreatic cancer tissue. Scale bars 
correspond to 200 μm.  
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Interestingly, although Gal-1 did not appear in the list of genes consistently misregulated in 
pancreatic cancer that were gathered in 12 core signaling pathways (Jones et al., 2008), 54 of 
the genes found overexpressed encoded secreted or cell surface proteins, putative and 
already known Gal-1 binding targets, like laminin. Thus, Gal-1 overexpression might be 
involved in the functional outcome of these overrepresented molecules, playing a role in 
some of the key identified signaling pathways such as homophilic cell adhesion, integrin 
signaling and regulation of invasion. Gal-1 could have been excluded from the reported list 
because this important global genomic analysis was based on tumoral epithelial cells, 
leaving out the stroma, whose population seems to be the one predominantly affected by 
Gal-1 increased levels.  
Gal-1 could be involved in tumor progression in pancreatic cancer by remodeling the ECM 
in the formation of the desmoplastic reaction. Indeed, Gal-1 is able to induce activation 
(increased collagen synthesis), proliferation and chemokine production (MCP-1 and CINC-
1) of pancreatic stellate cells, through Erk1/2, Jnk, NF-кB and AP-1 activation. At the same 
time, activated pancreatic stellate cells secrete Gal-1, which can be acting autocrinely and 
might be also regulating the tumor immune response (Fitzner et al., 2005; Masamune et al., 
2006).   
As it has been described above, Gal-1 displays a wide variety of biological functions which 
bring up a high degree of complexity when trying to understand its involvement in cancer. 
Thus, Gal-1 might not always tilt the balance in the same direction. In pancreatic cancer 
cells, for example, stable transfection of the tumor suppressor p16/Ink4a can induce Gal-1 
expression and its affinity for the fibronectin receptor, resulting in increased susceptibility 
towards anoikis (Andre et al., 2007). Another Gal-1 antitumoral role is presented by the fact 
that it is downregulated in gemcitabine resistant pancreatic cancer cells (Kuramitsu et al., 
2010). The ability of Gal-1 to induce opposite effects regarding proliferation and adhesion, as 
well as its reduced expression found in some tumors (Choufani et al., 1999), hint at Gal-1 as 
a double side coin and question its nature as a protumoral molecule. Many variables might 
be influencing the final outcome, such as cell type and activation status, Gal-1 levels and 
localization, as well as its quaternary structure.  
3.5 Gal-1 establishing protein/glycan interactions  
Gal-1 interactions involving its CRD domain and lectin activity are involved in many of Gal-
1 important functions (Table 1). N-glycans from cell surface glycoproteins are the major 
ligands for Gal-1 and Gal-3, although they also bind to mucins, proteoglycans and the ECM. 
Although both proteins have high affinity for β-galactosides and indeed they share many 
interacting partners such as CD45, laminin, fibronectin and integrins, a fine specificity level 
results in binding differences. The general rule is that Gal-3 prefers repeating lactosamine 
units whereas Gal-1 recognizes independent lactosamine disaccharides with low affinity 
(Kd=50 μM) but deeply increases avidity when presented in multiantennary repeating units 
(Kd=5 μM) and when the lectin is surface bound to cell membranes or to the ECM. Indeed, 
Gal-1 is involved in microdomain (lattice) formation within membranes by crosslinking 
ligands in a glycoside cluster effect that greatly increases its affinity. However, as a matter of 
fact, Gal-1 is able to recognize only about 1/40 of the total N-glycans present in human 
serum glycoproteins (Kita et al., 2007), and around 1/8 of the sites supposed to be galectin 
specific. It is believed that part of Gal-1 specificity is mediated by additional binding sites 
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Finally, Gal-1 is involved in the tumor immune response promoting an immunosuppressive 
environment at tumor sites by inhibiting full T cell activation, triggering T cell growth arrest 
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Interestingly, although Gal-1 did not appear in the list of genes consistently misregulated in 
pancreatic cancer that were gathered in 12 core signaling pathways (Jones et al., 2008), 54 of 
the genes found overexpressed encoded secreted or cell surface proteins, putative and 
already known Gal-1 binding targets, like laminin. Thus, Gal-1 overexpression might be 
involved in the functional outcome of these overrepresented molecules, playing a role in 
some of the key identified signaling pathways such as homophilic cell adhesion, integrin 
signaling and regulation of invasion. Gal-1 could have been excluded from the reported list 
because this important global genomic analysis was based on tumoral epithelial cells, 
leaving out the stroma, whose population seems to be the one predominantly affected by 
Gal-1 increased levels.  
Gal-1 could be involved in tumor progression in pancreatic cancer by remodeling the ECM 
in the formation of the desmoplastic reaction. Indeed, Gal-1 is able to induce activation 
(increased collagen synthesis), proliferation and chemokine production (MCP-1 and CINC-
1) of pancreatic stellate cells, through Erk1/2, Jnk, NF-кB and AP-1 activation. At the same 
time, activated pancreatic stellate cells secrete Gal-1, which can be acting autocrinely and 
might be also regulating the tumor immune response (Fitzner et al., 2005; Masamune et al., 
2006).   
As it has been described above, Gal-1 displays a wide variety of biological functions which 
bring up a high degree of complexity when trying to understand its involvement in cancer. 
Thus, Gal-1 might not always tilt the balance in the same direction. In pancreatic cancer 
cells, for example, stable transfection of the tumor suppressor p16/Ink4a can induce Gal-1 
expression and its affinity for the fibronectin receptor, resulting in increased susceptibility 
towards anoikis (Andre et al., 2007). Another Gal-1 antitumoral role is presented by the fact 
that it is downregulated in gemcitabine resistant pancreatic cancer cells (Kuramitsu et al., 
2010). The ability of Gal-1 to induce opposite effects regarding proliferation and adhesion, as 
well as its reduced expression found in some tumors (Choufani et al., 1999), hint at Gal-1 as 
a double side coin and question its nature as a protumoral molecule. Many variables might 
be influencing the final outcome, such as cell type and activation status, Gal-1 levels and 
localization, as well as its quaternary structure.  
3.5 Gal-1 establishing protein/glycan interactions  
Gal-1 interactions involving its CRD domain and lectin activity are involved in many of Gal-
1 important functions (Table 1). N-glycans from cell surface glycoproteins are the major 
ligands for Gal-1 and Gal-3, although they also bind to mucins, proteoglycans and the ECM. 
Although both proteins have high affinity for β-galactosides and indeed they share many 
interacting partners such as CD45, laminin, fibronectin and integrins, a fine specificity level 
results in binding differences. The general rule is that Gal-3 prefers repeating lactosamine 
units whereas Gal-1 recognizes independent lactosamine disaccharides with low affinity 
(Kd=50 μM) but deeply increases avidity when presented in multiantennary repeating units 
(Kd=5 μM) and when the lectin is surface bound to cell membranes or to the ECM. Indeed, 
Gal-1 is involved in microdomain (lattice) formation within membranes by crosslinking 
ligands in a glycoside cluster effect that greatly increases its affinity. However, as a matter of 
fact, Gal-1 is able to recognize only about 1/40 of the total N-glycans present in human 
serum glycoproteins (Kita et al., 2007), and around 1/8 of the sites supposed to be galectin 
specific. It is believed that part of Gal-1 specificity is mediated by additional binding sites 
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Gal-1 partners Biological context Functional Outcome 
CA-125 cervical cancer cells Gal-1 export to cell surface 
CD2/CD3 T cells  T cell activation and apoptosis 
CD4 T cells Unclear 
CD43, CD45 T cells Gal-1 induced T cell death (depending on 
specific receptor glycosylation). Redistribution 
of the receptors in the cell surface.  
CD7 T cells Induction of apoptosis 
CEA colon carcinoma cells Unclear 
Chondroitin 
sulphate 
SMC Incorporation of ECM components important 
for SMC 
Fibronectin placenta  
ovary carcinoma cells 
Control of cell adhesion 
1B2 glycolipid olfactory neurons Adhesion between adjacent axons and with 
the ECM resulting in olfactory axon 
fasciculation 
Glycoprotein 90K  melanoma cells Formation of multicell aggregates 
GM1 ganglioside neuroblastoma cells Sialidase dependent cell growth inhibition  
HBGp82 brain Unknown 
INTEGRINS   
α1β1, α7β1 SMC 
skeletal myocytes 
Intracellular signaling leading to adhesion, 
FAK activation, migration 
α5β1 colon, breast, 
ovarian, hepatocellular 
carcinoma cells, 
Antiproliferative effects, induction of anoikis  
αMβ2 macrophages Possibly crosslinking receptors or affecting 
receptor-ligand binding affinity 
Laminin placenta,  
smooth muscle cells, 
leydig cells 





colon carcinoma cells 
Tumor cell adhesion and metastasis 
Mucin gastrointestinal tract Protection from the epithelial surface 




B cells Cell differentiation, adhesion 
Osteopontin, 
vitronectin 
SMC Adhesion, ECM assembly 
Thrombospondin SMC Adhesion 
Table 1. Proteins that are known to interact with Gal-1 through their CRD. Description of the 
best characterized Gal-1 interactors, specifying the biological context in which the 
interaction has been identified, and the consequent functional outcome. SMC: smooth 
muscle cells. Detailed references can be found at (Camby et al., 2006).  
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recognizing more than the canonical galactose. Thus, the particular structural context of 
galectin binding sites depicts a complex scenario and impairs stating generalizations. For 
instance, Gal-1 is able to induce T cell death by binding a glycan ligand without 
lactosamine units, that is very abundant but less preferred (Hernandez et al., 2006). 
Normally though, Gal-1 recognition capacity is deeply influenced by specific conditions 
regarding carbohydrate content and linkage. Minor alterations in N-glycan chains have 
been reported to influence Gal-1 binding in such a way that changes the overall biological 
outcome (Andre et al., 2007). Cell type specific expression patterns of several proteins and 
their glycans can modulate different Gal-1 mediated effects (Gu et al., 1994; Moiseeva et 
al., 1999). Particular glycosylation structures are known to mask glycans to Gal-1, which 
impede Gal-1 induced T-lymphocyte (Liu & Rabinovich, 2010) and cancer cell (Valenzuela 
et al., 2007) death. For instance, in contrast to Th1 and Th17 cells, Th2 cells are protected 
from Gal-1 induced apoptosis by presenting α2-6 sialylation of cell surface glycoproteins 
(Toscano et al., 2007).   
In the ECM, Gal-1 displays high affinity for laminin, fibronectin, thrombospondin, 
vitronectin, osteopontin and glycosamine glycans such as chondroitin sulfate (Table 1). 
Depending on the cell type and cell activation status, these interactions finally lead to a pro-
adhesive or an anti-adhesive effect.   
In the cell membrane, Gal-1 has many interactors resulting in very different effects (Table 1). 
Glycosylated cell surface receptors are closely linked to the adhesive properties mediated by 
Gal-1. For instance, Gal-1 interaction with α7β1 integrin interferes with integrin/laminin 
binding and controls cell adhesion. Gal-1 interaction with NRP-1 has been involved in 
migration and adhesion of endothelial cells (Hsieh et al., 2008). Gal-1 can also function as a 
regulator of the immune response through its interaction with CD7, CD45 and CD43. 
Moreover, Gal-1 has also been involved in cell growth inhibition through its interaction with 
α5β1 integrin, GM1 ganglioside or the glycoprotein 90K/MAC-2BP. Gal-1 can also recognize 
HBGp82 in the brain, CA125 in ovarian cancer cells, LAMP-1, LAMP-2 and CEA in colon 
carcinoma cells and 1B2 glycolipid in olfactory axons.  
4. tPA: Connecting galectins and cancer protein glycosylation? 
4.1 tPA: General features 
Our group has recently characterized how an interaction between Gal-1 and a glycosylated 
protein –tPA- is involved in pancreatic cancer progression (Roda et al., 2009). tPA is mainly 
synthesized by endothelial cells, but it has also been detected in the central nervous system, 
being secreted by neurons and glial cells and it can also be produced by keratinocytes, 
melanocytes and various tumor cells. tPA best documented role is the conversion of 
plasminogen into plasmin, which degrades fibrin clots in blood vessels after thrombosis 
through a well-orchestrated process involving several regulators. Besides, tPA is also 
involved –by its catalytic activity- in the activation of growth factors and matrix 
metalloproteinases in the ECM (Fig.6). In addition to these proteolytic activities, we and 
others have demonstrated that tPA can exert catalytic-independent functions in different cell 
types, including neurons (Medina M.G. et al., 2005), kidney fibroblasts (Hu et al., 2006) and 
tumors (Ortiz-Zapater et al., 2007).   
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recognizing more than the canonical galactose. Thus, the particular structural context of 
galectin binding sites depicts a complex scenario and impairs stating generalizations. For 
instance, Gal-1 is able to induce T cell death by binding a glycan ligand without 
lactosamine units, that is very abundant but less preferred (Hernandez et al., 2006). 
Normally though, Gal-1 recognition capacity is deeply influenced by specific conditions 
regarding carbohydrate content and linkage. Minor alterations in N-glycan chains have 
been reported to influence Gal-1 binding in such a way that changes the overall biological 
outcome (Andre et al., 2007). Cell type specific expression patterns of several proteins and 
their glycans can modulate different Gal-1 mediated effects (Gu et al., 1994; Moiseeva et 
al., 1999). Particular glycosylation structures are known to mask glycans to Gal-1, which 
impede Gal-1 induced T-lymphocyte (Liu & Rabinovich, 2010) and cancer cell (Valenzuela 
et al., 2007) death. For instance, in contrast to Th1 and Th17 cells, Th2 cells are protected 
from Gal-1 induced apoptosis by presenting α2-6 sialylation of cell surface glycoproteins 
(Toscano et al., 2007).   
In the ECM, Gal-1 displays high affinity for laminin, fibronectin, thrombospondin, 
vitronectin, osteopontin and glycosamine glycans such as chondroitin sulfate (Table 1). 
Depending on the cell type and cell activation status, these interactions finally lead to a pro-
adhesive or an anti-adhesive effect.   
In the cell membrane, Gal-1 has many interactors resulting in very different effects (Table 1). 
Glycosylated cell surface receptors are closely linked to the adhesive properties mediated by 
Gal-1. For instance, Gal-1 interaction with α7β1 integrin interferes with integrin/laminin 
binding and controls cell adhesion. Gal-1 interaction with NRP-1 has been involved in 
migration and adhesion of endothelial cells (Hsieh et al., 2008). Gal-1 can also function as a 
regulator of the immune response through its interaction with CD7, CD45 and CD43. 
Moreover, Gal-1 has also been involved in cell growth inhibition through its interaction with 
α5β1 integrin, GM1 ganglioside or the glycoprotein 90K/MAC-2BP. Gal-1 can also recognize 
HBGp82 in the brain, CA125 in ovarian cancer cells, LAMP-1, LAMP-2 and CEA in colon 
carcinoma cells and 1B2 glycolipid in olfactory axons.  
4. tPA: Connecting galectins and cancer protein glycosylation? 
4.1 tPA: General features 
Our group has recently characterized how an interaction between Gal-1 and a glycosylated 
protein –tPA- is involved in pancreatic cancer progression (Roda et al., 2009). tPA is mainly 
synthesized by endothelial cells, but it has also been detected in the central nervous system, 
being secreted by neurons and glial cells and it can also be produced by keratinocytes, 
melanocytes and various tumor cells. tPA best documented role is the conversion of 
plasminogen into plasmin, which degrades fibrin clots in blood vessels after thrombosis 
through a well-orchestrated process involving several regulators. Besides, tPA is also 
involved –by its catalytic activity- in the activation of growth factors and matrix 
metalloproteinases in the ECM (Fig.6). In addition to these proteolytic activities, we and 
others have demonstrated that tPA can exert catalytic-independent functions in different cell 
types, including neurons (Medina M.G. et al., 2005), kidney fibroblasts (Hu et al., 2006) and 
tumors (Ortiz-Zapater et al., 2007).   
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Fig. 6. tPA physiological functions. The best documented role for tPA is the activation of the 
zymogen plasminogen into plasmin, which degrades fibrin clots in blood vessels after 
thrombosis. Moreover, tPA is also involved in activation of matrix metalloproteinases and 
growth factors and in the ECM degradation, participating in cell migration and tissue 
remodeling events.  
tPA is a glycoprotein of 527 aminoacids and around 70 KDa, depending on specific 
glycosylation. tPA is synthesized as a single-chain protein but it is quickly hydrolyzed by 
plasmin, forming a two-chain structure maintained together by a disulfide bond. 
Structurally, apart from a typical signal peptide and a prosequence, tPA is formed by 5 
different autonomous domains, which are encoded by separate exons or sets of exons: 1) 
The fibronectin type I domain in the amino terminus, which mediates fibrin affinity; 2) An 
EGF-like domain which is probably involved in cell surface receptor binding; 3) Two kringle 
regions with a triple looped structure, with a high degree of homology with plasminogen 
kringle domains and 4) A serine protease domain with the active site residues His322, 
Asp371 and Ser478.  
Due to the size of tPA and the presence of glycosylated chains in the molecule, the complete 
structure of the protease remains still undetermined. However, the detailed structure has 
been revealed for some of the domains by NMR or X-Ray diffraction as for the fibronectin 
type I domain (Downing et al., 1992), EGF domain (Smith et al., 1995), kringle 2 (Byeon et 
al., 1991; Byeon & Llinas, 1991; de Vos et al., 1992) and the catalytic domain (Lamba et al., 
1996; Renatus et al., 1997a; Renatus et al., 1997b).   
Glycosylation differences describe two different tPA isoforms (type I and type II), 
displaying species, cell and site-specific patterns of these post-translational modifications. In 
type I tPA, 4 glycosylation sites are occupied in separate domains, which play a role in 
different biological and pathological tPA functions: an O-linked fucose in Thr61 (EGF 
domain) and three N-linked carbohydrate chains; an oligomannosidic structure highly 
conserved between species at Asn117 (in kringle 1), and two complex and hybrid type 
structures at Asn184 (in kringle 2) and Asn448 (in the catalytic domain). Type II tPA lacks 
the glycosylation at Asn184 and this absence allows the conversion of single-chain to two-
chain tPA, through plasmin mediated cleavage of the polypeptide backbone between 
Arg275 and Ile276. The presence of glycan chains at site Asn184 affects the structure of the 
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glycan population at Asn448, being two-chain tPA a more active tPA regarding clot lytic 
activity and fibrin-binding capacity. 
4.2 Role of tPA and tPA receptors in pancreatic cancer 
tPA overexpression correlates with poor prognosis in several cancers. In pancreatic cancer 
studies, tPA is found to be highly expressed in well differentiated human pancreatic cancer 
cultures and overexpressed in 95% of pancreatic ductal adenocarcinomas (PDAs), being 
absent in normal pancreas (Paciucci et al., 1996, 1998; Ryu et al., 2002) (Fig.7).   
 
Fig. 7. tPA is overexpressed in human pancreatic cancer. tPA expression assessed by 
immunohistochemistry in normal pancreas (normal), showing no tPA expression, whereas, 
in human pancreatic ductal adenocarcinoma (PDA), high expression levels of tPA are 
detected in ducts.   
In vitro and in vivo studies have determined that tPA contributes to pancreatic cancer 
progression by increasing cell invasion, Erk1/2 phosphorylation, cell proliferation and 
angiogenesis (Aguilar S et al., 2004; Diaz et al., 2004; Paciucci et al., 1998). These effects are 
mediated through tPA interaction with different cell membrane receptors. In this regard, 
EGFR is overexpressed in pancreatic cancer and it has been demonstrated to participate in 
tPA effects in cell proliferation (Hurtado et al., 2007; Ortiz-Zapater et al., 2007). AnxA2 -the 
best characterized tPA receptor and its major receptor in endothelial cells- has also been 
clearly involved in tPA-mediated pancreatic cancer cell invasion, proliferation and 
angiogenesis (Diaz et al., 2004; Ortiz-Zapater et al., 2007). Nevertheless, AnxA2 does not 
seem to be the only functional tPA pancreatic cancer receptor as its interaction with the 
protease only explains part of the tPA found in the cell membrane (Diaz et al., 2004; Ortiz-
Zapater et al., 2007). These data and the fact that AnxA2 seems to be inappropriate as a 
target for pancreatic therapy due to its important physiological functions in blood 
coagulation homeostasis moved us to find new tPA receptors that could be involved in tPA 
protumoral functions in pancreatic cancer. As described in the next section, we have 
recently demonstrated that Gal-1 is a new functional tPA receptor (Roda et al., 2006, 2009). 
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glycan population at Asn448, being two-chain tPA a more active tPA regarding clot lytic 
activity and fibrin-binding capacity. 
4.2 Role of tPA and tPA receptors in pancreatic cancer 
tPA overexpression correlates with poor prognosis in several cancers. In pancreatic cancer 
studies, tPA is found to be highly expressed in well differentiated human pancreatic cancer 
cultures and overexpressed in 95% of pancreatic ductal adenocarcinomas (PDAs), being 
absent in normal pancreas (Paciucci et al., 1996, 1998; Ryu et al., 2002) (Fig.7).   
 
Fig. 7. tPA is overexpressed in human pancreatic cancer. tPA expression assessed by 
immunohistochemistry in normal pancreas (normal), showing no tPA expression, whereas, 
in human pancreatic ductal adenocarcinoma (PDA), high expression levels of tPA are 
detected in ducts.   
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protease only explains part of the tPA found in the cell membrane (Diaz et al., 2004; Ortiz-
Zapater et al., 2007). These data and the fact that AnxA2 seems to be inappropriate as a 
target for pancreatic therapy due to its important physiological functions in blood 
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Pancreatic Cancer – Molecular Mechanism and Targets 318
4.3 tPA/Gal-1 interaction: Glycosylation involvement and role in pancreatic cancer  
Interaction between tPA and Gal-1 was first identified in total tumoral pancreatic cell lysates 
by affinity capture with tPA-sepharose followed by 2D- electrophoresis (Roda et al., 2006). 
However these data did not prove whether tPA/Gal-1 interaction was direct or mediated 
through other proteins. In a more recent work, using recombinant proteins and surface 
plasmon resonance, we proved that tPA/Gal-1 interaction was direct and specific (Roda et 
al., 2009). Furthermore, Gal-1 was able to increase tPA mediated plasmin generation, 
suggesting interesting functional outcomes from their interaction.   
Taken into account that 1) galectins are lectins with high affinity for β-galactosides, 2) Gal-1 
binds galactose, and lactose with even higher affinity, through its CRD, and 3) tPA is a 
glycoprotein, we hypothesized that tPA and Gal-1 interaction was N-glycan mediated. In 
order to know whether that was the case, surface plasmon resonance was used to determine 
if carbohydrates were able to interfere with this interaction. Galactose (in a dose dependent 
manner) and lactose (with even higher effectiveness), inhibited tPA/Gal-1 interaction (Roda 
et al., 2009). Proving galactose specificity, neither glucose nor cellobiose was able to do so. 
These data demonstrated that the Gal-1 CRD was involved in tPA interaction and as 
expected, pointed at galactose in a β-anomeric position as its high affinity epitope.   
Importantly, our results showed that this Gal-1/tPA interaction was not only relevant in 
vitro, but also in vivo where the lectin was actively involved in tPA induced Erk1/2 
activation, proliferation, migration and invasion. tPA/Gal-1 effects were not restricted to 
pancreatic cells but were also found in tPA-mediated protumoral effects in fibroblasts from 
the tumor stroma, demonstrating the important role for tPA/Gal-1 interaction in the 
epithelial/fibroblast crosstalk and in pancreatic cancer tumor progression (Roda et al., 2009).  
 
Fig. 8. Gal-1 is acting as a functional tPA receptor in pancreatic cell lines and fibroblasts. 
Gal-1 in pancreatic cancer cells can activate Erk1/2, induce proliferation, migration and 
invasion by binding to tPA in an autocrine fashion. Gal-1 can also act in a paracrine fashion 
over fibroblasts, triggering the same pathological effects that could be involved in the 
desmoplastic reaction.  
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Thus, we propose a model in which tPA secreted from pancreatic epithelial cells could act 
both in a paracrine and in an autocrine manner. In the latter, it would bind to Gal-1 in the 
cell surface of pancreatic tumoral cells triggering Erk1/2 activation and subsequent 
proliferation, as well as invasion. These events would be favoring tumor progression. On 
the other hand, tPA could bind in a paracrine fashion to Gal-1 from fibroblasts, what would 
induce the same events but in this mesenchymal cell line, leading to the desmoplastic 
reaction (Fig.8).   
5. Glycans and Gal-1 in pancreatic cancer diagnosis and therapy  
5.1 Glycans in diagnosis and therapy 
Serum glycoproteins constitute the most frequent family of current tumor markers (Ludwig 
& Weinstein, 2005). Among others, two main characteristics highlight glycans in diagnosis: 
their altered structure upon tumorigenesis and the fact that they are frequently found in 
secreted proteins, what might facilitate their accessibility in the clinics. The most frequently 
used glycoproteins in this context are highly glycosylated mucins like CA19-9, CA125, 
CA27-29, CA15-3 but other proteins like PSA, AFP, CEA, RNase1 and hCG-β have also been 
considered (Peracaula et al., 2008).   
Glycans have been closely involved in several events driving tumor progression, so 
therapeutic strategies targeting them have been studied with special attention (Dube & 
Bertozzi, 2005; Fuster & Esko, 2005). For example, the carbohydrate moiety of growth factor 
receptors is key in the regulation of cell signaling towards proliferation. Besides, several 
molecules like mucins, proteoglycans and gangliosides, modulate growth factor receptor 
activity through their glycan structures. Thus, different approaches directed to these glycans 
have already been designed and are being tested in the clinics such as peptide-based 
vaccines and monoclonal antibodies against mucins or gangliosides. The possibility of 
altering glycan synthesis and their maduration has also been proposed. One of the most 
studied effects of glycans over tumor development is their role in invasion due to their 
structurally altered presence in proteins well known for their effects upon adhesion and 
migration like E-cadherin, integrins, syndecans, proteoglycans and hyaluronan. Therefore, 
several strategies with the aim to block tumor specific patterns of glycosylation have been 
planned such as the inhibition of GnTV (responsible of increased β1,6-branched N-glycans) 
or polysialyltransferases. The reduction of tumor angiogenesis has also been addressed 
through glycan-based therapy by the use of modified heparin fragments or compounds 
inhibiting heparanase. Anti-selectin antibodies or mimetics of selectin ligands have been 
proposed to be useful against metastasis. 
5.2 Gal-1 in diagnosis and therapy 
Galectins are overexpressed in many different tumors and their expresssion has been 
related to poor prognosis suggesting their possible use as markers for diagnosis (Lahm et 
al., 2001; Rabinovich, 2005; Salatino et al., 2008). Indeed, Gal-1 detection in serum has been 
proven to be useful to monitor tumor progression and clinical severity in patients with 
head and neck squamous cell carcinoma (Saussez et al., 2008) and ovarian carcinoma 
(Allen et al., 1993).    
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In pancreatic cancer therapy, Gal-1 fulfills interesting requirements to be considered for 
targeting such as not being expressed in normal pancreas, increasing drug selectivity. 
Moreover, the use of Gal-1 inhibitors is particularly appealing because Gal-1 knockout mice 
are viable and fertile and do not show overt abnormalities (Poirier & Robertson, 1993), 
probably due to redundant functions from other members of the galectin family. 
Nevertheless, the dichotomous effects of Gal-1 must be well considered for efficient 
targeting, as depending on many intrinsic and extrinsic factors, the lectin can exert contrary 
effects (mitogenic or antiproliferative and pro or anti-adhesive). That is so the case that even 
Gal-1 and Gal-1 mimetic compounds have been also proposed for anticancer therapy 
(Fischer et al., 2005). Thus, special attention must be paid concerning Gal-1 conformation, 
quaternary structure, oxidation state, concentration, subcellular localization, ability to 
establish protein/protein or protein/glycan interactions, target cell type and presence of 
specific glycan receptors with certain glycosylation signatures, among others. Another 
interesting aspect to take into account for the use of Gal-1 in cancer therapy is its role as a 
master regulator of the immune response. Indeed, downregulating Gal-1 expression inhibits 
migration and restores susceptibility to apoptosis and so to cytotoxic drugs, making its 
inhibition a promising target in cancer therapy (Salatino et al., 2008; Rabinovich, 2005).  
Finally, it has been reported that the huge stromal reaction accompanied with an important 
lack of angiogenesis impairs drug delivery and cause pancreatic cancer resistance. The 
stroma has been shown to be decisive in tumor progression, which can be inhibited 
maintaining a normal context. Different stromal cells have been under the scope for therapy 
as they are more accessible to pharmacological agents and genetically stable, which makes 
them less prone to acquire resistance. Indeed, therapies targeting other molecules involved 
in the desmoplastic reaction and vasculature have proven to improve efficiency delivery of 
gemcitabine in a pancreatic cancer mice model (Olive et al., 2009). Interestingly, silencing 
Gal-1 results in increased chemotherapy toxicity in glioblastoma cell lines (Le Mercier et al., 
2008; Puchades et al., 2007). Gal-1 importance in tumor microenvironment 
immunosuppression is also considered in treatment. As a matter of fact, Gal-1 inhibition as 
adjuvant with vaccine immunotherapy significantly reduces breast tumor progression in 
mice (Stannard et al., 2010).  
6. Conclusion 
Overall, this context provides us with a whole universe of possibilities that might help in the 
design of new diagnosis markers and therapies directed to hamper tumor development. 
Still, the huge versatility of most of the molecules containing a glycan fraction forces 
research to deeply evaluate the molecular mechanisms affected upon targeting in order to 
avoid undesirable secondary effects that might prevent their use in treatment. Regarding 
Gal-1, the same precautions must be taken, considering the vast amount of partners and 
biological outcomes to which it is link. This complexity impairs analyzing the role of 
molecules independently and requires that each and every interaction is studied in detail. In 
this sense, a much finer approach in cancer therapy would result from targeting specific 
protein/protein interactions instead of individual proteins.  
Our work has made an important contribution by specifically deciphering the relevance of 
Gal-1 interaction with a glycosylated protein – tPA- in the context of pancreatic tumor 
progression. Our data add valuable knowledge to enable a better understanding of 
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pancreatic cancer molecular biology. The relevant functional outcomes from Gal-1/tPA 
interplay open the door to new therapeutic strategies targeting the complex without 
interfering with tPA and Gal-1 independent physiological functions. Therefore, we stand for 
tPA/Gal-1 interaction as a promising target for pancreatic cancer, which could delay or even 
revert tumoral progression in this devastating disease.  
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1. Introduction 
Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor disease with a still 
dismal prognosis for the patients. Since the tumor is mostly detected only in an advanced 
stage when the tumor has already metastasized, therapeutic options are quite limited. 
Moreover, this tumor is characterized by a profound resistance towards cytostatic drugs 
essentially hampering chemotherapy and reducing survival times of PDAC patients. The 
expression of the adhesion molecule L1CAM (CD171) has been recently reported to be 
associated with a chemoresistant and migratory phenotype of PDAC cells. L1CAM is a 
member of the immunoglobulin superfamily and has been initially found to play a role 
during the development of the nervous system. Meanwhile, L1CAM has been detected in 
numerous cancer tissues including PDAC and its elevated expression correlates with poor 
prognosis for the patients. Moreover, L1CAM has been shown to play an important role in 
different cellular processes involved in tumorigenesis such as cell migration and invasion, 
proliferation, survival and chemoresistance. Accordingly, inhibition of L1CAM by means of 
RNA interference or antibody-mediated blockade markedly reduced migration and 
proliferation of tumor cells and increased their chemosensitivity. Several preclinical studies 
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comprises six Ig-like domains followed by 5 fibronectin type III repeats. The transmembrane 
domain is followed by a short cytoplasmic tail of 32kD (Hortsch, 1996; Weidle et al., 2009) 
(Figure 1).  L1CAM can be expressed and mediate its effects as a membrane-bound form but 
it can also be proteolytically cleaved by different proteases releasing a soluble ectodomain 
that is likewise functionally active. To date, the metalloproteases ADAM 10 and 17 as well 
as plasmin have been described to cleave L1CAM generating a soluble 200 kD and 150 kD 
form, respectively (Maretzky et al., 2005; Mechtersheimer et al., 2001; Weidle et al., 2009) 
(Figure 1). After ADAM-mediated cleavage, the membrane-bound intracellular C-terminal 
fragment of L1CAM can be further processed by the presenilin/-secretase complex giving 
rise of a 28 kD fragment (Maretzky et al., 2005). This small intracellular fragment 
translocates into the nucleus where it is thought to contribute to L1CAM-dependent gene 
regulation (Maretzky et al., 2005; Riedle et al., 2009). 
 
Fig. 1. Scheme of the L1CAM molecular structure. The extracellular, transmembrane and 
intracellular domains are indicated on the left. Cleavage sites for different proteases 
(plasmin, ADAM, -secretase) are indicated by the arrow heads and the dashed lines. The 
respective cleavage products (L1-200, L1-150, L1-85, L1-32, L1-28) are indicated by the 
vertical arrowed lines. 
L1CAM can bind to different substrates/molecules in a cell and context dependent manner. 
Thus, it can undergo homophilic binding to itself as a membrane-bound or shedded form 
(de Angelis et al., 1999). In addition, a plethora of other proteins have been described with 
which L1CAM can interact, e.g. integrins or (Ebeling et al., 1996; 
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Montgomery et al., 1996; Oleszewski et al., 1999) as well as neuropilin-1 (Stoeck et al., 2005), 
CD24 (Kadmon et al., 1995), neurocan (Oleszewski et al., 1999) and axonin-1/TAX-1 (Kuhn 
et al., 1991). 
L1CAM was originally identified in cells of the nervous system (Rathjen & Schacher, 1984) 
and is regarded as a major player in its development being involved in neurite outgrowth 
and fasciculation, synapse formation as well as neuronal cell survival in the developing and 
adult brain (Hortsch, 1996; Loers et al., 2005; Maness & Schachner, 2007). The pivotal role of 
this adhesion molecule in the nervous system is underscored by the fact that mutations of 
the L1CAM gene cause severe neurodevelopmental disorders referred to as L1 syndrome or 
CRASH syndrome (Fransen et al., 1997; Weller et al., 2001). The different mutations and 
their resulting malfunctions of L1CAM in the nervous system are outlined in more detail in 
a recently published review (Schäfer & Altevogt, 2010). The L1CAM gene is located at 
chromosome Xq28 comprising 28 exons. Two splicing variants of L1CAM have been 
identified, the full-length form which is predominantly expressed by neuronal cells and a 
shorter non-neuronal isoform lacking exon 2 and exon 27 which is expressed by most types 
of cancer (de Angelis et al., 2001; Gast et al., 2005; Geismann et al., 2011; Kallunki et al., 1997; 
Meli et al., 1999; Shtutman et al., 2006). Besides its expression on neuronal cells, L1CAM 
expression has been also found in certain populations of hematopoietic cells (Ebeling et al., 
1996; Pancook et al., 1997) and recent reports suggested a role for L1CAM in 
transendothelial migration and trafficking of murine dendritic cells (Maddaluno et al., 2009). 
Furthermore, L1CAM is expressed by renal tubular epithelial cells under physiological 
conditions being involved in branching of renal tubes in the kidney (Debiec et al., 1998). 
However, distribution of L1CAM in adults is quite restricted so that its elevated expression 
in cancerous tissues which is discussed in the next paragraph favours its suitability as 
therapeutic target in anti-cancer therapy. 
3. L1CAM expression in tumors 
To date, two comprehensive analyses on L1CAM tissue expression have been performed 
using a wide array of different normal and tumor tissues (Huszar et al., 2006; Rawnaq et al.; 
2010). Moreover, systematic analyses of L1CAM expression in many types of tissues and 
tumors provided additional data on L1CAM expression in cancer and cancer related 
diseases. Elevated expression of L1CAM has meanwhile been detected in a variety of 
tumors such as neuroblastoma, glioma, melanoma, gynaecological tumors, colon cancer and 
gastrointestinal stromal tumors (GIST) (reviewed in Raveh et al., 2009). Tumoral L1CAM 
expression is often found at the invasive front of primary tumors (Gast et al., 2005; Zecchini 
et al., 2008) strongly supporting a role for L1CAM in metastasis. Hence, elevated tumor 
associated L1CAM expression correlates with tumor cell dissemination in lymph nodes and 
the bone marrow indicating micrometastatic spread (Kaifi et al., 200), more advanced tumor 
stages (Li & Galileo, 2010) and consequently reduced patient´s survival (Fogel et al., 2003; 
Kaifi et al., 2007; Zecchini et al., 2008). Besides L1CAM expression in tumor tissues, soluble 
L1CAM was detectable in the serum of 80 % and 90% of ovarian and uterine carcinoma 
patients at stage III-IV, respectively (Fogel et al., 2003). Zander et al. recently demonstrated 
that serum concentrations of soluble L1CAM were also elevated in GIST patients compared 
to healthy controls being particularly enhanced in patients with recurrence and relapse 
(Zander et al., 2011).  
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3.1 L1CAM expression in pancreatic tumors  
Regarding the expression of L1CAM in PDAC, discrepant data have been published. This 
might rely on the variable usage of i) the number of analysed tissues, ii) tissue microarrays 
versus areal sections, iii) detection methods (mostly immunohistochemistry but also western 
blotting, microarrays), iv) staining protocols (e.g. the pH during antigen retrieval essentially 
impacts on the staining intensity) and v) scoring systems to determine L1CAM positivity. 
With respect to the latter, determination of L1CAM positivity can occur e.g. by scoring the 
staining intensity (weak = < 30% of tumor cells L1CAM+, strong= > 30% of tumor cells 
L1CAM+) (Rawnaq et al., 2010) or by consideration of tissue samples L1CAM positive when 
more than 10% of tumor cells exhibited a strong membranous staining (Huszar et al., 2006).  
An analysis of a small number of samples by Huszar et al. revealed no L1CAM expression 
in PDAC and pancreatic neuroendocrine tumors (Huszar et al., 2006). Kaifi et al. 
demonstrated L1CAM expression in 2 % (2/111 samples) of PDAC and 7,9 % of pancreatic 
neuroendocrine tumors (5/63 cases). In the latter, L1CAM expression was mostly found in 
poorly differentiated pancreatic neuroendocrine carcinomas that are described to have the 
worst prognosis (Kaifi et al., 2006a, 2006b; Rawnaq et al., 2010). A study with 15 tissues of 
undifferentiated (anaplastic) pancreatic cancer and pancreatic carcinoma with osteoclast-like 
giant cells revealed L1CAM positivity in 80 % of the analysed samples (Bergmann et al., 
2010a). Our group was the first who documented considerable L1CAM expression in a small 
series of PDAC samples (Sebens Müerköster et al., 2007). An extended analysis with 110 
primary PDAC tissues, 15 lymph node and 14 liver metastases revealed tumoral L1CAM 
expression in 92,7 %, 80 % and 100 % of the samples, respectively (Bergmann et al., 2010b). 
Another study demonstrated L1CAM expression in 82 % of poorly-differentiated and in 14 
% of moderately-differentiated PDAC tumors being absent in well-differentiated PDAC and 
normal pancreatic tissues (Chen et al., 2011). In line with these data, Ben et al. described 
L1CAM positivity in PDAC correlating with nodal involvement, vascular and perineural 
invasion, a higher degree of pain and accordingly with poor survival (Ben et al., 2010). 
Similarly, Tsutsumi et al. reported L1CAM expression in 23/107 PDAC samples (21,5 %) 
being predominantly found at the invasive front of the tumors. Again, L1CAM expression 
was significantly associated with histological grade, lymph node involvement, metastasis 
and short survival (Tsutsumi et al., 2011). Recently, a functional genome approach analysing 
PDAC tissues compared to normal pancreatic tissues identified a panel of seven 
differentially expressed genes including L1CAM which was named “migration signature” 
according to the functional involvement of the deregulated genes in tumorigenesis 
(Balasenthil et al., 2011). In search for the mechanisms leading to upregulation of L1CAM in 
tumors, we analysed pancreatic precursor lesions such as Pancreatic Intraepithelial 
Neoplasias (PanINs) and tissues of chronic pancreatitis. Indeed, considerable L1CAM 
expression - albeit weaker than in tumors - was already found in PanINs predominantly in 
high-grade PanINs 2 and 3 (Bergmann et al., 2010b) as well as in the majority of chronic 
pancreatitis (Geismann et al., 2009). 
In summary, L1CAM expression is found – albeit at varying degree – in PDAC and 
correlates with advanced tumor stage, poor prognosis and short survival. Notably, L1CAM 
expression is already present in precursor lesions of PDAC and later on in tumor cells in 
primary tumors and metastases pointing to a role of this adhesion molecule in pancreatic 
tumorigenesis. This will be outlined in more detail in the next paragraph. 
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4. L1CAM function in tumorigenesis 
L1CAM expression in tumors can be associated with the activation of several signalling 
pathways that are known to play a pivotal role in tumor progression e.g. the MAPK/ERK 
and AKT pathway or FAK-mediated signalling. Current knowledge on the L1CAM-
mediated cellular alterations in tumorigenesis largely derived from studies with various 
types of tumor cells. Nevertheless, these alterations seem to be relevant also in pancreatic 
tumorigenesis and we will therefore discuss findings on the role of L1CAM in tumor 
manifestation and progression from studies with PDAC as well as other tumor entities. We 
also like to refer to the excellent reviews outlining in more detail the current knowledge on 
L1CAM-mediated signalling (Herron et al., 2009; Kiefel et al., 2011). 
4.1 L1CAM and EMT 
Epithelial-mesenchymal transition (EMT) represents a key event in the transformation 
process of an epithelial cell and is characterized by morphological and phenotypical 
alterations. Through EMT, epithelial/carcinoma cells acquire a motile phenotype so that 
they become enabled to leave the cellular context and disseminate into distant organs. The 
first hint that L1CAM might be connected with EMT was provided by the group of 
Shtutman (Shtutman et al., 2006). In the mamma carcinoma cell line MCF7, L1CAM 
expression leads to the disruption of E-cadherin- containing adherens junctions and thereby 
to increased transcriptional activity of -catenin (Shtutman et al., 2006). Since L1CAM is a 
target gene of -catenin signalling (Gavert et al., 2005), activation of -catenin contributes to 
sustained L1CAM expression and enhanced cell motility in the cells (Shtutman et al., 2006). 
In line with these findings, immunohistochemical stainings of endometrial carcinomas 
revealed L1CAM expression at the leading edge of the tumor while E-cadherin expression 
was lost which could be linked to an aggressive subtype of this tumor (Huszar et al., 2010). 
Stimulation of endometrium carcinoma cells with the well-known EMT inducer TGF-1 led 
to the upregulation of vimentin and concomitantly to the downregulation of E-cadherin 
depending on the transcription factor Slug. As a result, stimulated LCAM expressing tumor 
cells acquired a migratory phenotype (Huszar et al., 2010). In contrast, Gavert et al. recently 
showed that L1CAM mediated metastasis of colon cancer cells was dispensable of EMT 
induction and an altered expression of epithelial and mesenchymal marker proteins (Gavert 
et al., 2011). Thus, the impact of L1CAM on EMT might be either tumor specific and/or 
tumor stage dependent. However, stimulation of pancreatic ductal epithelial cells with  
TGF-1 led to the acquisition of a spindle-shaped cell morphology, upregulation of 
mesenchymal proteins and L1CAM expression which was dependent on JNK-mediated 
activation of Slug (Geismann et al., 2009). Accordingly, elevated cell migration and 
apoptosis resistance could be abolished by interfering with TGF-1 signalling or by 
suppression of Slug or L1CAM. Further studies are required to elaborate whether 
upregulation of L1CAM is part of the EMT or even the inducing event. 
4.2 L1CAM and cell motility and migration 
On the one hand, the importance of L1CAM for cell migration, invasion and metastasis is 
based on the detection of L1CAM expressing tumor cells in metastases as well as at the 
invasive front of the primary tumor (Bergmann et al., 2010b; Chen et al., 2011; Gavert et al., 
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invasive front of the primary tumor (Bergmann et al., 2010b; Chen et al., 2011; Gavert et al., 
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2005; Kaifi et al., 2007). On the other hand, numerous in vitro and in vivo studies provide 
compelling evidence for the role of L1CAM in cell migration of various tumor entities such 
as ovarian cancer (Arlt et al., 2006; Gast et al., 2005; Zecchini et al., 2008), colon cancer 
(Gavert et al., 2005; Gavert et al., 2011), melanoma (Meier et al., 2006), glioma (Yang et al., 
2009; Yang et al., 2011), glioblastoma stem cells (Cheng et al., 2011), breast cancer (Li & 
Galileo, 2010) and PDAC (Chen et al., 2010; Geismann et al., 2009). Cleavage of L1CAM 
seemed to be a prequisite for promoting the adhesion and migration of breast cancer cells 
(Li & Galileo, 2010) as well as for the motility of glioma (Yang et al., 2009), ovarian cancer 
(Mechtersheimer et al. 2001) and colon cancer cells (Gavert et al., 2005). In the latter, ADAM 
10 has been shown to enhance L1CAM cleavage in L1CAM expressing colon cancer cells 
and to induce liver metastasis in a mouse model system (Gavert et al., 2007). In addition, 
ligation of L1CAM to integrins such as v3 (Meier et al., 2006) or v5 (Mechtersheimer et 
al., 2001) seemed to be pivotal for L1CAM-mediated cell migration leading to the activation 
of Erk1/2 (Gast et al., 2007) and FAK signalling (Yang et al., 2011). As a result of the 
L1CAM-mediated Erk1/2 activation genes encoding for pro-migratory proteins such as 
cathepsin-B or 3-integrins were upregulated (Gast et al., 2007). Besides its ability to induce 
Erk1/2 and FAK signalling pathways, L1CAM can also lead to the activation of NF-B, so 
that inhibition of NF-B reduced L1CAM-mediated metastasis of colon cancer cells (Gavert 
et al., 2010). 
4.3 L1CAM and angiogenesis 
Besides its ability to directly increase motility and migratory behavior of tumor cells, 
L1CAM might also promote metastasis via its pro-angiogenic properties. Thus, soluble 
L1CAM was able to stimulate growth and invasion of bovine aortic endothelial cells to a 
similar extent as the vascular endothelial growth factor VEGF-A165 (Friedli et al., 2009). 
Moreover, stimulation with soluble L1CAM led to tube formation of bovine aortic 
endothelial cells in vitro and increased angiogenesis in vivo (Friedli et al., 2009). The pro-
angiogenic effect of soluble L1CAM could be abolished by treatment with the L1CAM 
specific antibody chCE7. Issa et al. showed that endothelial cells in PDAC are characterized 
by elevated L1CAM expression compared to HUVEC cells where L1CAM expression can be 
induced by TNFIFNor TGF-1 (Issa et al., 2009). Antibody-mediated blockade of 
L1CAM abolished tube formation and tumor endothelial cell transmigration (Issa et al., 
2009). Overall, these data point to a role of L1CAM as a pro-angiogenic factor and the 
potential of an anti-L1CAM antibody therapy in interfering with tumor angiogenesis (see 
below).  
4.4 L1CAM and cell growth 
Overexpression of L1CAM has been shown to promote tumor cell proliferation. 
Accordingly, inhibition of L1CAM expression or function suppresses proliferation of tumor 
cells, e.g. in cholangiocarcinoma (Min et al. 2010) or ovarian carcinoma (Arlt et al., 2006; 
Novak-Hofer et al, 2008). Zecchini et al. confirmed the stimulating effect of L1CAM on 
proliferation of ovarian cancer cells and additionally demonstrated that L1CAM expression 
does not alter proliferation of non-tumorigenic ovarian epithelial cells (Zecchini et al., 2008). 
Moreover, inhibition of L1CAM by genetic interference or antibody-mediated blockade 
impaired growth of tumor cells resulting in a reduced phosphorylation of Erk1/2 (Arlt et al., 
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2006; Zecchini et al., 2008). Cotreatment of SKOV3ip ovarian carcinoma cells with anti-
L1CAM antibodies and the soy-derived isoflavone Genistein potentiated the anti-
proliferative effects of the anti-L1CAM antibody along with reduced activation of Erk1/2, 
Akt and Src kinase (Novak-Hofer et al., 2008). The growth promoting effect of L1CAM can 
be attributed to the activation of the Erk1/2 and Akt-pathway of which both are known to 
accelerate proliferation and growth of tumor cells (Gast et al., 2007, Novak-Hofer et al., 
2008). For the induction of these signalling pathways, the interaction with integrins seems to 
be important as well as the cytoplasmic part of L1CAM because mutations in the RGD 
binding site which mediates binding to integrins or of the cytoplasmic tail abrogated 
L1CAM-mediated signalling and cellular responses (Gast et al., 2007; Sebens Müerköster et 
al., 2009; Kiefel et al., 2011).  
4.5 L1CAM and apoptosis resistance 
Besides its role in proliferation, several reports show that L1CAM is involved in apoptosis 
resistance. Loers et al. reported on a role for L1CAM in neuroprotection (Loers et al., 2005) 
by conferring protection from apoptosis induction in neuronal cells. In their experiments, 
murine cerebellar neurons grown on L1CAM substrate were protected from apoptosis 
induced by serum deprivation, oxidative stress and staurosporine treatment. L1CAM-
mediated apoptosis resistance was associated with enhanced activation of Erk1/2, Akt and 
Bad as well as inhibition of caspases (Loers et al., 2005). Our group demonstrated that 
L1CAM plays a pivotal role in the mediation of chemoresistance of tumor cells which is a 
hallmark of PDAC. Thus, L1CAM expressing PDAC cell lines such as Colo357 and Panc1 
responded much less towards treatment with cytostatic drugs than cells lacking L1CAM 
expression (Sebens Müerköster et al., 2007) and integrin has been identified as a ligand 
for L1CAM-mediated chemoresistance (Sebens Müerköster et al., 2009). This 
chemoresistance was seen in response to drugs exerting different modes of action such as 
gemcitabine and etoposide indicating a broad protection against drug-induced apoptosis 
through L1CAM-mediated alterations in cell signalling and gene expression. Thus, 
interaction of 5-integrin and L1CAM led to an increased activity of the inducible nitric 
oxide synthase (iNOS) and subsequent increased release of nitric oxide (NO) resulting in the 
inhibition of caspases. In addition, interaction of 5-integrin and L1CAM led to constitutive 
activation of NF-B via an increased production and secretion of IL-1 (Kiefel et al., 2010) 
which both are likewise important mediators of chemoresistance in PDAC cells (Arlt et al., 
2002; Arlt et al., 2003; Müerköster et al., 2003). Stoeck et al. also demonstrated that L1CAM 
in its membrane-bound as well as in its soluble form confers apoptosis resistance in ovarian 
carcinoma cells towards C2-ceramide, staurosporine, cisplatin and hypoxia. Long-term 
treatment with the cytostatic drug cisplatin increased L1CAM expression level in ovarian 
carcinoma cells m130 (Stoeck et al., 2008) which was similarly observed in PDAC cells after 
long-term incubation with etoposide indicating a role for L1CAM in the acquired 
chemoresistance of tumor cells (Sebens Müerköster et al., 2007). Immunohistochemical 
analyses of pancreatic tissues together with data from coculture experiments indicate that 
L1CAM is not only upregulated during chemotherapy but also under the influence of the 
cellular microenvironment. Thus, L1CAM was upregulated in the pancreatic  
ductal epithelial cell line H6c7 when cultured in the presence of activated 
fibroblasts/myofibroblasts resembling the situation of a chronic pancreatitis (Geismann et 
al., 2009). Again elevated L1CAM expression conferred an apoptosis resistant phenotype 
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treatment with the cytostatic drug cisplatin increased L1CAM expression level in ovarian 
carcinoma cells m130 (Stoeck et al., 2008) which was similarly observed in PDAC cells after 
long-term incubation with etoposide indicating a role for L1CAM in the acquired 
chemoresistance of tumor cells (Sebens Müerköster et al., 2007). Immunohistochemical 
analyses of pancreatic tissues together with data from coculture experiments indicate that 
L1CAM is not only upregulated during chemotherapy but also under the influence of the 
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ductal epithelial cell line H6c7 when cultured in the presence of activated 
fibroblasts/myofibroblasts resembling the situation of a chronic pancreatitis (Geismann et 
al., 2009). Again elevated L1CAM expression conferred an apoptosis resistant phenotype 
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even in non-tumorigenic pancreatic epithelial cells. Recent data by Min et al. similarly 
showed that L1CAM diminished the apoptotic response of cholangiocarcinoma cells 
towards drug treatment with gemcitabine (Min et al., 2010). In glioblastoma stem cells, a 
role for L1CAM in the control of DNA damage checkpoint responses and resistance to 
radiotherapy has been described (Cheng et al., 2011). Radioresistance was mediated by 
nuclear translocation of L1CAM and subsequent regulation of NBS1 expression which is 
part of the MRE11-RAD50-NBS1 (MRN) complex and involved in early checkpoint 
responses. Since L1CAM has been identified as a marker for glioma stem cells being 
important for tumor formation in vivo (Bao et al., 2008), targeting of L1CAM might be a 
strategy to eliminate therapy-resistant tumor stem cells that are presumably responsible for 
therapy relapses.  
Overall, all these findings underscore the importance of L1CAM in protection from 
apoptosis which might i) imply a survival advantage for genetically altered cells during 
tumorigenesis thereby promoting tumor formation and ii) explain the profound innate and 
acquired chemo- (radio-)resistance of therapy resistant tumors such as PDAC. 
5. L1CAM as target structure in cancer treatment – preclinical results 
The soluble form of L1CAM was not only detected in culture medium of several tumor cell 
lines (Fogel et al., 2003; Gavert et al., 2005; Gavert et al., 2007; Gutwein et al., 2005; Yang et 
al., 2009) but also in serum and ascites of uterine and ovarian carcinoma patients being 
associated with poor prognosis (Fogel et al., 2003; Gutwein et al., 2005). In contrast, a first 
screening of serum samples from patients with chronic pancreatitis or PDAC did not reveal 
elevated levels of soluble L1CAM (unpublished observations) indicating that soluble 
L1CAM plays only a minor role in pancreatic tumorigenesis. Accordingly, cell culture 
experiments revealed no effect of sheddase inhibitors in PDAC cells with regard to 
chemoresistance and EMT (Sebens Müerköster et al. 2007).  However, detection of soluble 
L1CAM in serum for diagnostic and predictive purposes would allow a viable screening 
without exposing patients to expensive and troublesome interventions. To validate the 
specificity of elevated L1CAM ectodomain levels as a tumor serum marker, further 
screenings of serum samples from patients at earlier tumor stages and also with other 
diseases  (e.g. inflammation)  that may lead to upregulation and shedding of L1CAM are 
required. 
The fact that tumoral L1CAM expression is often associated with an advanced tumor stage, 
metastasis and poor clinical outcome strongly suggests its suitability as a predictive marker 
in malignancies such as PDAC. In view of its multiple functions in tumor development and 
progression as well as its prevailing expression in tumors compared to normal tissues, 
L1CAM represents a promising target structure in anti-cancer therapy. This notion is 
substantially supported by several preclinical studies using anti-L1CAM antibodies or 
strategies based on genetic interference. Biweekly treatment with the anti-L1CAM antibody 
L1-11A dose-dependently inhibited tumor growth of intraperitoneally inoculated SKOV3ip 
ovarian carcinoma cells and ascites formation by up to 75 % in nude mice (Arlt et al., 2006). 
In the same tumor model system, therapeutic efficacy of L1CAM antibodies with different 
isotypes has been evaluated demonstrating that therapy with the L1-9.3/IgG2a antibody 
results in the best anti-tumor response in terms of reduced tumor burden and prolonged 
survival (Wolterink et al., 2010). Expression profiling of mRNA isolated from tumors 
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revealed an altered gene expression after L1CAM antibody treatment including genes 
involved in apoptosis, chemotaxis, angiogenesis and inflammatory responses. Moreover, 
antibody-treatment caused a massive infiltration of macrophages into the tumor suggesting 
that efficacy of anti-L1CAM antibody therapy is based on immunologically and non-
immunologically mediated mechanisms (Wolterink et al., 2010). Therapeutic efficacy of 
radiolabeled anti-L1CAM antibodies has been proven in nude mice orthotopically 
inoculated with SKOV3ip ovarian carcinoma cells or with neuroblastoma xenografts 
(Hoefnagel et al. 2001; Knogler et al., 2007). Furthermore, it was demonstrated that mutation 
of the anti-L1CAM antibody chCE7 led to improved blood clearance and a single 10.5 MBq 
dose of 67Cu-labeled mutated chCE7 antibody reduced tumor growth and prolonged 
survival of the mice (Knogler et al., 2007). Min et al. demonstrated in a nude mouse model 
with subcutaneously inoculated cholangiocarcinoma Choi-CK cells that treatment with an 
anti-L1CAM antibody three times per week resulted in reduced tumor outgrowth compared 
to therapy with a control antibody. Similar results were obtained with the 
cholangiocarcinoma cell line SCK in which L1CAM expression was suppressed by short 
hairpin RNA (shRNA) (Min et al. 2010). Targeting of L1CAM using lentiviral-mediated 
shRNA interference in glioma tumor stem cells before injection into nude mice reduced 
tumor formation and prolonged survival of tumor bearing mice as well (Bao et al., 2008).  
Overall, these data highlight the importance of L1CAM in tumor growth and development 
and the suitability of L1CAM as therapeutic target in anti-cancer therapy. Nevertheless, it 
has to be critically stated, that in all of the above mentioned studies, antibody treatment 
started 2 to 3 days after tumor cell inoculation which does not reflect the clinical conditions 
of a high tumor load in advanced tumor patients but rather the situation of micrometastatic 
spread.  
The fact that even in these models no complete cures were achieved by L1CAM antibody 
treatment alone points to the need of appropriate combination therapies. In particular for 
highly malignant tumors such as PDAC, therapeutic targeting of L1CAM alone will not be 
an effective therapy for cure. Hence, therapeutic strategies combining L1CAM targeting and 
chemo- or radiotherapy might act synergistically and lead to improved anti-tumor 
responses. This approach was followed by our group to provide an improved therapy for 
PDAC. In a SCID mouse model with subcutaneously grown Colo357 tumors, combined 
treatment with 10 mg/kg anti-L1CAM antibodies (L1-14.10 or L1-9.3/2a) and gemcitabine 
significantly reduced tumor growth compared to treatment with chemotherapy alone or in 
combination with control antibodies. This stronger anti-tumor effect could be attributed to 
an increased number of apoptotic tumor cells along with a reduced tumor vascularization 
and increased macrophage infiltration (unpublished observation). These data are in line 
with the findings from Wolterink et al. and suggest that the L1CAM antibody-mediated 
anti-tumor effect might not only rely on interference with L1CAM-mediated signalling in 
the tumor cells but also on the induction of anti-tumor immune reactivity. Combined 
treatment with L1CAM antibodies and chemotherapy has been proven to be an effective 
anti-tumor therapy also in other tumor models (unpublished observation). 
Certainly, these subcutaneous tumor models do not reflect the pathological conditions of 
PDAC and are therefore limited in their clinical significance. Addressing this issue we used 
a SCID mouse tumor model with H6c7 cells that were intrapancreatically co-inoculated with 
pancreatic myofibroblasts (PMFs) (see above). Whilst H6c7 cells inoculated without PMFs 
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the tumor cells but also on the induction of anti-tumor immune reactivity. Combined 
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anti-tumor therapy also in other tumor models (unpublished observation). 
Certainly, these subcutaneous tumor models do not reflect the pathological conditions of 
PDAC and are therefore limited in their clinical significance. Addressing this issue we used 
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did not produce measurable tumors and metastases, PMF co-inoculated H6c7 cells became 
highly tumorigenic leading to the formation of primary, stroma enriched tumors in 88% and 
to liver metastases in 75 % of the inoculated mice, as determined by high-resolution 
ultrasound. Intriguingly, treatment of these already tumor-bearing mice with 10 mg/kg of 
the anti-L1CAM antibody L1-9.3/2a resulted in a complete tumor remission and reduced 
formation of liver metastases in 50 % of the animals (unpublished observation).  
6. Conclusions 
Originally identified in the nervous system, L1CAM has meanwhile been detected in 
numerous cancers including PDAC. Aberrant expression of L1CAM in tumors has been 
identified to be a key player in tumor formation, progression and metastasis. PDAC is also 
characterized by elevated L1CAM expression in the primary tumor as well as in metastases. 
The fact that upregulation of L1CAM expression occurs already in PDAC precursor lesions 
such as PanINs and chronic pancreatitis strongly favours its involvement in pancreatic 
tumorigenesis. Accordingly, several studies demonstrated a pivotal role of L1CAM in tumor 
cell migration, survival and chemoresistance of PDAC cells. In view of its broad impact in 
PDAC progression and its favourably restricted expression in adult tissues, L1CAM 
represents a promising target to improve treatment of PDAC. Moreover, results from 
preclinical studies demonstrating that antibody-mediated targeting of L1CAM significantly 
ameliorated the efficacy of chemotherapy in PDAC cells and resulted in improved anti-
tumor responses give rise to optimism. Hence, these findings should be validated in clinical 
studies and at the same time we have to continue to deepen our understanding on the 
mechanisms by which L1CAM impacts on tumor cell biology. Targeting of L1CAM alone 
will definitely not be effective enough in eliminating highly malignant tumors such as 
PDAC but it rather provides an appropriate therapeutic tool for combined treatment. In this 
context, more work and efforts are still needed to identify the most effective combination of 
therapeutic strategies. 
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represents a promising target to improve treatment of PDAC. Moreover, results from 
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tumor responses give rise to optimism. Hence, these findings should be validated in clinical 
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mechanisms by which L1CAM impacts on tumor cell biology. Targeting of L1CAM alone 
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1. Introduction   
Pancreatic ductal adenocarcinoma (PDAC) devours two American lives every 30 minutes 
(annual death rate >37,000) and is the fourth leading cause of cancer-related deaths in the US 
(Jemal et al. 2010). Median survival is 4 to 6 months and the 5-year survival is less than 5% 
(Baxter et al. 2007). The standard chemotherapeutic agent gemcitabine shows dismal response 
rate and has little impact. Recently, clinicians have incorporated platinum-based genotoxic 
regimens such as oxaliplatin nevertheless such combinations have little impact on improving 
the overall survival of PDAC patients (Wang et al. 2011). There are critical unanswered 
questions regarding the mechanism of drug failure in PDAC and investigations are still a long 
way from identifying novel drug combination regimens to achieve cure. Therefore, 
management of PDAC is an ongoing challenge and novel clinically-translatable therapeutic 
agents that can improve on the dismal survival statistics of PDAC are urgently needed.  
To date, PDAC carcinogenesis and drug resistance are only partly understood, due to the 
heterogeneity of this disease at the cell/tissue level. In general carcinogenesis progresses 
through the accumulation of genetic alterations resulting in a gain of cell growth and 
proliferation, and subsequently, in increased dissemination and metastatic potential and 
PDAC is not an exception (Whitcomb and Greer 2009). Loss or gain of gene function may 
appear in the form of up-regulation of oncogenes, down-regulation of tumor suppressor 
genes, and deregulation of genomic maintenance/DNA repair genes, house-keeping genes, 
and genes that control the apoptosis/cell death/immortalization cascade (Sohn 2002; 
Hruban et al. 2007; Hruban et al. 1999). PDAC arises from precursor lesions called pancreatic 
intraepithelial neoplasms (PanINs), which are characterized by the sequential accumulation of 
alterations in the K-ras oncogene and loss of the CDKN2A, TP53 (p53), and/or SMAD4 tumor 
suppressors (Hruban et al. 2000). Although we know the frequencies of such mutations in 
PDAC, their specific functions during the development of PDAC remain unclear. K-ras and 
p53 are considered to be among the most critically deregulated genes that participate in cross 
talk to render PDAC therapy resistance (Hollstein et al. 1998; Hollstein et al. 1994). In the 
forthcoming passages we will first describe the impact of de-regulated p53 signaling on 
therapy resistance and then update on the pharmaceutical progress of small molecule 
inhibitors against p53 and related targets for the treatment of PDAC.   
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1. Introduction   
Pancreatic ductal adenocarcinoma (PDAC) devours two American lives every 30 minutes 
(annual death rate >37,000) and is the fourth leading cause of cancer-related deaths in the US 
(Jemal et al. 2010). Median survival is 4 to 6 months and the 5-year survival is less than 5% 
(Baxter et al. 2007). The standard chemotherapeutic agent gemcitabine shows dismal response 
rate and has little impact. Recently, clinicians have incorporated platinum-based genotoxic 
regimens such as oxaliplatin nevertheless such combinations have little impact on improving 
the overall survival of PDAC patients (Wang et al. 2011). There are critical unanswered 
questions regarding the mechanism of drug failure in PDAC and investigations are still a long 
way from identifying novel drug combination regimens to achieve cure. Therefore, 
management of PDAC is an ongoing challenge and novel clinically-translatable therapeutic 
agents that can improve on the dismal survival statistics of PDAC are urgently needed.  
To date, PDAC carcinogenesis and drug resistance are only partly understood, due to the 
heterogeneity of this disease at the cell/tissue level. In general carcinogenesis progresses 
through the accumulation of genetic alterations resulting in a gain of cell growth and 
proliferation, and subsequently, in increased dissemination and metastatic potential and 
PDAC is not an exception (Whitcomb and Greer 2009). Loss or gain of gene function may 
appear in the form of up-regulation of oncogenes, down-regulation of tumor suppressor 
genes, and deregulation of genomic maintenance/DNA repair genes, house-keeping genes, 
and genes that control the apoptosis/cell death/immortalization cascade (Sohn 2002; 
Hruban et al. 2007; Hruban et al. 1999). PDAC arises from precursor lesions called pancreatic 
intraepithelial neoplasms (PanINs), which are characterized by the sequential accumulation of 
alterations in the K-ras oncogene and loss of the CDKN2A, TP53 (p53), and/or SMAD4 tumor 
suppressors (Hruban et al. 2000). Although we know the frequencies of such mutations in 
PDAC, their specific functions during the development of PDAC remain unclear. K-ras and 
p53 are considered to be among the most critically deregulated genes that participate in cross 
talk to render PDAC therapy resistance (Hollstein et al. 1998; Hollstein et al. 1994). In the 
forthcoming passages we will first describe the impact of de-regulated p53 signaling on 
therapy resistance and then update on the pharmaceutical progress of small molecule 
inhibitors against p53 and related targets for the treatment of PDAC.   
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2. Impact of dysfunctional p53 signaling on PDAC therapy resistance
p53 tumor suppressor gene is mutationally inactivated in >50% of PDAC (Hohne et al. 1992; 
Kalthoff et al. 1993), predominantly through missense mutations (Pellegata et al. 1994). 
These often result in accumulation of mutant p53 protein, with potentially gain-of-function 
or dominant-negative properties. The fact that p53 is mutated, rather than deleted, in the 
majority of PDAC suggests that mutant p53 provides some tumor cell growth advantage. 
Murine models support this as mice expressing the accumulating p53 mutants p53R172H or 
p53R270H have increased incidence of osteosarcoma and epithelial carcinomas, some of which 
spread to distant organs (Lang et al. 2004; Olive et al. 2004). In contrast, mice that harbor a 
p53 null allele rarely develop metastases. It has also been recognized that mut-p53 and 
family member p63 protein can inhibit wt-p53 function, indicating that bi-allelic inactivation 
may not be necessary for loss of function. The third family member, p73, is rarely mutated 
and has been shown to possess apoptotic function in response to small molecule inhibitors 
and platinum drugs-induce apoptosis. Furthermore, in the other 50% of PDAC, the p53 gene 
is normal (wild type wt-) but its function is inhibited by MDM2 (human double minute 2); a 
protein that is over expressed in PDAC and is the primary focus of this chapter.  
The activity of wt-p53 is mainly regulated at the post-translational level through its 
proteolytic turn over (Brooks and Gu 2006). This is achieved through the interaction with 
MDM2, which induces wt-p53 degradation by ubiquitin-mediated proteolysis (Bottger et al. 
1997). In normal, non-stressed cells, MDM2 induces p53 degradation constantly, making it a 
short-lived protein. However, in response to DNA damage, MDM2 is auto-poly-
ubiquitinated, resulting in its degradation and an associated increase in p53 levels and 
activity. This regulatory mechanism is subject to a feedback loop since p53 in turn, regulates 
the level of MDM2 transcription, giving rise to subtle balances between the amounts of p53 
and MDM2 (Fig1) (Lahav 2008; Bose and Ghosh 2007). Although other isoforms of MDM2 
are also present, i.e. HDM4 (Mancini et al. 2009a; Okamoto et al. 2009; Mancini et al. 2009b), 
but carry have lesser impact on p53. Despite being an energy consuming process, the 
MDM2-post-translational regulation of the amount of p53 is advantageous for cells because 
it is rapid and it increases the odds of having functional p53 following genotoxic stress and 
is in contrast to transcriptional regulation which is slower and sensitive to DNA damage 
(Millau et al. 2009). A common Mdm2 promoter polymorphism is the T→G transformation 
at nucleotide 309. This Mdm2 309T/G promoter polymorphism has been associated with the 
development of a variety of tumors including PDAC (Grochola et al. 2010b; Bond et al. 2004; 
Ohmiya et al. 2006b; Galic et al. 2007; Lind et al. 2006). Its significance in clinical outcome is 
not well outlined, but recent associations with prognosis have been found in lung and 
gastric cancer (Ohmiya et al. 2006a). The G allele is associated with increased affinity for Sp1 
binding and higher MDM2 mRNA and protein levels, leading to diminished tumor 
suppressor activity of the p53 pathway (Iwakuma and Lozano 2003). Over-expression of 
MDM2 in cancers prevents this normal balance and thus inhibits p53 even though it may 
not be mutated (bdel-Fattah et al. 2000; Watanabe et al. 1994; Watanabe et al. 1996). Based on 
functional significance of MDM2 in the biology of p53, one attractive pharmacological 
approach to wt-p53 activation is to use a small molecule weight inhibitor (SMI) to block the 
MDM2–p53 interaction (Klein and Vassilev 2004; Secchiero et al. 2008; Vassilev 2004b). 
Further, it is well recognized that genotoxic drugs such as oxaliplatin work through 
activation of p53 signaling, however, mutations in the gene or over-expression of MDM2 is 
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logical to thwart proper p53 response and therefore diminish the therapeutic potential of 
these drugs. Thus, re-activation of p53 by blocking MDM2 is an attractive pharmacological 
approach for treatment MDM2 over expressing subtype of PDAC (Azmi 2011; Azmi et al. 
2010c). Nevertheless, there are additional de-regulated signaling molecules and p53 
masking mechanisms that come into play. It is the lack of understanding of these regulatory 
control mechanisms that had led to failure in the effective design of drugs. As discussed 
below, the success of novel drugs is possible if the proper combination is identified that hits 
each component of the PDAC resistant network to achieve clinically beneficial outcome.   
 
Fig. 1. MDM2 is a Master Regulator of p53: MDM2 blocks p53 activity at multiple levels. (1) 
MDM2 can bind directly to p53 activation domain and suppress its transcription. (2) MDM2 
acts as E3 ligase and promotes p53 proteasomal degradation. (3) MDM2 has a nuclear export 
signal sequence in its domain structure that is responsible for p53 nuclear export. 
Cytoplasmic retention of p53 suppresses its nuclear transactivation activity. (4) MDM2 can 
block post-translational modifications of p53 (acetylation, phosphorylation etc necessary for 
p53 activity). (5) In turn, the transcription of MDM2 is regulated by p53. (Adopted from 
Azmi et al. 2011)  
2.1 Regulation of p53 by hedgehog driven K-ras-snail axis  
PDAC is an oncogenic K-ras driven disease and it is well established that majority of PDAC 
tumors show alteration in this pathway (Laghi et al. 2002). Although 3 kinds of oncogenic 
Ras have similar roles in induction of cell proliferation, survival, and invasion through the 
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2.1 Regulation of p53 by hedgehog driven K-ras-snail axis  
PDAC is an oncogenic K-ras driven disease and it is well established that majority of PDAC 
tumors show alteration in this pathway (Laghi et al. 2002). Although 3 kinds of oncogenic 
Ras have similar roles in induction of cell proliferation, survival, and invasion through the 
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stimulation of several pathways (Downward 2003), the mutation rate of K-ras is relatively 
higher than others, which indicates that the genetic alteration of K-ras is a major driving 
force for PDAC. Recently, the regulatory network of mutant K-ras signaling on p53 pathway 
has been established. Studies indicate that in cancer, p53 activity is suppressed via a novel 
mechanism of K-ras activation and consequent stabilization of snail (Fig2).   
 
Fig. 2. Schematic diagram showing snail-p53 interaction that suppresses therapeutic 
response of genotoxic p53 re-activating regimens. Snail is activated through oncogenic K-ras 
driven ATR pathway while genotoxic regimens additionally induce snail. Novel agents 
targeting snail can have therapeutic implications against K-ras driven PDAC. 
Snail stabilization occurs through activated ATR in K-ras mutated cells that demonstrates a 
strong direct interaction between snail and DNA-binding domain of p53, resulting in 
elimination of both protein from the cells (Horiguchi et al. 2009). This novel regulatory 
network has been shown to be independent of MDM2 or ARF-mediated p53 regulation. In 
normal cells, activation of oncogenic K-ras has been shown to provoke apoptosis or 
senescence through p53 activity, indicating that the loss of functions through p53 mutation 
is inevitable for the tumor progression by oncogenic K-ras (Gorgoulis and Halazonetis 
2010). In mouse models, the adenoma is evoked by oncogenic K-ras despite the intact p53 
system, which highlights that the additional and unique function of K-ras may enable cancer 
cells to avoid the tumor suppressive function of p53. Recent studies have also demonstrated 
the apparent tumorigenic function of oncogenic K-ras in mouse cell transformation (White 
et al. 2011). While normal mouse fibroblast transfected with N- or H-ras induce apoptosis or 
senescence, K-ras12V transfected cells become resistant and this is consistent with the 
multistep carcinogenesis model of colon or PDAC. In fact, genetic mutations of K-ras occur 
in the early adenoma stage without p53 mutation. However, large portion of adenoma can 
p53 Re-Activating Small Molecule Inhibitors for the Treatment of Pancreatic Cancer 349
be progressed into carcinoma without impaired p53 system or consequent apoptosis or 
senescence. These observations strongly indicate that oncogenic K-ras-snail axis possesses 
strong p53 suppressive effects downstream of MDM2 that cannot be ignored. Additionally, 
hedgehog signaling that is considered driver for PDAC induces Gli that in-turn induces 
snail adds to the existing ATR-driven suppressive mechanisms (Marigo et al. 1996). Thus, 
strategies that overcome these inhibitory pathways need to be incorporated in any genotoxic 
regimen that targets activation of p53 system. In sum, these findings demonstrate that in 
addition to MDM2 suppression targeting p53-snail binding can bring additional benefit to 
genotoxic therapy to achieve clinically superior therapeutic effects in PDAC.  
Because the interaction between MDM2 and p53 is a primary mechanism for inhibition of 
the p53 function in cancers retaining wild-type p53, targeting the MDM2-p53 interaction by 
small molecules to reactivate p53 has emerged as a promising new cancer therapeutic 
strategy. In this chapter, the emerging SMIs of MDM2-p53 interaction are evaluated with 
additional discussions on new snail-p53 interaction inhibitors for the treatment of pancreatic 
cancer.  
3. Reactivating the wild-type p53 
Inhibition of p53 activity in tumors by the increased expression of MDM2 has been the 
target of development for many small-molecule-, peptide- and aptamer-based therapies 
(Lehman et al. 2008). MDM2 is over expressed in many human tumors including PDAC, 
often owing to an amplification of a chromosome segment that includes Mdm2, although 
over expression of the protein is possible without gene amplification (Do et al. 2009; 
Assmann et al. 2009; Shinohara et al. 2009; Grochola et al. 2010a; Lang et al. 2009; 
Economopoulos and Sergentanis 2009; Perfumo et al. 2009). There has been extensive 
validation of MDM2 as a target, ranging from studies with aptamers and peptides through 
to antisense approaches and, perhaps most significantly, was described in a path breaking 
study using a hypomorphic allele of Mdm2 in the mouse (Mendrysa et al. 2003). In this 
study, nominal reductions in MDM2 levels were found to be sufficient to trigger a mild p53 
response (as shown by increased levels of lymphopenia and apoptosis in intestinal crypts) in 
response to increased p53 activity. The volume of the thymus is also reduced and there is a 
small effect on weight gain during development. Gene dosage studies have found levels of 
MDM2 that selectively inhibit the development of colon carcinoma induced by the absence of 
adenomatous polyposis coli (APDAC) without adverse affects on normal tissues. These 
powerful studies provided proof of a therapeutic index for MDM2 inhibition that has now 
been confirmed by the first small molecule candidates, including Nutlin (Vassilev et al. 2004), 
MI-219 (Shangary and Wang 2009) and reactivation of p53 and induction of tumor cell 
apoptosis (RITA) also known as NSC 652287 (Hedstrom et al. 2009), which produce tumor 
regression in vivo in human tumor xenografts in nude mice. These initial studies paved way 
for large scale investigations on different types of MDM2 inhibitors and are discussed below. 
3.1 Non-peptidic small-molecule inhibitors of MDM2-p53 interaction 
The progress in the design of nonpeptidic, small-molecule inhibitors of the MDM2-p53 
interaction (mentioned herein as MDM2 inhibitors; sometimes also called as MDM2i 
inhibitors) proceeded very slowly for almost a decade after the publication of the crystal 
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structures. The very first class of bona fide, potent, nonpeptidic, small-molecule MDM2 
inhibitors, known as Nutlins, was reported in 2004 (Vassilev 2007; Vassilev 2005; Vassilev 
2004a). The Nutlins contain a cis-amidazole core structure and one analogue, Nutlin-3, has 
potent in vivo antitumor activity in xenograft models of human cancer-retaining wild-type 
p53. The discovery of the Nutlins provided the important proof-of-concept and fueled 
enthusiasm for the design and development of small-molecule MDM2 inhibitors. In the last 
4 years, several new classes of small-molecule MDM2 inhibitors have been discovered using 
different approaches (Canner et al. 2009; Shangary et al. 2008a; Fotouhi and Graves 2005). 
Using a computational structure-based de novo design strategy, a new class of spiro-
oxindoles that are potent inhibitors of MDM2 (Ding et al. 2006), as exemplified by MI-63 and 
MI-219 were designed. In this regard Nutlin-3 a cis-imidazole has been well studied in 
different cancers. Our MI series of MDM2 inhibitors belong to different class (spiro-
oxindole) and have a slightly higher affinity towards MDM2 when compared to Nutlins. 
Using a structure-based de novo design strategy it was shown that the interaction between 
p53 and MDM2 is primarily mediated by four key hydrophobic residues (Phe 19, Leu 22, 
Trp 23 and Leu 26) of p53 and a small but deep hydrophobic cleft in MDM2. Nutlin-3 
mimics the interactions of the p53 peptide to a high degree, with one bromophenyl moiety 
sitting deeply in the Trp pocket, the other bromophenyl group occupying the Leu pocket, 
and the ethyl ether side chain directed toward the Phe pocket. In essence, the imidazoline 
scaffold replaces the helical backbone of the peptide and is able to direct, in a fairly rigid 
fashion, the projection of three groups into the pockets normally occupied by Phe19, Trp23, 
and Leu26 of p53. However, unlike Nutlin-3 in case of our inhibitors (MI series), 
computational modeling predicted that MI-219 mimics the four (instead of three in case of 
Nutlin-3) key binding residues in p53 (Phe-19, Leu-22, Trp-23 and Leu-26) resulting in 
optimal hydrogen bonding and hydrophobic interactions with MDM2. Both Nutlins and 
MI-219 enter many types of cultured cells and inhibit the p53–MDM2 interaction with a high 
degree of specificity, leading to the stabilization of p53 and the activation of the p53 
pathway. Proliferating cancer cells that express wild-type p53 are effectively arrested in the 
G1 and G2 phases of the cell cycle or can undergo apoptosis when treated with micro molar 
concentrations of Nutlins (Shangary et al. 2008b). This indicates that some cells are more 
susceptible to Nutlin-induced apoptosis than other cells in which a reversible cell cycle 
arrest is observed. The key cellular characteristics that underlie this difference in response 
are the subject of intense investigation. This differential response may occur owing to 
abnormalities further downstream in the p53 pathway. Other small molecules that have 
been developed to target the p53–MDM2 interaction include benzodiazepenes (Patel and 
Player 2008). The benzodiazepene-based derivatives disrupt the MDM2–p53 interaction in 
vitro with IC50 values of 0.5–2 µM and have also been shown to suppress the growth of cell 
lines containing wild-type p53. Administration of the benzodiazepene derivative 
TDP665759 to normal mice led to an increase in p21 (also known as WAF1 and CIP1) levels 
in liver samples (Koblish et al. 2006). Finally, TDP665759 synergizes with doxorubicin both 
in culture and in xenografts of A375 melanoma cells to decrease tumor growth.  
With so many targets identified against the MDM2-p53 interaction and supporting 
preclinical laboratory evidence it is imperative that effective MDM2 inhibitors will become a 
major form of therapy in the coming years. However, several potential drawbacks to 
targeting the MDM2–P53 interaction can be envisioned. First, MDM2 is induced by p53 
activation as part of an inducible feedback loop that negatively regulates the p53 response. 
p53 Re-Activating Small Molecule Inhibitors for the Treatment of Pancreatic Cancer 351
Therefore, the drugs would induce their target, limiting their potential efficacy. Second, the 
current molecules fail to effectively target MDM4. The binding pocket of the N terminus of 
MDM2 has shown itself to be eminently druggable, and a future challenge is whether or not 
these drugs can proceed to the clinic and whether they can also be refined to target other 
MDM2 family members such as MDM4. Apart from this avenue of research, other target 
sites have been identified in this p53 regulatory pathway that show the potential for drug 
development, and it remains to be seen if they generate therapeutic leads that have low 
toxicity in normal tissues. 
3.2 Compounds that target p53 regulators 
Activated p53 is under multiple post-translational control that includes acetylation, 
methylation, phosphorylation, neddylation and sumoylation (Lee and Gu 2010; Kruse and 
Gu 2009; Halaby and Yang 2007; Schumacher and Gartner 2006; Chuikov et al. 2004; Haupt 
2004; Brooks and Gu 2003; Wiederschain et al. 2001; Somasundaram 2000; Craig et al. 1999). 
Activating p53 using small may not be sufficient for proper p53 function and combinations 
with agents that suppress post-translational p53 blockers such as acetylation would benefit 
the overall outcome of such therapy. An example of this type of agent which was identified 
through a p53-based phenotypic screen are tenovin-1 and its more water-soluble derivative 
tenovin-6 (Lain et al. 2008; Brooks and Gu 2008). Tenovins rapidly increase p53 levels in cells 
treated with low micro molar concentrations, and daily intraperitoneal injection of tenovin-6 
at 50 mg per kg delays xenograft tumor growth in mouse models. Through a yeast genetic 
screen and subsequent enzymatic assays tenovins were shown to inhibit the NAD+-
dependent deacetylase activity of SIRT1 and SIRT2 (Canto and Auwerx 2009; Campisi and 
Yaswen 2009), two members of the sirtuin family of class III histone deacetylases. p53 
deacetylation by SIRT1 impairs p53 stability and transcriptional activity. Therefore, 
inhibiting the sirtuins should lead to increased p53 stability. Indeed, treatment of MCF-7 
cells with tenovins led to the accumulation of acetylated p53 and acetylated tubulin, which 
are established substrates of SIRT1 and SIRT2, respectively. Further chemical optimization 
of the potency of the tenovins is now possible owing to the elucidation of SIRT1 and SIRT2 
as the cellular targets. The discovery and characterization of the tenovins is an example of 
how current technological advances in target identification and p53 basic research 
contribute to the understanding of the mechanism of action of bioactive small molecules. 
3.3 Snail-p53 interaction inhibitors 
Rapid progress has been made in the development of novel chemicals which can block the 
K-Ras-mediated p53 suppression through the screening of the chemical library. Using 
ELISA-based chemical screening for discovering potent chemical inhibitors that are effective 
to prevent the binding were discovered. Interestingly, one group of the chemical library 
particularly showed high effects in blocking the interaction of Snail and p53 (Lee et al. 
2010b). Since this chemical library was arranged in accordance with its chemical structural 
similarity, it strongly implies that the similar structural motif of chemicals can impact p53-
snail interaction. Among the compounds of this group, B3 and C2 were selected as 
candidates that could effectively provoke p53 and its target genes, such as p21 and PUMA, 
in K-Ras mutated cancer cell lines (Lee et al. 2009a). GN25 and GN29 has been revealed to 
show substantial results that induce p53 and p21 expression, as much as Nutlin-3 (small 
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structures. The very first class of bona fide, potent, nonpeptidic, small-molecule MDM2 
inhibitors, known as Nutlins, was reported in 2004 (Vassilev 2007; Vassilev 2005; Vassilev 
2004a). The Nutlins contain a cis-amidazole core structure and one analogue, Nutlin-3, has 
potent in vivo antitumor activity in xenograft models of human cancer-retaining wild-type 
p53. The discovery of the Nutlins provided the important proof-of-concept and fueled 
enthusiasm for the design and development of small-molecule MDM2 inhibitors. In the last 
4 years, several new classes of small-molecule MDM2 inhibitors have been discovered using 
different approaches (Canner et al. 2009; Shangary et al. 2008a; Fotouhi and Graves 2005). 
Using a computational structure-based de novo design strategy, a new class of spiro-
oxindoles that are potent inhibitors of MDM2 (Ding et al. 2006), as exemplified by MI-63 and 
MI-219 were designed. In this regard Nutlin-3 a cis-imidazole has been well studied in 
different cancers. Our MI series of MDM2 inhibitors belong to different class (spiro-
oxindole) and have a slightly higher affinity towards MDM2 when compared to Nutlins. 
Using a structure-based de novo design strategy it was shown that the interaction between 
p53 and MDM2 is primarily mediated by four key hydrophobic residues (Phe 19, Leu 22, 
Trp 23 and Leu 26) of p53 and a small but deep hydrophobic cleft in MDM2. Nutlin-3 
mimics the interactions of the p53 peptide to a high degree, with one bromophenyl moiety 
sitting deeply in the Trp pocket, the other bromophenyl group occupying the Leu pocket, 
and the ethyl ether side chain directed toward the Phe pocket. In essence, the imidazoline 
scaffold replaces the helical backbone of the peptide and is able to direct, in a fairly rigid 
fashion, the projection of three groups into the pockets normally occupied by Phe19, Trp23, 
and Leu26 of p53. However, unlike Nutlin-3 in case of our inhibitors (MI series), 
computational modeling predicted that MI-219 mimics the four (instead of three in case of 
Nutlin-3) key binding residues in p53 (Phe-19, Leu-22, Trp-23 and Leu-26) resulting in 
optimal hydrogen bonding and hydrophobic interactions with MDM2. Both Nutlins and 
MI-219 enter many types of cultured cells and inhibit the p53–MDM2 interaction with a high 
degree of specificity, leading to the stabilization of p53 and the activation of the p53 
pathway. Proliferating cancer cells that express wild-type p53 are effectively arrested in the 
G1 and G2 phases of the cell cycle or can undergo apoptosis when treated with micro molar 
concentrations of Nutlins (Shangary et al. 2008b). This indicates that some cells are more 
susceptible to Nutlin-induced apoptosis than other cells in which a reversible cell cycle 
arrest is observed. The key cellular characteristics that underlie this difference in response 
are the subject of intense investigation. This differential response may occur owing to 
abnormalities further downstream in the p53 pathway. Other small molecules that have 
been developed to target the p53–MDM2 interaction include benzodiazepenes (Patel and 
Player 2008). The benzodiazepene-based derivatives disrupt the MDM2–p53 interaction in 
vitro with IC50 values of 0.5–2 µM and have also been shown to suppress the growth of cell 
lines containing wild-type p53. Administration of the benzodiazepene derivative 
TDP665759 to normal mice led to an increase in p21 (also known as WAF1 and CIP1) levels 
in liver samples (Koblish et al. 2006). Finally, TDP665759 synergizes with doxorubicin both 
in culture and in xenografts of A375 melanoma cells to decrease tumor growth.  
With so many targets identified against the MDM2-p53 interaction and supporting 
preclinical laboratory evidence it is imperative that effective MDM2 inhibitors will become a 
major form of therapy in the coming years. However, several potential drawbacks to 
targeting the MDM2–P53 interaction can be envisioned. First, MDM2 is induced by p53 
activation as part of an inducible feedback loop that negatively regulates the p53 response. 
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Therefore, the drugs would induce their target, limiting their potential efficacy. Second, the 
current molecules fail to effectively target MDM4. The binding pocket of the N terminus of 
MDM2 has shown itself to be eminently druggable, and a future challenge is whether or not 
these drugs can proceed to the clinic and whether they can also be refined to target other 
MDM2 family members such as MDM4. Apart from this avenue of research, other target 
sites have been identified in this p53 regulatory pathway that show the potential for drug 
development, and it remains to be seen if they generate therapeutic leads that have low 
toxicity in normal tissues. 
3.2 Compounds that target p53 regulators 
Activated p53 is under multiple post-translational control that includes acetylation, 
methylation, phosphorylation, neddylation and sumoylation (Lee and Gu 2010; Kruse and 
Gu 2009; Halaby and Yang 2007; Schumacher and Gartner 2006; Chuikov et al. 2004; Haupt 
2004; Brooks and Gu 2003; Wiederschain et al. 2001; Somasundaram 2000; Craig et al. 1999). 
Activating p53 using small may not be sufficient for proper p53 function and combinations 
with agents that suppress post-translational p53 blockers such as acetylation would benefit 
the overall outcome of such therapy. An example of this type of agent which was identified 
through a p53-based phenotypic screen are tenovin-1 and its more water-soluble derivative 
tenovin-6 (Lain et al. 2008; Brooks and Gu 2008). Tenovins rapidly increase p53 levels in cells 
treated with low micro molar concentrations, and daily intraperitoneal injection of tenovin-6 
at 50 mg per kg delays xenograft tumor growth in mouse models. Through a yeast genetic 
screen and subsequent enzymatic assays tenovins were shown to inhibit the NAD+-
dependent deacetylase activity of SIRT1 and SIRT2 (Canto and Auwerx 2009; Campisi and 
Yaswen 2009), two members of the sirtuin family of class III histone deacetylases. p53 
deacetylation by SIRT1 impairs p53 stability and transcriptional activity. Therefore, 
inhibiting the sirtuins should lead to increased p53 stability. Indeed, treatment of MCF-7 
cells with tenovins led to the accumulation of acetylated p53 and acetylated tubulin, which 
are established substrates of SIRT1 and SIRT2, respectively. Further chemical optimization 
of the potency of the tenovins is now possible owing to the elucidation of SIRT1 and SIRT2 
as the cellular targets. The discovery and characterization of the tenovins is an example of 
how current technological advances in target identification and p53 basic research 
contribute to the understanding of the mechanism of action of bioactive small molecules. 
3.3 Snail-p53 interaction inhibitors 
Rapid progress has been made in the development of novel chemicals which can block the 
K-Ras-mediated p53 suppression through the screening of the chemical library. Using 
ELISA-based chemical screening for discovering potent chemical inhibitors that are effective 
to prevent the binding were discovered. Interestingly, one group of the chemical library 
particularly showed high effects in blocking the interaction of Snail and p53 (Lee et al. 
2010b). Since this chemical library was arranged in accordance with its chemical structural 
similarity, it strongly implies that the similar structural motif of chemicals can impact p53-
snail interaction. Among the compounds of this group, B3 and C2 were selected as 
candidates that could effectively provoke p53 and its target genes, such as p21 and PUMA, 
in K-Ras mutated cancer cell lines (Lee et al. 2009a). GN25 and GN29 has been revealed to 
show substantial results that induce p53 and p21 expression, as much as Nutlin-3 (small 
Pancreatic Cancer – Molecular Mechanism and Targets 352
molecule inhibitor that specifically blocks p53-MDM2 binding). Strong candidates (GN25 
and GN29) can activate the p53 in K-Ras mutation dependent manner (Lee et al. 2010a) (Fig 
2). GN chemicals show similar activity on p53 activation only in K-Ras mutated cell. 
Moreover, GN25 shows no cytotoxic effect in normal or K-Ras wild type cancer cells.  
Of importance is the observation that GN chemicals can induce p53 and p21 occurred as 
strong as in the treatment of DNA damaging agents such as adriamycin or etoposide, and 
the anti-proliferating effect of GN chemicals was even stronger than Nutlin-3. In addition, in 
normal fibroblast, any significant differences not only on the p53 expression level, but also 
on its proliferation and viability was not detectable by GN chemicals, but by Nutlin-3, which 
reveals that GN chemicals possess the powerful and specific property unique to other 
chemicals. The extensive duration of the p53 activity response to low concentration of GN25 
and GN29 was shown for over 24 hours, which indicate that these chemicals successfully 
remedy problem of very short re-activation of p53. One crucial fact is that another additional 
derivative, GN25-1 containing the same side chain but a modified nuclear structure of 
GN25, has no effect on the induction of p53, which suggest that the conserved nuclear 
structure of the GN chemical is critical in increasing p53 activity.  
In the condition of disrupted Snail, p53 induction could be shown in K-Ras mutated cancer 
cells, but there is no synergic and additional effect by GN25 and 29, which clearly indicate 
that p53 induction by GN25 and 29 can occur through interfering Snail-p53 binding. To 
identify the specificity of these chemicals on Snail-p53 binding, several surrounding factors 
involved in the p53 function should be checked. Since the middle region of Snail is normally 
targeted for CK1/GSK3β-dependent phosphorylation (Cano et al. 2000). In addition, 
although p53 has no influence on β-Catenin phosphorylation by CK1/GSK3β, recombinant 
p53 sufficiently interferes with CK1/GSK3β-mediated Snail phosphorylation (Yook et al. 
2006). Indeed, quercetin (inhibitor of Snail-p53 binding) and GN25 could recover CK1/GSK-
3β-mediated Snail phosphorylation even in the presence of p53 (Lee et al. 2009b). In 
contrast, GN25 did not affect the physical interaction of p53 with other proteins such as 
WRN making it a p53 specific targeted SMI (Blander et al. 1999).  
One of very exciting feature is that GN25 and GN29 block the interaction between Snail with 
wild type p53 but not with mutant type p53. This is resulted from the property of chemicals, 
which can bind to wild type p53. Indeed, GN chemical can rescue the only wild type p53 in 
wild and mutant p53 expressed cells from K-Ras or Snail-mediated p53 suppression. Thus, 
GN chemical can work in p53 mutated cancer cells, if it possesses single copy of p53. In fact, 
although GN25 and 29 decrease total p53 expression level in p53 WT/MT cells (no effect on 
the transcriptional level), it can induce p21 and PUMA and reduce the proliferation and 
viability of cells. This result was not accomplished by other DNA-damaging agents 
including Adriamycin or Nutlin-3. By the use of GN chemicals, all of the p53 proteins might 
be protected from Snail-mediated elimination in p53 WT/WT status. These features of GN 
chemical can extend the application range from p53 wild type cancer to p53 mutated cancer 
and from early cancer to late stage cancers.   
4. MDM2 inhibitor investigations in PDAC  
Testing of MDM2 inhibitors have been restricted in PDAC and this may be due to lack of 
suitable cell lines (Capan-2 is the only wt-p53 PDAC cell line). To this end our laboratory is 
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the first to show the growth inhibitory and apoptotic potential of MDM2 inhibitors MI-319, 
MI-219 and Nutlin-3 in PDAC (Azmi et al. 2010b). These inhibitors specifically induced cell 
growth inhibition and apoptosis in wt-p53 PDAC cells. Growth inhibition and apoptosis by 
MDM2 inhibitors was accompanied by increase in levels of p53 along with p21WAF1 and the 
proapoptotic Puma. In these studies immunoprecipitation-western blot analysis revealed 
reduced association of MDM2-p53 interaction in drug exposed PDAC cells. Further, using 
wt-p53 xenograft of Capan-2, we found that oral administration of MI-319 at 300 mg/kg for 
14 days resulted in significant tumor growth inhibition without any observed toxicity to the 
animals. No tumor inhibition was found in mut-p53 BxPC-3 xenografts. We also explored 
combination treatments of these inhibitors with chemotherapeutics such as gemcitabine and 
cisplatin. Interestingly MI-319, MI-219 combination specifically enhanced cell growth 
inhibition and apoptosis in PDAC cells with wt-p53 suggesting that this potent combination 
can be used in the clinic for wt-p53 population in this dreadful disease. We also tested the 
combination of MI-319 with cisplatin which although less popular for PDAC yet is a potent 
p53 inducer. Apart from being a potent combination in wt-p53 PDAC tumors most 
interestingly MDM2 inhibitor-cisplatin combination drastically induced growth inhibition 
apoptosis and tumor growth inhibition in mut-p53 PDAC cell lines and xenografts 
respectively (Azmi et al. 2010a). Mechanistically using siRNA silencing it was proven that 
the p53 family member p73 (which is rarely mutated in PDAC and other cancers) was found 
to be responsible for the observed anticancer/anti-tumor effects. That the combination 
worked in a p53 null system (HCT116--) further reiterated that MI-319-cisplatin combination 
could effectively induce apoptosis through a p73 dependent mechanism. However, further 
in-depth mechanistic studies are warranted specifically in PDAC.   
The availability of potent and specific MDM2 inhibitors, such as Nutlin-3 and MI-219, has 
provided the opportunity to examine in detail the molecular mechanism of p53 activation. 
In competition with a p53-based peptide, Nutlin-3 and MI-219 bind with high affinity to 
MDM2 (Ki = 36 and 5 nmol/L, respectively). They block the intracellular MDM2-p53 
interaction and induce the accumulation of p53 and the activation of the p53 pathway in 
tumor and normal cells. Conventional genotoxic anticancer agents and radiation also induce 
the accumulation and activation of p53, but they do so by posttranslational modifications of 
p53, such as phosphorylation. In contrast, Nutlin-3 induces neither DNA damage nor p53 
phosphorylation in cells. Hence, small-molecule MDM2 inhibitors represent a new class of 
non-genotoxic agents that can reactivate the p53 function. Apart from regulating p53 recent 
studies have shown p53 independent functions of MDM2. In this regard Zhang and co-
workers have extensively reviewed a whole range on targets governed by MDM2 (Zhang 
and Zhang 2005). Targeting MDM2 by agents such as MI-219 or Nutlin may affect a myriad 
of other key cellular molecules that play significant role in cell growth and apoptosis. In-
depth mechanistic studies on the mode of action of inhibitors on MDM2 and the consequent 
p53 reactivation are lacking and it was of interest to us to explore the roles of crucial 
proteins that are involved in the regulation of p53. Activated p53 is known to be influenced 
by multiple post-translational control processes such as phosphorylation and acetylation 
that positively regulate p53 function (Stommel and Wahl 2005). Acetylation is an important 
epigenetic phenomenon in the biology of p53 (Gu et al. 2004; Ito et al. 2002). Upon stress, 
p53 is acetylated at Lys382 which enhances its DNA binding activity (Hasegawa and 
Yoshikawa 2008). Moreover, deacetylation of p53 by SIRT1 has been shown to repress p53 
mediated cell cycle regulation and apoptosis. SIRT1 is also known to deacetylate another 
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molecule inhibitor that specifically blocks p53-MDM2 binding). Strong candidates (GN25 
and GN29) can activate the p53 in K-Ras mutation dependent manner (Lee et al. 2010a) (Fig 
2). GN chemicals show similar activity on p53 activation only in K-Ras mutated cell. 
Moreover, GN25 shows no cytotoxic effect in normal or K-Ras wild type cancer cells.  
Of importance is the observation that GN chemicals can induce p53 and p21 occurred as 
strong as in the treatment of DNA damaging agents such as adriamycin or etoposide, and 
the anti-proliferating effect of GN chemicals was even stronger than Nutlin-3. In addition, in 
normal fibroblast, any significant differences not only on the p53 expression level, but also 
on its proliferation and viability was not detectable by GN chemicals, but by Nutlin-3, which 
reveals that GN chemicals possess the powerful and specific property unique to other 
chemicals. The extensive duration of the p53 activity response to low concentration of GN25 
and GN29 was shown for over 24 hours, which indicate that these chemicals successfully 
remedy problem of very short re-activation of p53. One crucial fact is that another additional 
derivative, GN25-1 containing the same side chain but a modified nuclear structure of 
GN25, has no effect on the induction of p53, which suggest that the conserved nuclear 
structure of the GN chemical is critical in increasing p53 activity.  
In the condition of disrupted Snail, p53 induction could be shown in K-Ras mutated cancer 
cells, but there is no synergic and additional effect by GN25 and 29, which clearly indicate 
that p53 induction by GN25 and 29 can occur through interfering Snail-p53 binding. To 
identify the specificity of these chemicals on Snail-p53 binding, several surrounding factors 
involved in the p53 function should be checked. Since the middle region of Snail is normally 
targeted for CK1/GSK3β-dependent phosphorylation (Cano et al. 2000). In addition, 
although p53 has no influence on β-Catenin phosphorylation by CK1/GSK3β, recombinant 
p53 sufficiently interferes with CK1/GSK3β-mediated Snail phosphorylation (Yook et al. 
2006). Indeed, quercetin (inhibitor of Snail-p53 binding) and GN25 could recover CK1/GSK-
3β-mediated Snail phosphorylation even in the presence of p53 (Lee et al. 2009b). In 
contrast, GN25 did not affect the physical interaction of p53 with other proteins such as 
WRN making it a p53 specific targeted SMI (Blander et al. 1999).  
One of very exciting feature is that GN25 and GN29 block the interaction between Snail with 
wild type p53 but not with mutant type p53. This is resulted from the property of chemicals, 
which can bind to wild type p53. Indeed, GN chemical can rescue the only wild type p53 in 
wild and mutant p53 expressed cells from K-Ras or Snail-mediated p53 suppression. Thus, 
GN chemical can work in p53 mutated cancer cells, if it possesses single copy of p53. In fact, 
although GN25 and 29 decrease total p53 expression level in p53 WT/MT cells (no effect on 
the transcriptional level), it can induce p21 and PUMA and reduce the proliferation and 
viability of cells. This result was not accomplished by other DNA-damaging agents 
including Adriamycin or Nutlin-3. By the use of GN chemicals, all of the p53 proteins might 
be protected from Snail-mediated elimination in p53 WT/WT status. These features of GN 
chemical can extend the application range from p53 wild type cancer to p53 mutated cancer 
and from early cancer to late stage cancers.   
4. MDM2 inhibitor investigations in PDAC  
Testing of MDM2 inhibitors have been restricted in PDAC and this may be due to lack of 
suitable cell lines (Capan-2 is the only wt-p53 PDAC cell line). To this end our laboratory is 
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the first to show the growth inhibitory and apoptotic potential of MDM2 inhibitors MI-319, 
MI-219 and Nutlin-3 in PDAC (Azmi et al. 2010b). These inhibitors specifically induced cell 
growth inhibition and apoptosis in wt-p53 PDAC cells. Growth inhibition and apoptosis by 
MDM2 inhibitors was accompanied by increase in levels of p53 along with p21WAF1 and the 
proapoptotic Puma. In these studies immunoprecipitation-western blot analysis revealed 
reduced association of MDM2-p53 interaction in drug exposed PDAC cells. Further, using 
wt-p53 xenograft of Capan-2, we found that oral administration of MI-319 at 300 mg/kg for 
14 days resulted in significant tumor growth inhibition without any observed toxicity to the 
animals. No tumor inhibition was found in mut-p53 BxPC-3 xenografts. We also explored 
combination treatments of these inhibitors with chemotherapeutics such as gemcitabine and 
cisplatin. Interestingly MI-319, MI-219 combination specifically enhanced cell growth 
inhibition and apoptosis in PDAC cells with wt-p53 suggesting that this potent combination 
can be used in the clinic for wt-p53 population in this dreadful disease. We also tested the 
combination of MI-319 with cisplatin which although less popular for PDAC yet is a potent 
p53 inducer. Apart from being a potent combination in wt-p53 PDAC tumors most 
interestingly MDM2 inhibitor-cisplatin combination drastically induced growth inhibition 
apoptosis and tumor growth inhibition in mut-p53 PDAC cell lines and xenografts 
respectively (Azmi et al. 2010a). Mechanistically using siRNA silencing it was proven that 
the p53 family member p73 (which is rarely mutated in PDAC and other cancers) was found 
to be responsible for the observed anticancer/anti-tumor effects. That the combination 
worked in a p53 null system (HCT116--) further reiterated that MI-319-cisplatin combination 
could effectively induce apoptosis through a p73 dependent mechanism. However, further 
in-depth mechanistic studies are warranted specifically in PDAC.   
The availability of potent and specific MDM2 inhibitors, such as Nutlin-3 and MI-219, has 
provided the opportunity to examine in detail the molecular mechanism of p53 activation. 
In competition with a p53-based peptide, Nutlin-3 and MI-219 bind with high affinity to 
MDM2 (Ki = 36 and 5 nmol/L, respectively). They block the intracellular MDM2-p53 
interaction and induce the accumulation of p53 and the activation of the p53 pathway in 
tumor and normal cells. Conventional genotoxic anticancer agents and radiation also induce 
the accumulation and activation of p53, but they do so by posttranslational modifications of 
p53, such as phosphorylation. In contrast, Nutlin-3 induces neither DNA damage nor p53 
phosphorylation in cells. Hence, small-molecule MDM2 inhibitors represent a new class of 
non-genotoxic agents that can reactivate the p53 function. Apart from regulating p53 recent 
studies have shown p53 independent functions of MDM2. In this regard Zhang and co-
workers have extensively reviewed a whole range on targets governed by MDM2 (Zhang 
and Zhang 2005). Targeting MDM2 by agents such as MI-219 or Nutlin may affect a myriad 
of other key cellular molecules that play significant role in cell growth and apoptosis. In-
depth mechanistic studies on the mode of action of inhibitors on MDM2 and the consequent 
p53 reactivation are lacking and it was of interest to us to explore the roles of crucial 
proteins that are involved in the regulation of p53. Activated p53 is known to be influenced 
by multiple post-translational control processes such as phosphorylation and acetylation 
that positively regulate p53 function (Stommel and Wahl 2005). Acetylation is an important 
epigenetic phenomenon in the biology of p53 (Gu et al. 2004; Ito et al. 2002). Upon stress, 
p53 is acetylated at Lys382 which enhances its DNA binding activity (Hasegawa and 
Yoshikawa 2008). Moreover, deacetylation of p53 by SIRT1 has been shown to repress p53 
mediated cell cycle regulation and apoptosis. SIRT1 is also known to deacetylate another 
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protein Ku70 which, in turn, interacts with Bax and is responsible for blocking Bax entry 
into mitochondria. Therefore, we sought to determine whether acetylation of p53 could be 
influenced by our inhibitors in PDAC cells. Indeed our results showed that MI-219 
treatment suppresses SIRT1 protein and simultaneously enhances acetylation of p53. Using 
state of the art Surface plasmon resonance techniques we studied the binding between MI-
319 or Nutlin-3 and Ku70 and our results confirm high affinity association between the two. 
Interestingly MI-219 treatment resulted in the suppression of Ku70 expression along with 
disruption of Ku70-Bax interaction. This observation is of great importance because it 
proves that MDM2 inhibitor not only blocks MDM2 which is its primary target but also 
suppresses two secondary targets the negative regulator ‘SIRT1’, which is a molecule that 
regulates p53 function and Ku70. Although it is too preliminary to confirm the true 
binding/interaction site of Ku70 or SIRT1 to MI-319, yet is can be speculated that MI-319 or 
Nutlin-3 may interact with peptide sequence (LSQETFSDLWKLL) similar to p53 
transactivation domain towards which both Nutlin-3 or MI series of inhibitors were built.  
As MI-219 does not alter MDM2 expression yet Ku70 and SIRT1 are suppressed suggesting 
that these drugs may have a MDM2 independent role in the biology of cells. However, 
compelling evidence in literature supports to a MDM2 dependent mechanism of action of 
these drugs on Ku70 and SIRT1. Our cell free FRET based SIRT1 activity assay showed 
inhibition of SIRT1 activity by MDM2 inhibitors. Yet in a cellular system the dynamics of 
SIRT1 is complex. Studies so far suggest that only wt-p53 can inhibit SIRT1 while cells that 
have lost or have mutations in p53 have over expressed SIRT1 and cannot repress it. This 
certainly points out that the suppression of SIRT1 in our system is p53 dependent however 
elucidation of the exact mechanism of action requires further work. As far as Ku70 is 
concerned, very recently Nutlin, a drug with similar mode of action as MI-219 was shown to 
disrupt MDM2-Ku70 interaction. Based on our results and those of others we propose 
multiple mode of action MI-219 on SIRT1 and Ku70. MDM2 inhibitors down regulate SIRT1 
that in principle may prevent Ku70 and p53 deacetylation. Surface plasmon resonance and 
Co-IP results confirm that MI drugs directly bind to Ku70 as well as disrupt Ku70-Bax 
interaction. Although yet to be proved, it is suggested that such a direct binding may induce 
conformational changes in Ku70 rendering it ineffective in binding to Bax and therefore 
allowing the latter to induce apoptosis. MI drugs also directly suppress Ku70 mRNA and 
protein expression which in turn allows p53 induced free Bax to mediate apoptotic events.  
Additionally, we have utilized a systems biology and network modeling approach to 
investigate in mechanistic detail the mechanism of action of MDM2 inhibitor and its 
oxaliplatin combination in PDAC (Azmi et al. 2010d; Azmi et al. 2011). Microarray profiling 
of a wt-p53–containing PDAC cell line (Capan-2) treated with either MI-219, oxaliplatin, or 
their combination, revealed some very interesting results that may have clinical 
implications. Global analysis of genes showed that MI-219 treatment resulted in the 
alteration of only 48 genes, which highlights the targeted nature of MDM2 inhibitor MI-219. 
On the other hand, oxaliplatin is a cytotoxic agent and caused alteration of 761 genes. The 
combination of MI-219 with oxaliplatin resulted in 767 genes being altered. The most 
important aspect of this finding is the emergence of 286 synergy-specific unique genes that 
were not found in the MI-219 alone or in the oxaliplatin-treated group. This finding 
confirms that the synergy between MI-219 and oxaliplatin is at the gene level. Principle 
component analysis showed that the global gene signatures between single treatments 
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versus combination treatments were non-overlapping and could be differentiated at 
different time points. Molecular network modeling of a total of 767 gene-associated 
pathways revealed a total of 22 statistically enriched functional groups that were linked to 
biologically distinct functional pathways. Interestingly, network modeling of the 286 
synergy-unique genes showed statistical enrichment of 14 disease (cancer) relevant 
pathways. This finding suggests that these pathways are relevant to cancer, further 
indicating that the combination synergy between MI-219 and oxaliplatin is at the gene level, 
comprising distinct biologically meaningful processes. Further analysis of the combination 
treatment network revealed the presence of several local networks, or hubs, rather than a 
single hub of activity interconnecting MDM2-p53. Central players such as the CREB binding 
protein (CREBBP; i.e., ubiquitously expressed gene) that is involved in the transcriptional 
coactivation of many different transcription factors, including p53, collaborates/cooperates 
with ARF (CARF) that is responsible for p53 stability, and NF-κB and early growth response 
protein (EGR1) tumor suppressor module, all of which are known to positively affect p53 
reactivation, which in principle would drive cells toward increased apoptosis. Most 
importantly, these observed gene changes could also be validated at the mRNA and  
protein level.  
Other investigators have also performed expression signature analysis of Nutlin-3. For 
example gene expression profiling of Nutlin-3 has been done by Zauli and group in B-cell 
lymphocytic leukemia (B-CLL) (Zauli et al. 2009). In their study B-CLL patient samples were 
exposed to Nultin-3 and cDNA expression profiling was performed. With the exception of a 
few cases, the authors noted induction of a characteristic gene expression profile (GEP) 
signature that was similar in the majority of B-CLL patient samples. Most significantly, lack 
of characteristic signatures correlated with poor response to Nutlin-3. However, partial lack 
of response in these wt-p53 B-CLL samples was not due to defects in the ability of Nutlin-3 
to promote p53 induction, but suggested the involvement of secondary masking 
mechanisms. Nutlin-3 gene signatures were all related to the p53 network and included 
downstream affector genes such as Fas and Bax and activation of auto-regulatory MDM2. 
Such type of biological analysis, if coupled with network modeling may provide further 
information on the entire set of genes modulated by Nutlin-3 in B-CLL patients. Results of 
these studies will significantly aid in the design of clinically successful drug combinations 
for other malignancies, which will ultimately benefit the overall survival of patients 
irrespective of the mutational and functional status of p53. In another study, a large-scale 
RNA interference–based short hairpin RNA (shRNA) barcode screen was applied to gain 
insight in the mechanism of action of Nutlin-3 (Brummelkamp et al. 2006). In this study it 
was shown that aside from p53, 53BP1 was critical mediator of Nutlin-3–induced 
cytotoxicity. 53BP1 is part of a signaling network induced by DNA damage that is 
frequently activated in cancer but not in healthy tissues (DiTullio, Jr. et al. 2002). These 
results suggest that tumor specificity of Nutlin-3 may result from its ability to turn a cancer 
cell–specific property (activated DNA damage signaling) into a weakness that can be 
exploited therapeutically.  
5. Current status of MDM2 Inhibitors in the clinic 
Although proven to be successful in the laboratory in multiple cancer models, MDM2 
inhibitors or approaches that utilize reactivation of p53 have a long way to go before they 
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are acceptable in the clinic for PDAC. Currently some SMIs that reactivate the mut-p53 
through protein conformational changes are currently in Phase I clinical trials (Brown et al. 
2009). In addition to the potential clinical applications, discovery of the first MDM2 
antagonist, Nutlin-3a provided the initial proof of concept that inhibition of protein-protein 
interactions was a feasible approach to pharmaceutical design. Since that time, a deluge of 
patents and reports have disclosed a high number of diverse molecules showing potency 
and selectivity toward MDM2 at the same time lacking in solubility. Careful attention to 
medical chemistry was employed to improve bioavailability of these scaffolds leading to 
compounds with optimized PK properties. The intense labor of research has finally begun to 
bear fruit as demonstrated by the advancement of JNJ-26854165 and RG7112, into early 
phase clinical trials. Preliminary data from trials of both compounds suggest potential for 
advancement to Phase II trials and beyond. A few examples are PRIMA (Phase I APR-246), 
CP-31398 (Phase I) and PhiKan-08 (Phase I). SMIs that activate p53 through disruption of 
MDM2-p53 binding such as MI-219, Nutlin-3 are in phase I. RITA a p53 binding targeted 
agent, tenovin (SIRT1 inhibitor are still in a pre-clinical testing phase. Leptomycin B (a 
CRM1 (Exportin 1) binding agent that mediates p53 reactivation) is in Phase I while 
Actinomycin D (an RPL11 and RPL5 (Ribosomal protein L) releasing agent) has been 
approved for Phase I (Choong et al. 2009). Certain combinations such as nutlin with mitotic 
inhibitors for example BI-2536 (PLK1 (Polo-Like Kinase) inhibitor) or with VX680 (Aurora 
kinase inhibitor) are also in Phase I.  
6. Conclusion  
In PDAC, multiple de-regulated signaling especially the MDM2 over-expression and hyper 
activated K-ras driven pathways hone in on p53 and suppress its proper function in 
controlling various cellular processes. Studies indicate that these suppressive mechanisms 
render p53 re-activating genotoxic therapies ineffective. The well-studied role of p53 in 
coordinating cellular response to stress, aberrant growth signals and genomic instability has 
established a solid rationale for the targeting of MDM2 and K-ras driven snail to restore 
therapeutic response to treatment of PDAC. The entry of orally-administered MDM2 
antagonists into clinical trials represents a significant advancement for the field of small 
molecule drug discovery in PDAC.   
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1. Introduction 
Toll-Like Receptors (TLRs) are critical mediators of the innate immune response and 
subsequent activation of adaptive immune responses to pathogens that invade the body. 
TLRs on immune cells are the basis of our multigenic, innate immune, inflammatory 
response to pathogenic signature molecules that cause tissue damage. Functional TLRs 
are expressed not only on immune cells, but also on non-immune cells including cancer 
cells. TLRs are critical mediators of cellular transformation, tumor progression, and 
metastasis.  
2. Toll-Like Receptors 
TLRs are pattern recognition receptors that were originally identified in immune cells and 
described to recognize pathogen-associated molecular patterns (PAMPs) and initiate an 
innate immune response and subsequent adaptive immune responses against infection or 
tissue damage. They protect mammals from pathogenic organisms, such as viruses, by 
generating an “innate immune” response to products of the pathogenic organism (Takeda et 
al., 2003). This response results in increases in genes for several inflammatory cytokines and 
chemokines, major histocompatibility (MHC) genes I and II, as well as co-stimulatory 
molecules, and is critical for the development of antigen-specific adaptive immunity 
(Takeda et al., 2003). In addition to their presence on immune cells, TLRs are also found to 
be expressed normally on multiple non-immune cell types including, but not limited to 
epithelial cells that line the digestive system, lungs, and female reproductive tract, as well as 
on pancreatic beta cells, and keratinocytes in the skin where they function to regulate 
cellular proliferation and apoptosis in response to infection and/or other damaging 
environmental insults (radiation, chemicals, etc.)(Andonegui et al., 2003; Ortega-Cava et al., 
2003; Giarratana et al., 2004; Schroder & Maurer, 2007; Nasu & Narahara, 2010; Yamasaki et 
al., 2010; Ayari et al., 2011). Regardless of cell type, TLRs recognize not only exogenous 
PAMPs, but also endogenous damage-associated molecular patterns (DAMPs) (Table 1). 
Eleven TLRs have been described in humans to date (TLR1 to TLR11) (Sato et al., 2009). 
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TLRs are located both on the cell surface and in the cytoplasm, are differentially expressed 
in different cell types under a variety of conditions and disease states, and recognize 
different PAMPs and DAMPs (Table 1).  
Perhaps two of the most well studied TLRs are TLR3 and TLR4. In non-immune cells, as is 
the case for immune cells, dsRNA can activate two distinct anti-viral response pathways by 
activating TLR3 signaling. One, coupled via the adapter molecule, Toll-IL-1 receptor (TIR) 
domain-containing adapter inducing IFN- (TRIF) (also called TIR domain-containing 
adaptor molecule-1 [TICAM-1]), i.e. (TRIF/TICAM)-1, activates IFN regulatory factor (IRF)-
3 and the production of type 1 interferons (IFN-α or IFN-β) via TRAF-3 (Oganesyan et al., 
2006; Schneider et al., 2006). The type 1 IFNs, acting as autocrine/paracrine ligands increase 
STAT-1 and IRF-1 activation, critical factors in expression of chemokines such as CXCL10 
and genes such as VCAM-1. Specifically, TLR3 is expressed in the endosomal membrane 
and recognizes extracellular viral dsRNA and/or its synthetic analog poly I:C. Upon 
binding to dsRNA, TLR3 becomes dimerized, and two specific tyrosine residues (Tyr759 and 
Tyr858) in the TIR domain of TLR3 become phosphorylated and are essential for dsRNA-
induced recruitment of the adaptor protein TRIF/TICAM-1 (Sarkar et al., 2004). 
Phosphatidylinositol 3-kinase (PI3K) is then recruited to the two phosphorylated tyrosine 
residues and is required for phosphorylation and activation of IRF-3. Additionally, it has 
been shown that TLR3 associates with c-Src in response to dsRNA and that c-Src is 
necessary for PI3K-dependent activation of IRF-3, although the precise role of c-Src in this 
process is currently not well understood (Johnsen et al., 2006). TRIF/TICAM-1 dissociates 
from TLR3 and forms a complex with receptor interacting protein 1 (RIP1), TRAF-3 and NF-
B activating kinase (NAK)-associated protein 1 (NAP1). The TRIF/TICAM-1/TRAF-3/RIP-
1/NAP-1 complex participates in the recruitment and activation of TBK-1 and IKK which 
phosphorylate and activate IRF-3 (Sasai et al., 2005; Hacker et al., 2006; Oganesyan et al., 
2006). Once phosphorylated IRF-3 translocates into the nucleus and together with nuclear 
factor kappa-light chain-enhancer of activated B cells (NF-κB) and AP-1 induces IFN-β gene 
transcription (Sato et al., 2000). The second pathway is coupled to a different site on 
TRIF/TICAM-1 via TRAF-6 and activates NF-B and MAP Kinase pathways important in 
the production of pro-inflammatory and inflammatory cytokines, e.g. TNF-α, IL-1β, and IL-
6, as well as chemokines e.g. MCP-1. 
TLR4 signaling has both a MyD88-dependent and MyD88–independent mechanism when 
activated [reviewed in (Lu et al., 2008)]. There is significant homology between TLR3 and 
TLR4 IRF-3/IFN signaling (the MyD88-independent TLR4  pathway); TRIF/TICAM-1 is a 
common signaling intermediate in both signaling pathways. As is the case with dsRNA-
induced TLR3 signaling, activation of TLR4 signaling leads to TRIF/TICAM-1 recruiting 
TRAF-3 and RIP-1 which in turn leads to the recruitment and activation of TBK-1 and IKK 
(Hacker et al., 2006; Oganesyan et al., 2006; Guo & Cheng, 2007). The TRIF/TICAM-
1/TRAF-3/RIP-1/TBK-1/IKK complex phosphorylates and activates IRF-3 (Fitzgerald et 
al., 2003; Hemmi et al., 2004). Once phosphorylated IRF-3 translocates into the nucleus and 
together with NF-κB and AP-1 induces IFN-β gene transcription (Sato et al., 2000). The 
MyD88-dependent pathway activates IRAK-4, IRAK-1, TRAF-6, and others to lead to the 
activation of transcription factors NF-B, AP-1, and IRF-5, which induce the expression of 
pro-inflammatory cytokines.   
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TLR2 Plasma Membrane glycolipids, triacyl 
lipopeptides, heat shock 
proteins, high mobility 
group box 1 protein, rare 








fimbriae, Yersinia virulence 
factors, CMV virions, 
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poly I:C 







TLR4 Plasma Membrane lipopolysaccherides, 
saturated free fatty acids, 
fibrinogen, fibronectin, 
heat shock proteins, 
flavolipins, S. pneumoniae 
pneumolysin, heparan 
sulfate, hyaluronic acid, 
high mobility group box 1 
protein, MMTV envelope 
proteins, nickel,  
paclitaxel, RSV fusion 
protein, respiratory 
syncytial virus coat 
protein, mannuronic  
acid polymers,  
teichuronic acids,  
bacterial fimbriae, 
surfactant protein A, -
defensin 2 
cancer, type 2 
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TLR10 Plasma Membrane Unknown cancer, asthma, 
nephropathy, viral 
keratitis 
Table 1. Toll-Like Receptors; Cellular Localization, Agonists, and Disease Associations 
3. TLRs, chronic inflammation, and cancer 
Overwhelming evidence suggests that chronic inflammation is crucial to the onset and 
progression of a multiplicity of human cancers, including pancreatic cancer (Kuper et al., 
2000; Garcia et al., 2004; von Hafe et al., 2004; Berstein, 2005; Otake et al., 2005; Lu et al., 
2006). The exact link between chronic inflammation and carcinogenesis is unclear, however 
many studies have shown that pro-inflammatory cytokines (TNF-α, IL-6, IL-1, etc.) are 
important for the proliferation, survival, metastasis, and escape from immune surveillance 
of many of these cancers (Garcea et al., 2005; Lu et al., 2006), and have identified nuclear 
factor-ĸB (NF-ĸB) as a key modulator of inflammation-induced carcinogenesis (Chen et al., 
1995; Guttridge et al., 1999; Hinz et al., 1999; Perkins, 2000; Coussens & Werb, 2002; Esposito 
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et al., 2002; Ghosh & Karin, 2002; Karin et al., 2002; Karin & Lin, 2002; Li & Verma, 2002; 
O'Hanlon et al., 2002; Alexiou et al., 2003; Chen et al., 2003; Furbert-Harris et al., 2003; Lin & 
Karin, 2003; Greten et al., 2004; Huber et al., 2004; Luo et al., 2004; Niu et al., 2004; Pikarsky 
et al., 2004; Stoffel et al., 2004; Heyninck & Beyaert, 2005; Preciado et al., 2005; Yang et al., 
2005a). Chronic inflammation as a result of disease, microbial infection, and/or obesity is an 
important risk factor for the development of a variety of cancers (Khatami; Kuper et al., 
2000; Calle & Kaaks, 2004; Khatami, 2011) (Table 2). Chronic inflammation is thought to 
induce malignant transformation via activation of oncogenes, induction of 
immunosuppression, and inhibition of tumor suppressors.  
It is now recognized that TLRs are important in development of carcinogenesis and tumor 
progression. The chronic inflammatory state observed in autoimmune disease, microbial 
infection, and obesity is mediated via activation of TLR signaling on both immune and non-
immune cells. TLRs on immune cells recognize PAMPs and DAMPs and initiate an innate 
immune response and subsequent adaptive immune responses against infection or tissue 
damage. As part of this acute, innate immune response cytokines and chemokines are 
produced and released by the immune cells, which will subsequently upregulate TLR 
expression on non-immune cells. When this occurs, the TLRs on the non-immune cells can 
become stimulated by the same PAMPs and DAMPs that activated the TLRs on the immune 
cells, leading to very high levels of disease-causing inflammatory proteins. In a prolonged 
state of infection and/or tissue damage, sustained high levels of inflammatory proteins can 
lead to autoimmune, inflammatory diseases, and cancer in individuals with certain genetic 
and/or environmental susceptibilities (Table 1). 
Multiple TLRs have been implicated in a variety of cancers including pancreatic cancer, 
melanoma, breast cancer, prostate cancer, colorectal cancer, lung cancer, cervical cancer, liver 
cancer, etc. (McCall et al., 2007; Sato et al., 2009; Schwartz et al., 2009) (Table 3). Activation of 
TLRs on cancer cells promotes chronic inflammation which stimulates cancer cell proliferation, 
migration, tumor angiogenesis, and creates a tumor microenvironment which impairs the anti-
tumor function of the immune system allowing tumors to develop and survive. 
4. Mechanisms of TLR regulation of carcinogenesis 
4.1 Activation of TLR signaling leads to the production of cytokines that control 
growth 
As previously described, chronic TLR activation and signaling in both immune and non-
immune cells by environmental antigens are now linked to oncogenesis, tumor growth, and 
invasive spread (Schmausser et al., 2005; Kelly et al., 2006; Fukata et al., 2007; He et al., 2007; 
Ilvesaro et al., 2007; Goto et al., 2008; Kim et al., 2008; Yoneda et al., 2008; Curtin et al., 2009; 
Xie et al., 2009; Zhou et al., 2009). Activation of TLR signaling results in the activation of 
transcription factors NF-ĸB and AP-1, as well as Type I Interferon (IFN) signaling pathways 
with subsequent production of “oncogenic” cytokines, and the activation of MAPK and  
AKT signaling pathways (Figure 1). Multiple TLR-induced cytokines including TNF-α, IL-1, 
IL-6, IL-8, IL-10, IL-23, etc. have been linked to oncogenesis. TLR activation also upregulates 
many growth factors such as TGF-β, VEGF, CXCR4, and adhesion molecules such as ICAM-
1 (Kelly et al., 2006; He et al., 2007; Ren et al., 2007; Zhou et al., 2009). These TLR-mediated 
processes have been linked to various cancers including colon, pancreas, melanoma, breast, 
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cells, leading to very high levels of disease-causing inflammatory proteins. In a prolonged 
state of infection and/or tissue damage, sustained high levels of inflammatory proteins can 
lead to autoimmune, inflammatory diseases, and cancer in individuals with certain genetic 
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Type of Cancer Disease/Infection Association 
Thyroid Cancer Hashimoto's Thyroiditis 
  Obesity 
Colorectal Cancer Inflammatory Bowel Disease 
  Colitis 
  Crohn's Disease 
  Obesity 
Cervical Cancer Human Papilloma Virus 
Liver Cancer Hepatitis Virus B and C 
Pancreatic Cancer Helobacter pylori 
  Obesity 
Prostate Cancer Obesity 
Hematologic Malignancies Epstein-Barr Virus 
  Cytomegalovirus 
Esophageal Adenocarcinoma Obesity 
Renal Cancer Obesity 
Endometrial Cancer Obesity 
Gallbladder Cancer Obesity 
Breast Cancer Obesity 
Gastric Cancer Epstein-Barr Virus 
  Helobacter pylori 
  Obesity 
Non-Hodgkin's Lymphoma Epstein-Barr Virus 
  Human Herpes Virus 8 
  Human Immunodeficiency Virus 
Hodgkin's Disease Epstein-Barr Virus 
Nasopharyngeal Carcinoma Epstein-Barr Virus 
Burkitt's Lymphoma Epstein-Barr Virus 
Vulvar Cancer Human Papilloma Virus 
Anus Cancer Human Papilloma Virus 
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Type of Cancer Disease/Infection Association 
Penis Cancer Human Papilloma Virus 
Head and Neck Cancer Human Papilloma Virus 
Kaposi's Sarcoma Human Herpes Virus 8 
  Human Immunodeficiency Virus 
Casteleman's Disease Human Herpes Virus 8 
Adult T-cell Leukaemia Human Thymus-Derived-Cell Leukaemia/Lymphoma Virus-1 
Bladder Cancer Schistosomes (S. haematobium) 
Table 2. Associations Between Disease, Infection, Obesity, and Cancer.  
prostate and many others (Sato et al., 2009). In addition, these cytokines also activate 
transcription factors that induce the expression of several tumor promoting and anti-
apoptotic genes which will be discussed in Section 4.2 below. 
Toll-Like Receptor Type of Cancer 
TLR1 Colon, Prostate 
TLR2 Brain, Breast, Colorectal, Gastric, Hepatocellular Carcinoma, 
Laryngeal, Lung, Melanoma, Ovarian 
TLR3 Breast, Colorectal, Hepatocellular Carcinoma, Laryngeal, Lung, 
Melanoma, Ovarian, Pancreatic 
TLR4 Bladder, Brain, Breast, Cervical, Colorectal, Gastric, Hepatocellular 
Carcinoma, Laryngeal, Lung, Melanoma, Ovarian, Pancreatic, 
Prostate 
TLR5 Cervical, Colorectal, Gastric, Ovarian 
TLR6 Hepatocellular Carcinoma, Prostate 
TLR7 Chronic Lymphocytic Leukemia, Lung 
TLR8 Lung 
TLR9 Breast, Cervical, Colorectal, Gastric, Glioma, Hepatocellular 
Carcinoma, Lung, Pancreatic, Prostate 
TLR10 Nasopharyngeal, Prostate 
TLR11 None 
Table 3. TLRs are Associated with Human Cancers 
These immune-response and tumor-associated cytokines have complex and often 
contradictory effects depending on the specific tumor, the specific TLRs activated, and the 
innate immune response to the malignancy. Indeed, the tumor microenvironment which 
includes tumor cells, tumor-derived fibroblasts, as, well as macrophages, T cells, and APCs 
each produce inflammatory cytokines forming a “milieu” which on one hand facilitates the 
differentiation and expansion of tumors and on the other tries to suppress this process. 
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Fig. 1. TLR Signaling 
The most important TLR-mediated cytokines involved in initiation and growth of malignant 
tumors appear to be tumor-derived IL-1, TNF-α and IL-6. TNF-α and IL-6 are potent 
activators of NF-κB pathways and JAK-STAT signaling pathways which also directly 
contribute to tumor induction and growth (See Section 4.2). TNF- and IL-6 also induce 
anti-aptotic genes such as Mcl-1, Bcl-x, cell-cycle regulators (cyclins D1/D2, c-Myc), and 
inducers of angiogenesis (VEGF) (Calo et al., 2003). TNF-α in the tumor microenvironment 
also increases myeloid cell recruitment via IL-17. Importantly, IL-6 is one of the most potent 
activators of the oncogenic transcription factor STAT3 (Calo et al., 2003).  
TLR mediated IL-1 expression within tumors directly stimulates tumor growth as well as 
stimulating angiogenesis which enhances a tumor’s capacity to spread or metastasize 
(Gemma et al., 2001; Elaraj et al., 2011). Expression of IL-1 within tumors, the surrounding 
tissues, or endothelial cells is associated with aggressive growth characteristics (Elaraj et al., 
2006; Sawai et al., 2006).  
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In contrast, IL-10 is normally an inhibitory cytokine which blocks NF-κB activity and the 
JAK-STAT signaling pathway but has been shown to help certain tumors escape normal 
immune surveillance (Linehan & Goedegebuure, 2005; Perrone et al., 2008; Strauss et al., 
2009). IL-10 can induce CD4+CD25+Foxp3+ regulatory T cells (Tregs) in the tumor 
microenvironment which secrete additional IL-10 and TGFβ, which can then suppress the 
anti-tumor function of non-Treg T cells (Linehan & Goedegebuure, 2005; Perrone et al., 2008; 
Strauss et al., 2009). 
4.2 TLR signaling activates transcription factors important for tumorigenesis 
Two of the most notorious and well-studied oncogenic transcription factors are nuclear 
factor kappa-light chain-enhancer of activated B cells (NF-B) and signal transducer and 
activator of transcription 3 (STAT3). Both NF-B and STAT3 are activated by a variety of 
stimuli (stressors, cytokines, etc.), and while they are regulated by entirely different 
signaling mechanisms, they both control the expression of proliferation-enhancing, anti-
apoptotic, angiogenic, and immune-modulating genes. NF-kB and STAT3 also interact and 
mediate crosstalk between tumor cells and inflammatory cells within the tumor 
microenvironment to promote the development and progression of multiple types of human 
cancers including but not limited to pancreatic, colon, gastric, skin, head and neck, and liver 
cancers (Grivennikov & Karin; Lin et al.; Bromberg et al., 1999; Greten et al., 2004; Yu & Jove, 
2004; Yu et al., 2009).  
NF-B, which is directly activated via the MyD88-dependent branch of TLR signaling, is one 
of the most studied transcription factors and arguably the most important for tumor 
promotion (Chaturvedi et al., 2011). NF-B is constitutively activated in most cancers 
typically due to stimulation of TLRs, pro-inflammatory cytokine receptors (such as TNF- 
and IL-1), and antigen receptors (Dinarello, 1994; Kruglov et al., 2008; Bezbradica & 
Medzhitov, 2009; Karin & Gallagher, 2009). This constitutive activation of NF-B has been 
linked to inflammation, transformation, proliferation, angiogenesis, invasion, metastasis, 
chemoresistance and radioresistance (Beg & Baltimore, 1996; Liu et al., 1996; Van Antwerp et 
al., 1996; Wang et al., 1996; Huang & Miyamoto, 2001; Joyce et al., 2001; Luo et al., 2004; 
Mantovani et al., 2008; Chaturvedi et al., 2011). Activation of NF-B results in the 
upregulation of several genes and cytokines which are associated with cell growth and 
proliferation. These include critical cellular progression genes and anti-apoptotic genes 
including specific inhibitor of caspase 8, c-FLIP29, the caspase inhibitors cIAP1 & cIAP2, the 
anti-apoptotic member of the B-cell leukaemia/lymphoma 2 (Bcl2) family, Bcl-XL BCL2 and 
BCL-XL, c-myc, c-myb. Cyclin D1/2 stimulation by NF-kB activation has also been shown to 
stimulate cell-cycle progression. Many of these together upregulate JNK activity and 
subsequent activation of the AP-1 transcription factor which also enhances cell survival 
(Karin, 2006). Inhibitors of NF-B have been shown to decrease tumor cell proliferation and 
aid in the potency of chemotherapeutics (Luo et al., 2004; Chaturvedi et al., 2011). 
In non-stimulated cells, STAT3 is kept in an inactive form in the cytoplasm (Darnell et al., 
1994; Yu & Jove, 2004). Upon stimulation STAT3 is phosphorylated at two critical residues; 
tyrosine 705 (Tyr705) and serine 727 (Ser727) (Wen et al., 1995; Barboza et al., 2004; Gartsbein 
et al., 2006; Yeh et al., 2006), dimerizes (Yoshimura et al., 2007), and translocates to the 
nucleus where it activates a wide array of genes critical for tumor development and 
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progression. STAT3 is activated by many cytokines, including those cytokines that are 
products of the TLR signaling pathway, including cytokines of the IL-6 family that signal 
through gp130 (IL-6, IL-11, IL-27, etc.), the IL-10 family (IL-10, IL-22, IL-19, IL-20), and the 
epidermal growth factor (EGF) family (VEGF, IL-21, IL-23, HGF). Like NF-B, STAT3 also 
activates anti-apoptotic genes such as Bcl-xL, Bcl-2, and c-IAP2 (Yu & Jove, 2004; Chang et 
al., 2006; Rebouissou et al., 2009), cell cycle and proliferation genes such as Cyclin D1 and c-
Myc (Levy & Darnell, 2002; Naugler & Karin, 2008; Bollrath et al., 2009), and members of the 
AP-1 family such as c-Jun and c-Fos (Hirano et al., 2000; Yang et al., 2005b; Yang et al., 2007), 
whereas others such as Mcl-1 and Survivin are STAT-3-dependent (Yu & Jove, 2004). Thus, 
STAT3 is an attractive target for anti-cancer therapy and numerous strategies have been 
employed to inhibit constitutive STAT3 signaling in cancer cells (Meydan et al., 1996; 
Turkson et al., 2001; Coleman et al., 2005; Song et al., 2005; Duan et al., 2006; Schust et al., 
2006; Iwamaru et al., 2007; Siddiquee et al., 2007; Goel et al., 2008; Hatcher et al., 2008; Lin et 
al., 2010a; Lin et al., 2010b). 
Activator Protein 1 (AP-1) transcriptional complexes also play a pivitol role in malignant 
cellular transformation (Lopez-Bergami et al., 2009). AP-1 can be activated through the TLR 
Myd88-dependent pathway by a variety of growth factors and cytokines (Akira, 2006). 
Increased exposure to environmental carcinogens such as tobacco, nicotine and asbestos 
have been shown to increase AP-1 activity and correlate with tumorgenesis, tumor invasion 
and metastasis (Lopez-Bergami et al., 2009). AP-1 can induce the activation of well-known 
oncogenes including FOS and Jun which are observed in many cancers (Lopez-Bergami et 
al., 2009). The expression of Jun can further activate other oncogenes including Ras, BRAF 
and EGFR. Increased FOS expression has been associated with poor prognosis and 
progression (Lopez-Bergami et al., 2009). Inhibition of AP-1 complexes as well as Jun and 
FOS have been shown to inhibit tumor formation suggesting that AP-1 may be a viable 
target for therapeutic intervention (Lopez-Bergami et al., 2009).  
4.3 Activation of TLR signaling leads to the production of cytokines and upregulation 
of other proteins that control metastasis 
An important effect of inflammation on cancer is the ability to stimulate tumor invasiveness 
and metastasis. This ability depends in part, on activation of TLRs on immune cells and 
cancer cells. The pro-inflammatory microenvironment contributes to shaping the gene 
expression profile that is required for metastatic behavior of cancer cells. 
4.3.1 NF-B 
TLR activation of MyD88, TRAF6, and NF-B in inflammatory cells and tumor cells within 
the tumor microenvironment play a key role not only in cancer development but also in 
tumor progression (Gohda et al., 2004; Greten et al., 2004; Pikarsky et al., 2004; Kaisho & 
Akira, 2006; Inoue et al., 2007). A correlation was found between the amount of tumor 
associated macrophages (TAMs) present in the tumor and prognosis; the higher the density 
of TAMs, the poorer the prognosis (Duncan et al., 1998). TLR-mediated pro-inflammatory 
cytokine production from tumor associated macrophages (TAMs) play a key role in tumor 
progression and metastasis (Gohda et al., 2004; Inoue et al., 2007). For example, activation of 
the TLR-TRAF6- NF-B pathway in tumor associated inflammatory cells, and the 
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subsequent release of pro-inflammatory cytokines from those cells has been shown to result 
in the activation of NF-B in precancerous cells which drives the growth and malignant 
transformation of those cells (Gohda et al., 2004; Inoue et al., 2007). In addition, TLR-
mediated activation of NF-B is necessary for the differentiation and maturation of 
osteoclasts, which drive the resorption of bone and generate a microenvironment ideal for 
tumor cells to proliferate and colonize, thus enhancing bone metastasis of certain types of 
cancer cells, particularly breast cancer cells (Coleman & Rubens, 1987; Sasaki et al., 1995; 
Lomaga et al., 1999; Naito et al., 1999; Kobayashi et al., 2001). Several genes regulated by 
NF-B encode adhesion molecules, MMPs, serine proteases, heparanase, and chemokines 
that have been shown to be important for tumor invasion and metastasis (Karin & Greten, 
2005). Blockade of NF-B activation reduces proliferation, metastatic ability, and enhances 
apoptosis of cancer cells (Nakanishi & Toi, 2005; Inoue et al., 2007). 
4.3.2 TLR4 
TLR4 signaling has been directly implicated in the regulation of cancer cell metastasis. 
Activation of TLR4 signaling in cancer cells by lipopolysaccharide (LPS), an exogenous ligand 
for TLR4, induces synthesis of IL-6, inducible nitric oxide synthase (iNOS), and IL12 p40. This 
effect on cancer cells is similar to what is observed during the activation of macrophages. 
Blockade of the TLR4 pathway has been found to delay tumor growth and prolong survival in 
mice (Huang et al., 2005a). Recently it was demonstrated that LPS increases the invasiveness of 
pancreatic cancer cells and that increases in invasiveness by LPS was hampered by blocking 
the NF-κB signaling pathway. More specifically, the LPS-dependent invasiveness was 
decreased by blocking the TLR4/MyD88/NF-κB signaling pathway, once again connecting 
TLR-mediated inflammation with cancer invasion and progression (Ikebe et al., 2009). In fact, a 
clinical study of 30 cases of pancreatic ductal adenocarcinoma found that TLR4, NF-κB and 
hypoxia-inducible factor 1-alpha (HIF1α) were over-expressed compared to surrounding 
tissues. Survival of patients with an absence of TLR4 expression in tumor tissues was 
significantly longer than those with TLR4 expression (Zhang et al.). 
4.3.3 Wnt5a 
Wnt proteins are a family of secreted glyocoproteins involved in critical cellular processes 
during embryogenesis. Wnt5a is a member of the Wnt family that has been implicated in 
carcinogenesis and inflammation. Non-canonical Wnt5a activates B-catenin-independent 
pathways important for cell migration and polarity.  
Wnt5a has been implicated in pancreatic cancer for many years. A decade ago the gene 
expression of Wnt5a signaling members were found in tissue samples of pancreatic 
adenocarcinomas (Crnogorac-Jurcevic et al., 2001). Wnt5a expression was found to be 
gradually increased in pancreatic intraepithelial lesions and highly expressed in advanced 
pancreatic cancer (Ripka et al., 2007). Despite these associations, the role of Wnt5a in cancer 
remains controversial as some studies show that Wnt5a may work as a tumor suppressor 
while others show an oncogenic effect (McDonald & Silver, 2009). Although the exact role of 
Wnt5a in cancer remains unclear, the expression of Wnt5a in tumor samples has been 
correlated with advanced stages and poor prognosis in gastric, colon, prostate, lung, and 
malignant melanoma (Iozzo et al., 1995; Lejeune et al., 1995; Saitoh et al., 2002; Weeraratna et 
al., 2002; Huang et al., 2005b).  
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progression. STAT3 is activated by many cytokines, including those cytokines that are 
products of the TLR signaling pathway, including cytokines of the IL-6 family that signal 
through gp130 (IL-6, IL-11, IL-27, etc.), the IL-10 family (IL-10, IL-22, IL-19, IL-20), and the 
epidermal growth factor (EGF) family (VEGF, IL-21, IL-23, HGF). Like NF-B, STAT3 also 
activates anti-apoptotic genes such as Bcl-xL, Bcl-2, and c-IAP2 (Yu & Jove, 2004; Chang et 
al., 2006; Rebouissou et al., 2009), cell cycle and proliferation genes such as Cyclin D1 and c-
Myc (Levy & Darnell, 2002; Naugler & Karin, 2008; Bollrath et al., 2009), and members of the 
AP-1 family such as c-Jun and c-Fos (Hirano et al., 2000; Yang et al., 2005b; Yang et al., 2007), 
whereas others such as Mcl-1 and Survivin are STAT-3-dependent (Yu & Jove, 2004). Thus, 
STAT3 is an attractive target for anti-cancer therapy and numerous strategies have been 
employed to inhibit constitutive STAT3 signaling in cancer cells (Meydan et al., 1996; 
Turkson et al., 2001; Coleman et al., 2005; Song et al., 2005; Duan et al., 2006; Schust et al., 
2006; Iwamaru et al., 2007; Siddiquee et al., 2007; Goel et al., 2008; Hatcher et al., 2008; Lin et 
al., 2010a; Lin et al., 2010b). 
Activator Protein 1 (AP-1) transcriptional complexes also play a pivitol role in malignant 
cellular transformation (Lopez-Bergami et al., 2009). AP-1 can be activated through the TLR 
Myd88-dependent pathway by a variety of growth factors and cytokines (Akira, 2006). 
Increased exposure to environmental carcinogens such as tobacco, nicotine and asbestos 
have been shown to increase AP-1 activity and correlate with tumorgenesis, tumor invasion 
and metastasis (Lopez-Bergami et al., 2009). AP-1 can induce the activation of well-known 
oncogenes including FOS and Jun which are observed in many cancers (Lopez-Bergami et 
al., 2009). The expression of Jun can further activate other oncogenes including Ras, BRAF 
and EGFR. Increased FOS expression has been associated with poor prognosis and 
progression (Lopez-Bergami et al., 2009). Inhibition of AP-1 complexes as well as Jun and 
FOS have been shown to inhibit tumor formation suggesting that AP-1 may be a viable 
target for therapeutic intervention (Lopez-Bergami et al., 2009).  
4.3 Activation of TLR signaling leads to the production of cytokines and upregulation 
of other proteins that control metastasis 
An important effect of inflammation on cancer is the ability to stimulate tumor invasiveness 
and metastasis. This ability depends in part, on activation of TLRs on immune cells and 
cancer cells. The pro-inflammatory microenvironment contributes to shaping the gene 
expression profile that is required for metastatic behavior of cancer cells. 
4.3.1 NF-B 
TLR activation of MyD88, TRAF6, and NF-B in inflammatory cells and tumor cells within 
the tumor microenvironment play a key role not only in cancer development but also in 
tumor progression (Gohda et al., 2004; Greten et al., 2004; Pikarsky et al., 2004; Kaisho & 
Akira, 2006; Inoue et al., 2007). A correlation was found between the amount of tumor 
associated macrophages (TAMs) present in the tumor and prognosis; the higher the density 
of TAMs, the poorer the prognosis (Duncan et al., 1998). TLR-mediated pro-inflammatory 
cytokine production from tumor associated macrophages (TAMs) play a key role in tumor 
progression and metastasis (Gohda et al., 2004; Inoue et al., 2007). For example, activation of 
the TLR-TRAF6- NF-B pathway in tumor associated inflammatory cells, and the 
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subsequent release of pro-inflammatory cytokines from those cells has been shown to result 
in the activation of NF-B in precancerous cells which drives the growth and malignant 
transformation of those cells (Gohda et al., 2004; Inoue et al., 2007). In addition, TLR-
mediated activation of NF-B is necessary for the differentiation and maturation of 
osteoclasts, which drive the resorption of bone and generate a microenvironment ideal for 
tumor cells to proliferate and colonize, thus enhancing bone metastasis of certain types of 
cancer cells, particularly breast cancer cells (Coleman & Rubens, 1987; Sasaki et al., 1995; 
Lomaga et al., 1999; Naito et al., 1999; Kobayashi et al., 2001). Several genes regulated by 
NF-B encode adhesion molecules, MMPs, serine proteases, heparanase, and chemokines 
that have been shown to be important for tumor invasion and metastasis (Karin & Greten, 
2005). Blockade of NF-B activation reduces proliferation, metastatic ability, and enhances 
apoptosis of cancer cells (Nakanishi & Toi, 2005; Inoue et al., 2007). 
4.3.2 TLR4 
TLR4 signaling has been directly implicated in the regulation of cancer cell metastasis. 
Activation of TLR4 signaling in cancer cells by lipopolysaccharide (LPS), an exogenous ligand 
for TLR4, induces synthesis of IL-6, inducible nitric oxide synthase (iNOS), and IL12 p40. This 
effect on cancer cells is similar to what is observed during the activation of macrophages. 
Blockade of the TLR4 pathway has been found to delay tumor growth and prolong survival in 
mice (Huang et al., 2005a). Recently it was demonstrated that LPS increases the invasiveness of 
pancreatic cancer cells and that increases in invasiveness by LPS was hampered by blocking 
the NF-κB signaling pathway. More specifically, the LPS-dependent invasiveness was 
decreased by blocking the TLR4/MyD88/NF-κB signaling pathway, once again connecting 
TLR-mediated inflammation with cancer invasion and progression (Ikebe et al., 2009). In fact, a 
clinical study of 30 cases of pancreatic ductal adenocarcinoma found that TLR4, NF-κB and 
hypoxia-inducible factor 1-alpha (HIF1α) were over-expressed compared to surrounding 
tissues. Survival of patients with an absence of TLR4 expression in tumor tissues was 
significantly longer than those with TLR4 expression (Zhang et al.). 
4.3.3 Wnt5a 
Wnt proteins are a family of secreted glyocoproteins involved in critical cellular processes 
during embryogenesis. Wnt5a is a member of the Wnt family that has been implicated in 
carcinogenesis and inflammation. Non-canonical Wnt5a activates B-catenin-independent 
pathways important for cell migration and polarity.  
Wnt5a has been implicated in pancreatic cancer for many years. A decade ago the gene 
expression of Wnt5a signaling members were found in tissue samples of pancreatic 
adenocarcinomas (Crnogorac-Jurcevic et al., 2001). Wnt5a expression was found to be 
gradually increased in pancreatic intraepithelial lesions and highly expressed in advanced 
pancreatic cancer (Ripka et al., 2007). Despite these associations, the role of Wnt5a in cancer 
remains controversial as some studies show that Wnt5a may work as a tumor suppressor 
while others show an oncogenic effect (McDonald & Silver, 2009). Although the exact role of 
Wnt5a in cancer remains unclear, the expression of Wnt5a in tumor samples has been 
correlated with advanced stages and poor prognosis in gastric, colon, prostate, lung, and 
malignant melanoma (Iozzo et al., 1995; Lejeune et al., 1995; Saitoh et al., 2002; Weeraratna et 
al., 2002; Huang et al., 2005b).  
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In vitro studies have shown that Wnt5a induces cell migration, proliferation and invasion in 
a variety of cancer cell lines (Weeraratna et al., 2002; Kurayoshi et al., 2006; McDonald & 
Silver, 2009), lending support to the hypothesis that Wnt5a may be involved in invasion or 
metastasis of several different cancers. At present the precise mechanisms linking Wnt5a 
with cancer invasion and metastatis are still largely unknown, however recent studies have 
hinted at possible molecular mechanisms. The Ca2+ signaling and subsequent protein 
kinase C (PKC) activation was suggested as the mechanism for enhanced motility and 
invasiveness for malignant melanoma (Weeraratna et al., 2002). In addition, a recent study 
associated polarized cell migration with the Wnt5a-ROR2 signaling pathway (Nishita et al.). 
Wnt5a involvement during EMT in pancreatic cancer was also suggested (Ripka et al., 2007). 
Wnt5a was described as a target of the homeobox transcription factor CULT1, enhancing 
migration, proliferation and invasiveness during pancreatic tumorigenensis (Ripka et al., 
2007).  
An IL-6 / STAT3 / Wnt5a signaling loop has been described by different groups (Katoh, 
2007; McCall et al., 2007). Our group demonstrated that IL-6, a TLR signaling product, can 
activate STAT3 with resulting overexpression of Wnt5a in papillary thyroid carcinoma cells 
and that phenylmethimazole (C10), a derivative of the anti-thyroidal medication 
methimazole, has the ability to block TLR3 signaling, IL-6 production, as well as decrease 
growth and migration of papillary thyroid carcinoma cells (McCall et al., 2007). We 
hypothesized that the C10 effect on growth and migration of the papillary thyroid cancer 
cells was related to its suppressive effect on TLR3 signaling which led to the 
downregulation of TLR-mediated STAT3 and Wnt5a signaling (McCall et al., 2007). This 
was the first study that linked TLR signaling with Wnt5a and cancer cell growth and 
migration. 
More recently our group has shown that TLR3 and Wnt5a RNA are constitutively expressed 
in human pancreatic cancer and malignant melanoma cell lines in culture. In similar 
findings to what we reported in human papillary thyroid cells, C10 inhibits TLR3 expression 
and signaling in addition to growth and migration of these human pancreatic cancer and 
malignant melanoma cells. Moreover, in this report we established in vivo efficacy by 
showing that C10 delays tumor growth in mouse models of human pancreatic cancer and 
malignant melanoma. These studies showed that this phenomenon was also associated with 
inhibition of STAT3 activation (Schwartz et al., 2009). Since STAT3 activation is a strong 
regulator of Wnt5a expression, and since C10 can block migration of these pancreatic and 
malignant melanoma cells in vitro as well as Wnt5a expression and signaling, we suspect 
that C10 may also act to prevent metastasis in vivo. 
4.3.4 Other TLR-related molecules 
Tumor necrosis factor alpha (TNF-), a product of TLR signaling, is a critical cytokine that 
induces expression of other inflammatory mediators and proteases important for tumor 
invasiveness and metastasis. Although at high doses extrinsic TNF- cause hemorrhagic 
necrosis, at low concentrations it acts as an endogenous tumor promoter. It can be produced 
by malignant epithelial cells or stromal cells (Balkwill, 2002). The tumor promotion capacity 
depends on activation of NF-B (Luo et al., 2004; Pikarsky et al., 2004). TNF- 
expression/production is associated with poor prognosis, loss of hormone responsiveness 
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and cachexia (Luo et al., 2004). TNF- increases vascular permeability, can stimulate the 
migration and extravasation or intravasation of cancer cells or can acts as a growth factor 
(Luo et al., 2004). 
TLR signaling products IL-1 and IL-1 in the tumor microenvironment both contribute to 
increased invasiveness and metastasis (Gemma et al., 2001; Elaraj et al., 2011). IL-1 can 
promote metastasis by different mechanisms; first by increasing the adhesiveness of the 
endothelium via VCAM-1 or mannose receptor expression in endothelial cells. A second 
mechanism may involve induction of MMPs, cytokines and chemokines in tumor or stromal 
cells (Anasagasti et al., 1997; Song et al., 2003). A third mechanism is via the induction of 
angiogenic factors such as VEGF and IL-8 (Lewis et al., 2006). In 2003 two groups 
independently established that IL-1 and IL-1 were critical for the invasiveness and 
metastasis of pancreatic cancer and melanoma tumor cells (Sawai et al., 2003; Voronov et al., 
2003). IL-1 is mainly produced by myeloid cells, with intricate transcriptional and post-
transcriptional control. IL-1 increases tumor invasiveness and metastasis by promoting the 
production of angiogenic factors by stromal mononuclear cells (Saijo et al., 2002). IL-1 is 
secreted mainly by epithelial cells undergoing necrosis (Sakurai et al., 2008). In liver it was 
found that IL-1 released by necrotic hepatocytes induces IL-6 synthesis by Kupffer cells 
which activates pro-oncogenic transcription factor STAT3 (Naugler et al., 2007). IL-1 
receptor activation by either form of IL-1 can lead to induction of IL-6. In multiple myeloma 
IL-6 promotes survival and proliferation of cancer cells via activation of STAT3 and 
extracellular signal – regulated kinase ERK signaling (Honemann et al., 2001). IL-6 - STAT3 
signaling was also found in chemically induced liver carcinogenesis as well as many other 
types of cancers (Calo et al., 2003; McCall et al., 2007; Naugler et al., 2007; Schwartz et al., 
2009). 
COX-2, a TLR4 signaling product (Fukata et al., 2006), is highly expressed in a variety of 
cancers such as colorectal, gastric, esophageal, breast and prostate carcinomas. COX-2-
produced prostaglandin E2 (PGE2) increases tumor invasiveness and metastasis and 
enhances production of IL-6, IL-8, VEGF, iNOS, MMP2 and MMP9 among others (Gasparini 
et al., 2003). COX-2 inhibition shows chemopreventive and antimetastatic activity in a 
variety of human cancers through disruption of the inflammatory microenvironment (Baek 
& Eling, 2006). 
TLR-induced TGF-β is produce by myeloid cells, mesenchymal cells and cancer cells in 
hypoxic and inflammatory conditions (He et al., 2007; Ren et al., 2007; Zhou et al., 2009). It is 
one of the most highly expressed cytokines in the tumor microenvironment and has a large 
influence on tumor cell invasiveness and metastasis (Yang et al., 2010). The induction of 
angiopoietin-like 4 (ANGPTL4) in cancer cells by TGF-β disrupts vascular endothelial cell 
cell to cell junctions, increases the permeability of lung capillaries, and facilitates the trans-
endothelial passage of tumor cells (Padua et al., 2008).  
Versican is an aggregating chondroitin sulfate proteoglycan highly expressed in several 
cancers (Pirinen et al., 2005). Versican enhances tumor cell migration, growth and 
angiogenesis (Zheng et al., 2004). Versican has pro-inflammatory activity, it induces 
macrophages activation and stimulates the secretion of TNF- and other cytokines (Wight, 
2002; Kim & Karin, 2011). In addition, versican interacts with several adhesion molecules 
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In vitro studies have shown that Wnt5a induces cell migration, proliferation and invasion in 
a variety of cancer cell lines (Weeraratna et al., 2002; Kurayoshi et al., 2006; McDonald & 
Silver, 2009), lending support to the hypothesis that Wnt5a may be involved in invasion or 
metastasis of several different cancers. At present the precise mechanisms linking Wnt5a 
with cancer invasion and metastatis are still largely unknown, however recent studies have 
hinted at possible molecular mechanisms. The Ca2+ signaling and subsequent protein 
kinase C (PKC) activation was suggested as the mechanism for enhanced motility and 
invasiveness for malignant melanoma (Weeraratna et al., 2002). In addition, a recent study 
associated polarized cell migration with the Wnt5a-ROR2 signaling pathway (Nishita et al.). 
Wnt5a involvement during EMT in pancreatic cancer was also suggested (Ripka et al., 2007). 
Wnt5a was described as a target of the homeobox transcription factor CULT1, enhancing 
migration, proliferation and invasiveness during pancreatic tumorigenensis (Ripka et al., 
2007).  
An IL-6 / STAT3 / Wnt5a signaling loop has been described by different groups (Katoh, 
2007; McCall et al., 2007). Our group demonstrated that IL-6, a TLR signaling product, can 
activate STAT3 with resulting overexpression of Wnt5a in papillary thyroid carcinoma cells 
and that phenylmethimazole (C10), a derivative of the anti-thyroidal medication 
methimazole, has the ability to block TLR3 signaling, IL-6 production, as well as decrease 
growth and migration of papillary thyroid carcinoma cells (McCall et al., 2007). We 
hypothesized that the C10 effect on growth and migration of the papillary thyroid cancer 
cells was related to its suppressive effect on TLR3 signaling which led to the 
downregulation of TLR-mediated STAT3 and Wnt5a signaling (McCall et al., 2007). This 
was the first study that linked TLR signaling with Wnt5a and cancer cell growth and 
migration. 
More recently our group has shown that TLR3 and Wnt5a RNA are constitutively expressed 
in human pancreatic cancer and malignant melanoma cell lines in culture. In similar 
findings to what we reported in human papillary thyroid cells, C10 inhibits TLR3 expression 
and signaling in addition to growth and migration of these human pancreatic cancer and 
malignant melanoma cells. Moreover, in this report we established in vivo efficacy by 
showing that C10 delays tumor growth in mouse models of human pancreatic cancer and 
malignant melanoma. These studies showed that this phenomenon was also associated with 
inhibition of STAT3 activation (Schwartz et al., 2009). Since STAT3 activation is a strong 
regulator of Wnt5a expression, and since C10 can block migration of these pancreatic and 
malignant melanoma cells in vitro as well as Wnt5a expression and signaling, we suspect 
that C10 may also act to prevent metastasis in vivo. 
4.3.4 Other TLR-related molecules 
Tumor necrosis factor alpha (TNF-), a product of TLR signaling, is a critical cytokine that 
induces expression of other inflammatory mediators and proteases important for tumor 
invasiveness and metastasis. Although at high doses extrinsic TNF- cause hemorrhagic 
necrosis, at low concentrations it acts as an endogenous tumor promoter. It can be produced 
by malignant epithelial cells or stromal cells (Balkwill, 2002). The tumor promotion capacity 
depends on activation of NF-B (Luo et al., 2004; Pikarsky et al., 2004). TNF- 
expression/production is associated with poor prognosis, loss of hormone responsiveness 
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and cachexia (Luo et al., 2004). TNF- increases vascular permeability, can stimulate the 
migration and extravasation or intravasation of cancer cells or can acts as a growth factor 
(Luo et al., 2004). 
TLR signaling products IL-1 and IL-1 in the tumor microenvironment both contribute to 
increased invasiveness and metastasis (Gemma et al., 2001; Elaraj et al., 2011). IL-1 can 
promote metastasis by different mechanisms; first by increasing the adhesiveness of the 
endothelium via VCAM-1 or mannose receptor expression in endothelial cells. A second 
mechanism may involve induction of MMPs, cytokines and chemokines in tumor or stromal 
cells (Anasagasti et al., 1997; Song et al., 2003). A third mechanism is via the induction of 
angiogenic factors such as VEGF and IL-8 (Lewis et al., 2006). In 2003 two groups 
independently established that IL-1 and IL-1 were critical for the invasiveness and 
metastasis of pancreatic cancer and melanoma tumor cells (Sawai et al., 2003; Voronov et al., 
2003). IL-1 is mainly produced by myeloid cells, with intricate transcriptional and post-
transcriptional control. IL-1 increases tumor invasiveness and metastasis by promoting the 
production of angiogenic factors by stromal mononuclear cells (Saijo et al., 2002). IL-1 is 
secreted mainly by epithelial cells undergoing necrosis (Sakurai et al., 2008). In liver it was 
found that IL-1 released by necrotic hepatocytes induces IL-6 synthesis by Kupffer cells 
which activates pro-oncogenic transcription factor STAT3 (Naugler et al., 2007). IL-1 
receptor activation by either form of IL-1 can lead to induction of IL-6. In multiple myeloma 
IL-6 promotes survival and proliferation of cancer cells via activation of STAT3 and 
extracellular signal – regulated kinase ERK signaling (Honemann et al., 2001). IL-6 - STAT3 
signaling was also found in chemically induced liver carcinogenesis as well as many other 
types of cancers (Calo et al., 2003; McCall et al., 2007; Naugler et al., 2007; Schwartz et al., 
2009). 
COX-2, a TLR4 signaling product (Fukata et al., 2006), is highly expressed in a variety of 
cancers such as colorectal, gastric, esophageal, breast and prostate carcinomas. COX-2-
produced prostaglandin E2 (PGE2) increases tumor invasiveness and metastasis and 
enhances production of IL-6, IL-8, VEGF, iNOS, MMP2 and MMP9 among others (Gasparini 
et al., 2003). COX-2 inhibition shows chemopreventive and antimetastatic activity in a 
variety of human cancers through disruption of the inflammatory microenvironment (Baek 
& Eling, 2006). 
TLR-induced TGF-β is produce by myeloid cells, mesenchymal cells and cancer cells in 
hypoxic and inflammatory conditions (He et al., 2007; Ren et al., 2007; Zhou et al., 2009). It is 
one of the most highly expressed cytokines in the tumor microenvironment and has a large 
influence on tumor cell invasiveness and metastasis (Yang et al., 2010). The induction of 
angiopoietin-like 4 (ANGPTL4) in cancer cells by TGF-β disrupts vascular endothelial cell 
cell to cell junctions, increases the permeability of lung capillaries, and facilitates the trans-
endothelial passage of tumor cells (Padua et al., 2008).  
Versican is an aggregating chondroitin sulfate proteoglycan highly expressed in several 
cancers (Pirinen et al., 2005). Versican enhances tumor cell migration, growth and 
angiogenesis (Zheng et al., 2004). Versican has pro-inflammatory activity, it induces 
macrophages activation and stimulates the secretion of TNF- and other cytokines (Wight, 
2002; Kim & Karin, 2011). In addition, versican interacts with several adhesion molecules 
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expressed by inflammatory cells (Wight, 2002) and activates endothelial cells, fibroblasts 
and macrophages in the tumor microenviroment (Wang et al., 2009). Importantly, versican 
activates TLR2 on macrophages to induce NF-B and MAP kinase (MAPK) signaling with 
the subsequent production of pro-inflammatory cytokines such as IL-6 and TNF- (Wang et 
al., 2009). The inhibition of versican expression in LCC cells eliminates their metastatic 
behavior (Kim et al., 2009). In addition, a related proteoglycan, biglycan was found to 
activate macrophages through TLR2 and TLR4 (Schaefer et al., 2005). 
Helix-loop-helix protein Twist, is a key transcription factor that regulates cell movement 
and tissue reorganization during early embryogenesis with a role in the epithelial-
mesenchymal transition (EMT) process during normal development. Suppression of Twist 
in metastatic 4T1 mammary carcinoma cells specifically inhibits their ability to metastasize 
to lung but not their ability to form primary tumors (Yang et al., 2004) and loss of Twist 
expression prevents the entry of metastatic cells into the circulation (Yang et al., 2004). 
Together, these findings suggest that Twist can contribute to invasion and metastasis by 
promoting the EMT developmental program in cancer. Interestingly, Twist expression can 
be induced in response to NF-ĸB activation and is therefore upregulated in response to 
inflammation (Pham et al., 2007). This could be a mechanism through which tumor-
associated inflammation may stimulate metastatic progression through induction of Twist-
dependent EMT (Yang et al., 2004; Pham et al., 2007). 
Another mechanism of cancer invasiveness and metastasis was identified in a metastatic 
prostate cancer model that involves the repression of Maspin. Maspin is a member of the 
serpin family with well-established anti-metastatic activity in breast and prostate cancers. It 
was found that the metastatic behavior of isolated cells was dependent on the activation and 
nuclear accumulation of IKKα (Preciado et al., 2005). Repression of Maspin transcription 
required nuclear translocation of catalytically active IKKα, which occur only in advanced 
prostate tumors that contain inflammatory infiltrates and cells that express receptor 
activator of nuclear factor kappa-B ligand (RANKL) and LTα:β (Preciado et al., 2005). 
RANKL can lead to repression of maspin-expression in an IKKα-dependent manner (Zou et 
al., 1994; Luo et al., 2007). Thus, IKKα infers its pro-mestastatic effect by repressing 
transcription of the maspin gene. 
Although the molecular mechanisms involved in these metastatic processes seem to be 
complex and not well understood, TLR signaling and related proteins appear to play an 
important role. 
4.4 TLRs have an important role in tumor angiogenesis  
In 1995, Judah Folkman wrote (Folkman, 1995) that “recent discoveries of endogenous 
negative regulators of angiogenesis, thrombospondin, angiostatin, and glioma-derived 
angiogenesis inhibitory factor, all associated with neovascularized tumors, suggest a new 
paradigm of tumorigenesis. It is now helpful to think of the switch to the angiogenic 
phenotype as a net balance of positive and negative regulators of blood vessel growth. The 
extent to which the negative regulators are decreased during this switch may dictate 
whether a primary tumor grows rapidly or slowly and whether metastasis grows at all.” 
Folkman recognized that cancer has the ability to spread to adjacent or distant organs; he 
recognized that tumor cells could penetrate blood or lymphatic vessel walls, spread through 
Toll-Like Receptors as Novel Therapeutic Targets for the Treatment of Pancreatic Cancer 375 
the blood or lymphatic vessels to another site, where they could proliferate; but he further 
recognized that the key to the metastatic or tumor growth process was angiogenesis. At that 
time he did not envision the importance of the Toll-like receptor and signal system in 
regulating this switch from normal to pathologically driven angiogenesis. 
Cell growth, cell development, and cell migration, independent of whether immune or non-
immune cell in origin, require blood vessel formation to feed the inflamed areas with 
nutrients and oxygen, particularly chronically inflamed and growing tissues. This is 
reviewed in Grote, et al, whose work can be construed not only as an important component 
of the following discussion but the “bible” on which it is based (Grote et al., 2011). Vascular 
growth is termed angiogenesis or vasculogenesis. Angiogenesis is the formation of new 
blood vessels by sprouting or by intussusception of preexisting vessels; vasculogenesis 
defines a process whereby progenitor cells differentiate into endothelial cells (Ribatti, 2010). 
Both processes often occur together and are often termed neovascularization, as for example 
in atherosclerotic lesions. 
Tumor angiogenesis is a multistep process (Nishida et al., 2006). Simplistically, first the 
basement membrane in tissues is injured locally with resultant tissue destruction and 
hypoxia. Second, endothelial cells activated by angiogenic factors migrate into the damaged 
area. Third, endothelial cells stimulated by angiogenic factors proliferate and stabilize. Then, 
angiogenic factors continue to influence tissue nutrient supply and waste removal. It is 
intuitive that this is not a simple process and must be highly controlled (Carmeliet, 2000).  
One example of this is the role of hypoxia in tumor angiogenesis. The irregular pattern and 
organization of the tumor vasculature result in some cells being more than 100 μm from a 
blood vessel, the accepted diffusion limit for oxygen. Progressive hypoxia with distance 
from the oxygen source results in induction in hypoxia-inducer factor 1 alpha (HIF-1α) and 
1 beta (HIF-1β) and, upregulated gene expression (VEGF, Ang2, iNOS, PDGF-B), increased 
glycolysis, and stimulation of angiogenesis.  
Secondly, blood vessels have endothelial cell walls, a media composed of fibroblasts, fat 
cells, collagen molecules, and mesenchymal tissue, and a surrounding smooth muscle and 
epithelial cell layer in arteries or just an epithelial cell layer in non arterial vasculature. 
Blood vessels form in a regular pattern as part of a normal vascular network but in a 
disordered array in chronic inflammatory states or cancer. In examining angiogenesis, one 
must thus consider multiple cell types, multiple coordinated interactions, and complex 
regulatory networks. 
The complexity is evidenced molecularly (Carmeliet, 2000; Olsson et al., 2006). VEGF 
(vascular endothelial growth factor) is now recognized to be 5 VEGF ligands (A-D) in 
different spliced or processed variants, yet each is a dimeric glycoprotein of about 40K. 
Placenta growth factor (PLGF) is also a family member. They bind to 3 receptor tyrosine 
kinases (VEGFR 1-3) which can have an overlapping functional pattern, and can have 
multiple co-receptors, including neuropilins, proteoglycans, and heparin-sulfate. Each 
VGFR has a different function: VEGFR1 is important in hematopoetic progenitor cell 
recruitment; it also regulates monocyte migration; VEGFR2 and 3 control endothelial cell 
function during angiogenesis. Lest this complexity overwhelm us, Tie receptors and their 
angiopoitin (Ang) ligands are a second endothelial cell-specific receptor tyrosine kinase 
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expressed by inflammatory cells (Wight, 2002) and activates endothelial cells, fibroblasts 
and macrophages in the tumor microenviroment (Wang et al., 2009). Importantly, versican 
activates TLR2 on macrophages to induce NF-B and MAP kinase (MAPK) signaling with 
the subsequent production of pro-inflammatory cytokines such as IL-6 and TNF- (Wang et 
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behavior (Kim et al., 2009). In addition, a related proteoglycan, biglycan was found to 
activate macrophages through TLR2 and TLR4 (Schaefer et al., 2005). 
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mesenchymal transition (EMT) process during normal development. Suppression of Twist 
in metastatic 4T1 mammary carcinoma cells specifically inhibits their ability to metastasize 
to lung but not their ability to form primary tumors (Yang et al., 2004) and loss of Twist 
expression prevents the entry of metastatic cells into the circulation (Yang et al., 2004). 
Together, these findings suggest that Twist can contribute to invasion and metastasis by 
promoting the EMT developmental program in cancer. Interestingly, Twist expression can 
be induced in response to NF-ĸB activation and is therefore upregulated in response to 
inflammation (Pham et al., 2007). This could be a mechanism through which tumor-
associated inflammation may stimulate metastatic progression through induction of Twist-
dependent EMT (Yang et al., 2004; Pham et al., 2007). 
Another mechanism of cancer invasiveness and metastasis was identified in a metastatic 
prostate cancer model that involves the repression of Maspin. Maspin is a member of the 
serpin family with well-established anti-metastatic activity in breast and prostate cancers. It 
was found that the metastatic behavior of isolated cells was dependent on the activation and 
nuclear accumulation of IKKα (Preciado et al., 2005). Repression of Maspin transcription 
required nuclear translocation of catalytically active IKKα, which occur only in advanced 
prostate tumors that contain inflammatory infiltrates and cells that express receptor 
activator of nuclear factor kappa-B ligand (RANKL) and LTα:β (Preciado et al., 2005). 
RANKL can lead to repression of maspin-expression in an IKKα-dependent manner (Zou et 
al., 1994; Luo et al., 2007). Thus, IKKα infers its pro-mestastatic effect by repressing 
transcription of the maspin gene. 
Although the molecular mechanisms involved in these metastatic processes seem to be 
complex and not well understood, TLR signaling and related proteins appear to play an 
important role. 
4.4 TLRs have an important role in tumor angiogenesis  
In 1995, Judah Folkman wrote (Folkman, 1995) that “recent discoveries of endogenous 
negative regulators of angiogenesis, thrombospondin, angiostatin, and glioma-derived 
angiogenesis inhibitory factor, all associated with neovascularized tumors, suggest a new 
paradigm of tumorigenesis. It is now helpful to think of the switch to the angiogenic 
phenotype as a net balance of positive and negative regulators of blood vessel growth. The 
extent to which the negative regulators are decreased during this switch may dictate 
whether a primary tumor grows rapidly or slowly and whether metastasis grows at all.” 
Folkman recognized that cancer has the ability to spread to adjacent or distant organs; he 
recognized that tumor cells could penetrate blood or lymphatic vessel walls, spread through 
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the blood or lymphatic vessels to another site, where they could proliferate; but he further 
recognized that the key to the metastatic or tumor growth process was angiogenesis. At that 
time he did not envision the importance of the Toll-like receptor and signal system in 
regulating this switch from normal to pathologically driven angiogenesis. 
Cell growth, cell development, and cell migration, independent of whether immune or non-
immune cell in origin, require blood vessel formation to feed the inflamed areas with 
nutrients and oxygen, particularly chronically inflamed and growing tissues. This is 
reviewed in Grote, et al, whose work can be construed not only as an important component 
of the following discussion but the “bible” on which it is based (Grote et al., 2011). Vascular 
growth is termed angiogenesis or vasculogenesis. Angiogenesis is the formation of new 
blood vessels by sprouting or by intussusception of preexisting vessels; vasculogenesis 
defines a process whereby progenitor cells differentiate into endothelial cells (Ribatti, 2010). 
Both processes often occur together and are often termed neovascularization, as for example 
in atherosclerotic lesions. 
Tumor angiogenesis is a multistep process (Nishida et al., 2006). Simplistically, first the 
basement membrane in tissues is injured locally with resultant tissue destruction and 
hypoxia. Second, endothelial cells activated by angiogenic factors migrate into the damaged 
area. Third, endothelial cells stimulated by angiogenic factors proliferate and stabilize. Then, 
angiogenic factors continue to influence tissue nutrient supply and waste removal. It is 
intuitive that this is not a simple process and must be highly controlled (Carmeliet, 2000).  
One example of this is the role of hypoxia in tumor angiogenesis. The irregular pattern and 
organization of the tumor vasculature result in some cells being more than 100 μm from a 
blood vessel, the accepted diffusion limit for oxygen. Progressive hypoxia with distance 
from the oxygen source results in induction in hypoxia-inducer factor 1 alpha (HIF-1α) and 
1 beta (HIF-1β) and, upregulated gene expression (VEGF, Ang2, iNOS, PDGF-B), increased 
glycolysis, and stimulation of angiogenesis.  
Secondly, blood vessels have endothelial cell walls, a media composed of fibroblasts, fat 
cells, collagen molecules, and mesenchymal tissue, and a surrounding smooth muscle and 
epithelial cell layer in arteries or just an epithelial cell layer in non arterial vasculature. 
Blood vessels form in a regular pattern as part of a normal vascular network but in a 
disordered array in chronic inflammatory states or cancer. In examining angiogenesis, one 
must thus consider multiple cell types, multiple coordinated interactions, and complex 
regulatory networks. 
The complexity is evidenced molecularly (Carmeliet, 2000; Olsson et al., 2006). VEGF 
(vascular endothelial growth factor) is now recognized to be 5 VEGF ligands (A-D) in 
different spliced or processed variants, yet each is a dimeric glycoprotein of about 40K. 
Placenta growth factor (PLGF) is also a family member. They bind to 3 receptor tyrosine 
kinases (VEGFR 1-3) which can have an overlapping functional pattern, and can have 
multiple co-receptors, including neuropilins, proteoglycans, and heparin-sulfate. Each 
VGFR has a different function: VEGFR1 is important in hematopoetic progenitor cell 
recruitment; it also regulates monocyte migration; VEGFR2 and 3 control endothelial cell 
function during angiogenesis. Lest this complexity overwhelm us, Tie receptors and their 
angiopoitin (Ang) ligands are a second endothelial cell-specific receptor tyrosine kinase 
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system which interacts with the VEGF-VEGFR kinase system during angiogenesis (Partanen 
et al., 1992; Augustin et al., 2009). Ang-Tie interactions normally control signals leading to 
vessel quiescence and the last steps of vessel maturation. 
Capillaries develop and grow with a VEGF gradient. Endothelial cells at the leading edge of 
the capillary tube, tip cells, have filopodia and express multiple VEGFR family members. 
“Behind them” in the advancing gradient of growth and development are highly 
proliferative, differentiating “stalk” cells and resting cells expressing components of the 
Ang-Tie system. A key component regulating the “sprouting” tip cells vs stalk cells is the 
Delta/Notch Signaling system (Gridley, 2010). Again complexity exists. There are 4 different 
Notch Receptors, Notch 1-4. Notch receptors have a single transmembrane domain binding 
to membrane ligands Delta-like (Dll) 1-4 and Jagged. Notch signaling in stalk cells induces a 
quiescent endothelial cell phenotype whereas TIP cells enriched in DLL4 promote sprouting 
activity and capillary growth (Gridley, 2010). Other factors in associated cells, such as basic 
fibroblast growth factor (bFGF) and platelet derived growth factor (PDGF) control 
“endothelial cell coverage” by pericytes and smooth muscle cells to establish vasculature 
stability and maturation (Distler et al., 2003).  
In sum, the regulated action of a multiplicity of angiogenic factors and receptor kinases 
control capillary sprouting, growth, differentiation (e.g., tip vs stalk) and endothelial cell 
“coverage” and “stabilization.” Moreover this list does not even consider a multiplicity of 
cytokines, chemokines, and growth factors with pro-angiogenic importance (Bussolino et al., 
1991). Together, these, plus controlling inhibitory factors such as angiostatin, define a 
balanced pro- or anti-angiogenic system in normal tissues. It is now accepted that the 
“angiogenic switch” is “off” when the effect of pro-angiogenic molecules is balanced by that 
of anti-angiogenic molecules and is “on” when the net balance is tipped in favor of 
angiogenesis. A list of angiogenic stimulators and angiogenic inhibitors was summarized in 
“Angiogenesis in cancer and other disease” an Insight Review Article by Peter Carmeliet 
and Rakesh Jain (Carmeliet & Jain, 2000). This multiplicity is much expanded now, and 
offers an array of targets to stimulate angiogenesis, for example after a myocardial infarction 
(Vandervelde et al., 2005), or to inhibit angiogenesis to control dysregulated cell growth 
precipitated by chronic inflammation, for example in cancer, atherosclerosis, or obesity-
induced diabetes (Cao, 2009). A VEGF-neutralizing monoclonal, anti-TNF-α, is one of many 
therapies targeting single gene products in this complex cascade. Of interest, numerous 
individual specific antibodies and inhibitors of specific tyrosine kinases have been evaluated 
in the past 10-15 years; however, not surprisingly, this approach has had limited success in a 
complex, interrelated, redundant signal system/pathway. 
4.4.1 Inflammation and angiogenesis 
Accumulating evidence supports a link between inflammation and angiogenesis. The two 
processes are intimately intertwined in inflammation-associated wound healing and tissue 
regeneration. Thus, the acute gene response set off by the innate immune process results in 
cytokines, chemokines, and growth factors produced at the site of the injury, which not only 
induce inflammation but also successive tissue repair. Angiogenesis is an important 
component of this tissue repair as evidenced by increased expression of VEGF. The 
inflammation-induced wound healing includes, in addition, pro-angiogenic factors such as 
basic fibroblast growth factor (bFGF), TGF-β, TNF-α, insulin-like growth factor-1 (IGF-1), 
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monocyte chemotactic protein-1 (MCP-1), IL-6 and IL-8, PDGF, to name but a few, which 
attract endothelial cells, smooth muscle cells, and epithelial cells needed for vessel growth 
and maturation.  
Chronic inflammation leading to different pathological states, such as obesity-induced 
diabetes, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, and cancer, 
nevertheless have a common gene activation process and angionesis component. That 
chronic inflammation leads to diverse pathologic states involving the same molecular events 
should not be a surprise if one recognizes the commonality of inflammation and wound 
repair in all tissues, despite their varied differentiated states. Organ specific diseases do not 
negate common mechanisms of wound repair and angiogenesis in each. 
4.4.2 Toll-like receptor signaling in inflammation and angiogenesis 
To date, most studies linking TLR signaling to angiogenesis are in vitro and are largely 
descriptive. Thus, there is literature describing the use of several TLR agonists to induce 
expression and secretion of multiple angiogenic factors in an array of different cell types in 
vitro. The majority, however use LPS to stimulate TLR4 signaling with increased VEGF as a 
marker of angiogenesis.  
1. LPS activation of TLR4 signaling in vitro increases adenosine promotion of angiogenesis 
through the A2A Receptor system to increase VEGF (Hara et al., 2009). This cardio-
protective nucleoside stimulates angiogenesis by increasing VEGF in macrophages, 
thereby likely offering tissue protection after ischemic injury. Moreover, there is a 
synergistic down-regulation of TNF-α (Leibovich et al., 2002). This angiogenic “switch” 
was noted also with TLR2, TLR7, and TLR9 agonists (Pinhal-Enfield et al., 2003). There 
is an in vivo correlate, since MyD88-deficient mice had decreased generation of new 
capillaries in response to an A2AR agonist (Macedo et al., 2007). 
2. LPS-increased TLR4 signaling was shown to increase endothelial sprouting in vitro via a 
TRAF6, NF-κB, JNK stimulatory process (Pollet et al., 2003). The requirement for TRAF6 
in vitro and in vivo was established using a retrovirally expressed dominant negative 
TRAF6 in endothelial cells (Pollet et al., 2003). Moreover, inhibition of c-Jun N-terminal 
kinase (JNK) activity or NF-κB activity downstream of TRAF6 inhibited LPS-induced 
endothelial sprouting. Inhibition of only NF-κB but not JNK activity blocked bFGF, not 
TRAF6 induced angiogenesis. In sum, a direct endothelial role of TLR4 activation via 
TRAF6 is important in inducing angiogenesis in endothelial cells (Pollet et al., 2003). 
This has a pathologic counterpart in pathological corneal neovascularization that can 
cause impaired vision when induced by infections wherein TLR4 and VEGF are 
increased (Rodriguez-Martinez et al., 2006).  
3. Bactonella henselae infections increase MCP-1 in endothelial cells, which chemotactically 
attracts monocytes to produce VEGF and increase angiogenesis (McCord et al., 2005). 
This is an NF-κB dependent process independent of TLR4 or LPS. 
4. The TLR4/MyD88 signal system is important in VEGF production and angiogenesis in 
liver endothelial cells stimulated with LPS (Jagavelu et al., 2010). 
5. Mycoplasma infections of the pulmonary tract causing a chronic inflammatory process 
increase angiogenesis and vascular remodeling (McDonald, 2001). This appears to be 
associated with a TLR2/6-dependent induction of NF-κB and a MAPK cascade by a 2 
kDa macrophage activating diacylated lipopeptide (MALP-2) present in the 
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system which interacts with the VEGF-VEGFR kinase system during angiogenesis (Partanen 
et al., 1992; Augustin et al., 2009). Ang-Tie interactions normally control signals leading to 
vessel quiescence and the last steps of vessel maturation. 
Capillaries develop and grow with a VEGF gradient. Endothelial cells at the leading edge of 
the capillary tube, tip cells, have filopodia and express multiple VEGFR family members. 
“Behind them” in the advancing gradient of growth and development are highly 
proliferative, differentiating “stalk” cells and resting cells expressing components of the 
Ang-Tie system. A key component regulating the “sprouting” tip cells vs stalk cells is the 
Delta/Notch Signaling system (Gridley, 2010). Again complexity exists. There are 4 different 
Notch Receptors, Notch 1-4. Notch receptors have a single transmembrane domain binding 
to membrane ligands Delta-like (Dll) 1-4 and Jagged. Notch signaling in stalk cells induces a 
quiescent endothelial cell phenotype whereas TIP cells enriched in DLL4 promote sprouting 
activity and capillary growth (Gridley, 2010). Other factors in associated cells, such as basic 
fibroblast growth factor (bFGF) and platelet derived growth factor (PDGF) control 
“endothelial cell coverage” by pericytes and smooth muscle cells to establish vasculature 
stability and maturation (Distler et al., 2003).  
In sum, the regulated action of a multiplicity of angiogenic factors and receptor kinases 
control capillary sprouting, growth, differentiation (e.g., tip vs stalk) and endothelial cell 
“coverage” and “stabilization.” Moreover this list does not even consider a multiplicity of 
cytokines, chemokines, and growth factors with pro-angiogenic importance (Bussolino et al., 
1991). Together, these, plus controlling inhibitory factors such as angiostatin, define a 
balanced pro- or anti-angiogenic system in normal tissues. It is now accepted that the 
“angiogenic switch” is “off” when the effect of pro-angiogenic molecules is balanced by that 
of anti-angiogenic molecules and is “on” when the net balance is tipped in favor of 
angiogenesis. A list of angiogenic stimulators and angiogenic inhibitors was summarized in 
“Angiogenesis in cancer and other disease” an Insight Review Article by Peter Carmeliet 
and Rakesh Jain (Carmeliet & Jain, 2000). This multiplicity is much expanded now, and 
offers an array of targets to stimulate angiogenesis, for example after a myocardial infarction 
(Vandervelde et al., 2005), or to inhibit angiogenesis to control dysregulated cell growth 
precipitated by chronic inflammation, for example in cancer, atherosclerosis, or obesity-
induced diabetes (Cao, 2009). A VEGF-neutralizing monoclonal, anti-TNF-α, is one of many 
therapies targeting single gene products in this complex cascade. Of interest, numerous 
individual specific antibodies and inhibitors of specific tyrosine kinases have been evaluated 
in the past 10-15 years; however, not surprisingly, this approach has had limited success in a 
complex, interrelated, redundant signal system/pathway. 
4.4.1 Inflammation and angiogenesis 
Accumulating evidence supports a link between inflammation and angiogenesis. The two 
processes are intimately intertwined in inflammation-associated wound healing and tissue 
regeneration. Thus, the acute gene response set off by the innate immune process results in 
cytokines, chemokines, and growth factors produced at the site of the injury, which not only 
induce inflammation but also successive tissue repair. Angiogenesis is an important 
component of this tissue repair as evidenced by increased expression of VEGF. The 
inflammation-induced wound healing includes, in addition, pro-angiogenic factors such as 
basic fibroblast growth factor (bFGF), TGF-β, TNF-α, insulin-like growth factor-1 (IGF-1), 
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monocyte chemotactic protein-1 (MCP-1), IL-6 and IL-8, PDGF, to name but a few, which 
attract endothelial cells, smooth muscle cells, and epithelial cells needed for vessel growth 
and maturation.  
Chronic inflammation leading to different pathological states, such as obesity-induced 
diabetes, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, and cancer, 
nevertheless have a common gene activation process and angionesis component. That 
chronic inflammation leads to diverse pathologic states involving the same molecular events 
should not be a surprise if one recognizes the commonality of inflammation and wound 
repair in all tissues, despite their varied differentiated states. Organ specific diseases do not 
negate common mechanisms of wound repair and angiogenesis in each. 
4.4.2 Toll-like receptor signaling in inflammation and angiogenesis 
To date, most studies linking TLR signaling to angiogenesis are in vitro and are largely 
descriptive. Thus, there is literature describing the use of several TLR agonists to induce 
expression and secretion of multiple angiogenic factors in an array of different cell types in 
vitro. The majority, however use LPS to stimulate TLR4 signaling with increased VEGF as a 
marker of angiogenesis.  
1. LPS activation of TLR4 signaling in vitro increases adenosine promotion of angiogenesis 
through the A2A Receptor system to increase VEGF (Hara et al., 2009). This cardio-
protective nucleoside stimulates angiogenesis by increasing VEGF in macrophages, 
thereby likely offering tissue protection after ischemic injury. Moreover, there is a 
synergistic down-regulation of TNF-α (Leibovich et al., 2002). This angiogenic “switch” 
was noted also with TLR2, TLR7, and TLR9 agonists (Pinhal-Enfield et al., 2003). There 
is an in vivo correlate, since MyD88-deficient mice had decreased generation of new 
capillaries in response to an A2AR agonist (Macedo et al., 2007). 
2. LPS-increased TLR4 signaling was shown to increase endothelial sprouting in vitro via a 
TRAF6, NF-κB, JNK stimulatory process (Pollet et al., 2003). The requirement for TRAF6 
in vitro and in vivo was established using a retrovirally expressed dominant negative 
TRAF6 in endothelial cells (Pollet et al., 2003). Moreover, inhibition of c-Jun N-terminal 
kinase (JNK) activity or NF-κB activity downstream of TRAF6 inhibited LPS-induced 
endothelial sprouting. Inhibition of only NF-κB but not JNK activity blocked bFGF, not 
TRAF6 induced angiogenesis. In sum, a direct endothelial role of TLR4 activation via 
TRAF6 is important in inducing angiogenesis in endothelial cells (Pollet et al., 2003). 
This has a pathologic counterpart in pathological corneal neovascularization that can 
cause impaired vision when induced by infections wherein TLR4 and VEGF are 
increased (Rodriguez-Martinez et al., 2006).  
3. Bactonella henselae infections increase MCP-1 in endothelial cells, which chemotactically 
attracts monocytes to produce VEGF and increase angiogenesis (McCord et al., 2005). 
This is an NF-κB dependent process independent of TLR4 or LPS. 
4. The TLR4/MyD88 signal system is important in VEGF production and angiogenesis in 
liver endothelial cells stimulated with LPS (Jagavelu et al., 2010). 
5. Mycoplasma infections of the pulmonary tract causing a chronic inflammatory process 
increase angiogenesis and vascular remodeling (McDonald, 2001). This appears to be 
associated with a TLR2/6-dependent induction of NF-κB and a MAPK cascade by a 2 
kDa macrophage activating diacylated lipopeptide (MALP-2) present in the 
Pancreatic Cancer – Molecular Mechanism and Targets 378 
mycoplasma and secretion of GM-CSF from endothelial cells and monocytes. MALP-2 
induced angiogenesis in vitro and in vivo is suppressed by GM-CSF, explaining both 
angiogenesis and remodeling in the same tissues.  
6. Increased VEGF in chondrocytes and VEGF and IL-8 in fibroblasts are associated with 
inflammatory cell induced angiogenesis in chronically inflamed joints associated with 
arthritis. This progressive self-destructive angiogenic process involves a peptidoglycan 
(PGN) TLR2 ligand from Gram-positive bacteria (Cho et al., 2007).  
4.4.3 Toll-like receptor signaling in tumor angiogenesis 
Cancer is associated with, or induced, by chronic inflammation. Nevertheless, a clear 
definition of TLR induced angiogenesis varies because of the diversity of cancers and 
incomplete studies of all.  
In gastric cancer linked to chronic H. pylori infections, cyclooxygenase 2 (COX-2) plays a 
critical role. Thus, H. Pylori activation of TLR2 and TLR9 signals activate the MAPK cascade 
leading to increased COX-2 and COX-2-dependent prostaglandin E2 (PGE2) release. This 
contributes to cancer cell invasion and angiogenesis (Chang et al., 2005). The COX-2 increase 
can be attenuated by the specific COX-2 inhibitor, NS398 or celecoxib. The cAMP response 
element (CRE) and AP-1 sites, but not NF-κB on the COX-2 promoter, are involved in 
MAPK-regulated COX-2 expression. Differential binding of CREB-1, ATF-2, and c-jun to the 
CRE site and c-fos, c-jun, and ATF-2 to the AP1 site were demonstrated and attenuated by 
different MAPK inhibitors as well as mutants of TLR2 and TLR9. In sum, these results 
showed that H. pylori activated TLR2 and TLR9 to activate MAKs, particularly p38, and 
downstream transcription factors (CREB-1, ATF-2, c-jun, and c-fos) resulting in activations 
of CRE and AP-1 on the COX-2 promoter (Chang et al., 2005). 
Sustained pro-inflammatory processes in cancer, as well as diabetes, atherosclerosis, and 
rheumatoid disease are associated with increased angiogenesis and disease progression. 
Necrotic cells release high mobility group B1 (HMGB1), a pro-inflammatory cytokine, 
which signals TLR2 and TLR4 and the receptor for advanced glycation end products 
(RAGE) to increase angiogenesis by up-regulating NF-κB and VEGF in hematopoietic cells 
and endothelial cells (van Beijnum et al., 2008). HMGB1 seems to be involved in a positive 
feedback mechanism that sustains inflammation and angiogenesis contributing to disease 
progression. Endothelial cells express HMGB1 as well as RAGE receptors, TLR2 and 
TLR4. The HMGB1 can increase NF-κB activity, which can, in turn, increase HMGB1 
receptors.  
Inflammation-induced oxidative stress and angiogenesis are a common theme in tissue 
regeneration and remodeling in cancers. End products of lipid oxidation, such as ω-(2-
carboxyethyl)pyrrole (CEP), are generated, accumulate, and are recognized by TLR2 in 
endothelial cells, leading to a MyD88-dependent angiogenic responses independent of 
VEGF (West et al., 2010). These endogenous ligands accumulating during cancer-induced 
tissue disruption promote angiogenesis via a TLR-dependent pathway. Grote, et. al., 
summarize this visually in Figure 4 of their review (Grote et al., 2011). 
Nevertheless, a counter-regulatory TLR path can be activated as well, which inhibits 
angiogenesis and cancer progression. For example, the immune-modulatory TLR9 agonist, 
IMO, inhibits micro-vessel formation and cancer growth (Damiano et al., 2006). Similarly the 
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TLR7 agonist imidazoquinoline and the TLR9 agonist un-methylated cytosine- phosphate-
guanosine (CpG) oligonucleotide exhibit strong local activity against leukemia in Phase I/II 
trials at different centers (Spaner & Masellis, 2007). Their importance appears, however, to 
be to sensitize CLL cells to other cytotoxic agents so any future lies with combined 
chemotherapy, radiotherapy, or other more “toxic” agents. 
Resistance to anti-HER2 monoclonal antibody, trastuzumab is an issue in breast cancer 
patients. The novel Toll-like receptor 9 (TLR9) agonist termed IMO, immune modulatory 
oligonucleotide, potentiates the anti-EGFR/HER2 signaling of monoclonal trastuzumab. It 
modulates a functional interaction between TLR9 and HER receptors at a membrane level, 
producing a cooperative antiangiogenic effect (Damiano et al., 2009).  
In skin cancer, strategies to inhibit neovascularization and angiogenesis include blockade of 
COX-2, m-TOR, sonic hedgehog, growth factor receptor activation, and activation of TLR by 
imiquimod (Li & Li, 2008). Separately, Myricetin, a phytochemical from onions, berries and 
red wine, suppresses ultraviolet (UV) B-induced angiogenesis by inhibiting PI-3 kinase 
activity in vivo in mouse skin. The chronic UVB exposure induced neovascularization that is 
associated with increased VEGF, matrix metalloproteinase (MMP)-9 and MMP-13 
expression. The myricetin inhibited UVB-induced hypoxia inducible factor-1α expression. 
The myricetin effect was associated with attenuation of UVB-induced PI-3kinase activity 
and phosphorylation of Akt/p-70(S6K) (Jung et al., 2010). 
The complexity of TLR3 action in individual tumors with both increased and decreased 
angiogenic activity was suggested in vitro by Paone, et al. (Paone et al., 2010). These authors 
had shown TLR3 activation in LNCaP and PC3 lines, with more efficiency in the former cells 
from a less aggressive tumor. They subsequently describe novel pro-tumor machinery. 
Triggered by TLR3 activation by polyI:C in PC3 cells, they show increased expression of the 
specific 1.3 isoform of HIF-1 alpha and nuclear accumulation of this complex in PC3 cells 
with decreased apoptosis and in secretion of functional VEGF. This is not the case in less 
aggressive LNCaP cells. However, in both cell lines, transfection of the 1.3 isoform of HIF-1 
alpha causes decreased apoptosis and increased secretion of functional VEGF. They suggest 
basal levels of the 1.3 isoform of HIF-1 alpha distinguish differential responses to TLR 
activation. 
In sum, the role of TLR in inducing signaling to increase tumor growth and angiogenesis is 
clear but largely poorly defined. Nevertheless, Grote et al. and others (Chang et al., 2005; 
Spaner & Masellis, 2007; Damiano et al., 2009) suggest that future modulation of TLR 
signaling could be the basis for a therapeutic approach to cancer and inhibition or control of 
abnormal angiogenesis to limit tumor growth. However, this is potentially difficult because 
not only are there TLR-induced pro-angiogenic signals but also anti-angiogenic signals. 
Moreover, the different cells interacting in the process present a complex network to control. 
Trials of anti-VEGF monotherapy provide a caution as well (Freedman et al., 2002; Henry et 
al., 2003) since they have not yielded consistent beneficial results. It is now recognized that 
not one (VEGF) but a multiplicity of potent angiogenic factors act in concert with VEGF for 
proper vessel formation and maturation (Augustin et al., 2009; Gridley, 2010). Rather than a 
unique anti-angiogenic “bullet,” what may be needed is a broadly acting agent acting on a 
multiplicity of cells and a multiplicity of steps in the TLR stimulated cascade as in the case 
of diabetes.  
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5. TLR Involvement in pancreatic cancer 
Toll-like receptors were first implicated in the pathogenesis of pancreatic cancer in 2009 in 
two separate reports. First, TLR3 was first described by our laboratory to play a role in the 
regulation of pancreatic cancer growth and migration. In this report we demonstrated that 
TLR3 and Wnt5a were coordinately constitutively expressed in a human pancreatic cell line 
(PANC-1) derived from a human pancreatic ductal adenocarcinoma, and that 
phenylmethimazole (a TLR signaling inhibitor) inhibits growth and migration of these 
pancreatic cancer cells in cell culture and inhibits pancreatic cancer tumor growth in vivo in 
a nude (nu/nu mice, which lack T cells) mouse model of human pancreatic cancer (Schwartz 
et al., 2009). In a separate 2009 report, Ikebe et. al., showed that LPS activation of the 
TLR4/MyD88 signaling pathway increases the invasive ability of PANC-1 and Aspc-1 
(another pancreatic cancer cell line derived from a human pancreatic ductal 
adenocarcinoma) cells, while blockade of TLR4, MyD88, or NF-kB signaling decreases the 
LPS-dependent increased invasive ability (Ikebe et al., 2009). Together, these studies were 
the first to implicate TLR expression and signaling in pancreatic cancer cells as playing a 
role(s) in pancreatic tumor growth and migration. These studies helped establish that TLR 
expression and signaling in the pancreatic cancer cells (i.e. non-immune cells) themselves 
may be an important contributor to disease development, an idea that is now widely 
accepted for a multitude of autoimmune/inflammatory diseases including cancer. As briefly 
mentioned earlier, clinical relevance of these findings has recently been noted in a study that 
investigated the expression and clinical relevance of TLR4, NF-B, and hypoxia-inducible 
transcription factor- (HIF-1) in pancreatic adenocarcinoma (Zhang et al., 2010). In this 
study, TLR4 and HIF-1 expression was measured via real time polymerase chain reaction 
(PCR) in 30 cases of pancreatic ductal adenocarcinoma and its adjacent tissues, and TLR4, 
NFB, p65, and HIF-1 protein expression was measured by immunohistochemistry in 65 
cases of pancreatic ductal adenocarcinoma and 38 cases of corresponding adjacent tissues. In 
addition, the relationship between TLR4 or HIF-1 and pathologic features, and the 
association between TLR4 and HIF-1were also analyzed. The Kaplan-Meier method was 
used to assess the impact of expression of TLR4 and HIF-1 on survival of the patients with 
pancreatic cancer. Results of these analysis revealed that TLR4, NF-B, and HIF-1 are all 
overexpressed in pancreatic adenocarcinoma, that TLR4 may regulate HIF-1 expression, 
and that TLR4 and HIF-1 act synergistically to promote the development of pancreatic 
adenocarcinoma.  
6. TLRs as potential therapeutic targets for pancreatic and other cancers 
The therapeutic use of TLR agonists has been investigated in several cancer models. The 
rationale for inducing TLR signaling in a tumor setting is that: (a) TLR signaling will target 
tumor cells, inducing apoptosis or inhibiting the generation of factors that augment tumor 
growth or, (b) TLR signaling will enhance a resident or therapy-driven antitumor immune 
response that will eventually lead to tumor cell destruction. At present, mixed results have 
been obtained using TLR agonists against different TLRs. For example, with respect to the 
effect of TLR agonists on tumor cells, it has been shown in mouse breast xenograft cancer 
models that the antitumor effect of TLR3 agonists was dependent on the expression of TLR3 
receptors in tumor cells, and that dsRNA treatment improved outcomes in patients 
harboring TLR3-positive breast tumors (Salaun et al., 2011). Similarly, CpG treatment was 
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able to trigger tumor cell death in human neuroblastoma cells, and tumor-targeted delivery 
of this TLR9 agonist increased survival in a xenograft model of mouse neuroblastoma 
(Brignole et al., 2010). In human patients harboring low-grade B-cell lymphoma, when CpG 
was delivered intratumorally in combination with radiotherapy almost 50% of the patients 
showed complete regression (Brody et al., 2010). CpG molecules were able to interact with 
the transformed B cells that express TLR9 receptors. 
Treatment with TLR agonists has also shown to induce an antitumor response by either 
enhancing dendritic cell (DC) vaccination or T cell adoptive therapies. For example, tumor-
localized delivery TLR agonists such as poly(I:C) or CpG combined with adoptive transfer 
immunotherapy was effective to control tumor growth in an established model of 
aggressive murine B16F10 melanoma(Amos et al., 2011). In particular, it is proposed that 
TLR agonists enhance T cell adoptive therapy by inducing a better interaction of these cells 
with activated resident DCs and by augmenting the activity of these T cells through IFNγ 
induction (Amos et al., 2011). TLR agonists have also been proposed as adjuvants for DC 
antitumor vaccination. In particular, TLR agonists have been shown to enhance the efficacy 
of DC vaccines in mouse models of melanoma and brain tumors (TLR7/8 agonist) (Prins et 
al., 2006; Ma et al., 2010), sarcoma (TLR3/9 agonists) (Zheng et al., 2008); or lung tumors 
(TLR9)(Cho et al., 2009) among others. 
On the other hand, it has also been shown that TLR agonists can promote cancer cell 
survival and migration, and tumor progression. For example, TLR agonists have been 
shown to increase tumor viability and metastasis of human lung cancer cells (TLR7/8) 
(Cherfils-Vicini et al., 2010); proliferation of human myeloma cells (TLR3) (Chiron et al., 
2009); adhesion and metastasis of human colorectal cancer cells (TLR4) (Hsu et al., 2011); 
and migration of human glioblastoma (TLR4) or human breast cancer cells (TLR2) 
(Thuringer et al., 2010).  
We considered that these contradictory results are due to the complex nature of the tumor 
microenvironment. Tumors are more than cancer cells; they are also composed of non-
tumor cells and the extracellular matrix. In particular, in pancreatic cancer the tumor 
microenvironment is composed of endothelial cells, leukocytes (lymphocytes, macrophages, 
dendritic cells, mast cells and neutrophils), mesenchymal cells (stellate cells and fibroblasts), 
neural cells and an extracellular matrix rich in fibronectin, collagen and periostin (Farrow et 
al., 2008; Erkan et al., 2011). These components of the tumor microenvironment often 
support tumor cell growth, or suppress immune responses against tumor cells. For example, 
stellate cells mediate fibrosis by generating high amounts of extracellular matrix 
components (Masamune et al., 2009), while fibroblasts release hepatocyte growth factor (Xu 
et al., 2010) facilitating tumor cell proliferation. Similarly, macrophages generate cytokines 
and growth factors (Pinhal-Enfield et al., 2003) that stimulate both tumor cell proliferation 
and angiogenesis. However the tumor microenvironment can also hamper therapeutic 
efforts. In addition, the nature of the tumor endothelium can prevent the delivery of 
antitumor factors within the tumor as has been previously shown for ovarian cancer 
(Buckanovich et al., 2008). In the same way, the presence of tumor-associated regulatory T 
cells or myeloid derived suppressor cells can render attempts to generate a powerful 
antitumor immune response by therapeutic vaccination ineffective (Whiteside, 2008).  
Interestingly, although both tumor cells and tumor-associated leukocytes can express TLR, 
their signaling can induce the generation of different molecules (Palha De Sousa et al., 2010). 
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Thus, TLRs are present both in tumor cells and leukocytes, but may have different activities. 
Further, the signaling pathway may be not the same among different leukocyte populations 
such as T cell or antigen presenting cells. Indeed, TLR signaling on mast cells (Oldford et al., 
2010) or Tregs cells (Zhang et al., 2011) may contribute to tumor inhibition, while TLR 
signaling on macrophages can contribute to tumor progression (Pinhal-Enfield et al., 2003). 
Thus there are diverse effects that TLR signaling can induce on different cells within the 
tumor microenvironment. Together, this data argues for specific targeting of tumor 
microenvironment components when applying TLR agonist therapies for cancer. For 
example, TLR agonists can be prepared for their delivery to particular cells within the tumor 
microenvironment (Bourquin et al., 2010). This type of strategy was successfully used to 
activate tumor-associated DCs in ovarian cancer, promoting antitumor immune response in 
vivo (Cubillos-Ruiz et al., 2009; Scarlett et al., 2009).  
On the other hand, the use of TLR antagonists may prove beneficial for those tumors in 
which the tumor microenvironment promotes tumor cell survival and metastasis upon TLR 
signaling. TLR antagonists might also decrease the levels of activation of stromal cells, such 
as tumor-associated macrophages. Macrophages express an array of TLRs and are able to 
produce several growth factors via TLR signaling (Pinhal-Enfield et al., 2003). Moreover, 
abrogation of TLR-4 signaling in tumor-associated macrophages was able to decrease tumor 
growth (Lee et al., 2009). In particular for pancreatic cancer, it has been shown that TLR3 
and TLR4 signaling promotes the invasiveness of pancreatic tumor cells (Ikebe et al., 2009). 
In this context, our recently published manuscript showing that C10 inhibited tumor growth 
in an in vivo model of pancreatic cancer highlights the relevance of using TLR antagonists 
for tumor therapies (Schwartz et al., 2009). Since C10 abrogates both TLR3 and TLR4 
signaling (Schwartz et al., 2009; McCall et al., 2010), this molecule will be extremely relevant 
as a novel therapeutic agent for the treatment of those cancers whose microenvironment 
induces tumor progression via TLR signaling. 
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Thus, TLRs are present both in tumor cells and leukocytes, but may have different activities. 
Further, the signaling pathway may be not the same among different leukocyte populations 
such as T cell or antigen presenting cells. Indeed, TLR signaling on mast cells (Oldford et al., 
2010) or Tregs cells (Zhang et al., 2011) may contribute to tumor inhibition, while TLR 
signaling on macrophages can contribute to tumor progression (Pinhal-Enfield et al., 2003). 
Thus there are diverse effects that TLR signaling can induce on different cells within the 
tumor microenvironment. Together, this data argues for specific targeting of tumor 
microenvironment components when applying TLR agonist therapies for cancer. For 
example, TLR agonists can be prepared for their delivery to particular cells within the tumor 
microenvironment (Bourquin et al., 2010). This type of strategy was successfully used to 
activate tumor-associated DCs in ovarian cancer, promoting antitumor immune response in 
vivo (Cubillos-Ruiz et al., 2009; Scarlett et al., 2009).  
On the other hand, the use of TLR antagonists may prove beneficial for those tumors in 
which the tumor microenvironment promotes tumor cell survival and metastasis upon TLR 
signaling. TLR antagonists might also decrease the levels of activation of stromal cells, such 
as tumor-associated macrophages. Macrophages express an array of TLRs and are able to 
produce several growth factors via TLR signaling (Pinhal-Enfield et al., 2003). Moreover, 
abrogation of TLR-4 signaling in tumor-associated macrophages was able to decrease tumor 
growth (Lee et al., 2009). In particular for pancreatic cancer, it has been shown that TLR3 
and TLR4 signaling promotes the invasiveness of pancreatic tumor cells (Ikebe et al., 2009). 
In this context, our recently published manuscript showing that C10 inhibited tumor growth 
in an in vivo model of pancreatic cancer highlights the relevance of using TLR antagonists 
for tumor therapies (Schwartz et al., 2009). Since C10 abrogates both TLR3 and TLR4 
signaling (Schwartz et al., 2009; McCall et al., 2010), this molecule will be extremely relevant 
as a novel therapeutic agent for the treatment of those cancers whose microenvironment 
induces tumor progression via TLR signaling. 
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Growth factor receptors are transmembrane glycoproteins involved in many aspects of cell 
biology ranging from protein and nucleic acid synthesis, cell growth, differentiation and 
migration to ultimate death of cells (Kiel et al., 2010; Lemmon et al., 2010). On binding by 
growth factors, the receptors undergo dimerization and autophosphorylation (Burz et al., 
2009; Prenzel et al., 2001). The receptor phosphorylation is in turn responsible for recruiting 
intracellular molecules so as to form a network of signalling complexes critical for the 
transfer of the signal to downstream events. One class of cytoplasmic proteins recruited in 
such a way is the growth factor receptor binding (Grb) proteins. As the name implies, Grb 
proteins were originally identified because of their ability to associate with growth factor 
receptors (Margolis et al., 1994). Characteristically, Grb proteins form supramolecular 
complexes with growth factor receptors essential for growth factor mediated signal 
transduction (Songyang et al., 1993, 1994), though interactions with non-growth factor 
receptors is also well documented (Margolis et al., 1994; Songyang et al., 1994). Currently 14 
Grb proteins are identified, with several implicated in the genesis and development of 
human cancers (Margolis et al., 1994). 
Growth factor receptor bound protein 7 (Grb7) belongs to a subfamily of Grb proteins 
comprising Grb7, growth factor receptor bound protein 10 (Grb10) (Frantz et al., 1997; 
Lim et al., 2004) and growth factor receptor bound protein 14 (Grb14) (Cariou et al., 2004; 
Holt et al 2005). The Grb7 family of adaptor proteins share high sequence and functional 
homology (Songyang et al., 1993; Holt et al 2005). The group was discovered using a 
technique dubbed CORT (cloning of receptor targets), an expression/cloning system that 
uses a tyrosine phosphorylated receptor as a probe to screen protein libraries (Margolis et 
al., 1992). Specifically, Grb7 was identified using CORT screening of a mouse cDNA 
expression library with tyrosine phosphorylated C-terminus of the epidermal growth 
factor receptor (Skolnik et al., 1991; Lowenstein et al.,1992). In common with other 
adaptor proteins, Grb7 facilitates the coupling of multiple transmembrane and 
cytoplasmic receptors to downstream effectors molecules (Margolis et al., 1994; Yokote et 
al., 1994). Grb7 has attracted particular attention since it was noticed to be massively 
overexpressed, along with EGFR2, in a number of cancers including pancreatic cancer 
(Stein et al., 1994; Tanaka et al., 1997). 
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1.1 Expression of Grb7 
The human Grb7 gene is located on the positive strand of chromosome 17. Cytogenetic 
analysis shows that the gene is mapped to the 17q12-q21 loci, as documented by the 
National Centre for Biotechnology Information(NCBI) (http://www.ncbi.nlm.nih.gov/ 
mapview/). The human Grb7 gene is 9, 352 nucleotides in length and known to encode a 
primary Grb7 RNA transcript of 4,596 nucleotides in size with the mature Grb7 mRNA 
known to be composed of 14 exons comprising 1,599 nucleotides. The chromosomal location 
of Grb7 is found within the erbB2 amplicon (Lucas-Fernández et al.,2008; Kauraniemi et al., 
2007), a region known to comprise genes frequently over amplified in cancers (Mano et 
al.,2006). As will be described later, the localization of Grb7 on this amplicon appears to 
explain the occurrence of Grb7 over-expression. Fig. 1 shows the overall organization of 
Grb7 gene and its products. 
 
Fig. 1. The overall organization of Grb7 and its products. Grb7 is localized on the long arm 
of chromosome 17, at 17q12-q21. It is comprised of 14 exons, indicated by filled boxes. In 
Grb7 mRNA all the exons are merged and represented by single full filled rectangle. The 
numbers on top of each structure represent the start and end of a given nucleotide sequence. 
Grb7 amino acids are represented by a string of ellipses. 
Grb7 protein displays a distinct expression profile across species, tissues and organs 
(Margolis et al., 1992). Under normal conditions it is expressed in human tissues including 
placenta, intestine, brain, lung, kidney, esophagus, mouth, prostate, mammary gland, 
uterus, ovary, cervix, liver, pancreas, testis, embryonic tissue, lymph node, trachea, larynx, 
bladder, thymus, skin, eye, ascites, stomach, pharynx and connective tissue [Unigene, 
www.ncbi.org].  Grb7 is an intracellular protein primarily found in the cytosol though it is 
localised to focal contacts, mitochondria and cell membrane under certain circumstances 
(Shen et al., 2004). In addition, Grb7 is found to be localized as an integral component of 
stress granules (Tsai et al., 2008). It is found to be conserved amongst mammals as the gene 
and its protein product are found in a number of mammalian species with high sequence 
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homology. Nonetheless, it is the over expression of Grb7 that is associated with a number of 
human maladies such as pancreatic and other cancers. 
1.2 Grb7 as a mediator of multiple signalling pathways 
Grb7 was initially identified as a binding partner of growth factor receptor (Margolis et al., 
1992; Han et al., 2001). It has been shown in numerous studies to interact with a diverse 
spectrum of biomolecules since its initial identification. These include the various growth 
factor receptors, transmembrane receptor tyrosine kinases, cytoplasmic protein kinases (in 
particular focal adhesion kinase (FAK)), phosphatases, GTPases, ligases, adaptor proteins, 
caveolins, phosphoinositides and other biomolecules (Shen et al., 2004; Han et al., 2001; Daly 
et al., 1998; Holt et al., 2005). These binding partners are known to participate in a myriad of 
biochemical signalling in their own right. Noteably, while a large number of binding 
partners functioning upstream of Grb7 have been identified, the precise downstream events 
leading to Grb7 effects are not yet elucidated. The most recent data suggest that Grb7 is able 
to recruit RasGTPases leading to phosphorylation of ERK1/2 and cell proliferation (Chu et 
al., 2010). Another set of studies have identified interactions between Grb7, RNA and the 
RNA-binding protein HuR leading to the proposal that Grb7 can act at the level of 
translational regulation (Tsai et al., 2007, 2008). 
 
Fig. 2. Grb7 as a mediator of several signalling pathways. 
Fig. 2 displays various identified binding partners of Grb7. Importantly, many upstream 
binding partners of Grb7 are connected with cancer cell properties (Pero et al., 2003; 
Golubovskaya et al., 2009). For example, the integrin pathway via FAK is important for cell 
migration (Golubovskaya et al., 2009 ; Zhao et al., 2009). In addition, various growth factor 
receptors are frequently implicated in growth and proliferation of cancer cells (Witsch et al,. 
2010). Indeed there are clinically available anticancer drugs in use that act on EGFR2 such as 
Trastuzumab (Herceptin®)( Roy et al., 2009), Erlotinib(Tarceva®)(Kim et al., 2002), and 
Gefitinib(Iressa®)( Velcheti et al., 2010). Trastuzumab is a humanized monoclonal antibody 
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Grb7 amino acids are represented by a string of ellipses. 
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www.ncbi.org].  Grb7 is an intracellular protein primarily found in the cytosol though it is 
localised to focal contacts, mitochondria and cell membrane under certain circumstances 
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stress granules (Tsai et al., 2008). It is found to be conserved amongst mammals as the gene 
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2010). Indeed there are clinically available anticancer drugs in use that act on EGFR2 such as 
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that binds to the extracellular domain of EGFR2 whereas Gefitinib and Erlotinib are a small 
molecule drugs binding to the ATP binding site of the intracellular kinase domain of the 
receptor. Apart from the above shown interaction partners of Grb7, a number of membrane 
bound macromolecules such as phosphoinositides are reported as important partners of 
Grb7 mediated signalling (Reiske et al., 2000). 
2. Grb7 in pancreatic cancer  
Grb7’s overexpression in cancer cells has prompted investigation of its role in different 
properties of cancer cells such as migration, proliferation, invasion and metastasis. Other 
disease states related with cell development have also been at the centre of investigation. 
Pancreatic cancer is among the most aggressive and leading causes of cancer deaths 
worldwide (Bardeesy et al., 2002). The clinical relevance of Grb7 expression in pancreatic 
cancer was studied by Tanaka and co-workers with the application of immunohistochemical 
analysis (Tanaka et al., 2006). Through a comparative study of Grb7 overexpression in 
normal vs maliginant cells, they showed that Grb7 was expressed in 61% of pancreatic 
cancer cell lines as compared to non-cancerous samples. Furthermore, the study reported 
Grb7 and erbB2 genes co-amplification as high as 59% in the pancreatic tumour cells that 
overexpress Grb7 but not in those cells that did not over express Grb7. Furthermore, 
upregulation of Grb7 has also been separately reported in pancreatic cancer cell lines 
(Jonson et al., 2003). 
Interestingly, Grb7 overexpression was noted to contribute to the migratory, proliferative, 
metastatic and invasive properties of pancreatic cancer cells. For example, in a study of 
patients with lymph node metastasis, Grb7 overexpression was noted in 67% of the studied 
cases, indicating a relationship between Grb7 level and metastatic potential of pancreatic 
tumours (Tanaka et al., 2006). In a cell motility assay, Grb7 over-expression was shown to 
directly correlate with the migratory potential of NIH 3T3 cell lines, particularly when it is 
phosphorylated by FAK (Han et al., 1999). In addition, the association of Grb7 with FAK is 
reportedly an important factor in the regulation of cell proliferation, and cancer cell growth 
indicating the crucial role of Grb7 in tumourigenesis. To further evaluate the role of Grb7 in 
mediating tumourigenesis, BrdU incorporation assay was conducted on A431 carcinoma 
cells to find out that the knockdown of Grb7 resulted in an evident inhibition of cell 
proliferation (Chu et al., 2009). A similar conclusion was reached with the use of siRNA to 
knockout Grb7 and assess its impact on pancreatic cancer cell migration by Tanaka et al. 
They showed that the use of siRNA to knock down Grb7 in pancreatic cell was associated 
with reduction of migratory potential of pancreatic cancer cell lines (Tanaka et al., 2006). In a 
recent experiment, Furuyuma and co-workers have examined the signicance of FAK in 
pancreatic cancer formation to discover that FAK was expressed in up to 48 % of the studied 
cases and, importantly, its expression was found to relate to tumour size (Furuyama, et al., 
2006). Since Grb7 is a binding partner of FAK and Grb7 over expression has been implicated 
in tumour size of other cancers, it might be the case that Grb7 has been co-implicated in the 
pancreatic tumour size. Genes on 17q12-q22 chromosomal region, which also includes the 
Grb7 locus, are noted to be amplified in some pancreatic tumours (Bashyam et al., 2005).  
Finally, the druggability of Grb7 protein has been investigated by using a specific peptide 
inhibitor on different properties of cancer cells. With the use of cell migration experiments 
using a modified Boyden assay, a Grb7 peptide inhibitor was found to have a reduced the 
Grb7 – A Newly Emerging Target in Pancreatic Cancer 403 
migratory potential of a pancreatic cell line. This was specifically noted in pancreatic cancer 
cell lines that over expressed Grb7 (such as MiaPaca2 and PK8 cells), but was not found to 
reduce migration of other human pancreatic cancer cell lines that did not over express Grb7 
(such as KLM1 cells) (Tanaka et al., 2006). Likewise, in an attempt to determine whether the 
Grb7 peptide inhibitor could arrest the metastasis of pancreatic cancer cells, Tanaka et al 
performed a peritoneal metastasis experiment to find out that treatment by the peptide 
resulted in a fewer peritoneal metastases of pancreas cancer cells as compared to the control. 
In addition, they report that the number as well as the total weight of tumour nodules per 
mouse was significantly reduced on treatment by the Grb7 selective peptide inhibitor. 
3. Grb7 in other cancers   
Apart from its role in pancreatic cancer, Grb7 has been extensively investigated as a target in 
a number of other human cancers including breast, gastric, hepatic, blood and testicular 
cancers. In breast cancer, for example, it is found to be over-expressed in a number of breast 
cancer cell lines. In particular, its co‐over expression and co‐amplification with ErbB2 is 
widely investigated (Shen et al., 2004). This might emanate from the fact that ErbB2 and 
Grb7 are found on the same chromosomal region at 17q12‐q21, termed the erbB2 amplicon 
(Kauraniemi et al. 2006; Glynn et al., 2020). Moreover, Grb7 and ErbB2 form a functional 
association in growth factor dependent signalling (Holt et al., 2005) and are shown to 
synergistically enhance tumour formation. The mechanism of Grb7 dependent tumour 
formation as described in a recent paper (Chu et al., 2010) is proposed to involve 
Ras‐GTPases which in turn promote phosphorylation of ERK1/2, thereby stimulating 
tumour growth. Moreover, co‐overexpression of Grb7 and ErbB2 have also been associated 
with worse outcomes in some breast cancer subjects (Nadler et al., 2010). The fact that Grb7 
is found within the core of the ErbB2 amplicon at 17q12 is what explains most of the 
co‐implications in breast cancer. However, a study conducted to identify the contribution of 
co‐amplified genes has demonstrated that Grb7 alone may be a factor in breast cancer 
carcinogenesis. With the use of RNA interference technology, it is has been shown that Grb7 
knockout SKBR3 and BT474 breast cancer cell lines possessed decreased cell proliferation 
and cell‐cycle progression (Kao et al., 2006). Furthermore, recent experiments involving 
siRNA have shown that removal of Grb7 by RNA‐interference reduced the viability of 
BT474 xenograft cancer cells and increased the activity of the antitumour drug lapatinib 
(Nencioni et al., 2010). 
Grb7 has also been identified as a culprit in other cancers. For example, in gastric cancer, 
over expression of Grb7 was found in up to 31% of esophageal carcinomas and that the over 
expression was shown to strongly correlate with extra mucosal invasive potential of gastric 
tumours (Tanaka et al., 1997). In a related study, more than 8‐fold amplification and over 
expression of ErbB2 and Grb7 in primary gastric cancer cells was reported and the over 
expression was associated with the development of more aggressive gastric cancer 
phenotypes (Kishi et al., 1997). Similarly, up to 45% Grb7 overexpression was noted in some 
esophageal carcinomas as compared to normal mucosa (Tanaka et al., 2000) which was 
directly related with the development of lymph node metastases (Tanaka et al., 1997) 
suggesting that Grb7 overexpression is a major risk factor in such cancer populations. Itoh et 
al. showed that Grb7 overexpression was correlated with the level of FAK in Hep3B cells 
and that such over expression was a cause for invasive and metastatic potential exhibited by 
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the hepatocellular carcinoma (HCC) cell lines and that suppression of Grb7 expression 
delayed the onset of HCC tumour formation in mice (Itoh et al., 2007). Studies by Haran et 
al showed that Grb7 was not only over expressed but its expression correlated with the 
severity of the Chronic lymphocytic leukemia. They showed that up to 88 % of Grb7 
expression was detected in Stage IV as compared to 18 % in the Stage I of leukemia 
(Haran et al., 2004). In other studies, mutations, copy number and expression levels of 
genes have shown Grb7 to be involved in the development of testicular germ cell tumours 
with up to a 63 % increase in Grb7 expression in primary tumour samples (McIntyre et al., 
2005). These studies indicate the emergence of Grb7 as promising therapeutic target in a 
number of malignancies. The developments efforts made against Grb7 will be discussed 
below. 
4. The molecular architecture of Grb7 protein
Human Grb7 protein is comprised of 532 amino acids. Its constituent residues are organized 
into a number of protein domains that serve different but complementary functions to the 
overall signalling role of Grb7 (Margolis et al., 1994). Grb7 domain components are well 
conserved across the species, and serve similar roles in different proteins (Han et al., 2001; 
Margolis et al., 1994). The modular structure of Grb7 is composed of a proline rich domain, a 
Ras-associating domain, a pleckstrin homology (PH) domain, Src homology 2 (SH2) domain 
and a BPS domain (between the PH and SH2 domains) (Filippakopoulos et al., 2009; 
Pawson, 1994). Fig. 3 illustrates the various domains of Grb7 together with the approximate 
amino acid residue bounds. The amino acid composition and the specific roles of each 
domain will be described in greater detail under each heading.  
 
Fig. 3. The modular organization of Grb7 protein. Numbers indicate the residue number of 
the amino acids. 
4.1 The N-terminal domain  
The N-terminal domain of Grb7 comprises the first 100 residues of Grb7. It is a proline rich 
motif comprising a conserved sequence made of residues PS/AIPNPFPEL and is likely to 
exist as an unstructured domain in the absence of a binding partner. Up until now little has 
been known as to the binding partners of Grb7 via its N-terminal domain. Recently, 
however, experiments have indicated novel potential binding partners. For instance, mouse 
Grb7 has been shown to interact with HuR (Tsai et al., 2008), an RNA-binding protein 
important in regulation of nuclear-to–cytoplasmic shuttling of mRNA (Doller et al., 2008). 
The Grb7-HuR interaction is found to be mediated by the N-terminal domain of Grb7 (Tsai 
et al., 2008). Moreover, mouse Grb7 is also found to bind RNA via its proline rich N-
terminal domain (Doller et al., 2008). These interactions have yet to be verified for human 
Grb7 and their physiological function remain to be elucidated. 
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4.2 The central GM region  
The region of Grb7 bounded by the N- and C-terminal domains is what is referred to as the 
central GM, for Grb and Mig domain (Han et al., 2001). It consists of the longest stretch of 
Grb7 protein comprising about 300 amino acid residues. Its role in Grb7 signalling is much 
more studied and better known compared to the N-terminal domain. It characteristically 
displays more than 50% sequence similarity with the Caenorhabditis elegans protein Mig-10 
(Manser et al., 1997; Ooi et al., 1995) from which it derives part of its name. Mig-10 
(Migratory-10) is established to be critical for cell migration during embryogenesis (Manser 
et al., 1990). The presence of such a conserved sequence with known function lured 
researchers to investigate the role of Grb7 in cell migration, which predictably was proven 
to be the case. It is postulated that it is this domain that makes Grb7 an important cell 
migratory protein (Siamakpour-Reihani et al., 2009; Shen et al., 2002). The GM region is 
known to comprise three well conserved but non-contiguous domains: Pleckstrin homology 
(PH) domain, RA (Ras-associating) domain and a BPS (between PH and SH2) domain (Stein 
et al, 1994; Margolis et al., 1994).  
The PH domain contains is a 110 amino acid long domain corresponding to residues 229-
338 of Grb7. It is suggested to bind membrane bound phosphoinositides, thereby 
assisting Grb7’s association to these molecules. Moreover, it is found to interact with 
FHL2, a signalling protein important in transcription regulation and cytoskeletal re-
arrangement (Siamakpour-Reihani et al., 2009). Recently it is also reported to interact 
with Hax-1 (Hs-1 Associated protein X-1), another protein important in cell migration 
and apoptosis, and to explain a role for Grb7 dimerization in a head to tail manner 
(Siamakpour-Reihani et al., 2009, 2010). As a part of the GM region, it is proposed to play 
a role in cell migration 
The RA domain of Grb7 is 87 amino acids long stretching from residues 100 to 186. Along 
with the PH domain, it is found to be important in the intramolecular dimerization of Grb7 
by interacting with the SH2 domain, where the interaction is found to occur with 
micromolar affinity (Siamakpour-Reihani et al., 2010; Depetris et al., 2009). The phenomenon 
of dimerization is an important mechanism for the functioning of Grb7 (Porter et al., 2005). 
The RA domain is found in a number of proteins. It is also suggested to have a role in the 
involvement of Grb7 in Ras signalling pathway and for cell proliferation (Stein, et al, 2001). 
Together with the PH domain, the RA domain is reported to interact with the Hax-1 protein 
(Siamakpour-Reihani et al., 2010). 
The BPS domain is a functional region of about 65 residues corresponding to residues 
365-413 of Grb7. It is found between the PH and SH2 domain. The BPS region is thought 
to facilitate the interactions of SH2 domain to upstream partners of Grb7 (Stein, et al, 
2001). Moreover, it is suggested the BPS domain could contribute to the specificity of Grb7 
binding to its partners (Stein et al., 2003; Scharf et al., 2004). In the other Grb7 families 
such as Grb10 and Grb14, the BPS domain is found to interact with the activated IR and 
IGFR (He et al., 1998). It displays up to 60% sequence similarity among the Grb7 family 
members, The BPS domain is found to be intrinsically unstructured (Moncoq et al., 2003), 
though a very short structured stretch of about 9 residues was identified for Grb14 protein 
(Moncoq et al., 2004). 
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been known as to the binding partners of Grb7 via its N-terminal domain. Recently, 
however, experiments have indicated novel potential binding partners. For instance, mouse 
Grb7 has been shown to interact with HuR (Tsai et al., 2008), an RNA-binding protein 
important in regulation of nuclear-to–cytoplasmic shuttling of mRNA (Doller et al., 2008). 
The Grb7-HuR interaction is found to be mediated by the N-terminal domain of Grb7 (Tsai 
et al., 2008). Moreover, mouse Grb7 is also found to bind RNA via its proline rich N-
terminal domain (Doller et al., 2008). These interactions have yet to be verified for human 
Grb7 and their physiological function remain to be elucidated. 
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4.2 The central GM region  
The region of Grb7 bounded by the N- and C-terminal domains is what is referred to as the 
central GM, for Grb and Mig domain (Han et al., 2001). It consists of the longest stretch of 
Grb7 protein comprising about 300 amino acid residues. Its role in Grb7 signalling is much 
more studied and better known compared to the N-terminal domain. It characteristically 
displays more than 50% sequence similarity with the Caenorhabditis elegans protein Mig-10 
(Manser et al., 1997; Ooi et al., 1995) from which it derives part of its name. Mig-10 
(Migratory-10) is established to be critical for cell migration during embryogenesis (Manser 
et al., 1990). The presence of such a conserved sequence with known function lured 
researchers to investigate the role of Grb7 in cell migration, which predictably was proven 
to be the case. It is postulated that it is this domain that makes Grb7 an important cell 
migratory protein (Siamakpour-Reihani et al., 2009; Shen et al., 2002). The GM region is 
known to comprise three well conserved but non-contiguous domains: Pleckstrin homology 
(PH) domain, RA (Ras-associating) domain and a BPS (between PH and SH2) domain (Stein 
et al, 1994; Margolis et al., 1994).  
The PH domain contains is a 110 amino acid long domain corresponding to residues 229-
338 of Grb7. It is suggested to bind membrane bound phosphoinositides, thereby 
assisting Grb7’s association to these molecules. Moreover, it is found to interact with 
FHL2, a signalling protein important in transcription regulation and cytoskeletal re-
arrangement (Siamakpour-Reihani et al., 2009). Recently it is also reported to interact 
with Hax-1 (Hs-1 Associated protein X-1), another protein important in cell migration 
and apoptosis, and to explain a role for Grb7 dimerization in a head to tail manner 
(Siamakpour-Reihani et al., 2009, 2010). As a part of the GM region, it is proposed to play 
a role in cell migration 
The RA domain of Grb7 is 87 amino acids long stretching from residues 100 to 186. Along 
with the PH domain, it is found to be important in the intramolecular dimerization of Grb7 
by interacting with the SH2 domain, where the interaction is found to occur with 
micromolar affinity (Siamakpour-Reihani et al., 2010; Depetris et al., 2009). The phenomenon 
of dimerization is an important mechanism for the functioning of Grb7 (Porter et al., 2005). 
The RA domain is found in a number of proteins. It is also suggested to have a role in the 
involvement of Grb7 in Ras signalling pathway and for cell proliferation (Stein, et al, 2001). 
Together with the PH domain, the RA domain is reported to interact with the Hax-1 protein 
(Siamakpour-Reihani et al., 2010). 
The BPS domain is a functional region of about 65 residues corresponding to residues 
365-413 of Grb7. It is found between the PH and SH2 domain. The BPS region is thought 
to facilitate the interactions of SH2 domain to upstream partners of Grb7 (Stein, et al, 
2001). Moreover, it is suggested the BPS domain could contribute to the specificity of Grb7 
binding to its partners (Stein et al., 2003; Scharf et al., 2004). In the other Grb7 families 
such as Grb10 and Grb14, the BPS domain is found to interact with the activated IR and 
IGFR (He et al., 1998). It displays up to 60% sequence similarity among the Grb7 family 
members, The BPS domain is found to be intrinsically unstructured (Moncoq et al., 2003), 
though a very short structured stretch of about 9 residues was identified for Grb14 protein 
(Moncoq et al., 2004). 
Pancreatic Cancer – Molecular Mechanism and Targets 406 
4.3 The C-terminal domain  
By far the most widely investigated and thoroughly characterized region of Grb7 is the C-
terminal Src homology 2 (SH2) domain (Pawson, 1994; Daly, 1997). It corresponds to 
residues 415-535 of the Grb7 protein. SH2 domains are phosphotyrosine peptide binding 
modules that are also found in a number of related proteins (Janes et al., 1997). Indeed, the 
discovery of Grb7 as an adaptor protein was dependent on this property of the SH2 domain. 
It is known to mediate the physical association Grb7 with a diverse array of membrane 
bound and cytoplasmic binding partners of Grb7 (Daly et al., 1998; Margolis et al., 1992). In 
particular, the SH2 domain is responsible for the recognition of specific phosphotyrosines 
(pTyr) residues via a well-described cationic pocket and surrounding peptide-binding cleft 
(Janes et al., 1997). The SH2 mediated association of Grb7 with its binding partners 
commences the first step in Grb7 dependent signal transduction. As such it forms an 
essential module for the variety of Grb7 mediated oncogenic transformations (Daly et al., 
1998; Pero et al., 2003). 
The binding specificity of the SH2 domain to upstream partners of Grb7 has been studied 
and characterized at length (Margolis et al., 1992;Daly et al., 1998). These studies have 
deciphered the sequence around the phosphorylated tyrosine recognized by Grb7 to be 
more or less conserved, from which a recognition motif of the sequence pYXN has been 
established. In other words, the presence of asparagine at a +2 position relative to 
phosphorylated tyrosine (pY) is what the SH2 domain of Grb7 specifically demands of its 
binding partners (Margolis et al., 1992; Daly et al., 1998). The position at +1 to the pY residue, 
indicated as X, is where any amino acid would be tolerated. This condition for recognition 
by SH2 domain is found in the great majority of established Grb7 binding partners 
including erbB2 (Stein et al., 1994) [60], Tek(Jones et al., 1999), c-Kit (Thömmes et al., 1999), 
SHPTP (Keegan et al., 1996), Shc(Frantz et al., 1997), PDGFR (Yokote et al., 1994).  
However, some exceptions has been noted where the +2 Asparagine is not required as in 
FAK (pYAE) (Han et al., 2001), EphB1(pYRD) (Han et al., 2002), cavoelin (pYRD)  
 
Fig. 4. Domain fold of Grb7 SH2 protein. Cartoon representation of the Grb7 SH2 domain 
shown as helix (red); B‐sheet (yellow) and loops (green) and the structural motif labeling.  
Grb7 – A Newly Emerging Target in Pancreatic Cancer 407 
(Lee et al., 2000) or where the tyrosine does not have to be phosphorylated as in 
RndI(YDN)(Vayssière et al., 2000). Typically, the YXN recognition stretch is known to 
bind in a turn conformation as is established for a number of Grb2 antagonist peptides 
reported. 
The experimental structure of Grb7 SH2 domain has been solved both by NMR and X-ray 
crystallography (Porter et al., 2007; Ivancic et al., 2003). The crystal structure is solved to 2.1 
Å resolution with an overall tetrameric assembly by our group (PDB ID: 2QMS). As shown 
in Fig. 4, the Grb7 SH2 domain comprises two pairs of anti-parallel -sheets flanked by a 
pair of -helices (Porter et al., 2007). Such a structure is a general feature of SH2 domain 
proteins (Pawson, 1994; Margolis et al., 1994). According to the accepted nomenclature 
(Margolis et al., 1994), the central anti-parallel β-sheet is formed by the βB, βC and βD loops 
where as the two α-helices are labeled αA and αB (see Fig. 4 for details) which implies that 
the domain fold of Grb7 could be described as αAβBβCβDαB. 
5. The development of Grb7 antagonists  
Grb7 has become a promising target in pancreatic and other human cancers. Though Grb7 is 
a multidomain protein, most of the inhibitor development efforts are focused on the 
identification of agents that interact with its SH2 domain. This is because the SH2 domain 
commences the first and hence the fate determining step in the entire process of Grb7 
dependent signalling (Holt et al., 2005). Moreover, the SH2 domain possesses a well defined 
and characterized binding pocket amenable to a variety of ligand design efforts (Porter et 
al., 2007). In addition, the requirement of the SH2 domain to bind to Grb7’s myriad of 
upstream partners is generally conserved (Margolis et al., 1994; Han et al., 2001) where a 
minimal recognition motif is put forth. These factors endow the SH2 domain as an attractive 
module to target in the development of Grb7 based therapeutic agents. Hence all the Grb7 
antagonists identified are specifically designed to act on the SH2 domain of the protein.  
5.1 Polypeptide antagonists of Grb7 
Inspired by the conservative motif requirement of Grb7 SH2 domain to bind its upstream 
binding partners, Pero et al conducted a PHAGE display experiment to identify the first 
polypeptide antagonist of Grb7 (Pero et al., 2002). The peptide was initially discovered as a 
19 residue polypeptide flanked by Cys residues at positions 1 and 11. Interestingly, it was 
shown that the peptide was inactive in its open form and cyclization via disulphide 
formation was necessary for activity against Grb7. The original 19 residue structure was 
then simplified by removing residues outside the two Cys residues and the disulfide linkage 
was replaced with a thioether moiety to effect the ring closure. This 11 residue cyclic 
polypeptide, named G7-18NATE (sequence: WFEGYDNTFPC), was tested and proved to 
posses the same affinity as the larger disulfide containing form (Pero et al., 2002). An 
important attribute of this lead peptide is its selectivity for Grb7 and the fact that it is not 
phosphorylated. The chemical structure of G7-18NATE is displayed in Fig. 5.  
The binding affinity of the G7-18NATE prototype peptide has been characterized 
extensively by isothermal titration calorimetry (Porter et al., 2007; Spuches et al., 2007; 
Ambaye et al., 2011a), surface plasmon resonance (Gunzburg et al., 2010) and ELISA assays 
(Luzy et al., 2008). Such investigations provide invaluable information that should guide the  
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(Lee et al., 2000) or where the tyrosine does not have to be phosphorylated as in 
RndI(YDN)(Vayssière et al., 2000). Typically, the YXN recognition stretch is known to 
bind in a turn conformation as is established for a number of Grb2 antagonist peptides 
reported. 
The experimental structure of Grb7 SH2 domain has been solved both by NMR and X-ray 
crystallography (Porter et al., 2007; Ivancic et al., 2003). The crystal structure is solved to 2.1 
Å resolution with an overall tetrameric assembly by our group (PDB ID: 2QMS). As shown 
in Fig. 4, the Grb7 SH2 domain comprises two pairs of anti-parallel -sheets flanked by a 
pair of -helices (Porter et al., 2007). Such a structure is a general feature of SH2 domain 
proteins (Pawson, 1994; Margolis et al., 1994). According to the accepted nomenclature 
(Margolis et al., 1994), the central anti-parallel β-sheet is formed by the βB, βC and βD loops 
where as the two α-helices are labeled αA and αB (see Fig. 4 for details) which implies that 
the domain fold of Grb7 could be described as αAβBβCβDαB. 
5. The development of Grb7 antagonists  
Grb7 has become a promising target in pancreatic and other human cancers. Though Grb7 is 
a multidomain protein, most of the inhibitor development efforts are focused on the 
identification of agents that interact with its SH2 domain. This is because the SH2 domain 
commences the first and hence the fate determining step in the entire process of Grb7 
dependent signalling (Holt et al., 2005). Moreover, the SH2 domain possesses a well defined 
and characterized binding pocket amenable to a variety of ligand design efforts (Porter et 
al., 2007). In addition, the requirement of the SH2 domain to bind to Grb7’s myriad of 
upstream partners is generally conserved (Margolis et al., 1994; Han et al., 2001) where a 
minimal recognition motif is put forth. These factors endow the SH2 domain as an attractive 
module to target in the development of Grb7 based therapeutic agents. Hence all the Grb7 
antagonists identified are specifically designed to act on the SH2 domain of the protein.  
5.1 Polypeptide antagonists of Grb7 
Inspired by the conservative motif requirement of Grb7 SH2 domain to bind its upstream 
binding partners, Pero et al conducted a PHAGE display experiment to identify the first 
polypeptide antagonist of Grb7 (Pero et al., 2002). The peptide was initially discovered as a 
19 residue polypeptide flanked by Cys residues at positions 1 and 11. Interestingly, it was 
shown that the peptide was inactive in its open form and cyclization via disulphide 
formation was necessary for activity against Grb7. The original 19 residue structure was 
then simplified by removing residues outside the two Cys residues and the disulfide linkage 
was replaced with a thioether moiety to effect the ring closure. This 11 residue cyclic 
polypeptide, named G7-18NATE (sequence: WFEGYDNTFPC), was tested and proved to 
posses the same affinity as the larger disulfide containing form (Pero et al., 2002). An 
important attribute of this lead peptide is its selectivity for Grb7 and the fact that it is not 
phosphorylated. The chemical structure of G7-18NATE is displayed in Fig. 5.  
The binding affinity of the G7-18NATE prototype peptide has been characterized 
extensively by isothermal titration calorimetry (Porter et al., 2007; Spuches et al., 2007; 
Ambaye et al., 2011a), surface plasmon resonance (Gunzburg et al., 2010) and ELISA assays 
(Luzy et al., 2008). Such investigations provide invaluable information that should guide the  
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Fig. 5. Chemical structures of G7-18NATE lead polypeptide Grb7 antagonist. 
further optimization of this lead polypeptide. The three ITC experiments concur on the 
affinity of the peptide for Grb7 SH2 domain (34.5 M, 13.5 M, 35.7 M) indicating moderate 
affinity binding. Though this represents a breakthrough in Grb7 antagonist development, the 
affinity is not sufficient for animal experimentation. In other words, further optimization is 
necessary to transform the peptide into a clinical candidate. An important clue in this regard is 
afforded by isothermal titration calorimetry where deconvolution of the binding affinity into 
its components shows that the binding of G7-18NATE is enthalpically driven and entropically 
forbidden. This appears in line with the observation that the open form of G7-18NATE is 
devoid of any antagonistic activity (Pero et al., 2002). This knowledge could help in optimizing 
the lead peptide structure so as to improve the affinity. 
Grb7 is an intracellular protein. Since G7-18NATE is a polypeptide, the plasma membrane 
represent a potential obstacle for it use in cellular systems. However, this has been overcome 
by the use of other peptides known to assist in crossing biological membranes. For this 
purpose, G7-18NATE was synthesized with a 19 residue long cell-penetrating sequence 
termed Penetratin for in vivo studies (see Fig. 6). The cell proliferation and migration 
inhibition assay conducted with this cell permeable derivative (G7-18NATE-Penetratin) 
demonstrate the combined effect of membrane crossing (Penetratin) and Grb7 inhibition 
(G7-18NATE) (Tanaka et al., 2006; Pero et al., 2007). Another cell-penetrating peptide with 
an 11 residue arginine rich sequence was also investigated for the cell permeablising effect 
(Pero et al., 2007). Both peptides were shown to have a synergistic effect with Doxorubicin in 
decreasing cancer cell proliferation. A related experiment conducted on pancreatic cancer 
cell migration effect clearly established the potential of G7-18NATE in diverse cancer cell 
lines (Tanaka et al., 2006). Our experience with G7-18NATE is that the length of the 
Penetratin tail can be cut short and still enter cells (Ambaye et al., 2011a). A Penetratin 
sequence consisting of only the last 8 residues was sufficient for membrane translocation of 
G7-18NATE. The cytoplasmic localization of G7-18NATE with this short penetratin was also 
confirmed (Ambaye et al., 2011a). Moreover, the possible interference on binding of G7-
18NATE by the short Penetratin sequence was investigated by ITC and shown not to 
impede G7-18NATE binding. These experiments demonstrate that comparable in vitro-in 
vivo correlations can be achieved with the use of a shorter Penetratin. 
Most recently the structure of the G7-18NATE peptide was determined in complex with the 
Grb7-SH2 domain using X-ray crystallography (Ambaye et al., 2011c). This revealed the 
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critical residues involved in binding the Grb7-SH2 domain, and their conformational 
arrangement. The same study also reported other phage-display derived Grb7-SH2 binding 
peptides with similar binding affinities for Grb7-SH2 domain as the lead G7-18NATE. These 
peptides all possessed the amino acid residues shown by the structure to be critical for 
binding by the structural study. This information will help to guide the design of future 
peptides with improved affinity and maintained specificity for Grb7. 
 
Fig. 6. Sequence and Chemical Structures of cell permeable G7-18NATE derivatives (Pero et 
al., 2007; Tanaka et al., 2007). One letter amino acid symbols in the sequence is indicated in 
bold fonts. 
5.2 Short peptide antagonists of Grb7 
Other short phosphorylated peptides based on the consensus recognition motif have also 
been developed and tested [Howl et al., 2007), see Fig.7. This includes peptides based on the 
sequence around the phosphotyrosine residue of erbB1, erbB2, erbB3 and ephB1 on Grb7 
Pancreatic Cancer – Molecular Mechanism and Targets 408 
 
Fig. 5. Chemical structures of G7-18NATE lead polypeptide Grb7 antagonist. 
further optimization of this lead polypeptide. The three ITC experiments concur on the 
affinity of the peptide for Grb7 SH2 domain (34.5 M, 13.5 M, 35.7 M) indicating moderate 
affinity binding. Though this represents a breakthrough in Grb7 antagonist development, the 
affinity is not sufficient for animal experimentation. In other words, further optimization is 
necessary to transform the peptide into a clinical candidate. An important clue in this regard is 
afforded by isothermal titration calorimetry where deconvolution of the binding affinity into 
its components shows that the binding of G7-18NATE is enthalpically driven and entropically 
forbidden. This appears in line with the observation that the open form of G7-18NATE is 
devoid of any antagonistic activity (Pero et al., 2002). This knowledge could help in optimizing 
the lead peptide structure so as to improve the affinity. 
Grb7 is an intracellular protein. Since G7-18NATE is a polypeptide, the plasma membrane 
represent a potential obstacle for it use in cellular systems. However, this has been overcome 
by the use of other peptides known to assist in crossing biological membranes. For this 
purpose, G7-18NATE was synthesized with a 19 residue long cell-penetrating sequence 
termed Penetratin for in vivo studies (see Fig. 6). The cell proliferation and migration 
inhibition assay conducted with this cell permeable derivative (G7-18NATE-Penetratin) 
demonstrate the combined effect of membrane crossing (Penetratin) and Grb7 inhibition 
(G7-18NATE) (Tanaka et al., 2006; Pero et al., 2007). Another cell-penetrating peptide with 
an 11 residue arginine rich sequence was also investigated for the cell permeablising effect 
(Pero et al., 2007). Both peptides were shown to have a synergistic effect with Doxorubicin in 
decreasing cancer cell proliferation. A related experiment conducted on pancreatic cancer 
cell migration effect clearly established the potential of G7-18NATE in diverse cancer cell 
lines (Tanaka et al., 2006). Our experience with G7-18NATE is that the length of the 
Penetratin tail can be cut short and still enter cells (Ambaye et al., 2011a). A Penetratin 
sequence consisting of only the last 8 residues was sufficient for membrane translocation of 
G7-18NATE. The cytoplasmic localization of G7-18NATE with this short penetratin was also 
confirmed (Ambaye et al., 2011a). Moreover, the possible interference on binding of G7-
18NATE by the short Penetratin sequence was investigated by ITC and shown not to 
impede G7-18NATE binding. These experiments demonstrate that comparable in vitro-in 
vivo correlations can be achieved with the use of a shorter Penetratin. 
Most recently the structure of the G7-18NATE peptide was determined in complex with the 
Grb7-SH2 domain using X-ray crystallography (Ambaye et al., 2011c). This revealed the 
Grb7 – A Newly Emerging Target in Pancreatic Cancer 409 
critical residues involved in binding the Grb7-SH2 domain, and their conformational 
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5.2 Short peptide antagonists of Grb7 
Other short phosphorylated peptides based on the consensus recognition motif have also 
been developed and tested [Howl et al., 2007), see Fig.7. This includes peptides based on the 
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upstream binding partners. The phosphorylated peptides range from 6 to 11 residues with a 
dissociation equilibrium constant varying from 0.6 M to 366 M. Finally, peptides that 
were previously reported as Grb2 antagonists were tested for their inhibitory effect on Grb7. 
Interestingly, the results show that not only do the peptides retain the Grb7 inhibitory effect, 
but that the activity rank is maintained on both Grb2 and Grb7 antagonism, though a 
quantitative difference is observed (Spuches et al., 2007). These peptides, unlike G7-
18NATE, do not show selectivity for Grb7. 
 
Fig. 7. Sequence and chemical structure of phosphorylated peptide antagonists of Grb7 
(Howl et al., 2007). One letter amino acid symbols in the sequence is indicated in bold fonts. 
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5.3 Small molecule antagonists of Grb7 
Recently, we embarked upon identifying small molecule antagonists of Grb7 (Ambaye et al., 
2011b). In particular, the availability of the structure of peptides bound to SH2 domains has 
allowed us to apply series of computational chemistry approaches to idenitify potential 
antagonists of Grb7. Fig. 8 shows the structures of the most potent antagonists. The binding 
activity was examined first with ThermoFluor based denaturation followed by full 
thermodynamic characterization by isothermal titration calorimetry. This correlated with 
growth inhibition of Grb7 oversexpressing cancer cells. The result indicates near equivalent 
micromolar affinity values indicating the potential of non-peptide structures in cell based 




Fig. 8. Small molecule inhibitors of Grb7 (Ambaye et al., 2011b). 
6. Conclusion and future outlook  
Pancreatic cancer remains one of the leading causes of morbidity and mortality with the 
impact expected to rise in our aging societies. The limited efficacy and intolerable toxicity 
of available treatments means novel drugs with a novel mechanism of action are always 
sought. From the clinical standpoint, new targets provide novel drugs, novel mechanistic 
bases and potentially more efficacious means to treat diseases. Given its established role 
in malignancies such as pancreatic cancer and the fact that there is no drug that acts on it, 
Grb7 based drug development is likely to be a promising endeavour in the foreseeable 
future.  
Grb7 is found a diverse array of signalling events critical for carcinogenetic transformation 
of human cells. Its druggablity is proven with the use of synthetic peptides, and an excellent 
start is made with the discovery of a peptide with specificity for Grb7. The major challenge 
for the use of peptide based drugs, however, comes from its intracellular localization. The 
recent development of cell permeable Grb7 antagonists is encouraging, and suggests that 
the permeability issue could be surmounted with little extra effort. Remaining issues to be 
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of human cells. Its druggablity is proven with the use of synthetic peptides, and an excellent 
start is made with the discovery of a peptide with specificity for Grb7. The major challenge 
for the use of peptide based drugs, however, comes from its intracellular localization. The 
recent development of cell permeable Grb7 antagonists is encouraging, and suggests that 
the permeability issue could be surmounted with little extra effort. Remaining issues to be 
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solved, however, include the need for a higher affinity peptide and the generally poor 
stability and metabolism of peptide-based drugs. Though several challenges are still ahead, 
the data obtained so far seem strongly encouraging to pursue Grb7 based anti-tumour drug 
development. 
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1. Introduction 
Resistance to gemcitabine is the major problem in pancreatic cancer chemotherapy, and 
recent evidence suggests that down-regulation of hTERT mRNA could enhance the 
antitumor efficacy of other well known chemotherapy agents targeting DNA. The aim of 
this study was to evaluate the combined antitumor efficacy of antisense oligonucleotides 
(AS-ODN) targeting hTERT mRNA and gemcitabine in human pancreatic cancer cells. Our 
results showed that transient transfection in clones of the human pancreatic cancer cell lines 
BxPC-3 and Panc-1 with 0.2µM hTERT AS-ODN for 24 h diminished the abundance of hTERT 
mRNA and inhibited telomerase activity, but only resulted in a slightly attenuated ability of 
proliferation. While pretreatment with 0.2µM AS-ODN for 24 h followed by gemcitabine in 
BxPC-3 or Panc-1 cells led to tumor cell growth suppression more significantly than 
gemcitabine alone in MTT, and the IC50 of gemcitabine was reduced to about 8.7 times in 
Panc-1 cells, and 4.2 times in BxPC-3 cells. Likewise, after treatment with gemcitabine for 48 h, 
the AS-ODN-transfected cells exhibited significantly decreased colony formation ability 
relative to the parental cells. Apoptosis analysis indicated that hTERT AS-ODN increased the 
gemcitabine-induced apoptosis in both cell lines. All together, these findings implied that 
hTERT AS-ODN could increase the chemosensitivity of gemcitabine through down-regulation 
of hTERT mRNA expression and inhibition of telomerase activity, which may make it an 
attractive agent for the sensitization of pancreatic cancer cells to gemcitabine.  
Pancreatic cancer is one of the most common causes of cancer death in the world. Surgery is 
the only chance for cure, unfortunately, late diagnosis often results in less than 20% of 
patients for tumor resection [1,2]. Gemcitabine, a novel pyrimidine nucleoside analogue, has 
become the standard first-line chemotherapeutic agent used in patients with pancreatic 
cancer [1]. It is, however, moderately effective, showing a tumor response rate of only 12% 
[3] and a median survival time of 5 months [4]. Increasing the susceptibility of pancreatic 
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1. Introduction 
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hTERT AS-ODN could increase the chemosensitivity of gemcitabine through down-regulation 
of hTERT mRNA expression and inhibition of telomerase activity, which may make it an 
attractive agent for the sensitization of pancreatic cancer cells to gemcitabine.  
Pancreatic cancer is one of the most common causes of cancer death in the world. Surgery is 
the only chance for cure, unfortunately, late diagnosis often results in less than 20% of 
patients for tumor resection [1,2]. Gemcitabine, a novel pyrimidine nucleoside analogue, has 
become the standard first-line chemotherapeutic agent used in patients with pancreatic 
cancer [1]. It is, however, moderately effective, showing a tumor response rate of only 12% 
[3] and a median survival time of 5 months [4]. Increasing the susceptibility of pancreatic 
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cancer cells to gemcitabine, therefore, is of importance to the outcome of therapy. In order to 
investigate the mechanisms of gemcitabine -resistance, multiple mechanisms have been 
proposed, including enhanced NF-kB activation [5], increased activity of Src tyrosine kinase 
and expression of the M2 subunit of ribonucleotide reductase (RRM2) [6], deficiency in 
deoxycytidine kinase (dCK) [7], and altered transport over the cell membrane [8]. Recent 
studies indicate that acquired gemcitabine resistance in pancreatic cancer cells may be 
mainly attributed to an altered apoptotic threshold [9].  
Telomerase is an RNA-dependent DNA polymerase that is rarely present in normal somatic 
cells but is observed in 85% of all cancer cells tested, making the telomerase enzyme an 
attractive target for anticancer therapeutics [10,11]. The human telomerase is composed of a 
constitutively expressed RNA subunit (hTR), human telomerase-associated protein (TEP1) 
and a catalytic protein subunit (hTERT). The protein subunit hTERT is a reverse 
transcriptase, and hTERT expression is the rate-limiting component of the telomerase 
complex and therefore determines telomerase activity [12]. The main function of the 
telomerase is the lengthening and capping of the ends of linear chromosomes, the telomeres 
[13-15].Uncapped or critically shortened telomeres cause cell apoptosis (15). Many labs have 
reported that telomerase may play an active role in the response to DNA damaging agents 
[16-18], and could been implicated in suppression of apoptosis [19]. It has also been 
demonstrated recently that antisense-mediated down-regulation of hTERT quickly induced 
programmed cell death in human tumour cells [20-23] and sensitized cancer cells to DNA 
damaging agents through the activation of the apoptotic program [24-26]. For pancreatic 
cancer, it was not known so far whether hTERT mRNA silencing leads to sensitization to 
gemcitabine as the standard of care for pancreatic cancer. 
In this study, sequence-specific antisense oligonucleotides targeting the coding region of the 
protein component of human telomerase were designed to examine whether hTERT mRNA 
and telomerase activity could be inhibited and chemosensitivity to gemcitabine could be 
increased in pancreatic cancer cells.  
2. Materials and methods 
2.1 Oligonucleotides and drug  
Based on the hTERT gene cDNA sequence (4015 nt; accession no. AF015950), the antisense 
oligonucleotide was designed to be complementary to the translation initiation region of 
hTERT mRNA; the antisense oligodeoxynucleotide sequence (AS-ODN) is 5′-
GGAGCGCGCGGCATCGCGGG-3′; Non-specific oligodeoxynucleotide sequence (NS-
ODN) is 5′-CATTTCTTGCTCTCCACGCG-3′as a control, having the same base number as 
the antisense oligonucleotide but with different sequence. All oligodeoxynucleotides were 
fully phosphorothioate, and were synthesized by Invotrogen (Carlsbad, CA, USA). Their 
lack of significant interfering homology was validated using BLAST analysis. Gemcitabine 
was obtained from Eli Lilly, and the dilutions of gemcitabine were freshly prepared before 
each experiment.  
2.2 Cell culture and transfection  
Pancreatic cancer cell lines BxPC-3 and Panc-1 were kindly provided by the center 
laboratory of the Second Hospital of ChangZhou in China, and were routinely incubated in 
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DMEM (GIBCO BRL) supplemented with 10% fetal calf serum (GIBCO BRL), 4 mM 
glutamine, 50 U/ml penicillin, and 50 µg/ml streptomycin. Cells were grown at 37  in a 
humidified chamber of 95% air containing 5% CO2. The transfection procedure of 
oligonucleotides(ODN) was performed according to the user manual of Oligofectamine TM 
Reagent(Invitrogen, Carlsbad, CA, USA). Briefly, The cells were seeded the day before the 
experiment in different culture plates at different density per well at 30% to 50% confluence 
on the day of the experiment, and then were transfected with 0.2µM of Oligofectamine and 
0.2µM of oligonucleotides (ODN) in the serum-free DMEM, incubated at 37  for 4 hr, and 
then added different volume of growth medium containing 3× the normal concentration of 
serum according to the different culture plates without removing the transfection mixture. 
To assess ODN uptake, pancreatic cancer cells were transfected with the FITC-labeled ODN, 
and then Flow cytofluorometry (FACScalibur, Becton Dickinson, Franklin Lakes, NJ, USA) 
was used to quantify FITC -positive cells at defined times after transfection. 
2.3 Quantitative RT-PCR  
Pancreatic cancer cell lines BxPC-3 and Panc-1 were harvested with trypsin, washed with 
PBS, and collected by centrifugation at 1,000 rpm for 5 min. Total RNA was extracted using 
SV Total RNA isolation system ( Promega, Madison, WI, USA) following the manufacturer’s 
protocol. And its purity and quality were measured by Bio-visible spectrophotometer 
(Eppendorf, Germany); 1% agarose gel electrophoresis was used to assess the integrity of 
the obtained RNA. cDNA with a total volume of 20µl was synthesized using the reverse 
transcription system containing reverse transcriptase (Promega, Madison, WI, USA) 
according to the recommended protocol by the manufacturer. Real-time quantitative PCR of 
the target hTERT gene and β-actin as internal control was carried out with icycler iQ 
Multicolor Real-time PCR Detection System (Bio-Rad Laboratories, Inc., USA). The 20 μl 
PCR reaction mixture contained 1× primers and probe mixture [Applied Biosystems, Foster 
city , CA. Assay IDs: Hs99999022_m1 (hTERT); Hs99999903 _m1 (β-actin)], 1× Absolute 
QPCR Mix (ABgene, Surrey, UK). The PCR conditions were 50°C for 2 min, 95°C for 15 min, 
followed by 45 cycles at 95°C for 15 s and 60°C for 1 min. Relative gene expression 
quantifications were calculated according to the comparative Ct method using β-actin as an 
endogenous control and commercial human total RNA (BD Clontech, CA, USA) as 
calibrators. Final results were determined by the formula2-ΔΔCT method[27].  
2.4 Telomerase activity assay 
A commercial telomerase PCR ELISA kit (Roche Diagnostics. Scandinavia AB, Stockholm, 
Sweden) was used to determine telomerase activity in cells according to the manufacturer’s 
instructions. Briefly, 5µl amplification product which had been denaturated at room 
temperature for 10 min with 20µl denaturation reagent was hybridized with a digoxigenin-
labeled probe specific for human telomeric repeats. The probe bound to the strand with the 
labeled biotin at the 5' end. The hybrid was immobilized to a streptavidin-coated microtiter 
plate via the biotin-labeled primer at 37 ºC on a shaker for 2 h, and washed 3 times. The 
reaction product was detected with 100µl anti-digoxigeninperoxidase and 100µl peroxidase 
substrate TMB. Color intensities were measured with a model 450 microplate reader (BIO-
RAD) at 450 nm. 
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2.5 Cell viability assay  
Cytotoxicity was determined by CellTiter 96 AQueous One Solution Cell Proliferation Assay 
kit (Promega, Madison, WI, USA). Briefly, ODN-transfected and Oligofactamine- transfected 
cancer cells growing in log-phase were trypsinized and seed at 2×103 cells per well into 96-
well plates and allowed to attach overnight. Medium in each well was replaced with fresh 
medium or medium with various concentrations of drug in at least 6 replicate wells and left 
contact for 48 h. One-fifth volume of CellTiter 96 AQueous One Solution was added to each 
well and incubated for an additional 3 h, Absorbance was determined with a microplate 
reader (BIO-RAD) at 490 nm. The blank control wells were used for zeroing absorbance. 
Each experiment was allocated ten wells containing drug-free medium for the control. The 
inhibition rate (I %) was calculated using the background-corrected absorbance by the 
following equation: I% = 100× (A untreated control well–A experimental well) /A untreated control well. The 
IC50 was defined as the concentration required for 50% inhibition of cell growth. Each 
experiment was performed in triplicate, with representative data presented. 
2.6 Colony-forming cell assay  
Pancreatic tumor cells were transfected with 0.2µM AS-ODN or NS-ODN for 24 h, and then 
the transfected cells were treated with gemcitabine at 0.05μM in BxPC-3 cells and 0.8μM in 
Panc-1cells for 48 h. Subsequently, gemcitabine-treated cells and parental cells (300 cells 
/well) were plated in triplicate in 60-mm Petri dishes. On day 7, the plates were fixed in 70% 
methanol and treated with Giemsa stain. Clonogenic survival was determined by counting 
the macroscopically visible colonies. 
2.7 Apoptosis assay  
Cells quantification of apoptosis cells was performed using an Annexin-V- FITC Apoptosis 
Detection Kit ( Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. 
Briefly, cells were plateded in a 60-mm Petri disk and treated with drugs for 48h .Then cells 
were collected and resuspended in 500µl of binding buffer, and 5µl of Annexin- V-
fluorescein isothiocyanate (FITC) and 5µl of propidium iodide (PI) were added. Analyses 
were performed with a flow cytometer (FACScalibur, Becton Dickinson, Franklin Lakes, NJ, 
USA). 
2.8 Statistical methods  
Values were expressed as means ±standard deviations. Statistical comparison was 
performed using Student’s t-test, and a p value of less than 0.05 was considered statistically 
significant.  
3. Results 
3.1 Assessment of AS-ODN uptake by pancreatic cancer cells 
The use of 0.2µM Oligofectamine allowed a very efficient internalization of ODNs already 
after 4 h of transfection (> 20% FITC-positive cells), and at 24 h, the fluorescence intensity in 
both cell lines reached the strongest (> 30% FITC-positive cells), and then gradually 
decreased (data not shown). In contrast, transfection without Oligofectamine resulted in 
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<10% FITC-positive cells. After a 24-h transfection, the percentages of FITC-positive cells 
could attain to 33.6% in BxPC-3 cells and 41.8% in Panc-1 cells. 
3.2 hTERT antisense oligodeoxynucleotide(AS-ODN) down-regulates hTERT mRNA 
expression and telomerase activity of pancreatic cancer cells  
We first examined the mRNA expression of hTERT mRNA in BxPC-3 and Panc-1 using 
quantitative RT-PCR. The expression levels of hTERT mRNA in Panc-1 cells was higher than 
that in BxPC-3 cells (p＜0.001) (Fig. 1). We further examined whether hTERT AS-ODN could 
downregulate the expression levels of hTERT mRNA in both cell lines. As shown in Fig. 1, 
treatment with 0.2µM hTERT AS-ODN for 24 h down-regulated the levels of hTERT mRNA 
in BxPC-3 to 29 % and in Panc-1 cells to 35 %, relative to the Oligofectamine- treated control. 
While the same concentration of NS-ODN sequence did not down-regulate the levels of 
hTERT mRNA expression in both cell lines. We also examined the effects of gemcitabine on 
the levels of hTERT mRNA expression, and the results showed that gemcitabine alone at 
IC50 for 24 h only led to moderate down-regulation of hTERT mRNA in BxPC-3 cell lines 
and slight up-regulation of that in Panc-1 cell lines. Additionally, we examined the effect of 
suppressing hTERT mRNA on telomerase activity. We found that NS-ODN control clones 
showed significant telomerase activity, equal to parental cells, whereas 0.2µM AS-ODN  
  
Fig. 1. Sequence-specific suppression of hTERT mRNA by hTERT antisense oligonucleotide 
in BxPC-3 cells (A) and Panc-1 cells (B). Both cell lines were treated with 0.2µM ODN or 
gemcitabine at IC50 for 24 h. Cells were harvested for RNA analysis after 24 h incubation. 
Relative gene expression quantifications were calculated according to the comparative Ct 
method. Final results were determined by the formula2-ΔΔCT method. Values represent 
means ± SD, from three independent experiments; *p < 0.001 vs oligofectamine transfected 
BxPC-3 control cells. **p < 0.05 vs oligofectamine transfected control group. 
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Fig. 1. Sequence-specific suppression of hTERT mRNA by hTERT antisense oligonucleotide 
in BxPC-3 cells (A) and Panc-1 cells (B). Both cell lines were treated with 0.2µM ODN or 
gemcitabine at IC50 for 24 h. Cells were harvested for RNA analysis after 24 h incubation. 
Relative gene expression quantifications were calculated according to the comparative Ct 
method. Final results were determined by the formula2-ΔΔCT method. Values represent 
means ± SD, from three independent experiments; *p < 0.001 vs oligofectamine transfected 
BxPC-3 control cells. **p < 0.05 vs oligofectamine transfected control group. 
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clones expressed significantly decreased levels of telomerase activity in both cell lines (Fig. 
2) at 24 h as assessed by TRAP-ELISA Assay. At the same time, we found the level of 
telomerase activity in Panc-1 parental cells was higher than that in BxPC-3 parental cells 
(p=0.003), and gemcitabine at IC50 for 24 h moderately down-regulated the telomerase 
activity in both cell lines(data not shown). 
 
Fig. 2. Telomerase activity in transfected cells of BxPC-3 (A) and Panc-1 (B). Telomerase PCR 
ELISA was performed 24 h after transfection in triplicates. Values represent the mean 
Absorbance ± SD, from three independent experiments; *p < 0.001 vs oligofectamine 
transfected BxPC-3 control cells. **p < 0.001 vs oligofectamine transfected control group. 
3.3 hTERT antisense oligodeoxynucleotide (AS-ODN) increases gemcitabine-induced 
cytotoxicity in pancreatic cancer cells  
We next investigated whether the addition of hTERT AS-ODN could indeed increase 
gemcitabine sensitivity. BxPC-3 and Panc-1 cells were treated with gemcitabine in the 
presence of 0.2µM hTERT AS-ODN at different concentrations. Fig. 3 shows the IC50 value 
of gemcitabine in BxPC-3 and Panc-1 cells were 0.23µM and 7.13µM, respectively. That is 
to say Panc-1 cells were 31-fold more resistant to gemcitabine than BxPC-3 cells, 
suggesting that the more higher expression of hTERT mRNA or telomerase activity, the 
more resistant of cancer cells to gemcitabine. hTERT AS-ODN was able to reduce the IC50 
of gemcitabine to about 8.7 times in Panc-1 cells, and only about 4.2 times in BxPC-3 cells, 
suggesting hTERT antisense oligodeoxynucleotide could increase gemcitabine- induced 
cytotoxicity in both cell lines, and sensitize the gemcitabine -resistant cells. But the same 
concentration NS-ODN control sequence could not increase gemcitabine-induced 
cytotoxicity in both cells (data not shown). At the same time, we found AS-ODN 
treatment at 0.2µM for 24 h resulted in a slightly attenuated ability of proliferation in both 
cell lines (data not shown), suggesting that a lag phase between telomerase inhibition and 
growth inhibition and/or cell death may limited the application of telomerase inhibition 
therapy alone in solid cancer treatment. 
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Fig. 3. hTERT antisense oligodeoxynucleotide(AS-ODN) increases gemcitabine-induced 
cytotoxicity in BxPC-3(A) and Panc-1(B) cells. Briefly, ODN transfected cells and parental 
cells were treated with gemcitabine at different concentrations. The inhibition rate (I %) was 
calculated using the background-corrected absorbance by the following equation: I% = 100× 
(A untreated control well–A experimental well) /A untreated control well. Values represent the mean inhibition 
rates ± SD, from three independent experiments, compared to an untreated control cells. 
 
 
Fig. 4. Cells treatment with gemcitabine (GEM) in presence of AS-ODN exhibited 
significantly decreased colony formation ability in BxPC-3 (A) and Panc-1(B) cells. Briefly, 
cells were transfected with 0.2μM AS-ODN or NS-ODN for 24 h, and then the transfected 
cells and parental cells were treated with gemcitabine at 0.05μM in BxPC-3 cells and 0.8μM 
in panc-1cells for 48 h. Subsequently, gemcitabine-treated cells and parental cells (300 cells/ 
well) were plated in triplicate in 60-mm Petri dishes. On day 7, the plates were fixed in 70% 
methanol and were treated with Giemsa stain. Clonogenic survival was determined by 
counting the macroscopically visible colonies. The relative colony formation ability 
normalized to the untreated parental control is displayed. Data represent the mean values ± 
SD, from three independent experiments. *P<0.05 vs. the group of (control +GEM ).  
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3.4 Cells treatment with gemcitabine in presence of AS-ODN exhibited significantly 
decreased colony formation ability  
To further investigate the combined antitumor efficacy of hTERT AS-ODN and gemcitabine 
in human pancreatic cancer cells, colony formation ability was evaluated by colony 
formation assays. The ability of isolated cells to proliferate and generate colonies was clearly 
reduced in the cells treatment with gemcitabine in presence of AS-ODN, but not in presence 
of NS-ODN (Fig. 4). In particular, treatment with 0.8µM gemcitabine for 48 h, the AS-ODN-
transfected Panc-1 cells showed a remarkable decrease of ≥50% in the relative colony 
number. Furthermore, after treatment with gemcitabine for 48 h, colonies arising from AS-
ODN- transfected cells were smaller than colonies originating from NS-ODN-treated cells or 
parental control cells. 
3.5 hTERT antisense oligodeoxynucleotide increases gemcitabine- induced apoptosis 
in both cell lines  
We further examined whether down-regulation of hTERT mRNA and telomerase activity 
could increase cytotoxicity of gemcitabine by induction of apoptosis. Gemcitabine single agent 
treatment at 0.2µM for 48 h resulted in 30.5% of early apoptosis in BxPC-3 cells, and at 7µM for 
48 h resulted in 15.8% of early apoptosis in Panc-1 cells, but when 0.2µM AS-ODN was 
previously added to both cell lines for 24 h, the effects were dramatically increased to 58.5% 
and 29.2%, respectively. At the same time, the percentages of late apoptosis were increased to 
21.3% in BxPC-3 cells and 18.5% in Panc-1 cells. While when AS-ODN was added alone at 
0.2µM for 24 h, the percentages of early apoptosis in BxPC-3 and Panc-1 cells were only 8.4% 
and 5.2%, respectively, and the same concentration of NS-ODN control sequence resulted in 
the similar percentage of early apoptosis as parental cells (data not shown). Thus, it appears 
that hTERT suppressing might increase gemcitabine -induced apoptosis in both cell lines and 
subsequently lead to an increased cytotoxicity of gemcitabine (see Fig. 5). 
4. Discussion 
Pancreatic cancer has a poor prognosis, even after curative resection. Gemcitabine is 
established as the reference treatment for pancreatic cancer patients [28]. However, clinical 
efficacy with gemcitabine as a single agent remains poor. Gemcitabine-based combinations 
are needed to improve outcomes. In the present study, we evaluated the effect of a 
combined gemcitabine and antisense hTERT gene therapy on tumor growth in human 
BxPC-3 and Panc-1 pancreatic cancer cell lines in vitro. We initially demonstrated that an 
AS-ODN complementary to the translation region of hTERT mRNA inhibited the expression 
of hTERT mRNA and telomerase activity in both cell lines, while gemcitabine alone resulted 
in only moderate down-regulation of hTERT expression in BxPC-3 cells and slight up-
regulation of hTERT expression in Panc-1 cell lines. Then we demonstrated that down-
regulation of the human telomerase reverse transcriptase mRNA and inhibition of 
telomerase activity by AS-ODN could sensitize both cell lines to gemcitabine, leading to 
enhanced cytotoxicity in vitro. These consequences suggest that the anti-proliferative effect 
of the combination gemcitabine and antisense hTERT therapy in human pancreatic cancer 
are mediated through the down-regulation of hTERT mRNA and inhibition of telomerase 
activity. These findings also make an antisense technology for hTERT inhibition therapy an 
attractive approach for the sensitization of pancreatic cancer cells to gemcitabine. 
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performed using an Annexin-V- FITC Apoptosis Detection Kit according to the 
manufacturer’s instructions. Briefly, cells were plateded in a 60-mm Petri disk and treated 
with drugs for 48 h .Then cells were collected and resuspended in 500µl of binding buffer, 
and 5µl of Annexin-V-fluoresce in isothiocyanate (FITC) and 5µl of propidium iodide (PI) 
were added. Analyses were performed with a flow cytometer. A1, B1: both cell lines were 
treated without drug.A2, B2: both cell lines were treated with AS-ODN alone.A3, B3: both 
cell lines were treated with gemcitabine alone.A4, B4: both cell lines were treated with AS-
ODN for 24 h followed by gemcitabine treatment for 48 h. Early apoptotic cells are defined 
as Annexin V-positive, PI- negative cells, late apoptotic cells are defined as Annexin V-
positive, PI- positive cells. 
Telomerase is a ribonucleoprotein enzyme responsible for lengthening and capping the ends 
of linear chromosomes, the telomeres [13-15]. Telomerase activation is required for the 
survival and proliferation of the large majority of tumor cells. Uncapped or critically 
shortened telomeres cause cellular responses such as inhibition of cell proliferation and 
apoptosis. It is currently unclear how telomerase is regulated in human cancer cells. 
Previous studies indicated that telomerase activity is strongly correlated with the abundance 
of hTERT mRNA but not the hTER[29-31], and ectopic expression of hTERT in somatic cells 
is sufficient to restore telomerase activity[32-35].Thus, strategies targeting hTERT may be a 
new approach for inhibition of telomerase activity and gene therapy of cancer. Recent 
studies indicate that down-regulation of hTERT expression or expression of dominant -
negative hTERT could inhibit telomerase activity and prevent the malignant proliferation of 
tumor cells after considerable passages in culture [21,36-38]. In our experiments, we have 
demonstrated that treatment of pancreatic cancer cells with hTERT AS-ODN could down-
regulate the levels of hTERT mRNA expression, inhibit the telomerase activity, but result in 
a slightly attenuated ability of proliferation in both cell lines. In fact, as human cells reduce 
their telomere length by 50-100 base pairs per cell division, a long lag phase is required 
before growth arrest can be obtained, even in cancer cells with relatively short telomeres 
[10,39]. Thus , in present study, the moderate anticancer efficacy of hTERT AS-ODN in both 
cell lines may be independent of telomere shortening ,but partially dependent of the loss of 
the hTERT-mediated capping function of telomerase [40]. 
It was obvious that anti-telomerase therapy alone was not the best selection of cancer 
treatment for its requiring long time to reduce the telomere length [10,39].However, 
transiently transfection of hTERT AS-ODN may enhance the anticancer efficacy of other 
well known chemotherapy agents targeting DNA [25,26]. Gemcitabine (2',2'-
difluorodeoxycytidine, dFdC) is a synthetic pyrimidine nucleoside analogue, the 
diphosphate (dFdCDP) and triphosphate (dFdCTP) forms of the drug play an important 
role in the cytotoxic effect: dFdCDP is an inhibitor of ribonucleotide reductase, while 
dFdCTP is incorporated into DNA, both leading to the inhibition of DNA synthesis and 
making genomic instability[41]. Thus, we speculate that hTERT mRNA silencing may lead 
to sensitization of pancreatic cancer cells to gemcitabine. Our study showed that hTERT AS-
ODN significantly increased the gemcitabine- induced cytotoxicity in both cell lines, 
especially sensitize the gemcitabine -resistant cells. Apoptosis test further demonstrated that 
hTERT suppressing could increase gemcitabine-induced apoptosis in both cell lines, but the 
same concentration NS-ODN control sequence could not increase gemcitabine-induced 
cytotoxicity in any of pancreatic cancer cell lines. The similar results were also acquired by 
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other report in the bladder cancer cell lines [26]. Assessment of AS-ODN uptake showed 
that Panc-1 cells are more easily to be transfected with Oligofectamine than BxPC-3 cells, 
which might partly explain why the sensitizing effects of hTERT AS-ODN on Panc-1 cells 
are more obvious than on BxPC-3 cells. 
It is not clear of the relationship between the expression levels of telomerase activity or 
hTERT mRNA and chemotherapy resistanse. In our study, we initially found that the 
expression levels of hTERT mRNA and telomerase activity in Panc-1 cells were higher than 
those in BxPC-3 cells. Then we found Panc-1 cells were 31-fold more resistant to gemcitabine 
than BxPC-3 cells. It seems that the more higher expression of hTERT mRNA or telomerase 
activity, the more resistant of cancer cells to gemcitabine. Our following study showed that 
down- regulation of hTERT mRNA and telomerase activity could increase the sensitivity of 
cancer cells to gemcitabine, especially could restore the sensitivity of gemcitabine-resistant 
cells to gemcitabine, which indirectly denmonstrated hTERT mRNA or telomerase may be 
implicated in gemcitabine resistance. Xi and his associates introduced vectors encoding 
dominate negative (DN)-hTERT, wild-type (WT)-hTERT, or a control vector expressing only 
a drug-resistance marker into HeLa cells. Results showed that DN-hTERT transfected HeLa 
cells with shortened telomeres were more susceptible to multiple chemotherapeutic agents 
and radiation. WT-hTERT transfected HeLa cells with longer telomeres exhibited resistance 
to radiation and chemotherapeutic agents [42]. Our results showed that at least in part, 
gemcitabine resistance was associated with the high expression of hTERT mRNA or high 
telomerase activity.  
In conclusion, our results demonstrate that down-regulation of hTERT mRNA and 
inhibition of telomerase activity by hTERT AS-ODN could increase the sensitivity of 
pancreatic cancer cells to gemcitabine and especially sensitize the gemcitabine -resistant 
cells. These findings should further be explored in vivo. 
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